PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	RUSSELL, RM				RUSSELL, RM			NUTRITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANS-FATTY-ACIDS; WOMEN				RUSSELL, RM (corresponding author), TUFTS UNIV,JEAN MAYER HUMAN NUTR RES CTR AGING,BOSTON,MA 02111, USA.							ALOIA JF, 1994, ANN INTERN MED, V120, P97, DOI 10.7326/0003-4819-120-2-199401150-00001; ASCHERIO A, 1994, CIRCULATION, V89, P94, DOI 10.1161/01.CIR.89.1.94; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; GOLDSTEIN DJ, 1994, AM J CLIN NUTR, V60, P647, DOI 10.1093/ajcn/60.5.647; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; GREENBERG RE, 1994, NEW ENGL J MED, V331, P141; KUCAMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; 1994, DIABETES CARE, V17, P519; 1994, STATEMENT T FATTY AC, P1; 1994, JAMA-J AM MED ASSOC, V272, P1942; 1994, NEW ENGL J MED, V330, P1029	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1699	1700						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752424				2022-12-24	WOS:A1995RB09700032
J	RADY, PL; YEN, A; ROLLEFSON, JL; ORENGO, I; BRUCE, S; HUGHES, TK; TYRING, SK				RADY, PL; YEN, A; ROLLEFSON, JL; ORENGO, I; BRUCE, S; HUGHES, TK; TYRING, SK			HERPESVIRUS-LIKE DNA-SEQUENCES IN NON-KAPOSIS SARCOMA SKIN-LESIONS OF TRANSPLANT PATIENTS	LANCET			English	Note								Herpesvirus-like DNA sequences (KSHV) have been reported to be associated with various forms of Kaposi's sarcoma (KS). To determine if KSHV was associated with other proliferative skin lesions from non-AIDS immunocompromised patients, 33 shin lesions (basal cell carcinomas, squamous cell carcinomas, actinic keratoses, verruca vulgaris, atypical squamous proliferations, and seborrhoeic keratosis) from 4 organ-transplant patients receiving immunosuppressive therapy were tested for KSHV by PCR. KSHV sequences were detected in 82% of these skin lesions. Our results suggest that KSHV is associated with lesions other than KS in non-AIDS immunocompromised patients, and may also be involved in the pathogenesis of the various forms of proliferative skin lesions from organ-transplant patients.	UNIV TEXAS,MED BRANCH,DEPT IMMUNOL MICROBIOL,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT DERMATOL,GALVESTON,TX 77550; BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine			RADY, PETER/AAA-4481-2021					Brash DE, 1991, P NATL ACAD SCI USA, V101, P24; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; EUVRARD S, 1993, CANCER, V72, P2198, DOI 10.1002/1097-0142(19931001)72:7<2198::AID-CNCR2820720722>3.0.CO;2-Q; HUANG YQ, 1995, LANCET, V45, P759; MCGREGOR JM, 1994, J AM ACAD DERMATOL, V30, P701, DOI 10.1016/S0190-9622(08)81498-3; RADY P, 1992, CANCER RES, V52, P3804; RESNICK RM, 1990, JNCI-J NATL CANCER I, V82, P1477, DOI 10.1093/jnci/82.18.1477; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5	9	201	206	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1339	1340						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752756				2022-12-24	WOS:A1995RA14800009
J	CRAIR, MC; MALENKA, RC				CRAIR, MC; MALENKA, RC			A CRITICAL PERIOD FOR LONG-TERM POTENTIATION AT THALAMOCORTICAL SYNAPSES	NATURE			English	Article							DEPENDENT SYNAPTIC PLASTICITY; NMDA RECEPTOR CHANNEL; VISUAL-CORTEX; SOMATOSENSORY CORTEX; BARREL CORTEX; MECHANISMS; TRANSMISSION; RESPONSES; PATTERNS; CURRENTS	IN mammalian development, the refinement of topographical projections from the thalamus to the cortex is thought to arise through an activity-dependent process in which thalamic axons compete for cortical targets(1,2). In support of this view, if activity is altered during a critical period in early development, normal connectivity is disrupted(1,2). It has been proposed that synaptic connections are strengthened during development by correlated pre- and postsynaptic activity(3,4), and a likely mechanism for this process would be N-methyl-D-aspartate (NMDA) receptor-dependent long-term potentiation (LTP)(5,6). However, the evidence that LTP is involved in normal development remains inconclusive. We have examined LTP in the thalamocortical synapses that form whisker barrels in rat somatosensory cortex (S1). We report here that the period during which LTP can be induced matches closely the critical period during which the barrels can be modified by sensory perturbations. Moreover, the loss of susceptibility to LTP with age is accompanied by a decrease in NMDA receptor-mediated synaptic currents. These findings provide compelling evidence that LTP is important for the development of cortical circuitry.	UNIV CALIF SAN FRANCISCO, CTR NEUROBIOL & PSYCHIAT, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	CRAIR, MC (corresponding author), UNIV CALIF SAN FRANCISCO, CTR NEUROBIOL & PSYCHIAT, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA.							AGMON A, 1992, J NEUROPHYSIOL, V68, P345, DOI 10.1152/jn.1992.68.1.345; AGMON A, 1991, NEUROSCIENCE, V41, P365, DOI 10.1016/0306-4522(91)90333-J; Bear M F, 1993, Curr Opin Neurobiol, V3, P197, DOI 10.1016/0959-4388(93)90210-P; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CHIAIA NL, 1992, DEV BRAIN RES, V66, P244, DOI 10.1016/0165-3806(92)90086-C; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DIAMOND ME, 1994, SCIENCE, V265, P1885, DOI 10.1126/science.8091215; FOX K, 1992, J NEUROSCI, V12, P1826; FOX K, 1993, TRENDS NEUROSCI, V16, P116, DOI 10.1016/0166-2236(93)90136-A; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HEBB DO, 1949, ORG BEHAVIOR; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; KANDEL ER, 1992, SCIENCE, V258, P243, DOI 10.1126/science.1411522; KILLACKEY HP, 1975, BRAIN RES, V86, P469, DOI 10.1016/0006-8993(75)90897-5; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOONEY R, 1993, NEURON, V10, P815, DOI 10.1016/0896-6273(93)90198-Z; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; SCHLAGGAR BL, 1993, NATURE, V364, P623, DOI 10.1038/364623a0; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K; WOOLSEY TA, 1976, J COMP NEUROL, V170, P53, DOI 10.1002/cne.901700105; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	29	578	589	0	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					325	328		10.1038/375325a0	http://dx.doi.org/10.1038/375325a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753197				2022-12-24	WOS:A1995RA03000053
J	WEINER, JP; PARENTE, ST; GARNICK, DW; FOWLES, J; LAWTHERS, AG; PALMER, RH				WEINER, JP; PARENTE, ST; GARNICK, DW; FOWLES, J; LAWTHERS, AG; PALMER, RH			VARIATION IN OFFICE-BASED QUALITY - A CLAIMS-BASED PROFILE OF CARE PROVIDED TO MEDICARE PATIENTS WITH DIABETES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMBULATORY CARE; FAMILY PHYSICIANS; SPECIALTIES; POPULATION; INTERNISTS; ASSURANCE; OUTCOMES; SYSTEMS; MIX	Objectives.-To demonstrate that claims data ''profiling'' can be used as an ongoing method to support ambulatory care quality improvement; to measure the quality of office-based care provided to elderly patients with diabetes in three states; and to identify factors associated with better attainment of quality standards. Study Design.-A cross-sectional study based on a 100% sample of the Medicare claims (Part B and Part A) submitted between July 1, 1990, and June 30, 1991. Setting.-All primary care practices (both solo and group) actively seeing Medicare patients with diabetes in Alabama, Iowa, and Maryland (n=2980). Patients.-All elderly (greater than or equal to 65 years) Medicare patients seen by the study physicians and assigned a diagnosis of diabetes (n=97 388) by any office-based physician during the year. Main Outcome Measures.-The proportion of patients with diabetes receiving the following procedures (from any provider) at least once during the study period: hemoglobin A(1C) measurement, ophthalmologic examination, total cholesterol measurement, and blood glucose measurement. We considered the first three services to be optimally recommended and blood glucose measurement to be of limited use. Results.-Based on analyses of services provided in the ambulatory setting, we found that 84% of diabetics did not appear to receive the recommended hemoglobin A(1C) measurement, 54% did not see an ophthalmologist, and 45% received no cholesterol screening. Practice patterns varied considerably across the three states (up to 2.38-fold), even after adjusting for patient case mix and physician characteristics. Patients of general practitioners were less likely to meet recommended quality criteria than patients of internists or family practitioners. Patients receiving care from rural practitioners were less likely to receive services, either recommended or not, than those in urban locations. Conclusions.-Elderly patients with diabetes do not appear to be receiving optimal care. This study underscores the value of practice guideline development and dissemination in the ambulatory arena. This study provides substantial evidence that existing administrative claims data can be used to support ambulatory quality improvement activities.	BRANDEIS UNIV,HELLER GRAD SCH,INST HLTH POLICY,WALTHAM,MA 02254; PK NICOLLET MED FDN,MINNEAPOLIS,MN; HARVARD UNIV,SCH PUBL HLTH,CTR QUAL CARE RES & EDUC,BOSTON,MA 02115	Brandeis University; Harvard University; Harvard T.H. Chan School of Public Health	WEINER, JP (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,JOHNS HOPKINS HLTH SERV RES & DEV CTR,BALTIMORE,MD 21205, USA.		Garnick, Deborah w/I-9009-2012					ALLERHEILIGEN DA, 1990, DIABETES MELLITUS RE; BRANCH WT, 1987, OFFICE PRACTICE MED; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CHERKIN DC, 1987, MED CARE, V25, P455, DOI 10.1097/00005650-198706000-00001; Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; DIEHR P, 1990, HEALTH SERV RES, V24, P741; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; Garnick D W, 1994, J Ambul Care Manage, V17, P44; Garnick D W, 1994, Int J Qual Health Care, V6, P163; GARNICK DW, 1994, JOINT COMM J QUAL IM, V20, P679, DOI 10.1016/S1070-3241(16)30117-1; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENWALD HP, 1984, MED CARE, V22, P14, DOI 10.1097/00005650-198401000-00002; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; LASKER RD, 1992, INQUIRY-J HEALTH CAR, V29, P287; LATHERS A, 1995, J AMB CARE MANAGE, V18, P56; Lawthers A G, 1993, Jt Comm J Qual Improv, V19, P552; Leatherman S, 1991, QRB Qual Rev Bull, V17, P349; LINN LS, 1984, INQUIRY-J HEALTH CAR, V21, P266; Lohr K.N., 1990, MEDICARE STRATEGY QU, V1; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; PALMER RH, 1988, INQUIRY-J HEALTH CAR, V25, P119; PALMER RH, 1994, FINAL REPORT EXTERNA; PALSEY B, 1987, AM J PUBLIC HEALTH, V77, P659; Romano P S, 1993, Med Care Rev, V50, P451, DOI 10.1177/002570879305000404; STARFIELD B, 1994, JAMA-J AM MED ASSOC, V272, P1903, DOI 10.1001/jama.272.24.1903; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; STARFIELD B, 1993, PRACTICE VARIATION O; TOBIN T, 1959, ECONOMETRICA, V26, P24; Weiner J P, 1990, QRB Qual Rev Bull, V16, P424; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WELCH HG, 1994, NEW ENGL J MED, V330, P607, DOI 10.1056/NEJM199403033300906; 1994, HLTH 1993; 1993, DEV EVALUATING METHO; 1988, DIABETES CARE, V11, P745; 1994, REPORT C 1994; 1989, DIABETES CARE, V12, P365	38	291	292	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1503	1508		10.1001/jama.273.19.1503	http://dx.doi.org/10.1001/jama.273.19.1503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX418	7739076				2022-12-24	WOS:A1995QX41800032
J	SERENO, MI; DALE, AM; REPPAS, JB; KWONG, KK; BELLIVEAU, JW; BRADY, TJ; ROSEN, BR; TOOTELL, RBH				SERENO, MI; DALE, AM; REPPAS, JB; KWONG, KK; BELLIVEAU, JW; BRADY, TJ; ROSEN, BR; TOOTELL, RBH			BORDERS OF MULTIPLE VISUAL AREAS IN HUMANS REVEALED BY FUNCTIONAL MAGNETIC-RESONANCE-IMAGING	SCIENCE			English	Article							POSITRON-EMISSION TOMOGRAPHY; HUMAN STRIATE CORTEX; HUMAN BRAIN; RETINOTOPIC ORGANIZATION; CORTICAL AREAS; MACAQUE MONKEY; TOPOGRAPHY; MRI; REPRESENTATION; CONNECTIONS	The borders of human visual areas V1, V2, VP, V3, and V4 were precisely and noninvasively determined. Functional magnetic resonance images were recorded during phase-encoded retinal stimulation. This volume data set was then sampled with a cortical surface reconstruction, making it possible to calculate the local visual field sign (mirror image Versus non-mirror image representation). This method automatically and objectively outlines area borders because adjacent areas often have the opposite field sign. Cortical magnification factor curves for striate and extrastriate cortical areas were determined, which showed that human visual areas have a greater emphasis on the center-of-gaze than their counterparts in monkeys. Retinotopically organized visual areas in humans extend anteriorly to overlap several areas previously shown to be activated by written words.	UNIV OSLO,DEPT NEUROPHYSIOL,N-0316 OSLO,NORWAY; HARVARD MIT DIV HLTH SCI & TECHNOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,NUCL MAGNET RESONANCE CTR,BOSTON,MA 02129	University of Oslo; Harvard University; Harvard University; Massachusetts General Hospital	SERENO, MI (corresponding author), UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093, USA.		Dale, Anders M/A-5180-2010; Sereno, Martin I/F-7657-2012	Sereno, Martin I/0000-0002-7598-7829; Kwong, Kenneth K./0000-0001-5056-2173	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD022614] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047035] Funding Source: NIH RePORTER; NEI NIH HHS [EY07980] Funding Source: Medline; NICHD NIH HHS [NICHD22614] Funding Source: Medline; NIMH NIH HHS [MH47035] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAKER JR, 1993, P SOC MAG RESON MED, V12, P1400; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BOUSSAOUD D, 1991, J COMP NEUROL, V306, P554, DOI 10.1002/cne.903060403; Carman G.J., 1990, THESIS CALTECH; CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103; CUSICK CG, 1984, J COMP NEUROL, V230, P311, DOI 10.1002/cne.902300302; DACEY DM, 1993, J NEUROSCI, V13, P5334, DOI 10.1523/JNEUROSCI.13-12-05334.1993; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DESIMONE R, 1986, J COMP NEUROL, V248, P164, DOI 10.1002/cne.902480203; DEYOE EA, 1994, J NEUROSCI METH, V54, P171, DOI 10.1016/0165-0270(94)90191-0; ENGEL SA, 1994, NATURE, V369, P525, DOI 10.1038/369525a0; FELLEMAN D J, 1986, Society for Neuroscience Abstracts, V12, P1182; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FOSTER KH, 1985, J PHYSIOL-LONDON, V365, P331, DOI 10.1113/jphysiol.1985.sp015776; FOX PT, 1987, J NEUROSCI, V7, P913; GATTASS R, 1988, J NEUROSCI, V8, P1831; HORTON JC, 1991, ARCH OPHTHALMOL-CHIC, V109, P816, DOI 10.1001/archopht.1991.01080060080030; Jouandet M L, 1989, J Cogn Neurosci, V1, P88, DOI 10.1162/jocn.1989.1.1.88; Kaas JH, 1991, NEUROANATOMY VISUAL, P302; KRUBITZER LA, 1990, VISUAL NEUROSCI, V5, P165, DOI 10.1017/S0952523800000213; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; NEUENSCHWANDER S, 1994, J COMP NEUROL, V340, P65, DOI 10.1002/cne.903400106; NEWSOME WT, 1986, J COMP NEUROL, V252, P129; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; OLAVARRIA J, 1985, J NEUROSCI METH, V15, P191, DOI 10.1016/0165-0270(85)90098-6; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; ROSA MGP, 1993, VISUAL NEUROSCI, V10, P827, DOI 10.1017/S0952523800006064; SCHNEIDER W, 1993, NATURE, V365, P150, DOI 10.1038/365150a0; Schwartz E.L., 1990, COMPUTATIONAL NEUROS, P295; Schwartz Eric L., 1994, Cerebral Cortex, V10, P359; Sereno Martin I., 1991, P160; SERENO MI, 1994, CEREB CORTEX, V4, P601, DOI 10.1093/cercor/4.6.601; SERENO MI, IN PRESS CEREB CORTE; TOLHURST DJ, 1988, HUM NEUROBIOL, V6, P247; TOOTELL RB, 1981, SCIENCE, V214, P813, DOI 10.1126/science.7292014; TOOTELL RBH, 1982, SCIENCE, V218, P902, DOI 10.1126/science.7134981; TOOTELL RBH, 1985, J NEUROSCI, V5, P2786; TOOTELL RBH, 1995, CEREB CORTEX, V5, P39, DOI 10.1093/cercor/5.1.39; TOOTELL RBH, IN PRESS J NEUROSCI; VANESSEN DC, 1984, VISION RES, V24, P429, DOI 10.1016/0042-6989(84)90041-5; VANESSEN DC, 1980, J COMP NEUROL, V191, P255, DOI 10.1002/cne.901910208; VANESSEN DC, 1992, SCIENCE, V255, P419, DOI 10.1126/science.1734518; VANESSEN DC, 1978, J PHYSIOL-LONDON, V277, P193; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; WISMER GL, 1988, J COMPUT ASSIST TOMO, V12, P259, DOI 10.1097/00004728-198803000-00014; ZEKI S, 1991, J NEUROSCI, V11, P641	49	1925	1952	6	126	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					889	893		10.1126/science.7754376	http://dx.doi.org/10.1126/science.7754376			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754376				2022-12-24	WOS:A1995QX85000043
J	ICHTCHENKO, K; HATA, Y; NGUYEN, T; ULLRICH, B; MISSLER, M; MOOMAW, C; SUDHOF, TC				ICHTCHENKO, K; HATA, Y; NGUYEN, T; ULLRICH, B; MISSLER, M; MOOMAW, C; SUDHOF, TC			NEUROLIGIN-1 - A SPLICE SITE-SPECIFIC LIGAND FOR BETA-NEUREXINS	CELL			English	Article							BINDING PROTEIN; AGRIN; SEQUENCE; MEMBRANE; LAMININ	Neurexins are neuronal cell surface proteins with hundreds of isoforms generated by alternative splicing. Here we describe neuroligin 1, a neuronal cell surface protein that is enriched in synaptic plasma membranes and acts as a splice site-specific ligand for beta-neurexins. Neuroligin 1 binds to beta-neurexins only if they lack an insert in the alternatively spliced sequence of the G domain, but not if they contain an insert, The extracellular sequence of neuroligin 1 is composed of a catalytically inactive esterase domain homologous to acetylcholinesterase. In situ hybridization reveals that alternative splicing of neurexins at the site recognized by neuroligin 1 is highly regulated. These findings support a model whereby alternative splicing of neurexins creates a family of cell surface receptors that confers Interactive specificity onto their resident neurons.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ICHTCHENKO, K (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Missler, Markus/0000-0001-8008-984X	NIMH NIH HHS [R01-MH52804] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; DELAESCALERA S, 1990, EMBO J, V11, P3593; DILAURO R, 1985, EUR J BIOCHEM, V148, P7; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SIKORAV JL, 1987, EMBO J, V7, P1865; Summers MD, 1987, MANUAL METHODS BACUL; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAKAGI Y, 1988, FEBS LETT, V282, P17; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V11, P4683; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0	25	540	557	1	19	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					435	443		10.1016/0092-8674(95)90396-8	http://dx.doi.org/10.1016/0092-8674(95)90396-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736595	Bronze			2022-12-24	WOS:A1995QW89400015
J	GULY, UM; MITCHELL, RG; COOK, R; STEEDMAN, DJ; ROBERTSON, CE				GULY, UM; MITCHELL, RG; COOK, R; STEEDMAN, DJ; ROBERTSON, CE			PARAMEDICS AND TECHNICIANS ARE EQUALLY SUCCESSFUL AT MANAGING CARDIAC-ARREST OUTSIDE HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							VENTRICULAR-FIBRILLATION; CARDIOPULMONARY-RESUSCITATION; HEARTSTART-SCOTLAND; FLYING SQUAD; DEFIBRILLATION; SURVIVAL; EMERGENCY; EXPERIENCE; EPINEPHRINE; STATEMENT	Objective-To examine the effect on survival of treatment by ambulance paramedics and ambulance technicians after cardiac arrest outside hospital. Design-Prospective study over two years from 1 April 1992 to 31 March 1994. Setting-Accident and emergency department of university teaching hospital. Subjects-502 consecutive adult patients with out of hospital cardiopulmonary arrest of cardiac origin. Interventions-Treatment by ambulance technicians or paramedics both equipped with semiautomatic defibrillators. Main outcome measures-Rate of return of spontaneous circulation, hospital admission, and survival to hospital discharge. Results-Rates of return of spontaneous circulation, hospital admission, and survival to hospital discharge were not significantly different for patients treated by paramedics as opposed to ambulance technicians. Paramedics spent significantly longer at the scene of the arrest than technicians (P<0.0001). Conclusions-The response of ambulance paramedics to patients with cardiopulmonary arrest outside hospital does not provide improved outcome when compared with ambulance technicians using basic techniques and equipped with semi-automatic defibrillators.	ROYAL EDINBURGH INFIRM,DEPT ACCID & EMERGENCY MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh								ANDERSON IWR, 1987, BRIT MED J, V294, P228, DOI 10.1136/bmj.294.6566.228; BOSSAERT L, 1989, RESUSCITATION, V17, pS55, DOI 10.1016/0300-9572(89)90091-9; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1991, RESUSCITATION, V21, P960; CUMMINS RO, 1995, JAMA-J AM MED ASSOC, V253, P2408; CUSACK S, 1992, ARCH EMERG MED, V9, P203; DARK PM, 1990, SCOT MED J, V35, P73, DOI 10.1177/003693309003500304; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; DICKEY W, 1991, Q J MED, V80, P729; DYBVIK T, 1995, IN PRESS RESUSCITATI; HAMER DW, 1993, RESUSCITATION, V26, P31, DOI 10.1016/0300-9572(93)90160-R; HARRISON EE, 1981, ANN EMERG MED, V10, P420, DOI 10.1016/S0196-0644(81)80309-5; JAKOBSSON J, 1987, ACTA MED SCAND, V222, P117; KERN KB, 1990, RESUSCITATION, V20, P221, DOI 10.1016/0300-9572(90)90005-Y; KOSTER R, 1992, RESUSCITATION, V24, P143, DOI 10.1016/0300-9572(92)90020-D; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; LINDNER KH, 1992, RESUSCITATION, V24, P147, DOI 10.1016/0300-9572(92)90021-4; MARTIN DR, 1993, RESUSCITATION, V26, P63, DOI 10.1016/0300-9572(93)90164-L; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; OLSON DW, 1989, ANN EMERG MED, V18, P806, DOI 10.1016/S0196-0644(89)80200-8; PANTRIDG.JF, 1967, LANCET, V2, P271; ROWLEY JM, 1987, BRIT MED J, V295, P1387, DOI 10.1136/bmj.295.6610.1387; SCHUTTLER J, 1991, ANAESTHESIST, V40, P172; SEDGWICK ML, 1994, RESUSCITATION, V27, P55, DOI 10.1016/0300-9572(94)90022-1; SEDGWICK ML, 1992, RESUSCITATION, V24, P73, DOI 10.1016/0300-9572(92)90175-C; SMITH JP, 1986, CAN J PREHOSP MED, V1, P5; STIELL IG, 1992, NEW ENGL J MED, V327, P1047; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; STULTS KR, 1986, AM J EMERG MED, V4, P491, DOI 10.1016/S0735-6757(86)80001-8; VONPLANTA M, 1992, RESUSCITATION, V24, P227, DOI 10.1016/0300-9572(92)90182-C; WEAVER WD, 1990, CIRCULATION, V82, P2027, DOI 10.1161/01.CIR.82.6.2027; 1991, NATIONAL HLTH SERVIC; 1993, HLTH NATION KEY AREA	36	59	59	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1091	1094		10.1136/bmj.310.6987.1091	http://dx.doi.org/10.1136/bmj.310.6987.1091			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742673	Green Published			2022-12-24	WOS:A1995QW61800012
J	FRASER, AM; BROCKERT, JE; WARD, RH				FRASER, AM; BROCKERT, JE; WARD, RH			ASSOCIATION OF YOUNG MATERNAL AGE WITH ADVERSE REPRODUCTIVE OUTCOMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-BIRTH-WEIGHT; TEENAGE PREGNANCY; PRENATAL-CARE; ADOLESCENT PREGNANCY; PRETERM DELIVERY; ADULT WOMEN; RISK; POPULATION; HEALTH; GROWTH	Background. Pregnancy in adolescence is associated with an excess risk of poor outcomes, including low birth weight and prematurity, Whether this association simply reflects the deleterious sociodemographic environment of most pregnant teenagers or whether biologic immaturity is also causally implicated is not known, Methods. To determine whether a young age confers an intrinsic risk of adverse outcomes of pregnancy, we performed stratified analyses of 134,088 white girls and women, 13 to 24 years old, in Utah who delivered singleton, first-born children between 1970 and 1990. Relative risk for subgroups of this study population was examined to eliminate the confounding influence of marital status, educational level, and the adequacy of prenatal care, The adjusted relative risk for the entire study group was calculated as the weighted average of the stratum-specific risks. Results. Among white married mothers with educational levels appropriate for their ages who received adequate prenatal care, younger teenage mothers (13 to 17 years of age) had a significantly higher risk (P<0.001) than mothers who were 20 to 24 years of age of delivering an infant who had low birth weight (relative risk, 1.7; 95 percent confidence interval, 1.5 to 2.0), who was delivered prematurely (relative risk, 1.9; 95 percent confidence interval, 1.7 to 2.1), or who was small for gestational age (relative risk, 1.3; 95 percent confidence interval, 1.2 to 1.4). Older teenage mothers (18 or 19 years of age) also had a significant increase in these risks, Even though sociodemographic variables associated with teenage pregnancy increase the risk of adverse outcomes, the relative risk remained significantly elevated for both younger and older teenage mothers after adjustment for marital status, level of education, and adequacy of prenatal care. Conclusions. In a study of mothers 13 to 24 years old who had the characteristics of most white, middle-class Americans, a younger age conferred an increased risk of adverse pregnancy outcomes that was independent of important confounding sociodemographic factors.	UNIV UTAH,ECCLES INST HUMAN GENET 2100,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UTAH DEPT HLTH,BUR VITAL RECORDS,SALT LAKE CITY,UT	Utah System of Higher Education; University of Utah					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023492] Funding Source: NIH RePORTER; NICHD NIH HHS [1R01 HD23492] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahmed F, 1990, J Community Health, V15, P35, DOI 10.1007/BF01350184; ANNIE E, 1992, KIDS COUNT DATA BOOK, P110; BROWN HL, 1991, SOUTHERN MED J, V84, P46, DOI 10.1097/00007611-199101000-00012; BUCHI KF, 1993, OBSTET GYNECOL, V81, P239; DAVID RJ, 1983, SOUTHERN MED J, V76, P1401, DOI 10.1097/00007611-198311000-00020; DIXON WJ, 1990, BMDP STATISTICAL SOF, V1, P231; DUNN PM, 1985, ACTA PAEDIATR SC   S, V319, P7; EISNER V, 1979, AM J PUBLIC HEALTH, V69, P887, DOI 10.2105/AJPH.69.9.887; ELSTER AB, 1984, AM J OBSTET GYNECOL, V149, P845, DOI 10.1016/0002-9378(84)90602-1; FRIEDE A, 1987, PUBLIC HEALTH REP, V102, P192; GALE R, 1989, J ADOLESCENT HEALTH, V10, P404, DOI 10.1016/0197-0070(89)90219-2; HAIEK L, 1989, J ADOLESCENT HEALTH, V10, P16, DOI 10.1016/0197-0070(89)90041-7; HEDIGER ML, 1989, OBSTET GYNECOL, V74, P6; HORON IL, 1983, AM J OBSTET GYNECOL, V146, P444, DOI 10.1016/0002-9378(83)90826-8; KETTERLINUS RD, 1990, J ADOLESCENT HEALTH, V11, P423, DOI 10.1016/0197-0070(90)90090-O; LEE KS, 1988, AM J OBSTET GYNECOL, V158, P84, DOI 10.1016/0002-9378(88)90783-1; MAKINSON C, 1985, FAM PLANN PERSPECT, V17, P132, DOI 10.2307/2135024; MCANARNEY ER, 1987, AM J DIS CHILD, V141, P1053, DOI 10.1001/archpedi.1987.04460100031017; Rothman K, 1986, MODERN EPIDEMIOLOGY; Scholl T O, 1989, Paediatr Perinat Epidemiol, V3, P357, DOI 10.1111/j.1365-3016.1989.tb00524.x; SCHOLL TO, 1988, LANCET, V1, P701, DOI 10.1016/S0140-6736(88)91494-8; SCHOLL TO, 1987, OBSTET GYNECOL, V69, P312; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; TRUSSELL J, 1988, FAM PLANN PERSPECT, V20, P262, DOI 10.2307/2135482; TURNER RJ, 1990, J HEALTH SOC BEHAV, V31, P43, DOI 10.2307/2137044; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203; 1993, EXECUTIVE SUMMARY MA; 1993, MMWR-MORBID MORTAL W, V42, P230; 1992, 162 UT STAT U DEP SO; 1993, MMWR-MORBID MORTAL W, V42, P255; [No title captured]; 1993, 167 UT STAT U DEP SO; 1993, MON VITAL STAT REP S, V42; 1991, STATISTICAL ABSTRACT, P63	34	609	642	0	46	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	1995	332	17					1113	1117		10.1056/NEJM199504273321701	http://dx.doi.org/10.1056/NEJM199504273321701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QU302	7700283				2022-12-24	WOS:A1995QU30200001
J	LUMB, KJ; KIM, PS				LUMB, KJ; KIM, PS			MEASUREMENT OF INTERHELICAL ELECTROSTATIC INTERACTIONS IN THE GCN4 LEUCINE-ZIPPER	SCIENCE			English	Article							X-RAY STRUCTURE; COILED-COIL; PROTEINS; STABILITY; DIMERIZATION; REGION; DNA; SPECTROSCOPY; TROPOMYOSIN; CONTRIBUTE	The dimerization specificity of the bZIP transcription factors resides in the leucine zipper region. It is commonly assumed that electrostatic interactions between oppositely charged amino acid residues on different helices of the leucine zipper contribute favorably to dimerization specificity. Crystal structures of the GCN4 leucine zipper contain interhelical salt bridges between Glu(20) and Lys(15') and between Glu(22) and Lys(27'). C-13-nuclear magnetic resonance measurements of the glutamic acid pK(a) values at physiological ionic strength indicate that the salt bridge involving Glu(22) does not contribute to stability and that the salt bridge involving Glu(20) is unfavorable, relative to the corresponding situation with a neutral (protonated) Glu residue, Moreover, the substitution of Glu(20) by glutamine is stabilizing. Thus, salt bridges will not necessarily contribute favorably to bZIP dimerization specificity and may indeed be unfavorable, relative to alternative neutral-charge interactions.	MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute				Lumb, Kevin/0000-0003-2778-9956	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044162] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BERGER B, IN PRESS P NATL ACAD; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN JS, 1970, NATURE, V228, P642, DOI 10.1038/228642a0; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ENGEL M, 1991, BIOCHEMISTRY-US, V30, P3161, DOI 10.1021/bi00227a002; Fersht A R, 1972, Cold Spring Harb Symp Quant Biol, V36, P71; GOODMAN EM, 1991, BIOCHEMISTRY-US, V30, P11615, DOI 10.1021/bi00114a002; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; Honig B., 1992, CURR OPIN STRUC BIOL, V2, P40; JOHN M, 1994, J BIOL CHEM, V269, P16247; Kirkwood JG, 1938, J CHEM PHYS, V6, P506, DOI 10.1063/1.1750302; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LETAI A, 1995, P NATL ACAD SCI USA, V92, P92, DOI 10.1073/pnas.92.1.92; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; LUMB KJ, UNPUB; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; NILGES M, 1991, PROTEIN ENG, V4, P649, DOI 10.1093/protein/4.6.649; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; OSHEA EK, 1992, CELL, V66, P699; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; SALI D, 1991, J MOL BIOL, V220, P779, DOI 10.1016/0022-2836(91)90117-O; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SHAKA AJ, 1983, J MAGN RESON, V53, P313, DOI 10.1016/0022-2364(83)90035-5; STONE D, 1975, PROTEINS CONTRACTILE, P125; TALBOT JA, 1982, ACCOUNTS CHEM RES, V15, P224, DOI 10.1021/ar00079a006; THOMPSON KS, 1993, BIOCHEMISTRY-US, V32, P5491, DOI 10.1021/bi00072a001; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	49	180	184	2	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					436	439		10.1126/science.7716550	http://dx.doi.org/10.1126/science.7716550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716550				2022-12-24	WOS:A1995QU57200046
J	SANGUINETTI, MC; JIANG, CG; CURRAN, ME; KEATING, MT				SANGUINETTI, MC; JIANG, CG; CURRAN, ME; KEATING, MT			A MECHANISTIC LINK BETWEEN AN INHERITED AND AN ACQUIRED CARDIAC-ARRHYTHMIA - HERG ENCODES THE I-KR POTASSIUM CHANNEL	CELL			English	Article							PIG VENTRICULAR MYOCYTES; III ANTIARRHYTHMIC AGENT; RECTIFIER K+-CURRENT; DELAYED RECTIFIER; CELLS; KINETICS; BLOCK; PROLONGATION; MODULATION; DOFETILIDE	Mutations in HERG cause an inherited cardiac arrhythmia, long QT syndrome (LQT), To define the function of HERG, we expressed the protein in Xenopus oocytes. The biophysical properties of expressed HERG are nearly identical to the rapidly activating delayed rectifier K+ current (I-Kr) in cardiac myocytes. HERG current is K+ selective, declines with depolarizations above 0 mV, is activated by extracellular K+, and is blocked by lanthanum. Interestingly, HERG current is not blocked by drugs that specifically block I-Kr in cardiac myocytes, These data indicate that HERG proteins form I-Kr channels, but that an additional subunit may be required for drug sensitivity. Since block of I-Kr is a known mechanism for drug-induced cardiac;arrhythmias, the finding that HERG encodes I-Kr channels provides a mechanistic link between certain forms of inherited and acquired LQT.	UNIV UTAH,HLTH SCI CTR,DIV CARDIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	SANGUINETTI, MC (corresponding author), UNIV UTAH,HLTH SCI CTR,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112, USA.		Sanguinetti, Michael/AAN-2615-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052338] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL48074, P50-HL 52338-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BALSER JR, 1990, J GEN PHYSIOL, V96, P835, DOI 10.1085/jgp.96.4.835; BLUMENTHAL EM, 1992, J NEUROSCI, V12, P290; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; CARMELIET E, 1992, J PHARMACOL EXP THER, V262, P809; CHINN K, 1993, J PHARMACOL EXP THER, V264, P553; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; CURRY P, 1976, LANCET, V2, P231; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FOLLMER CH, 1992, AM J PHYSIOL, V262, pC75, DOI 10.1152/ajpcell.1992.262.1.C75; GINTANT GA, 1992, HEART CARDIOVASCULAR, P1121; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; LYNCH JJ, 1994, J PHARMACOL EXP THER, V269, P541; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; ROSEN DM, 1988, CONTROL CARDIAC ARRH, P559; SANGUINETTI MC, 1991, CIRC RES, V68, P77, DOI 10.1161/01.RES.68.1.77; SANGUINETTI MC, 1992, PFLUG ARCH EUR J PHY, V420, P180, DOI 10.1007/BF00374988; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; SANGUINETTI MC, 1990, AM J PHYSIOL, V259, pH1881, DOI 10.1152/ajpheart.1990.259.6.H1881; SCAMPS F, 1989, AM J PHYSIOL, V257, pC1086, DOI 10.1152/ajpcell.1989.257.6.C1086; SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571; SURAWICZ B, 1989, J AM COLL CARDIOL, V14, P172, DOI 10.1016/0735-1097(89)90069-7; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; YANG T, 1994, CIRC RES, V75, P870, DOI 10.1161/01.RES.75.5.870	32	2002	2090	4	115	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					299	307		10.1016/0092-8674(95)90340-2	http://dx.doi.org/10.1016/0092-8674(95)90340-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736582	Bronze			2022-12-24	WOS:A1995QV41000019
J	DAS, G; HINKLEY, CS; HERR, W				DAS, G; HINKLEY, CS; HERR, W			BASAL PROMOTER ELEMENTS AS A SELECTIVE DETERMINANT OF TRANSCRIPTIONAL ACTIVATOR FUNCTION	NATURE			English	Article							RNA POLYMERASE-II; TRANS-ACTIVATOR; SNRNA PROMOTER; BINDING; DOMAINS; OCT-1; SPECIFICITY; EXPRESSION; ENHANCER; DISTINCT	IN eukaryotes, activation of transcription involves an interplay between activators bound to cis-regulatory elements and factors bound to basal elements near the start site of transcription. The basal elements, for example the TATA box or proximal sequence element (PSE) of small nuclear RNA (snRNA) promoters, nucleate the assembly of basal transcription complexes, components of which interact with activators(1,2). Although one basal transcription complex can interact with many activators, it is unclear whether different basal transcription complexes can direct different responses to particular activators. We show here that changing the arrangement of basal elements can alter the response to transcriptional activation domains. Indeed, in the human U6 snRNA promoter, point mutation of either a TATA box or PSE results in diametrically opposed responses to VP16- and Sp1-derived activation domains. These basal elements can even discriminate small changes in an activation domain. Thus the arrangement of basal promoter elements provides a mechanism for differential regulation of transcription.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Herr, Winship/E-6491-2012	Herr, Winship/0000-0002-3606-4546				BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAS G, 1993, J BIOL CHEM, V268, P25026; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TANAKA M, 1994, MOL CELL BIOL, V16, P6046; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3	30	105	111	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					657	660		10.1038/374657a0	http://dx.doi.org/10.1038/374657a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715708				2022-12-24	WOS:A1995QT18900064
J	GEISSLER, A; ANDUS, T; ROTH, M; KULLMANN, F; CAESAR, I; HELD, P; GROSS, V; FEUERBACH, S; SCHOLMERICH, J				GEISSLER, A; ANDUS, T; ROTH, M; KULLMANN, F; CAESAR, I; HELD, P; GROSS, V; FEUERBACH, S; SCHOLMERICH, J			FOCAL WHITE-MATTER LESIONS IN BRAIN OF PATIENTS WITH INFLAMMATORY BOWEL-DISEASE	LANCET			English	Note							CROHNS-DISEASE	Inflammatory bowel diseases are often associated with extra-intestinal manifestations, such as arthritis and iritis/uveitis. Using magnetic-resonance imaging we found hyperintense focal white-matter lesions in the brain in 20 of 48 (42%) patients with Crohn's disease, in 11 of 24 (46%) patients with ulcerative colitis, but in only 8 of 50 (16%) healthy age-matched controls (relative risk [95% CI] vs controls 2.6 [1.3-5.3] and 2.9 [1.3-6.2], respectively). These findings may represent another extra-intestinal manifestation of inflammatory bowel disease.	UNIV REGENSBURG,DEPT INTERNAL MED 1,D-93042 REGENSBURG,GERMANY; UNIV REGENSBURG,DEPT RADIOL,D-93042 REGENSBURG,GERMANY	University of Regensburg; University of Regensburg								ADAMEK RJ, 1993, LEBER MAGEN DARM, V23, P91; BELL CL, 1991, ARTHRITIS RHEUM, V34, P432, DOI 10.1002/art.1780340408; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; ERDEM E, 1993, NEURORADIOLOGY, V35, P142, DOI 10.1007/BF00593971; HORIKOSHI T, 1993, NEURORADIOLOGY, V35, P151, DOI 10.1007/BF00593975; ISHIKAWA O, 1994, J RHEUMATOL, V21, P87; MEGURO K, 1993, NEURORADIOLOGY, V35, P125, DOI 10.1007/BF00593968; MORRISSEY SP, 1993, BRAIN, V116, P135, DOI 10.1093/brain/116.1.135; RACHMILEWITZ D, 1989, BRIT MED J, V198, P82; WAKEFIELD AJ, 1989, LANCET, V2, P1057	10	96	99	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					897	898						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707814				2022-12-24	WOS:A1995QR06700013
J	RICHARD, I; BROUX, O; ALLAMAND, V; FOUGEROUSSE, F; CHIANNILKULCHAI, N; BOURG, N; BRENGUIER, L; DEVAUD, C; PASTURAUD, P; ROUDAUT, C; HILLAIRE, D; PASSOSBUENO, MR; ZATZ, M; TISCHFIELD, JA; FARDEAU, M; JACKSON, CE; COHEN, D; BECKMANN, JS				RICHARD, I; BROUX, O; ALLAMAND, V; FOUGEROUSSE, F; CHIANNILKULCHAI, N; BOURG, N; BRENGUIER, L; DEVAUD, C; PASTURAUD, P; ROUDAUT, C; HILLAIRE, D; PASSOSBUENO, MR; ZATZ, M; TISCHFIELD, JA; FARDEAU, M; JACKSON, CE; COHEN, D; BECKMANN, JS			MUTATIONS IN THE PROTEOLYTIC-ENZYME CALPAIN-3 CAUSE LIMB-GIRDLE MUSCULAR-DYSTROPHY TYPE-2A	CELL			English	Article							ACTIVATED NEUTRAL PROTEASE; CALCIUM-DEPENDENT PROTEASE; FUNCTIONAL IMPLICATIONS; BINDING PROTEINS; SEQUENCES; MUSCLE; GENE; TRANSCRIPTION; EXPRESSION; LINKAGE	Limb-girdle muscular dystrophies (LGMDs) are a group of inherited diseases whose genetic etiology has yet to be elucidated, The autosomal recessive forms (LGMD2) constitute a genetically heterogeneous group with LGMD2A mapping to chromosome 15q15.1-q21.1, The gene encoding the muscle-specific calcium-activated neutral protease 3 (CANP3) large subunit is located in this region. This cysteine protease belongs to the family of intracellular calpains, Fifteen nonsense, splice site, frameshift, or missense calpain mutations cosegregate with the disease in LGMD2A families, six of which were found within La Reunion island patients, A digenic inheritance model is proposed to account for the unexpected presence of multiple independent mutations in this small inbred population. Finally, these results demonstrate an enzymatic rather than a structural protein defect causing a muscular dystrophy, a defect that may have regulatory consequences, perhaps in signal transduction.	UNIV SAO PAULO, INST BIOCIENCIAS, DEPT BIOL, BR-05508900 SAO PAULO, BRAZIL; INDIANA UNIV, SCH MED, DEPT MED & MOLEC GENET, INDIANAPOLIS, IN 46202 USA; CNRS, UNITE A614, INSERM, F-75005 PARIS, FRANCE; HENRY FORD HOSP, DETROIT, MI 48202 USA; CTR ETUD POLYMORPHISME HUMAIN, FDN JEAN DAUSSET, F-75010 PARIS, FRANCE	Universidade de Sao Paulo; Indiana University System; Indiana University-Purdue University Indianapolis; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Henry Ford Health System; Henry Ford Hospital; Foundation Jean Dausset-CEPH	RICHARD, I (corresponding author), GENETHON, 1 RUE INT, F-91000 EVRY, FRANCE.		Beckmann, Jacques S/A-9772-2008; Allamand, Valérie/AAH-6272-2021; Zatz, Mayana/M-5338-2015; Richard, isabelle/J-8298-2013; Allamand, Valerie/M-4333-2017; Passos-Bueno, Maria Rita/I-6796-2016	Beckmann, Jacques S/0000-0002-9741-1900; Allamand, Valérie/0000-0001-8997-9742; Zatz, Mayana/0000-0003-3970-8025; Passos-Bueno, Maria Rita/0000-0002-9248-3008; Tischfield, Jay/0000-0003-3217-8287				ALLAMAND V, 1995, HUM MOL GENET, V4, P459, DOI 10.1093/hmg/4.3.459; ALLAMAND V, 1995, IN PRES AM J HUM GEN; BACH G, 1993, AM J HUM GENET, V53, P330; BASHIR R, 1994, HUM MOL GENET, V3, P455, DOI 10.1093/hmg/3.3.455; BECKMANN JS, 1991, CR ACAD SCI III-VIE, V312, P141; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Bushby K.M.D., 1994, DIAGNOSTIC CRITERIA, P25; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHIANNILKULCHAI N, 1995, IN PRESS HUM MOL GEN, V4; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; EMORI Y, 1986, FEBS LETT, V194, P249, DOI 10.1016/0014-5793(86)80094-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOUGEROUSSE F, 1994, HUM MOL GENET, V3, P285, DOI 10.1093/hmg/3.2.285; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HEINISCH U, 1995, AM J HUM GENET, V56, P51; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; IMAJOH S, 1986, J BIOCHEM-TOKYO, V100, P633, DOI 10.1093/oxfordjournals.jbchem.a121755; JACKSON CE, 1961, PEDIATRICS, V28, P77; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KEEN J, 1991, TRENDS GENET, V7, P5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MATSUMURA K, 1993, LANCET, V341, P521, DOI 10.1016/0140-6736(93)90279-P; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIYAMOTO S, 1994, NATL ACAD SCI US, V94, P12740; MURACHI T, 1989, BIOCHEM INT, V18, P263; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; OHNO S, 1989, CYTOGENET CELL GENET, V51, P1054; OPPENHEIM A, 1990, HUM GENET, V86, P175; PASSOSBUENO MR, 1993, J MED GENET, V30, P385, DOI 10.1136/jmg.30.5.385; RICHARD I, 1994, GENOMICS, V23, P619, DOI 10.1006/geno.1994.1550; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; RODIUS F, 1994, AM J HUM GENET, V54, P1050; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Sambrook J., 1989, MOL CLONING LAB MANU; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WALTON JN, 1954, BRAIN, V77, P169, DOI 10.1093/brain/77.2.169; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; YOUNG K, 1992, GENOMICS, V13, P1370, DOI 10.1016/0888-7543(92)90074-3	54	794	822	1	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 7	1995	81	1					27	40		10.1016/0092-8674(95)90368-2	http://dx.doi.org/10.1016/0092-8674(95)90368-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720071	Bronze			2022-12-24	WOS:A1995QR97000005
J	MAYER, B; JAUCH, KW; GUNTHERT, U; FIGDOR, CG; SCHILDBERG, FW; FUNKE, I; JOHNSON, JP				MAYER, B; JAUCH, KW; GUNTHERT, U; FIGDOR, CG; SCHILDBERG, FW; FUNKE, I; JOHNSON, JP			DE-NOVO EXPRESSION OF CD44 AND SURVIVAL IN GASTRIC-CANCER	LANCET			English	Article							LYMPHOCYTE HOMING RECEPTOR; GLYCOPROTEIN; CARCINOMA; MOLECULE; VARIANT; CELLS	We have examined the cell surface molecule CD44, which is attracting interest because of reports that isoforms are associated with metastasis. The prognostic value of CD44 expression has yet to be assessed for a solid tumour. Benign (59) and malignant (primary 61, metastatic 59) gastric tissues were examined with antibodies directed at epitopes common to known CD44 isoforms. Normal mucosa was CD44 negative. In atrophic gastritis and intestinal metaplasia expression was restricted to the epithelial cells of the basal glands and was positively correlated with an increased leucocyte infiltrate and with the expression of HLA DR by mucosal cells. These observations suggest a role for chronic inflammation in the induction of CD44 expression on benign mucosa. No such association was observed between inflammatory infiltrate and CD44 expression on gastric tumours. CD44 expression, observed in only 49% of primary tumours, was associated with distant metastases at time of diagnosis and, among 31 curatively resected patients, with tumour recurrence (p=0.0014) and increased mortality (p=0.001) during follow-up averaging 17 months. When we used an antibody directed against the CD44 variant exon 9v, we found a good correlation between the expression of total CD44 and of exon 9v containing isoforms, and 9v expression in primary tumours was significantly and positively associated with tumour recurrence and mortality.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS; UNIV MUNICH,INST IMMUNOL,D-81366 MUNICH,GERMANY	Netherlands Cancer Institute; University of Munich	MAYER, B (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT SURG,D-81366 MUNICH,GERMANY.		Figdor, Carl G/A-4232-2010	Figdor, Carl G/0000-0002-2366-9212				ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CAMP RL, 1991, J EXP MED, V173, P763, DOI 10.1084/jem.173.3.763; CREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160; DUARTE I, 1981, HUM PATHOL, V12, P237, DOI 10.1016/S0046-8177(81)80124-4; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUNTHERT U, IN PRESS CURR TOP MI; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1991, CANCER RES, V51, P5292; HORST E, 1990, LEUKEMIA, V4, P595; JACKSOND G, 1993, LANCET, V341, P252; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; MACKAY CR, 1988, IMMUNOLOGY, V65, P93; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MAYER B, 1993, CANCER RES, V53, P1690; PALS ST, 1989, J IMMUNOL, V143, P851; SCHMITZMOORMANN P, 1979, GASTRIC CANCER, P172; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; WAHAB ZA, 1985, INT J CANCER, V36, P677, DOI 10.1002/ijc.2910360610	22	229	245	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1019	1022		10.1016/0140-6736(93)92879-X	http://dx.doi.org/10.1016/0140-6736(93)92879-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	7692200	Green Submitted			2022-12-24	WOS:A1993MD06600010
J	BROCKE, S; GAUR, A; PIERCY, C; GAUTAM, A; GIJBELS, K; FATHMAN, CG; STEINMAN, L				BROCKE, S; GAUR, A; PIERCY, C; GAUTAM, A; GIJBELS, K; FATHMAN, CG; STEINMAN, L			INDUCTION OF RELAPSING PARALYSIS IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS BY BACTERIAL SUPERANTIGEN	NATURE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; STAPHYLOCOCCAL ENTEROTOXIN-B; MYELIN BASIC-PROTEIN; T-CELLS; MICE; ANERGY; INVIVO	THE role of infection in the pathogenesis of clinical relapses that occur in most autoimmune diseases, including multiple sclerosis, remains to be established1,2. Experimental autoimmune encephalomyelitis (EAE) serves as a model for multiple sclerosis, with episodes of relapsing paralysis3-9. In certain strains of mice, T-lymphocytes expressing the Vbeta8 T-cell receptor (TCR)6-8 engage the amino-terminal epitope Ac1-11 of myelin basic protein, leading to EAE. The bacterial superantigen staphylococcal enterotoxin B (SEB) activates Vbeta8-expressing T cells. Here we show that after immunization with Ac1-11, or after transfer of encephalitogenic T-cell lines or clones reactive to Ac1-11, SEB induces exacerbation or relapses of paralytic disease in mice that are in clinical remission following an initial episode of paralysis, and triggers paralysis in mice with subclinical disease. Tumour necrosis factor has a critical role in the mechanism underlying SEB-induced exacerbation of disease, because anti-tumour necrosis factor antibody given in vivo delays the onset of paralysis triggered by SEB. On reactivation of autoaggressive cells through their T-cell receptor, superantigens may induce clinical relapses of autoimmune disease.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305	Stanford University	BROCKE, S (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305, USA.			Steinman, Lawrence/0000-0002-2437-2250				ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALLEN I, 1991, MCALPINES MULTIPLE S; Alvord EC, 1984, EXPT ALLERGIC ENCEPH; BEHIKE MA, 1986, P NATL ACAD SCI USA, V83, P767; BELL RB, 1993, J IMMUNOL, V150, P4085; BROCKE S, 1991, INFECT IMMUN, V59, P4531, DOI 10.1128/IAI.59.12.4531-4539.1991; GAUR A, 1993, J IMMUNOL, V150, P3062; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; POSER CM, 1992, J NEUROL SCI, V107, P127, DOI 10.1016/0022-510X(92)90280-X; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; ROTT O, 1992, INT IMMUNOL, V4, P347, DOI 10.1093/intimm/4.3.347; SOOS JM, 1993, J NEUROIMMUNOL, V43, P39, DOI 10.1016/0165-5728(93)90073-8; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; ZAMVIL SS, 1988, J EXP MED, V167, P1586, DOI 10.1084/jem.167.5.1586; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	23	234	244	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					642	644		10.1038/365642a0	http://dx.doi.org/10.1038/365642a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	7692305				2022-12-24	WOS:A1993MB84600057
J	SHER, GD; GINDER, GD; LITTLE, J; YANG, SY; DOVER, GJ; OLIVIERI, NF				SHER, GD; GINDER, GD; LITTLE, J; YANG, SY; DOVER, GJ; OLIVIERI, NF			EXTENDED THERAPY WITH INTRAVENOUS ARGININE BUTYRATE IN PATIENTS WITH BETA-HEMOGLOBINOPATHIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SICKLE-CELL-ANEMIA; GLOBIN GENE-EXPRESSION; INCREASED FETAL HEMOGLOBIN; ADULT ERYTHROID-CELLS; HYDROXYUREA INDUCTION; DIABETIC MOTHERS; SODIUM-BUTYRATE; F PRODUCTION; DISEASE; 5-AZACYTIDINE	Background. Enhanced production of fetal hemoglobin lessens the severity of beta-thalassemia and sickle cell disease, Intravenous infusion of arginine butyrate can increase the number of reticulocytes containing fetal_hemoglobin in patients with these disorders, and it has induced a substantial increase in hemoglobin in one patient with thalassemia. We therefore tested the efficacy of this agent in patients with beta-hemoglobinopathies. Methods. We treated 10 patients with severe beta-thalassemia or sickle cell disease with arginine butyrate at an initial dose of 500 mg per kilogram of body weight per day (final dose, 2000 mg per kilogram per day), 6 days per week, for a mean (+/-SD) of 10+/-1.2 weeks (range, 9 to 13). A hematologic response was defined as an increase in the hemoglobin concentration of at least 2 g per deciliter in patients with thalassemia and as a twofold increase in fetal hemoglobin in patients with sickle cell disease. Results. There were increases in gamma-globin messenger RNA and in reticulocytes containing fetal hemoglobin, but no increases in hemoglobin, in the patients with thalassemia, A small, unsustained increase in fetal hemoglobin was observed in two patients with sickle cell disease, Drug toxicity was minimal at standard doses. One patient had a grand mat seizure after inadvertently receiving 2000 mg of arginine butyrate per kilogram over a period of six hours. Conclusions. Ten weeks of intravenous arginine butyrate did not produce a hematologic response in 10 patients with either severe beta-thalassemia or sickle cell disease.	HOSP SICK CHILDREN,HAEMOGLOBINOPATHY PROGRAM,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,TORONTO,ON,CANADA; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Minnesota System; University of Minnesota Twin Cities; Johns Hopkins University			Olivieri, Nancy/AAI-2250-2020		NIDDK NIH HHS [DK 29902] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029902, R01DK029902] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARD H, 1985, PEDIATRICS, V75, P1143; BRITTENHAM GM, 1985, BLOOD, V65, P183; CAO A, 1994, BLOOD REV, V8, P1, DOI 10.1016/0268-960X(94)90002-7; CHARACHE S, 1992, BLOOD, V79, P2555; CHARACHE S, 1987, BLOOD, V69, P109; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; Constantoulakis P, 1989, Prog Clin Biol Res, V316B, P351; CONSTANTOULAKIS P, 1991, BLOOD, V77, P1326; DESFORGES JF, 1993, NEW ENGL J MED, V329, P1038, DOI 10.1056/NEJM199309303291413; DESIMONE J, 1982, P NATL ACAD SCI-BIOL, V79, P4428, DOI 10.1073/pnas.79.14.4428; DOVER GJ, 1986, BLOOD, V67, P735; DOVER GJ, 1992, NEW ENGL J MED, V327, P569; DOVER GJ, 1994, BLOOD, V84, P339; DOVER GJ, 1978, BLOOD, V52, P664; DOVER GJ, 1992, SEMIN ONCOL, V19, P61; DOVER GJ, 1985, BLOOD, V66, P527; FIBACH E, 1993, BLOOD, V82, P2203, DOI 10.1182/blood.V82.7.2203.bloodjournal8272203; GINDER GD, 1984, P NATL ACAD SCI-BIOL, V81, P3954, DOI 10.1073/pnas.81.13.3954; GLAUBER JG, 1991, MOL CELL BIOL, V11, P4690, DOI 10.1128/MCB.11.9.4690; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; LETVIN NL, 1984, NEW ENGL J MED, V310, P869, DOI 10.1056/NEJM198404053101401; LEY TJ, 1983, BLOOD, V62, P370; LITTLE J, 1994, CLIN RES, V42, pA238; LITTLE JA, 1995, BLOOD, V85, P1712, DOI 10.1182/blood.V85.7.1712.bloodjournal8571712; MILLER BA, 1987, NEW ENGL J MED, V316, P244, DOI 10.1056/NEJM198701293160504; MILLER BA, 1986, BLOOD, V67, P104; NATHAN DG, 1990, ANN NY ACAD SCI, V612, P179; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; PACE B, 1994, BLOOD, V84, P4344, DOI 10.1182/blood.V84.12.4344.bloodjournal84124344; PAPAYANNOPOULOU T, 1984, SCIENCE, V224, P617, DOI 10.1126/science.6200940; PEMBREY ME, 1978, BRIT J HAEMATOL, V40, P415, DOI 10.1111/j.1365-2141.1978.tb05813.x; PERRINE RP, 1972, LANCET, V2, P1163; PERRINE SP, 1989, BLOOD, V74, P454; PERRINE SP, 1988, P NATL ACAD SCI USA, V85, P8540, DOI 10.1073/pnas.85.22.8540; PERRINE SP, 1987, BIOCHEM BIOPH RES CO, V148, P694, DOI 10.1016/0006-291X(87)90932-6; PERRINE SP, 1985, NEW ENGL J MED, V312, P334, DOI 10.1056/NEJM198502073120602; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172/JCI111464; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; RODGERS GP, 1992, SEMIN ONCOL, V19, P67; RODGERS GP, 1990, NEW ENGL J MED, V322, P1037, DOI 10.1056/NEJM199004123221504; VEITH R, 1985, NEW ENGL J MED, V313, P1571, DOI 10.1056/NEJM198512193132503; VICHINSKY EP, 1994, BLOOD, V83, P1124; WAYE JS, 1991, BLOOD, V77, P1100; WEATHERALL DJ, 1981, THALASSEMIA SYNDROME, P148; WOOD WG, 1980, BRIT J HAEMATOL, V45, P431, DOI 10.1111/j.1365-2141.1980.tb07163.x	47	133	143	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1606	1610		10.1056/NEJM199506153322404	http://dx.doi.org/10.1056/NEJM199506153322404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753139				2022-12-24	WOS:A1995RC19200004
J	GROTE, E; HAO, JC; BENNETT, MK; KELLY, RB				GROTE, E; HAO, JC; BENNETT, MK; KELLY, RB			A TARGETING SIGNAL IN VAMP REGULATING TRANSPORT TO SYNAPTIC VESICLES	CELL			English	Article							MEMBRANE-PROTEIN; RAT-BRAIN; SYNAPTOPHYSIN; FUSION; SYNAPTOBREVIN; GENES; BIOGENESIS; RECEPTORS; TETANUS; PATHWAY	VAMP is a synaptic vesicle membrane protein required for fusion. Synaptic vesicle targeting was measured for mutants of an epitope-tagged form of VAMP in transfected PC12 cells. A signal within a predicted amphipathic alpha helix is essential for targeting to synaptic vesicles. Cellubrevin, a nonneural VAMP homolog, contains this signal and is also targeted to synaptic vesicles. Amino acid substitutions within the synaptic vesicle targeting signal either enhance or inhibit sorting of VAMP to synaptic vesicles, but do not affect the ability of VAMP to form complexes with syntaxin and SNAP-25.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	GROTE, E (corresponding author), UNIV CALIF SAN FRANCISCO,HORMONE RES INST,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NIDDK NIH HHS [DK33937, DK09878] Funding Source: Medline; NIGMS NIH HHS [GM51313] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009878, R01DK033937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051313] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; HOLTZMAN E, 1971, SCIENCE, V173, P733, DOI 10.1126/science.173.3998.733; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JOHNSTON PA, 1990, J BIOL CHEM, V265, P8869; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MULLER SR, 1990, DNA CELL BIOL, V9, P221, DOI 10.1089/dna.1990.9.221; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TRIMBLE WS, 1993, J PHYSL, V87, P10; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WIEDENMANN B, 1988, FEBS LETT, V240, P71, DOI 10.1016/0014-5793(88)80342-9; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	36	139	139	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					581	589		10.1016/0092-8674(95)90079-9	http://dx.doi.org/10.1016/0092-8674(95)90079-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758112	Bronze			2022-12-24	WOS:A1995QZ71000015
J	GREENGOLD, MC				GREENGOLD, MC			SUDDEN-DEATH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1496	1496		10.1001/jama.273.19.1496	http://dx.doi.org/10.1001/jama.273.19.1496			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739074				2022-12-24	WOS:A1995QX41800030
J	FEANY, MB; QUINN, WG				FEANY, MB; QUINN, WG			A NEUROPEPTIDE GENE DEFINED BY THE DROSOPHILA MEMORY MUTANT AMNESIAC	SCIENCE			English	Article							STIMULATES ADENYLATE-CYCLASE; SUBSTANCE-P-LIKE; IMMUNOREACTIVE NEURONS; MOLECULAR-CLONING; INITIATION CODON; LEARNING MUTANT; CDNA CLONES; MELANOGASTER; RUTABAGA; DUNCE	Mutations in genes required for associative learning and memory in Drosophila exist, but isolation of the genes has been difficult because most are defined by a single, chemically induced allele. Here, a simplified genetic screen was used to identify candidate genes involved in learning and memory. Second site suppressors of the dunce (dnc) female sterility phenotype were isolated with the use of transposon mutagenesis. One suppressor mutation that was recovered mapped in the amnesiac (amn) gene. Cloning of the locus revealed that amn encodes a previously uncharacterized neuropeptide gene. Thus, with the cloning of amn, specific neuropeptides are implicated in the memory process.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	FEANY, MB (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,E25-618,CAMBRIDGE,MA 02139, USA.			Feany, Mel/0000-0003-0315-7970				ACEVESPINA EO, 1983, COLD SPRING HARB SYM, V48, P831, DOI 10.1101/SQB.1983.048.01.086; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELLEN HJ, 1987, DEV BIOL, V121, P432, DOI 10.1016/0012-1606(87)90180-1; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; BELLEN HJ, 1988, ROUX ARCH DEV BIOL, V197, P258, DOI 10.1007/BF00380019; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; DUDAI Y, 1984, NEUROSCI LETT, V47, P119, DOI 10.1016/0304-3940(84)90416-6; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; ENGLES WR, 1985, FOCUS, V8, P6; FEANY MB, 1990, P NATL ACAD SCI USA, V87, P2795, DOI 10.1073/pnas.87.7.2795; FEANY MB, UNPUB; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HAMILTON BA, 1991, NUCLEIC ACIDS RES, V19, P1951, DOI 10.1093/nar/19.8.1951; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HEINKOFF S, 1987, METHOD ENZYMOL, V154, P156; KIMURA C, 1990, BIOCHEM BIOPH RES CO, V166, P81, DOI 10.1016/0006-291X(90)91914-E; LEE CS, 1987, GENETICS, V116, P55; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; LUNDQUIST T, 1990, J COMP NEUROL, V294, P161, DOI 10.1002/cne.902940202; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; NASSEL DR, 1990, BRAIN RES, V507, P225, DOI 10.1016/0006-8993(90)90276-H; NICHOLS R, 1988, J BIOL CHEM, V263, P12167; OGI K, 1990, BIOCHEM BIOPH RES CO, V173, P1271, DOI 10.1016/S0006-291X(05)80924-6; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; QIU YH, 1991, J MOL BIOL, V222, P553, DOI 10.1016/0022-2836(91)90496-S; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; QUINN WG, 1979, NATURE, V277, P212, DOI 10.1038/277212a0; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUGIHARA H, 1990, J BIOL CHEM, V265, P21714; TULLY T, 1986, J NEUROGENET, V3, P33, DOI 10.3109/01677068609106893; TULLY T, 1990, COLD SH Q B, V55, P203; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZHONG Y, 1995, NEURON, V14, P527, DOI 10.1016/0896-6273(95)90309-7	39	227	232	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					869	873		10.1126/science.7754370	http://dx.doi.org/10.1126/science.7754370			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754370				2022-12-24	WOS:A1995QX85000037
J	FERNANDEZSALGUERO, P; PINEAU, T; HILBERT, DM; MCPHAIL, T; LEE, SST; KIMURA, S; NEBERT, DW; RUDIKOFF, S; WARD, JM; GONZALEZ, FJ				FERNANDEZSALGUERO, P; PINEAU, T; HILBERT, DM; MCPHAIL, T; LEE, SST; KIMURA, S; NEBERT, DW; RUDIKOFF, S; WARD, JM; GONZALEZ, FJ			IMMUNE-SYSTEM IMPAIRMENT AND HEPATIC-FIBROSIS IN MICE LACKING THE DIOXIN-BINDING AH RECEPTOR	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; GENETIC-DIFFERENCES; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; EXPRESSION; CLONING; CANCER; TOXICITY; LOCUS; CDNA	The aryl hydrocarbon (Ah) receptor (AHR) mediates many carcinogenic and teratogenic effects of environmentally toxic chemicals such as dioxin. An AHR-deficient (Ahr(-/-)) mouse line was constructed by homologous recombination in embryonic stem cells. Almost half of the mice died shortly after birth, whereas survivors reached maturity and were fertile. The Ahr(-/-) mice showed decreased accumulation of lymphocytes in the spleen and lymph nodes, but not in the thymus. The livers of Ahr(-/-) mice were reduced in size by 50 percent and showed bile duct fibrosis. Ahr(-/-) mice were also nonresponsive with regard to dioxin-mediated induction of genes encoding enzymes that catalyze the metabolism of foreign compounds, Thus, the AHR plays an important role in the development of the liver and the immune system.	NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892; NCI,GENET LAB,BETHESDA,MD 20892; NIMH,MOLEC GENET UNIT,BETHESDA,MD 20892; UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267; NCI,OFF LAB ANIM SCI,VET & TUMOR PATHOL SECT,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fernandez-Salguero, Pedro M./J-8437-2014	Fernandez-Salguero, Pedro M./0000-0003-2839-5027	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096, R01ES006811] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES06096, R01 ES06811] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTT BD, 1994, TOXICOL APPL PHARM, V126, P16, DOI 10.1006/taap.1994.1085; BERTAZZI PA, 1993, EPIDEMIOLOGY, V4, P398, DOI 10.1097/00001648-199309000-00004; BIRNBAUM LS, 1994, ENVIRON HEALTH PERSP, V102, P676, DOI 10.2307/3432197; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; DEVITO MJ, 1994, TOXICOL APPL PHARM, V124, P82, DOI 10.1006/taap.1994.1011; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; HAYASHI S, 1994, CARCINOGENESIS, V15, P801, DOI 10.1093/carcin/15.5.801; HILBERT DM, 1993, EUR J IMMUNOL, V23, P2412, DOI 10.1002/eji.1830231006; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUOSKONEN H, 1994, TOXICOL APPL PHARM, V124, P174; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; LI H, 1994, J BIOL CHEM, V269, P28098; LI W, 1994, ARCH BIOCHEM BIOPHYS, V315, P279, DOI 10.1006/abbi.1994.1501; LUCIER GW, 1993, ENVIRON HEALTH PERSP, V101, P36, DOI 10.2307/3431569; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MINERS JO, 1991, PHARMACOL THERAPEUT, V51, P347, DOI 10.1016/0163-7258(91)90065-T; NEBERT DW, 1991, PHARMACOGENETICS, V1, P68, DOI 10.1097/00008571-199111000-00003; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; NEBERT DW, 1989, CRIT REV TOXICOL, V20, P153, DOI 10.3109/10408448909017908; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; ROBERTSON RW, 1994, NUCLEIC ACIDS RES, V22, P1741, DOI 10.1093/nar/22.9.1741; SAVAS U, 1994, J BIOL CHEM, V269, P14905; SHEN ZY, 1994, DNA CELL BIOL, V13, P763, DOI 10.1089/dna.1994.13.763; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343	34	885	909	2	49	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					722	726		10.1126/science.7732381	http://dx.doi.org/10.1126/science.7732381			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732381				2022-12-24	WOS:A1995QW60300050
J	LOWE, J; STOCK, D; JAP, R; ZWICKL, P; BAUMEISTER, W; HUBER, R				LOWE, J; STOCK, D; JAP, R; ZWICKL, P; BAUMEISTER, W; HUBER, R			CRYSTAL-STRUCTURE OF THE 20S PROTEASOME FROM THE ARCHAEON T-ACIDOPHILUM AT 3.4-ANGSTROM RESOLUTION	SCIENCE			English	Article							MULTICATALYTIC PROTEINASE COMPLEXES; ATP-DEPENDENT PROTEASES; THERMOPLASMA-ACIDOPHILUM; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; MECHANISM; GENE; REFINEMENT; PEPTIDASE; FEATURES	The three-dimensional structure of the proteasome from the archaebacterium Thermoplasma acidophilum has been elucidated by x-ray crystallographic analysis by means of isomorphous replacement and cyclic averaging. The atomic model was built and refined to a crystallographic R factor of 22.1 percent. The 673-kilodalton protease complex consists of 14 copies of two different subunits, alpha and beta, forming a barrel-shaped structure of four stacked rings. The two inner rings consist of seven beta subunits each, and the two outer rings consist of seven alpha subunits each. A narrow channel controls access to the three inner compartments. The alpha(7) beta(7) beta(7) alpha(7) subunit assembly has 72-point group symmetry. The structures of the alpha and beta subunits are similar, consisting of a core of two antiparallel beta sheets that is flanked by alpha helices on both sides. The binding of a peptide aldehyde inhibitor marks the active site in the central cavity at the amino termini of the beta subunits and suggests a novel proteolytic mechanism.	MAX PLANCK INST BIOCHEM,STRUKT FORSCH ABT,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST BIOCHEM,STRUKT BIOL ABT,D-82152 MARTINSRIED,GERMANY	Max Planck Society; Max Planck Society			Löwe, Jan/X-6998-2019; Löwe, Jan/B-3882-2011	Lowe, Jan/0000-0002-5218-6615				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BROTHERS HM, 1990, BIOCHEMISTRY-US, V29, P7468, DOI 10.1021/bi00484a016; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; BRUENGER AT, 1992, XPLOR VERSION 3 1 SY; CHEN CCH, 1993, J MOL BIOL, V234, P165, DOI 10.1006/jmbi.1993.1571; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DAHLMANN B, 1992, EUR J BIOCHEM, V208, P789, DOI 10.1111/j.1432-1033.1992.tb17249.x; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DAUTER Z, 1990, ACTA CRYSTALLOGR B, V46, P833, DOI 10.1107/S0108768190008059; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20887; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DICK LR, 1994, J IMMUNOL, V152, P3884; DJABALLAH H, 1992, BIOCHEMISTRY-US, V31, P4133, DOI 10.1021/bi00131a033; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FAGAN JM, 1992, J BIOL CHEM, V267, P23015; FINKE RG, 1986, J AM CHEM SOC, V108, P2947, DOI 10.1021/ja00271a025; GHUYSEN JM, 1981, TOP MOL PHARM, V1, P63; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HEGERL R, 1991, FEBS LETT, V283, P117, DOI 10.1016/0014-5793(91)80567-M; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JAP B, 1983, J MOL BIOL, V234, P881; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KELLY JA, 1989, J MOL BIOL, V209, P281, DOI 10.1016/0022-2836(89)90277-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHN PJ, 1965, INORG CHEM, V4, P1482, DOI 10.1021/ic50032a028; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; LUPAS A, 1994, FEBS LETT, V354, P45, DOI 10.1016/0014-5793(94)01082-X; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2579; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Puehler Gabriela, 1994, Systematic and Applied Microbiology, V16, P734; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; RECHSTEINER M, 1993, J BIOL CHEM, V268, P60; RICHTERRUOFF B, 1993, FEBS LETT, V336, P34, DOI 10.1016/0014-5793(93)81603-W; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SEEMULLER E, 1995, FEBS LETT, V359, P173, DOI 10.1016/0014-5793(95)00036-9; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; STEIGEMANN W, 1991, CRYSTALLOGRAPHIC COM, V5; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TANAKA K, 1992, NEW BIOL, V4, P173; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; TURK D, 1992, THESIS TU MUNCHEN; WENZEL T, 1993, FEBS LETT, V326, P215, DOI 10.1016/0014-5793(93)81793-Y; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; ZWICKL P, 1990, J STRUCT BIOL, V103, P197, DOI 10.1016/1047-8477(90)90037-D; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004; 1979, CCP4 SERC4 DAR LAB S	68	1329	1355	1	56	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					533	539		10.1126/science.7725097	http://dx.doi.org/10.1126/science.7725097			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725097				2022-12-24	WOS:A1995QV40700028
J	HARRIS, JM; PARKER, AJ				HARRIS, JM; PARKER, AJ			INDEPENDENT NEURAL MECHANISMS FOR BRIGHT AND DARK INFORMATION IN BINOCULAR STEREOPSIS	NATURE			English	Article							SPATIAL-INTERVAL DISCRIMINATION; VISUAL-SYSTEM; EFFICIENCY; SEGREGATION; AFFERENTS; DISPARITY; CHANNELS; VISION; CORTEX	EARLY visual processing is organized into a number of independent channels. In the retina, increments and decrements of brightness are processed independently by different groups of neurons', For psychophysical measurements of human vision, independence can be tested statistically, Using this criterion in a depth judgement task, we show here that, for binocular stereo vision, increments and decrements are treated independently, at least as far as the level at which information from the left and right eyes is first combined, At later stages of stereo processing, the information from the two channels is no longer independent, Because the signals for stereo vision are first combined at the visual cortex, these results suggest that the neural 'on' and 'off' channels remain independent right up to early cortical stages, Theoretical studies of stereo vision have proposed that visual features in the views of the two eyes are matched on the basis of 'similarity'(2). Our results show that stereo matching treats features as statistically independent (and therefore dissimilar) if they appear perceptually bright and dark relative to the background, If features differ perceptually but only in the degree of brightness or darkness, human stereo vision treats them as similar.	SMITH KETTLEWELL EYE RES INST,SAN FRANCISCO,CA 94115	The Smith-Kettlewell Eye Research Institute	HARRIS, JM (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.		Parker, Andrew J/I-7867-2013	Parker, Andrew J/0000-0001-5800-0407; Harris, Julie/0000-0002-3497-4503	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER HH, 1981, 7TH P INT JOINT C AR, P631; BARLOW HB, 1979, VISION RES, V19, P783, DOI 10.1016/0042-6989(79)90154-8; BARLOW HB, 1978, VISION RES, V18, P637, DOI 10.1016/0042-6989(78)90143-8; BJORKLUND RA, 1981, PERCEPTION, V10, P511, DOI 10.1068/p100511; BURGESS A, 1983, VISION RES, V23, P811, DOI 10.1016/0042-6989(83)90204-3; BURTON GJ, 1977, BIOL CYBERN, V27, P189, DOI 10.1007/BF00344140; DEVALOIS KK, 1977, VISION RES, V17, P209, DOI 10.1016/0042-6989(77)90084-0; DOLAN RP, 1994, VISUAL NEUROSCI, V11, P23, DOI 10.1017/S095252380001107X; EDWARDS M, 1994, VISION RES, V34, P2849, DOI 10.1016/0042-6989(94)90054-X; HANLY M, 1979, EXP BRAIN RES, V35, P37; HARRIS JM, 1994, VISION RES, V34, P2761, DOI 10.1016/0042-6989(94)90231-3; HARRIS JM, 1992, J OPT SOC AM A, V1, P14; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; KAUFMAN L, 1969, PERCEPT PSYCHOPHYS, V6, P10, DOI 10.3758/BF03210666; LEVI DM, 1987, J OPT SOC AM A, V4, P1304, DOI 10.1364/JOSAA.4.001304; LEVI DM, 1990, VISION RES, V30, P1735, DOI 10.1016/0042-6989(90)90156-F; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; MARR D, 1976, SCIENCE, V194, P283, DOI 10.1126/science.968482; MCCONNELL SK, 1984, P NATL ACAD SCI-BIOL, V81, P1590, DOI 10.1073/pnas.81.5.1590; MORGAN MJ, 1991, VISION RES, V31, P2075, DOI 10.1016/0042-6989(91)90165-2; POLLARD SB, 1985, PERCEPTION, V14, P449, DOI 10.1068/p140449; SCHILLER PH, 1986, NATURE, V322, P824, DOI 10.1038/322824a0; SCHILLER PH, 1992, TRENDS NEUROSCI, V15, P86, DOI 10.1016/0166-2236(92)90017-3; WATT RJ, 1985, VISION RES, V25, P1661, DOI 10.1016/0042-6989(85)90138-5; ZAHS KR, 1988, J NEUROPHYSIOL, V59, P1410, DOI 10.1152/jn.1988.59.5.1410	25	36	36	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					808	811		10.1038/374808a0	http://dx.doi.org/10.1038/374808a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723825				2022-12-24	WOS:A1995QV31500046
J	OAKLEY, A; BENDELOW, G; BARNES, J; BUCHANAN, M; HUSAIN, OAN				OAKLEY, A; BENDELOW, G; BARNES, J; BUCHANAN, M; HUSAIN, OAN			HEALTH AND CANCER PREVENTION - KNOWLEDGE AND BELIEFS OF CHILDREN AND YOUNG-PEOPLE	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	Objective-To collect information from children and young people about their knowledge of and attitudes towards cancer and their understanding of health and health related behaviours to inform future health promotion work. Design-Questionnaire survey of 15-16 year olds, and interviews with play materials with 9-10 year old children. Setting-Six inner city, suburban, and rural schools. Subjects-226 children aged 15-16 years and 100 aged 9-10 years. Main outcome measures-Knowledge about different types of cancer; beliefs about health; sources of information; quality of research data obtainable from young children about cancer and health. Results-Both samples knew most about lung cancer, but there was also some knowledge of breast and skin cancer and leukaemia. Smoking, together with pollution and other environmental factors, were seen as the dominant causes of cancer. Environmental factors were mentioned more often by the inner city samples. Television and the media were the most important sources of information. Young people were more worried about unemployment than about ill health. More than half the young people did not describe their health as good, and most said they did not have a healthy lifestyle. Children were able to provide detailed information about their knowledge and understanding by using drawings as well as interviews. Conclusions-Children and young people possess considerable knowledge about cancer, especially about lung cancer and smoking, and show considerable awareness of predominant health education messages. Despite this knowledge, many lead less than healthy lifestyles. Health is not seen as the most important goal in life by many young people; the circumstances in which many children and young people live are not experienced as health promoting.	WOMENS NATIONWIDE CANC CONTROL CAMPAIGN,MED ADVISORY COMM,LONDON EC2A 3AR,ENGLAND		OAKLEY, A (corresponding author), UNIV LONDON,INST EDUC,SOCIAL SCI RES UNIT,LONDON WC1H 0NS,ENGLAND.		Bendelow, Gillian A/B-2943-2018	Bendelow, Gillian A/0000-0002-9293-5297				Backett K., 1991, HEALTH EDUC J, V50, P34, DOI [10.1177/001789699105000110, DOI 10.1177/001789699105000110]; BLAXTER M, 1983, SOC SCI MED, V17, P59, DOI 10.1016/0277-9536(83)90356-8; BRANNEN J, 1993, YOUNG PEOPLE HLTH FA; Calnan M., 1987, HLTH ILLNESS LAY PER; Cornwell J., 1985, HARD EARNED LIVES AC; HARDING G, 1989, 9 T COR RES UN OCC P; IVERSON DC, 1983, J SCHOOL HEALTH, V53, P294, DOI 10.1111/j.1746-1561.1983.tb05347.x; KALNINS I, 1992, HEALTH PROMOT INT, V7, P55; MAYALL B, 1993, SOCIOL HEALTH ILL, V15, P464; OAKLEY A, 1989, SOCIOL HEALTH ILL, V11, P311, DOI 10.1111/1467-9566.ep11372513; Qvortrup J., 1994, CHILDHOOD MATTERS SO, P1; Qvortrup Jens, 1993, CHILDHOOD SOCIAL PHE; SONTAG Susan, 1977, ILLNESS METAPHOR; TONES K, 1990, HLTH ED J, V49, P2; 1990, INCIDENCE UK MALES F	15	73	74	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1029	1033		10.1136/bmj.310.6986.1029	http://dx.doi.org/10.1136/bmj.310.6986.1029			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV313	7728055	Green Accepted, Green Published			2022-12-24	WOS:A1995QV31300014
J	UTSCHIG, LM; BRYSON, JW; OHALLORAN, TV				UTSCHIG, LM; BRYSON, JW; OHALLORAN, TV			HG-199 NMR OF THE METAL RECEPTOR-SITE IN MERR AND ITS PROTEIN-DNA COMPLEX	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SOLID-STATE HG-199; TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; METALLOREGULATORY PROTEIN; POPLAR PLASTOCYANIN; BIOSENSOR MERR; BINDING DOMAIN; THIOLATE; SPECTROSCOPY	Structural insights have been provided by mercury-199 nuclear magnetic resonance (NMR) into the metal receptor site of the MerR metalloregulatory protein alone and in a complex with the regulatory target, DNA, The one- and two-dimensional NMR data are consistent with a trigonal planar Hg-thiolate coordination environment consisting only of Cys side chains and resolve structural aspects of both metal ion recognition and the allosteric mechanism. These studies establish Hg-199 NMR techniques as useful probes of the metal coordination environment of regulatory proteins, copper enzymes, and zinc transcription factor complexes as large as 50 kilodaltons.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELLULAR BIOL, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA	Northwestern University; Northwestern University			O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NIGMS NIH HHS [GM-08061, GM-38784, R01 GM038784, GM-45972] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038784, R01GM038784, R01GM045972, R37GM038784] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1995, NATURE, V374, P371; ARMITAGE IM, 1976, J AM CHEM SOC, V98, P5710, DOI 10.1021/ja00434a058; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BERTINI I, 1994, BIOINORG CHEM, P43; BLAKE PR, 1994, NEW J CHEM, V18, P387; BRYSON JW, UNPUB; CARSON GK, 1982, INORG CHIM A-BIOINOR, V66, P157, DOI 10.1016/S0020-1693(00)85806-5; CHURCH WB, 1986, J BIOL CHEM, V261, P234; COLEMAN JE, 1993, METHOD ENZYMOL, V227, P16; ELLIS PD, 1983, SCIENCE, V221, P1141, DOI 10.1126/science.221.4616.1141; FALCHUK KH, 1977, CHEM MERCURY, P260; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; FREY MH, 1985, J AM CHEM SOC, V107, P6847, DOI 10.1021/ja00310a017; GARRETT TPJ, 1984, J BIOL CHEM, V259, P2822; GOVINDASWAMY N, 1992, INORG CHEM, V31, P5343, DOI 10.1021/ic00052a001; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; KUBICKI MM, 1981, J ORGANOMET CHEM, V219, P329, DOI 10.1016/S0022-328X(00)90018-4; Lippard S. J., 1994, PRINCIPLES BIOINORGA; LIVE DH, 1985, J AM CHEM SOC, V107, P3043, DOI 10.1021/ja00297a008; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MOORE JM, 1991, J MOL BIOL, V221, P533, DOI 10.1016/0022-2836(91)80071-2; NATAN MJ, 1990, J AM CHEM SOC, V112, P3255, DOI 10.1021/ja00164a080; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; OTVOS JD, 1985, J MAGN RESON, V61, P579, DOI 10.1016/0022-2364(85)90202-1; PARKHILL J, 1993, EMBO J, V12, P413, DOI 10.1002/j.1460-2075.1993.tb05673.x; RALSTON DM, 1990, P NATL ACAD SCI USA, V87, P3846, DOI 10.1073/pnas.87.10.3846; ROSS W, 1989, J BACTERIOL, V171, P4009, DOI 10.1128/jb.171.7.4009-4018.1989; SANTOS RA, 1991, J AM CHEM SOC, V113, P469, DOI 10.1021/ja00002a014; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SUDMEIER JL, 1977, J AM CHEM SOC, V99, P7732, DOI 10.1021/ja00465a067; SUMMERS MF, 1988, COORDIN CHEM REV, V86, P43, DOI 10.1016/0010-8545(88)85012-4; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; UTSCHIG LM, 1993, METHOD ENZYMOL, V226, P71, DOI 10.1016/0076-6879(93)26006-U; UTSCHIG LM, UNPUB; UTSCHIG LM, IN PRESS INORG CHEM; WATTON SP, 1990, J AM CHEM SOC, V112, P2824, DOI 10.1021/ja00163a067; Wrackmeyer B., 1992, ANN REP NMR SPECTROS, V24, P267, DOI [10.1016/S0066-4103(08)60200-8., DOI 10.1016/S0066-4103(08)60200-8]; WRIGHT JG, 1990, PROG INORG CHEM, V38, P323; WRIGHT JG, 1990, J AM CHEM SOC, V112, P2434, DOI 10.1021/ja00162a062	43	147	149	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	1995	268	5209					380	385		10.1126/science.7716541	http://dx.doi.org/10.1126/science.7716541			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716541				2022-12-24	WOS:A1995QU57200028
J	CHITTENDEN, T; HARRINGTON, EA; OCONNOR, R; FLEMINGTON, C; LUTZ, RJ; EVAN, GI; GUILD, BC				CHITTENDEN, T; HARRINGTON, EA; OCONNOR, R; FLEMINGTON, C; LUTZ, RJ; EVAN, GI; GUILD, BC			INDUCTION OF APOPTOSIS BY THE BCL-2 HOMOLOG BAK	NATURE			English	Article							PROGRAMMED CELL-DEATH; SEQUENCE SIMILARITY; GENE; PROTEINS	CELLS are eliminated in a variety of physiological settings by apoptosis, a genetically encoded process of cellular suicide(1,2). Apoptosis comprises an intrinsic cellular defence against tumorigenesis, which, when suppressed, may contribute to the development of malignancies(3). The bcl-2 oncogene, which is activated in follicular lymphomas, functions as a potent suppressor of apoptosis under diverse conditions(4). Here we describe the complementary DNA cloning and functional analysis of a new Bcl-2 homologue, Bak, which promotes cell death and counteracts the protection from apoptosis provided by Bcl-2. Moreover, enforced expression of Bak induces rapid and extensive apoptosis of serum-deprived fibroblasts. This raises the possibility that Bak is directly involved in activating the cell death machinery.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	CHITTENDEN, T (corresponding author), APOPTOSIS TECHNOL INC, 148 SIDNEY ST, CAMBRIDGE, MA 02139 USA.		O'Connor, Rosemary/B-7902-2014	O'Connor, Rosemary/0000-0002-0687-3422				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; ELLIS RE, 1991, REV CELL BIOL, V7, P663; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LIN EY, 1993, J IMMUNOL, V151, P1979; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	22	679	727	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	1995	374	6524					733	736		10.1038/374733a0	http://dx.doi.org/10.1038/374733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715730				2022-12-24	WOS:A1995QU30400053
J	BHATTI, N; LAW, MR; MORRIS, JK; HALLIDAY, R; MOOREGILLON, J				BHATTI, N; LAW, MR; MORRIS, JK; HALLIDAY, R; MOOREGILLON, J			INCREASING INCIDENCE OF TUBERCULOSIS IN ENGLAND AND WALES - A STUDY OF THE LIKELY CAUSES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine factors responsible for the recent increase in tuberculosis in England and Wales. Design-Study of the incidence of tuberculosis (a) in the 403 local authority districts in England and Wales, ranked according to Jarman score, and (b) in one deprived inner city district, according to ethnic origin and other factors. Setting-(a) England and Wales 1980-92, and (b) the London borough of Hackney 1986-93. Main outcome measure-Age and sex adjusted rate of tuberculosis. Results-In England and Wales notifications of tuberculosis increased by 12% between 1988 and 1992. The increase was 35% in the poorest 10th of the population and 13% in the next two; and in the remaining 70% there was no increase. In Hackney the increase affected traditionally high risk and low risk ethnic groups to a similar extent. In the ''low risk'' white and West Indian communities the incidence increased by 58% from 1986-8 (78 cases) to 1991-3 (123), whereas in residents of Indian subcontinent origin the increase was 41% (from 51 cases to 72). Tuberculosis in recently arrived immigrants-refugees (11% of the Hackney population) and Africans (6%)-accounted for less than half of the overall increase, and the proportion of such residents was much higher than in most socioeconomically deprived districts. The local increase was not due to an increase in the proportion of cases notified, to HIV infection, nor to an increase in homeless people. Conclusions-The national rise in tuberculosis affects only the poorest areas. Within one such area all residents (white and established ethnic minorities) were affected to a similar extent. The evidence indicates a major role for socioeconomic factors in the increase in tuberculosis and only a minor role for recent immigration from endemic areas.	ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1M 6BQ,ENGLAND; E LONDON & CITY DIST HLTH AUTHOR,DEPT PUBL HLTH,LONDON E3 2AN,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT RESP MED,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London				Morris, Joan/0000-0002-7164-612X				AWAIH J, 1992, HLTH CITY HACKNEY AN, P24; JACOBSON B, 1992, BRIT MED J, V305, P1344, DOI 10.1136/bmj.305.6865.1344; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; JENKINS SP, 1994, DISCUSSION PAPER SER, V9407; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; WATSON JM, 1993, BRIT MED J, V306, P221, DOI 10.1136/bmj.306.6872.221; WATSON JM, 1991, COMMUN DIS REP CDR R, V1, P13; 1994, HLTH STATISTICS 1992; 1994, COMMUNICABLE DISEASE	9	119	119	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					967	969		10.1136/bmj.310.6985.967	http://dx.doi.org/10.1136/bmj.310.6985.967			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728031	Green Published			2022-12-24	WOS:A1995QT90400018
J	GROVER, SA; LOWENSTEYN, I; ESREY, KL; STEINERT, Y; JOSEPH, L; ABRAHAMOWICZ, M				GROVER, SA; LOWENSTEYN, I; ESREY, KL; STEINERT, Y; JOSEPH, L; ABRAHAMOWICZ, M			DO DOCTORS ACCURATELY ASSESS CORONARY RISK IN THEIR PATIENTS - PRELIMINARY-RESULTS OF THE CORONARY HEALTH ASSESSMENT STUDY	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; COST-EFFECTIVENESS; LIFE EXPECTANCY; CHOLESTEROL; HYPERCHOLESTEROLEMIA; PHYSICIANS; PREVENTION; FRAMINGHAM; HYPERLIPIDEMIA; INTERNISTS	Objective-To evaluate the ability of doctors in primary care to assess risk patients) risk of coronary heart disease. Design-Questionnaire survey. Setting-Continuing medical education meetings, Ontario and Quebec, Canada. Subjects-Community based doctors who agreed to enrol in the coronary health assessment study. Main outcome measure-Ratings of coronary risk factors and estimates by doctors of relative and absolute coronary risk of two hypothetical patients and the ''average'' 40 year old Canadian man and 70 year old Canadian woman. Results-253 doctors answered the questionnaire. For 30 year olds the doctors rated cigarette smoking as the most important risk factor and raised serum triglyceride concentrations as the least important; for 70 year old patients they rated diabetes as the most important risk factor and raised serum triglyceride concentrations as the least important. They rated each individual risk factor as significantly less important for 70 year olds than for 30 year olds (all risk factors, P < 0.001). They showed a strong understanding of the relative importance of specific risk factors, and most were confident in their ability to estimate coronary risk. While doctors accurately estimated the relative risk of a specific patient (compared with the average adult) they systematically overestimated the absolute baseline risk of developing coronary disease and the risk reductions associated with specific interventions. Conclusions-Despite guidelines on targeting patients at high risk of coronary disease accurate assessment of coronary risk remains difficult for many doctors. Additional strategies must be developed to help doctors to assess better their patients' coronary risk.	SIR MORTIMER B DAVIS JEWISH HOSP,DEPT FAMILY MED,MONTREAL,PQ H3T 1E2,CANADA	McGill University	GROVER, SA (corresponding author), MONTREAL GEN HOSP,CTR ANAL COST EFFECT CARE,DIV CLIN EPIDEMIOL,MONTREAL,PQ H3G 1A4,CANADA.			Abrahamowicz, Michal/0000-0002-3172-3952				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; DEFRIESE GH, 1990, PREVENTING DISEASE R, P460; DUNNIGAN MG, 1993, BRIT MED J, V306, P1355, DOI 10.1136/bmj.306.6889.1355; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GROVER SA, 1992, JAMA-J AM MED ASSOC, V267, P816; GROVER SA, 1991, CAN MED ASSOC J, V144, P161; GROVER SA, 1994, ARCH INTERN MED, V154, P679, DOI 10.1001/archinte.154.6.679; GROVER SA, 1994, ARCH INTERN MED, V154, P1697, DOI 10.1001/archinte.154.15.1697; GROVER SA, 1993, CARDIOVASC DRUG THER, V7, P761, DOI 10.1007/BF00878927; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LANGNER NR, 1989, CAN MED ASSOC J, V141, P33; LAUPACIS A, 1990, CAN MED ASSOC J, V142, P329; LEAVERTON PE, 1987, J CHRON DIS, V40, P775, DOI 10.1016/0021-9681(87)90129-9; MANN KV, 1989, PREV MED, V18, P45, DOI 10.1016/0091-7435(89)90053-4; MCBRIDE PE, 1992, AM HEART J, V123, P817, DOI 10.1016/0002-8703(92)90535-4; NAYLOR CD, 1990, J CLIN EPIDEMIOL, V43, P1021; OLIVER MF, 1992, BMJ-BRIT MED J, V304, P393, DOI 10.1136/bmj.304.6824.393; OLIVER MF, 1993, CARDIOVASC DRUG THER, V7, P785, DOI 10.1007/BF00878931; OPIE LH, 1993, CARDIOVASC DRUG THER, V7, P779, DOI 10.1007/BF00878930; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; SCHWARTZ JS, 1991, ANN INTERN MED, V114, P46, DOI 10.7326/0003-4819-114-1-46; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; TANNENBAUM TN, 1990, CAN MED ASSOC J, V143, P875; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; [No title captured]; 1981, 82538 HLTH WELF CAN; 1993, CAN MED ASSOC J, V148, P521; 1987, LANCET, V1, P377; 1993, JAMA-J AM MED ASSOC, V269, P3015; [No title captured]	34	130	131	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					975	978		10.1136/bmj.310.6985.975	http://dx.doi.org/10.1136/bmj.310.6985.975			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728035	Green Published, Green Submitted			2022-12-24	WOS:A1995QT90400022
J	HENRY, RW; SADOWSKI, CL; KOBAYASHI, R; HERNANDEZ, N				HENRY, RW; SADOWSKI, CL; KOBAYASHI, R; HERNANDEZ, N			A TBP-TAF COMPLEX REQUIRED FOR TRANSCRIPTION OF HUMAN SNRNA GENES BY RNA-POLYMERASE-II AND RNA-POLYMERASE-III	NATURE			English	Article							TATA-BINDING PROTEIN; FACTOR-TFIIIB	THE TATA-box-binding protein TBP exists in the cell complexed with different sets of TBP-associated factors (TAFs)(1). In general, each of these TBP-TAP complexes is dedicated to transcription by a single RNA polymerase. Thus, SL1, TFIID and TFIIIB are required for transcription by polymerases I, II and III, respectively(2-10). Here we characterize a fourth TBP-TAF complex called SNAPc(11). Unlike the other TBP-TAF complexes, SNAPc is implicated in transcription by two types of polymerases; it is required for transcription of both the RNA polymerase II and III small-nuclear RNA genes and binds specifically to the proximal sequence element PSE, a non-TATA-box basal promoter element common to these two types of genes(11-13). In addition to TBP, SNAPc is composed of at least three TAFs, SNAP43, SNAP45 and SNAP50. The predicted amino-acid sequence of SNAP43 reveals that it corresponds to a new protein.	SUNY STONY BROOK, DEPT PHARMACOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	HENRY, RW (corresponding author), COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, POB 100, COLD SPRING HARBOR, NY 11724 USA.			Hernandez, Nouria/0000-0003-1465-4585				COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	16	126	127	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 13	1995	374	6523					653	656		10.1038/374653a0	http://dx.doi.org/10.1038/374653a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715707				2022-12-24	WOS:A1995QT18900063
J	WELSH, JP; LANG, EJ; SUGIHARA, I; LLINAS, R				WELSH, JP; LANG, EJ; SUGIHARA, I; LLINAS, R			DYNAMIC ORGANIZATION OF MOTOR CONTROL WITHIN THE OLIVOCEREBELLAR SYSTEM	NATURE			English	Article							INFERIOR OLIVARY NEURONS; CEREBELLAR; RAT; INVITRO; NUCLEUS; CAT	WHAT is the role of the cerebellum in motor coordination? Such coordination depends upon the integrity of the inferior olive, a major cerebellar afferent, as its lesion produces ataxic and dysmetric movement abnormalities(1,2). Using multiple-microelectrode recordings, we report here that there are domains of Purkinje cell activity that are generated by olivary input during skilled tongue movements in rats, Such activity domains are highly rhythmic and time-locked to movement, Patterns of synchronous olivocerebellar activity are geometrically complex and can change during a sequence of movements. The results support the view that the inferior olive organizes movement in time, by entraining motor-neuronal firing through rhythmic activation of the cerebellum, and in space, by synchronously activating cell ensembles that allow the use of individual muscles. Dynamic repatterning of olivocerebellar synchrony may allow different combinations of muscles to be used for movements intended to have varying spatial structures.			WELSH, JP (corresponding author), NYU,MED CTR,DEPT PHYSIOL & NEUROSCI,550 1ST AVE,NEW YORK,NY 10016, USA.		Lang, Eric J/A-1136-2017	Lang, Eric J/0000-0002-8524-9854				BOX GEP, 1994, TIME SERIES ANAL; Brooks VB, 1981, HDB PHYSL NERVOUS SY, V2, P877; BUISSERETDELMAS C, 1993, PROG NEUROBIOL, V40, P63, DOI 10.1016/0301-0082(93)90048-W; CICERATA F, 1992, EXPL BRAIN RES, V89, P352; DESCLIN JC, 1974, BRAIN RES, V77, P365, DOI 10.1016/0006-8993(74)90628-3; DEZEEUW CI, 1989, J COMP NEUROL, V284, P12, DOI 10.1002/cne.902840103; ECCLES JC, 1966, J PHYSIOL-LONDON, V182, P268, DOI 10.1113/jphysiol.1966.sp007824; GERSTEIN GL, 1960, BIOPHYS J, V1, P15, DOI 10.1016/S0006-3495(60)86872-5; KEEHN JD, 1960, SCIENCE, V132, P739, DOI 10.1126/science.132.3429.739; KING JS, 1976, J COMP NEUROL, V165, P387, DOI 10.1002/cne.901650307; LANG E I, 1990, Society for Neuroscience Abstracts, V16, P894; Larsell O., 1970, COMP ANATOMY HISTOLO; LLINAS R, 1989, EUR J NEUROSCI, V1, P587, DOI 10.1111/j.1460-9568.1989.tb00365.x; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P549, DOI 10.1113/jphysiol.1981.sp013763; LLINAS R, 1986, J PHYSIOL-LONDON, V376, P163, DOI 10.1113/jphysiol.1986.sp016147; LLINAS R, 1991, MOTOR CONTROL CONCEP, P223; MURPHY MG, 1971, ARCH NEUROL-CHICAGO, V24, P145, DOI 10.1001/archneur.1971.00480320073007; SASAKI K, 1989, EUR J NEUROSCI, V1, P572, DOI 10.1111/j.1460-9568.1989.tb00364.x; SOTELO C, 1974, J NEUROPHYSIOL, V37, P541, DOI 10.1152/jn.1974.37.3.541; SOTELO C, 1986, J COMP NEUROL, V252, P32, DOI 10.1002/cne.902520103; SUGIHARA I, 1993, J PHYSIOL-LONDON, V470, P243, DOI 10.1113/jphysiol.1993.sp019857; VALLBO AB, 1993, J PHYSIOL-LONDON, V469, P673, DOI 10.1113/jphysiol.1993.sp019837; WILSON WC, 1945, J COMP NEUROL, V83, P69, DOI 10.1002/cne.900830104; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; ZIEGLER HP, 1991, THIRST PHYSL PSYCHOL, P241	25	500	504	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					453	457		10.1038/374453a0	http://dx.doi.org/10.1038/374453a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700354				2022-12-24	WOS:A1995QP89900058
J	MARSH, GN; DAWES, ML				MARSH, GN; DAWES, ML			ESTABLISHING A MINOR ILLNESS NURSE IN A BUSY GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To study the feasibility of a practice nurse caring for patients with minor illnesses. Design-Nurse given training in dealing with patients with minor illnesses. Patients requesting a same day appointment were offered a nurse consultation. Setting-Group practice in Stockton on Tees. Main outcome measures-Number of consultations which required a doctor contact, treatment, and rate of reconsultation. Results-Of 696 consultations in six months, 602 (86%) required no doctor contact. 549 (79%) patients did not reconsult about that episode of illness, and 343 (50%) patients were given advice on self care only. Conclusion-Trained nurses could diagnose and treat a large proportion of patients currently consulting general practitioners about minor illness provided that the nurse has immediate access to a doctor.			MARSH, GN (corresponding author), NORTON MED CTR,STOCKTON ON TEES TS20 1AN,CLEVELAND,ENGLAND.			Dawes, Martin/0000-0003-3624-2477				ATKIN K, 1993, NURSES COUNT NATIONA; BARNES G, 1985, J ROY COLL GEN PRACT, V35, P447; BOWLING A, 1988, NURSE FAMILY PRACTIC; CHAN CA, 1994, BR J GEN PRACT, V44, P263; JEWELL D, 1988, PRACTITIONER, V232, P484; JEWELL D, 1994, BRIT MED J, V308, P735, DOI 10.1136/bmj.308.6931.735; MARSH GN, 1991, EFFICIENT CARE GENER; READ SM, 1992, BRIT MED J, V305, P1466, DOI 10.1136/bmj.305.6867.1466; ROSS FM, 1994, BRIT J GEN PRACT, V44, P15; WAINE C, 1992, DIABETES GENERAL PRA; 1994, STATISTICAL B, V4	11	42	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					778	780		10.1136/bmj.310.6982.778	http://dx.doi.org/10.1136/bmj.310.6982.778			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711584	Green Published			2022-12-24	WOS:A1995QP60900021
J	HOHMANN, AW; BOOTH, K; PETERS, V; GORDON, DL; COMACCHIO, RM				HOHMANN, AW; BOOTH, K; PETERS, V; GORDON, DL; COMACCHIO, RM			COMMON EPITOPE ON HIV P24 AND HUMAN PLATELETS	LANCET			English	Note							IMMUNE THROMBOCYTOPENIC PURPURA; HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; GLYCOPROTEINS; DISEASE	Mimicry of human antigen by HIV may underlie the autoreactivity seen in AIDS. A mouse monoclonal antibody (VIC8) raised against HIV p24 cross-reacted with human platelets; binding could be abolished by recombinant p24 antigen. VIC8 bound less well to platelets from patients with HIV than to those from healthy individuals. In the HIV group, binding was not related to p24 antigenaemia, disease stage, or platelet counts. This cross-reactivity is another example of antigenic mimicry by HIV and may be mechanistically important in HIV-associated autoimmune-like thrombocytopenia.	FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT CLIN IMMUNOL,BEDFORD PK,SA 5042,AUSTRALIA; FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT MICROBIOL & INFECT DIS,BEDFORD PK,SA 5042,AUSTRALIA	Flinders University South Australia; Flinders University South Australia				Gordon, David/0000-0003-3276-9685				BALLEM PJ, 1992, NEW ENGL J MED, V327, P1779, DOI 10.1056/NEJM199212173272503; BETTAIEB A, 1992, BLOOD, V80, P162; DEKEYSER F, 1992, CLIN IMMUNOL IMMUNOP, V62, P285, DOI 10.1016/0090-1229(92)90104-V; LOUACHE F, 1991, BLOOD, V78, P1697; MORROW WJW, 1991, CLIN IMMUNOL IMMUNOP, V58, P163, DOI 10.1016/0090-1229(91)90134-V; QUADRI MI, 1992, CLIN LAB HAEMATOL, V14, P109; STRICKER RB, 1991, HEMATOL ONCOL CLIN N, V5, P249, DOI 10.1016/S0889-8588(18)30439-8; ZAULI G, 1991, AIDS, V5, P1345, DOI 10.1097/00002030-199111000-00010	8	36	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1274	1275		10.1016/0140-6736(93)92363-X	http://dx.doi.org/10.1016/0140-6736(93)92363-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7694021				2022-12-24	WOS:A1993MH56600013
J	CHILLON, M; CASALS, T; MERCIER, B; BASSAS, L; LISSENS, W; SILBER, S; ROMEY, MC; RUIZROMERO, J; VERLINGUE, C; CLAUSTRES, M; NUNES, V; FEREC, C; ESTIVILL, X				CHILLON, M; CASALS, T; MERCIER, B; BASSAS, L; LISSENS, W; SILBER, S; ROMEY, MC; RUIZROMERO, J; VERLINGUE, C; CLAUSTRES, M; NUNES, V; FEREC, C; ESTIVILL, X			MUTATIONS IN THE CYSTIC-FIBROSIS GENE IN PATIENTS WITH CONGENITAL ABSENCE OF THE VAS-DEFERENS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REGULATOR CFTR GENE; MESSENGER-RNA TRANSCRIPTS; HUMAN FETAL TISSUES; BILATERAL ABSENCE; CONDUCTANCE; EXPRESSION; IDENTIFICATION; DNA; FORM; MEN	Background. Congenital bilateral absence of the vas deferens (CBAVD) is a form of male infertility in which mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have been identified. The molecular basis of CBAVD is not completely understood. Although patients with cystic fibrosis have mutations in both copies of the CFTR gene, most patients with CBAVD have mutations in only one copy of the gene. Methods. To investigate CBAVD at the molecular level, we have characterized the mutations in the CFTR gene in 102 patients with this condition. None had clinical manifestations of cystic fibrosis. We also analyzed a DNA variant (the 5T allele) in a noncoding region of CFTR that causes reduced levels of the normal CFTR protein. Parents of patients with cystic fibrosis, patients with types of infertility other than CBAVD, and normal subjects were studied as controls. Results. Nineteen of the 102 patients with CBAVD had mutations in both copies of the CFTR gene, and none of them had the 5T allele. Fifty-four patients had a mutation in one copy of CFTR, and 34 of them (63 percent) had the 5T allele in the other CFTR gene. In 29 patients no CFTR mutations were found, but 7 of them (24 percent) had the 5T allele. In contrast, the frequency of this allele in the general population was about 5 percent. Conclusions. Most patients with CBAVD have mutations in the CFTR gene. The combination of the 5T allele in one copy of the CFTR gene with a cystic fibrosis mutation in the other copy is the most common cause of CBAVD. The 5T allele mutation has a wide range of clinical presentations, occurring in patients with CBAVD or moderate forms of cystic fibrosis and in fertile men.	HOSP DURAN & REYNALS, CANC RES INST, DEPT MOLEC GENET, E-08907 LHOSPITALET DE LLOBREGAT, SPAIN; UNIV HOSP BREST, INST BIOGENET, BREST, FRANCE; FDN PUIGVERT, INST UROL NEPHROL MED GENET, DEPT ANDROL, BARCELONA, SPAIN; ST LUKES HOSP, DEPT UROL & MICROSURG, ST LOUIS, MO USA; FREE UNIV BRUSSELS, DEPT MED GENET, BRUSSELS, BELGIUM; INST BIOL, BIOCHIM GENET LAB, MONTPELLIER, FRANCE; HOSP CLIN BARCELONA, GENET SERV, BARCELONA, SPAIN	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; CHU Brest; Universite de Bretagne Occidentale; Fundacio Puigvert; Saint Luke's Hospital - Missouri; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Barcelona; Hospital Clinic de Barcelona			Nunes, Virginia/AAD-1014-2019; Ferec, Claude/ABG-9699-2020; Lissens, Willy/B-2892-2013; ROMEY-CHATELAIN, Marie-Catherine/A-9623-2008; Estivill, Xavier/A-3125-2013; Chillon, Miguel/A-2466-2009	Nunes, Virginia/0000-0002-5747-9310; Ferec, Claude/0000-0002-2325-0710; Lissens, Willy/0000-0003-3875-9955; Estivill, Xavier/0000-0002-0723-2256; Chillon, Miguel/0000-0003-0840-2111				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; AUDREZET MP, 1993, HUM MOL GENET, V2, P51, DOI 10.1093/hmg/2.1.51; AUDREZET MP, 1993, HUM MOL GENET, V2, P496, DOI 10.1093/hmg/2.4.496-a; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; BREMER S, 1992, EUR J BIOCHEM, V206, P137, DOI 10.1111/j.1432-1033.1992.tb16911.x; CASALS T, 1995, HUM GENET, V95, P205; CHILLON M, 1994, HUM GENET, V93, P447; CHILLON M, 1995, AM J HUM GENET, V56, P623; CHILLON M, 1994, HUM MUTAT, V3, P223, DOI 10.1002/humu.1380030308; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; CULARD JF, 1994, HUM GENET, V93, P467; CUPPENS H, 1994, HUM MOL GENET, V3, P607, DOI 10.1093/hmg/3.4.607; DELANEY SJ, 1993, NAT GENET, V4, P426, DOI 10.1038/ng0893-426; DORK T, 1994, HUM GENET, V93, P67; DUMUR V, 1990, LANCET, V336, P512, DOI 10.1016/0140-6736(90)92066-Q; Fleiss JL, 1981, STAT METHODS RATES P; GERVAIS R, 1993, NEW ENGL J MED, V328, P446, DOI 10.1056/NEJM199302113280619; HAMOSH A, 1993, NEW ENGL J MED, V329, P1308; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; JEQUIER AM, 1985, J ANDROL, V6, P15; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; MERCIER B, 1995, AM J HUM GENET, V56, P272; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; OSBORNE LR, 1993, HUM MOL GENET, V2, P1605, DOI 10.1093/hmg/2.10.1605; OSBORNE LR, 1993, HUM MOL GENET, V2, P1990; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; SLOMSKI R, 1992, HUM GENET, V89, P615; STRONG TV, 1993, HUM MOL GENET, V2, P225, DOI 10.1093/hmg/2.3.225; TIZZANO EF, 1993, HUM MOL GENET, V2, P219, DOI 10.1093/hmg/2.3.219; TREZISE AEO, 1993, HUM MOL GENET, V2, P213, DOI 10.1093/hmg/2.3.213; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	36	718	743	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1475	1480		10.1056/NEJM199506013322204	http://dx.doi.org/10.1056/NEJM199506013322204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739684	Green Published			2022-12-24	WOS:A1995RA14000004
J	LOPEZLOPEZ, JR; SHACKLOCK, PS; BALKE, CW; WIER, WG				LOPEZLOPEZ, JR; SHACKLOCK, PS; BALKE, CW; WIER, WG			LOCAL CALCIUM TRANSIENTS TRIGGERED BY SINGLE L-TYPE CALCIUM-CHANNEL CURRENTS IN CARDIAC-CELLS	SCIENCE			English	Article							PIG VENTRICULAR MYOCYTES; SARCOPLASMIC-RETICULUM; INDUCED RELEASE; CA2+ RELEASE; HEART-CELLS; CONTRACTION; MUSCLE; DEPENDENCE; EXCHANGE; CA-2+	Excitation-contraction coupling was studied in mammalian cardiac cells in which the opening probability of L-type calcium (Ca2+) channels was reduced. Confocal microscopy during voltage-clamp depolarization revealed distinct local transients in the concentration of intracellular calcium ions ([Ca2+](i)). When voltage was varied, the latency to occurrence and the relative probability of occurrence of local [Ca2+](i) transients varied as predicted if Ca2+ release from the sarcoplasmic reticulum (SR) was linked tightly to Ca2+ flux through L-type Ca2+ channels but not to that through the Na-Ca exchanger or to average [Ca2+](i). Voltage had no effect on the amplitude of local [Ca2+](i) transients. Thus, the most efficacious ''Ca2+ signal'' for activating Ca2+ release from the SR may be a transient microdomain of high [Ca2+](i) beneath an individual, open L-type Ca2+ channel.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT MED,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			López, José Ramón López/A-5541-2009; Wier, Withrow/AAE-2451-2020	López, José Ramón López/0000-0002-3870-421X; 	NHLBI NIH HHS [HL50435, HL29473, HL02466] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050435, R01HL029473] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARCENASRUIZ L, 1987, CIRC RES, V61, P148, DOI 10.1161/01.RES.61.1.148; BERS DM, 1991, EXCITATION CONTRACTI; BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; BEUCKELMANN DJ, 1988, J PHYSIOL-LONDON, V405, P233, DOI 10.1113/jphysiol.1988.sp017331; BOUCHARD RA, 1993, J PHYSIOL-LONDON, V472, P391, DOI 10.1113/jphysiol.1993.sp019953; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CARMELIET E, 1986, J PHYSIOL-LONDON, V376, P143, DOI 10.1113/jphysiol.1986.sp016146; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; DUBELL WH, 1989, AM J PHYSIOL, V257, pH746, DOI 10.1152/ajpheart.1989.257.3.H746; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; GYORKE S, 1993, AM J PHYSIOL, V264, pC1505, DOI 10.1152/ajpcell.1993.264.6.C1505; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; ISENBERG G, 1994, J PHYSIOL-LONDON, V480, P423, DOI 10.1113/jphysiol.1994.sp020372; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LEVI AJ, 1994, AM J PHYSIOL, V266, pH1422, DOI 10.1152/ajpheart.1994.266.4.H1422; LIPP P, 1994, J PHYSIOL-LONDON, V474, P439, DOI 10.1113/jphysiol.1994.sp020035; LOPEZLOPEZ JA, UNPUB; LOPEZLOPEZ JR, 1994, J PHYSIOL-LONDON, V480, P21, DOI 10.1113/jphysiol.1994.sp020337; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; PELZER D, 1984, INSERM, V124, P415; RIOS E, 1994, BIOPHYS J, V67, P7, DOI 10.1016/S0006-3495(94)80451-5; ROSE WC, 1992, J PHYSIOL-LONDON, V456, P267, DOI 10.1113/jphysiol.1992.sp019336; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; SHAM JSK, 1992, SCIENCE, V255, P850, DOI 10.1126/science.1311127; SIPIDO KR, 1991, J PHYSIOL-LONDON, V435, P605, DOI 10.1113/jphysiol.1991.sp018528; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; VARRO A, 1993, PFLUG ARCH EUR J PHY, V423, P158, DOI 10.1007/BF00374975; WIER WG, 1980, SCIENCE, V207, P1085, DOI 10.1126/science.7355274; WIER WG, 1994, J PHYSIOL-LONDON, V474, P463, DOI 10.1113/jphysiol.1994.sp020037; WIER WG, 1993, BIOPHYS J, V65, P2270, DOI 10.1016/S0006-3495(93)81287-6; YASUI K, 1994, BIOPHYS J, V67, P457, DOI 10.1016/S0006-3495(94)80501-6	35	416	424	0	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1042	1045						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754383				2022-12-24	WOS:A1995QY93400039
J	EMANUEL, L				EMANUEL, L			THE PRIVILEGE AND THE PAIN	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											EMANUEL, L (corresponding author), HARVARD UNIV, SCH MED, DIV MED ETH, 641 HUNTINGTON AVE, BOSTON, MA 02115 USA.								0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					797	798		10.7326/0003-4819-122-10-199505150-00012	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717605				2022-12-24	WOS:A1995QX14700012
J	HOOPER, DC				HOOPER, DC			FROM FLUOROQUINOLONES TO 2-PYRIDONES	LANCET			English	Editorial Material							NALIDIXIC-ACID; DNA GYRASE				HOOPER, DC (corresponding author), MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114, USA.							ALDER JD, 1994, 34TH INT C ANT AG CH; CHIN NX, 1994, 34TH INT C ANT AG CH; CHU DTW, 1994, 34TH INT C ANT AG CH; ELIOPOULOS GM, 1994, 34TH INT C ANT AG CH; FLAMM RK, 1994, 34TH INT C ANT AG CH; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Hooper David C., 1993, P53; Hooper David C., 1993, P489; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; LESHER GY, 1962, J MED PHARMACEUT CH, V5, P1063, DOI 10.1021/jm01240a021; MEULBROEK JA, 1994, 34TH INT C ANT AG CH; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1192	1193		10.1016/S0140-6736(95)91986-4	http://dx.doi.org/10.1016/S0140-6736(95)91986-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739303				2022-12-24	WOS:A1995QX86100004
J	BAYER, R; STRYKER, J; SMITH, MD				BAYER, R; STRYKER, J; SMITH, MD			TESTING FOR HIV-INFECTION AT HOME	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FALSE POSITIVE RATE; ANTIBODY		UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94105 USA; HENRY J KAISER JR FAMILY FDN, MENLO PK, CA 94024 USA	University of California System; University of California San Francisco	BAYER, R (corresponding author), COLUMBIA UNIV, SCH PUBL HLTH, 600 W 168TH ST, NEW YORK, NY 10032 USA.				NIMH NIH HHS [P50-MH43520] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH043520] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON JE, 1992, AM J PUBLIC HEALTH, V82, P1533, DOI 10.2105/AJPH.82.11.1533; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; Doll Lynda S., 1994, P302; GWINN M, 1992, J ACQ IMMUN DEF SYND, V5, P505; HARRIS HR, 1994, WASH POST       0409, pG1; HENRY K, 1988, JAMA-J AM MED ASSOC, V259, P229, DOI 10.1001/jama.259.2.229; KOOP CE, 1994, FDA BLOOD PRODUCTS A; Leary Warren E, 1994, N Y Times Web, pA18; LEARY WE, 1989, NY TIMES        0316, P15; MEYER KB, 1987, NEW ENGL J MED, V317, P238, DOI 10.1056/NEJM198707233170410; OCAMB K, 1994, POZ              JUN, P48; OSSIPKLEIN DJ, 1991, J CONSULT CLIN PSYCH, V59, P325, DOI 10.1037/0022-006X.59.2.325; PHILLIPS KA, 1995, NEW ENGL J MED, V332, P1308, DOI 10.1056/NEJM199505113321918; ROSIN H, 1994, NEW REPUBLIC    0103, P12; SALBU SR, 1995, HASTINGS LAW J, V46, P403; SCHONBERG SK, 1994, COMMISSIONER FO 0629; Starace F, 1993, Int J Soc Psychiatry, V39, P64, DOI 10.1177/002076409303900107; VALDISERRI RO, 1993, PUBLIC HEALTH REP, V108, P12; WOFSY CB, 1987, SURGEON GENERALS WOR, P32; 1995, FED REGISTER, V60, P10087; 1990, JAMA-J AM MED ASSOC, V264, P2416; 1995, AIDS POLICY LAW, V10, P10; 1989, TIME            0418, P26; 1995, BUS WIRE        0208; 1994, HOME TESTING PRINCIP; 1994, ADV DATA VITAL HLTH, V243; 1995, FED REGISTER, V60, P10086	27	41	41	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1296	1299		10.1056/NEJM199505113321911	http://dx.doi.org/10.1056/NEJM199505113321911			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QW600	7708077				2022-12-24	WOS:A1995QW60000011
J	FENTEANY, G; STANDAERT, RF; LANE, WS; CHOI, S; COREY, EJ; SCHREIBER, SL				FENTEANY, G; STANDAERT, RF; LANE, WS; CHOI, S; COREY, EJ; SCHREIBER, SL			INHIBITION OF PROTEASOME ACTIVITIES AND SUBUNIT-SPECIFIC AMINO-TERMINAL THREONINE MODIFICATION BY LACTACYSTIN	SCIENCE			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; THERMOPLASMA-ACIDOPHILUM; MICROBIAL METABOLITE; NEUROBLASTOMA-CELLS; DEGRADATION; CYCLIN; GENE; SEQUENCE; PATHWAY	Lactacystin is a Streptomyces metabolite that inhibits cell cycle progression and induces neurite outgrowth in a murine neuroblastoma cell line. Tritium-labeled lactacystin was used to identify the 20S proteasome as its specific cellular target. Three distinct peptidase activities of this enzyme complex (trypsin-like, chymotrypsin-like, and peptidylglutamyl-peptide hydrolyzing activities) were inhibited by lactacystin, the first two irreversibly and all at different rates. None of five other proteases were inhibited, and the ability of lactacystin analogs to inhibit cell cycle progression and induce neurite outgrowth correlated with their ability to inhibit the proteasome. Lactacystin appears to modify covalently the highly conserved amino-terminal threonine of the mammalian proteasome subunit X (also called MB1), a close homolog of the LMP7 proteasome subunit encoded by the major histocompatibility complex. This threonine residue may therefore have a catalytic role, and subunit X/MB1 may be a core component of an amino-terminal-threonine protease activity of the proteasome.	HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard University			Standaert, Robert F/D-9467-2013; Standaert, Robert F./AAI-1532-2021; Fenteany, Gabriel/F-4944-2018	Standaert, Robert F/0000-0002-5684-1322; Fenteany, Gabriel/0000-0001-7407-2195; Fenteany, Gabriel/0000-0003-0335-4587				AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DESS DB, 1991, J AM CHEM SOC, V113, P7277, DOI 10.1021/ja00019a027; DUGGLEBY HJ, 1995, NATURE, V373, P265; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRUH K, 1992, J BIOL CHEM, V267, P22131; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HAFFTER P, 1991, NUCLEIC ACIDS RES, V19, P5075, DOI 10.1093/nar/19.18.5075; HAGLER J, UNPUB; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; TANAKA K, 1992, NEW BIOL, V4, P173; TSUBUKI, 1993, BIOCHEM BIOPH RES CO, V96, P1195; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	35	1472	1531	5	105	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					726	731		10.1126/science.7732382	http://dx.doi.org/10.1126/science.7732382			6	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732382				2022-12-24	WOS:A1995QW60300051
J	GILBERT, RE; STANFORD, MR; JACKSON, H; HOLLIMAN, RE; SANDERS, MD				GILBERT, RE; STANFORD, MR; JACKSON, H; HOLLIMAN, RE; SANDERS, MD			INCIDENCE OF ACUTE SYMPTOMATIC TOXOPLASMA RETINOCHOROIDITIS IN SOUTH LONDON ACCORDING TO COUNTRY OF BIRTH	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL TOXOPLASMOSIS; OCULAR TOXOPLASMOSIS; INFECTION; PREGNANCY; SEROPREVALENCE; PREVALENCE; WEST	Objective-To determine the incidence of acute symptomatic toxoplasma retinochoroiditis presenting to ophthalmologists for patients born in Britain and elsewhere. Design-Population based, cross sectional study. Setting-11 districts in south Greater London. Subjects-All patients presenting ophthalmologists with symptoms due toxoplasma retinochoroiditis in 1992-3. Main outcome measure-Intraocular inflammation in association with a retinochoroidal scar, active adjoining retinitis, and IgG serum antibodies to toxoplasma. Results-The estimated incidence of acute symptomatic retinochoroiditis for all people born in Britain was 0.4/100 000/year and for black people born in west Africa 57/100 000/year. If a mean of two symptomatic episodes per lifetime is assumed, 100 people born in Britain may be affected each year, about a fifth of the estimated 500-600 congenitally infected people born each year. Conclusions-A substantial proportion of people with acute symptomatic toxoplasma retinochoroiditis were born outside the country, and the number born in Britain was smaller than the number previously estimated to develop retinochoroidal lesions due to congenital toxoplasmosis. These findings suggest that prenatal screening for toxoplasmosis in Britain may be of limited benefit.	ST THOMAS HOSP,MED EYE UNIT,LONDON SE1 7EH,ENGLAND; ST GEORGE HOSP,DEPT OPHTHALMOL,LONDON SW17 0QT,ENGLAND; ST GEORGE HOSP,PUBL HLTH LAB SERV,TOXOPLASMA REFERENCE UNIT,LONDON SW17 0QT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; St Georges University London; Public Health England; St Georges University London	GILBERT, RE (corresponding author), INST CHILD HLTH,DEPT BIOSTAT & EPIDEMIOL,LONDON WC1N 1EH,ENGLAND.			Gilbert, Ruth/0000-0001-9347-2709	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADES AE, 1992, EPIDEMIOL INFECT, V108, P367, DOI 10.1017/S0950268800049839; ADES AE, 1993, AM J EPIDEMIOL, V137, P1022, DOI 10.1093/oxfordjournals.aje.a116758; ADES AE, IN PRESS EPIDEMIC MO; BERREBI A, 1994, LANCET, V344, P36, DOI 10.1016/S0140-6736(94)91054-5; Chatterton JMW., 1992, HUMAN TOXOPLASMOSIS, P144; CHESTERTON JR, 1967, BRIT J OPHTHALMOL, V51, P617, DOI 10.1136/bjo.51.9.617; CONYNVANSPAENDO.MA, 1989, INT OPHTHALMOL, V13, P403; Couvreur J., 1988, Handbook of Clinical Neurology. Vol 52, Revised Series 8. Microbial Disease., P351; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; DESMONTS G, 1990, LANCET, V336, P1017, DOI 10.1016/0140-6736(90)92485-Z; FATHY VC, 1993, PUBLIC HEALTH, V107, P19, DOI 10.1016/S0033-3506(05)80488-3; FRIEDMAN.CT, 1969, ARCH OPHTHALMOL-CHIC, V81, P481; GILBERT RE, 1993, BRIT MED J, V306, P185, DOI 10.1136/bmj.306.6871.185; GLASNER PD, 1992, AM J OPHTHALMOL, V114, P136, DOI 10.1016/S0002-9394(14)73976-5; GUERINA NG, 1994, NEW ENGL J MED, V330, P1858, DOI 10.1056/NEJM199406303302604; HALL SM, 1992, BMJ-BRIT MED J, V305, P291, DOI 10.1136/bmj.305.6848.291; HARTUP C, 1992, LANCET, V340, P118, DOI 10.1016/0140-6736(92)90444-8; HOLLIMAN RE, 1990, SERODIAG IMMUN INF D, V4, P83, DOI 10.1016/0888-0786(90)90031-I; HOYEN DO, 1992, HUMAN TOXOPLASMOSIS, P56; JOSS AWL, 1988, PUBLIC HEALTH, V102, P409, DOI 10.1016/S0033-3506(88)80078-7; JOSS AWL, 1990, PUBLIC HEALTH, V104, P9, DOI 10.1016/S0033-3506(05)80340-3; JOYNSON DHM, 1988, LANCET, V2, P795; KOPPE JG, 1989, INT OPHTHALMOL, V13, P387, DOI 10.1007/BF02306486; LAKHANPAL V, 1983, AM J OPHTHALMOL, V95, P605, DOI 10.1016/0002-9394(83)90378-1; NOKES DJ, 1993, PARASITOLOGY, V107, P33, DOI 10.1017/S0031182000079373; PERKINS ES, 1973, BRIT J OPHTHALMOL, V57, P1, DOI 10.1136/bjo.57.1.1; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; ROTHOVA A, 1993, BRIT J OPHTHALMOL, V77, P371, DOI 10.1136/bjo.77.6.371; SILVEIRA C, 1988, AM J OPHTHALMOL, V106, P362, DOI 10.1016/0002-9394(88)90382-0; STAGNO S, 1980, PEDIATRICS, V65, P706; Thalhammer O., 1979, PERINATAL MED, P51; THORP JM, 1988, NEW ENGL J MED, V319, P372, DOI 10.1056/NEJM198808113190615; THOUMSIN H, 1992, SCAND J INFECT DIS S, V84, P84; WILLIAMS KAB, 1981, J INFECTION, V3, P219, DOI 10.1016/S0163-4453(81)90773-8; WILSON CB, 1980, PEDIATRICS, V66, P767; 1994, ETHNIC GROUP COUNTRY, V1, P214; 1992, PRENATAL SCREENING T	37	38	41	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1037	1040		10.1136/bmj.310.6986.1037	http://dx.doi.org/10.1136/bmj.310.6986.1037			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV313	7728057	Green Published			2022-12-24	WOS:A1995QV31300016
J	RADICELLA, JP; PARK, PU; FOX, MS				RADICELLA, JP; PARK, PU; FOX, MS			ADAPTIVE MUTATION IN ESCHERICHIA-COLI - A ROLE FOR CONJUGATION	SCIENCE			English	Article							DIRECTED MUTATION; MUTANTS; ORIGIN	When subjected to selective conditions that impose starvation, a bacterial population can accumulate mutations, called adaptive, that allow colony formation. Here, the reversion of a lac allele under selective conditions, in a model system using Escherichia coli with the lac mutation on an F' plasmid, was shown to require the conjugational capacity of the plasmid. Reversion associated with transfer was shown, and when the same lac allele was chromosomal, reversion to Lac(+) was 25 to 50 times less frequent. Postplating reversion was 25 times less when mating was inhibited by the presence of detergent. Mutability associated with conjugation provides new ways of thinking about the origin of adaptive mutations.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Radicella, J. Pablo/AAU-3178-2020	Radicella, J. Pablo/0000-0002-8807-7226; Park, Peter U./0000-0002-6892-3018	PHS HHS [A105388] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACHTMAN M, 1978, J BACTERIOL, V135, P1053, DOI 10.1128/JB.135.3.1053-1061.1978; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CHARLESWORTH D, 1988, NATURE, V336, P525, DOI 10.1038/336525a0; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1994, SCIENCE, V265, P407, DOI 10.1126/science.8023164; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; FOSTER PL, 1994, GENETICS, V138, P253; FOSTER PL, IN PRESS P NATL ACAD; FOX M, 1993, MOL GEN GENET, V240, P355, DOI 10.1007/BF00280386; GALITSKI T, 1995, SCIENCE, V268, P421, DOI 10.1126/science.7716546; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; HAYES W, 1952, NATURE, V169, P118, DOI 10.1038/169118b0; LEDERBERG J, 1952, GENETICS, V37, P720; LEDERBERG J, 1952, J BACTERIOL, V63, P399, DOI 10.1128/JB.63.3.399-406.1952; LENSKI RE, 1993, SCIENCE, V259, P188, DOI 10.1126/science.7678468; LENSKI RE, 1993, SCIENCE, V260, P1222, DOI 10.1126/science.260.5112.1222; LENSKI RE, 1988, NATURE, V336, P123; LICHTEN M, 1983, GENETICS, V103, P5; Luria SE, 1943, GENETICS, V28, P491; Miller J. H., 1972, EXPT MOL GENETICS, P431; NOVICK A, 1950, P NATL ACAD SCI USA, V36, P708, DOI 10.1073/pnas.36.12.708; PARTRIDGE L, 1988, NATURE, V336, P22, DOI 10.1038/336022a0; PETERS JE, 1995, J BACTERIOL, V177, P847, DOI 10.1128/jb.177.3.847-850.1995; ROSENBERG SM, 1994, SCIENCE, V265, P405, DOI 10.1126/science.8023163; RYAN FJ, 1959, J GEN MICROBIOL, V21, P530, DOI 10.1099/00221287-21-3-530; RYAN FJ, 1961, Z VEREBUNGSL, V92, P38, DOI 10.1007/BF01854099; SHAPIRO JA, 1984, MOL GEN GENET, V194, P79, DOI 10.1007/BF00383501; SINGER M, 1989, MICROBIOL REV, V53, P1; STAHL FW, 1992, GENETICS, V132, P865; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; STEWART FM, 1990, GENETICS, V124, P175; SYMONDS N, 1989, NATURE, V337, P119, DOI 10.1038/337119a0; TESSMAN I, 1988, NATURE, V336, P527, DOI 10.1038/336527b0	34	102	105	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					418	420		10.1126/science.7716545	http://dx.doi.org/10.1126/science.7716545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716545				2022-12-24	WOS:A1995QU57200040
J	OTT, A; BRETELER, MMB; VANHARSKAMP, F; CLAUS, JJ; VANDERCAMMEN, TJM; GROBBEE, DE; HOFMAN, A				OTT, A; BRETELER, MMB; VANHARSKAMP, F; CLAUS, JJ; VANDERCAMMEN, TJM; GROBBEE, DE; HOFMAN, A			PREVALENCE OF ALZHEIMERS-DISEASE AND VASCULAR DEMENTIA - ASSOCIATION WITH EDUCATION - THE ROTTERDAM STUDY	BRITISH MEDICAL JOURNAL			English	Article							MENTAL STATE; HEALTH; EPIDEMIOLOGY; DIAGNOSIS; IMPACT	Objective-To estimate the prevalence of dementia and its subtypes in the general population and examine the relation of the disease to education. Design-Population based cross sectional study. Setting-Ommoord, a suburb of Rotterdam. Subjects-7528 participants of the Rotterdam study aged 55-106 years. Results-474 cases of dementia were detected, giving an overall prevalence of 6.3%, Prevalence ranged from 0.4% (5/1181 subjects) at age 55-59 years to 43.2% (19/44) at 95 years and over. Alzheimer's disease was the main subdiagnosis (339 cases; 72%); it was also the main cause of the pronounced increase in dementia with age. The relative proportion of vascular dementia (76 cases; 16%), Parkinson's disease dementia (30; 6%), and other dementias (24; 5%) decreased with age. A substantially higher prevalence of dementia was found in subjects with a low level of education. The association with education was not due to confounding by cardiovascular disease. Conclusions-The prevalence of dementia increases exponentially with age. About one third of the population aged 85 and over has dementia. Three quarters of all dementia is due to Alzheimer's disease. In this study an inverse dose-response relation was found between education and dementia -in particular, Alzheimer's disease.			OTT, A (corresponding author), ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		Grobbee, Diederick/C-7651-2014; Breteler, Monique M.B./J-5058-2014	Grobbee, Diederick/0000-0003-4472-4468; Breteler, Monique M.B./0000-0002-0626-9305				BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; BRETELER MMB, 1992, NEUROEPIDEMIOLOGY, V11, P23, DOI 10.1159/000110957; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; DARTIGUES JF, 1991, REV NEUROL-FRANCE, V147, P225; DEWEY ME, 1990, CASE FINDING DEMENTI; FELDMAN JJ, 1989, AM J EPIDEMIOL, V129, P919, DOI 10.1093/oxfordjournals.aje.a115225; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRIEDLAND RP, 1993, NEUROLOGY, V43, P246, DOI 10.1212/WNL.43.2.246; HASHINSKI V, 1983, NEUROL CLIN, V1, P27; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HOFMAN A, 1991, INT J EPIDEMIOL, V20, P735; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; ROCCA WA, 1991, ANN NEUROL, V30, P381, DOI 10.1002/ana.410300310; ROCCA WA, 1990, NEUROLOGY, V40, P626, DOI 10.1212/WNL.40.4.626; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Roth M, 1988, CAMDEX CAMBRIDGE EXA; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412; 1987, DIAGNOSTIC STATISTIC; 1987, SOI1978 NETH CENTR B; 1974, STATISTISCH JB	25	597	604	1	35	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					970	973		10.1136/bmj.310.6985.970	http://dx.doi.org/10.1136/bmj.310.6985.970			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT904	7728032	Green Published			2022-12-24	WOS:A1995QT90400019
J	SACKS, DL; KENNEY, RT; KREUTZER, RD; JAFFE, CL; GUPTA, AK; SHARMA, MC; SINHA, SP; NEVA, FA; SARAN, R				SACKS, DL; KENNEY, RT; KREUTZER, RD; JAFFE, CL; GUPTA, AK; SHARMA, MC; SINHA, SP; NEVA, FA; SARAN, R			INDIAN KALA-AZAR CAUSED BY LEISHMANIA-TROPICA	LANCET			English	Note							OPERATION DESERT-STORM	Kala-azar, or visceral leishmaniasis, in India is generally assumed to be a result of infection with Leishmania donovani. 15 parasite isolates collected over the past 10 years from patients with classical disease were typed by monoclonal antibodies, isoenzymes, and kDNA analysis. 4 were shown to be L tropica, a species historically associated with cutaneous disease and more recently a mild ''visceralising'' disease from the Desert Storm experience. The results confirm that L tropica is a co-endemic agent of visceral leishmaniasis in India, and may shed light on the rising frequency of therapeutic unresponsiveness to sodium antimony gluconate, which complicates treatment of this lethal disease.	YOUNGSTOWN STATE UNIV,DEPT BIOL,YOUNGSTOWN,OH; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT PARASITOL,JERUSALEM,ISRAEL; INDIAN COUNCIL MED RES,RAJENDRA MEM RES INST,PATNA,BIHAR,INDIA	University System of Ohio; Youngstown State University; Hebrew University of Jerusalem; Indian Council of Medical Research (ICMR); ICMR - Rajendra Memorial Research Institute of Medical Sciences (RMRI)	SACKS, DL (corresponding author), NIAID,PARASIT DIS LAB,BLDG 4,ROOM 126,BETHESDA,MD 20892, USA.		Jaffe, Charles/AAU-8686-2020	Jaffe, Charles/0000-0002-2042-9993				JAFFE CL, 1987, J IMMUNOL, V138, P1310; KREUTZER RD, 1993, AM J TROP MED HYG, V49, P357, DOI 10.4269/ajtmh.1993.49.357; MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904; MEBRAHTU Y, 1989, AM J TROP MED HYG, V41, P289, DOI 10.4269/ajtmh.1989.41.289; SCHNUR LF, 1989, NATO ADV SCI I SERIE, P939; SMYTH AJ, 1992, PARASITOLOGY, V105, P183, DOI 10.1017/S0031182000074096; TOLSON DL, 1989, MOL BIOCHEM PARASIT, V35, P109, DOI 10.1016/0166-6851(89)90113-8	7	96	101	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					959	961		10.1016/S0140-6736(95)90703-3	http://dx.doi.org/10.1016/S0140-6736(95)90703-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715298				2022-12-24	WOS:A1995QT91900013
J	STAMP, T				STAMP, T			GREY HAIRS, FALSE TEETH, AND BAD BONES	LANCET			English	Editorial Material							PHOTON-ABSORPTIOMETRY; RISK-FACTORS; OSTEOPOROSIS; WOMEN				STAMP, T (corresponding author), ROYAL NATL ORTHOPAED HOSP, STANMORE HA7 4LP, MIDDX, ENGLAND.							ARNOLD HL, 1990, ANDREWS DISEASES SKI, P891; COOPER C, 1991, OSTEOPOROSIS INT, V2, P48, DOI 10.1007/BF01627079; GLASSER M, 1991, MED HYPOTHESES, V36, P404, DOI 10.1016/0306-9877(91)90020-Y; HOUKI K, 1994, J BONE MINER RES  S1, V9, pS211; JEFFCOAT MK, 1993, J AM DENT ASSOC, V124, P49, DOI 10.14219/jada.archive.1993.0225; KEOGH EV, 1965, NATURE, V207, P877, DOI 10.1038/207877a0; KLEEREKOPER M, 1989, BONE MINER, V7, P171, DOI 10.1016/0169-6009(89)90074-3; ROSEN CJ, 1994, J CLIN ENDOCR METAB, V79, P854, DOI 10.1210/jc.79.3.854; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; SPECTOR TD, 1992, CURRENT RES OSTEOPOR, V11, P86; 1993, J BONE MINER RES S2, V8, pS443; 1994, REPORT ADVISORY GROU, P76	12	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 8	1995	345	8954					876	876		10.1016/S0140-6736(95)90006-3	http://dx.doi.org/10.1016/S0140-6736(95)90006-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707808				2022-12-24	WOS:A1995QR06700006
J	AFSHAR, K; BARTON, NR; HAWLEY, RS; GOLDSTEIN, LSB				AFSHAR, K; BARTON, NR; HAWLEY, RS; GOLDSTEIN, LSB			DNA-BINDING AND MEIOTIC CHROMOSOMAL LOCALIZATION OF THE DROSOPHILA NOD KINESIN-LIKE PROTEIN	CELL			English	Article							DISTRIBUTIVE SEGREGATION; GENETIC-ANALYSIS; MELANOGASTER; SATELLITE; FEMALES; SPINDLE; DOMAIN	The Drosophila no distributive disjunction (nod) gene encodes a kinesin-like protein that has been proposed to push chromosomes toward the metaphase plate during female meiosis. We report that the nonmotor domain of the nod protein can mediate direct binding to DNA. Using an antiserum prepared against bacterially expressed nod protein, we show that during prometaphase nod protein is localized on oocyte chromosomes and is not restricted to either specific chromosomal regions or to the kinetochore. Thus, motor-based chromosome-microtubule interactions are not limited to the centromere, but extend along the chromosome arms, providing a molecular explanation for the polar ejection force.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093	University of California System; University of California San Diego	AFSHAR, K (corresponding author), UNIV CALIF DAVIS,DEPT GENET,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616, USA.			Hawley, R. Scott/0000-0002-6478-0494				ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; ABERCROMBIE BD, 1978, EUR J BIOCHEM, V84, P173, DOI 10.1111/j.1432-1033.1978.tb12154.x; BAKER BS, 1972, GENETICS, V71, P255; BUSTIN M, 1990, J BIOL CHEM, V265, P20077; CARPENTER AT, 1973, GENETICS, V73, P393; CARPENTER ATC, 1991, CELL, V64, P885, DOI 10.1016/0092-8674(91)90313-N; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; CHODOSH LA, 1991, CURRENT PROTOCOLS MO, V2; CRIPPA MP, 1992, J MOL BIOL, V228, P442, DOI 10.1016/0022-2836(92)90833-6; FUGE H, 1990, PROTOPLASMA, V158, P1, DOI 10.1007/BF01323267; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GRELL RF, 1976, GENET BIOL DROSOPHIL, P435; HARLOW E, 1988, ANTIBODIES LABORATOR; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; HAWLEY RS, 1993, ANNU REV GENET, V27, P281; HAWLEY RS, 1993, TRENDS GENET, V9, P310; HAWLEY RS, 1993, DEV GENET, V13, P440; LE MH, 1995, IN PRESS GENETICS; LOHE AR, 1986, P NATL ACAD SCI USA, V83, P696, DOI 10.1073/pnas.83.3.696; MCKIM KS, 1993, NATURE, V362, P364, DOI 10.1038/362364a0; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RASOOLY RS, 1991, GENETICS, V129, P409; RASOOLY RS, 1994, MOL GEN GENET, V242, P145, DOI 10.1007/BF00391007; REEVES R, 1993, J BIOL CHEM, V268, P21137; Rhoades MM, 1942, GENETICS, V27, P0395; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Salmon ED, 1989, MITOSIS MOL MECHANIS, P119; Sambrook J., 1989, MOL CLONING LAB MANU; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHANG P, 1990, GENETICS, V125, P115	35	123	125	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					129	138		10.1016/0092-8674(95)90377-1	http://dx.doi.org/10.1016/0092-8674(95)90377-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720068	Bronze			2022-12-24	WOS:A1995QR97000014
J	SHEETS, MD; WU, M; WICKENS, M				SHEETS, MD; WU, M; WICKENS, M			POLYADENYLATION OF C-MOS MESSENGER-RNA AS A CONTROL POINT IN XENOPUS MEIOTIC MATURATION	NATURE			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA; UNWINDING ACTIVITY; OOCYTE MATURATION; POLY(A) ADDITION; ANTISENSE RNA; CELL-CYCLE; INVITRO	c-mos protein, encoded by a proto-oncogene, is essential for the meiotic maturation of frog oocytes. Polyadenylation of c-mos messenger RNA is shown here to be a pivotal regulatory step in meiotic maturation. Maturation is prevented by selective amputation of polyadenylation signals from c-mos mRNA. Injection of a prosthetic RNA, which restores c-mos polyadenylation signals by base pairing to the amputated mRNA, rescues maturation and can stimulate translation in trans. Prosthetic RNAs may provide a general strategy by which to alter patterns of mRNA expression in vivo.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Berkeley								AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; Bachvarova R, 1985, Dev Biol (N Y 1985), V1, P453; BALLANTYNE S, IN PRESS RNA; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Bass Brenda L., 1992, Seminars in Developmental Biology, V3, P425; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BILGER A, 1994, GENE DEV, V8, P1106, DOI 10.1101/gad.8.9.1106; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FOX CA, 1992, EMBO J, V11, P5021, DOI 10.1002/j.1460-2075.1992.tb05609.x; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GEBAUER F, 1994, EMBO J, V13, P5712, DOI 10.1002/j.1460-2075.1994.tb06909.x; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; Maller J L, 1985, Dev Biol (N Y 1985), V1, P289; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V333, P519; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; SMITH RC, 1990, DEVELOPMENT, V110, P769; STANDART N, 1994, BIOCHIMIE, V78, P867; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; VANDEWOUDE GF, 1994, NATURE, V370, P20, DOI 10.1038/370020a0; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1993, NATURE, V363, P305, DOI 10.1038/363305a0; WICKENS M, 1992, SEM DEV BIOL, V3, P399; Wickens Marvin, 1992, Seminars in Developmental Biology, V3, P363; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	36	202	203	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					511	516		10.1038/374511a0	http://dx.doi.org/10.1038/374511a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700377				2022-12-24	WOS:A1995QR06900042
J	SINGH, P; COE, J; HONG, WJ				SINGH, P; COE, J; HONG, WJ			A ROLE FOR RETINOBLASTOMA PROTEIN IN POTENTIATING TRANSCRIPTIONAL ACTIVATION BY THE GLUCOCORTICOID RECEPTOR	NATURE			English	Article							GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; ADENOVIRUS E1A; LARGE-T; PHOSPHORYLATION; TRANSFORMATION; EXPRESSION; GROWTH; FAMILY	THE Saccharomyces cerevisiae SNF2/SWI2 protein is essential for the regulated expression of a variety of genes(1,2). A human SW12/SNF2 homologue, hBrm, is a positive participant in glucocorticoid-receptor-mediated transcription(3), but its mechanism of action is not known. The retinoblastoma protein, RB, has also been shown to stimulate the transcription of several genes(4-10), although the target for RB has not been identified in any of these transcriptional events. Here we show that RB upregulates glucocorticoid-receptor-mediated transcription. The effect of either RB or hBrm is dependent on the presence of the other. Furthermore, we demonstrate that RB and hBrm interact with one another in vitro and in vivo. These results highlight a new role for RB, which is to interact with hBrm in order to potentiate glucocorticoid-receptor-activated transcription.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,MEMBRANE BIOL LAB,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			HONG, Wanjin/E-9927-2010					BOCCO JL, 1993, ONCOGENE, V8, P2977; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; HARPER JW, 1993, CELL, V75, P805; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LU YM, 1994, ONCOGENE, V9, P1015; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; SCHEFFNER M, 1989, P NATL ACAD SCI USA, V88, P5523; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	26	169	171	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					562	565		10.1038/374562a0	http://dx.doi.org/10.1038/374562a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700385				2022-12-24	WOS:A1995QR06900058
J	YAO, RJ; COOPER, GM				YAO, RJ; COOPER, GM			REQUIREMENT FOR PHOSPHATIDYLINOSITOL-3 KINASE IN THE PREVENTION OF APOPTOSIS BY NERVE GROWTH-FACTOR	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; TRK PROTOONCOGENE PRODUCT; PC12 CELLS; NEURONAL DIFFERENTIATION; TYROSINE KINASE; FACTOR RECEPTOR; PHEOCHROMOCYTOMA CELLS; PDGF RECEPTOR; BINDING-SITE; MAP KINASE	Nerve growth factor (NGF) induces both differentiation and survival of neurons by binding to the Trk receptor protein tyrosine kinase. Although Pas is required for differentiation, it was not required for NGF-mediated survival of rat pheochromocytoma PC-12 cells in serum-free medium. However, the ability of NGF to prevent apoptosis (programmed cell death) was inhibited by wortmannin or LY294002, two specific inhibitors of phosphatidylinositol (PI)-3 kinase. Moreover, platelet-derived growth factor (PDGF) prevented apoptosis of PC-12 cells expressing the wild-type PDGF receptor, but not of cells expressing a mutant receptor that failed to activate PI-3 kinase. Cell survival thus appears to be mediated by a PI-3 kinase signaling pathway distinct from the pathway that mediates differentiation.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [R01 CA 18689] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; ROVELLI G, 1993, P NATL ACAD SCI USA, V90, P8717, DOI 10.1073/pnas.90.18.8717; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO R, UNPUB	52	1254	1331	1	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					2003	2006		10.1126/science.7701324	http://dx.doi.org/10.1126/science.7701324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701324				2022-12-24	WOS:A1995QQ06800047
J	LETSOU, A; ARORA, K; WRANA, JL; SIMIN, K; TWOMBLY, V; JAMAL, J; STAEHLINGHAMPTON, K; HOFFMANN, FM; GELBART, WM; MASSAGUE, J; OCONNOR, MB				LETSOU, A; ARORA, K; WRANA, JL; SIMIN, K; TWOMBLY, V; JAMAL, J; STAEHLINGHAMPTON, K; HOFFMANN, FM; GELBART, WM; MASSAGUE, J; OCONNOR, MB			DROSOPHILA DPP SIGNALING IS MEDIATED BY THE PUNT GENE-PRODUCT - A DUAL LIGAND-BINDING TYPE-II RECEPTOR OF THE TGF-BETA RECEPTOR FAMILY	CELL			English	Article							GROWTH-FACTOR-BETA; VISCERAL MESODERM; ACTIVIN RECEPTOR; GERM LAYERS; MELANOGASTER; EXPRESSION; KINASE; EMBRYOS; PATTERN; COMPLEX	Signaling by TGF beta-related factors requires ligand-induced association between type I and type II transmembrane serine/threonine kinases. In Drosophila, the saxophone (sax) and thick veins (tkv) genes encode type I receptors that mediate signaling by decapentaplegic (dpp), a member of the bone morphogenetic protein (BMP) subgroup of TGF beta-type factors. In this report, we demonstrate that the Drosophila punt gene encodes atr-ll, a previously described type II receptor that on its own is able to bind activin but not BMP2, a vertebrate ortholog of dpp. Mutations in punt produce phenotypes similar to those exhibited by tkv, sax, and dpp mutants. Furthermore, punt will bind BMP2 in concert with tkv or sax, forming complexes with these receptors. We suggest that punt functions as a type II receptor for dpp and propose that BMP signaling in vertebrates may also involve sharing of type II receptors by diverse ligands.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,GENET LAB,MADISON,WI 53706	University of California System; University of California Irvine; University of California System; University of California Irvine; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Harvard University; University of Wisconsin System; University of Wisconsin Madison	LETSOU, A (corresponding author), UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.		O'Connor, Michael B/C-9977-2014; Wrana, Jeffrey/F-8857-2013	O'Connor, Michael B/0000-0002-3067-5506; Massague, Joan/0000-0001-9324-8408; Hoffmann, F. Michael/0000-0002-2770-9656				AFFOLTER M, 1994, DEVELOPMENT, V120, P3105; ARORA K, 1992, DEVELOPMENT, V114, P1003; ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; CHOU TB, 1993, DEVELOPMENT, V119, P1359; DOCTOR JS, 1992, DEV BIOL, V151, P491, DOI 10.1016/0012-1606(92)90188-M; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Maniatis T., 1982, MOL CLONING; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NUSSLEINVOLHARD C, 1984, W ROUXS ARCH DEV BIO, V183, P267; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; REUTER R, 1990, DEVELOPMENT, V110, P1031; ROBERTSON HM, 1988, GENETICS, V118, P461; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SEGAL D, 1985, GENETICS, V109, P119; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STAEHLINGHAMPTO.K, 1994, DEV BIOL, V164, P502; STAEHLINGHAMPTO.K, 1994, NATURE, V372, P783; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TERRACOL R, 1994, GENETICS, V138, P165; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	50	236	243	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					899	908		10.1016/0092-8674(95)90293-7	http://dx.doi.org/10.1016/0092-8674(95)90293-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697720	Bronze			2022-12-24	WOS:A1995QP61200009
J	BEHRENS, RH; ROBERTS, JA				BEHRENS, RH; ROBERTS, JA			IS TRAVEL PROPHYLAXIS WORTH WHILE - ECONOMIC APPRAISAL OF PROPHYLACTIC MEASURES AGAINST MALARIA, HEPATITIS-A, AND TYPHOID IN TRAVELERS	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; HEALTH	Objectives-To estimate the costs and benefits of prophylaxis against travel acquired malaria, typhoid fever, and hepatitis A in United Kingdom residents during 1991. Design-Retrospective analysis of national epidemiological and economic data. Main outcome measures-Incidence of travel associated infections in susceptible United Kingdom residents per visit; costs of prophylaxis provision from historical data; benefits to the health sector, community, and individuals in terms of avoided morbidity and mortality based on hospital and community costs of disease. Results-The high incidence of imported malaria (0.70%) and the low costs of providing chemoprophylaxis resulted in a cost-benefit ratio of 0.19 for chloroquine and proguanil and 0.57 for a regimen containing mefloquine. Hepatitis A infection occurred in 0.05% of visits and the cost of prophylaxis invariably exceeded the benefits for immunoglobulin (cost-benefit ratio 5.8) and inactivated hepatitis A vaccine (cost-benefit ratio 15.8). Similarly, low incidence of typhoid (0.02%) and its high cost gave whole cell killed, polysaccharide Vi, and oral Ty 21a typhoid vaccines cost-benefit ratios of 18.1, 18.0, and 22.0 respectively. Conclusions-Fewer than one third of travellers receive vaccines but the total cost of providing typhoid and hepatitis A prophylaxis of pound 25.8m is significantly higher than the treatment costs to the NHS (pound 1.03m) of cases avoided by prophylaxis. Neither hepatitis A prophylaxis nor typhoid prophylaxis is cost effective, but costs of treating malaria greatly exceed costs of chemoprophylaxis, which is therefore highly cost effective.	UNIV LONDON LONDON SCH HYG & TROP MED,HLTH SERV RES UNIT,LONDON WC1T 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	BEHRENS, RH (corresponding author), HOSP TROP DIS,TRAVEL CLIN,LONDON NW1 0PE,ENGLAND.							BEHRENS RH, 1990, T ROY SOC TROP MED H, V84, P611, DOI 10.1016/0035-9203(90)90123-V; BEHRENS RH, 1993, T ROY SOC TROP MED H, V87, P361; BRADDICK MR, 1993, PUBLIC HEALTH, V107, P193, DOI 10.1016/S0033-3506(05)80441-X; Bradley D J, 1993, Commun Dis Rep CDR Rev, V3, pR25; COSSAR JH, 1990, J INFECTION, V21, P27, DOI 10.1016/0163-4453(90)90600-D; Cumberland N S, 1994, J R Army Med Corps, V140, P71; DAVIDSON RN, 1993, J INFECTION, V26, P348, DOI 10.1016/0163-4453(93)96241-H; FORBES A, 1988, J ROY COLL PHYS LOND, V22, P237; MARIN A, 1983, 3 BANKS REV, V138, P20; Paris J A, 1992, Commun Dis Rep CDR Rev, V2, pR43; PHILLIPSHOWARD PA, 1990, BMJ-BRIT MED J, V300, P499, DOI 10.1136/bmj.300.6723.499; POLAKOFF S, 1990, J INFECTION, V21, P111, DOI 10.1016/0163-4453(90)90853-Z; STEFFEN R, 1991, T ROY SOC TROP MED H, V85, P156, DOI 10.1016/0035-9203(91)90005-J; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W; STEFFEN R, 1987, J INFECT DIS, V156, P84, DOI 10.1093/infdis/156.1.84; TILZEY AJ, 1991, BMJ-BRIT MED J, V302, P1552, DOI 10.1136/bmj.302.6792.1552; WOODRUFF BA, 1991, JAMA-J AM MED ASSOC, V265, P756, DOI 10.1001/jama.265.6.756; ZUCKERMAN AJ, 1991, BRIT MED J, V303, P991, DOI 10.1136/bmj.303.6808.991-a; 1991, MA6 GOV STAT SERV CE; 1993, EMPLOYMENT GAZET JUN, P50; 1991, COMMUNICABLE DISEASE; 1990, GENERAL MED PRACTITI; 1994, INT TRAVEL HLTH VACC, P41; 1992, IMMUNISATION INFECTI; 1991, CHEM DRUGGIST, V32	25	83	84	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 8	1994	309	6959					918	922		10.1136/bmj.309.6959.918	http://dx.doi.org/10.1136/bmj.309.6959.918			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7726905	Green Published			2022-12-24	WOS:A1994PL78100018
J	PULEO, PR; MEYER, D; WATHEN, C; TAWA, CB; WHEELER, S; HAMBURG, RJ; ALI, N; OBERMUELLER, SD; TRIANA, JF; ZIMMERMAN, JL; PERRYMAN, MB; ROBERTS, R				PULEO, PR; MEYER, D; WATHEN, C; TAWA, CB; WHEELER, S; HAMBURG, RJ; ALI, N; OBERMUELLER, SD; TRIANA, JF; ZIMMERMAN, JL; PERRYMAN, MB; ROBERTS, R			USE OF A RAPID ASSAY OF SUBFORMS OF CREATINE-KINASE MB TO DIAGNOSE OR RULE OUT ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEST PAIN; INITIAL ELECTROCARDIOGRAM; MARATHON RUNNERS; SKELETAL-MUSCLE; ISOENZYME; PLASMA; EMERGENCY; ADMISSION; SERUM; UNIT	Background. Ruling out myocardial infarction in patients coming to the emergency room with chest pain is hindered by the lack of a specific early diagnostic marker. Less than 30 percent of patients admitted to coronary care units have infarction, resulting in substantial unnecessary expenditures. We developed a rapid assay of the subforms of creatine kinase MB (OK-MB) and prospectively analyzed its sensitivity and specificity in diagnosing myocardial infarction in the first six hours after the onset of chest pain. Methods. In 1110 consecutive patients who came to the emergency room with chest pain, blood samples were collected every 30 to 60 minutes until at least 6 hours after the onset of symptoms; in patients who were then admitted to the hospital, samples were collected every 4 hours for up to 48 hours. The samples were analyzed for CK-MB subforms, and the diagnosis of myocardial infarction was confirmed by conventional CK-MB analysis. Results. Of the 1110 patients evaluated, 121 had myocardial infarction. The sensitivity of the assay of OK-MB subforms to detect myocardial infarction in the first six hours after the onset of symptoms was 95.7 percent, as compared with only 48 percent for the conventional CK-MB assay; the specificity was 93.9 percent among patients hospitalized without myocardial infarction and 96.2 percent among those sent home. Among the patients with myocardial infarction, definitive results of the subform assay were available a mean (+/-SD) of 1.22+/-1.17 hours after their arrival in the emergency room. Conclusions. The assay of CK-MB subforms reliably detected myocardial infarction within the first six hours after the onset of symptoms, and its use could reduce admission to the coronary care unit by 50 to 70 percent, thereby reducing costs.	BAYLOR COLL MED, DEPT MED, CARDIOL SECT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, CRIT CARE SECT, HOUSTON, TX 77030 USA; CHRIST HOSP, DEPT MED, CARDIOL SECT, CINCINNATI, OH 45219 USA	Baylor College of Medicine; Baylor College of Medicine; Christ Hospital - Ohio					NHLBI NIH HHS [P50-HL42267] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNESLEY TM, 1985, CLIN CHEM, V31, P402; APPLE FS, 1986, CLIN CHEM, V32, P41; APPLE FS, 1984, CLIN CHEM, V30, P413; Armitage P, 1987, STAT METHODS MED RES, V2, P117; BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; COLLINSON PO, 1989, J CLIN PATHOL, V42, P1126, DOI 10.1136/jcp.42.11.1126; FESMIRE FM, 1989, ARCH INTERN MED, V149, P1294, DOI 10.1001/archinte.149.6.1294; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; FRIEDMAN DL, 1993, CLIN CHEM, V39, P1598; GASPOZ JM, 1991, AM J CARDIOL, V68, P145, DOI 10.1016/0002-9149(91)90734-3; GEORGE S, 1984, J BIOL CHEM, V259, P2667; GIBLER WB, 1990, ANN EMERG MED, V19, P1359, DOI 10.1016/S0196-0644(05)82598-3; GIBLER WB, 1991, ANN EMERG MED, V20, P420; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRACE A, 1982, CLIN CHIM ACTA, V123, P59, DOI 10.1016/0009-8981(82)90114-0; GRENADIER E, 1983, AM HEART J, V105, P408, DOI 10.1016/0002-8703(83)90357-5; HENRY PD, 1975, CLIN CHEM, V21, P844; HEYNDRICKX GR, 1985, J AM COLL CARDIOL, V6, P1299, DOI 10.1016/S0735-1097(85)80216-3; JAFFE AS, 1986, CIRCULATION, V74, P105, DOI 10.1161/01.CIR.74.1.105; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; LEE TH, 1989, ANN INTERN MED, V110, P957, DOI 10.7326/0003-4819-110-12-957; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; MARMOR A, 1981, AM J CARDIOL, V48, P603, DOI 10.1016/0002-9149(81)90137-5; MICHAEL LH, 1985, AM J PHYSIOL, V248, pH350, DOI 10.1152/ajpheart.1985.248.3.H350; MORELLI RL, 1983, CIRCULATION, V67, P1283, DOI 10.1161/01.CIR.67.6.1283; OHMAN EM, 1990, CIRCULATION, V82, P1073, DOI 10.1161/01.CIR.82.3.1073; PRAGER NA, 1992, J AM COLL CARDIOL, V20, P414, DOI 10.1016/0735-1097(92)90111-Y; PULEO PR, 1990, CIRCULATION, V82, P759, DOI 10.1161/01.CIR.82.3.759; PULEO PR, 1989, CLIN CHEM, V35, P1452; ROBERTS R, 1988, CHEST, V93, pS3; SELKER HP, 1989, AM J MED, V87, P491; STARK ME, 1987, ARCH INTERN MED, V147, P843, DOI 10.1001/archinte.147.5.843; TURI ZG, 1985, AM J CARDIOL, V55, P1463, DOI 10.1016/0002-9149(85)90954-3; WEINGARTEN SR, 1989, AM J MED, V87, P494, DOI 10.1016/S0002-9343(89)80603-5; WEVERS RA, 1978, CLIN CHIM ACTA, V86, P323, DOI 10.1016/0009-8981(78)90388-1; WU AHB, 1989, CLIN CHEM, V35, P1752; YASMINEH WG, 1978, CLIN CHEM, V24, P1985; YOUNG MJ, 1987, ARCH INTERN MED, V147, P1219, DOI 10.1001/archinte.147.7.1219; 1984, AM HEART ASS MONOGRA, V100, P77	40	246	252	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					561	566		10.1056/NEJM199409013310901	http://dx.doi.org/10.1056/NEJM199409013310901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	7702648				2022-12-24	WOS:A1994PD69900001
J	KANAAR, R; ROCHE, SE; BEALL, EL; GREEN, MR; RIO, DC				KANAAR, R; ROCHE, SE; BEALL, EL; GREEN, MR; RIO, DC			THE CONSERVED PREMESSENGER RNA SPLICING FACTOR-U2AF FROM DROSOPHILA - REQUIREMENT FOR VIABILITY	SCIENCE			English	Article							AUXILIARY FACTOR; CLONING; YEAST; HOMOLOG; GENE; RIBONUCLEOPROTEIN; REGULATORS; PROTEINS; ACCURATE; DOMAIN	The large subunit of the human pre-messenger RNA splicing factor U2 small nuclear ribonucleoprotein auxiliary factor (hU2AF65) is required for spliceosome assembly in vitro. A complementary DNA clone encoding the large subunit of Drosophila U2AF (dU2AF50) has been isolated. The dU2AF50 protein is closely related to its mammalian counterpart and contains three carboxyl-terminal ribonucleoprotein consensus sequence RNA binding domains and an amino-terminal arginine- and serine-rich (R/S) domain. Recombinant dU2AF50 protein complements mammalian splicing extracts depleted of U2AF activity. Germline transformation of Drosophila with the dU2AF50 complementary DNA rescues a lethal mutation, establishing that the dU2AF50 gene is essential for viability. R/S domains have been found in numerous metazoan splicing factors, but their function is unknown. The mutation in Drosophila U2AF will allow in vivo analysis of a conserved R/S domain-containing general splicing factor.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Massachusetts System; University of Massachusetts Worcester					NICHD NIH HHS [R01-HD28063] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028063] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHBURNER M, 1989, DROSOPHILA LABORATOR; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P1333, DOI 10.1093/nar/21.5.1333; BIRNEY E, 1992, NUCLEIC ACIDS RES, V20, P4663, DOI 10.1093/nar/20.17.4663; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HARLOW E, 1989, ANTIBODIES LABORATOR; JONES KR, 1990, NEURON, V4, P711, DOI 10.1016/0896-6273(90)90197-N; KANAAR R, UNPUB; KIM YJ, 1992, GENE DEV, V6, P2569, DOI 10.1101/gad.6.12b.2569; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MATTOX W, 1992, J BIOL CHEM, V267, P19023; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; MORE M, 1993, RNA WORLD, P303; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; RIO DC, 1988, P NATL ACAD SCI USA, V85, P2904, DOI 10.1073/pnas.85.9.2904; RUBY SW, 1991, TRENDS GENET, V7, P79; RYMOND BC, IN PRESS MOL CELLULA; SAILER A, 1992, NUCLEIC ACIDS RES, V20, P2374, DOI 10.1093/nar/20.9.2374; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH V, 1991, EMBO J, V10, P2627, DOI 10.1002/j.1460-2075.1991.tb07805.x; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	41	80	84	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1993	262	5133					569	573		10.1126/science.7692602	http://dx.doi.org/10.1126/science.7692602			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC935	7692602				2022-12-24	WOS:A1993MC93500041
J	NEUHOLD, LA; WOLD, B				NEUHOLD, LA; WOLD, B			HLH FORCED DIMERS - TETHERING MYOD TO E47 GENERATES A DOMINANT POSITIVE MYOGENIC FACTOR INSULATED FROM NEGATIVE REGULATION BY ID	CELL			English	Article							HELIX-LOOP-HELIX; CREATINE-KINASE ENHANCER; MUSCLE-SPECIFIC ENHANCER; LIGATION-MEDIATED PCR; PAN-NEURAL GENE; DNA-BINDING; TRANSCRIPTION FACTORS; CYCLIC AMPLIFICATION; SEX DETERMINATION; NUCLEAR FACTOR	Basic-helix-loop-helix (bHLH) class transcription factors bind DNA as hetero- and homodimers. In murine myogenic cells the HLH network includes multiple members of the E protein, MyoD, and Id families; changes in the network characterize muscle determination and differentiation and have been proposed as causal for these developmental transitions. To test the importance of HLH partner choice in these cellular decisions, we have designed a strategy in which the identity of a bHLH dimer is specified by joining two monomers via a flexible polypeptide linker. A MyoD is similar to E47 polyprotein avidly bound the same DNA target as its unlinked counterpart, but, unlike intermolecular dimers that are very sensitive to inhibition by Id, MyoD is similar E47 was resistant to Id challenge. In cells MyoD is similar to E47 acted as a dominant positive myogenic factor, capable of initiating myogenic determination and also substantially bypassing negative regulation of differentiation by serum growth factors.			NEUHOLD, LA (corresponding author), CALTECH,DIV BIOL,156-29,PASADENA,CA 91125, USA.							ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIER E, 1992, GENE DEV, V6, P2137, DOI 10.1101/gad.6.11.2137; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1991, EUR J BIOCHEM, V198, P187, DOI 10.1111/j.1432-1033.1991.tb16000.x; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CABRERA CV, 1992, DEVELOPMENT, V115, P893; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FARMER K, 1992, J BIOL CHEM, V267, P5631; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FLORINI JR, 1990, J BIOL CHEM, V265, P13435; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MINER JH, 1992, DEVELOPMENT, V114, P853; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Sambrook J., 1989, MOL CLONING LAB MANU; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, CELL, V66, P423, DOI 10.1016/0092-8674(81)90003-9; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YOUNGERSHEPHERD S, 1992, CELL, V70, P911, DOI 10.1016/0092-8674(92)90242-5; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUTSEY KE, 1992, NUCLEIC ACIDS RES, V20, P5105	65	134	136	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1033	1042		10.1016/0092-8674(93)90725-6	http://dx.doi.org/10.1016/0092-8674(93)90725-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	7691411				2022-12-24	WOS:A1993LY49300010
J	MARZUK, PM; TARDIFF, K; LEON, AC; HIRSCH, CS; STAJIC, M; PORTERA, L; HARTWELL, N; IQBAL, MI				MARZUK, PM; TARDIFF, K; LEON, AC; HIRSCH, CS; STAJIC, M; PORTERA, L; HARTWELL, N; IQBAL, MI			FATAL INJURIES AFTER COCAINE USE AS A LEADING CAUSE OF DEATH AMONG YOUNG-ADULTS IN NEW-YORK-CITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLICATIONS; PREVALENCE; EXCRETION; HOMICIDE; HUMANS; COUNTY; ABUSE; CRACK	Background. Cocaine intoxication can lead to fatal cardiovascular and cerebrovascular events. In addition, the neurobehavioral effects of cocaine may increase the likelihood that a user will receive violent fatal injuries. Since New York City is a center for the importation and distribution of cocaine, we sought to determine the extent of cocaine use among city residents with fatal injuries. Methods. Among a total of 14,843 residents of New York City who received fatal injuries from 1990 through 1992, we determined the proportion who had used cocaine shortly before their deaths. We also determined the population-based rates of fatal injuries that were known to follow cocaine use and the proportion of all deaths of New York City residents that was represented by these cases for each demographic stratum. For people 15 to 44 years of age, fatal injury after cocaine use was ranked with other causes of death as though it was a separate cause. Results. Cocaine use, as measured by the detection of the metabolite benzoylecgonine in urine or blood, was found in 26.7 percent of all New York City residents receiving fatal injuries; free cocaine was detected in 18.3 percent. Approximately one third of deaths after cocaine use were the result of drug intoxication, but two thirds involved traumatic injuries resulting from homicides, suicides, traffic accidents, and falls. If fatal injury after cocaine use was considered as a separate cause of death, it would rank among the five leading causes of death among those 15 to 44 years of age in New York City. Conclusions. Fatal injuries among cocaine users account for a substantial proportion of all deaths among young adults in New York City.	CORNELL UNIV, COLL MED, DEPT PSYCHIAT, EPIDEMIOL SECT, NEW YORK, NY USA; CORNELL UNIV, COLL MED, DEPT PUBL HLTH, NEW YORK, NY USA; NYU, SCH MED, DEPT FORENS MED, NEW YORK, NY USA; OFF CHIEF MED EXAMINER, NEW YORK, NY USA	Cornell University; Cornell University; New York University					NIDA NIH HHS [DA-06534] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006534] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMBRE J, 1985, J ANAL TOXICOL, V9, P241, DOI 10.1093/jat/9.6.241; ARMITAGE P, 1987, STATISTICAL METHODS; BAILEY DN, 1989, J FORENSIC SCI, V34, P407; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BASELT RC, 1983, J CHROMATOGR, V268, P502, DOI 10.1016/S0021-9673(01)95449-4; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; HAMID A, 1991, INT J ADDICT, V26, P913, DOI 10.3109/10826089109058930; HAMILTON HE, 1977, J FORENSIC SCI, V22, P697; HANZLICK R, 1991, JAMA-J AM MED ASSOC, V6, P760; HARRUFF RC, 1988, J FORENSIC SCI, V33, P1231; LEVINE SR, 1990, NEW ENGL J MED, V323, P699, DOI 10.1056/NEJM199009133231102; LIU Y, 1982, J CHROMATOGR, V248, P318; LOWRY PW, 1988, AM J EPIDEMIOL, V128, P1130; MARZUK P M, 1992, Journal of the American Medical Association, V267, P2635, DOI 10.1001/jama.267.19.2635; MARZUK PM, 1992, AM J PSYCHIAT, V149, P371; MARZUK PM, 1990, JAMA-J AM MED ASSOC, V263, P250, DOI 10.1001/jama.263.2.250; ROGERS C, 1993, J FORENSIC SCI, V38, P831; TARDIFF K, 1989, J FORENSIC SCI, V34, P53; 1992, CP134 BUR CENS PUBL; 1993, DHHS PHS931980 RES T; 1989, DHHS PHS891260 PUBL, V1	23	75	78	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1753	1757		10.1056/NEJM199506293322606	http://dx.doi.org/10.1056/NEJM199506293322606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760893				2022-12-24	WOS:A1995RE66700006
J	HOOGERBRUGGE, PM; BROUWER, OF; BORDIGONI, P; RINGDEN, O; KAPAUN, P; ORTEGA, JJ; OMEARA, A; CORNU, G; SOUILLET, G; FRAPPAZ, D; BLANCHE, S; FISCHER, A				HOOGERBRUGGE, PM; BROUWER, OF; BORDIGONI, P; RINGDEN, O; KAPAUN, P; ORTEGA, JJ; OMEARA, A; CORNU, G; SOUILLET, G; FRAPPAZ, D; BLANCHE, S; FISCHER, A			ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LYSOSOMAL STORAGE DISEASES	LANCET			English	Article							CENTRAL NERVOUS-SYSTEM; GAUCHER DISEASE; MICE	Patients with lysosomal storage disorders have visceral, skeletal, and neurological abnormalities and a limited life expectancy. Bone marrow transplantation has been used to correct the metabolic defects and leads to metabolic improvements in most patients However, the long-term effect of such therapy is uncertain. We analysed the data from 63 patients transplanted for lysosomal storage diseases. The transplant-related mortality was 10% if an HLA-identical sibling marrow donor was available (n=40) and 20-25% if mismatched tissue was used. Data on the effect of bone transplantation on biochemical and clinical variables were available in 29 of the 63. 28 had a follow-up duration of 1.0-10.2 years; 1 patient died of disease progression in the first year after stable engraftment. 13 patients who had severe neurological symptoms at the time of transplantation showed disease progression. Engraftment of bone marrow in 5 patients with non-neuronopathic Gaucher's disease led to complete disappearance of symptoms. 11 patients had skeletal symptoms because of various mucopolysaccharidoses (MPSs). There was stabilisation of the skeletal lesions during the observation period of 1.4-6.4 years, but none of the patients showed significant regression of the skeletal symptoms. The visceral features (hepatosplenomegaly, cardiac hypertrophy, and upper airway obstruction) in these patients abated after transplantation. We could not evaluate the biochemical and clinical variables in 34 patients because of graft rejection, transplant-related mortality, or follow-up of less than 1 year. There were significant beneficial effects of bone marrow transplantation in patients with non-neuronopathic Gaucher's disease, Stabilisation of disease was observed in patients with MPS-I and MPS-II; this potential benefit needs to be confirmed by longer follow-up, Bone marow transplantation was not effective if severe neurological symptoms were already present at the time of transplantation.	UNIV LEIDEN HOSP, DIV GENE THERAPY, 2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT NEUROL, LEIDEN, NETHERLANDS; HOP ENFANTS, SERV PEDIAT 2, NANCY, FRANCE; UNIV HOSP BRUSSELS, BRUSSELS, BELGIUM; UNIV HAMBURG, HOSP EPPENDORF, HAMBURG, GERMANY; HOSP INFANTIL VAN HEBRON, BARCELONA, SPAIN; OUR LADYS HOSP SICK CHILDREN, DUBLIN, IRELAND; HOP DEBROUSSE, LYON, FRANCE; HOP NORD ST ETIENNE, SERV PEDIAT, ST ETIENNE, FRANCE; HOP NECKER ENFANTS MALAD, PARIS, FRANCE; HUDDINGE HOSP, FRANCE & BMT UNIT, S-14186 HUDDINGE, SWEDEN	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); CHU de Nancy; University Hospital Brussels; University of Hamburg; Hospital Universitari Vall d'Hebron; Our Ladys Children Hospital Crumlin; CHU Lyon; CHU de St Etienne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	HOOGERBRUGGE, PM (corresponding author), UNIV LEIDEN HOSP, DEPT PEDIAT, POB 9600, 2300 RC LEIDEN, NETHERLANDS.		Hoogerbrugge, Peter M./H-8049-2014					Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BARRANGER JA, 1984, NEW ENGL J MED, V311, P1629, DOI 10.1056/NEJM198412203112509; BARRANGER JA, 1984, MOL BASIS LYSOSOMAL, P1; BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913; BAYEVER E, 1992, J INHERIT METAB DIS, V15, P919, DOI 10.1007/BF01800234; BAYEVER E, 1985, LANCET, V2, P471; GALE RP, 1978, SCIENCE, V192, P1016; GREENFIELD JG, 1963, GREENFIELDS NEUROPAT, P475; HASKINS M, 1991, TREATMENT GENETIC DI, P183; HOBBS JR, 1987, LANCET, V1, P1111; HOOGERBRUGGE PM, 1987, TRANSPLANTATION, V43, P609, DOI 10.1097/00007890-198705000-00001; HOOGERBRUGGE PM, 1988, SCIENCE, V239, P1035, DOI 10.1126/science.3278379; HOOGERBRUGGE PM, 1989, BONE MARROW TRANSPL, P331; HOPWOOD JJ, 1993, J INHERIT METAB DIS, V16, P1024, DOI 10.1007/BF00711520; Hugh-Jones K, 1986, Birth Defects Orig Artic Ser, V22, P25; KOLODNY EH, 1989, METABOLIC BASIS INHE, P1721; KRIVIT W, 1984, NEW ENGL J MED, V311, P1606, DOI 10.1056/NEJM198412203112504; KRIVIT W, 1990, NEW ENGL J MED, V322, P28, DOI 10.1056/NEJM199001043220106; KRIVIT W, 1991, TREATMENT GENETIC DI, P203; Krivit W., 1989, BONE MARROW TRANSPL, P367; OLSEN I, 1983, NATURE, V306, P75, DOI 10.1038/306075a0; RINGDEN O, 1988, TRANSPLANTATION, V46, P66, DOI 10.1097/00007890-198807000-00011; RINGDEN O, 1990, TRANSPL P, V22, P198; SAKIYAMA T, 1983, BIOCHEM BIOPH RES CO, V113, P605, DOI 10.1016/0006-291X(83)91769-2; SHAPIRO E, 1991, TREATMENT GENETIC DI, P223; SHULL RM, 1987, J CLIN INVEST, V79, P435, DOI 10.1172/JCI112830; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; TAYLOR RM, 1987, TRANSPLANT P, V19, P2730; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; TSAI P, 1992, PEDIATR RES, V31, P503, DOI 10.1203/00006450-199205000-00019; VELLODI A, 1992, J INHERIT METAB DIS, V15, P911, DOI 10.1007/BF01800232; WALKLEY SU, 1994, P NATL ACAD SCI USA, V91, P2970, DOI 10.1073/pnas.91.8.2970; WHITLEY CB, 1993, AM J MED GENET, V46, P209, DOI 10.1002/ajmg.1320460222	33	207	220	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 3	1995	345	8962					1398	1402		10.1016/S0140-6736(95)92597-X	http://dx.doi.org/10.1016/S0140-6736(95)92597-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760610				2022-12-24	WOS:A1995RB44100009
J	LIU, GS; TSIEN, RW				LIU, GS; TSIEN, RW			PROPERTIES OF SYNAPTIC TRANSMISSION AT SINGLE HIPPOCAMPAL SYNAPTIC BOUTONS	NATURE			English	Article							LONG-TERM POTENTIATION; QUANTAL ANALYSIS; SLICES; CURRENTS; NEURONS; VARIABILITY; MINIATURE; SYNAPSES	SYNAPTIC transmission between individual presynaptic terminals and postsynaptic dendrites is a fundamental element of communication among central nervous system neurons. Yet little is known about evoked neurotransmission at the level of single presynaptic boutons(1-5). Here we describe key functional characteristics of individual presynaptic boutons of hippocampal neurons in culture. Excitatory postsynaptic currents (e.p.s.cs) were evoked by localized application of elevated K+/Ca2+ solution to single functional boutons, visually identified by staining with the vital dye FM1-43 (refs 6, 7). Frequent repetitive stimulation produced a decline in the incidence of e.p.s.cs as the pool of releasable vesicles was exhausted; typically, recovery proceeded with a time constant of about 40 s (23 degrees C), and involved a vesicular pool capable of generating about 90 e.p.s.cs without recycling. At individual synapses, synaptic currents were broadly distributed in amplitude(1), but this distribution was remarkably similar at multiple synapses on a given postsynaptic neuron. The average size of synaptic currents and of responses to focal glutamate application varied fourfold across different cells, decreasing markedly with increasingly dense synaptic innervation. This raises the possibility of a very effective mechanism for coordinating synaptic strength at multiple sites throughout the dendritic tree.	STANFORD UNIV,MED CTR,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University								BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BETZ WJ, 1993, J PHYSIOL-LONDON, V460, P287, DOI 10.1113/jphysiol.1993.sp019472; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; HORRIGAN FT, 1994, J NEURON, V13, P1119; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; JONES KA, 1991, NEURON, V7, P593, DOI 10.1016/0896-6273(91)90372-7; KATZ B, 1967, J PHYSIOL-LONDON, V189, P535, DOI 10.1113/jphysiol.1967.sp008183; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LAVIDIS NA, 1992, J PHYSIOL-LONDON, V454, P9, DOI 10.1113/jphysiol.1992.sp019252; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1; WU LG, 1994, NEURON, V12, P1139, DOI 10.1016/0896-6273(94)90321-2	22	253	257	1	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					404	408		10.1038/375404a0	http://dx.doi.org/10.1038/375404a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760934				2022-12-24	WOS:A1995RB10100053
J	STEWART, JD; BENKOVIC, SJ				STEWART, JD; BENKOVIC, SJ			TRANSITION-STATE STABILIZATION AS A MEASURE OF THE EFFICIENCY OF ANTIBODY CATALYSIS	NATURE			English	Article							HYDROLYSIS; SUBSTRATE	THERE are now about 60 examples of reactions that have been successfully catalysed by monoclonal antibodies(1-3). Not surprisingly, many of the early examples involved reactions that were already favoured kinetically (such as carbonate and ester hydrolysis). But it has since been shown that antibodies can also accelerate reaction pathways that are normally disfavoured kinetically (by at least a few kcal mol(-1))(4-7). Here we use transition-state theory to provide a quantitative analysis of the scope and limitations of antibody catalysis. We show that the observed rate accelerations can be predicted from the ratio of equilibrium binding constants of the reaction substrate and the transition-state analogue used to raise the antibody. This scheme allows us to rationalize the product selectivity displayed in antibody catalysis of disfavoured reactions, to predict the degree of rate acceleration that catalytic antibodies may ultimately afford, and to highlight some differences between the way that they and enzymes catalyse reactions.	PENN STATE UNIV,DEPT CHEM,UNIVERSITY PK,PA 16801	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	STEWART, JD (corresponding author), UNIV FLORIDA,DEPT CHEM,GAINESVILLE,FL 32611, USA.							ASHLEY JA, 1993, J AM CHEM SOC, V115, P2515, DOI 10.1021/ja00059a061; BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BENKOVIC SJ, 1988, P NATL ACAD SCI USA, V85, P5355, DOI 10.1073/pnas.85.15.5355; CAMPBELL DA, 1994, J AM CHEM SOC, V116, P2165, DOI 10.1021/ja00084a075; COCHRAN AG, 1991, J AM CHEM SOC, V113, P6670, DOI 10.1021/ja00017a046; COCHRAN AG, 1990, SCIENCE, V240, P781; CRAVATT BF, 1994, J AM CHEM SOC, V116, P6013, DOI 10.1021/ja00092a080; GIBBS RA, 1992, J AM CHEM SOC, V114, P3528, DOI 10.1021/ja00035a057; GOUVERNEUR VE, 1993, SCIENCE, V262, P204, DOI 10.1126/science.8211138; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HIRSCHMANN R, 1994, SCIENCE, V265, P234, DOI 10.1126/science.8023141; IVERSON BL, 1990, J AM CHEM SOC, V112, P5320, DOI 10.1021/ja00169a044; IWABUCHI Y, 1994, J AM CHEM SOC, V116, P771, DOI 10.1021/ja00081a049; JACKSON DY, 1991, P NATL ACAD SCI USA, V88, P58, DOI 10.1073/pnas.88.1.58; JACOBS J, 1987, J AM CHEM SOC, V109, P2174, DOI 10.1021/ja00241a042; JACOBS JW, 1991, BIO-TECHNOL, V9, P258, DOI 10.1038/nbt0391-258; JACOBSEN JR, 1994, P NATL ACAD SCI USA, V91, P5888, DOI 10.1073/pnas.91.13.5888; JACOBSEN JR, 1992, SCIENCE, V256, P365, DOI 10.1126/science.256.5055.365; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; JANDA KD, 1991, TETRAHEDRON, V47, P2503, DOI 10.1016/S0040-4020(01)81784-1; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LEWIS C, 1991, SCIENCE, V253, P1019, DOI 10.1126/science.1887215; LI TY, 1994, SCIENCE, V264, P1289, DOI 10.1126/science.8191282; MARTIN MT, 1991, BIOCHEMISTRY-US, V30, P9757, DOI 10.1021/bi00104a027; NA J, 1993, J AM CHEM SOC, V115, P8453, DOI 10.1021/ja00071a067; NAPPER AD, 1987, SCIENCE, V237, P1041, DOI 10.1126/science.3616626; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; POSNER B, 1994, TRENDS BIOCHEM SCI, V19, P145, DOI 10.1016/0968-0004(94)90273-9; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; REYMOND JL, 1991, ANGEW CHEM INT EDIT, V30, P1711, DOI 10.1002/anie.199117111; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SHOKAT KM, 1989, NATURE, V338, P269, DOI 10.1038/338269a0; STEWART JD, 1994, P NATL ACAD SCI USA, V91, P7404, DOI 10.1073/pnas.91.16.7404; STEWART JD, 1993, ACCOUNTS CHEM RES, V26, P396, DOI 10.1021/ar00032a002; STEWART JD, 1993, CHEM SOC REV, V22, P213, DOI 10.1039/cs9932200213; STEWART JD, 1994, BIOCHEMISTRY-US, V33, P1991; TRAMONTANO A, 1988, J AM CHEM SOC, V110, P2282, DOI 10.1021/ja00215a045; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; WOLFENDEN R, 1976, ANNU REV BIOPHYS BIO, V5, P271, DOI 10.1146/annurev.bb.05.060176.001415	39	105	108	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					388	391		10.1038/375388a0	http://dx.doi.org/10.1038/375388a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760931				2022-12-24	WOS:A1995RB10100048
J	BERRY, SM; LECOLIER, B; SMITH, RS; BERCAU, G; DOMBROWSKI, MP; PUDER, KS; KITHIER, K; BIDAT, L; JOHNSON, MP; COTTON, DB				BERRY, SM; LECOLIER, B; SMITH, RS; BERCAU, G; DOMBROWSKI, MP; PUDER, KS; KITHIER, K; BIDAT, L; JOHNSON, MP; COTTON, DB			PREDICTIVE VALUE OF FETAL SERUM BETA(2)-MICROGLOBULIN FOR NEONATAL RENAL-FUNCTION	LANCET			English	Note							BETA2-MICROGLOBULIN; MATURATION; INDEX	When fetal urinary-tract malformations (UTM) are discovered, management is based on the prediction of postnatal renal function, currently made by fetal urinary biochemistry and sonography, Serum beta(2)-microglobulin has been used postnatally to estimate renal function and does not cross the placenta. We investigated the relation between fetal serum beta(2)-microglobulin and renal function by comparing 64 unaffected fetuses and 15 fetuses with UTM. A beta(2)-microglobulin above a 5.6 mg/L cut-off gave cross-validated sensitivity of 88.9%, specificity of 98.6%, a positive predictive value of 88.9%, and a negative predictive value of 97.1% for our cohort study.	WAYNE STATE UNIV,HUTZEL HOSP,RECEIVING HOSP,DEPT OBSTET & GYNAECOL,DIV REPROD GENET,DETROIT,MI 48201; WAYNE STATE UNIV,HUTZEL HOSP,RECEIVING HOSP,DEPT PATHOL,DETROIT,MI 48201; HOP NOTRE DAME DE BON SECOURS,CTR PRENATAL DIAG,PARIS,FRANCE	Wayne State University; Wayne State University	BERRY, SM (corresponding author), WAYNE STATE UNIV,HUTZEL HOSP,RECEIVING HOSP,DEPT OBSTET & GYNAECOL,DIV MATERNAL FETAL MED,DETROIT,MI 48201, USA.							ASSADI FK, 1985, KIDNEY INT, V28, P153, DOI 10.1038/ki.1985.135; EUGENE M, 1994, AM J OBSTET GYNECOL, V170, P595, DOI 10.1016/S0002-9378(94)70235-7; GLICK PL, 1985, J PEDIATR SURG, V20, P376, DOI 10.1016/S0022-3468(85)80223-2; KITHIER K, 1974, CLIN CHIM ACTA, V52, P293, DOI 10.1016/0009-8981(74)90113-2; LIVERA LN, 1989, BRIT MED J, V298, P1421, DOI 10.1136/bmj.298.6685.1421; NICOLAIDES K H, 1992, Fetal Diagnosis and Therapy, V7, P1; NICOLINI U, 1992, BRIT J OBSTET GYNAEC, V99, P46, DOI 10.1111/j.1471-0528.1992.tb14391.x; NOLTE S, 1991, PEDIATR NEPHROL, V5, P573, DOI 10.1007/BF00856641; ONASSON LE, 1974, ACTA OBSTET GYNAECOL, V53, P48; WIBELL L, 1973, NEPHRON, V10, P320, DOI 10.1159/000180203	10	54	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1277	1278		10.1016/S0140-6736(95)90928-1	http://dx.doi.org/10.1016/S0140-6736(95)90928-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746060				2022-12-24	WOS:A1995QY93300012
J	MATTHES, DJ; SINK, H; KOLODKIN, AL; GOODMAN, CS				MATTHES, DJ; SINK, H; KOLODKIN, AL; GOODMAN, CS			SEMAPHORIN-II CAN FUNCTION AS A SELECTIVE INHIBITOR OF SPECIFIC SYNAPTIC ARBORIZATIONS	CELL			English	Article							GROWTH CONE GUIDANCE; DROSOPHILA-MELANOGASTER; C-ELEGANS; MOTONEURONS; EXPRESSION; MOLECULE; NEURONS; MUSCLES; PROTEIN; EMBRYO	Previous studies showed that grasshopper semaphorin I, a transmembrane semaphorin, functions in vivo to steer a pair of growth cones, prevent defasciculation, and inhibit branching; and that chick collapsin, a secreted semaphorin, can function in vitro to cause growth cone collapse. Semaphorin II, a secreted semaphorin in Drosophila, is transiently expressed by a single large muscle during motoneuron outgrowth and synapse formation. To test the in vivo function of semaphorin II, we created transgenic Drosophila that generate ectopic semaphorin II expression by muscles that normally do not express it. The results show that semaphorin II can function in vivo as a selective target-derived signal that inhibits the formation of specific synaptic terminal arbors.			MATTHES, DJ (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720, USA.		Matthes, David/N-3529-2017	Matthes, David/0000-0002-0198-9661	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021294, R01HD021294] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21294] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bate Michael, 1993, P1013; BROADIE K, 1993, DEVELOPMENT S, V119, P227; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Crossley AC, 1978, GENETICS BIOL DROS B, V2, P499; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; GOODMAN CS, 1993, CELL S, V10, P77; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V2, P61; HOOPER JE, 1986, EMBO J, V5, P2321, DOI 10.1002/j.1460-2075.1986.tb04500.x; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; RAMOS RGP, 1993, GENE DEV, V7, P2533, DOI 10.1101/gad.7.12b.2533; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TAGHERT PH, 1982, DEV BIOL, V94, P391, DOI 10.1016/0012-1606(82)90356-6; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WHARTON KA, 1993, MECH DEVELOP, V40, P141, DOI 10.1016/0925-4773(93)90072-6	32	183	184	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					631	639		10.1016/0092-8674(95)90084-5	http://dx.doi.org/10.1016/0092-8674(95)90084-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758117	Bronze			2022-12-24	WOS:A1995QZ71000020
J	BRITZCUNNINGHAM, SH; SHAH, MM; ZUPPAN, CW; FLETCHER, WH				BRITZCUNNINGHAM, SH; SHAH, MM; ZUPPAN, CW; FLETCHER, WH			MUTATIONS OF THE CONNEXIN43 GAP-JUNCTION GENE IN PATIENTS WITH HEART MALFORMATIONS AND DEFECTS OF LATERALITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPLANTATION MOUSE EMBRYO; CARDIAC DEFECTS; COMMUNICATION; PROTEIN; EXPRESSION; PHOSPHORYLATION; LOCALIZATION; CHANNEL; FAMILY; CELLS	Background. Gap junctions are thought to have a crucial role in the synchronized contraction of the heart and in embryonic development. Connexin43, the major protein of gap junctions in the heart, is targeted by several protein kinases that regulate myocardial cell-cell coupling. We hypothesized that mutations altering sites critical to this regulation would lead to functional or developmental abnormalities of the heart. Methods. Connexin43 DNA from 25 normal subjects and 30 children with a Variety of congenital heart diseases was amplified by the polymerase chain reaction and sequenced. Mutant DNA was expressed in cell culture and examined for its effect on the regulation of cell-cell communication. Results. The 25 normal subjects and 23 of the 30 children with heart disease had no amino acid substitutions in connexin43. All six children with syndromes that included complex heart malformations had substitutions of one or more phosphorylatable serine or threonine residues. Four of these children had two independent mutations, suggesting an autosomal recessive disorder. Five of these children had substitutions of proline for serine at position 364. A seventh child, with a different heart condition, also had a point mutation in connexin43. Transfected cells expressing the Ser364Pro mutant connexin43 sequence showed abnormalities in the regulation of cell-cell communication, as compared with cells expressing normal connexin43. Conclusions. Mutations in the connexin43 gap-junction gene, which lead to abnormally regulated cell-cell communication, are associated with visceroatrial heterotaxia.	LOMA LINDA UNIV, DEPT PATHOL & HUMAN ANAT, LOMA LINDA, CA 92354 USA; JERRY L PETTIS MEM VET AFFAIRS MED CTR, MOLEC CYTOL LAB, LOMA LINDA, CA USA	Loma Linda University	BRITZCUNNINGHAM, SH (corresponding author), LOMA LINDA UNIV, DEPT PHYSIOL, LOMA LINDA, CA 92354 USA.							ARNOLD GL, 1983, AM J MED GENET, V16, P35, DOI 10.1002/ajmg.1320160107; BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; CARMI R, 1992, AM J MED GENET, V44, P246, DOI 10.1002/ajmg.1320440228; CASEY B, 1993, NAT GENET, V5, P403, DOI 10.1038/ng1293-403; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; DRISCOLL DA, 1992, AM J HUM GENET, V50, P924; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; FORSTHOEFEL KF, 1992, AM J CLIN PATHOL, V98, P98, DOI 10.1093/ajcp/98.1.98; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GODWIN AJ, 1993, MOL CELL BIOCHEM, V128, P293, DOI 10.1007/BF01076779; GOSHIMA K, 1971, EXP CELL RES, V65, P161, DOI 10.1016/S0014-4827(71)80062-9; HOWITT G, 1961, BRIT HEART J, V23, P494; KALIMI GH, 1988, J CELL BIOL, V107, P241, DOI 10.1083/jcb.107.1.241; KALIMI GH, 1989, J CELL BIOL, V109, P3015, DOI 10.1083/jcb.109.6.3015; KATZ AM, 1992, PHYSL HEART, P521; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOJIMA H, 1969, LANCET, V2, P701; LAIRD DW, 1990, J CELL SCI, V97, P109; LO CW, 1979, CELL, V18, P411, DOI 10.1016/0092-8674(79)90060-6; LO CW, 1979, CELL, V18, P399, DOI 10.1016/0092-8674(79)90059-X; Lynberg M C, 1990, MMWR CDC Surveill Summ, V39, P1; MCCHANE RH, 1989, SOUTHERN MED J, V82, P1312, DOI 10.1097/00007611-198910000-00032; MCKUSICK VA, 1995, MENDELIAN INHERITANC, V2, P1236; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MURRAY SA, 1984, J CELL BIOL, V98, P1710, DOI 10.1083/jcb.98.5.1710; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; NISHI M, 1991, DEV BIOL, V146, P117, DOI 10.1016/0012-1606(91)90452-9; NOONAN JA, 1978, AM J DIS CHILD, V132, P17, DOI 10.1001/archpedi.1978.02120260019001; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; RUANGVORAVAT CP, 1992, DEV DYNAM, V194, P261, DOI 10.1002/aja.1001940403; Sambrook J., 1989, MOL CLONING LAB MANU; STAGG RB, 1990, ENDOCR REV, V11, P302, DOI 10.1210/edrv-11-2-302; SULLIVAN R, 1993, GENE, V130, P191, DOI 10.1016/0378-1119(93)90419-4; VANPATTEN SM, 1986, J BIOL CHEM, V261, P5514; VEENSTRA RD, 1986, SCIENCE, V233, P972, DOI 10.1126/science.2426781; WARNER AE, 1984, NATURE, V311, P127, DOI 10.1038/311127a0; WHITE RL, 1985, AM J PHYSIOL, V249, pC447, DOI 10.1152/ajpcell.1985.249.5.C447; WILLECKE K, 1990, EUR J CELL BIOL, V53, P275; ZELLERS TM, 1990, AM J CARDIOL, V65, P523, DOI 10.1016/0002-9149(90)90825-L; 1989, MMWR-MORBID MORTAL W, V38, P633	45	330	349	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 18	1995	332	20					1323	1329		10.1056/NEJM199505183322002	http://dx.doi.org/10.1056/NEJM199505183322002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX857	7715640	Bronze			2022-12-24	WOS:A1995QX85700002
J	TIAN, GL; VAINBERG, IE; TAP, WD; LEWIS, SA; COWAN, NJ				TIAN, GL; VAINBERG, IE; TAP, WD; LEWIS, SA; COWAN, NJ			SPECIFICITY IN CHAPERONIN-MEDIATED PROTEIN-FOLDING	NATURE			English	Article							CYTOPLASMIC CHAPERONIN; COMPLEX; TUBULIN; HOMOLOG	CHAPERONINS are ubiquitous multisubunit toroidal complexes that aid protein folding in an ATP-dependent manner(1-6). Current models of folding by the bacterial chaperonin GroEL depict its role as unfolding and releasing molecules that have misfolded, so that they can return to a potentially productive folding pathway in solution(7,8). Accordingly, a given target polypeptide might require several cycles of binding and ATP-driven release from different chaperonin complexes before reaching the native state. Surprisingly, cycling of a target protein does not guarantee its folding, and we report here that unfolded beta-actin or alpha-tubulin both form tight complexes when presented to either GroEL or its mitochondrial homologue, and both undergo cycles of release and rebinding upon incubation with ATP, but no native protein is produced. We conclude that different chaperonins produce distinctive spectra of folding intermediates.	NYU,MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	New York University								BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HORWICH AL, 1994, CELL, V74, P909; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	19	118	120	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					250	253		10.1038/375250a0	http://dx.doi.org/10.1038/375250a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746329				2022-12-24	WOS:A1995QY88100068
J	ELLERBECK, EF; JENCKS, SF; RADFORD, MJ; KRESOWIK, TF; CRAIG, AS; GOLD, JA; KRUMHOLZ, HM; VOGEL, RA				ELLERBECK, EF; JENCKS, SF; RADFORD, MJ; KRESOWIK, TF; CRAIG, AS; GOLD, JA; KRUMHOLZ, HM; VOGEL, RA			QUALITY OF CARE FOR MEDICARE PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION - A 4-STATE PILOT-STUDY FROM THE COOPERATIVE CARDIOVASCULAR PROJECT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUIDELINES; SURVIVAL; SMOKING	Objective.-To develop and test indicators of the quality of care for patients with acute myocardial infarction (AMI). Design.-Retrospective medical record review. Setting.-All acute care hospitals in Alabama, Connecticut, Iowa, and Wisconsin. Patients.-All hospitalizations for Medicare patients discharged with a principal diagnosis of AMI between June 1, 1992, and February 28, 1993, were identified (N=16 869). Main Outcome Measure.-Percentage of patients receiving appropriate interventions as defined by 11 quality-of-care indicators derived from clinical practice guidelines that were modified and updated in consultation with a national group of physicians and other health care professionals. Results.-We abstracted data from 16 124 (96%) of the hospitalizations, representing 14 108 primary hospitalizations and 2016 hospitalizations resulting from transfers. Potential exclusions to the use of standard treatments in AMI care were common with 90% and 70% of patients having potential exclusions for thrombolytics and beta-blockers, respectively. In cohorts of ''ideal candidates'' for specific interventions, 83% received aspirin, 69% received thrombolytics, and 70% received heparin during the initial hospitalization; 77% received aspirin and 45% received beta-blockers at discharge. Conclusions.-These data demonstrate that many Medicare patients may not be ideal candidates for standard AMI therapies, but these treatments are underused, even in the absence of discernible contraindications. Hospitals and physicians who apply these quality indicators to their practices are likely to find opportunities for improvement.	HLTH CARE FINANCING ADM,BUR HLTH STAND & QUAL,BALTIMORE,MD; CONNECTICUT PEER REVIEW ORG,MIDDLETOWN,CT; UNIV CONNECTICUT,DEPT CARDIOL,FARMINGTON,CT; IOWA FDN MED CARE,DES MOINES,IA; UNIV IOWA,DEPT SURG,IOWA CITY,IA 52242; ALABAMA QUAL ASSURANCE FDN,BIRMINGHAM,AL; UNIV ALABAMA,DEPT INTERNAL MED,BIRMINGHAM,AL; WISCONSIN PEER REVIEW ORG,MADISON,WI; MED COLL WISCONSIN,DEPT PREVENT MED,MILWAUKEE,WI 53226; UNIV WISCONSIN,MADISON,WI; YALE UNIV,SCH MED,CARDIOVASC SECT,NEW HAVEN,CT; UNIV MARYLAND,DEPT CARDIOL,BALTIMORE,MD	University of Connecticut; University of Iowa; University of Alabama System; University of Alabama Birmingham; Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison; Yale University; University System of Maryland; University of Maryland Baltimore			Ellerbeck, Edward/I-8438-2014; , Harlan/AAI-2875-2020	Ellerbeck, Edward/0000-0002-7774-2729; Kresowik, Timothy/0000-0003-4163-1573; Radford, Martha/0000-0001-7503-9557				[Anonymous], 1988, INT CLASSIFICATION D; AUDET AM, 1994, ANN INTERN MED, V120, P423, DOI 10.7326/0003-4819-120-5-199403010-00011; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; FISHER EB, 1990, AM REV RESPIR DIS, V142, P702, DOI 10.1164/ajrccm/142.3.702; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HORWITZ RI, 1990, AM J MED, V89, P630, DOI 10.1016/0002-9343(90)90182-D; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; KJEKSHUS J, 1990, EUR HEART J, V11, P43, DOI 10.1093/oxfordjournals.eurheartj.a059591; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; LAMBERTHUBER DA, 1994, CLIN PERFORMANCE QUA, V2, P219; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MCGUIRE LB, 1990, ANN INTERN MED, V113, P705, DOI 10.7326/0003-4819-113-9-705; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; SULLIVAN LW, 1992, 1992 HLTH CAR FIN AD; TIEFENBRUNN AJ, 1992, CIRCULATION, V85, P2311, DOI 10.1161/01.CIR.85.6.2311; VLIETSTRA RE, 1986, JAMA-J AM MED ASSOC, V255, P1023, DOI 10.1001/jama.255.8.1023; 1992, JAMA-J AM MED ASSOC, V268, P2199; 1994, EMERGENCY DEP RAPID; 1985, AM J CARDIOL, V56, pG1; 1990, JAMA-J AM MED ASSOC, V263, P2753; 1990, STATA RELEASE 2 REFE	26	343	344	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1509	1514		10.1001/jama.273.19.1509	http://dx.doi.org/10.1001/jama.273.19.1509			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739077				2022-12-24	WOS:A1995QX41800033
J	KASS, DM; YUNG, YL				KASS, DM; YUNG, YL			LOSS OF ATMOSPHERE FROM MARS DUE TO SOLAR WIND-INDUCED SPUTTERING	SCIENCE			English	Article							OXYGEN ION PRECIPITATION; SPATIAL DISTRIBUTIONS; ENERGY DEPOSITION; EVOLUTION; CLIMATE; VENUS; CONSEQUENCES	Because Mars does not have a strong intrinsic magnetic field, the atmosphere is eroded by interactions with the solar wind. Early solar-system conditions enhanced the sputtering loss. It is calculated that similar to 3 bars of carbon dioxide (CO2) have been sputtered over the last 3.5 billion years. This significant increase over the previous estimate by Luhmann et al. of similar to 0.14 bar of CO2 is the result of the development of a more complete model. The model also predicts slightly greater loss of water-similar to 80 meters instead of the similar to 50 meters predicted by Luhmann et al. Because estimates of CO2 on early Mars range from 0.5 to 5 bars, the 0.14-bar estimate is insignificant but the similar to 3-bar estimate will have a large effect on our understanding of the planet's evolution.			KASS, DM (corresponding author), CALTECH,DIV GEOL & PLANETARY SCI,PASADENA,CA 91125, USA.		Yung, Yuk/AAM-4850-2021	Yung, Yuk/0000-0002-4263-2562				FANALE FP, 1982, ICARUS, V50, P381, DOI 10.1016/0019-1035(82)90131-2; HODGES RR, 1993, J GEOPHYS RES-PLANET, V98, P10833, DOI 10.1029/93JE00998; HUNTEN DM, 1993, SCIENCE, V259, P915, DOI 10.1126/science.259.5097.915; ISHIMOTO M, 1986, J GEOPHYS RES, V91, P5793, DOI 10.1029/JA091iA05p05793; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; JOHNSON RE, 1992, J GEOPHYS RES-SPACE, V97, P13911, DOI 10.1029/92JA01142; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; LUHMANN JG, 1992, GEOPHYS RES LETT, V19, P2151, DOI 10.1029/92GL02485; LUHMANN JG, 1991, J GEOPHYS RES-SPACE, V96, P5457, DOI 10.1029/90JA01753; McElroy M. B., 1977, Journal of Geophysical Research, V82, P4379, DOI 10.1029/JS082i028p04379; MCKAY CP, 1991, ICARUS, V90, P214, DOI 10.1016/0019-1035(91)90102-Y; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; SMITH PH, 1978, SPACE SCI REV, V22, P301, DOI 10.1007/BF00239804; STEBBINGS RF, 1964, J GEOPHYS RES, V69, P2349, DOI 10.1029/JZ069i011p02349; ZAHNLE KJ, 1982, REV GEOPHYS, V20, P280, DOI 10.1029/RG020i002p00280; [No title captured]	16	84	85	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					697	699		10.1126/science.7732377	http://dx.doi.org/10.1126/science.7732377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732377				2022-12-24	WOS:A1995QW60300041
J	GUO, LF; DEGENSTEIN, L; DOWLING, J; YU, QC; WOLLMANN, R; PERMAN, B; FUCHS, E				GUO, LF; DEGENSTEIN, L; DOWLING, J; YU, QC; WOLLMANN, R; PERMAN, B; FUCHS, E			GENE TARGETING OF BPAG1 - ABNORMALITIES IN MECHANICAL STRENGTH AND CELL-MIGRATION IN STRATIFIED EPITHELIA AND NEUROLOGIC DEGENERATION	CELL			English	Article							BULLOUS PEMPHIGOID ANTIGEN; BASEMENT-MEMBRANE ADHESION; CDNA CLONING; HEMIDESMOSOMES; INTEGRIN; ALPHA-6-BETA-4; IDENTIFICATION; EXPRESSION; COMPONENT; PROTEIN	BPAG1 is the major antigenic determinant of autoimmune sera of bullous pemphigoid (BP) patients. It is made by stratified squamous epithelia, where it localizes to the inner surface of specialized integrin-mediated adherens junctions (hemidesmosomes). To explore the function of BPAG1 iind its relation to BP, we targeted the removal of the BPAG1 gene in mice. Hemidesmosomes are otherwise normal, but they lack the inner plate and have no cytoskeleton attached. Though not affecting cell growth or substratum adhesion, this compromises mechanical integrity and influences migration. Unexpectedly, the mice also develop severe dystonia and sensory nerve degeneration typical of dystonia musculorum (dt/dt) mice. We show that in at least one other strain of dt/dt mice, BPAG1 gene is defective.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago	GUO, LF (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.		Fuchs, Elaine/G-1565-2016					ANTON-LAMPBRECHT I, 1983, J INVEST DERMATOL S, V81, P149; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BROWN A, 1994, GENOMICS, V20, P371, DOI 10.1006/geno.1994.1190; CAMPBELL RM, 1992, NEURON, V9, P693, DOI 10.1016/0896-6273(92)90032-9; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CHAN YM, 1994, GENE DEV, V8, P2574, DOI 10.1101/gad.8.21.2574; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1993, GENOMICS, V15, P180, DOI 10.1006/geno.1993.1027; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; DIAZ LA, 1977, J IMMUNOL, V118, P455; Duchen L W, 1976, Adv Neurol, V14, P353; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GIUDICE GJ, 1991, J CLIN INVEST, V87, P734, DOI 10.1172/JCI115054; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HIEDA Y, 1992, J CELL BIOL, V116, P1497, DOI 10.1083/jcb.116.6.1497; Hogan B, 1994, MANIPULATING MOUSE E; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; KLATTE DH, 1989, J CELL BIOL, V109, P3377, DOI 10.1083/jcb.109.6.3377; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; KURPAKUS MA, 1991, J CELL BIOL, V115, P1737, DOI 10.1083/jcb.115.6.1737; LABIB RS, 1986, J IMMUNOL, V136, P1231; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MESSER A, 1980, NEUROSCIENCE, V5, P543, DOI 10.1016/0306-4522(80)90051-2; MUELLER S, 1989, J INVEST DERMATOL, V92, P33, DOI 10.1111/1523-1747.ep13070476; OWARIBE K, 1990, DIFFERENTIATION, V45, P207, DOI 10.1111/j.1432-0436.1990.tb00475.x; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RUGG EL, 1994, GENE DEV, V8, P2563, DOI 10.1101/gad.8.21.2563; SAWAMURA D, 1990, GENOMICS, V8, P722, DOI 10.1016/0888-7543(90)90261-R; SAWAMURA D, 1994, J INVEST DERMATOL, V103, P651, DOI 10.1111/1523-1747.ep12398405; SAWAMURA D, 1991, J INVEST DERMATOL, V96, P908, DOI 10.1111/1523-1747.ep12475433; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; SUGI T, 1989, J CLIN INVEST, V84, P1050, DOI 10.1172/JCI114266; TANAKA T, 1990, J INVEST DERMATOL, V94, P617, DOI 10.1111/1523-1747.ep12876200; WESTGATE GE, 1985, J INVEST DERMATOL, V84, P218, DOI 10.1111/1523-1747.ep12265229	41	390	395	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					233	243		10.1016/0092-8674(95)90333-X	http://dx.doi.org/10.1016/0092-8674(95)90333-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736575	Bronze			2022-12-24	WOS:A1995QV41000012
J	STEEL, M				STEEL, M			TELOMERASE THAT SHAPES OUR ENDS	LANCET			English	Editorial Material							HUMAN FIBROBLASTS; CELLS				STEEL, M (corresponding author), UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS,FIFE,SCOTLAND.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DENIS H, 1993, TRENDS GENET, V9, P7, DOI 10.1016/0168-9525(93)90065-P; GILSON E, 1993, TRENDS CELL BIOL, V33, P128; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; STEEL CM, 1994, BRIT MED BULL, V50, P536, DOI 10.1093/oxfordjournals.bmb.a072909	11	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					935	936		10.1016/S0140-6736(95)90692-4	http://dx.doi.org/10.1016/S0140-6736(95)90692-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715287				2022-12-24	WOS:A1995QT91900002
J	PISACANE, A; DELUCA, U; IMPAGLIAZZO, N; RUSSO, M; DECAPRIO, C; CARACCIOLO, G				PISACANE, A; DELUCA, U; IMPAGLIAZZO, N; RUSSO, M; DECAPRIO, C; CARACCIOLO, G			BREAST-FEEDING AND ACUTE APPENDICITIS	BRITISH MEDICAL JOURNAL			English	Article									OSPED SANTOBONO,DIV CHIRURG,USL REG CAMPANIA 40,NAPLES,ITALY		PISACANE, A (corresponding author), UNIV NAPLES,DEPT PEDIAT,I-80131 NAPLES,ITALY.							BARKER DJP, 1985, BRIT MED J, V290, P1125, DOI 10.1136/bmj.290.6475.1125; COGGON D, 1991, J EPIDEMIOL COMMUN H, V45, P244, DOI 10.1136/jech.45.3.244; GOLDMAN AS, 1993, PEDIATR INFECT DIS J, V12, P664, DOI 10.1097/00006454-199308000-00008; HEATON KW, 1987, BRIT MED J, V294, P1632, DOI 10.1136/bmj.294.6588.1632; NELSON M, 1986, J EPIDEMIOL COMMUN H, V40, P316, DOI 10.1136/jech.40.4.316	5	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					836	837		10.1136/bmj.310.6983.836	http://dx.doi.org/10.1136/bmj.310.6983.836			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711621	Green Published			2022-12-24	WOS:A1995QQ85700019
J	WEIL, J; COLINJONES, D; LANGMAN, M; LAWSON, D; LOGAN, R; MURPHY, M; RAWLINS, M; VESSEY, M; WAINWRIGHT, P				WEIL, J; COLINJONES, D; LANGMAN, M; LAWSON, D; LOGAN, R; MURPHY, M; RAWLINS, M; VESSEY, M; WAINWRIGHT, P			PROPHYLACTIC ASPIRIN AND RISK OF PEPTIC-ULCER BLEEDING	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTI-INFLAMMATORY DRUGS; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; CONTROLLED TRIAL; MORTALITY; ACID	Objective-To determine the risks of hospitalisation for bleeding peptic ulcer with the current prophylactic aspirin regimens of 300 mg daily or less. Design-A case-control study with hospital and community controls. Setting-Hospitals in Glasgow, Newcastle, Nottingham, Oxford, and Portsmouth. Subjects-1121 patients with gastric or duodenal ulcer bleeding matched with hospital and community controls. Results-144 (12.8%) cases had been regular users of aspirin (taken at least five days a week for at least the previous month) compared with 101 (9.0%) hospital and 77 (7.8%) community controls. Odds ratios were raised for all doses of aspirin taken, whether compared with hospital or community controls (compared with combined controls: 75 mg, 2.3 (95% confidence interval 1.2 to 4.3); 150 mg, 3.2 (1.7 to 6.5); 300 mg, 3.9 (2.5 to 6.3)). Results were not explained by confounding influences of age, sex, prior ulcer history or dyspepsia, or concurrent nonaspirin non-steroidal anti-inflammatory drug use. Risks seemed particularly high in patients who took non-aspirin non-steroidal anti-inflammatory drugs concurrently. Conclusion-No conventionally used prophylactic aspirin regimen seems free of the risk of peptic ulcer complications.	UNIV BIRMINGHAM, QUEEN ELIZABETH HOSP, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; W MIDLANDS REG HLTH AUTHOR, PUBL HLTH MED, BIRMINGHAM, W MIDLANDS, ENGLAND; QUEEN ALEXANDRA HOSP, PORTSMOUTH PO6 3LY, HANTS, ENGLAND; ROYAL INFIRM, GLASGOW G4 0SF, LANARK, SCOTLAND; UNIV NOTTINGHAM, NOTTINGHAM NG7 2UH, ENGLAND; UNIV OXFORD, HLTH CARE EPIDEMIOL UNIT, OXFORD OX2 6HE, ENGLAND; UNIV NEWCASTLE UPON TYNE, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; UNIV OXFORD, RADCLIFFE INFIRM, OXFORD OX2 6HE, ENGLAND; UNIV BIRMINGHAM, INST CANC STUDIES, BIRMINGHAM B15 2TJ, W MIDLANDS, ENGLAND	University of Birmingham; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; Royal Infirmary of Edinburgh; University of Nottingham; University of Oxford; Newcastle University - UK; Radcliffe Infirmary; University of Oxford; University of Birmingham								ALVAREZ AS, 1958, LANCET, V2, P179; [Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316; [Anonymous], 1991, Lancet, V338, P1345; [Anonymous], 1980, CIRCULATION, V62, P449; BJARNASON I, 1988, GASTROENTEROLOGY, V94, P1070, DOI 10.1016/0016-5085(88)90568-9; BJARNASON I, 1987, GASTROENTEROLOGY, V93, P480, DOI 10.1016/0016-5085(87)90909-7; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; BREDDIN K, 1980, HAEMOSTASIS, V9, P325; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; COGGON D, 1982, GUT, V23, P340, DOI 10.1136/gut.23.4.340; ELWOOD PC, 1974, BRIT MED J, V1, P436, DOI 10.1136/bmj.1.5905.436; ELWOOD PC, 1979, LANCET, V2, P1313; FAULKNER G, 1988, BRIT MED J, V297, P1311, DOI 10.1136/bmj.297.6659.1311; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; LANGMAN MJS, 1985, BRIT MED J, V290, P347, DOI 10.1136/bmj.290.6465.347; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEVY M, 1988, ARCH INTERN MED, V148, P281, DOI 10.1001/archinte.148.2.281; MEADE TW, 1992, THROMB HAEMOSTASIS, V68, P1; PETERSEN P, 1989, LANCET, V1, P175; PRITCHARD PJ, 1989, BRIT MED J, V298, P493; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; SHORROCK C J, 1992, Gastroenterology, V102, pA165; SOMERVILLE K, 1986, LANCET, V1, P462; SORENSEN PS, 1983, STROKE, V14, P15, DOI 10.1161/01.STR.14.1.15; The Aspirin Myocardial Infarction Study: final results, 1980, CIRCULATION S5, V62, pV79; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; WALLENTIN L, 1990, LANCET, V336, P827; 1976, J CHRON DIS, V29, P625	31	459	480	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	1995	310	6983					827	830		10.1136/bmj.310.6983.827	http://dx.doi.org/10.1136/bmj.310.6983.827			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711618	Green Published			2022-12-24	WOS:A1995QQ85700016
J	DALLOS, P; EVANS, BN				DALLOS, P; EVANS, BN			HIGH-FREQUENCY MOTILITY OF OUTER HAIR-CELLS AND THE COCHLEAR AMPLIFIER	SCIENCE			English	Article							GUINEA-PIG COCHLEA; ELECTROKINETIC SHAPE CHANGES; MECHANICAL RESPONSES; CURRENTS; ELECTROMOTILITY; SENSITIVITY; PHASE; ORGAN; CORTI	Outer hair cells undergo somatic elongation-contraction cycles in vitro when electrically stimulated. This ''electromotile'' response is assumed to underlie the high sensitivity and frequency selectivity of amplification in the mammalian cochlea. This process, presumably operating on a cycle-by-cycle basis at the frequency of the stimulus, is believed to provide mechanical feedback in vivo. However, if driven by the receptor potential of the cell, the mechanical feedback is expected to be severely attenuated at high frequencies because of electrical low-pass filtering by the outer hair cell basolateral membrane. It is proposed that electromotility at high frequencies is driven instead by extracellular potential gradients across the hair cell, and it is shown that this driving voltage is not subject to low-pass filtering and is sufficiently large. It is further shown that if the filtering properties of the cell membrane are canceled, taking advantage of the electrical characteristics of isolated outer hair cells in a partitioning glass microchamber, then the lower bound of the motor's bandwidth is approximately 22 kilohertz, a number determined only by the limitations of our instrumentation.	NORTHWESTERN UNIV,DEPT COMMUN SCI & DISORDERS,EVANSTON,IL 60208	Northwestern University	DALLOS, P (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,AUDIOL PHYSIOL LAB,HUGH KNOWLES CTR,EVANSTON,IL 60208, USA.		Dallos, Peter/Q-9360-2019	Dallos, Peter/0000-0002-9731-6591				Ashmore J. F., 1989, COCHLEAR MECH, P107; ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; ASHMORE JF, 1986, NATURE, V322, P368, DOI 10.1038/322368a0; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; CANNON MW, 1976, THESIS SYRACUSE U SY; CHEATHAM MA, UNPUB; Cooper N. P., 1993, BIOPHYSICS HAIR CELL, P249; CROWLEY DE, 1966, J COMP PHYSIOL PSYCH, V62, P427, DOI 10.1037/h0023953; DALLOS P, 1991, NATURE, V350, P155, DOI 10.1038/350155a0; DALLOS P, 1993, J NEUROPHYSIOL, V70, P299, DOI 10.1152/jn.1993.70.1.299; DALLOS P, 1985, J NEUROSCI, V5, P1591; DALLOS P, 1992, J NEUROSCI, V12, P4575; DALLOS P, 1983, HEARING RES, V12, P89, DOI 10.1016/0378-5955(83)90120-X; DAVIS H, 1983, HEARING RES, V9, P79, DOI 10.1016/0378-5955(83)90136-3; Davis H, 1981, Am J Otolaryngol, V2, P153, DOI 10.1016/S0196-0709(81)80034-8; Evans B.N., 1989, COCHLEAR MECHANISMS, P205; EVANS BN, 1993, P NATL ACAD SCI USA, V90, P8347, DOI 10.1073/pnas.90.18.8347; EVANS BN, 1991, HEARING RES, V52, P288, DOI 10.1016/0378-5955(91)90019-6; Fay R. R., 1988, HEARING VERTEBRATES; FORGE A, 1991, CELL TISSUE RES, V265, P473, DOI 10.1007/BF00340870; GEISLER CD, 1990, HEARING RES, V44, P241, DOI 10.1016/0378-5955(90)90084-3; GITTER AH, 1988, BASIC ISSUES HEARING, P32; HOPKINS CD, 1981, AM ZOOL, V21, P211; HOUSLEY GD, 1992, J PHYSIOL-LONDON, V448, P73, DOI 10.1113/jphysiol.1992.sp019030; HUBBARD AE, 1983, SCIENCE, V222, P510, DOI 10.1126/science.6623090; HUDSPETH AJ, 1977, P NATL ACAD SCI USA, V74, P2407, DOI 10.1073/pnas.74.6.2407; KACHAR B, 1986, NATURE, V322, P365, DOI 10.1038/322365a0; KALINEC F, 1992, P NATL ACAD SCI USA, V89, P8671, DOI 10.1073/pnas.89.18.8671; KOSSL M, 1992, HEARING RES, V60, P156, DOI 10.1016/0378-5955(92)90018-I; KOSSL M, 1992, J NEUROSCI, V12, P1575; MAMMANO F, 1993, NATURE, V365, P838, DOI 10.1038/365838a0; Marmarelis P.Z., 1978, ANAL PHYSL SYSTEMS; Moller A R, 1974, Scand J Rehabil Med Suppl, V3, P37; MOUNTAIN DC, 1993, BIOPHYSICS HAIR CELL, P361; NUTTALL AL, 1993, BIOPHYSICS HAIR CELL, P288; POLLAK G, 1972, SCIENCE, V176, P66, DOI 10.1126/science.176.4030.66; RUSSELL IJ, 1992, P ROY SOC B-BIOL SCI, V247, P97, DOI 10.1098/rspb.1992.0014; SANTOS-SACCHI J, 1988, HEARING RES, V35, P143, DOI 10.1016/0378-5955(88)90113-X; SANTOS-SACCHI J, 1989, J NEUROSCI, V9, P2954; SANTOS-SACCHI J, 1991, J NEUROSCI, V11, P3096, DOI 10.1523/jneurosci.11-10-03096.1991; SANTOS-SACCHI J, 1992, J NEUROSCI, V12, P1906; SELLICK PM, 1982, J ACOUST SOC AM, V72, P131, DOI 10.1121/1.387996; YATES GK, 1993, BIOPHYSICS HAIR CELL, P352; ZENNER HP, 1986, HEARING RES, V22, P83, DOI 10.1016/0378-5955(86)90082-1	44	262	268	1	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					2006	2009		10.1126/science.7701325	http://dx.doi.org/10.1126/science.7701325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701325				2022-12-24	WOS:A1995QQ06800048
J	MARTI, K; KIM, JS; THAKUR, AN; MCCOY, TJ; KEIL, K				MARTI, K; KIM, JS; THAKUR, AN; MCCOY, TJ; KEIL, K			SIGNATURES OF THE MARTIAN ATMOSPHERE IN GLASS OF THE ZAGAMI METEORITE	SCIENCE			English	Article							NOBLE-GASES; SHERGOTTITE METEORITES; SNC METEORITES; ORIGIN; NITROGEN; MARS; PETROGENESIS; EETA-79001; ABUNDANCES; XENON	Isotopic signatures of nitrogen, argon, and xenon have been determined in separated millimeter-sized pockets of shock-melted glass in a recently identified lithology of the meteorite Zagami, a shergottite. The ratio of nitrogen-15 to nitrogen-14, which is at least 282 per mil larger than the terrestrial value, the ratio of xenon-129 to xenon-132 = 2.40, and the argon isotopic abundances match the signatures previously observed in the glassy lithology of the Antarctic shergottite EETA 79001. These results show that the signatures in EETA 79001 are not unique but characterize the trapped gas component in shock-melted glass of shergottites. The isotopic and elemental ratios of nitrogen, argon, and xenon closely resemble the Viking spacecraft data for the martian atmosphere and provide compelling evidence for a martian origin of the two shergottites and, by extension, of the meteorites in the shergottites-nakhlites-chassignites (SNC) group.	UNIV HAWAII MANOA,HAWAII CTR VOLCANOL,HONOLULU,HI 96822; UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,CALIF SPACE INST,LA JOLLA,CA 92093; UNIV HAWAII MANOA,SCH OCEAN & EARTH SCI & TECHNOL,HAWAII INST GEOPHYS & PLANETOL,HONOLULU,HI 96822	University of Hawaii System; University of Hawaii Manoa; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Hawaii System; University of Hawaii Manoa	MARTI, K (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093, USA.			McCoy, Timothy/0000-0002-4573-3553				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BECKER RH, 1984, EARTH PLANET SC LETT, V69, P225, DOI 10.1016/0012-821X(84)90183-3; BECKER RH, 1993, METEORITICS, V28, P637, DOI 10.1111/j.1945-5100.1993.tb00634.x; BIEMANN K, 1976, SCIENCE, V194, P76, DOI 10.1126/science.194.4260.76; BOGARD DD, 1986, J GEOPHYS RES-SOLID, V91, pE99, DOI 10.1029/JB091iB13p00E99; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; BOGARD DD, 1984, GEOCHIM COSMOCHIM AC, V48, P1723, DOI 10.1016/0016-7037(84)90028-0; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; Dreibus G., 1982, LUNAR PLANETARY SCI, P186; EPSTEIN S, 1971, GEOCHIM COSM SUPPL, V2, P1421; EUGSTER O, 1994, METEORITICS, V29, P464; JAGOUTZ E, 1989, GEOCHIM COSMOCHIM AC, V53, P2429, DOI 10.1016/0016-7037(89)90363-3; KIM J, UNPUB; KIM JS, 1992, P LUNAR PLANET SCI, V22, P145; KIM JS, 1994, LUNAR PLANET SCI, V25, P701; MCCOY TJ, 1992, GEOCHIM COSMOCHIM AC, V56, P3571, DOI 10.1016/0016-7037(92)90400-D; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MCSWEEN HY, 1983, GEOCHIM COSMOCHIM AC, V47, P1501, DOI 10.1016/0016-7037(83)90309-5; NAKAMURA N, 1982, METEORITICS, V17, P257; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; OTT U, 1988, GEOCHIM COSMOCHIM AC, V52, P1937, DOI 10.1016/0016-7037(88)90017-8; OWEN T, 1976, SCIENCE, V193, P801, DOI 10.1126/science.193.4255.801; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; Owen T., 1977, J GEOPHYS RES, V82, P4635, DOI DOI 10.1029/JS082I028P04635; SHIH CY, 1982, GEOCHIM COSMOCHIM AC, V46, P2323, DOI 10.1016/0016-7037(82)90205-8; STOEFFLER D, 1986, GEOCHIM COSMOCHIM AC, V50, P889; STOLPER E, 1979, GEOCHIM COSMOCHIM AC, V43, P1475, DOI 10.1016/0016-7037(79)90142-X; SWINDLE TD, 1986, GEOCHIM COSMOCHIM AC, V50, P1001, DOI 10.1016/0016-7037(86)90381-9; Wadhwa M., 1993, METEORITICS, V28, P453; WALKER D, 1979, LUNAR PLANET SCI, V10, P1274; Wasson J.T., 1979, ASTEROIDS, P926; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WIENS RC, 1988, GEOCHIM COSMOCHIM AC, V52, P295, DOI 10.1016/0016-7037(88)90085-3; WIENS RC, 1986, EARTH PLANET SC LETT, V77, P149, DOI 10.1016/0012-821X(86)90156-1	34	96	96	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1981	1984		10.1126/science.7701319	http://dx.doi.org/10.1126/science.7701319			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701319				2022-12-24	WOS:A1995QQ06800040
J	ROGERS, DJ; PACKER, MJ				ROGERS, DJ; PACKER, MJ			VECTOR-BORNE DISEASES, MODELS, AND GLOBAL CHANGE	LANCET			English	Article											ROGERS, DJ (corresponding author), UNIV OXFORD,DEPT ZOOL,S PARKS RD,OXFORD OX1 3PS,ENGLAND.							Anderson RM, 1982, POPULATION DYNAMICS, V368, DOI [10.1007/978-1-4899-2901-3, DOI 10.1007/978-1-4899-2901-3]; MAURICE J, 1993, NEW SCI         1016; RAI KS, 1991, ANNU REV ENTOMOL, V36, P459, DOI 10.1146/annurev.en.36.010191.002331; ROGERS DJ, 1988, PARASITOLOGY, V97, P193, DOI 10.1017/S0031182000066853; ROGERS DJ, 1993, PARASITOL TODAY, V9, P266, DOI 10.1016/0169-4758(93)90074-P; 1990, WHO TDRCTDHH901	6	72	75	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1282	1284		10.1016/0140-6736(93)92367-3	http://dx.doi.org/10.1016/0140-6736(93)92367-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7695661				2022-12-24	WOS:A1993MH56600017
J	HATHCOCK, KS; LASZLO, G; DICKLER, HB; BRADSHAW, J; LINSLEY, P; HODES, RJ				HATHCOCK, KS; LASZLO, G; DICKLER, HB; BRADSHAW, J; LINSLEY, P; HODES, RJ			IDENTIFICATION OF AN ALTERNATIVE CTLA-4 LIGAND COSTIMULATORY FOR T-CELL ACTIVATION	SCIENCE			English	Article							EXPRESSION; PROLIFERATION; ANTIGEN-B7; MOLECULE; INVIVO; B7	Stimulation of T cell proliferation generally requires two signals: The first signal is provided by the T cell receptor binding to antigen, and the second signal or costimulus is provided by a different receptor-ligand interaction. In mouse and human, the CD28-B7 interaction has been identified as a source of costimulatory signals. We have identified a cell surface molecule (GL1) that is distinct from B7 and abundantly expressed on activated B cells. On activated B cells GL1, rather than B7, is the predominant ligand for the T cell-activation molecule CTLA-4. GL1 provides a critical signal for T cell-dependent responses in vitro and in vivo.	NIA,BETHESDA,MD 20892; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Bristol-Myers Squibb	HATHCOCK, KS (corresponding author), NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892, USA.							CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; HATHCOCK KS, 1992, J IMMUNOL, V149, P2286; HATHCOCK KS, UNPUB; LASZLO G, 1993, J IMMUNOL, V150, P5252; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; STEINMAN R, UNPUB; TAN RS, 1992, J IMMUNOL, V149, P3217; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102	16	524	555	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					905	907		10.1126/science.7694361	http://dx.doi.org/10.1126/science.7694361			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	7694361				2022-12-24	WOS:A1993MF43800037
J	CANDELIERE, GA; GLORIEUX, FH; PRUDHOMME, J; STARNAUD, R				CANDELIERE, GA; GLORIEUX, FH; PRUDHOMME, J; STARNAUD, R			INCREASED EXPRESSION OF THE C-FOS PROTOONCOGENE IN BONE FROM PATIENTS WITH FIBROUS DYSPLASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MCCUNE-ALBRIGHT SYNDROME; STIMULATORY G-PROTEIN; TRANSGENIC MICE; ADENYLYL CYCLASE; TUMORS; CELLS; PROTOONCOGENE; TRANSCRIPTION; CALCITRIOL; MUTATIONS	Background. Fibrous dysplasia is characterized by intense marrow fibrosis and increased rates of bone turnover. The lesions of fibrous dysplasia resemble those described in the long bones of transgenic mice overexpressing the c-fos proto-oncogene. Activating mutations in the a subunit of the stimulatory guanine-nucleotide-binding protein (G(s) alpha) linked to adenylate cyclase have recently been described in bone cells from patients with the McCune-Albright syndrome and fibrous dysplasia. Methods. We used in situ hybridization to determine the level of expression of c-fos in bone-biopsy specimens from two normal subjects, eight patients with fibrous dysplasia, and six patients with other bone disorders characterized by high rates of bone turnover. The probe used corresponded to the fourth exon of the c-fos gene. Results. High levels of c-fos expression were detected in the bone lesions from all eight patients with fibrous dysplasia. No expression of c-fos was detected in bone specimens from the normal subjects or from specimens of normal bone obtained from patients with fibrous dysplasia. The cells that expressed c-fos in the dysplastic lesions were fibroblastic and populated the marrow space. A very low level of c-fos expression was detected in the biopsy specimens from the patients with other bone diseases. One patient with polyostotic fibrous dysplasia and one patient with the McCune-Albright syndrome were tested for the previously described G(s) alpha gene mutations and were found to express these mutations in bone. Conclusions. Increased expression of the c-fos proto-oncogene, presumably a consequence of increased adenylate cyclase activity, may be important in the pathogenesis of the bone lesions in patients with fibrous dysplasia.	MCGILL UNIV,SHRINERS HOSP CRIPPLED CHILDREN,GENET UNIT,MONTREAL,PQ H3G 1A6,CANADA; MCGILL UNIV,DEPT SURG,MONTREAL,PQ H3A 2T5,CANADA; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ H3A 2T5,CANADA	McGill University; McGill University; McGill University								Abate C, 1990, Semin Cancer Biol, V1, P19; CANDELIERE GA, 1991, MOL ENDOCRINOL, V5, P1780, DOI 10.1210/mend-5-12-1780; CLAPHAM DE, 1993, CELL, V75, P1237, DOI 10.1016/0092-8674(93)90609-T; COLE DEC, 1983, AM J MED GENET, V14, P725, DOI 10.1002/ajmg.1320140414; GAIDDON C, 1994, J BIOL CHEM, V269, P22663; GLORIEUX FH, 1980, NEW ENGL J MED, V303, P1023, DOI 10.1056/NEJM198010303031802; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HOYLAND J, 1994, J BONE MINER RES, V9, P1191; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MALCHOFF CD, 1994, J CLIN ENDOCR METAB, V78, P803, DOI 10.1210/jc.78.3.803; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152; SHENKER A, 1994, J CLIN ENDOCR METAB, V79, P750, DOI 10.1210/jc.79.3.750; WALLACH S, 1991, Current Opinion in Rheumatology, V3, P472, DOI 10.1097/00002281-199106000-00022; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WATKINS S, 1989, CURRENT PROTOCOLS MO; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WU JX, 1990, ONCOGENE, V5, P989; YABUT SM, 1988, CLIN ORTHOP RELAT R, V228, P281; ZELLER R, 1989, CURRENT PROTOCOLS MO	27	115	118	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 8	1995	332	23					1546	1551		10.1056/NEJM199506083322304	http://dx.doi.org/10.1056/NEJM199506083322304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB196	7739708	Bronze			2022-12-24	WOS:A1995RB19600004
J	BRANDSTATER, ME				BRANDSTATER, ME			PHYSICAL MEDICINE AND REHABILITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											BRANDSTATER, ME (corresponding author), LOMA LINDA UNIV,LOMA LINDA,CA 92350, USA.							AGRE JC, 1991, ARCH PHYS MED REHAB, V72, P923, DOI 10.1016/0003-9993(91)90013-9; BACH JR, 1994, ARCH PHYS MED REHAB, V75, P626, DOI 10.1016/0003-9993(94)90183-X; BACH JR, 1992, ARCH PHYS MED REHAB, V73, P934; BORGSTEIN J, 1993, J HEAD TRAUMA REHAB, V8, P103; BOYESON MG, 1994, J HEAD TRAUMA REHAB, V9, P78, DOI 10.1097/00001199-199409000-00007; COPE DN, 1994, J HEAD TRAUMA REHAB, V9, P1, DOI 10.1097/00001199-199409000-00003; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hamilton B. B., 1987, REHABILITATION OUTCO, P137; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; KRAFT GH, 1992, ARCH PHYS MED REHAB, V73, P220; Saal J A, 1990, Orthop Rev, V19, P691; SAAL JS, 1990, SPINE, V15, P674, DOI 10.1097/00007632-199007000-00011; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; [No title captured]; B HLTH INSURANCE ASS, V287	16	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1710	1712		10.1001/jama.273.21.1710	http://dx.doi.org/10.1001/jama.273.21.1710			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752431				2022-12-24	WOS:A1995RB09700039
J	BOURGUET, W; RUFF, M; CHAMBON, P; GRONEMEYER, H; MORAS, D				BOURGUET, W; RUFF, M; CHAMBON, P; GRONEMEYER, H; MORAS, D			CRYSTAL-STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE HUMAN NUCLEAR RECEPTOR RXR-ALPHA	NATURE			English	Article							STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; THYROID-HORMONE; TRANSCRIPTIONAL ACTIVATION; ECDYSONE RECEPTOR; IDENTIFICATION; SUPERFAMILY; HETERODIMER; MUTATION	The crystal structure of the human retinoid-X receptor RXR-alpha ligand-binding domain reveals a previously undiscovered fold of an antiparallel alpha-helical sandwich, packed as dimeric units. Two helices and one loop form the homodimerization surface, and hydrophobic heptad repeats participate in stabilizing the fold. The existence of a ligand-binding pocket is proposed that would allow 9-cis retinoic acid to interact with different functional modules, including the AF-2 activating domain. Several lines of evidence indicate that the overall structure is a prototype fold of ligand-binding domains of nuclear receptors.	UNIV STRASBOURG 1,COLL FRANCE,INST GENET & BIOL MOLEC & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Bourguet, William/Y-6600-2019; Bourguet, William/I-5569-2013; Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/G-6240-2011; ruff, marc/J-3011-2013; Gronemeyer, Hinrich/H-7002-2016	Bourguet, William/0000-0002-0643-7719; Bourguet, William/0000-0002-0643-7719; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; ruff, marc/0000-0001-5451-6377; Gronemeyer, Hinrich/0000-0001-9454-2449				AMEZ JG, 1994, J APPL CRYSTALLOGR, V27, P649; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARLSTEDTDUKE J, 1988, J BIOL CHEM, V263, P6842; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHAMBON P, 1994, CELL BIOL, V5, P115; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V90, P1293; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HARD T, 1990, SCIENCE, V248, P157; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEDOUARIN B, IN PRESS EMBO J; LEE MS, 1993, SCIENCE, V269, P1117; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; REESE JC, 1992, MOL ENDOCRINOL, V6, P2160, DOI 10.1210/me.6.12.2160; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; SCHILTZ M, 1994, J APPL CRYSTALLOGR, V27, P950, DOI 10.1107/S0021889894005923; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; STROMSTEDT PE, 1990, J BIOL CHEM, V265, P12973; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WRENN CK, 1993, J BIOL CHEM, V268, P24089; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311	50	1007	1043	6	62	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					377	382		10.1038/375377a0	http://dx.doi.org/10.1038/375377a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760929				2022-12-24	WOS:A1995RB10100045
J	LIAO, DZ; HESSLER, NA; MALINOW, R				LIAO, DZ; HESSLER, NA; MALINOW, R			ACTIVATION OF POSTSYNAPTICALLY SILENT SYNAPSES DURING PAIRING-INDUCED LTP IN CA1 REGION OF HIPPOCAMPAL SLICE	NATURE			English	Article							LONG-TERM POTENTIATION; PRESYNAPTIC ENHANCEMENT; SYNAPTIC CURRENTS; NMDA RECEPTORS; EXPRESSION; RELEASE; PROBABILITY; MECHANISMS; RESPONSES; INDUCTION	LONG-TERM potentiation (LTP) is an enhancement of synaptic strength that can be produced by pairing of presynaptic activity with postsynaptic depolarization(1). LTP in the hippocampus has been extensively studied as a cellular model of learning and memory, but the nature of the underlying synaptic modification remains elusive, partly because our knowledge of central synapses is still limited(2,3). One proposal(4,5) is that the modification is postsynaptic, and that synapses expressing only NMDA (N-methyl-D-aspartate) receptors before potentiation are induced by LTP to express functional AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate) receptors. Here we report that a high proportion of synapses in hippocampal area CAI transmit with NMDA receptors but not AMPA receptors, making these synapses effectively non-functional at normal resting potentials. These silent synapses acquire AMPA-type responses following LTP induction, Our findings challenge the view(6-10) that LTP in CA1 involves a presynaptic modification, and suggest instead a simple postsynaptic mechanism for both induction and expression of LTP.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA; UNIV IOWA,NEUROSCI PROGRAM,IOWA CITY,IA	Cold Spring Harbor Laboratory; University of Iowa; University of Iowa			hessler, neal/A-7328-2010		NIMH NIH HHS [R29MH49159] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH049159] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AZTELY F, 1992, EUR J NEUROSCI, V4, P681; BASHIR ZI, 1991, NATURE, V349, P156, DOI 10.1038/349156a0; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; DAVIES SN, 1989, NATURE, V330, P500; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1994, SCIENCE, V266, P1195, DOI 10.1126/science.7973700; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MAREN S, 1993, P NATL ACAD SCI USA, V90, P9654, DOI 10.1073/pnas.90.20.9654; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; TSIEN RW, 1990, COLD SH Q B, V55, P147; VORONIN LL, 1993, NEUROSCIENCE, V56, P275, DOI 10.1016/0306-4522(93)90332-A; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WU LG, 1994, J NEUROSCI, V14, P645; XIE XP, 1992, J NEUROPHYSIOL, V67, P1009, DOI 10.1152/jn.1992.67.4.1009	30	1031	1056	2	52	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					400	404		10.1038/375400a0	http://dx.doi.org/10.1038/375400a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760933				2022-12-24	WOS:A1995RB10100052
J	AOKI, K; KAJIURA, S; MATSUMOTO, Y; OGASAWARA, M; OKADA, S; YAGAMI, Y; GLEICHER, N				AOKI, K; KAJIURA, S; MATSUMOTO, Y; OGASAWARA, M; OKADA, S; YAGAMI, Y; GLEICHER, N			PRECONCEPTIONAL NATURAL-KILLER-CELL ACTIVITY AS A PREDICTOR OF MISCARRIAGE	LANCET			English	Note							PREGNANCY	There is no immunological test for the prospective identification of alloimmune causes of miscarriage. We investigated whether activity of natural killer cells was predictive of subsequent abortion in women who had had unexplained recurrent abortions and had received no treatment. 24 women with high preconceptional NK activity, defined as mean plus 1 SD of NK activity of 47 controls, had a significantly higher abortion rate in the next pregnancy than 44 women with normal levels of NK activity (71 vs 20%; relative risk 3.5; 95% CI 1.8-6.5), The preconceptional evaluation of NK activity in women with recurrent miscarriages may thus be predictive of the risk of pregnancy loss at the next conception,	CTR HUMAN REPROD,CHICAGO,IL; FDN REPROD MED,CHICAGO,IL		AOKI, K (corresponding author), NAGOYA CITY UNIV,SCH MED,DEPT OBSTET & GYNAECOL,NAGOYA,AICHI 467,JAPAN.							BULMER JN, 1991, HUM REPROD, V6, P791, DOI 10.1093/oxfordjournals.humrep.a137430; CLARK DA, 1994, CELL IMMUNOL, V154, P143, DOI 10.1006/cimm.1994.1064; COULAM CB, 1992, AM J OBSTET GYNECOL, V167, P1844, DOI 10.1016/0002-9378(92)91785-9; HIGUCHI K, 1995, AM J REPROD IMMUNOL, V33, P221, DOI 10.1111/j.1600-0897.1995.tb00888.x; KING A, 1990, CELL IMMUNOL, V129, P435, DOI 10.1016/0008-8749(90)90219-H; MAKIDA R, 1991, LANCET, V338, P579, DOI 10.1016/0140-6736(91)91153-L; TARTOF D, 1984, CLIN EXP IMMUNOL, V57, P502; TODER V, 1984, J CLIN LAB IMMUNOL, V14, P129; 1994, AM J REPROD IMMUNOL, V32, P55	9	262	271	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1340	1342		10.1016/S0140-6736(95)92539-2	http://dx.doi.org/10.1016/S0140-6736(95)92539-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752757				2022-12-24	WOS:A1995RA14800010
J	HAYASHI, N; ITO, I; YANAGISAWA, A; KATO, Y; NAKAMORI, S; IMAOKA, S; WATANABE, H; OGAWA, M; NAKAMURA, Y				HAYASHI, N; ITO, I; YANAGISAWA, A; KATO, Y; NAKAMORI, S; IMAOKA, S; WATANABE, H; OGAWA, M; NAKAMURA, Y			GENETIC DIAGNOSIS OF LYMPH-NODE METASTASIS IN COLORECTAL-CANCER	LANCET			English	Article							SOMATIC MUTATIONS; APC GENE; TUMORS; OCCUR	If a regional lymph node taken during surgery for colorectal cancer is found to be free of tumour on histological examination this is taken to be a good sign. However, conventional staining may not be sensitive enough. Mutant-allele-specific amplification (MASA) is a technique that can detect, at the level of an individual cell, micrometastases to lymph nodes that are histologically diagnosed as negative. To examine the prognostic significance of such genetically detectable tumour cells we screened 120 colorectal cancers from patients who had no histologically detectable lymph-node metastasis at the time of surgery for mutations in K-ras (codons 12, 13, and 61) or p53 (exons 5-8). Somatic mutations were identified by MASA in 71 tumours, We next examined preserved tissues from corresponding regional lymph nodes, using MASA to look for the specific mutation found in the primary. Of 37 patients with genetically positive lymph nodes 27 had had a tumour recurrence within 5 years of surgery; none of the 34 patients who were MASA negative for lymph node metastasis had had a recurrence. Genetic diagnosis of lymph node metastasis may be a useful prognostic factor in colorectal cancer, and it could also serve as a selective marker for intensive postoperative adjuvant chemotherapy.	INST CANC RES,DEPT BIOCHEM,TOKYO,JAPAN; INST CANC RES,DEPT PATHOL,TOKYO,JAPAN; CTR ADULT DIS,DEPT SURG ONCOL,OSAKA 537,JAPAN; NIIGATA UNIV,SCH MED,DEPT PATHOL 1,NIIGATA 95021,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT SURG 2,KUMAMOTO 860,JAPAN; UNIV TOKYO,INST MED SCI,MOLEC MED LAB,MINATO KU,TOKYO 108,JAPAN	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Niigata University; Kumamoto University; University of Tokyo								BAKER SJ, 1990, CANCER RES, V50, P7717; BOS JL, 1989, CANCER RES, V49, P4682; BRODSKY JT, 1992, CANCER-AM CANCER SOC, V69, P322, DOI 10.1002/1097-0142(19920115)69:2<322::AID-CNCR2820690208>3.0.CO;2-B; COHEN AM, 1991, CANCER, V67, P1859, DOI 10.1002/1097-0142(19910401)67:7<1859::AID-CNCR2820670707>3.0.CO;2-A; HAYASHI N, 1994, CANCER RES, V54, P3853; KRONBORG O, 1993, EUR J CANCER, V29A, P575, DOI 10.1016/S0959-8049(05)80155-8; KUNE GA, 1990, DIS COLON RECTUM, V33, P938, DOI 10.1007/BF02139103; LEVINE AJ, 1991, NATURE, V358, P453; LOSI L, 1992, EUR J CANCER, V28A, P1115, DOI 10.1016/0959-8049(92)90468-H; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAKATSURU S, 1993, HUM MOL GENET, V2, P1463, DOI 10.1093/hmg/2.9.1463; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OVASKA J, 1990, AM J SURG, V159, P593, DOI 10.1016/S0002-9610(06)80074-7; PURDIE CA, 1991, AM J PATHOL, V138, P807; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; TAKEDA S, 1993, HUM MUTAT, V2, P112, DOI 10.1002/humu.1380020209	16	272	285	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1257	1259		10.1016/S0140-6736(95)90922-2	http://dx.doi.org/10.1016/S0140-6736(95)90922-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746054				2022-12-24	WOS:A1995QY93300006
J	CANNELL, MB; CHENG, H; LEDERER, WJ				CANNELL, MB; CHENG, H; LEDERER, WJ			THE CONTROL OF CALCIUM-RELEASE IN HEART-MUSCLE	SCIENCE			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; RAT VENTRICULAR MYOCYTES; CA-2+ RELEASE; SKELETAL-MUSCLE; CONTRACTION; ACTIVATION; RYANODINE; CHANNEL; TRANSIENTS; CELLS	The control of calcium release from intracellular stores (the sarcoplasmic reticulum) in cardiac muscle was examined with the use of a confocal microscope and voltage clamp techniques. Depolarization evoked graded calcium release by altering the extent of spatial and temporal summation of elementary calcium release events called ''calcium sparks.'' These evoked sparks were triggered by local L-type calcium channel currents in a stochastic manner, were similar at different potentials, and resembled spontaneous calcium sparks. Once triggered, the calcium release from the sarcoplasmic reticulum during a calcium spark was independent of the duration of the triggering calcium influx. These results were used to develop a unifying model for cardiac excitation-contraction coupling that explains the large (but paradoxically stable) amplification of the trigger calcium influx by a combination of digital and analog behavior.	ST GEORGE HOSP,SCH MED,DEPT PHARMACOL & CLIN PHARMACOL,LONDON SW17 0RE,ENGLAND; UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR MED BIOTECHNOL,BALTIMORE,MD 21201	St Georges University London; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Lederer, William/B-1285-2010; Heping, Cheng/AAE-2680-2019	Heping, Cheng/0000-0002-9604-6702	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036974, R01HL036974, R01HL025675] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36974, HL25675] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALKE CW, 1994, J PHYSIOL-LONDON, V474, P447, DOI 10.1113/jphysiol.1994.sp020036; BARCENASRUIZ L, 1987, CIRC RES, V61, P148, DOI 10.1161/01.RES.61.1.148; BERS DM, 1993, AM J PHYSIOL, V264, pC1587, DOI 10.1152/ajpcell.1993.264.6.C1587; CALLEWAERT G, 1988, P NATIONAL ACADEMY S, V82, P2009; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CANNELL MB, 1994, J PHYSIOL-LONDON, V477P, pP25; CHENG H, 1995, CIRC RES, V76, P236, DOI 10.1161/01.RES.76.2.236; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CHENG H, 1994, AM J PHYSIOL, V428, P415; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERGUSON DG, 1984, J CELL BIOL, V99, P1735, DOI 10.1083/jcb.99.5.1735; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LIPP P, 1994, J PHYSIOL-LONDON, V474, P439, DOI 10.1113/jphysiol.1994.sp020035; LOPEZLOPEZ JR, 1994, J PHYSIOL-LONDON, V480, P21, DOI 10.1113/jphysiol.1994.sp020337; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; NABAUER M, 1990, AM J PHYSIOL, V258, pC189, DOI 10.1152/ajpcell.1990.258.1.C189; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; ONEILL SC, 1990, AM J PHYSIOL, V258, pC1165, DOI 10.1152/ajpcell.1990.258.6.C1165; ROSE WC, 1992, J PHYSIOL-LONDON, V456, P267, DOI 10.1113/jphysiol.1992.sp019336; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; TRAFFORD AW, 1993, PFLUG ARCH EUR J PHY, V425, P181, DOI 10.1007/BF00374521; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; WIER WG, 1994, J PHYSIOL-LONDON, V474, P463, DOI 10.1113/jphysiol.1994.sp020037	31	502	512	0	51	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1045	1049		10.1126/science.7754384	http://dx.doi.org/10.1126/science.7754384			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754384				2022-12-24	WOS:A1995QY93400040
J	PANZNER, S; DREIER, L; HARTMANN, E; KOSTKA, S; RAPOPORT, TA				PANZNER, S; DREIER, L; HARTMANN, E; KOSTKA, S; RAPOPORT, TA			POSTTRANSLATIONAL PROTEIN-TRANSPORT IN YEAST RECONSTITUTED WITH A PURIFIED COMPLEX OF SEC PROTEINS AND KAR2P	CELL			English	Article							PREPRO-ALPHA-FACTOR; ENDOPLASMIC-RETICULUM MEMBRANE; POST-TRANSLATIONAL TRANSLOCATION; CELL-FREE SYSTEM; POLYPEPTIDE TRANSLOCATION; SACCHAROMYCES-CEREVISIAE; SECRETORY PROTEINS; ESCHERICHIA-COLI; SIGNAL SEQUENCE; INVITRO	We have reproduced the posttranslational mode of protein translocation across the endoplasmic reticulum membrane with reconstituted proteoliposomes containing a purified complex of seven yeast proteins. This Sec complex includes a heterotrimeric Sec61p complex, homologous to that in mammals, as well as all other membrane proteins found in genetic screens for translocation components. Efficient posttranslational translocation also requires the addition of lumenal Kar2p (BiP) and ATP. The trimeric Sec61p complex also exists as a separate entity that, in contrast with the large Sec complex, is associated with membrane-bound ribosomes. We therefore hypothesize that distinct membrane protein complexes function in co- and posttranslational translocation pathways.			PANZNER, S (corresponding author), MAX DELBRUCK CTR MOLEC MED,ROBERT ROSSLE STR 10,D-13125 BERLIN,GERMANY.		Hartmann, Enno/C-5687-2013					ALLISON DS, 1988, MOL CELL BIOL, V8, P1915, DOI 10.1128/MCB.8.5.1915; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FELDHEIM D, 1993, MOL BIOL CELL, V4, P931, DOI 10.1091/mbc.4.9.931; FELDHEIM D, 1994, J CELL BIOL, V126, P935, DOI 10.1083/jcb.126.4.935; GARCIA PD, 1988, J CELL BIOL, V106, P1043, DOI 10.1083/jcb.106.4.1043; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KURIHARA T, 1993, MOL BIOL CELL, V4, P919, DOI 10.1091/mbc.4.9.919; MEYER DI, 1982, NATURE, V297, P503; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NG DTW, 1994, CURR OPIN CELL BIOL, V6, P510, DOI 10.1016/0955-0674(94)90069-8; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SCHNEIDER HC, 1994, NATURE, V371, P7688; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1981, J CELL BIOL, V93, P557; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; YAMADA H, 1989, J BIOL CHEM, V264, P1723	37	317	327	1	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					561	570		10.1016/0092-8674(95)90077-2	http://dx.doi.org/10.1016/0092-8674(95)90077-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758110	Bronze			2022-12-24	WOS:A1995QZ71000013
J	SYMONS, JA; ALCAMI, A; SMITH, GL				SYMONS, JA; ALCAMI, A; SMITH, GL			VACCINIA VIRUS ENCODES A SOLUBLE TYPE-I INTERFERON RECEPTOR OF NOVEL STRUCTURE AND BROAD SPECIES-SPECIFICITY	CELL			English	Article							NUCLEOTIDE-SEQUENCE; GAMMA RECEPTOR; ALPHA RECEPTOR; MYXOMA VIRUS; CELLS; MICE; EXPRESSION; PROTEIN; GENOME; GENE	Vaccinia virus (VV) and other orthopoxviruses express a soluble type I interferon (IFN) receptor that for VV strain Western Reserve is encoded by gene B18R. The 60-65 kDa glycoprotein is related to the interleukin-l receptors and is a member of the immunoglobulin superfamily, unlike other type I IFN receptors, which belong to the class II cytokine receptor family. The receptor has high affinity (K-D, 174 pM) for human IFN alpha and, unlike other type I IFN receptors, has broad species specificity, binding to human, rabbit, bovine, rat, and mouse type I IFNs. This may have aided VV replication in multiple host species during evolution. A VV B18R deletion mutant is attenuated in a murine intranasal model. This type I IFN receptor represents the fourth VV protein that interferes with IFN and the fourth soluble cytokine receptor expressed by poxviruses.			SYMONS, JA (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,S PARKS RD,OXFORD OX1 3RE,ENGLAND.		Smith, Geoffrey L/G-2894-2012; Alcami, Antonio/F-8512-2015	Alcami, Antonio/0000-0002-3333-6016; Smith, Geoffrey L/0000-0002-3730-9955	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUADO B, 1992, J GEN VIROL, V73, P2887, DOI 10.1099/0022-1317-73-11-2887; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; AMANO H, 1979, J GEN VIROL, V44, P265, DOI 10.1099/0022-1317-44-1-265; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; Baxby D., 1981, TRENDS IMMUNOL, V3, P26; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; Downie AW, 1939, J PATHOL BACTERIOL, V48, P361, DOI 10.1002/path.1700480212; ENGELSTAD M, 1993, VIROLOGY, V194, P627, DOI 10.1006/viro.1993.1302; ESPOSITO J, 1981, J VIROL METHODS, V2, P175, DOI 10.1016/0166-0934(81)90036-7; FALKNER FG, 1990, J VIROL, V64, P3108, DOI 10.1128/JVI.64.6.3108-3111.1990; Fenner F., 1988, HIST INT PUBLIC HLTH; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HU FQ, 1994, VIROLOGY, V204, P343, DOI 10.1006/viro.1994.1539; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUGHES SJ, 1991, J BIOL CHEM, V266, P20103; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; ISAACS SN, 1990, VIROLOGY, V178, P626, DOI 10.1016/0042-6822(90)90367-Z; JOHNSON GP, 1993, VIROLOGY, V196, P381, DOI 10.1006/viro.1993.1494; KARUPIAH G, 1993, J VIROL, V67, P4214, DOI 10.1128/JVI.67.7.4214-4226.1993; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KERR SM, 1991, VIROLOGY, V180, P625, DOI 10.1016/0042-6822(91)90076-N; KOHONENCORISH MRJ, 1990, EUR J IMMUNOL, V20, P157, DOI 10.1002/eji.1830200123; LANGER JA, 1986, METHOD ENZYMOL, V119, P305; MACKETT M, 1979, J GEN VIROL, V45, P683, DOI 10.1099/0022-1317-45-3-683; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MORIKAWA S, 1993, VIROLOGY, V193, P753, DOI 10.1006/viro.1993.1184; MOSS B, 1981, J VIROL, V40, P387, DOI 10.1128/JVI.40.2.387-395.1981; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; NOVICK D, 1992, FEBS LETT, V314, P445, DOI 10.1016/0014-5793(92)81523-O; PARKINSON JE, 1994, VIROLOGY, V204, P376, DOI 10.1006/viro.1994.1542; PESKA S, 1987, ANNU REV BIOCHEM, V56, P727; RODRIGUEZ JR, 1991, VIROLOGY, V185, P929, DOI 10.1016/0042-6822(91)90575-V; SHCHELKUNOV SN, 1993, FEBS LETT, V319, P80, DOI 10.1016/0014-5793(93)80041-R; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; Smith Geoffrey L., 1994, Trends in Microbiology, V2, P81, DOI 10.1016/0966-842X(94)90539-8; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; SMITH GL, 1993, J GEN VIROL, V74, P1725, DOI 10.1099/0022-1317-74-9-1725; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SYMONS J A, 1990, Cytokine, V2, P190, DOI 10.1016/1043-4666(90)90015-L; Turner G S, 1967, J Gen Virol, V1, P399, DOI 10.1099/0022-1317-1-3-399; UEDA Y, 1972, VIROLOGY, V49, P794, DOI 10.1016/0042-6822(72)90535-1; UEDA Y, 1969, VIROLOGY, V38, P180, DOI 10.1016/0042-6822(69)90141-X; UEDA Y, 1990, VIROLOGY, V177, P588, DOI 10.1016/0042-6822(90)90524-U; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WILLIAMSON JD, 1990, J GEN VIROL, V71, P2761, DOI 10.1099/0022-1317-71-11-2761; [No title captured]	60	407	437	3	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					551	560		10.1016/0092-8674(95)90076-4	http://dx.doi.org/10.1016/0092-8674(95)90076-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758109	Bronze			2022-12-24	WOS:A1995QZ71000012
J	ROGGERO, E; ZUCCA, E; PINOTTI, G; PASCARELLA, A; CAPELLA, C; SAVIO, A; PEDRINIS, E; PATERLINI, A; VENCO, A; CAVALLI, F				ROGGERO, E; ZUCCA, E; PINOTTI, G; PASCARELLA, A; CAPELLA, C; SAVIO, A; PEDRINIS, E; PATERLINI, A; VENCO, A; CAVALLI, F			ERADICATION OF HELICOBACTER-PYLORI INFECTION IN PRIMARY LOW-GRADE GASTRIC LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE	ANNALS OF INTERNAL MEDICINE			English	Note							DISEASE; MALT	Objective: To determine the effect of eradicating Helicobacter pylori infection on the course of low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Design: Prospective cohort study. Setting: University internal medicine clinics, a referral oncology center in southern Switzerland, and a gastroenterology referral center in northern Italy. Patients: 26 patients with localized primary low-grade gastric MALT lymphoma. Intervention: Treatment for H. pylori infection (bismuth or omeprazole or both, amoxicillin, and metronidazole for 14 days). Main Outcome Measures: Endoscopic biopsy specimens of the gastric mucosa were obtained every 3 to 6 months after treatment for H. pylori infection. Results: Helicobacter pylori was completely eradicated in 25 of 26 patients, but 4 patients needed second-line antibiotic treatment to eradicate the microorganism. Disappearance or almost total regression of the lymphomatous tissue was observed in 15 of the 25 evaluable patients (60%; CI, 39% to 79%); however, disappearance or almost total regression was evident in the first biopsy specimen after treatment for H. pylori infection in only 8 of the 15 patients. Conclusions: Our study confirms recent anecdotal reports of regression of gastric MALT lymphoma after eradication of H. pylori and indicates that the growth of these extranodal lymphomas may depend on H. pylori.	OSPED SAN GIOVANNI BELLINZONA, SERV ONCOL, CH-6500 BELLINZONA, SWITZERLAND; OSPED MULTIZONALE, VARESE, ITALY; FBF, OSPED S ORSOLA, BRESCIA, ITALY; IST CANTONALE PATOL, LOCARNO, SWITZERLAND	Regional Hospital of Bellinzona & Valleys, San Giovanni				Zucca, Emanuele/0000-0002-5522-6109				BENAYED F, 1989, CANCER, V63, P1251, DOI 10.1002/1097-0142(19890401)63:7<1251::AID-CNCR2820630704>3.0.CO;2-H; DOGLIONI C, 1992, LANCET, V339, P834, DOI 10.1016/0140-6736(92)90280-G; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PINOTTI G, 1992, HAEMATOLOGICA, V77, P405; ROHATINER A, 1994, ANN ONCOL, V5, P397, DOI 10.1093/oxfordjournals.annonc.a058869; SPATARO V, 1994, ANN ONCOL, V5, P954, DOI 10.1093/oxfordjournals.annonc.a058738; STOLTE M, 1993, LANCET, V342, P568, DOI 10.1016/0140-6736(93)91404-A; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WOTHERSPOON AC, 1992, HISTOPATHOLOGY, V20, P29, DOI 10.1111/j.1365-2559.1992.tb00912.x	12	376	386	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					767	769		10.7326/0003-4819-122-10-199505150-00006	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717599				2022-12-24	WOS:A1995QX14700006
J	TOOTELL, RBH; REPPAS, JB; DALE, AM; LOOK, RB; SERENO, MI; MALACH, R; BRADY, TJ; ROSEN, BR				TOOTELL, RBH; REPPAS, JB; DALE, AM; LOOK, RB; SERENO, MI; MALACH, R; BRADY, TJ; ROSEN, BR			VISUAL-MOTION AFTEREFFECT IN HUMAN CORTICAL AREA MT REVEALED BY FUNCTIONAL MAGNETIC-RESONANCE-IMAGING	NATURE			English	Article							HUMAN BRAIN; SENSORY STIMULATION; CORTEX; INFORMATION; ACTIVATION; ADAPTATION; MOVEMENT	FUNCTIONAL magnetic resonance imaging (fMRI)(1-3) was used to measure local haemodynamic changes (reflecting electrical activity) in human visual cortex during production of the visual motion aftereffect, also known as the waterfall illusion(4,5). As in previous studies(6-9), human cortical area MT (V5) responded much better to moving than to stationary visual stimuli. Here we demonstrate a clear increase in activity in MT when subjects viewed a stationary stimulus undergoing illusory motion, following adaptation to stimuli moving in a single local direction. Control stimuli moving in reversing, opposed directions produced neither a perceptual motion aftereffect nor elevated fMRI levels postadaptation. The time course of the motion aftereffect (measured in parallel psychophysical tests) was essentially identical to the time course of the fMRI motion aftereffect. Because the motion aftereffect is direction specific, this indicates that cells in human area MT are also direction specific. In five other retinotopically defined cortical areas, similar motion-specific aftereffects were smaller than those in MT or absent.	UNIV CALIF SAN DIEGO, DEPT COGNIT SCI, LA JOLLA, CA 92093 USA; UNIV OSLO, DEPT NEUROPHYSIOL, OSLO, NORWAY	University of California System; University of California San Diego; University of Oslo	TOOTELL, RBH (corresponding author), MASSACHUSETTS GEN HOSP, NUCL MAGNET RESONANCE CTR, 149 13TH ST, BOSTON, MA 02129 USA.		Dale, Anders M/A-5180-2010; Sereno, Martin I/F-7657-2012	Sereno, Martin I/0000-0002-7598-7829				ADAMS R, 1834, PHILOS MAG, V5, P373; ALIMAN JM, 1981, CORTICAL SENSORY ORG, V2, P171; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BARLOW HB, 1963, NATURE, V200, P1345, DOI 10.1038/2001345a0; BORN RT, 1992, NATURE, V357, P497, DOI 10.1038/357497a0; CARNEY T, 1993, VISION RES, V33, P1977, DOI 10.1016/0042-6989(93)90022-O; CLARKE S, 1990, J COMP NEUROL, V298, P188, DOI 10.1002/cne.902980205; DEYOE EA, 1994, J NEUROSCI METH, V54, P171, DOI 10.1016/0165-0270(94)90191-0; DUPONT P, 1994, J NEUROPHYSIOL, V72, P1420, DOI 10.1152/jn.1994.72.3.1420; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Frith CD, 1995, HUM BRAIN MAPP, V3, P153, DOI 10.1002/hbm.460030209; HAMMOND P, 1985, EXP BRAIN RES, V60, P411; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LAGAE L, 1989, BRAIN RES, V496, P361, DOI 10.1016/0006-8993(89)91089-5; MARTIN SG, 1988, J NEUROPHYSIOL, V59, P1314; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; NISHIDA S, 1994, VISION RES, V34, P2707, DOI 10.1016/0042-6989(94)90227-5; NISHIDA S, 1992, VISION RES, V32, P1635, DOI 10.1016/0042-6989(92)90156-D; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PETERSEN SE, 1985, BRAIN RES, V346, P146, DOI 10.1016/0006-8993(85)91105-9; SCHNEIDER W, 1993, NATURE, V365, P150, DOI 10.1038/365150a0; SERENO MI, IN PRESS SCIENCE; TOOTELL RBH, 1995, CEREB CORTEX, V5, P39, DOI 10.1093/cercor/5.1.39; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; VAUTIN RG, 1977, J NEUROPHYSIOL, V40, P1051, DOI 10.1152/jn.1977.40.5.1051; VONDERHEYDT R, 1978, ARCH ITAL BIOL, V116, P248; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; Wohlgemuth A., 1911, AFTER EFFECT SEEN MO, V1; ZEKI S, 1991, J NEUROSCI, V11, P641; ZEKI S, 1993, P ROY SOC B-BIOL SCI, V252, P215, DOI 10.1098/rspb.1993.0068	30	452	459	3	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 11	1995	375	6527					139	141		10.1038/375139a0	http://dx.doi.org/10.1038/375139a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753168				2022-12-24	WOS:A1995QX74100049
J	SULLIVAN, EA; KREISWIRTH, BN; PALUMBO, L; KAPUR, V; MUSSER, JM; EBRAHIMZADEH, A; FRIEDEN, TR				SULLIVAN, EA; KREISWIRTH, BN; PALUMBO, L; KAPUR, V; MUSSER, JM; EBRAHIMZADEH, A; FRIEDEN, TR			EMERGENCE OF FLUOROQUINOLONE-RESISTANT TUBERCULOSIS IN NEW-YORK-CITY	LANCET			English	Note							CIPROFLOXACIN	22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.	NEW YORK CITY DEPT HLTH,NEW YORK,NY 10013; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341; PUBL HLTH RES INST,CTR TB,NEW YORK,NY; BAYLOR COLL MED,DEPT PATHOL,MOLEC PATHOBIOL SECT,HOUSTON,TX 77030	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA; Baylor College of Medicine			Sullivan, Elizabeth A/V-6742-2017; Kapur, Vivek/F-7610-2013	Sullivan, Elizabeth A/0000-0002-8718-2753; Kapur, Vivek/0000-0002-9648-0138	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009238] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09238, AI-37004] Funding Source: Medline; NIDA NIH HHS [DA-09238] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		CAMBAU E, 1994, J INFECT DIS, V170, P479, DOI 10.1093/infdis/170.2.479; COLLINS CH, 1985, J ANTIMICROB CHEMOTH, V16, P575, DOI 10.1093/jac/16.5.575; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; HOFFKEN G, 1985, EUR J CLIN MICROBIOL, V4, P345, DOI 10.1007/BF02013667; KAHANA LM, 1992, DCIP ANN PHARMACOTHE, V25, P919; KAPUR V, 1995, ARCH PATHOL LAB MED, V119, P131; KENNEDY N, 1993, AM REV RESPIR DIS, V148, P1547, DOI 10.1164/ajrccm/148.6_Pt_1.1547; Kent PT, 1985, GUIDE LEVEL 3 LAB; TAKIFF HE, 1994, ANTIMICROB AGENTS CH, V38, P773, DOI 10.1128/AAC.38.4.773; 1992, TUBERCLE LUNG DIS, V73, P59	10	105	112	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1148	1150		10.1016/S0140-6736(95)90980-X	http://dx.doi.org/10.1016/S0140-6736(95)90980-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723548				2022-12-24	WOS:A1995QW62200012
J	ALLEN, GJ; MUIR, SR; SANDERS, D				ALLEN, GJ; MUIR, SR; SANDERS, D			RELEASE OF CA2+ FROM INDIVIDUAL PLANT VACUOLES BY BOTH INSP(3) AND CYCLIC ADP-RIBOSE	SCIENCE			English	Article							INOSITOL TRISPHOSPHATE; CYTOPLASMIC CALCIUM; CHANNELS; MICROSOMES; MEMBRANE; PATHWAYS	Calcium mobilization from intracellular pools couples many stimuli to responses in plant cells. Cyclic adenosine 5'-diphosphoribose (cADPR), which interacts with a ryanodine receptor in certain animal cells, was shown to elicit calcium release at the vacuolar membrane of beet storage root. The vacuolar calcium release pathway showed similarities to cADPR-gated calcium release in animal cells, including inhibition by ruthenium red, ryanodine activation, and high affinity for cADPR [Michaelis constant (K-m) = 24 +/- 7 nanomolar]. Analysis by patch-clamping demonstrated that the cADPR-gated pathway in beet is voltage-dependent over the physiological range, does not spontaneously desensitize, and is colocalized with an inositol 1,4,5-trisphosphate (InsP(3))-gated calcium release pathway in individual vacuoles.			ALLEN, GJ (corresponding author), UNIV YORK, DEPT BIOL, PLANT LAB, POB 373, YORK YO1 5YW, N YORKSHIRE, ENGLAND.							ALEXANDRE J, 1990, NATURE, V343, P567, DOI 10.1038/343567a0; ALLEN GJ, 1994, PLANT CELL, V6, P685, DOI 10.1105/tpc.6.5.685; ALLEN GJ, 1994, PLANT J, V6, P687, DOI 10.1046/j.1365-313X.1994.6050687.x; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BERTL A, 1992, SCIENCE, V258, P873, DOI 10.1126/science.1439795; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BROSNAN JM, 1990, NATURE, V344, P593, DOI 10.1038/344593b0; BROSNAN JM, 1990, FEBS LETT, V260, P70, DOI 10.1016/0014-5793(90)80068-T; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; COTE GG, 1994, BIOESSAYS, V16, P39, DOI 10.1002/bies.950160106; FATT P, 1958, J PHYSIOL-LONDON, V142, P516, DOI 10.1113/jphysiol.1958.sp006034; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GEHRING CA, 1990, NATURE, V345, P528, DOI 10.1038/345528a0; GILROY S, 1993, J CELL SCI, V106, P453; HEDRICH R, 1987, NATURE, V329, P833, DOI 10.1038/329833a0; JOHANNES E, 1992, PLANT J, V2, P97, DOI 10.1111/j.1365-313X.1992.00097.x; JOHANNES E, 1992, PHILOS T R SOC B, V338, P105, DOI 10.1098/rstb.1992.0134; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; SITSAPESAN R, 1994, CIRC RES, V75, P596, DOI 10.1161/01.RES.75.3.596; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; WARD JM, 1994, PLANT CELL, V6, P669; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X	32	282	296	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 5	1995	268	5211					735	737		10.1126/science.7732384	http://dx.doi.org/10.1126/science.7732384			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732384				2022-12-24	WOS:A1995QW60300053
J	PREKER, PJ; LINGNER, J; MINVIELLESEBASTIA, L; KELLER, W				PREKER, PJ; LINGNER, J; MINVIELLESEBASTIA, L; KELLER, W			THE FIP1 GENE ENCODES A COMPONENT OF A YEAST PRE-MESSENGER-RNA POLYADENYLATION FACTOR THAT DIRECTLY INTERACTS WITH POLY(A) POLYMERASE	CELL			English	Article							MESSENGER-RNA POLYADENYLATION; SACCHAROMYCES-CEREVISIAE; 3' END; POLY(A)-BINDING PROTEIN; BINDING DOMAIN; EXPRESSION; SEQUENCE; PURIFICATION; CLEAVAGE; COMPLEX	We have identified an essential gene, called FIP1, encoding a 327 amino acid protein interacting with yeast poly(A) polymerase (PAP1) in the two-hybrid assay, Recombinant FIP1 protein forms a 1:1 complex with PAP1 in vitro. At 37 degrees C, a thermosensitive allele of FIP1 shows a shortening of poly(A) tails and a decrease in the steady-state level of actin transcripts. When assayed for 3'-end processing in vitro, fip1 mutant extracts exhibit normal cleavage activity, but fail to polyadenylate the upstream cleavage product. Polyadenylation activity is restored by adding polyadenylation factor I (PF I). Antibodies directed against FIP1 specifically recognize a polypeptide in these fractions. Coimmunoprecipitation experiments reveal that RNA14, a subunit of cleavage factor I (CF I), directly interacts with FIP1, but not with PAP1, We propose a model in which PF I tethers PAP1 to CF I, thereby conferring specificity to poly(A) polymerase for pre-mRNA substrates.			PREKER, PJ (corresponding author), UNIV BASEL, BIOZENTRUM, DEPT CELL BIOL, CH-4056 BASEL, SWITZERLAND.		Minvielle-Sebastia, Lionel/M-7154-2014	Lingner, Joachim/0000-0002-2853-5803				ABE A, 1990, EMBO J, V9, P3691, DOI 10.1002/j.1460-2075.1990.tb07581.x; AGUILERA A, 1994, GENETICS, V136, P87; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BLOCH JC, 1978, MOL GEN GENET, V165, P123, DOI 10.1007/BF00269900; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROWN NG, 1994, MOL CELL BIOL, V14, P1045, DOI 10.1128/MCB.14.2.1045; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guthrie C, 1991, GUIDE YEAST GENETICS; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; IRNIGER S, 1991, MOL CELL BIOL, V11, P3060, DOI 10.1128/MCB.11.6.3060; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; LEGRAIN P, 1993, GENE DEV, V7, P1390, DOI 10.1101/gad.7.7b.1390; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LINGNER J, 1993, NUCLEIC ACIDS RES, V21, P2917, DOI 10.1093/nar/21.12.2917; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PELTZ SW, 1994, PROG NUCLEIC ACID RE, V47, P271, DOI 10.1016/S0079-6603(08)60254-8; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; PROWELLER A, 1994, GENE DEV, V8, P2629, DOI 10.1101/gad.8.21.2629; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; RUSSO P, 1993, MOL CELL BIOL, V13, P7836, DOI 10.1128/MCB.13.12.7836; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; Sambrook J., 1989, MOL CLONING LAB MANU; SEE PY, 1989, PROTEIN STRUCTURE PR, P1; SMITH HE, 1990, MOL CELL BIOL, V10, P6103, DOI 10.1128/MCB.10.12.6103; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	54	113	115	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					379	389		10.1016/0092-8674(95)90391-7	http://dx.doi.org/10.1016/0092-8674(95)90391-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736590	Bronze			2022-12-24	WOS:A1995QW89400010
J	CARROLL, SB; WEATHERBEE, SD; LANGELAND, JA				CARROLL, SB; WEATHERBEE, SD; LANGELAND, JA			HOMEOTIC GENES AND THE REGULATION AND EVOLUTION OF INSECT WING NUMBER	NATURE			English	Article							DROSOPHILA EMBRYOS; ORIGIN; EXPRESSION; PROTEIN; SNAIL; LEG	THE evolution of wings catalysed the radiation of insects which make up some 75 per cent of known animals, Fossil evidence suggests that wings evolved from a segment of the leg(1) and that early pterygotes bore wings on all thoracic and abdominal segments(2). The pterygote body plan subsequently diverged producing orders bearing three, two or just one pair of thoracic wings. We have investigated the role of homeotic genes in pterygote evolution by examining their function in Drosophila wing development and their expression in a primitive apterygote. Wing formation is not promoted by any homeotic gene, but is repressed in different segments by different homeotic genes, We suggest here that wings first arose without any homeotic gene involvement in an ancestor with a homeotic 'groundplan' similar to modern winged insects and that wing formation subsequently fell under the negative control of individual homeotic genes at different stages of pterygote evolution.	UNIV WISCONSIN,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	CARROLL, SB (corresponding author), HOWARD HUGHES MED INST,1525 LINDEN DR,MADISON,WI 53706, USA.			Weatherbee, Scott/0000-0002-0915-1329				AKAM M, 1988, DEVELOPMENT, V104, P123; ALBERGA A, 1991, DEVELOPMENT, V111, P983; ANDREW DJ, 1994, EMBO J, V13, P1132, DOI 10.1002/j.1460-2075.1994.tb06362.x; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; BATE M, 1991, DEVELOPMENT, V112, P755; BRAND AH, 1993, DEVELOPMENT, V119, P401; Brower, 1991, DROSOPHILA INFORMATI, V70, P52; CARROLL SB, 1986, CELL, V47, P113, DOI 10.1016/0092-8674(86)90372-7; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; KEISH R, 1994, DEV GENET, V15, P19; Kukalova-Peck J., 1991, INSECTS AUSTR TXB ST, V1, P141; KUKALOVAPECK J, 1978, J MORPHOL, V156, P53, DOI 10.1002/jmor.1051560104; KUKALOVAPECK J, 1983, CAN J ZOOL, V61, P1618, DOI 10.1139/z83-217; LEVINE M, 1983, EMBO J, V2, P2037, DOI 10.1002/j.1460-2075.1983.tb01697.x; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MAHAFFEY JW, 1987, GENETICS, V117, P51; MANN RS, 1994, DEVELOPMENT, V121, P3205; MAUHIN V, 1993, NUCLEIC ACIDS RES, V21, P3951, DOI 10.1093/nar/21.17.3951; Raff R.A., 1983, EMBRYOS GENES EVOLUT; RILEY PD, 1987, GENE DEV, V1, P716, DOI 10.1101/gad.1.7.716; SIMPSON P, 1983, GENETICS, V105, P615; Snodgrass RE, 1935, PRINCIPLES INSECT MO; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WHITE RAH, 1985, EMBO J, V4, P2035, DOI 10.1002/j.1460-2075.1985.tb03889.x; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WILLIAMS JA, 1994, NATURE, V368, P298; WOOTTON R J, 1972, Palaeontology (Oxford), V15, P662	30	158	161	3	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					58	61		10.1038/375058a0	http://dx.doi.org/10.1038/375058a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723843				2022-12-24	WOS:A1995QW60400054
J	TINETTI, ME; INOUYE, SK; GILL, TM; DOUCETTE, JT				TINETTI, ME; INOUYE, SK; GILL, TM; DOUCETTE, JT			SHARED RISK-FACTORS FOR FALLS, INCONTINENCE, AND FUNCTIONAL DEPENDENCE - UNIFYING THE APPROACH TO GERIATRIC SYNDROMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY PERSONS; URINARY-INCONTINENCE; COMMUNITY; PREDICTORS; PEOPLE	Objective.-To determine whether a set of factors representing impairments in multiple areas could be identified that predisposes to falling, incontinence, and functional dependence. Design.-Population-based cohort with a 1-year follow-up. Setting.-General community. Participants.-A total of 927 New Haven, Conn, residents, aged 72 years and older who completed the baseline and 1-year interviews. Main Outcome Measures.-At least one episode of urinary incontinence per week, at least two falls during the follow-up year, and dependence on human help for one or more basic activities of daily living. Results.-At 1 year, urinary incontinence was reported by 16%, at least two falls by 10%, and functional dependence by 20% of participants. The four independent predisposing factors for the outcomes of incontinence, falling, and functional dependence included slow timed chair stands (lower extremity impairment), decreased arm strength (upper extremity impairment), decreased vision and hearing (sensory impairment), and either a high anxiety or depression score (affective impairment). There was a significant increase in each of incontinence, falling, and functional dependence as the number of these predisposing factors increased. For example, the proportion of participants experiencing functional dependence doubled (7% to 14% to 28% to 60%) (chi(2)=119.8; P<.001) as the number of predisposing factors increased from zero to one to two to at least three. Conclusions.-Our findings suggest that predisposition to geriatric syndromes and functional dependence may result when impairments in multiple domains compromise compensatory ability. It may be possible to restore compensatory ability and prevent or delay the onset of several geriatric syndromes and, perhaps, functional dependence by modifying a shared set of predisposing factors. Perhaps it is time to take a more unified approach to the geriatric syndromes and functional dependence.	YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06520 USA	Yale University	TINETTI, ME (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, 333 CEDAR ST, POB 208025, NEW HAVEN, CT 06520 USA.		Inouye, Sharon/R-7216-2019; Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368	NIA NIH HHS [P60AG10469, AG07449] Funding Source: Medline; PHS HHS [K08AB00524] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P60AG010469, R01AG007449] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXANDER NB, 1994, J AM GERIATR SOC, V42, P93, DOI 10.1111/j.1532-5415.1994.tb06081.x; [Anonymous], 1955, ARCH OPHTHALMOL-CHIC, V54, P462; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; Cahalan D., 1969, AM DRINKING PRACTICE; CORNONIHUNTLEY J, 1986, DHHS NIH862443 NAT I; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1992, JAMA-J AM MED ASSOC, V267, P827; HERZOG AR, 1990, J AM GERIATR SOC, V38, P273, DOI 10.1111/j.1532-5415.1990.tb03504.x; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; Houston K A, 1993, Clin Geriatr Med, V9, P157; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; LIPSITZ LA, 1992, JAMA-J AM MED ASSOC, V267, P1806, DOI 10.1001/jama.267.13.1806; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; MARTIN GR, 1993, ANNU REV MED, V44, P419, DOI 10.1146/annurev.me.44.020193.002223; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; NUTT JG, 1993, NEUROLOGY, V43, P268, DOI 10.1212/WNL.43.2.268; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RESNICK NM, 1994, J AM GERIATR SOC, V42, P202, DOI 10.1111/j.1532-5415.1994.tb04953.x; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; RESNICK NM, 1992, HOSP PRACT      1015, P552; Reuben D. B., 1991, GERIATRICS REV SYLLA, P117; RISCH HA, 1988, AM J EPIDEMIOL, V128, P420, DOI 10.1093/oxfordjournals.aje.a114982; ROBBINS AS, 1989, ARCH INTERN MED, V149, P1628, DOI 10.1001/archinte.1989.00390070138022; SIU AL, 1993, J AM GERIATR SOC, V41, P78, DOI 10.1111/j.1532-5415.1993.tb05952.x; SMITH LA, 1990, J AM GERIATR SOC, V38, P993, DOI 10.1111/j.1532-5415.1990.tb04422.x; Spielberger C., 1983, STAI MANUAL; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, IN PRESS J AM GERIAT; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212	33	599	616	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1348	1353		10.1001/jama.273.17.1348	http://dx.doi.org/10.1001/jama.273.17.1348			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715059				2022-12-24	WOS:A1995QV30700019
J	TORRENS, PR; LYNCH, BS; BONNIE, RJ				TORRENS, PR; LYNCH, BS; BONNIE, RJ			GROWING-UP TOBACCO FREE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											TORRENS, PR (corresponding author), INST MED,COMM PREVENTING NICOTINE ADDICT CHILDREN & YOUTH,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.								0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1326	1326						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV307	7715049				2022-12-24	WOS:A1995QV30700003
J	KLAGES, N; STRUBIN, M				KLAGES, N; STRUBIN, M			STIMULATION OF RNA-POLYMERASE-II TRANSCRIPTION INITIATION BY RECRUITMENT OF TBP IN-VIVO	NATURE			English	Article							TATA-BINDING PROTEIN; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ACTIVATION DOMAIN; YEAST; PROMOTER; DNA; ELEMENTS; COMPLEX; REGION	EUKARYOTIC transcriptional activators may stimulate RNA polymerase II activity by promoting assembly of preinitiation complexes on promoters through their interactions with one or more components of the basal machinery(1,2). On the basis of its central role in initiating transcription-complex formation upon binding to the TATA box, the general transcription factor TFIID, which includes the TATA-binding protein (TBP) and several TBP-associated factors(3-5), has been implicated as a target for activators. Consistent with this idea, an increasing number of activators have been reported to bind directly to TBP6-9. To assess the functional importance of these in vitro interactions for transcriptional regulation in vivo, we made use of a novel strategy in yeast to show that a physical interaction with TBP is sufficient for a sequence-specific DNA-binding protein to increase initiation of transcription by RNA polymerase II. These results imply that binding of TFIID to promoter elements is a limiting step in transcription complex assembly in vivo.			KLAGES, N (corresponding author), UNIV GENEVA,CTR MED,DEPT GENET & MICROBIOL,9 AVE CHAMPEL,CH-1211 GENEVA 4,SWITZERLAND.							AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; CORMACK BP, 1994, GENE DEV, V8, P1335, DOI 10.1101/gad.8.11.1335; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; SIKORSKI RS, 1989, GENETICS, V122, P19; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	25	162	162	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					822	823		10.1038/374822a0	http://dx.doi.org/10.1038/374822a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723829				2022-12-24	WOS:A1995QV31500051
J	KHUROO, MS; KAMILI, S; JAMEEL, S				KHUROO, MS; KAMILI, S; JAMEEL, S			VERTICAL TRANSMISSION OF HEPATITIS-E VIRUS	LANCET			English	Note							NON-B HEPATITIS; NON-A	Little is known about vertical transmission of hepatitis E virus from infected mothers to their infants. We studied eight babies born to mothers infected with hepatitis fin third trimester. One baby was icteric at birth with elevated transaminases and four babies had anicteric hepatitis. Two babies were born with hypothermia and hypoglycaemia and died within 24 h; one had massive hepatic necrosis. Hepatitis E virus RNA was detected by PCR in cord or birth blood samples of five infants. Six infants had evidence of hepatitis E infection. We conclude that hepatitis E virus is commonly transmitted from infected mothers to their babies with significant perinatal morbidity and mortality.	INT CTR GENET ENGN & BIOTECHNOL,NEW DELHI,INDIA	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	KHUROO, MS (corresponding author), SHERIKASHMIR INST MED SCI,DEPT GASTROENTEROL,POST BOX 27,SRINAGAR 190001,JAMMU & KASHMIR,INDIA.		Khuroo, Mohammad Sultan/N-3571-2014	Khuroo, Mohammad Sultan/0000-0003-2823-8814				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; JAMEEL S, 1992, J MED VIROL, V37, P263, DOI 10.1002/jmv.1890370405; KHUROO MS, 1981, AM J MED, V70, P252, DOI 10.1016/0002-9343(81)90758-0; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4	4	218	228	3	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1025	1026		10.1016/S0140-6736(95)90761-0	http://dx.doi.org/10.1016/S0140-6736(95)90761-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723501				2022-12-24	WOS:A1995QU57300013
J	TAPPERO, JW; SCHUCHAT, A; DEAVER, KA; MASCOLA, L; WENGER, JD				TAPPERO, JW; SCHUCHAT, A; DEAVER, KA; MASCOLA, L; WENGER, JD			REDUCTION IN THE INCIDENCE OF HUMAN LISTERIOSIS IN THE UNITED-STATES - EFFECTIVENESS OF PREVENTION EFFORTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPORADIC LISTERIOSIS; EPIDEMIC LISTERIOSIS; FOODS; MONOCYTOGENES; ASSOCIATION	Background.-Food-borne transmission is now recognized as a major cause of human listeriosis. Objective.-To assess the impact of prevention efforts, listeriosis rates before interventions were initiated in 1989 were compared with more recent rates (1990 through 1993). Design.-From 1989 through 1993, multistate, laboratory-based active surveillance was conducted to identify all cases in which Listeria monocytogenes was isolated from cultures or ordinarily sterile sites in an aggregate population of more than 19 million. Setting.-All laboratories serving acute care hospitals in up to nine surveillance areas in the United States. Interventions.-In 1989, a well-publicized case report of listeriosis linked to processed poultry led US regulatory agencies to enforce aggressive food monitoring policies and prompted industry to invest in cleanup efforts. In May 1992, consumer guidelines for listeriosis prevention were disseminated. Outcome Measures.-Cases of perinatal and nonperinatal listeriosis. Results.-The rate of listeriosis decreased in all surveillance areas. Projection of these rates to the US population suggests an estimated 1965 cases and 481 deaths occurred in 1989 compared with an estimated 1092 cases and 248 deaths in 1993, a 44% and 48% reduction in illness and death, respectively. Among adults 50 years of age and older, rates declined from 16.2 per 1 million in 1989 to 10.2 per 1 million in 1993 (P=.02). Perinatal disease decreased from 17.4 cases per 100 000 births in 1989 to 8.6 cases per 100 000 births in 1993 (P=.003). Three serotypes (1/2a, 1/2b, and 4b) of L monocytogenes accounted for more than 96% of cases during each year of the study (1989 through 1993). Conclusions. The incidence of listeriosis in study areas was substantially lower in 1993 than in 1989. The temporal association of this reduction with industry, regulatory, and educational efforts suggests these measures were effective.	LOS ANGELES CTY DEPT HLTH SERV, PUBL HLTH PROGRAMS & SERV, LOS ANGELES, CA USA		TAPPERO, JW (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, CHILDHOOD & RESP DIS BRANCH, ATLANTA, GA 30333 USA.				FDA HHS [FDA 224-88-2456] Funding Source: Medline	FDA HHS		ARCHER D L, 1988, Clinical Microbiology Reviews, V1, P377; Bernard D., 1994, Dairy, Food and Environmental Sanitation, V14, P140; BILLE J, 1990, T IND MICR, P71; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; FARBER JM, 1991, MICROBIOL REV, V55, P476, DOI 10.1128/MMBR.55.3.476-511.1991; FARBER JM, 1989, J FOOD PROTECT, V52, P456, DOI 10.4315/0362-028X-52.7.456; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FLEMING DW, 1985, NEW ENGL J MED, V312, P404, DOI 10.1056/NEJM198502143120704; GELLIN BG, 1991, AM J EPIDEMIOL, V133, P392, DOI 10.1093/oxfordjournals.aje.a115893; GELLIN BG, 1989, JAMA-J AM MED ASSOC, V261, P1313, DOI 10.1001/jama.261.9.1313; GILBERT RJ, 1989, LANCET, V1, P383; GOULET V, 1993, B EPIDEMIOL HEBDOM, V4, P13; HEDBERG CW, 1994, CLIN INFECT DIS, V18, P671, DOI 10.1093/clinids/18.5.671; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; MCLAUCHLIN J, 1991, BRIT MED J, V303, P773, DOI 10.1136/bmj.303.6805.773; McLauchlin J., 1990, PHLS Microbiology Digest, V7, P54; Newton L, 1992, Commun Dis Rep CDR Rev, V2, pR142; PINNER RW, 1992, JAMA-J AM MED ASSOC, V267, P2046, DOI 10.1001/jama.267.15.2046; RYSER ET, 1991, LISTERIA LISTERIOSIS, P405; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHUCHAT A, 1991, CLIN MICROBIOL REV, V4, P169, DOI 10.1128/CMR.4.2.169-183.1991; SCHUCHAT A, 1992, JAMA-J AM MED ASSOC, V267, P2041, DOI 10.1001/jama.267.15.2041; SCHWARTZ B, 1988, LANCET, V2, P779; Seeliger H.P.R., 1979, METHOD MICROBIOL, V13, P31, DOI [10.1016/S0580-9517(08)70372-6, DOI 10.1016/S0580-9517(08)70372-6]; SMITH JL, 1990, FOODBORNE LISTERIOSI, P137; THOMPSON P, 1990, LANCET, V336, P1557, DOI 10.1016/0140-6736(90)93320-O; TISLER JM, 1991, FOOD TECHNOL-CHICAGO, V45, P125; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WENGER JD, 1990, J FOOD PROTECT, V53, P1015, DOI 10.4315/0362-028X-53.12.1015; 1992, PREVENTING FOOD BORN; 1993, PUTTING CONSUMERS 1S; 1993, COMMUN DIS REP CDR W, V3, P136; 1992, MAKING CONNECTION US, P1; 1992, BACK GROUNDER LISTER; 1985, US PHS FDA229 US DEP; 1987, US PHS MI876 US DEP; 1992, JAMA-J AM MED ASSOC, V268, P180; 1992, PREVENTING FOODBORNE; 1986, MICROORGANISMS FOODS, P92; 1990, FSIS102401 FOOD SAF; 1987, FED REG         0311, V52, P7464; 1989, FED REG         0523, V54, P22345; 1992, MMWR-MORBID MORTAL W, V41, P251; 1988, MMWR-MORBID MORTAL W, V37, P764; 1992, MMWR-MORBID MORTAL W, V41, P257; 1992, FDA922232 PUBL; 1993, HIV AIDS SURVEILLANC, V5, P1; 1989, MMWR-MORBID MORTAL W, V38, P267	48	182	189	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1118	1122		10.1001/jama.273.14.1118	http://dx.doi.org/10.1001/jama.273.14.1118			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707600				2022-12-24	WOS:A1995QR05900031
J	KAMPER, J; REICHMANN, M; ROMEIS, T; BOLKER, M; KAHMANN, R				KAMPER, J; REICHMANN, M; ROMEIS, T; BOLKER, M; KAHMANN, R			MULTIALLELIC RECOGNITION - NONSELF-DEPENDENT DIMERIZATION OF THE BE AND BW HOMEODOMAIN PROTEINS IN USTILAGO-MAYDIS	CELL			English	Article							AUTONOMOUS PLASMIDS; FILAMENTOUS GROWTH; SEXUAL DEVELOPMENT; 2-HYBRID SYSTEM; U-MAYDIS; A-ALPHA; LOCUS; ALLELES; GENES; YEAST	In the plant pathogenic fungus Ustilago maydis, sexual and pathogenic development are controlled by the multiallelic b mating-type locus. The b locus encodes a pair of unrelated homeodomain proteins termed bE and bW, with allelic differences clustering in the N-terminal domains of both polypeptides. Only combinations of bE and bW of different allelic origin are active. We have investigated the underlying molecular mechanism for this intracellular self/nonself recognition phenomenon. By using the two-hybrid system, we were able to show that bE and bW dimerize only if they are derived from different alleles. Dimerization involves the N-terminal variable domains. Different point mutants of bE2 were isolated that function in combination with bW2. The majority of such bE2 mutant polypeptides were also able to form heterodimers with bW2 in the two-hybrid system. Nonself-dependent dimerization of bE and bW was supported with a biochemical interaction assay with immobilized proteins. Our results suggest a model for self/nonself recognition in which variable cohesive contacts direct dimerization.			KAMPER, J (corresponding author), UNIV MUNICH,INST GENET & MIKROBIOL,MARIA WARD STR 1A,D-80638 MUNICH,GERMANY.			Bolker, Michael/0000-0002-7366-3855				BAKKEREN G, 1993, PLANT CELL, V5, P123, DOI 10.1105/tpc.5.1.123; BANUETT F, 1991, P NATL ACAD SCI USA, V88, P3922, DOI 10.1073/pnas.88.9.3922; BANUETT F, 1992, TRENDS GENET, V8, P174, DOI 10.1016/0168-9525(92)90091-H; BANUETT F, 1989, P NATL ACAD SCI USA, V86, P5878, DOI 10.1073/pnas.86.15.5878; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BERGEMANN J, 1993, THESIS FREIE U BERLI; BOLKER M, 1992, CELL, V68, P441, DOI 10.1016/0092-8674(92)90182-C; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTENSEN JJ, 1963, AM PHYTOPATHOL SOC M, V2; DAHL M, 1991, ADV MOL GENETICS PLA, V1, P264; DAY PR, 1971, P NATL ACAD SCI USA, V68, P533, DOI 10.1073/pnas.68.3.533; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GILLISSEN B, 1992, CELL, V68, P647, DOI 10.1016/0092-8674(92)90141-X; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HO CY, 1994, EMBO J, V13, P1403, DOI 10.1002/j.1460-2075.1994.tb06394.x; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOLLIDAY R, 1961, GENET RES, V2, P204, DOI 10.1017/S0016672300000719; HURST HC, 1994, PROTEIN PROFILE, V1, P125; Innis M. A., 1990, PCR PROTOCOLS GUIDE, P3; KUES U, 1992, TRENDS GENET, V8, P154, DOI 10.1016/0168-9525(92)90207-K; KUES U, 1992, GENE DEV, V6, P568, DOI 10.1101/gad.6.4.568; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; Miller JH, 1972, EXPT MOL GENETICS; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PUHALLA JE, 1970, GENET RES, V16, P229, DOI 10.1017/S0016672300002457; PUHALLA JE, 1968, GENETICS, V60, P461; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; ROWELL JB, 1955, PHYTOPATHOLOGY, V45, P370; ROWELL JB, 1954, PHYTOPATHOLOGY, V44, P356; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; Sherman F., 1986, METHODS YEAST GENETI; SPECHT CA, 1992, P NATL ACAD SCI USA, V89, P7174, DOI 10.1073/pnas.89.15.7174; SPEE JH, 1993, NUCLEIC ACIDS RES, V21, P777, DOI 10.1093/nar/21.3.777; SPELLIG T, 1994, EMBO J, V13, P1620, DOI 10.1002/j.1460-2075.1994.tb06425.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSUKUDA T, 1988, MOL CELL BIOL, V8, P3703, DOI 10.1128/MCB.8.9.3703; WONG GJ, 1985, T BRIT MYCOL SOC, V84, P95, DOI 10.1016/S0007-1536(85)80223-0; YEE AR, 1993, P NATL ACAD SCI USA, V90, P664, DOI 10.1073/pnas.90.2.664; [No title captured]	44	203	210	2	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					73	83		10.1016/0092-8674(95)90372-0	http://dx.doi.org/10.1016/0092-8674(95)90372-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720075	hybrid			2022-12-24	WOS:A1995QR97000009
J	FUNATSU, T; HARADA, Y; TOKUNAGA, M; SAITO, K; YANAGIDA, T				FUNATSU, T; HARADA, Y; TOKUNAGA, M; SAITO, K; YANAGIDA, T			IMAGING OF SINGLE FLUORESCENT MOLECULES AND INDIVIDUAL ATP TURNOVERS BY SINGLE MYOSIN MOLECULES IN AQUEOUS-SOLUTION	NATURE			English	Article							ACTIN-FILAMENTS; INVITRO; SUBFRAGMENT-1; MICROSCOPY; HYDROLYSIS; MOVEMENT	VISUALIZATION of single actin filaments by fluorescence microscopy(1) led to the development of new in vitro assays for analysing actomyosin-based motility at the molecular level(2-5). The ability to manipulate actin filaments with a microneedle(6,7) or an optical trap(8) combined with position-sensitive detectors has enabled direct measurements of nanometre displacements and piconewton forces exerted by individual myosin molecules. To elucidate how myosin generates movement, it is necessary to understand how ATP hydrolysis is coupled to mechanical work at the level of the single molecule. But the most sensitive microscopic ATPase assay available still requires over 1,000 myosin(9). To enhance the sensitivity of such assays, we have refined epifluorescence and total internal reflection microscopies to visualize single fluorescent dye molecules. We report here that this approach can be used directly to image single fluorescently labelled myosin molecules and detect individual ATP turnover reactions. In contrast to pre,viously reported single fluorescent molecule imaging methods, which used specimens immobilized on an air-dried surface(10-12), method allows video-rate imaging of single molecules in aqueous solution, and hence can be applied to the study of man types of enzymes and biomolecules.	OSAKA UNIV, DEPT BIOPHYS ENGN, TOYONAKA, OSAKA 560, JAPAN	Osaka University	FUNATSU, T (corresponding author), JRDC, ERATO, BIOMOTRON PROJECT, SENBA HIGASHI 2-4-14, MINO, OSAKA 562, JAPAN.		Funatsu, Takashi/Q-1404-2015; Yanagida, Toshio/D-1919-2009	Funatsu, Takashi/0000-0002-9656-8308; Tokunaga, Makio/0000-0003-4586-8922				AXELROD D, 1989, METHOD CELL BIOL, V30, P245; Bagshaw CR., 1993, MUSCLE CONTRACTION, DOI 10.1007/978-94-015-6839-5; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HARADA Y, 1988, CELL MOTIL CYTOSKEL, V10, P71, DOI 10.1002/cm.970100112; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; ISHIKAWA M, 1994, JPN J APPL PHYS 1, V33, P1571, DOI 10.1143/JJAP.33.1571; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LINDBERG M, 1975, EUR J BIOCHEM, V53, P481, DOI 10.1111/j.1432-1033.1975.tb04089.x; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; SOUTHWICK PL, 1990, CYTOMETRY, V11, P418, DOI 10.1002/cyto.990110313; SOWERBY AJ, 1993, J MOL BIOL, V234, P114, DOI 10.1006/jmbi.1993.1567; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRAUTMAN JK, 1994, NATURE, V369, P40, DOI 10.1038/369040a0; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; YANAGIDA T, 1993, TRENDS BIOCHEM SCI, V18, P319, DOI 10.1016/0968-0004(93)90064-T	24	835	885	6	263	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	1995	374	6522					555	559		10.1038/374555a0	http://dx.doi.org/10.1038/374555a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700383				2022-12-24	WOS:A1995QR06900056
J	MEURMAN, JH; RAJASUO, A; MURTOMAA, H; SAVOLAINEN, S				MEURMAN, JH; RAJASUO, A; MURTOMAA, H; SAVOLAINEN, S			RESPIRATORY-TRACT INFECTIONS AND CONCOMITANT PERICORONITIS OF THE WISDOM TEETH	BRITISH MEDICAL JOURNAL			English	Article							3RD MOLARS	Objective-To discover if there is an association between respiratory tract infections and pericoronitis of erupting third molars in young adults. Design-Data from male military conscripts' medical records w ere collected over five years and the incidence of respiratory tract infection before and after acute pericoronitis (191 cases) and before and after standard (722 cases) and operative (741) extractions compared with that in controls (n=703) who had no infections in the third molar regions. Subjects-14 500 male military conscripts aged 20. Setting-Garrisons in Valkeala and Kouvola, Finland. Results-The incidence of respiratory tract infection was significantly higher during the two weeks before acute pericoronitis was diagnosed compared with that in controls. The highest incidence was observed in the three days before pericoronitis (odds ratio 6.8; 95% confidence interval 3.0 to 15.0). The incidence was also increased in the first week after pericoronitis (odds ratio 3.7; 1.6 to 8.4) and three days before (odds ratio 2.6; 0.9 to 7.5) and during the first week after extraction of third molars (odds ratio 2.6; 1.3 to 5.3). Conclusions-Respiratory tract infection may precipitate and occur concomitantly with acute pericoronitis. Third molar surgery for pericoronitis, on the other hand, may trigger respiratory tract infection.	VALKEALA MIL HOSP,VALKEALA,FINLAND; UNIV HELSINKI,INST DENT,HELSINKI,FINLAND; CENT MIL HOSP,HELSINKI,FINLAND	University of Helsinki	MEURMAN, JH (corresponding author), UNIV KUOPIO,FAC DENT,POB 1627,SF-70211 KUOPIO,FINLAND.			Meurman, Jukka/0000-0001-6702-6836				ALMADORI G, 1988, INT J PEDIATR OTORHI, V15, P157, DOI 10.1016/0165-5876(88)90067-5; BEAN LR, 1971, J AM DENT ASSOC, V83, P1074, DOI 10.14219/jada.archive.1971.0439; DEGRE M, 1986, SCAND J INFECT DIS S, V49, P140; DIXON RE, 1985, AM J MED, V78, P45, DOI 10.1016/0002-9343(85)90363-8; GURALNICK W, 1984, BRIT DENT J, V156, P389, DOI 10.1038/sj.bdj.4805380; GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68, DOI 10.1177/00034894810903S216; HURLEN B, 1984, ORAL SURG ORAL MED O, V58, P522, DOI 10.1016/0030-4220(84)90072-0; Kay L W, 1966, Br J Oral Surg, V3, P188; KREKMANOV L, 1986, INT J ORAL MAX SURG, V15, P25, DOI 10.1016/S0300-9785(86)80007-2; LUDWICK WE, 1974, MIL MED, V139, P121; MACGREGOR AJ, 1970, J ORAL SURG, V28, P885; Marsland D W, 1976, J Fam Pract, V3, P25; MOMBELLI A, 1990, J CLIN PERIODONTOL, V17, P48, DOI 10.1111/j.1600-051X.1990.tb01047.x; NITZAN DW, 1985, J ORAL MAXIL SURG, V43, P510, DOI 10.1016/S0278-2391(85)80029-X; PARNELL JL, 1966, NEW ENGL J MED, V274, P979, DOI 10.1056/NEJM196605052741801; PIIRONEN J, 1981, Proceedings of the Finnish Dental Society, V77, P278; RAJASUO A, 1991, MIL MED, V156, P16, DOI 10.1093/milmed/156.1.16; RAJASUO A, 1994, THESIS U HELSINKI; van Cauwenberge P B, 1985, Rhinology, V23, P273; VENTA I, 1993, THESIS U HELSINKI; WADE WG, 1991, ORAL MICROBIOL IMMUN, V6, P310, DOI 10.1111/j.1399-302X.1991.tb00499.x; 1993, ANNUAL REPORTS HLTH; 1977, MANUAL INT STATISTIC, V1	23	14	14	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					834	836		10.1136/bmj.310.6983.834	http://dx.doi.org/10.1136/bmj.310.6983.834			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711620	Green Published			2022-12-24	WOS:A1995QQ85700018
J	FOURCADE, O; SIMON, MF; VIODE, C; RUGANI, N; LEBALLE, F; RAGAB, A; FOURNIE, B; SARDA, L; CHAP, H				FOURCADE, O; SIMON, MF; VIODE, C; RUGANI, N; LEBALLE, F; RAGAB, A; FOURNIE, B; SARDA, L; CHAP, H			SECRETORY PHOSPHOLIPASE A(2) GENERATES THE NOVEL LIPID MEDIATOR LYSOPHOSPHATIDIC ACID IN MEMBRANE MICROVESICLES SHED FROM ACTIVATED CELLS	CELL			English	Article							HUMAN-ERYTHROCYTES; PLASMA-MEMBRANE; RED-CELL; PURIFIED PHOSPHOLIPASES; ASYMMETRIC DISTRIBUTION; PROCOAGULANT ACTIVITY; PLATELET AGGREGATION; POSSIBLE INVOLVEMENT; II PHOSPHOLIPASE-A2; EXPRESSION	Nonpancreatic secretory phospholipase A(2) (sPLA(2)) displays proinflammatory properties; however, its physiological substrate is not identified. Although inactive toward intact cells, sPLA(2) hydrolyzed phospholipids in membrane microvesicles shed from Ca2+-loaded erythrocytes as well as from platelets and from whole blood cells challenged with inflammatory stimuli. sPLA(2) was stimulated upon degradation of sphingomyelin (SPH) and produced lysophosphatidic acid (LPA), which induced platelet aggregation. Finally, lysophospholipid-containing vesicles and sPLA(2) were detected in inflammatory fluids in relative proportions identical to those used in vitro. We conclude that upon loss of phospholipid asymmetry, cell-derived microvesicles provide a preferential substrate for sPLA(2). SPH hydrolysis, which is provoked by various cytokines, regulates sPLA(2) activity, and the novel lipid mediator LPA can be generated by this pathway.	HOP PURPAN,INSERM,U326,F-31059 TOULOUSE,FRANCE; FAC ST CHARLES,INST CHIM BIOL,F-13331 MARSEILLE 3,FRANCE; HOP PURPAN,SERV RHUMATOL,F-31059 TOULOUSE,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse								AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; ALLAN D, 1981, BIOCHEM J, V198, P433, DOI 10.1042/bj1980433; ALLAN D, 1975, NATURE, V258, P348, DOI 10.1038/258348a0; ALLAN D, 1980, BIOCHEM J, V188, P881, DOI 10.1042/bj1880881; ALLAN D, 1976, BIOCHEM J, V156, P225, DOI 10.1042/bj1560225; ARDLIE NG, 1970, BRIT J HAEMATOL, V19, P7, DOI 10.1111/j.1365-2141.1970.tb01596.x; ARVAND M, 1990, J BIOL CHEM, V265, P14377; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P4917, DOI 10.1073/pnas.90.11.4917; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BEVERS EM, 1992, BLOOD, V79, P380, DOI 10.1182/blood.V79.2.380.380; BHAKDI S, 1994, MED MICROBIOL IMMUN, V183, P119, DOI 10.1007/BF00196048; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRA R, 1987, BIOCHIM BIOPHYS ACTA, V902, P253, DOI 10.1016/0005-2736(87)90303-8; CHANG CP, 1993, J BIOL CHEM, V268, P7171; CHAP HJ, 1977, BIOCHIM BIOPHYS ACTA, V467, P146, DOI 10.1016/0005-2736(77)90192-4; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; CONNOR J, 1994, J BIOL CHEM, V269, P2399; DEVAUX PF, 1993, CURR OPIN STRUC BIOL, V3, P489, DOI 10.1016/0959-440X(93)90072-S; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FADOK VA, 1992, J IMMUNOL, V149, P4029; FRANKEN PA, 1992, EUR J BIOCHEM, V203, P89, DOI 10.1111/j.1432-1033.1992.tb19832.x; GASSAMADIAGNE A, 1992, J BIOL CHEM, V267, P13418; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; HAMILTON KK, 1990, J BIOL CHEM, V265, P3809; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HIDI R, 1993, J IMMUNOL, V151, P5613; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUCO G, 1978, BIOCHIMIE, V60, P653, DOI 10.1016/S0300-9084(78)80784-6; MINTA JO, 1983, METHOD ENZYMOL, V93, P375; MIYAKE A, 1994, EUR J PHARMACOL, V253, P155; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; MOUNIER C, 1993, EUR J BIOCHEM, V216, P169, DOI 10.1111/j.1432-1033.1993.tb18129.x; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NICULESCU F, 1993, J IMMUNOL, V150, P214; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; PFEILSCHIFTER J, 1994, J CLIN INVEST, V92, P2516; RADVANYI F, 1989, ANAL BIOCHEM, V177, P103, DOI 10.1016/0003-2697(89)90022-5; RANSAC S, 1992, EUR J BIOCHEM, V204, P793, DOI 10.1111/j.1432-1033.1992.tb16697.x; RAVAL PJ, 1984, BIOCHIM BIOPHYS ACTA, V772, P192, DOI 10.1016/0005-2736(84)90043-9; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; RUGANI N, 1992, J CHROMATOGR-BIOMED, V583, P246, DOI 10.1016/0378-4347(92)80560-D; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SCHWARTZ RS, 1985, J CLIN INVEST, V75, P1965, DOI 10.1172/JCI111913; SCOTT S, 1984, BIOCHEM J, V224, P285, DOI 10.1042/bj2240285; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHUKLA SD, 1978, BIOCHIM BIOPHYS ACTA, V512, P341, DOI 10.1016/0005-2736(78)90258-4; SIMON MF, 1982, BIOCHEM BIOPH RES CO, V108, P1743, DOI 10.1016/S0006-291X(82)80113-7; STEIN JM, 1991, BIOCHEM J, V274, P381, DOI 10.1042/bj2740381; SUGIURA T, 1994, ARCH BIOCHEM BIOPHYS, V311, P358, DOI 10.1006/abbi.1994.1249; THANNHAUSER TW, 1985, BIOCHEMISTRY-US, V24, P7681, DOI 10.1021/bi00347a027; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; ZWAAL RFA, 1975, BIOCHIM BIOPHYS ACTA, V406, P83, DOI 10.1016/0005-2736(75)90044-9; ZWAAL RFA, 1992, BIOCHIM BIOPHYS ACTA, V1180, P1, DOI 10.1016/0925-4439(92)90019-J	70	473	481	0	14	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					919	927		10.1016/0092-8674(95)90295-3	http://dx.doi.org/10.1016/0092-8674(95)90295-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697722	Bronze			2022-12-24	WOS:A1995QP61200011
J	GRAY, DR; MORGAN, T; CHRETIEN, SD; KASHYAP, ML				GRAY, DR; MORGAN, T; CHRETIEN, SD; KASHYAP, ML			EFFICACY AND SAFETY OF CONTROLLED-RELEASE NIACIN IN DYSLIPOPROTEINEMIC VETERANS	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERLIPIDPROTEINEMIA; NIACIN; DELAYED-ACTION PREPARATIONS; HEPATITIS, TOXIC; DIABETES MELLITUS	DENSITY-LIPOPROTEIN CHOLESTEROL; NICOTINIC-ACID; HEPATIC-FAILURE; DRUG; THERAPY; TRIGLYCERIDES; MECHANISM; INGESTION; BENEFIT; RATIO	Objective: To evaluate the safety and efficacy of controlled-release niacin in patients with hyperlipoproteinemia. Design: A retrospective cohort study. Setting: A Department of Veterans Affairs Medical Center. Patients: A consecutive sample of 969 predominantly elderly male veterans treated for dyslipoproteinemia with controlled-release niacin between October 1988 and October 1991. Main Outcome Measures: Primary outcomes were lipid levels and lipoprotein cholesterol response, alterations in levels of hepatic enzymes and blood chemistry test results, and characterization of niacin-induced hepatotoxicity abstracted from the patient's medical, laboratory, and pharmacy records. Results: 93% (896 of 969) of the cohort was evaluable. Patients (age, 61.7 years [9.4 years], mean [SD]) were treated for 1 to 36 months (13.0 months [9.7 months]) with an average maintenance dose of 1.67 g/d (0.8 g/d). Niacin was discontinued in 48.5% (435 of 896) of the patients primarily because of adverse effects. Poor glycemic control led to discontinuation in 40.6% (43 of 106) of the patients with diabetes mellitus. The lipoprotein response was dose-related and favorable (levels of total cholesterol, -19.10/b; low-density lipoprotein cholesterol, -24.0%; high-density lipoprotein cholesterol, +5.7%; and triglycerides, -32.5%). Statistically but not clinically meaningful dose-related increases were seen in levels of liver enzymes and serum glucose (aspartate aminotransferase, +29%; alanine aminotransferase, +23%; alkaline phosphatase, +25%; and glucose, +7%; P= 0.0001). Twenty of 896 (12.2%) and 42 of 896 (4.7%) patients met biochemical criteria for probable and for possible or probable niacin-induced hepatotoxicity, respectively. Predisposing factors included high dose, alcohol use, preexisting liver disease, and concurrent oral sulfonylurea therapy. Conclusions: Controlled-release niacin is effective in treating dyslipoproteinemia in selected middle-aged and elderly veterans, but approximately one half of patients discontinued the drug because of adverse effects or other causes including noncompliance. Niacin should be avoided in patients with hepatic dysfunction or a history of liver disease, patients with diabetes mellitus, and patients who abuse alcohol. Because controlled-release niacin seems to be more potent than crystalline niacin, product substitution without dose adjustment should be avoided.	UNIV CALIF IRVINE, IRVINE, CA 92717 USA	University of California System; University of California Irvine	GRAY, DR (corresponding author), VET AFFAIRS MED CTR 119, 5901 E 7TH ST, LONG BEACH, CA 90822 USA.			Kashyap, Moti/0000-0002-0052-8302				ALDERMAN JD, 1989, AM J CARDIOL, V64, P725, DOI 10.1016/0002-9149(89)90754-6; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ALTSCHUL R, 1955, ARCH BIOCHEM BIOPHYS, V54, P558, DOI 10.1016/0003-9861(55)90070-9; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CHRISTENSEN N, 1961, JAMA-J AM MED ASSOC, V177, P546, DOI 10.1001/jama.1961.03040340010003; ETCHASON JA, 1991, MAYO CLIN PROC, V66, P23, DOI 10.1016/S0025-6196(12)61171-9; FERENCHICK G, 1989, AM J MED SCI, V298, P191, DOI 10.1097/00000441-198909000-00009; FIGGE HL, 1988, PHARMACOTHERAPY, V8, P287; FIGGE HL, 1988, J CLIN PHARMACOL, V28, P1136, DOI 10.1002/j.1552-4604.1988.tb05731.x; FOSSATI P, 1982, CLIN CHEM, V28, P2077; GARG A, 1990, JAMA-J AM MED ASSOC, V264, P723, DOI 10.1001/jama.264.6.723; GRUNDY SM, 1981, J LIPID RES, V22, P24; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HENKIN Y, 1991, AM J MED, V91, P239, DOI 10.1016/0002-9343(91)90122-E; HENKIN Y, 1990, JAMA-J AM MED ASSOC, V264, P241, DOI 10.1001/jama.264.2.241; HODIS HN, 1990, JAMA-J AM MED ASSOC, V264, P181, DOI 10.1001/jama.1990.03450020033012; KAHN SE, 1989, DIABETES, V38, P562, DOI 10.2337/diabetes.38.5.562; KEENAN JM, 1991, ARCH INTERN MED, V151, P1424, DOI 10.1001/archinte.151.7.1424; KNOPP RH, 1985, METABOLISM, V34, P642, DOI 10.1016/0026-0495(85)90092-7; LASAGNA L, 1994, JAMA-J AM MED ASSOC, V271, P709, DOI 10.1001/jama.271.9.709; LAVIE CJ, 1992, AM J CARDIOL, V69, P1083, DOI 10.1016/0002-9149(92)90868-Y; LURIA MH, 1988, ARCH INTERN MED, V148, P2493, DOI 10.1001/archinte.148.11.2493; MCKENNEY JM, 1994, JAMA-J AM MED ASSOC, V271, P672, DOI 10.1001/jama.271.9.672; MULLIN GE, 1989, ANN INTERN MED, V111, P253, DOI 10.7326/0003-4819-111-3-253; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; NEUVONEN PJ, 1991, BRIT J CLIN PHARMACO, V32, P473, DOI 10.1111/j.1365-2125.1991.tb03933.x; PARSONS WB, 1961, ARCH INTERN MED, V107, P653, DOI 10.1001/archinte.1961.03620050019003; SQUIRES RW, 1992, MAYO CLIN PROC, V67, P855, DOI 10.1016/S0025-6196(12)60824-6; STERN RH, 1991, CLIN PHARMACOL THER, V50, P66, DOI 10.1038/clpt.1991.104	31	47	49	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					252	258		10.7326/0003-4819-121-4-199408150-00003	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	7741833				2022-12-24	WOS:A1994PB10200003
J	WU, J; DENT, P; JELINEK, T; WOLFMAN, A; WEBER, MJ; STURGILL, TW				WU, J; DENT, P; JELINEK, T; WOLFMAN, A; WEBER, MJ; STURGILL, TW			INHIBITION OF THE EGF-ACTIVATED MAP KINASE SIGNALING PATHWAY BY ADENOSINE-3',5'-MONOPHOSPHATE	SCIENCE			English	Article							PROTEIN-KINASE; CORONARY-ARTERIES; RECEPTOR; CELLS; RAF	Mitogen-activated protein (MAP) kinases P42mapk and p44mapk are activated in cells stimulated with epidermal growth factor (EGF) and other agents. A principal pathway for MAP kinase (MAPK) activation by EGF consists of sequential activations of the guanine nucleotide exchange factor Sos, the guanosine triphosphate binding protein Ras, and the protein kinases Raf-1, MAPK kinase (MKK), and MAPK. Because adenosine 3',5'-monophosphate (cAMP) does not activate MAPK and has some opposing physiologic effects, the effect of increasing intracellular concentrations of cAMP with forskolin and 3-isobutyl-1-methylxanthine on the EGF-stimulated MAPK pathway was studied. Increased concentrations of cAMP blocked activation of Raf-1, MKK, and MAPK in Rat1hER fibroblasts, accompanied by a threefold increase in Raf-1 phosphorylation on serine 43 in the regulatory domain. Phosphorylation of Raf-1 in vitro and in vivo reduces the apparent affinity with which it binds to Ras and may contribute to the blockade by cAMP.	UNIV VIRGINIA, HLTH SCI CTR, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; CLEVELAND CLIN EDUC FDN, DEPT CELL BIOL, CLEVELAND, OH 44106 USA	University of Virginia; University of Virginia; University of Virginia; Cleveland Clinic Foundation			Wu, Jie/R-2404-2019	Wu, Jie/0000-0002-2864-1606	NATIONAL CANCER INSTITUTE [R37CA039076, R01CA039076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER; NCI NIH HHS [CA39076] Funding Source: Medline; NIDDK NIH HHS [DK41077] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHOW YL, UNPUB; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CONRAD KE, 1992, ONCOGENE, V7, P1279; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JIANG H, 1992, J BIOL CHEM, V267, P1015; JOHNSON GS, 1972, NATURE, V263, P247; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; ODA A, 1988, Hokkaido Journal of Medical Science, V63, P747; PARSONS WJ, 1988, MOL PHARMACOL, V34, P37; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1505; RHEE SG, 1993, ADV SEC MESS PHOSPH, V28, P57; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEBER MJ, 1974, P C MECHANISMS VIRUS, P327; WELLS JN, 1975, MOL PHARMACOL, V11, P775; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; Wu J.-Y., UNPUB; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	46	905	924	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1993	262	5136					1065	1069		10.1126/science.7694366	http://dx.doi.org/10.1126/science.7694366			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7694366				2022-12-24	WOS:A1993MG18700039
J	GAUCHAT, JF; HENCHOZ, S; MAZZEI, G; AUBRY, JP; BRUNNER, T; BLASEY, H; LIFE, P; TALABOT, D; FLORESROMO, L; THOMPSON, J; KISHI, K; BUTTERFIELD, J; DAHINDEN, C; BONNEFOY, JY				GAUCHAT, JF; HENCHOZ, S; MAZZEI, G; AUBRY, JP; BRUNNER, T; BLASEY, H; LIFE, P; TALABOT, D; FLORESROMO, L; THOMPSON, J; KISHI, K; BUTTERFIELD, J; DAHINDEN, C; BONNEFOY, JY			INDUCTION OF HUMAN IGE SYNTHESIS IN B-CELLS BY MAST-CELLS AND BASOPHILS	NATURE			English	Article							MESSENGER-RNA; INTERLEUKIN-4; LIGAND; CD40; IDENTIFICATION; CYCLOSPORINE; LEUKEMIA; LINE	IMMUNOGLOBULIN E (IgE) is central to the induction of allergic diseases through its binding to the high-affinity receptor (FcepsilonR1) on mast cells and basophils. Crosslinking by allergens of the bound IgE leads to the release of various inflammatory mediators. IgE production by B cells requires a physical interaction with T cells1, involving a number of surface adhesion molecules1,2, as well as the soluble factors interleukin-4 (IL-4)3,4 and IL-13 (ref. 5) produced by T cells6,7, basophils8 and mast cells9. Here we report that, in the presence of IL-4, mast and basophilic cell lines can provide the cell contact signals that are required for IgE synthesis. The human cell lines HMC-1 (mast) and KU812 (basophilic) both express the ligand for CD40 (CD40L) which is shown to be responsible for the IgE production. Moreover, freshly isolated purified human lung mast cells and blood basophils are also shown to express CD40L and to induce IgE production. This evidence suggests that mast cells and basophils may therefore play a key role in allergy not only by producing inflammatory mediators, but also by directly regulating IgE production independently of T cells.	GLAXO INST MOLEC BIOL,14 CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND; INSELSPITAL BERN,CH-3010 BERN,SWITZERLAND; GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND; NIIGATA UNIV,NIIGATA 951,JAPAN; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905	GlaxoSmithKline; GlaxoSmithKline; Niigata University; Mayo Clinic								ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; FANSLOW WC, 1992, J IMMUNOL, V149, P655; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GASCAN H, 1991, J IMMUNOL, V147, P8; GAUCHAT JF, 1989, EUR J IMMUNOL, V19, P1079, DOI 10.1002/eji.1830190618; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; PENE J, 1988, P NATL ACAD SCI USA, V85, P8166; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295	29	569	580	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					340	343		10.1038/365340a0	http://dx.doi.org/10.1038/365340a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	7690905				2022-12-24	WOS:A1993LY49600052
J	GACY, AM; GOELLNER, G; JURANIC, N; MACURA, S; MCMURRAY, CT				GACY, AM; GOELLNER, G; JURANIC, N; MACURA, S; MCMURRAY, CT			TRINUCLEOTIDE REPEATS THAT EXPAND IN HUMAN-DISEASE FORM HAIRPIN STRUCTURES IN-VITRO	CELL			English	Article							HUNTINGTONS-DISEASE; MISMATCH REPAIR; BASE PAIR; DNA; MUTATIONS; SEQUENCE; CANCER; DUPLEX; LENGTH; GENES	We show that repeating units from all reported disease genes are capable of forming hairpins of common structure and threshold stability, The threshold stability is roughly -50 kcal per hairpin and is influenced by the flanking sequence of the gene, Hairpin stability has two components, sequence and length; only DNA of select sequences and the correct length can form hairpins of threshold energy. There is a correlation among the ability to form hairpins of threshold stability, the sequence selectivity of expansion, and the length dependence of expansion. Additionally, hairpin formation provides a potential structural basis for the constancy of the CCG region of the Huntington's disease gene in individuals and explains the stabilizing effects of AGG interruptions in FMR1 alleles.	MAYO CLIN & MAYO GRAD SCH MED,DEPT PHARMACOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO GRAD SCH MED,MOLEC NEUROSCI PROGRAM,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	GACY, AM (corresponding author), MAYO CLIN & MAYO GRAD SCH MED,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905, USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANDREW SE, 1994, HUM MOL GENET, V3, P65, DOI 10.1093/hmg/3.1.65; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BAXTER SM, 1993, BIOCHEMISTRY-US, V32, P8702, DOI 10.1021/bi00084a042; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GACY AM, 1994, BIOCHEMISTRY-US, V33, P11951, DOI 10.1021/bi00205a034; GAO XL, 1987, J BIOL CHEM, V262, P16973; GOLDBERG YP, 1993, NAT GENET, V5, P174, DOI 10.1038/ng1093-174; HAN J, 1994, NUCLEIC ACIDS RES, V22, P1735, DOI 10.1093/nar/22.9.1735; HARAYAMA S, 1991, J BACTERIOL, V173, P7540, DOI 10.1128/jb.173.23.7540-7548.1991; HIRST MC, 1994, HUM MOL GENET, V9, P1553; HOELZEL AR, 1994, J MOL EVOL, V39, P191; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P100, DOI 10.1021/bi00401a017; KOHWI Y, 1993, NUCLEIC ACIDS RES, V21, P5651; KREMER B, 1994, NEW ENGL J MED, V330, P1401, DOI 10.1056/NEJM199405193302001; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; MANDEL JL, 1994, NAT GENET, V7, P453, DOI 10.1038/ng0894-453; MCMURRAY CT, 1994, BIOCHEMISTRY-US, V33, P11960, DOI 10.1021/bi00205a035; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; OHOY KL, 1993, SCIENCE, V259, P809, DOI 10.1126/science.8094260; PATEL DJ, 1984, BIOCHEMISTRY-US, V23, P3218, DOI 10.1021/bi00309a016; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P9373; REISS AL, 1994, HUM MOL GENET, V3, P393, DOI 10.1093/hmg/3.3.393; RENTEPERIS D, 1993, NUCLEIC ACIDS RES, V9, P133; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; RUBINSZTEIN DC, 1993, HUM MOL GENET, V2, P1713, DOI 10.1093/hmg/2.10.1713; SHELBOURNE P, 1992, HUM MOL GENET, V1, P467, DOI 10.1093/hmg/1.7.467; SNOW K, 1993, AM J HUM GENET, V53, P1217; SNOW K, 1994, HUM MOL GENET, V3, P1543, DOI 10.1093/hmg/3.9.1543; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	41	496	507	0	25	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					533	540						8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758107				2022-12-24	WOS:A1995QZ71000010
J	KEPPLER, E; FRANZ, M; KORTH, A; REUSS, MK; BLAKE, JB; SEIDEL, R; QUENBY, JJ; WITTE, M				KEPPLER, E; FRANZ, M; KORTH, A; REUSS, MK; BLAKE, JB; SEIDEL, R; QUENBY, JJ; WITTE, M			OBSERVATIONS OF ENERGETIC PARTICLES WITH EPAC ON ULYSSES IN POLAR LATITUDES OF THE HELIOSPHERE	SCIENCE			English	Article							SOLAR-WIND; EVOLUTION; STREAM	Measurements with the Energetic Particle Composition instrument (EPAC) aboard Ulysses show particles from near the ecliptic that were apparently accelerated by shocks associated with a corotating interaction region. The particles were detected together with the shocks and even when shocks no longer arrived at Ulysses up to -65 degrees of heliographic latitude but not beyond. Particles could have reached these latitudes along magnetic fields; such connections to the outer lower latitude heliosphere evidently do not exist above that latitude. The accelerated streams have composition similar to solar wind abundances, no dispersion, and a net inward anisotropy. The underlying composition between the recurrent stream is similar to the anomalous component of cosmic rays. The channel sensitive to high-energy protons (>230 megaelectron volts) shows a 26-day variation of the flux superimposed on the heliospheric modulation of galactic ions.	AEROSP CORP, SPACE SCI LAB, LOS ANGELES, CA 90009 USA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, BLACKETT LAB, LONDON, ENGLAND	Aerospace Corporation - USA; Imperial College London	KEPPLER, E (corresponding author), MAX PLANCK INST AERON, D-37191 KATLENBURG DUHM, GERMANY.							ADAMS J, 1993, 23RD P ICRC CALG, VSH, P358; BALOGH A, 1995, SPACE SCI REV, V72, P171, DOI 10.1007/BF00768774; BALOGH A, 1993, GEOPHYS RES LETT, V20, P2331, DOI 10.1029/93GL02621; BALOGH A, 1995, NUCL PHYS B, P69, DOI 10.1016/0920-5632(95)00008-W; BAME SJ, 1993, GEOPHYS RES LETT, V20, P2323, DOI 10.1029/93GL02630; BARNES CW, 1976, ASTROPHYS J, V210, pL91, DOI 10.1086/182311; CUMMINGS AC, 1995, GEOPHYS RES LETT, V22, P341, DOI 10.1029/94GL03343; CUMMINGS AC, 1993, 23RD P ICRC CALG, VSH, P202; FELDMAN WC, 1991, J GEOPHYS RES, V86, P5408; FRANZ M, 1995, SPACE SCI REV, V72, P339, DOI 10.1007/BF00768802; GLOECKLER G, 1995, SPACE SCI REV, V72, P321, DOI 10.1007/BF00768798; GOSLING JT, 1981, J GEOPHYS RES-SPACE, V86, P5438, DOI 10.1029/JA086iA07p05438; GOSLING JT, 1993, GEOPHYS RES LETT, V20, P2789, DOI 10.1029/93GL03116; GOSLING JT, 1995, SPACE SCI REV, V72, P99, DOI 10.1007/BF00768761; KEPPLER E, 1995, SPACE SCI REV, V72, P285, DOI 10.1007/BF00768792; KEPPLER E, 1992, ASTRON ASTROPHYS SUP, V92, P317; KEPPLER E, 1995, NUCL PHYS B, P87, DOI 10.1016/0920-5632(95)00010-7; KUNOW H, 1995, SPACE SCI REV, V72, P397, DOI 10.1007/BF00768811; MCKIBBEN RB, 1995, SPACE SCI REV, V72, P403, DOI 10.1007/BF00768812; PIZZO VJ, 1989, J GEOPHYS RES, V94, P8673, DOI 10.1029/JA094iA07p08673; REUSS MK, 1995, SPACE SCI REV, V72, P343, DOI 10.1007/BF00768803; RICHARDSON IG, 1993, J GEOPHYS RES-SPACE, V98, P13, DOI 10.1029/92JA01837; ROELOF EC, 1995, SPACE SCI REV, V72, P309, DOI 10.1007/BF00768796; SIMNETT GM, 1994, GEOPHYS RES LETT, V21, P1561, DOI 10.1029/94GL01061; SIMNETT GM, 1995, SPACE SCI REV, V72, P303, DOI 10.1007/BF00768795	25	28	28	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 19	1995	268	5213					1013	1016		10.1126/science.7754379	http://dx.doi.org/10.1126/science.7754379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754379				2022-12-24	WOS:A1995QY93400030
J	MARRERO, MB; SCHIEFFER, B; PAXTON, WG; HEERDT, L; BERK, BC; DELAFONTAINE, P; BERNSTEIN, KE				MARRERO, MB; SCHIEFFER, B; PAXTON, WG; HEERDT, L; BERK, BC; DELAFONTAINE, P; BERNSTEIN, KE			DIRECT STIMULATION OF JAK/STAT PATHWAY BY THE ANGIOTENSIN-II AT(1) RECEPTOR	NATURE			English	Article							PROTEIN-TYROSINE KINASE; SMOOTH-MUSCLE CELLS; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; JAK2	THE peptide angiotensin II is the effector molecule of the renin-angiotensin system. All the haemodynamic effects of angiotensin II, including vasoconstriction! and adrenal aldosterone release, are mediated through a single class of cell-surface receptors known as AT(1) (refs 1, 2). These receptors contain the structural features of the G-protein-coupled receptor superfamily(3). We show here that angiotensin II induces the rapid phosphorylation of tyrosine in the intracellular kinases Jak2 and Tyk2 in rat aortic smooth-muscle cells and that this phosphorylation is associated with increase activity of Jak2. The Jak family substrates STAT1 and STAT2 (for signal transducers and activators of transcription) are rapidly tyrosine-phosphorylated in response to angiotensin II. We also find that Jak2 co-precipitates with the AT(1) receptor, indicating that G-protein-coupled receptors may be able to signal through the intracellular phosphorylation pathways used by cytokine receptors(4,5).	EMORY UNIV,DEPT PATHOL & LAB MED,ATLANTA,GA 30322; EMORY UNIV,DEPT MED,DIV CARDIOL,ATLANTA,GA 30322; SANTA CRUZ BIOTECHNOL INC,SANTA CRUZ,CA 95060; UNIV WASHINGTON,DEPT MED,DIV CARDIOL,SEATTLE,WA 98195	Emory University; Emory University; University of Washington; University of Washington Seattle				Bernstein, Kenneth/0000-0001-8097-3272; Berk, Bradford/0000-0002-2767-4115; Delafontaine, Patrice/0000-0003-3744-3617				BHAT GJ, 1994, J BIOL CHEM, V269, P31443; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOHLMAN HG, 1992, ANNU REV BIOCHEM, V60, P651; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MIURA O, 1994, BLOOD, V84, P1501; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; PEACH MJ, 1981, BIOCHEM PHARMACOL, V30, P2745, DOI 10.1016/0006-2952(81)90410-X; RUI H, 1994, J BIOL CHEM, V269, P5364; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TIMMERMANS PBMWM, 1991, TRENDS PHARMACOL SCI, V12, P55, DOI 10.1016/0165-6147(91)90498-H; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0	28	645	664	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					247	250		10.1038/375247a0	http://dx.doi.org/10.1038/375247a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746328				2022-12-24	WOS:A1995QY88100067
J	HERBERT, J				HERBERT, J			THE AGE OF DEHYDROEPIANDROSTERONE	LANCET			English	Editorial Material							SULFATE; MEN		UNIV CAMBRIDGE,MRC,CAMBRIDGE CTR BRAIN REPAIR,CAMBRIDGE,ENGLAND	University of Cambridge	HERBERT, J (corresponding author), UNIV CAMBRIDGE,DEPT ANAT,CAMBRIDGE,ENGLAND.							ABADIE JM, 1993, DIABETES, V42, P662, DOI 10.2337/diabetes.42.5.662; BARRETTCONNOR E, 1994, J AM GERIATR SOC, V42, P420, DOI 10.1111/j.1532-5415.1994.tb07491.x; BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; BLAUER KL, 1991, ENDOCRINOLOGY, V129, P3174, DOI 10.1210/endo-129-6-3174; BROOKSGUNN J, 1989, CHILD DEV, V60, P40, DOI 10.1111/j.1467-8624.1989.tb02693.x; CASSON PR, 1993, AM J OBSTET GYNECOL, V169, P1536, DOI 10.1016/0002-9378(93)90431-H; DAYNES RA, 1990, EUR J IMMUNOL, V20, P793, DOI 10.1002/eji.1830200413; EBELING P, 1994, LANCET, V343, P1479, DOI 10.1016/s0140-6736(94)92587-9; EICH DM, 1993, CIRCULATION, V87, P261, DOI 10.1161/01.CIR.87.1.261; GOODYER IM, IN RESS PSYCHOL MED; GRAY A, 1991, PSYCHOSOM MED, V53, P375, DOI 10.1097/00006842-199107000-00003; HEDMAN M, 1992, CLIN EXP RHEUMATOL, V10, P25; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; MORALES AJ, 1994, J CLIN ENDOCR METAB, V78, P1360, DOI 10.1210/jc.78.6.1360; MURROS K, 1993, J NEUROL SCI, V116, P12, DOI 10.1016/0022-510X(93)90083-B; ORENTREICH N, 1992, J CLIN ENDOCR METAB, V75, P1002, DOI 10.1210/jc.75.4.1002; Sapolsky RM, 1992, STRESS AGING BRAIN M; SCHLEGEL ML, 1985, PHYSIOL BEHAV, V34, P867, DOI 10.1016/0031-9384(85)90005-8; SCHNEIDER LS, 1992, BIOL PSYCHIAT, V34, P867; WILLIAMS DP, 1993, J CLIN ENDOCR METAB, V77, P80, DOI 10.1210/jc.77.1.80	20	76	77	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1193	1194		10.1016/S0140-6736(95)91987-2	http://dx.doi.org/10.1016/S0140-6736(95)91987-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739304				2022-12-24	WOS:A1995QX86100005
J	FITTEN, LJ; PERRYMAN, KM; WILKINSON, CJ; LITTLE, RJ; BURNS, MM; PACHANA, N; MERVIS, JR; MALMGREN, R; SIEMBIEDA, DW; GANZELL, S				FITTEN, LJ; PERRYMAN, KM; WILKINSON, CJ; LITTLE, RJ; BURNS, MM; PACHANA, N; MERVIS, JR; MALMGREN, R; SIEMBIEDA, DW; GANZELL, S			ALZHEIMER AND VASCULAR DEMENTIAS AND DRIVING - A PROSPECTIVE ROAD AND LABORATORY STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GERIATRIC SUBJECTS; DISEASE; PERFORMANCE; ATTENTION; PERCEPTION; SKILLS	Objective.-To characterize on-the-road, behind-the-wheel driving abilities and related laboratory performances of subjects with mild Alzheimer's disease (AD) and vascular dementia. Design.-Prospective, experimental study involving two mild dementia and three age and health control groups. Road test reliability and validity were assessed. Setting.-Greater western Los Angeles. Subjects were enrolled from the community by referral and from the Veterans Affairs dementia and diabetes clinics. Participants.-Eighty-seven driving subjects were enrolled; 83 completed the study. A sample of eligible dementia clinic subjects consisting of 15 mild AD patients met National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association probable AD criteria, while 12 met Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition and Hachinski diagnostic criteria for multi-infarct dementia (vascular dementia). Clinic control subjects consisted of 15 age-matched patients with diabetes and without a history of stroke or dementia. Community controls consisted of 26 healthy, age-matched, older subjects (>60 years) and 16 young subjects (20 to 35 years). Main Outcome Measures.-Drive score from the Sepulveda (Calif) road test and laboratory measures of attention, perception, and memory. Results.-The drive scores in the mild AD group (mean, 22.1; SD, 3.8) and in the vascular dementia group (mean, 24.0; SD, 7.8) differed significantly (P<.001 studentized range test) from the drive scores in the diabetic control group (mean, 31.5; SD, 3.9), the older control group (mean, 32.6; SD, 2.8), and the young control group (mean, 33.6; SD, 3.2). Drive score among the three control groups did not vary significantly. Short-term memory (Sternberg), visual tracking, and Folstein Mini-Mental State Examination scores correlated best with drive score, with a cumulative R(2) of 0.68. Drive score and number of collisions and moving violations per 1000 miles driven were negatively correlated (r=-0.38; P<.02). Conclusions.-Based on this study, type and degree of cognitive impairment are better predictors of driving skills than age or medical diagnosis per se. Specific testing protocols for drivers with potential cognitive impairment may detect unsafe drivers more effectively than using age or medical diagnosis alone as criteria for license restriction or revocation.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BEHAV SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOMATH,LOS ANGELES,CA 90024; DEPT VET AFFAIRS MED CTR,GERIATR PSYCHIAT SECT,SEPULVEDA,CA 91343; SO CALIF RES INST,CULVER CITY,CA; UNIV MICHIGAN,DEPT BIOMATH,ANN ARBOR,MI; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT EPIDEMIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Michigan System; University of Michigan; University of California System; University of California Los Angeles			Little, Roderick/H-2440-2011; Pachana, Nancy A./C-6807-2016; Pachana, Nancy A./AAB-9235-2022; Pachana, Nancy A./HCI-4798-2022	Pachana, Nancy A./0000-0002-8927-4205; 				[Anonymous], ALZHEIMERS DIS; BRURSSON B, 1989, SCAND J SOC MED, V17, P253; BURNS M, 1990, J OCCUP ENVIRON MED, V32, P320, DOI 10.1097/00043764-199004000-00012; BURNS M, 1986, J CLIN PSYCHIAT, V47, P252; CARR D, 1990, J AM GERIATR SOC, V38, P1145, DOI 10.1111/j.1532-5415.1990.tb01379.x; CROSS PS, 1986, EPIDEMIOLOGY DEMENTI; DIXON WJ, 1988, BMDP STATISTICAL SOF, V2; DUBINSKY RM, 1992, J AM GERIATR SOC, V40, P1112, DOI 10.1111/j.1532-5415.1992.tb01799.x; EVANS L, 1988, J GERONTOLOGY S, V43, pS189; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; GILLEY DW, 1991, ARCH INTERN MED, V151, P941, DOI 10.1001/archinte.151.5.941; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.ne.11.030188.001033; GRACA JL, 1988, CLIN GERIATR MED, V2, P577; HILLS BL, 1980, PERCEPTION, V9, P183, DOI 10.1068/p090183; HUNT LA, 1990, ANN NEUROL, V28, P228; HYMAN BT, 1986, ANN NEUROL, V20, P472, DOI 10.1002/ana.410200406; LOGSDON RG, 1992, J GEN INTERN MED, V7, P583, DOI 10.1007/BF02599195; LUCASBLAUSTEIN MJ, 1988, J AM GERIATR SOC, V36, P1087, DOI 10.1111/j.1532-5415.1988.tb04394.x; Mackworth J, 1970, VIGILANCE ATTENTION; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MIRSKY AF, 1987, ENVIRON HEALTH PERSP, V74, P191, DOI 10.2307/3430449; MORRISON JH, 1987, BRAIN RES, V416, P331, DOI 10.1016/0006-8993(87)90914-0; MORRISON JH, 1990, IMAGING CEREBRAL TOP, P19; MOSKOWITZ H, 1986, NEUROPSYCHOBIOLOGY, V15, P38, DOI 10.1159/000118285; OLSON PL, 1986, HUM FACTORS, V28, P91, DOI 10.1177/001872088602800110; PARASURAMAN R, 1991, HUM FACTORS, V33, P539, DOI 10.1177/001872089103300506; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.neuro.13.1.25; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Rubin DB, 2004, MULTIPLE IMPUTATION; SCHAFER JL, 1991, THESIS HARVARD U BOS; STERNBERG S, 1975, Q J EXP PSYCHOL, V27, P1, DOI 10.1080/14640747508400459; SUNDERLAND T, 1989, J AM GERIATR SOC, V37, P725, DOI 10.1111/j.1532-5415.1989.tb02233.x; WOLFKLEIN GP, 1989, J AM GERIATR SOC, V37, P730, DOI 10.1111/j.1532-5415.1989.tb02234.x; 1987, DIAGNOSTIC STATISTIC; 1992, STATISTICAL ABSTRACT, P612	37	192	193	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1360	1365		10.1001/jama.273.17.1360	http://dx.doi.org/10.1001/jama.273.17.1360			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715061				2022-12-24	WOS:A1995QV30700021
J	OUSLANDER, JG; SCHNELLE, JF; UMAN, G; FINGOLD, S; NIGAM, JG; TUICO, E; BATESJENSEN, B				OUSLANDER, JG; SCHNELLE, JF; UMAN, G; FINGOLD, S; NIGAM, JG; TUICO, E; BATESJENSEN, B			PREDICTORS OF SUCCESSFUL PROMPTED VOIDING AMONG INCONTINENT NURSING-HOME RESIDENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-INCONTINENCE; MUSCLE EXERCISE; CARE; MANAGEMENT; FACILITIES; PATIENT; WOMEN	Objective.-To develop a simple, noninvasive assessment strategy that will enable nursing home staff to identify incontinent residents who respond well to prompted voiding. Design.-Incontinent nursing home residents underwent an extensive clinical and functional assessment and then 7 days of prompted voiding. Data from the assessment and the first 3 days of prompted voiding were used to predict responsiveness to the intervention. Setting.-Seven nursing homes. Patients.-A cohort of 191 incontinent, long-stay nursing home residents who passed a simple behavioral screen (able to state their name or reliably point to one of two named objects). Intervention.-Prompted voiding was carried out by trained research nurse's aides from 7 AM to 7 PM for 7 days, The intervention was maintained in responsive residents 5 days per week for an additional 9 weeks. Main Outcome Measures.-Physical checks for wetness were done by research staff hourly from 7 AM to 7 PM for 3 days in a baseline condition, during days 5 through 7 of the 7-day prompted voiding intervention, and for 3 days at the end of 9 weeks of prompted voiding in the responsive group. Outcome measures were percentage of checks wet and response to prompted voiding, with ''responders'' defined as residents with an average of one or fewer wet episode per day on days 5 through 7 of prompted voiding. Results.-Seventy-eight (41%) of the residents were responders. Their wet percentage went from 26.7% to 6.4% at the end of 1 week and was maintained at 9.6% after 9 weeks of prompted voiding. The best predictors of responsiveness were the wet percentage and the appropriate toileting percentage during the first 3 days of prompted voiding, the self-care subscale score of the Multidimensional Observational Scale for the Elderly, and the ability to ambulate without human assistance. The best sensitivity and specificity in identifying responders was achieved when either the wet percentage was lower than 20% or the appropriate toileting percentage was higher than 66% during the first 3 days of prompted voiding (sensitivity, 87%; specificity, 69%). Those residents falsely identified as responders by these criteria still had a 46% relative reduction in wetness. Conclusions.-A substantial proportion of nursing home residents respond well to prompted voiding, The most responsive residents can be easily identified using data collected during a 3-day trial of the intervention, The assessment strategy is consistent with federal guidelines and could be used to facilitate quality control by assessing changes in percentage of wetness from the expected norm.	UNIV CALIF LOS ANGELES,BORUN CTR GERONTOL RES,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,MULTICAMPUS PROGRAM GERIATR MED & GERONTOL,LOS ANGELES,CA 90024; JEWISH HOME AGING,RESEDA,CA 91335	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Bates-Jensen, Barbara/ABA-3726-2020		NATIONAL INSTITUTE ON AGING [R37AG008678] Funding Source: NIH RePORTER; NIA NIH HHS [R37AGO8678] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BURGIO LD, 1994, J AM GERIATR SOC, V42, P315, DOI 10.1111/j.1532-5415.1994.tb01758.x; BURNS PA, 1993, J GERONTOL, V48, pM167; BURTON JR, 1988, J AM GERIATR SOC, V36, P693, DOI 10.1111/j.1532-5415.1988.tb07170.x; COLLING J, 1988, NURS CLIN N AM, V23, P279; COLLING J, 1992, J AM GERIATR SOC, V39, P135; ELBADAWI A, 1993, J UROLOGY, V150, P1650, DOI 10.1016/S0022-5347(17)35866-4; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; HELMES E, 1987, J GERONTOL, V42, P395, DOI 10.1093/geronj/42.4.395; HU TW, 1989, JAMA-J AM MED ASSOC, V261, P2656, DOI 10.1001/jama.261.18.2656; Igou J, 1986, Clin Geriatr Med, V2, P873; OUSLANDER J, 1989, J AM GERIATR SOC, V37, P715, DOI 10.1111/j.1532-5415.1989.tb02232.x; OUSLANDER JG, 1987, J GERONTOL, V42, P631, DOI 10.1093/geronj/42.6.631; OUSLANDER JG, IN PRESS ANN INTERN; OUSLANDER JG, 1991, MED CARE NURSING HOM, P163; RESNICK NM, 1987, JAMA-J AM MED ASSOC, V257, P3076, DOI 10.1001/jama.257.22.3076; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; SCHNELLE JF, 1990, GERONTOLOGIST, V30, P373, DOI 10.1093/geront/30.3.373; SCHNELLE JF, 1993, J AM GERIATR SOC, V41, P1259, DOI 10.1111/j.1532-5415.1993.tb07312.x; SCHNELLE JF, 1991, J AM GERIATR SOC, V39, P165, DOI 10.1111/j.1532-5415.1991.tb01620.x; SCHNELLE JF, 1991, MANAGING URINARY INC; SCHNELLE JF, 1992, GERONTOLOGIST, V33, P114; WELLS TJ, 1990, J AM GERIATR SOC, V38, P333, DOI 10.1111/j.1532-5415.1990.tb03515.x; 1992, AHCPR920038 AG HLTH; 1991, RESIDENT ASSESSMENT; 1991, FED REG         0926, V56, P48865	25	91	91	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1366	1370						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715062				2022-12-24	WOS:A1995QV30700022
J	CHENG, KK; DUFFY, SW; DAY, NE; LAM, TH; CHUNG, SF; BADRINATH, P				CHENG, KK; DUFFY, SW; DAY, NE; LAM, TH; CHUNG, SF; BADRINATH, P			STOPPING DRINKING AND RISK OF ESOPHAGEAL CANCER	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; ESOPHAGEAL CANCER; ALCOHOL; CONSUMPTION	Objective-To examine the effect of stopping drinking on the risk of oesophageal cancer. Design-Hospital based case-control study. Setting-Surgical departments of four district general hospitals and general practices in Hong Kong. Subjects-Cases were 400 consecutive admissions of patients with histologically confirmed diagnosis of oesophageal cancer during a 21 month period in 1989-90 (87% response rate). Controls were 1598 patients selected from the same surgical departments as the cases and from the general practices from which the cases were originally referred (95% response rate). Main outcome measure-Relative risk of developing oesophageal cancer after stopping drinking (adjusted for age, education, place of birth, smoking, and diet). Results-Current light drinking (<200 g ethanol/week) was not associated with significant increase in risk. Among former drinkers risk fell more quickly in moderate (200-599 g/week) than heavy (greater than or equal to 600 g/week) drinkers. Even among heavy drinkers, however, risk had dropped substantially after five to nine years of not drinking. The results suggest that the time taken for risk to return to that in subjects who never drink was 10-14 years for moderate drinkers and 15 years or more, if ever, for heavy drinkers. Conclusion-Risk of oesophageal cancer decreases fairly rapidly with time after abstaining from drinking. This new finding could be used in health promotion to encourage behavioural changes, especially in heavy drinkers, who have a very high risk of developing oesophageal cancer. It also suggests that alcoholic beverages have a strong effect on the late stage of carcinogenesis.	MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND; UNIV HONG KONG,DEPT COMMUNITY MED,HONG KONG,HONG KONG; UNIV CAMBRIDGE,DEPT COMMUNITY MED,CAMBRIDGE,ENGLAND	MRC Biostatistics Unit; University of Hong Kong; University of Cambridge	CHENG, KK (corresponding author), UNIV BIRMINGHAM,DEPT EPIDEMIOL & PUBL HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Cheng, Kar/AAL-8899-2021; Lam, Tai Hing/C-4317-2009	Cheng, Kar/0000-0002-1516-1857; Chung, Siu Fung/0000-0001-6640-5893; Lam, Tai Hing/0000-0002-2033-9971				Alcohol Drinking, 1988, IARC MONOGRAPHS EVAL; ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; Breslow N, 1980, STATISTICAL METHODS, V32; BYERS T, 1982, LANCET, V1, P799; CHENG KK, 1992, LANCET, V339, P1314, DOI 10.1016/0140-6736(92)91960-G; CUZICK J, 1989, INT J CANCER, V43, P415, DOI 10.1002/ijc.2910430312; DAY NE, 1980, JNCI-J NATL CANCER I, V64, P977; HIATT RA, 1988, CANCER RES, V48, P2284; MARTINEZ I, 1969, J NATL CANCER I, V42, P1069; ROSENBERG L, 1982, LANCET, V1, P267; SHOPLAND DR, 1990, IARC SCI PUBL, V103, P77; VICTORA CG, 1987, INT J CANCER, V39, P710, DOI 10.1002/ijc.2910390610; [No title captured]; [No title captured]	14	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1094	1097		10.1136/bmj.310.6987.1094	http://dx.doi.org/10.1136/bmj.310.6987.1094			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742674	Green Published			2022-12-24	WOS:A1995QW61800013
J	VANMEERVELT, L; VLIEGHE, D; DAUTANT, A; GALLOIS, B; PRECIGOUX, G; KENNARD, O				VANMEERVELT, L; VLIEGHE, D; DAUTANT, A; GALLOIS, B; PRECIGOUX, G; KENNARD, O			HIGH-RESOLUTION STRUCTURE OF A DNA HELIX-FORMING (C-CENTER-DOT-G)ASTERISK-G BASE TRIPLETS	NATURE			English	Article								TRIPLE helices result from interaction between single- and double-stranded nucleic acids. Their formation is a possible mechanism for recombination of homologous gene sequences in nature and provides, inter alia, a basis for artificial control of gene activity, Triple-helix motifs have been extensively studied by a variety of techniques, but few high-resolution structural data are available, The only triplet structures characterized so far by X-ray diffraction were in protein-DNA complexes(1,2) studied at about 3 Angstrom resolution, We report here the X-ray analysis of a DNA nonamer, d(GCGAATTCG), to a resolution of 2.05 Angstrom, in which the extended crystal structure contains (C . G)*G triplets as a fragment of triple helix. The guanosine-containing chains are in a parallel orientation, This arrangement is a necessary feature of models for homologous recombination which results ultimately in replacement of one length of DNA by another of similar sequence, The present-structure agrees with many published predictions of tripler organization, and provides an accurate representation of an element that allows sequence-specific association between single- and double-stranded nucleic acids.	UNIV BORDEAUX 1, CRISTALLOG LAB, CNRS, ERS 133, F-33405 TALENCE, FRANCE; CAMBRIDGE CRYSTALLOG DATA CTR, CAMBRIDGE CB2 1EZ, ENGLAND	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of Cambridge	VANMEERVELT, L (corresponding author), KATHOLIEKE UNIV LEUVEN, DEPT CHEM, CELESTIJNENLAAN 200F, B-3001 HEVERLEE, BELGIUM.		Van Meervelt, Luc/AAD-2878-2022	Van Meervelt, Luc/0000-0003-2186-5209				ALLEN FH, 1991, J CHEM INF COMP SCI, V31, P187, DOI 10.1021/ci00002a004; [Anonymous], 1989, EMBO J, V8, P1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHENG YK, 1992, J AM CHEM SOC, V114, P4465, DOI 10.1021/ja00038a004; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OUALI M, 1993, J AM CHEM SOC, V115, P4264, DOI 10.1021/ja00063a049; PIRIOU JM, 1994, BIOPHYS CHEM, V50, P323, DOI 10.1016/0301-4622(93)E0103-C; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; WING R, 1980, NATURE, V287, P755, DOI 10.1038/287755a0; ZHURKIN VB, 1994, J MOL BIOL, V239, P181, DOI 10.1006/jmbi.1994.1362	12	63	64	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	1995	374	6524					742	744		10.1038/374742a0	http://dx.doi.org/10.1038/374742a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715732				2022-12-24	WOS:A1995QU30400056
J	GLYNN, JR; JENKINS, PA; FINE, PEM; PONNIGHAUS, JM; STERNE, JAC; MKANDWIRE, PK; NYASULU, S; BLISS, L; WARNDORFF, DK				GLYNN, JR; JENKINS, PA; FINE, PEM; PONNIGHAUS, JM; STERNE, JAC; MKANDWIRE, PK; NYASULU, S; BLISS, L; WARNDORFF, DK			PATTERNS OF INITIAL AND ACQUIRED ANTITUBERCULOSIS DRUG-RESISTANCE IN KARONGA DISTRICT, MALAWI	LANCET			English	Article							TUBERCULOSIS	There is concern that drug-resistant tuberculosis is increasing and may be concentrated among HIV-positive patients. Little information is available from developing countries, where surveillance studies are often unable to distinguish resistance in previously untreated patients (initial resistance) from resistance acquired following drug therapy, and where information on the HIV status of the patients is rare. Initial resistance patterns reflect the strains being transmitted in the community. We have studied patterns of resistance in northern Malawi, where the Lepra Evaluation Project has been collecting data on drug resistance since 1986. Initial drug sensitivity results were available for 373 new cases of tuberculosis. Initial resistance to at least one drug was found in 44 of these patients (11.8%, 95% CI 8.5-15.1): 13 were resistant to streptomycin alone, 13 to isoniazid alone, and 17 to more than one drug. Only 3 patients showed initial rifampicin resistance-1 in isolation, 1 in combination with streptomycin, and 1 with triple resistance. Drug resistance was not related to age, sex, or HIV status of the patient and there was no evidence of any increase over the period studied. There was no evidence of geographic clustering of the resistant strains, or of any increased risk of resistant strains in households with previous tuberculosis cases. Acquired resistance during follow-up was found in 5 of 329 patients with documented initially fully sensitive strains. 5 patients with initial resistance seemed to show reversion to sensitivity. The absence of an increase in drug resistance, despite an increase in tuberculosis cases over the period, is encouraging for the control programme. It emphasises the need to collect information from many areas before assuming that increases in antituberculosis drug resistance are occurring worldwide.	UNIV WALES HOSP,PHLS MYCOBACTERIUM REFERENCE UNIT,CARDIFF CF4 4XW,S GLAM,WALES; LEPRA,CHLLUMBA,MALAWI	Cardiff University	GLYNN, JR (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Sterne, Jonathan/Z-3106-2019	Sterne, Jonathan/0000-0001-8496-6053				BOHMER PD, 1992, S AFR MED J, V81, P382; Boulahbal F, 1989, Bull Int Union Tuberc Lung Dis, V64, P23; BRAUN MM, 1992, AIDS, V6, P1327, DOI 10.1097/00002030-199211000-00014; COWIE RL, 1990, TUBERCLE, V71, P39, DOI 10.1016/0041-3879(90)90059-H; DECALUWE P, 1989, ANN SOC BELG MED TR, V69, P143; Freiden T.E., 1993, NEW ENGL J MED, V328, P521; GITHUI W, 1992, TUBERCLE LUNG DIS, V73, P203, DOI 10.1016/0962-8479(92)90087-Z; Jenkins P. A., 1985, Isolation and identification of micro-organisms of medical and veterinary importance, P275; LEMMA E, 1984, ETHIOPIAN MED J, V22, P93; MITCHISON DA, 1984, BRIT MED BULL, V40, P84, DOI 10.1093/oxfordjournals.bmb.a071952; NKINDA S J, 1985, Tubercle, V66, P161; NUNN P, 1994, TUBERCLE LUNG DIS, V75, P163, DOI 10.1016/0962-8479(94)90001-9; Nyangulu D S, 1991, Bull Int Union Tuberc Lung Dis, V66, P173; SHENNAN D H, 1964, Tubercle, V45, P1, DOI 10.1016/S0041-3879(64)80080-5; SWAI OB, 1989, TUBERCLE, V70, P5; VARELDZIS BP, 1994, TUBERCLE LUNG DIS, V75, P1, DOI 10.1016/0962-8479(94)90096-5; WEYER K, 1992, TUBERCLE LUNG DIS, V73, P106, DOI 10.1016/0962-8479(92)90064-Q; WOLDE K, 1986, ETHIOPIAN MED J, V24, P15	18	44	45	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					907	910		10.1016/S0140-6736(95)90016-0	http://dx.doi.org/10.1016/S0140-6736(95)90016-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707817				2022-12-24	WOS:A1995QR06700016
J	STAMPF, DR; FELDER, CE; SUSSMAN, JL				STAMPF, DR; FELDER, CE; SUSSMAN, JL			PDBBROWSE - A GRAPHICS INTERFACE TO THE BROOKHAVEN PROTEIN DATA-BANK	NATURE			English	Article									WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	STAMPF, DR (corresponding author), BROOKHAVEN NATL LAB,DEPT CHEM,UPTON,NY 11973, USA.			Sussman, Joel/0000-0003-0306-3878				BARTON GJ, 1994, TRENDS BIOCHEM SCI, V19, P554, DOI 10.1016/0968-0004(94)90060-4; Ousterhout J. K., 1994, TCL TK TOOLKIT; PEITSCH MC, 1995, TRENDS BIOCHEM SCI, V20, P82, DOI 10.1016/S0968-0004(00)88963-X; SCHATZ BR, 1994, SCIENCE, V265, P895, DOI 10.1126/science.265.5174.895; SCHWARTZ RL, 1992, PROGRAMMING PERL; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899	6	27	28	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					572	574		10.1038/374572a0	http://dx.doi.org/10.1038/374572a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700388				2022-12-24	WOS:A1995QR06900061
J	CRAIG, AD; BUSHNELL, MC; ZHANG, ET; BLOMQVIST, A				CRAIG, AD; BUSHNELL, MC; ZHANG, ET; BLOMQVIST, A			A THALAMIC NUCLEUS SPECIFIC FOR PAIN AND TEMPERATURE SENSATION	NATURE			English	Article							NEURONS; AREA; CAT; STIMULI; MONKEY; TRACT	THE existence of a posterolateral thalamic relay nucleus for pain and temperature sensation was postulated in 1911, on the basis of the stroke-induced analgesia and thermanaesthesia found paradoxically in patients with thalamic pain syndrome(1). Pain or temperature sensations can be evoked in humans by electrical stimulation in a vaguely defined region of the posterolateral thalamus(2,3). Here we use anterograde tracing and single unit recordings to demonstrate that there is a distinct nucleus in the posterior thalamus of the macaque monkey that receives a dense, topographic input from spinothalamic lamina I neurons and in which almost all neurons are nociceptive- or thermoreceptive-specific. Immunohistochemical staining showed that this nucleus is defined by a dense calbindin-positive fibre plexus in the macaque, so we applied the same staining method to sections of human thalamus. We found a nearly identical fibre plexus localized within a distinct nucleus that is cytoarchitectonically homologous to the lamina I relay nucleus in the macaque thalamus. The stereotaxic coordinates of this nucleus and its location relative to the main somatosensory representation fit clinical descriptions of the pain-producing region in humans. We conclude that this is a specific thalamic nucleus for pain and temperature sensation in both monkey and human.	UNIV MONTREAL,FAC MED DENT,DEPT STOMATOL,MONTREAL H3C 3J7,PQ,CANADA; UNIV MONTREAL,FAC MED DENT,CTR RECH SCI NEUROL,MONTREAL H3C 3J7,PQ,CANADA; LINKOPING UNIV,FAC HLTH SCI,DEPT CELL BIOL,S-58185 LINKOPING,SWEDEN	Universite de Montreal; Universite de Montreal; Linkoping University	CRAIG, AD (corresponding author), BARROW NEUROL INST,DIV NEUROBIOL,350 W THOMAS RD,PHOENIX,AZ 85013, USA.		Blomqvist, Anders/K-3990-2019	Blomqvist, Anders/0000-0002-6928-4473				ANTAL M, 1990, J COMP NEUROL, V295, P467, DOI 10.1002/cne.902950310; BLOMQVIST A, 1993, J COMP NEUROL, V327, P584, DOI 10.1002/cne.903270409; BOGOUSSLAVSKY J, 1988, NEUROLOGY, V38, P837, DOI 10.1212/WNL.38.6.837; BUSHNELL MC, 1993, J NEUROPHYSIOL, V69, P739, DOI 10.1152/jn.1993.69.3.739; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; CHRISTENSEN BN, 1970, J NEUROPHYSIOL, V33, P293, DOI 10.1152/jn.1970.33.2.293; COGHILL RC, 1994, J NEUROSCI, V14, P4095; CRAIG AD, 1993, J COMP NEUROL, V331, P517, DOI 10.1002/cne.903310407; CRAIG AD, 1992, J COMP NEUROL, V322, P99, DOI 10.1002/cne.903220108; CRAIG AD, 1985, J PHYSIOL-LONDON, V365, P197, DOI 10.1113/jphysiol.1985.sp015767; CRAIG AD, 1994, SCIENCE, V265, P252, DOI 10.1126/science.8023144; CRAIG AD, 1991, J COMP NEUROL, V308, P56; CRAIG AD, PROGR PAIN RES MAN, V3; Dostrovsky JO, 1992, INT C SERIES, V989, P115; FRIEDMAN DP, 1986, J COMP NEUROL, V252, P348, DOI 10.1002/cne.902520305; Head H, 1911, BRAIN, V34, P102, DOI 10.1093/brain/34.2-3.102; HIRAI T, 1989, BRAIN RES REV, V14, P1, DOI 10.1016/0165-0173(89)90007-6; JEANMONOD D, 1994, NEUROREPORT, V4, P475; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; JONES EG, 1989, EUR J NEUROSCI, V1, P222, DOI 10.1111/j.1460-9568.1989.tb00791.x; LEIJON G, 1989, PAIN, V36, P13, DOI 10.1016/0304-3959(89)90107-3; LENZ FA, 1993, J NEUROPHYSIOL, V70, P200, DOI 10.1152/jn.1993.70.1.200; LENZ FA, 1993, BRAIN RES, V623, P235, DOI 10.1016/0006-8993(93)91433-S; PANNETON WM, 1991, J COMP NEUROL, V313, P377; Perl E. R., 1984, HDB PHYSL 2 1, VIII, P915; RALSTON HJ, 1992, PAIN, V48, P107, DOI 10.1016/0304-3959(92)90137-Z; RICHARDSON DE, 1967, CONFIN NEUROL, V29, P139; White JC., 1969, PAIN NEUROSURGEON, P6	28	417	427	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					770	773		10.1038/372770a0	http://dx.doi.org/10.1038/372770a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7695716				2022-12-24	WOS:A1994PY21200050
J	FREIER, JE				FREIER, JE			EASTERN EQUINE ENCEPHALOMYELITIS	LANCET			English	Article											FREIER, JE (corresponding author), USDA,CTR EPIDEMIOL & ANIM HLTH,ANIM & PLANT HLTH INSPECT SERV,VET SERV,555 S HOWES ST,FT COLLINS,CO 80525, USA.							CRANS WJ, 1977, MOSQ NEWS, V37, P85; MORRIS AC, 1989, MED VET ENTOMOL, V3, P1, DOI 10.1111/j.1365-2915.1989.tb00467.x; SCHWARZ D, 1985, SURVEILLANT SCI REMO, P53; TSAI TF, 1987, TXB PEDIATRIC INFECT, V2, P1417	4	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1281	1282		10.1016/0140-6736(93)92366-2	http://dx.doi.org/10.1016/0140-6736(93)92366-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7695660				2022-12-24	WOS:A1993MH56600016
J	ROBBINS, FC				ROBBINS, FC			ERADICATION OF POLIO IN THE AMERICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									PAN AMER HLTH ORG,INT COMMISS CERTIFICAT ERADICAT POLIO AMER,WASHINGTON,DC	Pan American Health Organization	ROBBINS, FC (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.							CHEN R, 1992, 32ND INT C ANT AG CH; RIORDAN JT, 1961, YALE J BIOL MED, V34, P512; SHALALA DE, 1993, JAMA-J AM MED ASSOC, V269, P144; 1992, MMWR MORB MORTAL WKL, V41, P917; 1993, MMWR MORB MORTAL WKL, V42, P337; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1993, JAMA-J AM MED ASSOC, V269, P1817	7	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1857	1859		10.1001/jama.270.15.1857	http://dx.doi.org/10.1001/jama.270.15.1857			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	7692114				2022-12-24	WOS:A1993MB46400031
J	KANAI, N; LU, R; SATRIANO, JA; BAO, Y; WOLKOFF, AW; SCHUSTER, VL				KANAI, N; LU, R; SATRIANO, JA; BAO, Y; WOLKOFF, AW; SCHUSTER, VL			IDENTIFICATION AND CHARACTERIZATION OF A PROSTAGLANDIN TRANSPORTER	SCIENCE			English	Article							ISOLATED PERFUSED LUNG; RENAL PROSTAGLANDIN; E RECEPTOR; PROSTACYCLIN PGI2; EXPRESSION SYSTEM; PREGNANT RABBITS; RNA-POLYMERASE; METABOLISM; CLONING; CDNA	Carrier-mediated prostaglandin transport has been postulated to occur in many tissues. On the basis of sequence homology, the protein of unknown function encoded by the rat matrin F/G complementary DNA was predicted to be an organic anion transporter. Expression of the matrin F/G complementary DNA in HeLa cells or Xenopus oocytes conferred the property of specific transport of prostaglandins. The tissue distribution of matrin F/G messenger RNA and the sensitivity of matrin F/G-induced prostaglandin transport to inhibitors were similar to those of endogenous prostaglandin transport. The protein encoded by the matrin F/G complementary DNA is thus preferably called PGT because it is likely to function as a prostaglandin transporter.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, DIV RENAL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PHYSIOL & BIOPHYS, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, MARION BESSIN LIVER RES CTR, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NIDDK NIH HHS [DK41296, DK23026, DK-38095, R01 DK049688] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK023026, P30DK041296, R01DK049688, R01DK038095] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; ANDERSON MW, 1976, PROSTAGLANDINS, V11, P645, DOI 10.1016/0090-6980(76)90067-8; BAROODY RA, 1981, PROSTAGLANDINS, V21, P133, DOI 10.1016/0090-6980(81)90203-3; BIKHAZI AB, 1983, J PHARM SCI, V72, P296, DOI 10.1002/jps.2600720322; BITO LZ, 1976, PROSTAGLANDINS, V12, P639, DOI 10.1016/0090-6980(76)90043-5; BITO LZ, 1976, ADV PROSTAG THROMB R, V1, P297; BITO LZ, 1978, AM J PHYSIOL, V234, pF80, DOI 10.1152/ajprenal.1978.234.1.F80; BITO LZ, 1976, J PHARMACOL EXP THER, V198, P481; BITO LZ, 1976, J PHYSIOL-LONDON, V256, P257, DOI 10.1113/jphysiol.1976.sp011324; BITO LZ, 1975, AM J PHYSIOL, V229, P1580, DOI 10.1152/ajplegacy.1975.229.6.1580; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BOHMAN SO, 1977, PROSTAG OTH LIPID M, V14, P729, DOI 10.1016/0090-6980(77)90201-5; BOIE Y, 1994, J BIOL CHEM, V269, P12173; CAO ZD, 1984, BIOL REPROD, V31, P505, DOI 10.1095/biolreprod31.3.505; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUTHBERT AW, 1984, BRIT J PHARMACOL, V82, P597, DOI 10.1111/j.1476-5381.1984.tb10798.x; DEVEREUX TR, 1987, PROSTAG LEUKOTR ESS, V27, P43, DOI 10.1016/0262-1746(87)90058-8; DIBENEDETTO FE, 1986, J NEUROCHEM, V46, P1725; DUSTING GJ, 1978, BRIT J PHARMACOL, V64, P315, DOI 10.1111/j.1476-5381.1978.tb17307.x; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; ELING TE, 1977, PROSTAGLANDINS, V14, P51, DOI 10.1016/0090-6980(77)90156-3; ELING TE, 1976, AGENTS ACTIONS, V6, P543, DOI 10.1007/BF01973277; FARMAN N, 1987, AM J PHYSIOL, V252, pF53, DOI 10.1152/ajprenal.1987.252.1.F53; FERREIRA SH, 1967, NATURE, V216, P868, DOI 10.1038/216868a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GARCIAPEREZ A, 1984, J CLIN INVEST, V74, P63, DOI 10.1172/JCI111419; GORDON JA, 1994, J AM SOC NEPHROL, V5, P680; HAKES DJ, 1991, P NATL ACAD SCI USA, V88, P6186, DOI 10.1073/pnas.88.14.6186; HAWKINS HJ, 1978, PROSTAGLANDINS, V16, P871, DOI 10.1016/0090-6980(78)90103-X; HAWKINS HJ, 1977, PROSTAGLANDINS, V14, P251, DOI 10.1016/0090-6980(77)90170-8; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA A, 1993, J BIOL CHEM, V268, P7759; IRISH JM, 1979, AM J PHYSIOL, V237, pF268, DOI 10.1152/ajprenal.1979.237.4.F268; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; JOHNSON M C R, 1970, Biochimica et Biophysica Acta, V218, P543, DOI 10.1016/0005-2760(70)90018-4; KANAI N, UNPUB; KATSUYAMA M, 1994, FEBS LETT, V344, P74, DOI 10.1016/0014-5793(94)00355-6; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVINE L, 1985, ADV PROST THROMBOX L, V13; LEVINE L, 1988, ARACHIDONATE METABOL; LEVINE L, 1986, DIGEST DIS SCI S2, V31; LEVINE L, 1986, AM J MED, P80; MCGIFF J C, 1969, Nature (London), V223, P742, DOI 10.1038/223742b0; MCGUIRE JC, 1978, ARCH BIOCHEM BIOPHYS, V189, P92, DOI 10.1016/0003-9861(78)90118-2; NAKAGAWA O, 1994, CIRCULATION, V90, P1643, DOI 10.1161/01.CIR.90.4.1643; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NARUMIYA S, 1993, J LIPID MEDIATOR, V6, P155; Neame K. D., 1972, ELEMENTARY KINETICS; OKITA RT, 1990, ARCH BIOCHEM BIOPHYS, V279, P242, DOI 10.1016/0003-9861(90)90488-K; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PIPER PJ, 1970, NATURE, V225, P600, DOI 10.1038/225600a0; PITT BR, 1983, J PHARMACOL EXP THER, V227, P531; QUIROGA J, 1993, PHARMACOL THERAPEUT, V58, P67, DOI 10.1016/0163-7258(93)90067-N; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; RENNICK BR, 1977, AM J PHYSIOL, V233, pF133, DOI 10.1152/ajprenal.1977.233.2.F133; ROBINSON C, 1982, BIOCHIM BIOPHYS ACTA, V712, P315, DOI 10.1016/0005-2760(82)90349-6; ROSEMAN TJ, 1973, J PHARM SCI-US, V62, P1680, DOI 10.1002/jps.2600621021; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; SCHLONDORFF D, 1986, AM J MED, V81, P1, DOI 10.1016/0002-9343(86)90903-4; SMITH WL, 1977, PROSTAGLANDINS, V13, P873, DOI 10.1016/0090-6980(77)90217-9; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; UEKAMA K, 1978, CHEM PHARM BULL, V26, pF58; ULMANN A, 1992, ACTA OBSTET GYN SCAN, V71, P278, DOI 10.3109/00016349209021052; ULMANN A, 1990, ADV PROST THROMBOX L, V21; ULMANN A, 1989, PROG CLIN BIOL RES, V312; ULMANN A, 1990, METHODS ENZYMOL, V187; WATABE A, 1993, J BIOL CHEM, V268, P20175; WONG PYK, 1978, BIOCHEM BIOPH RES CO, V83, P731, DOI 10.1016/0006-291X(78)91050-1; WONG PYK, 1981, FED PROC, V40, P2001	72	343	364	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	1995	268	5212					866	869		10.1126/science.7754369	http://dx.doi.org/10.1126/science.7754369			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754369				2022-12-24	WOS:A1995QX85000036
J	FLEG, JL; SHAPIRO, EP; OCONNOR, F; TAUBE, J; GOLDBERG, AP; LAKATTA, EG				FLEG, JL; SHAPIRO, EP; OCONNOR, F; TAUBE, J; GOLDBERG, AP; LAKATTA, EG			LEFT-VENTRICULAR DIASTOLIC FILLING PERFORMANCE IN OLDER MALE-ATHLETES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ECHOCARDIOGRAPHIC MEASUREMENTS; HEART-RATE; EXERCISE; AGE; HYPERTROPHY; CONTRACTION; POPULATION; INDEXES; PRELOAD; HUMANS	Objective.-To determine whether older men who have undergone intensive endurance training over many years demonstrate less age-associated impairment of early diastolic left ventricular (LV) filling performance than their sedentary peers. Design.-Cross-sectional prospective study. Setting.-Community-dwelling research volunteers. Participants.-Sixteen older competitive male endurance athletes aged 52 through 76 years and 17 young (40 years) and 23 older (52 through 76 years) sedentary control subjects from the Baltimore Longitudinal Study of Aging. Intervention.-All subjects underwent resting Doppler echocardiography and determination of maximal aerobic capacity (Vo(2)max) during graded treadmill exercise. Doppler echocardiographic studies were interpreted without knowledge of the subject's age or exercise habits. Main Outcome Measures.-Doppler-derived measures of LV diastolic filling performance: peak early (E) filling velocity, peak late (A) filling velocity, ratio of peak E to peak A velocities (E/A), and atrial filling fraction. Results.-Older athletes demonstrated higher Vo(2)max (47+/-6 mL/kg per minute [mean+/-SD]) than either the young controls (41 +/-7 mL/kg per minute) or older controls (30+/-7 mL/kg per minute) (P<.05) as evidence of their superior conditioning status. However, peak E diastolic LV filling velocity was higher in young controls (79+/-17 cm/s) than in older athletes (56+/-15 cm/s) or older controls 68+/-18 cm/s) (P<.001). This age difference persisted after normalizing peak E velocity for mitral stroke volume. Peak EIA ratio and atrial filling fraction were also similar in older athletes (1.2+/-0.5 and 0.41+/-0.1, respectively) and older controls (1.1+/-0.4 and 0.41+/-0.1, respectively), and differed significantly from corresponding values of 1.7+/-0.4 and 0.33+/-0.1 in young controls (P<.001 and P<.05, respectively), By multiple regression analysis, age but not treadmill Vo(2)max was a significant predictor of peak E velocity, peak A velocity, peak E/A ratio, and atrial filling fraction. Conclusion.-Older men with a long history of intensive endurance training demonstrate impaired early diastolic LV filling similar to that of their sedentary peers. Thus, impairment of early diastolic filling appears to be intrinsic to normative aging and not secondary to the reduction in aerobic capacity that accompanies the aging process.	JOHNS HOPKINS UNIV,BAYVIEW MED CTR,DIV CARDIOL,BALTIMORE,MD; UNIV MARYLAND,SCH MED,DIV GERONTOL,BALTIMORE,MD	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	FLEG, JL (corresponding author), NIA,GERONTOL RES CTR,CARDIOVASC SCI LAB,4940 EASTERN AVE,BALTIMORE,MD 21224, USA.		Lakatta, Edward G/AAL-1447-2020; Shapiro, Edward/AAG-1611-2020	Lakatta, Edward/0000-0002-4772-0035	NIA NIH HHS [AG-04402, R01-AG-07660] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007660, P01AG004402] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPLETON CP, 1991, J AM COLL CARDIOL, V17, P227, DOI 10.1016/0735-1097(91)90731-N; ARORA RR, 1987, J AM COLL CARDIOL, V9, P1255, DOI 10.1016/S0735-1097(87)80464-3; BONOW RO, 1988, J AM COLL CARDIOL, V11, P50, DOI 10.1016/0735-1097(88)90166-0; BOWMAN LK, 1988, J AM COLL CARDIOL, V12, P937, DOI 10.1016/0735-1097(88)90458-5; BRYG RJ, 1987, AM J CARDIOL, V59, P971, DOI 10.1016/0002-9149(87)91136-2; CHOONG CY, 1987, J AM COLL CARDIOL, V10, P800, DOI 10.1016/S0735-1097(87)80273-5; COLAN SD, 1985, J AM COLL CARDIOL, V6, P545, DOI 10.1016/S0735-1097(85)80111-X; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DOUGLAS PS, 1992, J APPL PHYSIOL, V72, P1969, DOI 10.1152/jappl.1992.72.5.1969; DOUGLAS PS, 1986, AM J CARDIOL, V58, P805, DOI 10.1016/0002-9149(86)90358-9; FAGARD R, 1987, J AM COLL CARDIOL, V9, P1250, DOI 10.1016/S0735-1097(87)80463-1; FINKELHOR RS, 1986, J AM COLL CARDIOL, V8, P289, DOI 10.1016/S0735-1097(86)80042-0; FLEG JL, 1988, J APPL PHYSIOL, V65, P1147, DOI 10.1152/jappl.1988.65.3.1147; FORMAN DE, 1992, J GERONTOL, V47, pM56, DOI 10.1093/geronj/47.2.M56; FORTNEY S, 1992, J APPL PHYSIOL, V73, P2693, DOI 10.1152/jappl.1992.73.6.2693; GARDIN JM, 1979, J CLIN ULTRASOUND, V7, P439, DOI 10.1002/jcu.1870070606; GERSTENBLITH G, 1977, CIRCULATION, V56, P273, DOI 10.1161/01.CIR.56.2.273; GRANGER CB, 1985, J AM COLL CARDIOL, V5, P862, DOI 10.1016/S0735-1097(85)80424-1; GWATHMEY JK, 1990, J APPL PHYSIOL, V69, P1366, DOI 10.1152/jappl.1990.69.4.1366; HARRISON MR, 1991, AM J CARDIOL, V87, P622; KITZMAN DW, 1991, J AM COLL CARDIOL, V18, P1243, DOI 10.1016/0735-1097(91)90542-H; LEVY WC, 1993, CIRCULATION, V88, P116, DOI 10.1161/01.CIR.88.1.116; MATSUDA M, 1983, J APPL PHYSIOL, V55, P323, DOI 10.1152/jappl.1983.55.2.323; MIYATAKE K, 1984, AM J CARDIOL, V53, P587; Rose G, 1968, CARDIOVASCULAR SURVE; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SARTORI MP, 1987, AM J CARDIOL, V59, P1179, DOI 10.1016/0002-9149(87)90871-X; SCHULMAN SP, 1992, AM J PHYSIOL, V263, pH1932, DOI 10.1152/ajpheart.1992.263.6.H1932; SHAPIRO LM, 1983, BRIT HEART J, V50, P534; SHOCK NW, 1984, NIH842450 PUBL, P45; SPURGEON HA, 1983, AM J PHYSIOL, V244, pH513, DOI 10.1152/ajpheart.1983.244.4.H513; STARNES JW, 1983, AM J PHYSIOL, V245, P560; STODDARD MF, 1989, CIRCULATION, V79, P1226, DOI 10.1161/01.CIR.79.6.1226; SWINNE CJ, 1992, AM J CARDIOL, V69, P823, DOI 10.1016/0002-9149(92)90518-4; TAKEMOTO KA, 1992, AM HEART J, V124, P143, DOI 10.1016/0002-8703(92)90932-L; TATE CA, 1990, AM J PHYSIOL, V258, pH431, DOI 10.1152/ajpheart.1990.258.2.H431	36	80	80	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1371	1375		10.1001/jama.273.17.1371	http://dx.doi.org/10.1001/jama.273.17.1371			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV307	7715063				2022-12-24	WOS:A1995QV30700023
J	KANE, RL				KANE, RL			IMPROVING THE QUALITY OF LONG-TERM-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NURSING-HOME PATIENTS; OUTCOMES; IMPACT	Quality of long-term care can be improved by changing the strategies used to monitor it. Nursing home care has been the subject of intensive regulations, while it has been neglected by physicians. Newer forms of long-term care are coming under stricter oversight, which may stifle the innovations they offer. Greater but different attention is needed: more creativity can be fostered with better accountability by emphasizing long-term care outcomes. It is unrealistic to require that long-term care patients will improve; good outcomes are defined as doing as well as or better than expected. The Minimum Data Set for nursing homes offers a mechanism to generate data on many pertinent outcomes. An outcomes focus would encourage more collective action by the various parties involved in providing long-term care, including physicians. Clinicians are reluctant to assume responsibility for outcomes they feel unable to strongly influence, but they must recognize that part of their role is to engender cooperation from the myriad participants in long-term care, including patients and their families. Better-quality long-term care may cost more, but it may be possible to use less expensive personnel more creatively if current regulations are modified. Managed care arrangements offer one vehicle for reorganizing care and could provide the appropriate incentives to make positive changes. However, they could also lead to minimalist strategies. Accountability for realistic outcomes can provide the needed countervailing regulatory pressure.			KANE, RL (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,MINNESOTA CHAIR LONG TERM CARE & AGING,420 DELAWARE ST SE,BOX 197,MINNEAPOLIS,MN 55455, USA.				NATIONAL INSTITUTE ON AGING [K07AG000622] Funding Source: NIH RePORTER; NIA NIH HHS [5K07-AG00622] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; ELSTEIN AS, 1972, J MED EDUC, V47, P85; FOX PD, 1991, INITIATIVES SERVICE; FRIEDMAN B, 1993, J AM GERIATR SOC, V41, P1144, DOI 10.1111/j.1532-5415.1993.tb06465.x; GARRARD J, 1990, MED CARE, V28, P271, DOI 10.1097/00005650-199003000-00007; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; Institute of Medicine report, 1986, IMPROVING QUALITY CA; Kane R.A., 1981, ASSESSING ELDERLY; Kane R L, 1976, J Community Health, V2, P1, DOI 10.1007/BF01349487; Kane R L, 1976, J Community Health, V1, P233, DOI 10.1007/BF01324582; KANE RA, 1994, HEALTH CARE FINANC R, V16, P69; KANE RA, 1988, INQUIRY-J HEALTH CAR, V25, P132; Kane RA, 1993, ASSISTED LIVING US N; KANE RA, IN PRESS MILBANK Q; KANE RA, 1995, DELEGATION NURSING A; KANE RA, 1990, EVERYDAY ETHICS SOLV; KANE RL, 1983, GERONTOLOGIST, V23, P200, DOI 10.1093/geront/23.2.200; KANE RL, 1983, J GERONTOL, V38, P385, DOI 10.1093/geronj/38.4.385; KANE RL, 1989, AM J PUBLIC HEALTH, V79, P1271, DOI 10.2105/AJPH.79.9.1271; KANE RL, 1991, J AM GERIATR SOC, V39, P359, DOI 10.1111/j.1532-5415.1991.tb02900.x; KANE RL, 1993, ANNU REV PUBL HEALTH, V14, P545, DOI 10.1146/annurev.pu.14.050193.002553; KUROWSKI BD, 1982, HE222C182 US DEP HLT; MALONE JK, 1993, J HLTH CARE BENE JAN, P51; MANGEN DJ, 1984, HLTH PROGRAM EVALUAT; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; MENDELSON MA, 1974, TENDER LOVING GREED; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; MORRIS R, 1974, GERONTOLOGIST, V14, P14, DOI 10.1093/geront/14.1.14; MORRIS R, 1980, AM J PUBLIC HEALTH, V70, P471, DOI 10.2105/AJPH.70.5.471; ROGERS A, 1989, PUBLIC HEALTH REP, V104, P222; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; SHAUGHNESSY PW, 1994, HEALTH CARE FINANC R, V16, P35; SIU AL, 1993, J CLIN EPIDEMIOL, V46, P1093, DOI 10.1016/0895-4356(93)90108-D; TERESI JA, 1992, GERONTOLOGIST, V32, P148, DOI 10.1093/geront/32.2.148; Vladeck B.C., 1980, UNLOVING CARE NURSIN; WEISSERT WG, 1989, HLTH CARE ELDERLY IN; 1990, MEDICARE STRATEGY QU; 1993, MEDICARE AM HLTH CAR	40	68	69	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1376	1380		10.1001/jama.273.17.1376	http://dx.doi.org/10.1001/jama.273.17.1376			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715064				2022-12-24	WOS:A1995QV30700024
J	LI, CJ; FRIEDMAN, DJ; WANG, CL; METELEV, V; PARDEE, AB				LI, CJ; FRIEDMAN, DJ; WANG, CL; METELEV, V; PARDEE, AB			INDUCTION OF APOPTOSIS IN UNINFECTED LYMPHOCYTES BY HIV-1 TAT PROTEIN	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROGRAMMED CELL-DEATH; T-CELLS; PERIPHERAL-BLOOD; ACTIVATION; AIDS; INDIVIDUALS; EXPRESSION; INFECTION; CD4	Infection by human immunodeficiency virus-type 1 (HIV-1) is typified by the progressive depletion of CD4 T lymphocytes and deterioration of immune function in most patients. A central unresolved issue in acquired immunodeficiency syndrome (AIDS) pathogenesis is the mechanism underlying this T cell depletion. HIV-1 Tat protein was shown to induce cell death by apoptosis in a T cell line and in cultured peripheral blood mononuclear cells from uninfected donors, This Tat-induced apoptosis was inhibitable by growth factors and was associated with enhanced activation of cyclin-dependent kinases.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; WORCESTER FDN EXPTL BIOL INC, SHREWSBURY, MA 01545 USA	Harvard University; Harvard Medical School; Worcester Foundation for Biomedical Research	LI, CJ (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELL GROWTH & REGULAT, 44 BINNEY ST, BOSTON, MA 02115 USA.		Metelev, Valeri/I-3238-2012	Friedman, David/0000-0002-0301-9298	NIAID NIH HHS [AI-35511] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMEISEN JC, 1992, IMMUNOL TODAY, V13, P388, DOI 10.1016/0167-5699(92)90086-M; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; CAPUTO A, 1990, J ACQ IMMUN DEF SYND, V6, P778; CARBONARI M, 1994, BLOOD, V83, P1268; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOU QP, 1993, CANCER RES, V53, P1493; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ESTAQUIER J, 1994, P NATL ACAD SCI USA, V91, P9431, DOI 10.1073/pnas.91.20.9431; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FINKEL TH, 1994, CURR OPIN IMMUNOL, V6, P605, DOI 10.1016/0952-7915(94)90149-X; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GOUGEON ML, 1993, SCIENCE, V262, P1356, DOI 10.1126/science.262.5138.1356; Green D R, 1992, Semin Immunol, V4, P379; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HELLAND DE, 1991, J VIROL, V65, P4547, DOI 10.1128/JVI.65.8.4547-4549.1991; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; LEDERMAN MM, COMMUNICATION; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Li C, UNPUB; LI CJ, 1993, P NATL ACAD SCI USA, V90, P1839, DOI 10.1073/pnas.90.5.1839; LI CJ, 1994, J BIOL CHEM, V269, P7051; MARTIN SJ, 1994, J IMMUNOL, V152, P330; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PANTALEO G, 1994, CURR OPIN IMMUNOL, V6, P600, DOI 10.1016/0952-7915(94)90148-1; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; ROSEN CA, 1986, J VIROL, V57, P379, DOI 10.1128/JVI.57.1.379-384.1986; ROSSI AD, 1994, VIROLOGY, V198, P234; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; ZAULI G, 1993, CANCER RES, V53, P4481	47	532	553	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	1995	268	5209					429	431		10.1126/science.7716549	http://dx.doi.org/10.1126/science.7716549			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716549				2022-12-24	WOS:A1995QU57200044
J	MULLER, KJ; ROMANO, N; GERSTNER, O; GARCIAMAROTO, F; POZZI, C; SALAMINI, F; ROHDE, W				MULLER, KJ; ROMANO, N; GERSTNER, O; GARCIAMAROTO, F; POZZI, C; SALAMINI, F; ROHDE, W			THE BARLEY HOODED MUTATION CAUSED BY A DUPLICATION IN A HOMEOBOX GENE INTRON	NATURE			English	Article							EXPRESSION; KNOTTED-1; ANTIRRHINUM; VECTORS; FAMILY; FATES; LOCUS	IN barley (Hordeum vulgare L.) the unit of inflorescence is the spikelet, which bears a fertile bract, the lemma, and the floret consisting of palea, two lodicules, three stamens and the pistil(1). The Hooded mutation causes the appearance of an extra flower of inverse polarity on the lemma(2). This phenotype is governed by the single dominant genetic locus K-3 Here we show that the homeobox gene Knox3 represents this locus, Ectopic Knox3 gene expression in the primordium of the extra floret is caused by a 305-base pair duplication in inh on 4, and phenocopies of the mutation are obtained in the heterologous tobacco system by Knox3 overexpression. It is concluded that homeotic genes of the Knox gene family are involved in floral evocation. Furthermore, the study of polarity of reproductive organs in K and related mutants can now focus on homeobox genes.	UNIV POLITECN MADRID,ETS INGN AGRON,DEPT BIOQUIM & BIOL MOLEC,E-28040 MADRID,SPAIN	Universidad Politecnica de Madrid	MULLER, KJ (corresponding author), MAX PLANCK INST ZUCHTUNGSFORSCH,CARL VON LINNE WEG 10,D-50829 COLOGNE,GERMANY.		Maroto, Federico Garcia/G-8616-2013	Maroto, Federico Garcia/0000-0002-0565-6995; Pozzi, Carlo Massimo/0000-0002-2899-177X				BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Bossinger G., 1992, Barley: genetics, biochemistry, molecular biology and biotechnology., P231; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; CLANCY M, 1994, PLANT SCI, V98, P151, DOI 10.1016/0168-9452(94)90005-1; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; Dahlgren R.M.T., 1985, FAMILIES MONOCOTYLED, P520, DOI [10.1007/978-3-642-61663-1, DOI 10.1007/978-3-642-61663-1]; DECANDOLLE C, 1891, MEM SOC PHYS HIST S, V6, P1; DICKINSON TA, 1978, BOT REV, V44, P181, DOI 10.1007/BF02919079; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; HAKE S, 1992, TRENDS GENET, V8, P109, DOI 10.1016/0168-9525(92)90065-C; HALFORD NG, 1992, PLANT J, V2, P791, DOI 10.1046/j.1365-313X.1992.t01-16-00999.x; HARLAN HARRY V., 1931, JOUR HEREDITY, V22, P264; JACKSON D, 1994, DEVELOPMENT, V120, P405; Nilan R.A., 1964, CYTOLOGY GENETICS BA; Sambrook J., 1989, MOL CLONING; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; SMITH LG, 1992, DEVELOPMENT, V116, P21; Stebbins G.L., 1974, FLOWERING PLANTS EVO, DOI 10.4159/harvard.9780674864856; STEBBINS GL, 1966, GENETICS, V54, P727; TAKAHASHI R, 1953, OHARA I LANDW FORSCH, V10, P29; TOPFER R, 1987, NUCLEIC ACIDS RES, V15, P5890, DOI 10.1093/nar/15.14.5890; VASIL V, 1989, PLANT PHYSIOL, V91, P1575, DOI 10.1104/pp.91.4.1575; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0; Weberling F, 1989, MORPHOLOGY FLOWERS I; WOLF N, 1992, MOL GEN GENET, V234, P33, DOI 10.1007/BF00272342; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	26	163	176	3	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					727	730		10.1038/374727a0	http://dx.doi.org/10.1038/374727a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715728				2022-12-24	WOS:A1995QU30400051
J	HENKIN, RI				HENKIN, RI			BODY ODOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HENKIN, RI (corresponding author), TASTE & SMELL CLIN,WASHINGTON,DC, USA.							GOLDBERG RL, 1985, PSYCHOSOMATICS, V26, P326; HENKIN RI, 1993, OTOLARYNGOLOGY, V2, P1; HENKIN RI, 1994, OLFACTION TASTE, V11, P568; Jackson JH., 1871, LANCET, V1, P376; MUNRO A, 1982, CAN J PSYCHIAT, V27, P374, DOI 10.1177/070674378202700504; PERRY TL, 1970, CLIN CHIM ACTA, V30, P721, DOI 10.1016/0009-8981(70)90266-4; PHILLIPS M, 1994, CLIN RES, V42, pA260; POTOLICCHIO SJ, 1986, CLIN RES, V34, P635; PRYSEPHILLIPS W, 1991, ACTA PSYCHIAT SCAND, V47, P484; RUBERT SL, 1961, ARCH GEN PSYCHIAT, V5, P313; SMITH K, 1969, SCIENCE, V166, P398, DOI 10.1126/science.166.3903.398; Taylor RB, 1992, DIFFICULT DIAGNOSIS, P348	12	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1171	1172						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT100	7707616				2022-12-24	WOS:A1995QT10000011
J	LIN, AN; MINDEN, A; MARTINETTO, H; CLARET, FX; LANGECARTER, C; MERCURIO, F; JOHNSON, GL; KARIN, M				LIN, AN; MINDEN, A; MARTINETTO, H; CLARET, FX; LANGECARTER, C; MERCURIO, F; JOHNSON, GL; KARIN, M			IDENTIFICATION OF A DUAL-SPECIFICITY KINASE THAT ACTIVATES THE JUN KINASES AND P38-MPK2	SCIENCE			English	Article							PROTEIN-KINASE; C-JUN; PHOSPHORYLATION; SERINE-63; PATHWAY; FAMILY; YEAST; RAF; MEK	One Ras-dependent protein kinase cascade leading from growth factor receptors to the ERK (extracellular signal-regulated kinases) subgroup of mitogen-activated protein kinases (MAPKs) is dependent on the protein kinase Raf-1, which activates the MEK(MAPK or ERK kinase) dual specificity kinases. A second protein kinase cascade leading to activation of the Jun kinases (JNKs) is dependent on MEKK (MEK kinase). A dual-specificity kinase that activates JNK, named JNKK, was identified that functions between MEKK and JNK. JNKK activated the JNKs but did not activate the ERKs and was unresponsive to Raf-1 in transfected Hela cells. JNKK also activated another MAPK, p38 (Mpk2; the mammalian homolog of HOG1 from yeast), whose activity is regulated similarly to that of the JNKs.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DIV BASIC SCI, DENVER, CO 80206 USA; SIGNAL PHARMACEUT, SAN DIEGO, CA 92110 USA	University of California System; University of California San Diego; National Jewish Health			Claret, Francois X/R-2104-2016	Claret, Francois X/0000-0003-4629-6495; Lange, Carol/0000-0003-2751-3976				AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHOI KY, 1994, CELL, V78, P499; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RE, UNPUB; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER C, UNPUB; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AL, UNPUB; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, UNPUB; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SU B, UNPUB; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	37	716	746	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	1995	268	5208					286	290		10.1126/science.7716521	http://dx.doi.org/10.1126/science.7716521			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716521				2022-12-24	WOS:A1995QT18500038
J	FRANCO, B; MERONI, G; PARENTI, G; LEVILLIERS, J; BERNARD, L; GEBBIA, M; COX, L; MAROTEAUX, P; SHEFFIELD, L; RAPPOLD, GA; ANDRIA, G; PETIT, C; BALLABIO, A				FRANCO, B; MERONI, G; PARENTI, G; LEVILLIERS, J; BERNARD, L; GEBBIA, M; COX, L; MAROTEAUX, P; SHEFFIELD, L; RAPPOLD, GA; ANDRIA, G; PETIT, C; BALLABIO, A			A CLUSTER OF SULFATASE GENES ON XP22.3 - MUTATIONS IN CHONDRODYSPLASIA PUNCTATA (CDPX) AND IMPLICATIONS FOR WARFARIN EMBRYOPATHY	CELL			English	Article							KALLMANN SYNDROME GENE; HUMAN ARYLSULFATASE-B; FULL-LENGTH CDNA; STEROID-SULFATASE; X-CHROMOSOME; NUCLEOTIDE-SEQUENCE; LINKED ICHTHYOSIS; Y-CHROMOSOME; SHORT ARM; EXPRESSION	X-linked recessive chondrodysplasia punctata (CDPX) is a congenital defect of bone and cartilage development characterized by aberrant bone mineralization, severe underdevelopment of nasal cartilage, and distal phalangeal hypoplasia. A virtually identical phenotype is observed in the warfarin embryopathy, which is due to the teratogenic effects of coumarin derivatives during pregnancy, We have cloned the genomic region within Xp22.3 where the CDPX gene has been assigned and isolated three adjacent genes showing highly significant homology to the sulfatase gene family. Point mutations in one of these genes were identified in five patients with CDPX, Expression of this gene in COS cells resulted in a heat-labile arylsulfatase activity that is inhibited by warfarin. A deficiency of a heat-labile arylsulfatase activity was demonstrated in patients with deletions spanning the CDPX region. These data indicate that CDPX is caused by an inherited deficiency of a navel sulfatase and suggest that warfarin embryopathy might involve drug-induced inhibition of the same enzyme.	BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; UNIV NAPLES,DEPT PEDIAT,I-80134 NAPLES,ITALY; INST PASTEUR,UNITE GENET MOLEC HUMAINE,CNRS,UNITE A1445,F-75724 PARIS 15,FRANCE; MURDOCH INST,ROYAL CHILDRENS HOSP,MELBOURNE,VIC 3050,AUSTRALIA; UNIV HEIDELBERG,INST HUMANGENET,D-69120 HEIDELBERG,GERMANY; UNIV SIENA,DEPT BIOL MOLEC,I-53100 SIENA,ITALY	Baylor College of Medicine; University of Naples Federico II; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Ruprecht Karls University Heidelberg; University of Siena			BALLABIO, Andrea/AAL-2672-2020; Melis, Daniela/AAD-3623-2019; Bernard, Loris/K-5953-2014; andria, generoso/V-7172-2019; FRANCO, Brunella/S-2882-2018	BALLABIO, Andrea/0000-0003-1381-4604; Melis, Daniela/0000-0002-9458-3926; parenti, giancarlo/0000-0002-6287-5748; Petit, Christine/0000-0002-9069-002X; FRANCO, Brunella/0000-0001-5588-4569	NINDS NIH HHS [NS31367-01] Funding Source: Medline; Telethon [TGM94000, TGM06S01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031367] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALL, 1995, METABOLIC MOL BASES, P2999; BALLABIO A, 1987, P NATL ACAD SCI USA, V84, P4519, DOI 10.1073/pnas.84.13.4519; BALLABIO A, 1985, HUM GENET, V70, P315, DOI 10.1007/BF00295367; Ballabio Andrea, 1992, Human Molecular Genetics, V1, P221, DOI 10.1093/hmg/1.4.221; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROWN CJ, 1990, NUCLEIC ACIDS RES, V18, P4191, DOI 10.1093/nar/18.14.4191; BURCH M, 1986, CLIN GENET, V30, P409; CHANG PL, 1985, ANAL BIOCHEM, V144, P362, DOI 10.1016/0003-2697(85)90129-0; CHANG PL, 1990, AM J HUM GENET, V46, P729; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; CURRY CJR, 1984, NEW ENGL J MED, V311, P1010, DOI 10.1056/NEJM198410183111603; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DELCASTILLO I, 1992, NAT GENET, V2, P305, DOI 10.1038/ng1292-305; FASCO MJ, 1982, J BIOL CHEM, V257, P1210; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HOWE AM, 1992, TERATOLOGY, V46, P379, DOI 10.1002/tera.1420460408; INCERTI B, 1992, NAT GENET, V2, P311, DOI 10.1038/ng1292-311; Kolodny E.H., 1995, METABOLIC MOL BASES, V7th, P2693; MAROTEAUX P, 1989, HUM GENET, V82, P167, DOI 10.1007/BF00284052; MUNROE DG, 1987, AM J HUM GENET, V40, P102; MUROOKA Y, 1990, J BACTERIOL, V172, P2131, DOI 10.1128/jb.172.4.2131-2140.1990; NEUFELD EF, 1995, METABOLIC MOL BASES, P2645; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAULI RM, 1987, AM J HUM GENET, V41, P566; PAULI RM, 1988, PATHOL IMMUNOPATH R, V7, P107, DOI 10.1159/000157104; PETERS C, 1990, J BIOL CHEM, V265, P3374; PRICE PA, 1985, VITAM HORM, V42, P65; ROBERTSON DA, 1988, BIOCHEM BIOPH RES CO, V157, P215; SASAKI H, 1988, EUR J BIOCHEM, V177, P9, DOI 10.1111/j.1432-1033.1988.tb14338.x; SCHAEFER L, 1993, NAT GENET, V4, P272, DOI 10.1038/ng0793-272; SCHUCHMAN EH, 1990, GENOMICS, V6, P149, DOI 10.1016/0888-7543(90)90460-C; SHEFFIELD LJ, 1976, J PEDIATR-US, V89, P916, DOI 10.1016/S0022-3476(76)80596-3; SMITH MJ, 1994, HUM MOL GENET, V3, P1575, DOI 10.1093/hmg/3.9.1575; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SPRANGER JW, 1970, HUM GENET, V11, P190; STEIN C, 1989, J BIOL CHEM, V264, P13865; STEIN C, 1989, J BIOL CHEM, V264, P1252; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOMATSU S, 1991, BIOCHEM BIOPH RES CO, V181, P677, DOI 10.1016/0006-291X(91)91244-7; WANG I, 1995, IN PRESS GENOMICS; WAPENAAR MC, 1994, HUM MOL GENET, V3, P1155, DOI 10.1093/hmg/3.7.1155; WICKER G, 1991, J BIOL CHEM, V266, P21386; WILSON PJ, 1990, P NATL ACAD SCI USA, V87, P8531, DOI 10.1073/pnas.87.21.8531; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7; YEN PH, 1987, CELL, V49, P443, DOI 10.1016/0092-8674(87)90447-8	48	191	210	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					15	25		10.1016/0092-8674(95)90367-4	http://dx.doi.org/10.1016/0092-8674(95)90367-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720070	Green Published, Bronze			2022-12-24	WOS:A1995QR97000004
J	SEATON, A; MACNEE, W; DONALDSON, K; GODDEN, D				SEATON, A; MACNEE, W; DONALDSON, K; GODDEN, D			PARTICULATE AIR-POLLUTION AND ACUTE HEALTH-EFFECTS	LANCET			English	Note							TIME-SERIES ANALYSIS; RESPIRATORY HEALTH; PULMONARY TOXICITY; PM-10 POLLUTION; PARTICLES; MORTALITY; ULTRAFINE; CHILDREN; DISEASE; UTAH	Epidemiological studies have consistently shown an association between particulate air pollution and not only exacerbations of illness in people with respiratory disease but also rises in the numbers of deaths from cardiovascular and respiratory disease among older people. Meta-analyses of these studies indicate associations are unlikely to be explained any confounder, and suggest that they represent cause and effect. We propose that the explanation lies in the nature of the urban particulate cloud, which may contain up to 100000 nanometer-sized particles per mt, in what may be a gravimetric concentration of only 100-200 mu g/m3 of pollutant. We suggest that such ultra-fine particles are able to provoke alveolar inflammation, with release of mediators capable, in susceptible individuals, of causing exacerbations of lung disease and of increasing blood coagulability, thus also explaining the observed increases in cardiovascular deaths associated with urban pollution episodes. This hypothesis is testable both experimentally and epidemiologically.	UNIV EDINBURGH,EDINBURGH,MIDLOTHIAN,SCOTLAND; NAPIER UNIV,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Edinburgh Napier University	SEATON, A (corresponding author), UNIV ABERDEEN,SCH MED,DEPT ENVIRONM & OCCUPAT MED,FORESTERHILL,ABERDEEN AB9 2ZD,SCOTLAND.			MacNee, William/0000-0002-3692-1448				AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; [Anonymous], [No title captured]; BATES DV, 1992, ENVIRON RES, V59, P336, DOI 10.1016/S0013-9351(05)80040-4; BRAUER M, 1989, ENVIRON SCI TECHNOL, V23, P1408, DOI 10.1021/es00069a013; CHOU JC, 1992, ATMOS ENVIRON, V24, P693; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587, DOI 10.1164/ajrccm/139.3.587; FERIN J, 1990, J AEROSOL SCI, V21, P381, DOI 10.1016/0021-8502(90)90064-5; FERIN J, 1992, AM J RESP CELL MOL, V6, P535, DOI 10.1165/ajrcmb/6.5.535; HELIN H, 1986, MED BIOL, V64, P167; HILLS BA, 1982, THORAX, V37, P713, DOI 10.1136/thx.37.10.713; HURLEY JF, 1990, MORTALITY 1967 1987; LAWTHER PJ, 1968, PROC R SOC LON SER-A, V307, P223, DOI 10.1098/rspa.1968.0186; LOWE GDO, 1993, THROMBOSIS AND ITS MANAGEMENT, P31; LOWE GDO, 1992, CLIN HEMORHEOL, V12, P535; MACNEE W, 1993, THORAX, V48, P79, DOI 10.1136/thx.48.1.79; MILLER BG, 1985, BRIT J IND MED, V42, P723; OTTAWAY CA, 1984, J CLIN IMMUNOL, V4, P348, DOI 10.1007/BF00917137; POPE CA, 1991, AM REV RESPIR DIS, V144, P668, DOI 10.1164/ajrccm/144.3_Pt_1.668; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211, DOI 10.1080/00039896.1992.9938351; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90, DOI 10.1080/00039896.1991.9937434; POPE CA, 1993, AM REV RESPIR DIS, V147, P1336, DOI 10.1164/ajrccm/147.6_Pt_1.1336; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118, DOI 10.1164/ajrccm/147.1.118; RUOSS K, 1991, J AEROSOL SCI, V22, pS629, DOI 10.1016/S0021-8502(05)80180-6; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; SCHWARTZ J, 1990, AM J EPIDEMIOL, V131, P185, DOI 10.1093/oxfordjournals.aje.a115473; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; TEPPER JS, 1994, AM J RESP CRIT CARE, V149, pA839; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133; WARHEIT DB, 1990, EXP MOL PATHOL, V52, P309, DOI 10.1016/0014-4800(90)90072-L	30	1529	1590	4	252	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					176	178		10.1016/S0140-6736(95)90173-6	http://dx.doi.org/10.1016/S0140-6736(95)90173-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7741860				2022-12-24	WOS:A1995QC55000016
J	KOTANIDES, H; REICH, NC				KOTANIDES, H; REICH, NC			REQUIREMENT OF TYROSINE PHOSPHORYLATION FOR RAPID ACTIVATION OF A DNA-BINDING FACTOR BY IL-4	SCIENCE			English	Article							STIMULATORY FACTOR-I; RECOMBINANT INTERLEUKIN-4; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; INTERFERON-ALPHA; IFN-GAMMA; PROTEIN; RECEPTOR; EXPRESSION; PROMOTER	Interleukin-4 (IL-4) is an immunoregulatory cytokine produced by activated T lymphocytes to promote the growth and differentiation of cells that participate in immune defense. This study demonstrates the rapid activation of a specific DNA binding factor by IL-4. The IL-4 nuclear-activated factor (IL-4 NAF) appeared within minutes of IL-4 stimulation and recognized a specific DNA sequence found in the promoters of IL-4-responsive genes. Activation of this putative transcription factor required tyrosine phosphorylation, and antibodies specific for phosphotyrosine recognize the IL-4 NAF-DNA complex. Thus, IL-4 appears to transduce a signal to the nucleus through tyrosine phosphorylation of a latent DNA binding factor.	SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794; SUNY STONY BROOK,GRAD PROGRAM MOLEC & CELLULAR BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R29CA050773] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA50773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOOTHBY M, 1988, SCIENCE, V242, P1559, DOI 10.1126/science.3144043; CAO H, 1989, J IMMUNOL, V143, P3524; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GERONDAKIS S, 1990, P NATL ACAD SCI USA, V87, P1581, DOI 10.1073/pnas.87.4.1581; GILMOUR KC, UNPUB; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; GUTCH MJ, UNPUB; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; ILLGES H, 1992, MOL IMMUNOL, V29, P1265, DOI 10.1016/0161-5890(92)90063-4; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KOTANIDES H, UNPUB; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MCGARVIE GM, 1989, IMMUNOL LETT, V22, P221, DOI 10.1016/0165-2478(89)90195-8; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; MOND JJ, 1986, J IMMUNOL, V137, P353; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PAUL WE, 1991, BLOOD, V77, P1859; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PURKERSON J, 1992, FASEB J, V6, P3245, DOI 10.1096/fasebj.6.14.1385241; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; SARFATI M, 1992, IMMUNOL RES, V11, P260, DOI 10.1007/BF02919132; SHINDLER C, 1992, SCIENCE, V257, P809; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; STUART PM, 1988, J IMMUNOL, V140, P1542; SUTER U, 1989, J IMMUNOL, V143, P3087; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; XU MZ, 1992, EMBO J, V11, P145, DOI 10.1002/j.1460-2075.1992.tb05037.x; YANG Q, 1993, J BIOL CHEM, V268, P6622; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	40	261	267	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1265	1267		10.1126/science.7694370	http://dx.doi.org/10.1126/science.7694370			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	7694370				2022-12-24	WOS:A1993MH32400039
J	ASHLEY, CT; WILKINSON, KD; REINES, D; WARREN, ST				ASHLEY, CT; WILKINSON, KD; REINES, D; WARREN, ST			FMR1 PROTEIN - CONSERVED RNP FAMILY DOMAINS AND SELECTIVE RNA-BINDING	SCIENCE			English	Article							FRAGILE-X-SYNDROME; ESCHERICHIA-COLI; GENE; DNA; INSTABILITY; SEQUENCE; METHYLATION; REPEAT; SITE	Fragile X syndrome is the result of transcriptional suppression of the gene FMR1 as a result of a trinucleotide repeat expansion mutation. The normal function of the FMR1 protein (FMRP) and the mechanism by which its absence leads to mental retardation are unknown. Ribonucleoprotein particle (RNP) domains were identified within FMRP, and RNA was shown to bind in stoichiometric ratios, which suggests that there are two RNA binding sites per FMRP molecule. FMRP was able to bind to its own message with high affinity (dissociation constant = 5.7 nM) and interacted with approximately 4 percent of human fetal brain messages. The absence of the normal interaction of FMRP with a X syndrome.	EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Emory University; Howard Hughes Medical Institute; Emory University; Emory University			excellency, Your/R-2357-2019; Warren, Stephen T/A-2498-2012	excellency, Your/0000-0003-0832-6243; 	NICHD NIH HHS [HD20521] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020521, R37HD020521] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BRAUER D, 1979, FEBS LETT, V106, P352, DOI 10.1016/0014-5793(79)80531-1; BROWN WT, 1990, AM J HUM GENET, V47, P175; BUTLER MG, 1991, CLIN GENET, V39, P347; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DELAHODDE A, 1986, NUCLEIC ACIDS RES, V14, P9213, DOI 10.1093/nar/14.22.9213; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GIDEON AK, 1992, NAT GENET, V1, P341; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; KAO CC, 1992, J VIROL, V66, P6322, DOI 10.1128/JVI.66.11.6322-6329.1992; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Price D, UNPUB; REGNIER P, 1987, J BIOL CHEM, V262, P63; SCHMIDT C, 1992, EUR J BIOCHEM, V206, P625, DOI 10.1111/j.1432-1033.1992.tb16967.x; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WOHRLE D, 1992, AM J HUM GENET, V51, P299; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; ZHANG XT, 1990, NUCLEIC ACIDS RES, V18, P6689, DOI 10.1093/nar/18.22.6689	31	599	612	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 22	1993	262	5133					563	566		10.1126/science.7692601	http://dx.doi.org/10.1126/science.7692601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC935	7692601				2022-12-24	WOS:A1993MC93500039
J	LIPSHULTZ, SE; LIPSITZ, SR; MONE, SM; GOORIN, AM; SALLAN, SE; SANDERS, SP; ORAV, EJ; GELBER, RD; COLAN, SD				LIPSHULTZ, SE; LIPSITZ, SR; MONE, SM; GOORIN, AM; SALLAN, SE; SANDERS, SP; ORAV, EJ; GELBER, RD; COLAN, SD			FEMALE SEX AND HIGHER DRUG DOSE AS RISK-FACTORS FOR LATE CARDIOTOXIC EFFECTS OF DOXORUBICIN THERAPY FOR CHILDHOOD-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CONGESTIVE HEART-FAILURE; RADIONUCLIDE ANGIOGRAPHY; OSTEO-SARCOMA; FREE SURVIVAL; GENDER; ANTHRACYCLINES; CHILDREN; ECHOCARDIOGRAPHY; CARDIOMYOPATHY	Background. Late cardiotoxic effects of doxorubicin are increasingly a problem for patients who survive childhood cancer. Cardiotoxicity is often progressive, and some patients have disabling symptoms. Our objective was to identify risk factors for late cardiotoxicity. Methods. We examined echocardiograms from 120 children and adults who had received cumulative doses of 244 to 550 mg of doxorubicin per square meter of body-surface area for the treatment of acute lymphoblastic leukemia or osteogenic sarcoma in childhood, a mean of 8.1 years earlier. Measurements of blood pressure and left ventricular function, contractility (measured as the stress-velocity index), end-diastolic posterior-wall thickness, end-diastolic dimension, mass, and afterload (measured as end-systolic wall stress) were compared with sex-specific values from a cohort of 296 normal subjects. Results. All echocardiographic measurements were abnormal at follow-up a minimum of two years after the end of therapy, with more frequent and severe abnormalities in female patients. In a multivariate analysis, female sex and a higher cumulative dose of doxorubicin were associated with depressed contractility (P less than or equal to 0.001), and there was an interaction between these two variables. independent and significant associations were found between a higher rate of administration of doxorubicin and increased afterload (P less than or equal to 0.001), left ventricular dilatation, and depressed left ventricular function; between a higher cumulative dose and depressed left ventricular function (P less than or equal to 0.001); between a younger age at diagnosis and reduced left-ventricular-wall thickness and mass and increased afterload; and between a longer time since the completion of doxorubicin therapy and reduced left-ventricular-wall thickness and increased afterload (P less than or equal to 0.001). Conclusions. Female sex and a higher rate of administration of doxorubicin were independent risk factors for cardiac abnormalities after treatment with doxorubicin for childhood cancer; the prevalence and severity of abnormalities increased with longer follow-up.	CHILDRENS HOSP,DEPT HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115; DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	LIPSHULTZ, SE (corresponding author), CHILDRENS HOSP,DEPT CARDIOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colan, Steven/ABB-4580-2020	Sanders, Stephen/0000-0003-3521-4044	NATIONAL CANCER INSTITUTE [P01CA034183, R29CA055576, P30CA006516, R01CA055576] Funding Source: NIH RePORTER; NCI NIH HHS [CA34183, CA55576, CA06516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, JAMA-J AM MED ASSOC, V263, P2189, DOI 10.1001/jama.263.16.2189; ADAMI HO, 1989, JNCI-J NATL CANCER I, V81, P1640, DOI 10.1093/jnci/81.21.1640; BLEYER WA, 1990, CA-CANCER J CLIN, V40, P355, DOI 10.3322/canjclin.40.6.355; BYRNE J, 1990, JAMA-J AM MED ASSOC, V264, P1810, DOI 10.1001/jama.1990.03450140030022; COLAN SD, 1992, J AM COLL CARDIOL, V19, P619, DOI 10.1016/S0735-1097(10)80282-7; CUTHBERTSON DD, 1994, CIRCULATION S, V90, P1; EYSMANN SB, 1993, CARDIOVASCULAR HLTH, P57; FRISANCHO AR, 1974, AM J CLIN NUTR, V27, P1052, DOI 10.1093/ajcn/27.8.1052; GOLAY CC, 1993, ONCOLOGY, V7, P77; GOLAY CC, 1993, ONCOLOGY, V7, P67; GOORIN AM, 1987, J CLIN ONCOL, V5, P1178, DOI 10.1200/JCO.1987.5.8.1178; GOORIN AM, 1990, J PEDIATR-US, V116, P144, DOI 10.1016/S0022-3476(05)81668-3; GOORIN AM, 1991, CLIN ORTHOP RELAT R, V270, P22; HANLEY PC, 1989, J AM COLL CARDIOL, V13, P624, DOI 10.1016/0735-1097(89)90603-7; HAUSDORF G, 1988, BRIT HEART J, V60, P309; HITCHCOCKBRYAN S, 1986, MED PEDIATR ONCOL, V14, P211, DOI 10.1002/mpo.2950140405; HRUSHESKY WJM, 1991, CIRCULATION, V84, P697, DOI 10.1161/01.CIR.84.2.697; KLEWER SE, 1992, J AM COLL CARDIOL, V19, P394, DOI 10.1016/0735-1097(92)90497-B; KREUGER A, 1993, PEDIATR HEMAT ONCOL, V10, P297, DOI 10.3109/08880019309029501; LARSEN RL, 1992, AM J CARDIOL, V70, P73, DOI 10.1016/0002-9149(92)91393-I; LEE YTN, 1982, MED PEDIATR ONCOL, V10, P259, DOI 10.1002/mpo.2950100306; LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; LIPSHULTZ SE, 1992, CIRCULATION, V86, P363; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; MATTHYS D, 1993, ACTA PAEDIATR, V82, P459, DOI 10.1111/j.1651-2227.1993.tb12722.x; MILLER DR, 1989, J CLIN ONCOL, V7, P316, DOI 10.1200/JCO.1989.7.3.316; MINOW RA, 1975, CANCER CHEMOTH REP 3, V6, P195; PALMERI ST, 1986, AM J CARDIOL, V58, P607, DOI 10.1016/0002-9149(86)90284-5; PIAZZA E, 1981, TUMORI, V67, P533, DOI 10.1177/030089168106700604; RODVOLD KA, 1988, J CLIN ONCOL, V6, P1321, DOI 10.1200/JCO.1988.6.8.1321; SALLAN SE, 1984, SEMIN ONCOL, V11, P19; SALLAN SE, 1994, ACUTE LEUKEMIA, V4, P322; SHUB C, 1994, MAYO CLIN P, V68, P205; SILBER JH, 1993, MED PEDIATR ONCOL, V21, P477, DOI 10.1002/mpo.2950210704; SMITH MA, 1991, JNCI-J NATL CANCER I, V83, P1460, DOI 10.1093/jnci/83.20.1460; STEINHERZ LJ, 1991, JAMA-J AM MED ASSOC, V266, P1672, DOI 10.1001/jama.266.12.1672; TANNER JM, 1975, ARCH DIS CHILD, V50, P142, DOI 10.1136/adc.50.2.142; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WEESNER KM, 1991, CANCER, V68, P435, DOI 10.1002/1097-0142(19910715)68:2<435::AID-CNCR2820680237>3.0.CO;2-#; YEUNG ST, 1991, LANCET, V337, P816, DOI 10.1016/0140-6736(91)92516-5	41	558	568	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1738	1743		10.1056/NEJM199506293322602	http://dx.doi.org/10.1056/NEJM199506293322602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760889				2022-12-24	WOS:A1995RE66700002
J	BRYANT, H; BRASHER, P				BRYANT, H; BRASHER, P			BREAST IMPLANTS AND BREAST-CANCER - REANALYSIS OF A LINKAGE STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP	Background. In 1992, Berkel and colleagues reported in the Journal the results of their study of the potential association of breast augmentation and breast cancer. The study reported that women who had breast augmentation had a significantly lower subsequent risk of breast cancer (P<0.01) than the general population, with a standardized incidence ratio of 0.48 overall. Assuming a 10-year induction period (that is, assuming that cancers found within 10 years of the augmentation might have been the result of a process begun before surgery and therefore should not be considered), the reported standardized incidence ratio was 0.16. Problems were later identified involving some of the study methods. This paper reports a second analysis of these data. Methods. We used a data set from Alberta Health Care to identify eligible women with bilateral breast augmentation. Using a combination of deterministic and probabilistic methods, we linked this data set to the Alberta Cancer Registry to identify subsequent breast cancers that developed during the study period. Multiple estimates of standardized incidence ratios were calculated on the basis of differing study-eligibility dates, induction periods, and types of breast-cancer (invasive only or invasive plus in situ). Results. The reanalysis found substantial differences in the numbers of person-years at risk, resulting in higher standardized incidence ratios than in the original analysis. The final ratios for all breast cancers, with October 1, 1973, used as the starting date of the study, were 0.76 (95 percent confidence interval, 0.55 to 1.02), 0.85 (95 percent confidence interval, 0.58 to 1.19), and 0.68 (95 percent confidence interval, 0.32 to 1.25) for induction periods of 0, 5, and 10 years, respectively. None of these standardized incidence ratios were significantly different from 1. Conclusions. On the basis of this reanalysis, the incidence of breast cancer among the women who had breast augmentation could not be said to be either significantly higher or lower than that among the general population over the period during which this cohort was followed.			BRYANT, H (corresponding author), ALBERTA CANC BOARD,DIV EPIDEMIOL PREVENT & SCREENING,1040 7TH AVE SW,SUITE 120,CALGARY,AB T2P 3G9,CANADA.							BAILAR JC, 1964, BIOMETRICS, V20, P639; BERKEL H, 1992, NEW ENGL J MED, V326, P1649, DOI 10.1056/NEJM199206183262501; BRYANT H, 1994, NEW ENGL J MED, V330, P293, DOI 10.1056/NEJM199401273300419; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HOWE GR, 1981, COMPUT BIOMED RES, V14, P327, DOI 10.1016/0010-4809(81)90004-5; WAJDA A, 1992, LINKPRO USERS MANUAL; 1993, STATISTICS CANADA	7	87	88	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 8	1995	332	23					1535	1539		10.1056/NEJM199506083322302	http://dx.doi.org/10.1056/NEJM199506083322302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB196	7739707	Bronze			2022-12-24	WOS:A1995RB19600002
J	MOOSA, AA; QUORTUM, HA; IBRAHIM, MD				MOOSA, AA; QUORTUM, HA; IBRAHIM, MD			RAPID DIAGNOSIS OF BACTERIAL-MENINGITIS WITH REAGENT STRIPS	LANCET			English	Article								Laboratory examination of cerebrospinal fluid (CSF) is not available in many parts of the world, and without knowledge of CSF glucose, protein, and cells, a diagnosis of meningitis may be missed. Testing CSF with urine reagent strips that measure glucose and protein has given variable results. We tested CSF samples from 234 children with suspected meningitis for glucose, protein, and leucocytes with Combur9 reagent strips. The results were compared with those obtained from the laboratory and also interpreted as indicating bacterial or viral meningitis. There was good agreement between the strip and laboratory method of estimating CSF glucose, protein, and leucocytes. All but 4 of the cases of meningitis were correctly identified by the strip method (sensitivity 97%). 2 (2.9%) of 69 cases of bacterial meningitis were judged by an independent observer to be viral, and 2 (3.3%) of 60 cases of viral meningitis as normal. No normal CSF was diagnosed as meningitis (specificity 100%). The results indicate that Combur9 reagent strips can distinguish normal from infected CSF and are of value in the diagnosis of meningitis.	FARWANIYA HOSP,MINIST PUBL HLTH,KUWAIT,KUWAIT		MOOSA, AA (corresponding author), KUWAIT UNIV,FAC MED,DEPT PAEDIAT,POB 24923,SAFAT 13110,KUWAIT.							FEINBLOO.RI, 1969, J PEDIATR, V74, P615, DOI 10.1016/S0022-3476(69)80047-8; MULLER PD, 1987, ANN TROP PAEDIATR, V7, P287, DOI 10.1080/02724936.1987.11748527; SCHWARTZ RP, 1971, J PEDIATR-US, V78, P677, DOI 10.1016/S0022-3476(71)80474-2	3	68	70	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1290	1291		10.1016/S0140-6736(95)90931-1	http://dx.doi.org/10.1016/S0140-6736(95)90931-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746063				2022-12-24	WOS:A1995QY93300015
J	LANZEROTTI, LJ; ARMSTRONG, TP; GOLD, RE; MACLENNAN, CG; ROELOF, EC; SIMNETT, GM; THOMSON, DJ; ANDERSON, KA; HAWKINS, SE; KRIMIGIS, SM; LIN, RP; PICK, M; SARRIS, ET; TAPPIN, SJ				LANZEROTTI, LJ; ARMSTRONG, TP; GOLD, RE; MACLENNAN, CG; ROELOF, EC; SIMNETT, GM; THOMSON, DJ; ANDERSON, KA; HAWKINS, SE; KRIMIGIS, SM; LIN, RP; PICK, M; SARRIS, ET; TAPPIN, SJ			OVER THE SOUTHERN SOLAR POLE - LOW-ENERGY INTERPLANETARY CHARGED-PARTICLES	SCIENCE			English	Article							ULYSSES	The heliosphere instrument for spectrum, composition, and anisotropy (HISCALE) recorded the fluxes of low-energy ions and electrons (>50 kiloelectron volts) when Ulysses crossed the southern solar polar region and revealed that the large-scale structure of the heliosphere to at least similar to-75 degrees was significantly influenced by the near-equatorial heliospheric current sheet. Electrons in particular were accelerated by the current sheet-produced and poleward-propagating interplanetary reverse shock at helioradii far from the Ulysses location. At heliolatitudes higher than similar to-75 degrees on the Ulysses ascent to the pole and similar to-50 degrees on the descent, small, less regular enhancements of the lowest energy electron fluxes were measured whose relations to the current sheet were less clear. The anomalous component of low-energy (similar to 2 to 5 megaelectron volts per nucleon) oxygen flux at the highest heliolatitudes was found to be similar to 10(-8) [per square centimeter per second per steradian (per kiloelectronvolt per nucleon)]; the anomalous Ne/O ratio was similar to 0.25.	UNIV KANSAS,DEPT PHYS,LAWRENCE,KS 66045; JOHNS HOPKINS UNIV,APPL PHYS LAB,LAUREL,MD 20723; UNIV BIRMINGHAM,BIRMINGHAM,W MIDLANDS,ENGLAND; UNIV CALIF BERKELEY,SPACE SCI LAB,BERKELEY,CA 94720; OBSERV PARIS,MEUDON,FRANCE; UNIV THRACE,XANTHI,GREECE	University of Kansas; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; University of Birmingham; University of California System; University of California Berkeley; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Democritus University of Thrace	LANZEROTTI, LJ (corresponding author), AT&T BELL LABS,600 MT AVE,MURRAY HILL,NJ 07974, USA.		Krimigis, Stamatios/G-4591-2019; Roelof, Edmond/G-6654-2019	Krimigis, Stamatios/0000-0003-2781-2386; Roelof, Edmond/0000-0002-2270-0652				BALOGH A, 1995, SCIENCE, V268, P1007, DOI 10.1126/science.268.5213.1007; BAME SJ, 1993, GEOPHYS RES LETT, V20, P2323, DOI 10.1029/93GL02630; CUMMINGS AC, 1995, GEOPHYS RES LETT, V22, P341, DOI 10.1029/94GL03343; GOSLING JT, 1993, GEOPHYS RES LETT, V20, P2789, DOI 10.1029/93GL03116; LANZEROTTI LJ, 1992, ASTRON ASTROPHYS SUP, V92, P349; LANZEROTTI LJ, 1995, GEOPHYS RES LETT, V22, P333, DOI 10.1029/94GL03210; LANZEROTTI LJ, UNPUB; PHILLIPS JL, 1995, SCIENCE, V268, P1030, DOI 10.1126/science.268.5213.1030; PHILLIPS JL, 1994, GEOPHYS RES LETT, V21, P1105, DOI 10.1029/94GL01065; PIZZO VJ, 1994, J GEOPHYS RES-SPACE, V99, P4173, DOI 10.1029/93JA03239; RICE SO, 1948, AT&T TECH J, V27, P109, DOI 10.1002/j.1538-7305.1948.tb01334.x; SARRIS ET, 1976, J GEOPHYS RES-SPACE, V81, P2341, DOI 10.1029/JA081i013p02341; SLEPIAN D, 1978, BELL SYST TECH J, V57, P1371, DOI 10.1002/j.1538-7305.1978.tb02104.x; SMITH EJ, 1993, GEOPHYS RES LETT, V20, P2327, DOI 10.1029/93GL02632; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; THOMSON DJ, 1990, PHILOS T R SOC A, V332, P539, DOI 10.1098/rsta.1990.0130; THOMSON DJ, UNPUB; TRATTNER KJ, 1995, GEOPHYS RES LETT, V22, P337, DOI 10.1029/94GL03305	18	21	21	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1010	1013		10.1126/science.7754378	http://dx.doi.org/10.1126/science.7754378			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754378				2022-12-24	WOS:A1995QY93400029
J	VALITUTTI, S; MULLER, S; CELLA, M; PADOVAN, E; LANZAVECCHIA, A				VALITUTTI, S; MULLER, S; CELLA, M; PADOVAN, E; LANZAVECCHIA, A			SERIAL TRIGGERING OF MANY T-CELL RECEPTORS BY A FEW PEPTIDE-MHC COMPLEXES	NATURE			English	Article							PROTEIN KINASE-C; CLASS-II; ANTIGEN RECEPTOR; RECOGNITION; EXPRESSION; BINDING	T LMPHOCYTES can recognize and be activated by a very small number of complexes of peptide with major histocompatibility complex (MHC) molecules displayed on the surface of antigen-presenting cells (APCs)(1,2). The interaction between the T-cell receptor (TCR) and its ligand has low affinity and high off-rate(3-6). Both findings suggest that an extremely small number of TCRs must be engaged in interaction with APCs and raise the question of how so few receptors can transduce an activation signal. Here we show that a small number of peptide-MHC complexes can achieve a high TCR occupancy, because a single complex can serially engage and trigger up to similar to 200 TCRs, Furthermore, TCR occupancy is proportional to the T cell's biological response. Our findings suggest that the lovv affinity of the TCR can be instrumental in enabling a small number of antigenic complexes to be detected.			VALITUTTI, S (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.		Cella, Marina/ABA-8564-2020; Valitutti, Salvatore/M-2999-2014; Cella, Marina/G-8850-2011	Valitutti, Salvatore/0000-0002-6432-4421; Cella, Marina/0000-0003-1230-1313; Padovan, Elisabetta/0000-0002-8212-508X				BOITEL B, 1992, J EXP MED, V175, P765, DOI 10.1084/jem.175.3.765; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CLARKE GR, 1994, EUR J IMMUNOL, V24, P837, DOI 10.1002/eji.1830240410; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; KARJALAINEN K, 1994, CURR OPIN IMMUNOL, V6, P9, DOI 10.1016/0952-7915(94)90027-2; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LUTON F, 1994, J IMMUNOL, V153, P63; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; PADOVAN E, 1995, J EXP MED, V181, P1587, DOI 10.1084/jem.181.4.1587; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; VOGT RF, 1989, CYTOMETRY, V10, P294, DOI 10.1002/cyto.990100308; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WILLIAMS AF, 1992, NATURE, V356, P746, DOI 10.1038/356746a0	25	970	988	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					148	151		10.1038/375148a0	http://dx.doi.org/10.1038/375148a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753171				2022-12-24	WOS:A1995QX74100052
J	TILZEY, AJ				TILZEY, AJ			HEPATITIS-B VACCINE BOOSTING - THE DEBATE CONTINUES	LANCET			English	Editorial Material							IMMUNOGENICITY; EFFICACY				TILZEY, AJ (corresponding author), ST THOMAS HOSP,GUYS & ST THOMAS HOSP TRUST,DEPT VIROL,LONDON,ENGLAND.							GESEMANN M, 1995, LANCET, V345, P395, DOI 10.1016/S0140-6736(95)90387-9; GILKS WR, 1995, LANCET, V345, P395; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; MARGOLIS HS, 1993, J INFECT DIS, V168, P9, DOI 10.1093/infdis/168.1.9; TILZEY AJ, 1994, LANCET, V344, P1438, DOI 10.1016/S0140-6736(94)90609-2; VANHATTUM J, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P774; VENTO S, 1989, LANCET, V1, P332; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; 1992, IMMUNISATION INFECTI; 1991, MMWR-MORBID MORTAL W, V40, P1; 1993, PROTECTING HLTH CARE	11	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1000	1001		10.1016/S0140-6736(95)90751-3	http://dx.doi.org/10.1016/S0140-6736(95)90751-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723493				2022-12-24	WOS:A1995QU57300003
J	THOMAS, PM; COTE, GJ; WOHLLK, N; HADDAD, B; MATHEW, PM; RABL, W; AGUILARBRYAN, L; GAGEL, RF; BRYAN, J				THOMAS, PM; COTE, GJ; WOHLLK, N; HADDAD, B; MATHEW, PM; RABL, W; AGUILARBRYAN, L; GAGEL, RF; BRYAN, J			MUTATIONS IN THE SULFONYLUREA RECEPTOR GENE IN FAMILIAL PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY	SCIENCE			English	Article							CYSTIC-FIBROSIS; POLYMORPHISM; CHANNELS; LINKAGE; MAP; DNA	Familial persistent hyperinsulinemic hypoglycemia of infancy (PHHI), an autosomal recessive disorder characterized by unregulated insulin secretion, is linked to chromosome 11p14-15.1. The newly cloned high-affinity sulfonylurea receptor (SUR) gene, a regulator of insulin secretion, was mapped to 11p15.1 by means of fluorescence in situ hybridization, Two separate SUR gene splice site mutations, which segregated with disease phenotype, were identified in affected individuals from nine different families, Both mutations resulted in aberrant processing of the RNA sequence and disruption of the putative second nucleotide binding domain of the SUR protein. Abnormal insulin secretion in PHHI appears to be caused by mutations in the SUR gene.	BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; ARAMCO,DHAHRAN HLTH CTR,DIV SPECIALTY PEDIAT,DHAHRAN 31311,SAUDI ARABIA; TECH UNIV MUNICH,KINDERKLIN,D-80804 MUNICH,GERMANY; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine; Saudi Aramco; Technical University of Munich; Baylor College of Medicine; Baylor College of Medicine	THOMAS, PM (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED SPECIALTIES,ENDOCRINOL SECT,BOX 15,HOUSTON,TX 77030, USA.			Wohllk, Nelson/0000-0002-7354-6894	NIDDK NIH HHS [DK44311, DK38146] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044311, R01DK038146] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1992, J BIOL CHEM, V267, P14934; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, pCH6; AYNSLEYGREEN A, 1981, ARCH DIS CHILD, V56, P496, DOI 10.1136/adc.56.7.496; GLASER B, 1994, NAT GENET, V7, P185, DOI 10.1038/ng0694-185; GRANDCHAMP B, 1989, NUCLEIC ACIDS RES, V17, P6637, DOI 10.1093/nar/17.16.6637; HIGASHI Y, 1988, P NATL ACAD SCI USA, V85, P7486, DOI 10.1073/pnas.85.20.7486; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KAISER N, 1990, DIABETOLOGIA, V33, P482, DOI 10.1007/BF00405110; KHAN RN, 1993, P ROY SOC B-BIOL SCI, V253, P225, DOI 10.1098/rspb.1993.0107; KHORANA S, 1994, NUCLEIC ACIDS RES, V22, P3425, DOI 10.1093/nar/22.16.3425; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LOU H, 1994, MOL ENDOCRINOL, V8, P1618, DOI 10.1210/me.8.12.1618; MATHEW PM, 1988, CLIN PEDIATR, V27, P148, DOI 10.1177/000992288802700307; MATSUTANI A, 1992, GENOMICS, V12, P319, DOI 10.1016/0888-7543(92)90380-B; MATSUTANI A, 1992, GENOMICS, V13, P495, DOI 10.1016/0888-7543(92)90116-A; PANTEN U, 1992, HORM METAB RES, V24, P549, DOI 10.1055/s-2007-1003387; SATOKATA I, 1990, P NATL ACAD SCI USA, V87, P9908, DOI 10.1073/pnas.87.24.9908; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; STOFFEL M, 1993, DIABETES, V42, P1215, DOI 10.2337/diabetes.42.8.1215; TAKAHASHI R, 1994, NAT GENET, V7, P79, DOI 10.1038/ng0594-79; THOMAS P, UNPUB; THOMAS PM, 1995, AM J HUM GENET, V56, P416; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WEIL D, 1989, J BIOL CHEM, V264, P16804	28	653	678	0	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					426	429		10.1126/science.7716548	http://dx.doi.org/10.1126/science.7716548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716548				2022-12-24	WOS:A1995QU57200043
J	ANTSON, AA; OTRIDGE, J; BRZOZOWSKI, AM; DODSON, EJ; DODSON, GG; WILSON, KS; SMITH, TM; YANG, M; KURECKI, T; GOLLNICK, P				ANTSON, AA; OTRIDGE, J; BRZOZOWSKI, AM; DODSON, EJ; DODSON, GG; WILSON, KS; SMITH, TM; YANG, M; KURECKI, T; GOLLNICK, P			THE STRUCTURE OF TRP RNA-BINDING ATTENUATION PROTEIN	NATURE			English	Article							BACILLUS-SUBTILIS; TRANSCRIPTION ATTENUATION; ESCHERICHIA-COLI; OPERON; EXPRESSION; GENE; ANTITERMINATION; PROGRAM	The crystal structure of the trp RNA-binding attenuation protein of Bacillus subtilis solved at 1.8 Angstrom resolution reveals a novel structural arrangement in which the eleven subunits are stabilized through eleven intersubunit beta-sheets to form a beta-wheel with a large central hole. The nature of the binding of L-tryptophan in clefts between adjacent beta-sheets in the beta-wheel suggests that this binding induces conformational changes in the flexible residues 25-33 and 49-52. It is argued that upon binding, the messenger RNA target forms a matching circle in which eleven U/GAG repeats are bound to the surface of the protein ondecamer modified by the binding of L-tryptophan.	SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260; DESY,EUROPEAN MOLEC BIOL LAB,D-22603 HAMBURG,GERMANY	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	ANTSON, AA (corresponding author), UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Antson, Alfred/N-2551-2016	Antson, Alfred/0000-0002-4533-3816; Wilson, Keith/0000-0002-3581-2194				AMZEL LM, 1979, JA REV BIOCH, V48, P967; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ANTSON AA, 1994, J MOL BIOL, V243, P1; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; HOFFMAN RJ, 1995, J BACTERIOL, V177, P839, DOI 10.1128/jb.177.3.839-842.1995; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JOZWIK CE, 1992, P NATL ACAD SCI USA, V89, P5053, DOI 10.1073/pnas.89.11.5053; KLEYWEGT GJ, 1994, FIRST MAP FINAL MODE, P59; KONG XP, 1993, CELL, V69, P425; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUODA MI, 1988, J BACTERIOL, V170, P3080; KURODA MI, 1986, J BACTERIOL, V167, P792, DOI 10.1128/jb.167.3.792-798.1986; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OLDFIELD TJ, 1992, J MOL GRAPHICS, V10, P247, DOI 10.1016/0263-7855(92)80077-Q; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SHEVITZ RW, 1985, NATURE, V317, P782; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; TURNER RJ, 1994, J BACTERIOL, V176, P7211; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; [No title captured]	38	177	184	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					693	700		10.1038/374693a0	http://dx.doi.org/10.1038/374693a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715723				2022-12-24	WOS:A1995QU30400041
J	CLARK, AL; COATS, AJS				CLARK, AL; COATS, AJS			SEVERITY OF HEART-FAILURE AND DOSAGE OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS	BRITISH MEDICAL JOURNAL			English	Article											CLARK, AL (corresponding author), NATL HEART & LUNG INST,DEPT CARDIAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.		Coats, Andrew J Stewart/E-4451-2012	Coats, Andrew J Stewart/0000-0002-2771-4260				[Anonymous], 1993, LANCET, V342, P821; Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, 1994, LANCET, V343, P1115; KLEBER FX, 1992, BRIT HEART J, V67, P289; MCMURRAY J, 1993, BR J MED EC, V6, P99; 1991, NEW ENGL J MED, V352, P293	5	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					973	974		10.1136/bmj.310.6985.973	http://dx.doi.org/10.1136/bmj.310.6985.973			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728033	Green Published			2022-12-24	WOS:A1995QT90400020
J	GERBER, HP; HAGMANN, M; SEIPEL, K; GEORGIEV, O; WEST, MAL; LITINGTUNG, Y; SCHAFFNER, W; CORDEN, JL				GERBER, HP; HAGMANN, M; SEIPEL, K; GEORGIEV, O; WEST, MAL; LITINGTUNG, Y; SCHAFFNER, W; CORDEN, JL			RNA-POLYMERASE-II C-TERMINAL DOMAIN REQUIRED FOR ENHANCER-DRIVEN TRANSCRIPTION	NATURE			English	Article							LARGEST SUBUNIT; STIMULATES TRANSCRIPTION; PROMOTER; ACTIVATION; EXPRESSION; REPEAT; CELLS; GENE; PROTEIN; INVITRO	THE RNA polymerase II carboxy-terminal domain (CTD) consists of tandem repeats of the sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser(1-3). The CTD may participate in activated transcription through interaction with a high-molecular-weight mediator complex(4-6). Such a role would be consistent with observations that some genes are preferentially sensitive to CTD mutations(7,8). Here we investigate the function of the mouse RNA polymerase CTD in enhancer-driven transcription. Transcription by alpha-amanitin-resistant CTD-deletion mutants was tested by transient transfection of tissue culture cells in the presence of alpha-amanitin in order to inhibit endogenous RNA polymerase II. Removal of most of the CTD abolishes transcriptional activation by all enhancers tested, whereas transcription from promoters driven by Sp1, a factor that typically activates housekeeping genes from positions proximal to the initiation sites, is not affected. These findings show that the CTD is essential in mediating 'enhancer'-type activation of mammalian transcription.	UNIV CALIF DAVIS,DIV BIOL SCI,PLANT BIOL SECT,DAVIS,CA 95616; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	University of California System; University of California Davis; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	GERBER, HP (corresponding author), UNIV ZURICH,INST MOLEK BIOL 2,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.			Seipel, Katja/0000-0003-3128-1573				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BARTOLOMEI MS, 1987, MOL CELL BIOL, V7, P586, DOI 10.1128/MCB.7.2.586; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; CORDEN JL, 1992, TRANSCRIPTIONAL REGU, P81; GERBER HP, 1992, NUCLEIC ACIDS RES, V20, P5855, DOI 10.1093/nar/20.21.5855; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GUARENTE L, 1984, CELL, V36, P799, DOI 10.1016/0092-8674(84)90028-X; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MULLER HP, 1989, CELL, V58, P767, DOI 10.1016/0092-8674(89)90110-4; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WIELAND S, 1990, ACTIVATION HORMONE G, P215; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351	28	142	144	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					660	662		10.1038/374660a0	http://dx.doi.org/10.1038/374660a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715709				2022-12-24	WOS:A1995QT18900065
J	TOHTONG, R; YAMASHITA, H; GRAHAM, M; HAEBERLE, J; SIMCOX, A; MAUGHAN, D				TOHTONG, R; YAMASHITA, H; GRAHAM, M; HAEBERLE, J; SIMCOX, A; MAUGHAN, D			IMPAIRMENT OF MUSCLE FUNCTION CAUSED BY MUTATIONS OF PHOSPHORYLATION SITES IN MYOSIN REGULATORY LIGHT-CHAIN	NATURE			English	Article							RABBIT SKELETAL-MUSCLE; INDIRECT FLIGHT-MUSCLE; DROSOPHILA-MELANOGASTER; STRETCH-ACTIVATION; STRIATED-MUSCLE; CROSS-BRIDGES; INSECT; KINETICS; FIBERS; MECHANISM	MYOSIN regulatory light chain is phosphorylated by myosin light chain kinase at conserved serine and threonine residues in a number of species(1). Phosphorylation of myosin regulatory light chain regulates smooth muscle contraction, but appears to have a modulatory role in striated muscle contraction(2). We assessed the in vivo role of myosin regulatory light chain phosphorylation in the striated muscles of Drosophila melanogaster by substituting alanine at each or both conserved myosin light chain kinase-dependent phosphorylation sites, serine 66 and serine 67. We report here that myosin light chain kinase-dependent phosphorylation is not required for myofibrillogenesis or for the development of maximal isometric force in Indirect flight muscles. However, mutants with substitutions at the major phosphorylation site (serine 66) or with the double substitutions had reduced power output in isolated flight muscle fibres and reduced flight ability, showing that myosin regulatory light chain phosphorylation is a key determinant of the stretch activation response in Drosophila.	OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH; UNIV VERMONT,DEPT MOLEC PHYSIOL & BIOPHYS,BURLINGTON,VT 05405	University System of Ohio; Ohio State University; University of Vermont								ABBOTT RH, 1984, J MUSCLE RES CELL M, V5, P387, DOI 10.1007/BF00818257; BERNSTEIN SI, 1993, INT REV CYTOL, V143, P63; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; DRUMMOND DR, 1991, MOL GEN GENET, V226, P70, DOI 10.1007/BF00273589; GRANZIER HLM, 1993, J GEN PHYSIOL, V101, P235, DOI 10.1085/jgp.101.2.235; GUTH K, 1981, BIOPHYS STRUCT MECH, V7, P139, DOI 10.1007/BF00539176; HYATT CJ, 1994, BIOPHYS J, V67, P1149, DOI 10.1016/S0006-3495(94)80582-X; JEWELL BR, 1966, PROC R SOC SER B-BIO, V164, P428, DOI 10.1098/rspb.1966.0042; Kawai M, 1980, J Muscle Res Cell Motil, V1, P279, DOI 10.1007/BF00711932; LAURIEAHLBERG CC, 1985, GENETICS, V111, P845; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; MOLLOY J, 1993, MECH MYOFILAMENT SLI, P165; PECKHAM M, 1992, J EXP BIOL, V168, P57; PECKHAM M, 1990, J MUSCLE RES CELL M, V11, P203, DOI 10.1007/BF01843574; PERSECHINI A, 1985, J BIOL CHEM, V260, P7951; PRINGLE JWS, 1978, PROC R SOC SER B-BIO, V201, P107, DOI 10.1098/rspb.1978.0035; REEDY MC, 1994, J MOL BIOL, V239, P52, DOI 10.1006/jmbi.1994.1350; SQUIRE JM, 1992, J MUSCLE RES CELL M, V13, P183, DOI 10.1007/BF01874155; Steiger G.J., 1977, P221; SWEENEY HL, 1986, AM J PHYSIOL, V250, pC657, DOI 10.1152/ajpcell.1986.250.4.C657; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P414, DOI 10.1073/pnas.87.1.414; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; TAKAHASHI S, 1987, ZOOL SCI, V4, P833; TAKAHASHI S, 1990, COMP BIOCHEM PHYS B, V95, P179, DOI 10.1016/0305-0491(90)90267-W; TAWADA K, 1990, BIOPHYS J, V57, P643, DOI 10.1016/S0006-3495(90)82582-0; THORSON J, 1983, J PHYSIOL-LONDON, V343, P59, DOI 10.1113/jphysiol.1983.sp014881; THORSON J, 1969, BIOPHYS J, V9, P360, DOI 10.1016/S0006-3495(69)86392-7; WARMKE J, 1992, J CELL BIOL, V119, P1523, DOI 10.1083/jcb.119.6.1523; WRAY JS, 1979, NATURE, V280, P325, DOI 10.1038/280325a0	30	112	114	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					650	653		10.1038/374650a0	http://dx.doi.org/10.1038/374650a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715706				2022-12-24	WOS:A1995QT18900062
J	BARBER, N				BARBER, N			WHAT CONSTITUTES GOOD PRESCRIBING	BRITISH MEDICAL JOURNAL			English	Article							DRUG	Drugs are the mainstay of medical treatment, yet there are few reports on what constitutes ''good prescribing.'' What is more, the existing guidance tends to imply that right answers exist, rather than recognising the complex trade offs that have to be made between conflicting aims. This paper proposes four aims that a prescriber should try to achieve, both on first prescribing a drug and on subsequently monitoring it. They are: to maximise effectiveness, minimise risks, minimise costs, and respect the patient's choices. This model of good prescribing brings together the traditional balancing of risks and benefits with the need to reduce costs and the right of the patient to make choices in treatment. The four aims are shown as a diagram plotting their commonest conflicts, which may be used as an aid to discussion and decision making.			BARBER, N (corresponding author), UNIV LONDON,SCH PHARM,29-39 BRUNSWICK SQ,LONDON WC1N 1AX,ENGLAND.							Barber N., 1991, PHARM J, V246, P671; BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; FINNEY DJ, 1965, J CHRON DIS, V18, P77, DOI 10.1016/0021-9681(65)90054-8; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; PARISH PA, 1973, J ROY SOC HEALTH, V4, P213; SCHWARTZ RK, 1989, SOC SCI MED, V28, P577, DOI 10.1016/0277-9536(89)90252-9; 1992, RISK ANAL PERCEPTION, P2	7	78	81	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					923	925		10.1136/bmj.310.6984.923	http://dx.doi.org/10.1136/bmj.310.6984.923			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719188	Green Published			2022-12-24	WOS:A1995QR97200032
J	ZHANG, XK; BLENIS, J; LI, HC; SCHINDLER, C; CHENKIANG, S				ZHANG, XK; BLENIS, J; LI, HC; SCHINDLER, C; CHENKIANG, S			REQUIREMENT OF SERINE PHOSPHORYLATION FOR FORMATION OF STAT-PROMOTER COMPLEXES	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; GROWTH-FACTOR; PROTEIN-PHOSPHORYLATION; INTERFERON-GAMMA; IFN-GAMMA; BINDING; GENE; INTERLEUKIN-6; ACTIVATION	Members of the interleukin-6 family of cytokines bind to and activate receptors that contain a common subunit, gp130. This leads to the activation of Stat3 and Stat1, two cytoplasmic signal transducers and activators of transcription (STATs), by tyrosine phosphorylation. Serine phosphorylation of Stat3 was constitutive and was enhanced by signaling through gp130. In cells of lymphoid and neuronal origins, inhibition of serine phosphorylation prevented the formation of complexes of DNA with Stat3-Stat3 but not with Stat3-Stat1 or Stat1-Stat1 dimers. In vitro serine dephosphorylation of Stat3 also inhibited DNA binding of Stat3-Stat3. The requirement of serine phosphorylation for Stat3-Stat3.DNA complex formation was inversely correlated with the affinity of Stat3-Stat3 for the binding site. Thus, serine phosphorylation appears to enhance or to be required for the formation of stable Stat3-Stat3 DNA complexes.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard Medical School; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University					NATIONAL CANCER INSTITUTE [R01CA046595, R37CA046595] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER; NCI NIH HHS [CA46595] Funding Source: Medline; NHLBI NIH HHS [HL 21006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HSU W, 1993, MOL CELL BIOL, V13, P2515, DOI 10.1128/MCB.13.4.2515; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LI HC, 1981, ARCH BIOCHEM BIOPHYS, V207, P270, DOI 10.1016/0003-9861(81)90034-5; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P4371; NATKUNAM Y, 1994, J IMMUNOL, V153, P3476; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Zhang X, UNPUB; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	33	517	525	1	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1990	1994		10.1126/science.7701321	http://dx.doi.org/10.1126/science.7701321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701321				2022-12-24	WOS:A1995QQ06800043
J	RIAD, H; NICHOLLS, A				RIAD, H; NICHOLLS, A			AN ETHICAL DEBATE - ELECTIVE VENTILATION OF POTENTIAL ORGAN DONORS	BRITISH MEDICAL JOURNAL			English	Article							DONATION	Elective ventilation describes the procedure of transferring selected patients dying from rapidly progressive intracranial haemorrhage from general medical wards to intensive care units for a brief period of ventilation before confirmation of brain stem death and harvesting of organs. This approach in Exeter has led to a rate of kidney retrieval and transplant higher than has been achieved elsewhere in the United Kingdom, with a stabilisation of numbers on patients on dialysis. Recently doubt has been cast on the legality of our practice of elective ventilation on the grounds that relatives are not permitted to consent to treatment of an incompetent person when that treatment is not in the patient's best interests. We are thus faced with the dilemma of a protocol that is ethical, practical, and operates for the greater good but which may be illegal. This article explores various objections to the protocol and calls for public, medical, and legal debate on the issues.	UNIV BRISTOL,BRISTOL ROYAL INFIRM,INTENS THERAPY UNIT,BRISTOL BS2 8HW,AVON,ENGLAND; ROYAL LIVERPOOL UNIV HOSP,RENAL TRANSPLANT UNIT,LIVERPOOL,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,FAC LAW,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; THREE SERJEANTS INN,LONDON EC4Y 1BQ,ENGLAND	Bristol Royal Infirmary; University of Bristol; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of Liverpool	RIAD, H (corresponding author), ROYAL DEVON & EXETER HOSP,EXETER EX2 5DW,DEVON,ENGLAND.		Sano, Michael/E-1715-2011					COLLINS CH, 1992, CARE CRITICALLY ILL, V8, P57; Conference of Medical Royal Colleges and their Faculties in the UK, 1979, LANCET, Vi, P261; FEEST TG, 1990, LANCET, V335, P1133, DOI 10.1016/0140-6736(90)91134-V; NEW B, 1994, 18 KINGS FUND I RES; NICHOLLS A, 1994, BRIT J HOSP MED, V51, P555; NICHOLLS A, 1993, BRIT MED J, V306, P517, DOI 10.1136/bmj.306.6876.517-d; NIELSEN MS, 1994, J ROY COLL PHYS LOND, V28, P85; RIAD H, 1994, BRIT J HOSP MED, V51, P555; RIAD H, 1993, BRIT J HOSP MED, V50, P438; ROBSON JG, 1981, LANCET, V2, P365; ROBSON JG, 1981, BMJ-BRIT MED J, V283, P505, DOI 10.1136/bmj.283.6289.505-a; Routh G, 1992, CARE CRIT ILL, V8, P60; SOMMERVILLE A, 1993, MED ETHICS TODAY ITS; WILLATTS SM, 1994, BRIT J HOSP MED, V51, P554; WILLIAMS R, 1993, J ROY COLL PHYS LOND, V27, P214; 1983, CADAVERIC ORGANS TRA; 1979, BRIT MED J, V1, P332; 1993, ISSUES NURSING SOC, V19	18	38	38	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					714	715		10.1136/bmj.310.6981.714	http://dx.doi.org/10.1136/bmj.310.6981.714			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711541	Green Published			2022-12-24	WOS:A1995QN46100024
J	WYLLIE, HR; DUNN, FG				WYLLIE, HR; DUNN, FG			PREHOSPITAL OPIATE AND ASPIRIN ADMINISTRATION IN PATIENTS WITH SUSPECTED MYOCARDIAL-INFARCTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article									STOBHILL GEN HOSP, DEPT CARDIAC, GLASGOW G21 3UW, SCOTLAND									ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; FORD JL, 1988, TXB PHARM SCI DOSAGE, P362; WILLARD JE, 1992, NEW ENGL J MED, V327, P175; YOUNG LY, 1992, TXB APPLIED THERAPEU, V3, P9	5	16	16	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	1994	308	6931					760	761		10.1136/bmj.308.6931.760a	http://dx.doi.org/10.1136/bmj.308.6931.760a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	7695672	Green Published			2022-12-24	WOS:A1994NC34800021
J	KAUFMAN, DL; CLARESALZLER, M; TIAN, JD; FORSTHUBER, T; TING, GSP; ROBINSON, P; ATKINSON, MA; SERCARZ, EE; TOBIN, AJ; LEHMANN, PV				KAUFMAN, DL; CLARESALZLER, M; TIAN, JD; FORSTHUBER, T; TING, GSP; ROBINSON, P; ATKINSON, MA; SERCARZ, EE; TOBIN, AJ; LEHMANN, PV			SPONTANEOUS LOSS OF T-CELL TOLERANCE TO GLUTAMIC-ACID DECARBOXYLASE IN MURINE INSULIN-DEPENDENT DIABETES	NATURE			English	Article							HEAT-SHOCK PROTEIN; AUTOANTIGEN; MOUSE; GAMMA; CD4+; ENCEPHALOMYELITIS; AUTOANTIBODIES; IDENTIFICATION; AUTOIMMUNITY; INDUCTION	INSULIN-DEPENDENT diabetes mellitus (IDDM) in non-obese diabetic (NOD) mice results from the T-lymphocyte-mediated destruction of the insulin-producing pancreatic beta-cells and serves as a model for human IDDM1. Whereas a number of autoantibodies are associated with IDDM2, it is unclear when and to what beta-cell antigens pathogenic T cells become activated during the disease process. We report here that a T-helper-1 (Th1) response to glutamate decarboxylase develops in NOD mice at the same time as the onset of insulitis. This response is initially limited to a confined region of glutamate decarboxylase, but later spreads intramolecularly to additional determinants. Subsequently, T-cell reactivity arises to other beta-cell antigens, consistent with intermolecular diversification of the response. Prevention of the spontaneous anti-glutamate decarboxylase response, by tolerization of glutamate decarboxylase-reactive T cells, blocks the development of T-cell autoimmunity to other beta-cell antigens, as well as insulitis and diabetes. Our data suggest that (1) glutamate decarboxylase is a key target antigen in the induction of murine IDDM; (2) autoimmunity to glutamate decarboxylase triggers T-cell responses to other beta-cell antigens, and (3) spontaneous autoimmune disease can be prevented by tolerization to the initiating target antigen.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,BRAIN RES INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV FLORIDA,COLL MED,DEPT PATHOL & LAB MED,GAINESVILLE,FL 32610	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; State University System of Florida; University of Florida	KAUFMAN, DL (corresponding author), UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024, USA.		Kaufman, Daniel/AAU-1228-2021; Forsthuber, Thomas/AID-8080-2022	Kaufman, Daniel/0000-0002-9844-5918; /0000-0003-0692-7125	NINDS NIH HHS [R01 NS022256] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BRADLEY LM, 1992, J IMMUNOL, V148, P324; BU DF, 1992, P NATL ACAD SCI USA, V89, P2115, DOI 10.1073/pnas.89.6.2115; CASTANO L, 1991, J CLIN ENDOCR METAB, V73, P1197, DOI 10.1210/jcem-73-6-1197; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CROFT M, 1992, J EXP MED, V176, P1431, DOI 10.1084/jem.176.5.1431; ELIAS D, 1991, P NATL ACAD SCI USA, V88, P3088, DOI 10.1073/pnas.88.8.3088; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GAMMON G, 1989, NATURE, V342, P183, DOI 10.1038/342183a0; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; KAUFMAN DL, 1986, SCIENCE, V232, P1138, DOI 10.1126/science.3518061; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; KAUFMAN DL, 1993, TRENDS PHARMACOL SCI, V14, P107, DOI 10.1016/0165-6147(93)90079-Y; LEE DS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P157, DOI 10.1016/0167-4781(93)90056-J; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; LEHMANN PV, 1993, IMMUNOL TODAY, V14, P203, DOI 10.1016/0167-5699(93)90163-F; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; PALMER JP, 1993, DIABETES REV, V1, P104; QIN HY, 1993, J IMMUNOL, V150, P2072; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; TAGUCHI T, 1990, J IMMUNOL, V145, P68; WATANABE R, 1983, NATURE, V305, P150, DOI 10.1038/305150a0; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	29	1039	1080	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					69	72		10.1038/366069a0	http://dx.doi.org/10.1038/366069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	7694152	Green Accepted			2022-12-24	WOS:A1993MF00700056
J	EGELHOFF, TT; LEE, RJ; SPUDICH, JA				EGELHOFF, TT; LEE, RJ; SPUDICH, JA			DICTYOSTELIUM MYOSIN HEAVY-CHAIN PHOSPHORYLATION SITES REGULATE MYOSIN FILAMENT ASSEMBLY AND LOCALIZATION IN-VIVO	CELL			English	Article							PROTEIN-KINASE-C; NULL MUTANTS; CYCLIC-GMP; DISCOIDEUM; CELLS; CYTOSKELETON; PURIFICATION; TAIL; GENE; COMPLEMENTATION	Three threonine residues in the tall region of Dictyostelium myosin II heavy chain have been implicated previously in control of myosin filament formation. Here we report the in vitro and in vivo consequences of converting these sites to alanine residues, which eliminates phosphorylation at these positions, or to aspartate residues, which mimics the negative charge state of the phosphorylated molecule. Alanine substitution allows in vitro assembly and in vivo contractile activity, although this myosin shows substantial over-assembly in vivo. Aspartate substitution eliminates filament assembly in vitro and renders the myosin unable to drive any tested contractile event in vivo. These results demonstrate that heavy chain phosphorylation plays a key modulatory role in controlling myosin function in vivo.	STANFORD UNIV, MED CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA	Stanford University					NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K11AR001829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046551, R37GM046551] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09151] Funding Source: Medline; NIAMS NIH HHS [AR01829] Funding Source: Medline; NIGMS NIH HHS [GM46551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1987, J BIOL CHEM, V262, P3918; CLARKE M, 1974, J MOL BIOL, V86, P209, DOI 10.1016/0022-2836(74)90013-8; COLLINS JH, 1982, BIOCHEMISTRY-US, V21, P6910, DOI 10.1021/bi00269a045; COTE GP, 1987, J BIOL CHEM, V262, P1065; COTE GP, 1987, J BIOL CHEM, V262, P13033; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EGELHOFF TT, 1990, DEV BIOL, V137, P359, DOI 10.1016/0012-1606(90)90260-P; EGELHOFF TT, 1989, MOL CELL BIOL, V9, P1965, DOI 10.1128/MCB.9.5.1965; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; GIULIANO KA, 1992, MOL BIOL CELL, V3, P1037, DOI 10.1091/mbc.3.9.1037; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUBALEK EW, 1992, MOL BIOL CELL, V3, P1455, DOI 10.1091/mbc.3.12.1455; KUCZMARSKI ER, 1987, J CELL BIOL, V105, P2989, DOI 10.1083/jcb.105.6.2989; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; LIU G, 1988, J CELL SCI, V90, P123; LIU G, 1991, J CELL SCI, V98, P483; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MALCHOW D, 1981, EUR J BIOCHEM, V17, P213; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MARUTA H, 1983, EMBO J, V2, P535, DOI 10.1002/j.1460-2075.1983.tb01459.x; OLIVER JM, 1988, PROG ALLERGY, V42, P185; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; PELTZ G, 1985, J CELL BIOL, V100, P1016, DOI 10.1083/jcb.100.4.1016; RAHMSDORF HJ, 1978, FEBS LETT, V88, P322, DOI 10.1016/0014-5793(78)80203-8; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; RAVID S, 1989, J BIOL CHEM, V264, P15144; RUPPEL KM, 1990, ANN NY ACAD SCI, V582, P147; Sambrook J., 1989, MOL CLONING LAB MANU; SPUDICH A, 1987, METHOD CELL BIOL, V28, P209; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TRUONG T, 1992, J BIOL CHEM, V267, P9767; VAILLANCOURT JP, 1988, J BIOL CHEM, V263, P10082; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002	42	241	244	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					363	371		10.1016/0092-8674(93)80077-R	http://dx.doi.org/10.1016/0092-8674(93)80077-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	7691416				2022-12-24	WOS:A1993MD88500017
J	COLDITZ, GA; HANKINSON, SE; HUNTER, DJ; WILLETT, WC; MANSON, JE; STAMPFER, MJ; HENNEKENS, C; ROSNER, B; SPEIZER, FE				COLDITZ, GA; HANKINSON, SE; HUNTER, DJ; WILLETT, WC; MANSON, JE; STAMPFER, MJ; HENNEKENS, C; ROSNER, B; SPEIZER, FE			THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST-CANCER IN POSTMENOPAUSAL WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; SEX-HORMONES; MORTALITY; WEIGHT; EPIDEMIOLOGY; PROGESTOGENS; SURVEILLANCE; HEIGHT	Background. The effect of adding progestins to estrogen therapy on the risk of breast cancer in postmenopausal women is controversial. Methods. To quantify the relation between the use of hormones and the risk of breast cancer in postmenopausal women, we extended our follow-up of the participants in the Nurses' Health Study to 1992. The women were asked to complete questionnaires every two years to update information on their menopausal status, use of estrogen and progestin preparations, and any diagnosis of breast cancer. During 725,550 person-years of follow-up, we documented 1935 cases of newly diagnosed invasive breastcancer. Results. The risk of breast cancer was significantly increased among women who were currently using estrogen alone (relative risk, 1.32; 95 percent confidence interval, 1.14 to 1.54) or estrogen plus progestin (relative risk, 1.41; 95 percent confidence interval, 1.15 to 1.74), as compared with postmenopausal women who had never used hormones. Women currently taking hormones who had used such therapy for 5 to 9 years had an adjusted relative risk of breast cancer of 1.46 (95 percent confidence interval, 1.22 to 1.74), as did those currently using hormones who had done so for a total of 10 or more years (relative risk, 1.46; 95 percent confidence interval, 1.20 to 1.76). The increased risk of breast cancer associated with five or more years of postmenopausal hormone therapy was greater among older women (relative risk for women 60 to 64 years old, 1.71; 95 percent confidence interval, 1.34 to 2.18). The relative risk of death due to breast cancer was 1.45 (95 percent confidence interval, 1.01 to 2.09) among women who had taken estrogen for five or more years. Conclusions. The addition of progestins to estrogen therapy does not reduce the risk of breast cancer among postmenopausal women, The substantial increase in the risk of breast cancer among older women who take hormones suggests that the trade-offs between risks and benefits should be carefully assessed.	BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	COLDITZ, GA (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40956] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; COLDITZ GA, 1993, AM J OBSTET GYNECOL, V168, P1473, DOI 10.1016/S0002-9378(11)90784-4; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COX DR, 1972, J R STAT SOC B, V34, P187; ETTINGER B, 1993, NEW ENGL J MED, V329, P1192, DOI 10.1056/NEJM199310143291610; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FEINLEIB M, 1968, JNCI-J NATL CANCER I, V41, P315; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JURGENS RW, 1992, AM J OBSTET GYNECOL, V167, P459, DOI 10.1016/S0002-9378(11)91429-X; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LILIENFELD AM, 1956, CANCER, V9, P927, DOI 10.1002/1097-0142(195609/10)9:5<927::AID-CNCR2820090510>3.0.CO;2-3; LONDON SJ, 1989, JAMA-J AM MED ASSOC, V262, P2853; MORRISON AS, 1979, AM J EPIDEMIOL, V109, P709, DOI 10.1093/oxfordjournals.aje.a112734; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; ROSE DP, 1977, OBSTET GYNECOL, V49, P80; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STANFORD JL, 1993, EPIDEMIOL REV, V15, P98, DOI 10.1093/oxfordjournals.epirev.a036120; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; WHITEHEAD MI, 1978, MATURITAS, V1, P87, DOI 10.1016/0378-5122(78)90015-4; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P2438; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360; 1991, ORAL CONTRACEPTIVES	33	1283	1328	1	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1589	1593		10.1056/NEJM199506153322401	http://dx.doi.org/10.1056/NEJM199506153322401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753136				2022-12-24	WOS:A1995RC19200001
J	WESSELY, S; CHALDER, T; HIRSCH, S; PAWLIKOWSKA, T; WALLACE, P; WRIGHT, DJM				WESSELY, S; CHALDER, T; HIRSCH, S; PAWLIKOWSKA, T; WALLACE, P; WRIGHT, DJM			POSTINFECTIOUS FATIGUE - PROSPECTIVE COHORT STUDY IN PRIMARY-CARE	LANCET			English	Article							POSTVIRAL FATIGUE; VIRUS; POPULATION; SYMPTOMS; ANTIBODY; SIGNS	The idea that chronic fatigue has an infectious origin has become popular, but the main evidence for such an association has come from retrospective case-control studies, which are subject to ascertainment bias. We report a prospective study of the outcome of clinically diagnosed infections in patients presenting to UK general practitioners. Questionnaires assessing fatigue and psychiatric morbidity were sent to all patients aged 18-45 years in the study practices. The prevalence of chronic fatigue and chronic fatigue syndrome was then ascertained among 1199 people aged 18-45 who presented to the general practitioners with symptomatic infections and in 1167 people who attended the surgeries for other reasons, 84% were followed up at 6 months. 9.9% of cases and 11.7% of controls reported chronic fatigue (odds ratio 1.0 [95% CI 0.6-1.1]). There were no differences in the proportions who met various criteria for chronic fatigue syndrome. No effect of infection was noted when we excluded subjects who reported fatigue or psychological morbidity at the baseline screening. The strongest independent predictors of postinfectious fatigue were fatigue assessed before presentation with clinical infection (3.0 [1.9-4.7]) and psychological distress before presentation (1.8 [1.2-2.9]) and at presentation with the acute infection (1.8 [1.1-2.8]). There was no effect of sex or social class. Our study shows no evidence that common infective episodes in primary care are related to the onset of chronic fatigue or chronic fatigue syndrome.	INST PSYCHIAT,DEPT PSYCHOL MED,LONDON SE5 8AF,ENGLAND; CHARING CROSS HOSP,SCH MED,DEPT PSYCHIAT,LONDON,ENGLAND; CHARING CROSS HOSP,SCH MED,DEPT MED MICROBIOL,LONDON,ENGLAND; THE SURGERY,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE,LONDON,ENGLAND	University of London; King's College London; Imperial College London; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	WESSELY, S (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT PSYCHOL MED,DENMARK HILL,LONDON SE5 9RS,ENGLAND.		Wessely, Simon C/A-8713-2008; Chalder, Trudie/A-5717-2011	Chalder, Trudie/0000-0003-0775-1045; Wessely, Simon Charles/0000-0002-6743-9929				BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; BUTLER S, 1961, J NEUROL NEUROSUR PS, V54, P153; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; CHALDER T, 1990, THESIS CITY U LONDON; COPE H, 1994, LANCET, V344, P864, DOI 10.1016/S0140-6736(94)92833-9; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Goldberg DP., 1972, DETECTION PSYCHIATRI; GOLDENBERG D L, 1989, Journal of Rheumatology, V16, P91; Gore, 1987, HLTH LIFESTYLE SURVE; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; HELLINGER WC, 1988, JAMA-J AM MED ASSOC, V260, P971; Hinds G. M. E., 1993, P R COLL PHYSICIANS, V23, P10; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; IMBODEN JB, 1961, ARCH INTERN MED, V108, P393, DOI 10.1001/archinte.1961.03620090065008; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; MILLER NA, 1991, BMJ-BRIT MED J, V302, P140, DOI 10.1136/bmj.302.6769.140; POWELL R, 1990, J PSYCHOSOM RES, V34, P665, DOI 10.1016/0022-3999(90)90111-G; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; TYRRELL DAJ, 1993, EPIDEMIOL INFECT, V111, P143, DOI 10.1017/S0950268800056764; Ware J. E., 1992, MEASURING FUNCTIONIN, P277; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WESSELY S, 1991, BRIT MED BULL, V47, P919, DOI 10.1093/oxfordjournals.bmb.a072521; WHITE P, IN PRESS PSYCHOL MED; WITTENBORN J, 1979, ARCH GEN PSYCHIAT, V84, P118; [No title captured]	29	141	141	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1333	1338		10.1016/S0140-6736(95)92537-6	http://dx.doi.org/10.1016/S0140-6736(95)92537-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752755				2022-12-24	WOS:A1995RA14800008
J	KIRKWOOD, A; LEE, HK; BEAR, MF				KIRKWOOD, A; LEE, HK; BEAR, MF			COREGULATION OF LONG-TERM POTENTIATION AND EXPERIENCE-DEPENDENT SYNAPTIC PLASTICITY IN VISUAL-CORTEX BY AGE AND EXPERIENCE	NATURE			English	Article							D-ASPARTATE RECEPTORS; MONOCULAR DEPRIVATION; SLICE PREPARATION; SENSITIVE PERIOD; STRIATE CORTEX; RAT; KITTENS; SUSCEPTIBILITY; HIPPOCAMPUS; NEOCORTEX	LONG-TERM potentiation (LTP) is a lasting enhancement of excitatory synaptic transmission that follows specific patterns of electrical stimulation(1). Although the mechanism of LTP has been intensively studied, particularly in the hippocampus, its significance for normal brain function remains unproven. It has been proposed that LTP-like mechanisms may contribute to naturally occurring, experience-dependent synaptic modifications in the visual cortex(2-8). The formation of normal binocular connections within the, visual cortex: requires simultaneous input from both eyes during a postnatal critical period(9-12) that can be delayed by rearing animals in complete darkness(13,14). To explore the role of LTP in this experience-dependent maturation process, we induced LTP in visual cortical slices taken at different ages from light-reared and dark-reared rats. Susceptibility to LTP coincides with the critical period and, like the critical period, can be prolonged by rearing animals in darkness. These findings support the hypothesis that LTP reflects a normal mechanism of experience-dependent synaptic modification in the developing mammalian brain.	BROWN UNIV, INST BRAIN & NEURAL SYST, PROVIDENCE, RI 02912 USA	Brown University	KIRKWOOD, A (corresponding author), BROWN UNIV, DEPT NEUROSCI, HOWARD HUGHES MED INST, PROVIDENCE, RI 02912 USA.			Lee, Hey-Kyoung/0000-0002-5554-983X; Bear, Mark/0000-0002-9903-2541				ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BEAR MF, 1992, J NEUROPHYSIOL, V67, P1; BERRY RL, 1989, BRAIN RES, V481, P221, DOI 10.1016/0006-8993(89)90797-X; BERRY RL, 1993, BRAIN RES, V628, P99, DOI 10.1016/0006-8993(93)90943-H; BLAKEMORE C, 1974, J PHYSIOL-LONDON, V237, P195, DOI 10.1113/jphysiol.1974.sp010478; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; BODEGREUEL KM, 1989, DEV BRAIN RES, V46, P197, DOI 10.1016/0165-3806(89)90283-6; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; DOMENICI L, 1991, P NATL ACAD SCI USA, V88, P8811, DOI 10.1073/pnas.88.19.8811; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; FREGNAC Y, 1994, J NEUROPHYSIOL, V71, P1403, DOI 10.1152/jn.1994.71.4.1403; FRIAUF E, 1991, J NEUROPHYSIOL, V66, P2059, DOI 10.1152/jn.1991.66.6.2059; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; KIMURA F, 1989, J PHYSIOL-LONDON, V414, P125, DOI 10.1113/jphysiol.1989.sp017680; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; KOMATSU Y, 1981, NEUROSCI LETT, V26, P269, DOI 10.1016/0304-3940(81)90144-0; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; KOMATSU Y, 1994, J NEUROSCI, V14, P6488; KOMATSU Y, 1983, DEV BRAIN RES, V8, P136, DOI 10.1016/0165-3806(83)90165-7; LUHMANN HJ, 1990, DEV BRAIN RES, V54, P287, DOI 10.1016/0165-3806(90)90152-O; MOWER GD, 1991, DEV BRAIN RES, V58, P151, DOI 10.1016/0165-3806(91)90001-Y; OLSON CR, 1980, EXP BRAIN RES, V39, P17; PERKINS AT, 1988, BRAIN RES, V439, P222; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6	30	359	365	1	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					328	331		10.1038/375328a0	http://dx.doi.org/10.1038/375328a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753198				2022-12-24	WOS:A1995RA03000054
J	WEIS, K; MATTAJ, IW; LAMOND, AI				WEIS, K; MATTAJ, IW; LAMOND, AI			IDENTIFICATION OF HSRP1-ALPHA AS A FUNCTIONAL RECEPTOR FOR NUCLEAR-LOCALIZATION SEQUENCES	SCIENCE			English	Article							RNA-POLYMERASE-II; BINDING-PROTEIN; 2 STEPS; IMPORT; TRANSLOCATION; ENVELOPE; SIGNALS; PATHWAY; PORE	Import of proteins into the nucleus is a two-step process, involving nuclear localization sequence (NLS)-dependent docking of the substrate at the nuclear envelope followed by translocation through the nuclear pore. A recombinant human protein, hSRP1 alpha, bound in vitro specifically and directly to substrates containing either a simple or bipartite NLS motif. hSRP1 alpha promoted docking of import substrates to the nuclear envelope and together with recombinant human Ran reconstituted complete nuclear protein import. Thus, hSRP1 alpha has the properties of a cytosolic receptor for both simple and bipartite NLS motifs.	EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Weis, Karsten/F-5719-2011	Weis, Karsten/0000-0001-7224-925X; Lamond, Angus/0000-0001-6204-6045; Mattaj, Iain/0000-0002-5537-8284				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER U, 1991, EMBO J, V10, P705; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRARLDE E, UNPUB; KATAOKA N, 1994, NUCLEIC ACIDS RES, V22, P3861, DOI 10.1093/nar/22.19.3861; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAUD N, 1993, EXP CELL RES, V208, P128, DOI 10.1006/excr.1993.1230; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; WEIS K, UNPUB; Yamasaki L, 1992, Trends Cell Biol, V2, P123, DOI 10.1016/0962-8924(92)90083-Y; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YAO R, 1994, P NATL ACAD SCI USA, V91, P6880; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	36	317	325	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 19	1995	268	5213					1049	1053		10.1126/science.7754385	http://dx.doi.org/10.1126/science.7754385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754385				2022-12-24	WOS:A1995QY93400041
J	KREGE, JH; JOHN, SWM; LANGENBACH, LL; HODGIN, JB; HAGAMAN, JR; BACHMAN, ES; JENNETTE, JC; OBRIEN, DA; SMITHIES, O				KREGE, JH; JOHN, SWM; LANGENBACH, LL; HODGIN, JB; HAGAMAN, JR; BACHMAN, ES; JENNETTE, JC; OBRIEN, DA; SMITHIES, O			MALE-FEMALE DIFFERENCES IN FERTILITY AND BLOOD-PRESSURE IN ACE-DEFICIENT MICE	NATURE			English	Article							ANGIOTENSIN-CONVERTING ENZYME; ESSENTIAL-HYPERTENSION; GENE; POLYMORPHISM; MOUSE; ASSOCIATION; EXPRESSION	ANGIOTENSIN-CONVERTING enzyme (ACE) is a dipeptidyl carboxypeptidase that generates the vasoconstricting peptide angiotensin II and inactivates the vasodilating peptide bradykinin(1). The gene encoding ACE is composed of two homologous regions and codes for both a somatic and testis isoenzyme(2-4). Experiments with hypertensive rats(5,6) and some(7-9), but not other(10-13), studies of humans suggest that sequences at or linked to the gene influence blood pressure. The testis-specific form of ACE has its own promoter within intron 12 (ref, 14), is encoded by the 3' region of the gene, and is found only in postmeiotic spermatogenic cells and sperm(15). Its function is unknown(16) Here we investigate the role of the Ace gene in blood pressure control and reproduction using mice generated to carry an insertional mutation that is designed to inactivate both forms of ACE. All homozygous female mutants were found to be fertile, but the fertility of homozygous male mutants was greatly reduced. Heterozygous males but not females had blood pressures that were 15-20 mm Hg less than normal, although both male and female heterozygotes had reduced serum ACE activity.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	KREGE, JH (corresponding author), UNIV N CAROLINA,DEPT INTERNAL MED,CHAPEL HILL,NC 27599, USA.			Jennette, John Charles/0000-0002-8081-6565	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026485] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; DURU K, 1994, AM J HYPERTENS, V7, P759, DOI 10.1093/ajh/7.8.759; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5313; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; FORESTA C, 1991, INT J ANDROL, V14, P333, DOI 10.1111/j.1365-2605.1991.tb01101.x; HARRAP SB, 1993, HYPERTENSION, V21, P455, DOI 10.1161/01.HYP.21.4.455; HIGASHIMORI K, 1993, BIOCHEM BIOPH RES CO, V191, P399, DOI 10.1006/bbrc.1993.1231; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; HOLMQUIST B, 1979, ANAL BIOCHEM, V95, P540, DOI 10.1016/0003-2697(79)90769-3; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KIM HS, IN PRESS P NATN ACAD; KREGE JH, IN PRESS HYPERTENSIO; LANGFORD KG, 1993, BIOL REPROD, V48, P1210, DOI 10.1095/biolreprod48.6.1210; MORISE T, 1994, LANCET, V343, P125, DOI 10.1016/S0140-6736(94)90859-1; SCHMIDT S, 1993, J HYPERTENS, V11, P345, DOI 10.1097/00004872-199304000-00003; SEN I, 1993, J BIOL CHEM, V268, P25748; SIBONY M, 1993, HYPERTENSION, V21, P827, DOI 10.1161/01.HYP.21.6.827; SMITHIES O, 1994, P NATL ACAD SCI USA, V91, P3612, DOI 10.1073/pnas.91.9.3612; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WILSON CM, 1981, BIOCHEM GENET, V19, P509, DOI 10.1007/BF00484623; ZEE RYL, 1992, BIOCHEM BIOPH RES CO, V184, P9, DOI 10.1016/0006-291X(92)91150-O	25	577	594	2	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					146	148		10.1038/375146a0	http://dx.doi.org/10.1038/375146a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753170				2022-12-24	WOS:A1995QX74100051
J	PSATY, BM; KOEPSELL, TD; YANEZ, ND; SMITH, NL; MANOLIO, TA; HECKBERT, SR; BORHANI, NO; GARDIN, JM; GOTTDIENER, JS; RUTAN, GH; SISCOVICK, DS; FURBERG, CD				PSATY, BM; KOEPSELL, TD; YANEZ, ND; SMITH, NL; MANOLIO, TA; HECKBERT, SR; BORHANI, NO; GARDIN, JM; GOTTDIENER, JS; RUTAN, GH; SISCOVICK, DS; FURBERG, CD			TEMPORAL PATTERNS OF ANTIHYPERTENSIVE MEDICATION USE AMONG OLDER ADULTS, 1989 THROUGH 1992 - AN EFFECT OF THE MAJOR CLINICAL-TRIALS ON CLINICAL-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR HEALTH; HIP FRACTURE; HYPERTENSION; DISEASE; RISK	Objective.-To describe the changing patterns of antihypertensive medication use in the years immediately before and after the publication of the results of three major clinical trials of the treatment of hypertension in older adults. Design.-In this cohort study, adults 65 years or older were examined annually on four occasions between June 1989 and May 1992, and the use of antihypertensive medications was assessed by inventory at each visit. The four visits defined the boundaries of three study periods. For each study period, participants receiving antihypertensive therapy were either continuous users (n = 1667, 1643, and 1605, respectively) or starters (n = 157, 142, 120) of hypertensive therapy. The large clinical trials that convincingly proved the efficacy and safety of low-dose diuretic therapy in older adults were published during the latter parts of period 2 and the early parts of period 3. Results.-Among starters, the proportion initiating therapy on diuretics increased from 35.9% in period 2 to 47.5% in period 3, significantly so among women (P=.04). The proportions initiating other drugs displayed no significant trends. Among continuous users, the use of diuretics, beta-blockers, and vasodilators generally decreased over the 3-year period, while the use of calcium channel blockers and angiotensin-converting enzyme inhibitors increased significantly in each of the three periods (P<.05). The decline of 2.7% in the prevalence of diuretic use in period 1 abated during period 2 (1.8% decline), and it slowed significantly (P=.03) to almost a complete halt during period 3 (0.2% decline). The rate of increase in the use of calcium channel blockers slowed significantly (P=.01) between period 1 (+6.7%) and period 3 (+2.8%). Conclusions.-Although other factors such as cost may have been important, the temporal trends in antihypertensive drug therapy coincided in time with and may have reflected in part the influence of the major clinical trials on the patterns of clinical practice.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98101; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98101; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98101; UNIV WASHINGTON,CTR CARDIOVASC HLTH STUDY COORDINATING,SEATTLE,WA 98101; NHLBI,BETHESDA,MD 20892; UNIV CALIF IRVINE,DIV CARDIOL,IRVINE,CA 92717; GEORGETOWN UNIV HOSP,DIV CARDIOL,WASHINGTON,DC 20007; VET ADM MED CTR,MEMPHIS,TN 38104; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California Irvine; Georgetown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	PSATY, BM (corresponding author), UNIV WASHINGTON,DEPT MED,CARDIOVASC HLTH RES UNIT,1730 MINOR AVE,SUITE 1360,SEATTLE,WA 98101, USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085081, N01HC085080, N01HC085079] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-85079, N01-HC-85080, H01-HC-85081] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Efron B., 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; FURBERG CD, 1994, J INTERN MED, V235, P387, DOI 10.1111/j.1365-2796.1994.tb01093.x; HEIDRICH FE, 1991, ANN INTERN MED, V115, P1, DOI 10.7326/0003-4819-115-1-1; HUNE AL, 1993, PHARMACOTHERAPY, V13, P244; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; NORUSIS MJ, 1990, SPSS PC PLUS 4 0 BAS; OPARIL S, 1993, NEW ENGL J MED, V328, P959, DOI 10.1056/NEJM199304013281311; PASTY BM, 1993, HYPERTENSION PRIMER, P197; PSATY BM, 1993, JAMA-J AM MED ASSOC, V270, P1837, DOI 10.1001/jama.270.15.1837; PSATY BM, 1992, JAMA-J AM MED ASSOC, V268, P1287, DOI 10.1001/jama.268.10.1287; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; RAY WA, 1989, LANCET, V1, P687; RAY WA, 1986, AM J MED, V81, P9, DOI 10.1016/0002-9343(86)90522-X; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; 1993, ARCH INTERN MED, V153, P154; 1994, HYPERTENSION, V23, P275; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1988, ARCH INTERN MED, V148, P1023	23	66	68	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1436	1438		10.1001/jama.273.18.1436	http://dx.doi.org/10.1001/jama.273.18.1436			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW279	7723157				2022-12-24	WOS:A1995QW27900031
J	LU, KP; HUNTER, T				LU, KP; HUNTER, T			EVIDENCE FOR A NIMA-LIKE MITOTIC PATHWAY IN VERTEBRATE CELLS	CELL			English	Article							CYCLIN-DEPENDENT KINASES; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; ASPERGILLUS-NIDULANS; MAMMALIAN-CELLS; XENOPUS-OOCYTE; MOUSE OOCYTES; MITOSIS; ACTIVATION	NIMA is essential for entry into mitosis in Aspergillus nidulans. To examine whether there is a NIMA-like pathway in other eukaryotic cell cycles, we expressed NIMA and its dominant negative mutants in two different eukaryotic systems. In Xenopus oocytes, NIMA induced germinal vesicle breakdown without activating Mos, CDC2, or MAP kinase. In HeLa cells, NIMA induced premature mitotic events without activating CDCS, whereas the mutants caused a specific G2 arrest but did not block mutant CDC2(T14AY15F)-induced premature entry into mitosis. A sequence essential for both these phenotypes was mapped to a region of similar to 100 amino acids lying just after the catalytic domain of NIMA that shows a significant similarity to protein interaction domains in other proteins. These results provide evidence for the existence of a NIMA-like mitotic pathway in vertebrate cells.			LU, KP (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NCI NIH HHS [CA14195, CA39780] Funding Source: Medline; NCRR NIH HHS [RR04050] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, R35CA039780] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; CHAN EKL, 1991, J EXP MED, V174, P1239, DOI 10.1084/jem.174.5.1239; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI T, 1991, DEVELOPMENT, V113, P789; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GARD DL, 1993, METHOD CELL BIOL, V38, P241; GAVIN AC, 1992, MOL REPROD DEV, V33, P287, DOI 10.1002/mrd.1080330309; GAVIN AC, 1994, J CELL SCI, V107, P275; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HARPER JW, 1993, CELL, V75, P805; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; HUCHON D, 1993, BIOL CELL, V77, P133, DOI 10.1016/S0248-4900(05)80181-9; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; JUNG T, 1993, INT J DEV BIOL, V37, P595; KITAGAWA M, 1994, ONCOGENE, V9, P2549; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUANG J, 1989, P NATL ACAD SCI USA, V86, P4982, DOI 10.1073/pnas.86.13.4982; LETWIN K, 1992, EMBO J, V10, P3521; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; LU KP, 1993, J BIOL CHEM, V268, P8769; LU KP, 1994, J BIOL CHEM, V269, P6603; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MERRIAM RW, 1971, EXP CELL RES, V68, P81, DOI 10.1016/0014-4827(71)90589-1; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PICKHAM KM, 1992, MOL CELL BIOL, V12, P3192, DOI 10.1128/MCB.12.7.3192; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	47	146	154	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					413	424		10.1016/0092-8674(95)90394-1	http://dx.doi.org/10.1016/0092-8674(95)90394-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736593	Bronze			2022-12-24	WOS:A1995QW89400013
J	CASTIELLO, U; SCARPA, M; BENNETT, K				CASTIELLO, U; SCARPA, M; BENNETT, K			A BRAIN-DAMAGED PATIENT WITH AN UNUSUAL PERCEPTUOMOTOR DEFICIT	NATURE			English	Article							CORTEX; PERCEPTION	WHEN interacting,vith objects, the pattern of movements is influenced by such object characteristics as size and position(1-4). Little is known about the effect of higher level categorical encoding of objects upon movements. Here we present evidence for an approval-for-action process which takes into account such encoding. For the brain-damaged subject L.P., the ability to complete actions involving two objects in central vision is influenced by the semantic or functional relationship between the objects. Even though she perceives only one object, she can integrate two related objects into a coordinated action. If the objects are not related she is unable to integrate them into a single motor act, We propose that selection-for-action systems(5) include processes which gate conceptually the behavioural disposition to action.	UNIV MODENA,NEUROL CLIN,I-41100 MODENA,ITALY; EUROPEAN MED CTR,BOLOGNA,ITALY; UNIV BOLOGNA,DIPARTIMENTO PSICOL,I-40127 BOLOGNA,ITALY	Universita di Modena e Reggio Emilia; University of Bologna				Castiello, Umberto/0000-0003-0629-1286				Allport D. A., 1987, PERSPECTIVES PERCEPT, V15, P395; ANDERSEN RA, 1989, ANNU REV NEUROSCI, V12, P377, DOI 10.1146/annurev.neuro.12.1.377; [Anonymous], 1982, BOSTON NAMING TEST; Arbib M. A., 2011, HDB PHYSL NERVOUS SY, P1449, DOI [DOI 10.1016/J.JPHYSPARIS.2008.03.001, 10.1002/cphy.cp010233]; CASTIELLO U, 1993, EXP BRAIN RES, V94, P165; COSLETT HB, 1991, BRAIN, V114, P1523, DOI 10.1093/brain/114.4.1523; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; FERRIGNO G, 1985, IEEE T BIO-MED ENG, V32, P943, DOI 10.1109/TBME.1985.325627; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.ne.11.030188.001033; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; Goodglass H., 2001, ASSESSMENT APHASIA R, V3rd; HUMPHREYS GW, 1994, COGNITIVE NEUROPSYCH, V11, P393, DOI 10.1080/02643299408251980; JAKOBSON LS, 1991, EXP BRAIN RES, V86, P199; JEANNEROD M, 1994, NEUROPSYCHOLOGIA, V32, P369, DOI 10.1016/0028-3932(94)90084-1; JEANNEROD M, 1988, OXFORD SCI PUBLICATI, V15; Jeannerod M., 1981, ATTENTION PERFORM, P153; KINSBOURNE M, 1963, BRAIN, V86, P697, DOI 10.1093/brain/86.4.697; KINSBOURNE M, 1962, BRAIN, V85, P461, DOI 10.1093/brain/85.3.461; Kugler P.N., 1980, TUTORIALS MOTOR BEHA, P49, DOI DOI 10.1016/S0166-4115(08)61937-8; LAIACONA M, 1993, CORTEX, V29, P727, DOI 10.1016/S0010-9452(13)80293-6; MILNER AD, 1991, BRAIN, V114, P405, DOI 10.1093/brain/114.1.405; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; Roy E. A., 1985, NEUROPSYCHOLOGICAL S, P45; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; WARRINGTON EK, 1978, PERCEPTION, V7, P695, DOI 10.1068/p070695; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; Weir PL, 1994, ADV PSYCHOL, V105, P129, DOI [10.1016/S0166-4115(08)61276-5, DOI 10.1016/S0166-4115(08)61276-5]	27	13	13	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					805	808		10.1038/374805a0	http://dx.doi.org/10.1038/374805a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QV315	7723824				2022-12-24	WOS:A1995QV31500045
J	TUGENDREICH, S; TOMKIEL, J; EARNSHAW, W; HIETER, P				TUGENDREICH, S; TOMKIEL, J; EARNSHAW, W; HIETER, P			CDC27HS COLOCALIZES WITH CDC16HS TO THE CENTROSOME AND MITOTIC SPINDLE AND IS ESSENTIAL FOR THE METAPHASE TO ANAPHASE TRANSITION	CELL			English	Article							EXPRESSED SEQUENCE TAGS; ASPERGILLUS-NIDULANS; SNAP HELIX; MITOSIS; FAMILY; IDENTIFICATION; PROTEINS; ENCODES; GENES; MOTIF	have isolated cDNAs and raised antibodies corresponding to the human homologs of the S. cerevisiae CDC27 and CDC16 proteins, which are tetratrico peptide repeat (TPR)-containing proteins essential for mitosis in budding yeast. We find that the CDC27Hs and CDC16Hs proteins colocalize to the centrosome at all stages of the mammalian cell circle, and to the mitotic spindle. Injection of affinity-purified anti-CDC27Hs antibodies into logarithmically growing HeLa cells causes a highly reproducible cell cycle arrest in metaphase with apparently normal spindle structure. We conclude that CDC27 and CDC16 are evolutionarily conserved components of the centrosome and mitotic spindle that control the onset of postmetaphase events during mitosis.	JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205	Johns Hopkins University	TUGENDREICH, S (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.		Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621				ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BOGUSKI MS, 1990, NATURE, V346, P114, DOI 10.1038/346114a0; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1974, SCIENCE, V183, P48; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; IRNIGER S, 1995, CELL, V81; JORDAN MA, 1992, J CELL SCI, V102, P401; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; MIRABITO PM, 1993, J CELL BIOL, V120, P959, DOI 10.1083/jcb.120.4.959; ODONNELL KL, 1991, J CELL SCI, V99, P711; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; WEINERT TA, 1993, GENETICS, V134, P63; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X	30	316	322	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					261	268		10.1016/0092-8674(95)90336-4	http://dx.doi.org/10.1016/0092-8674(95)90336-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736578	Bronze			2022-12-24	WOS:A1995QV41000015
J	WITKE, W; SHARPE, AH; HARTWIG, JH; AZUMA, T; STOSSEL, TP; KWIATKOWSKI, DJ				WITKE, W; SHARPE, AH; HARTWIG, JH; AZUMA, T; STOSSEL, TP; KWIATKOWSKI, DJ			HEMOSTATIC, INFLAMMATORY, AND FIBROBLAST RESPONSES ARE BLUNTED IN MICE LACKING GELSOLIN	CELL			English	Article							ACTIN DEPOLYMERIZING FACTOR; FILAMENT-SEVERING PROTEIN; D-BINDING-PROTEIN; F-ACTIN; CAPPING PROTEIN; SKELETAL-MUSCLE; PLASMA GELSOLIN; CALCIUM-ION; STEM-CELLS; POLYMERIZATION	Gelsolin, an 82 kDa actin-binding protein, has potent actin filament-severing activity in vitro. To investigate the in vivo function of gelsolin, transgenic gelsolinnull (Osn(-)) mice were generated and found to have normal embryonic development and longevity. However, platelet shape changes are decreased in Gsn(-) mice, causing prolonged bleeding times. Neutrolphil migration in vivo into peritoneal exudates and in vitro is delayed. Gsn(-) dermal fibroblasts have excessive actin stress fibers and migrate more slowly than wildtype fibroblasts, but have increased contractility in vitro. These observations establish the requirement of gelsolin for rapid motile responses in cell types involved in stress responses such as hemostasis, inflammation, and wound healing. Neither gelsolin nor other proteins with similar actin filament-severing activity are expressed in early embryonic cells, indicating that this mechanism of actin filament dynamics is not essential for motility during early embryogenesis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	WITKE, W (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV EXPTL MED,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 19429, HL 48743] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbondanzo SJ, 1993, GUIDE TECHNIQUES MOU, P803; ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; ANKENBAUER T, 1988, J CELL BIOL, V107, P1489, DOI 10.1083/jcb.107.4.1489; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; CASELLA JF, 1987, J CELL BIOL, V105, P371, DOI 10.1083/jcb.105.1.371; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CONDELLIS J, 1994, ANN RV CELL BIOL, V9, P411; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DELCASTILLO AR, 1992, THROMB HAEMOSTASIS, V67, P248; DIFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; GRINNELL F, 1984, J CELL SCI, V66, P51; HARTMANN H, 1989, J BIOL CHEM, V264, P12639; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HASEGAWA T, 1980, BIOCHEMISTRY-US, V19, P2677, DOI 10.1021/bi00553a021; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HOWARD T, 1990, J CELL BIOL, V110, P1983, DOI 10.1083/jcb.110.6.1983; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; ISENBERG G, 1980, NATURE, V288, P455, DOI 10.1038/288455a0; JANMEY PA, 1987, BLOOD, V70, P524; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; KURTH M, 1984, J BIOL CHEM, V2598, P7473; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P8239; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P5910; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAMB JA, 1993, J BIOL CHEM, V268, P8999; LEE J, 1993, NATURE, V3622, P167; LEE WM, 1992, NEW ENGL J MED, V326, P1335; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIND SE, 1986, J CLIN INVEST, V78, P736, DOI 10.1172/JCI112634; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; MARUYAMA K, 1965, BIOCHIM BIOPHYS ACTA, V94, P208, DOI 10.1016/0926-6585(65)90026-9; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHAFER DA, 1992, J CELL BIOL, V118, P335, DOI 10.1083/jcb.118.2.335; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133; YAMAMOTO K, 1982, J CELL BIOL, V95, P711, DOI 10.1083/jcb.95.3.711; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1981, J BIOL CHEM, V256, P9693; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YOUNG WO, 1987, J LAB CLIN MED, V110, P83; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	59	370	387	1	19	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					41	51		10.1016/0092-8674(95)90369-0	http://dx.doi.org/10.1016/0092-8674(95)90369-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720072	Bronze			2022-12-24	WOS:A1995QR97000006
J	CONDRA, JH; SCHLEIF, WA; BLAHY, OM; GABRYELSKI, LJ; GRAHAM, DJ; QUINTERO, JC; RHODES, A; ROBBINS, HL; ROTH, E; SHIVAPRAKASH, M; TITUS, D; YANG, T; TEPPLER, H; SQUIRES, KE; DEUTSCH, PJ; EMINI, EA				CONDRA, JH; SCHLEIF, WA; BLAHY, OM; GABRYELSKI, LJ; GRAHAM, DJ; QUINTERO, JC; RHODES, A; ROBBINS, HL; ROTH, E; SHIVAPRAKASH, M; TITUS, D; YANG, T; TEPPLER, H; SQUIRES, KE; DEUTSCH, PJ; EMINI, EA			IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS	NATURE			English	Article							REVERSE-TRANSCRIPTASE; IMMUNODEFICIENCY	INHIBITORS Of the human immunodeficiency virus type 1 (HIV-1) protease have entered clinical study as potential therapeutic agents for HIV-1 infection. The clinical efficacy of HIV-1 reverse transcriptase inhibitors has been limited bg the emergence of resistant viral variants. Similarly, variants expressing resistance to protease inhibitors have been derived in cell culture(1-10). We now report the characterization of resistant variants isolated from patients undergoing therapy with the protease inhibitor MX-639 (formerly designated L-735,524). Five of these variants, isolated from four patients, exhibited cross-resistance to all members of a panel of six structurally diverse protease inhibitors. This suggests that combination therapy with multiple protease inhibitors may not prevent loss of antiviral activity resulting from resistance selection. In addition, previous therapy with one compound may abrogate the benefit of subsequent treatment with a second inhibitor.	MERCK SHARP & DOHME LTD,RES LABS,DEPT CLIN PHARMACOL,W POINT,PA 19486; THOMAS JEFFERSON UNIV,DIV INFECT DIS,PHILADELPHIA,PA 19107; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294	Merck & Company; Jefferson University; University of Alabama System; University of Alabama Birmingham	CONDRA, JH (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,DEPT ANTIVIRAL RES,W POINT,PA 19486, USA.		Rhodes, Andrew/G-4265-2011	Rhodes, Andrew/0000-0002-8737-574X				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; BYRNES VW, 1993, ANTIMICROB AGENTS CH, V37, P1576, DOI 10.1128/AAC.37.8.1576; CHEN CM, J CELL BIOCHEM, V18, P16694; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S; DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001; ELFARRASH MA, 1994, J VIROL, V68, P233, DOI 10.1128/JVI.68.1.233-239.1994; GETMAN DP, 1993, J MED CHEM, V36, P288, DOI 10.1021/jm00054a014; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; JACOBSEN H, 1995, VIROLOGY, V206, P527, DOI 10.1016/S0042-6822(95)80069-7; KEMPF DJ, 1993, ABSTR PAP AM CHEM S, V206, P119; KEMPF DJ, 1994, J CELL BIOCHEM, V18, P130; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; MARKOWITZ M, 1995, J VIROL, V69, P701, DOI 10.1128/JVI.69.2.701-706.1995; MYERS G, 1993, HUMAN RETROVIRUSES A; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; OTTO MJ, 1993, ANTIMICROB AGENTS CH, V37, P2606, DOI 10.1128/AAC.37.12.2606; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; SINGH M, 1993, J CELL BIOCH E S, V17, P86; TISDALE M, 1994, 3RD INT WORKSH HIV D, P14; TUNG RD, 1994, 10TH INT C AIDS, P33; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; WINSLOW DL, 1994, AIDS, V8, P753, DOI 10.1097/00002030-199406000-00005; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	28	890	920	0	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					569	571		10.1038/374569a0	http://dx.doi.org/10.1038/374569a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700387				2022-12-24	WOS:A1995QR06900060
J	ABOUSSEKHRA, A; BIGGERSTAFF, M; SHIVJI, MKK; VILPO, JA; MONCOLLIN, V; PODUST, VN; PROTIC, M; HUBSCHER, U; EGLY, JM; WOOD, RD				ABOUSSEKHRA, A; BIGGERSTAFF, M; SHIVJI, MKK; VILPO, JA; MONCOLLIN, V; PODUST, VN; PROTIC, M; HUBSCHER, U; EGLY, JM; WOOD, RD			MAMMALIAN DNA NUCLEOTIDE EXCISION-REPAIR RECONSTITUTED WITH PURIFIED PROTEIN-COMPONENTS	CELL			English	Article							CELL NUCLEAR ANTIGEN; PIGMENTOSUM GROUP-F; BINDING-PROTEIN; DAMAGED DNA; REPLICATION PROTEIN; POLYMERASE-DELTA; TRANSCRIPTION FACTOR; PRIMATE CELLS; LIGASE-I; PURIFICATION	Nucleotide excision repair is the principal way by which human cells remove UV damage from DNA. Human cell extracts were fractionated to locate active components, including xeroderma pigmentosum (XP) and ERCC factors. The incision reaction was then reconstituted with the purified proteins RPA, XPA, TFIIH (containing XPB and XPD), XPC, UV-DDB, XPG, partially purified ERCC1/XPF complex, and a factor designated IF7. UV-DDB (related to XPE protein) stimulated repair but was not essential. ERCC1- and XPF-correcting activity copurified with an ERCC1-binding polypeptide of 110 kDa that was absent in XP-F cell extract. Complete repair synthesis was achieved by combining these factors with DNA polymerase epsilon, RFC, PCNA, and DNA ligase I. The reconstituted core reaction requires about 30 polypeptides.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV ZURICH IRCHEL,DEPT VET BIOCHEM,CH-8057 ZURICH,SWITZERLAND; NICHHD,DNA REPLICAT REPAIR & MUTAGENESIS,BETHESDA,MD 20892; TAMPERE UNIV HOSP,DEPT CLIN CHEM,SF-33521 TAMPERE,FINLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Zurich; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Tampere University; Tampere University Hospital			Wood, Richard D/M-6319-2018; MONCOLLIN, Vincent/R-1941-2017	Wood, Richard D/0000-0002-9495-6892; MONCOLLIN, Vincent/0000-0002-4163-0231				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; CALSOU P, 1994, BIOCHEM BIOPH RES CO, V202, P788, DOI 10.1006/bbrc.1994.1999; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; CLUGSTON CK, 1992, CANCER RES, V52, P6375; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FELDBERG RS, 1976, BIOCHEMISTRY-US, V15, P2402, DOI 10.1021/bi00656a024; FLORES O, 1992, J BIOL CHEM, V267, P2786; GEORGAKI A, 1993, NUCLEIC ACIDS RES, V21, P3659, DOI 10.1093/nar/21.16.3659; GERARD M, 1991, J BIOL CHEM, V266, P20940; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MIURA M, 1992, J CELL PHYSIOL, V150, P370, DOI 10.1002/jcp.1041500221; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; REARDON JT, 1993, J BIOL CHEM, V268, P21301; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SEROUSSI E, 1993, J BIOL CHEM, V268, P7147; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22729; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TREIBER DK, 1992, NUCLEIC ACIDS RES, V20, P5805, DOI 10.1093/nar/20.21.5805; VANASSENDELFT GB, 1993, NUCLEIC ACIDS RES, V21, P3399, DOI 10.1093/nar/21.15.3399; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WAGA S, 1994, J BIOL CHEM, V269, P10923; WEEDA G, 1993, SEMIN CANCER BIOL, V4, P105; WOOD RD, 1993, COLD SPRING HARB SYM, V58, P625, DOI 10.1101/SQB.1993.058.01.069; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	57	740	763	5	88	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					859	868		10.1016/0092-8674(95)90289-9	http://dx.doi.org/10.1016/0092-8674(95)90289-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697716	Bronze			2022-12-24	WOS:A1995QP61200005
J	WRIGHT, JD; PEARL, L				WRIGHT, JD; PEARL, L			KNOWLEDGE AND EXPERIENCE OF YOUNG-PEOPLE REGARDING DRUG MISUSE, 1969-94	BRITISH MEDICAL JOURNAL			English	Article							ABUSE	Objective-To monitor young people's knowledge and experience of illicit drugs between 1969 and 1994 at intervals of five years. Design-The same anonymously completed questionnaire was used throughout. Setting-Three Wolverhampton secondary schools representing three different socioeconomic groups. Subjects-392 pupils aged 14 to 15 completed the questionnaire in 1994. Previous sample sizes were 471 in 1969, 523 in 1974, 648 in 1979, 540 in 1984, and 380 in 1989. Main outcome measures-Self reported levels of knowledge and experience of illicit drugs. Results-Over 25 years the proportion of pupils who knew someone taking drugs more than quadrupled from 15% (71/471) to 65% (254/392), and the proportion who had been offered drugs increased ninefold from 5% (24) to 45% (175). Both of these proportions more than doubled over the past five years. In 1994 the proportions of pupils mentioning ''ecstasy'' (methylenedioxymethamphetamine), amphetamines, and crack cocaine increased significantly (P<0.01) and the proportion mentioning opiates decreased significantly (P<0.01). ''Poppers'' (amyl nitrite) were mentioned for the first time. ''To feel big, to show off, look grown up'' has continued to be the main perceived reason for taking drugs. Television has continued to be the main source of information. Conclusions-In the past five years in particular young people's exposure to illicit drugs has increased dramatically. Despite more education about drugs, pupils' knowledge remains limited. Social pressures remain the first perceived reason for taking drugs. The media have a responsibility not to glamorise drugs.	UNIV WOLVERHAMPTON,WOLVERHAMPTON WV1 1SB,ENGLAND	University of Wolverhampton								ALLEN FA, 1991, CRACK BROKEN PROMISE; BALDING J, 1994, YOUNG PEOPLE 1993; BEAN PT, 1988, HLTH ED J, V47, P79; BROWN C, 1988, ILLICIT DRUG USE POR; COHEN J, 1992, PSYCHOACTIVE DRUGS H; Davies OL, 1978, DESIGN ANAL IND EXPT; FRANCIS LJ, 1993, ADDICTION, V88, P665, DOI 10.1111/j.1360-0443.1993.tb02079.x; FRASER A, 1991, DRUG MISUSE LOCAL CO; Measham F., 1993, DRUGLINK, V8, P16; SMITH C, 1992, BRIT J ADDICT, V87, P227; Swadi Harith, 1992, Eur Child Adolesc Psychiatry, V1, P156, DOI 10.1007/BF02091901; WRIGHT JD, 1976, MED SCI LAW, V16, P252, DOI 10.1177/002580247601600408; WRIGHT JD, 1981, BRIT MED J, V282, P793, DOI 10.1136/bmj.282.6266.793; WRIGHT JD, 1986, BRIT MED J, V292, P179, DOI 10.1136/bmj.292.6514.179; WRIGHT JD, 1990, BRIT MED J, V300, P99, DOI 10.1136/bmj.300.6717.99; 1993, PHS6 ST GEORG HOSP M; 1993, DRUG ED SCH; 1993, HOME OFFICE STATISTI; 1993, DRUGS SOLVENTS YOU Y	19	61	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					20	24		10.1136/bmj.310.6971.20	http://dx.doi.org/10.1136/bmj.310.6971.20			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QB060	7755714	Green Published			2022-12-24	WOS:A1995QB06000022
J	SPENCER, K; CARPENTER, P				SPENCER, K; CARPENTER, P			PROSPECTIVE-STUDY OF PRENATAL SCREENING FOR DOWNS-SYNDROME WITH FREE BETA-HUMAN CHORIONIC-GONADOTROPIN	BRITISH MEDICAL JOURNAL			English	Article							SERUM ALPHA-FETOPROTEIN; UNCONJUGATED ESTRIOL; HUMAN CHORIOGONADOTROPIN; PREGNANCY; RISK; AGE; ABNORMALITIES; MARKERS; ASSAY; HCG	Objective-To assess the value and impact of a screening programme for Down's syndrome that uses the two maternal serum markers: alpha fetoprotein and free beta human chorionic gonadotrophin. Design-All women booked into clinics were screened. Further tests were offered to women with a risk of one in 300 or greater of having an affected baby. Follow up of outcome of all pregnancies. Setting-Biochemical screening laboratory serving two health districts. Subjects-8179 women of all ages with singleton pregnancies screened between 15 and 22 weeks' gestation from 1 April 1991 to 31 March 1992. Main outcome measures-Detection rate of Down's syndrome, false positive rate, uptake of screening, uptake of amniocentesis in women identified as at increased risk, prevalence of Down's syndrome at birth. Results-Overall 89% (8317/9345) of women underwent screening. The rate of detection of Down's syndrome was 69% (11/16; 95% confidence interval 41 to 89%) with a 5.2% false positive rate (426/8179; 4.7 to 5.7%). In women under 30 the detection rate was 50% (four out of eight; 32 to 86%) Uptake of amniocentesis was 89% (389/437), resulting in a reduction of prevalence of Down's syndrome at birth from 1.1 per 1000 in previous years (66/59 696) to 0.4 per 1000 during the screening year (4/9345). Additionally, several other abnormalities were identified. Conclusion-The benefit of a high detection rate with this approach and the additional anomalies identified should encourage others to introduce screening programmes for Down's syndrome that use free beta human chorionic gonadotrophin and alpha fetoprotein.			SPENCER, K (corresponding author), OLDCHURCH HOSP,DEPT CLIN BIOCHEM,ENDOCRINE UNIT,ROMFORD RM7 0BE,ESSEX,ENGLAND.							AITKEN DA, IN PRESS PRENAT DIAG; BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; CHENG EY, 1993, OBSTET GYNECOL, V81, P72; CROSSLEY JA, 1993, PRENATAL DIAG, V13, P271, DOI 10.1002/pd.1970130406; CUCKLE H, 1993, BRIT MED J, V306, P1199, DOI 10.1136/bmj.306.6886.1199; CUCKLE H, 1992, BRIT MED J, V305, P1017, DOI 10.1136/bmj.305.6860.1017; CUCKLE HS, 1984, LANCET, V1, P926; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; CUCKLE HS, 1990, PRENATAL DIAGNOSIS P, P67; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; LAUNDON C, 1993, J MED GENET, V30, P340; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MACRI JN, 1993, ANN CLIN BIOCHEM, V30, P94, DOI 10.1177/000456329303000117; MACRI JN, IN PRESS PRENAT DIAG; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; PARSONS L, 1992, BRIT MED J, V305, P1228, DOI 10.1136/bmj.305.6863.1228-a; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353; REYNOLDS T, 1992, CLIN CHEM, V38, P1888; REYNOLDS TM, 1990, ANN CLIN BIOCHEM, V27, P452, DOI 10.1177/000456329002700506; SPENCER K, 1985, BRIT MED J, V290, P1940, DOI 10.1136/bmj.290.6486.1940; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P506, DOI 10.1177/000456329202900504; SPENCER K, 1991, CLIN CHEM, V37, P809; SPENCER K, 1992, LANCET, V339, P1480, DOI 10.1016/0140-6736(92)92073-O; SPENCER K, 1993, ANN CLIN BIOCHEM, V30, P394, DOI 10.1177/000456329303000408; SPENCER K, 1993, BRIT MED J, V306, P1616, DOI 10.1136/bmj.306.6892.1616; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P349, DOI 10.1177/000456329202900319; SPENCER K, 1993, IN PRESS MEASUREMENT; SPENCER K, 1993, IN PRESS BMJ; WALD N, 1993, BRIT MED J, V306, P1198, DOI 10.1136/bmj.306.6886.1198-c; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; 1991, BIRTH STATISTICS 199	34	61	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1993	307	6907					764	769		10.1136/bmj.307.6907.764	http://dx.doi.org/10.1136/bmj.307.6907.764			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ478	7693095	Bronze, Green Published			2022-12-24	WOS:A1993LZ47800021
J	BROTCHIE, PR; ANDERSEN, RA; SNYDER, LH; GOODMAN, SJ				BROTCHIE, PR; ANDERSEN, RA; SNYDER, LH; GOODMAN, SJ			HEAD POSITION SIGNALS USED BY PARIETAL NEURONS TO ENCODE LOCATIONS OF VISUAL-STIMULI	NATURE			English	Article							SACCADE-RELATED ACTIVITY; LATERAL INTRAPARIETAL AREA; ASSOCIATION CORTEX; EYE-MOVEMENTS; SPACE; GAZE; MACAQUE; MEMORY; 7A	THE mechanism for object location in the environment, and the perception of the external world as stable when eyes, head and body are moved, have long been thought to be centred on the posterior parietal cortex(1-8). However, head position signals, and their integration with visual and eye position signals to form a representation of space referenced to the body, have never been examined in any area of the cortex. Here we show that the visual and saccadic activities of parietal neurons are strongly affected by head position. The eye and head position effects are equivalent for individual neurons, indicating that the modulation is a function of gaze direction, regardless of whether the eyes or head are used to direct gaze. These data are consistent with the idea that the posterior parietal cortex contains a distributed representation of space in body-centred coordinates.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Snyder, Lawrence H/A-4593-2017					ANDERSEN RA, 1987, EXP BRAIN RES, V67, P316; ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; ANDERSEN RA, 1983, J NEUROSCI, V3, P532; Andersen RA, 1987, HDB PHYSL 1, VV, P483; BARASH S, 1991, J NEUROPHYSIOL, V66, P1109, DOI 10.1152/jn.1991.66.3.1109; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; BIGUER B, 1988, BRAIN, V11, P1405; Critchley M., 1953, PARIETAL LOBES; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FETZ EE, 1992, BEHAV BRAIN SCI, V15, P679; FOGASSI L, 1992, EXP BRAIN RES, V89, P686, DOI 10.1007/BF00229894; FULLER JH, 1983, BRAIN RES, V271, P241, DOI 10.1016/0006-8993(83)90286-X; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOODMAN SJ, 1990, P INT JOINT C NEUR N, P381; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; GUITTON D, 1987, J NEUROPHYSIOL, V58, P427, DOI 10.1152/jn.1987.58.3.427; HYVARINEN J, 1982, PARIETAL CORTEX MONK; LACKNER JR, 1984, EXP NEUROL, V47, P177; LAURUTIS VP, 1986, J PHYSIOL-LONDON, V373, P209, DOI 10.1113/jphysiol.1986.sp016043; LYNCH JC, 1980, BEHAV BRAIN SCI, V3, P485, DOI 10.1017/S0140525X00006324; MOUNTCASTLE V B, 1976, Neurosciences Research Program Bulletin, V14, P1; ROLL R, 1991, EXP BRAIN RES, V85, P423; SAKATA H, 1985, VISION RES, V25, P453, DOI 10.1016/0042-6989(85)90070-7; Snyder L. H., 1993, Society for Neuroscience Abstracts, V19, P770; TAYLOR JL, 1991, BRAIN, V114, P755, DOI 10.1093/brain/114.2.755; TOMLINSON RD, 1990, J NEUROPHYSIOL, V64, P1873, DOI 10.1152/jn.1990.64.6.1873; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	28	260	263	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					232	235		10.1038/375232a0	http://dx.doi.org/10.1038/375232a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746323				2022-12-24	WOS:A1995QY88100062
J	CONOVER, JC; ERICKSON, JT; KATZ, DM; BIANCHI, LM; POUEYMIROU, WT; MCCLAIN, J; PAN, L; HELGREN, M; IP, NY; BOLAND, P; FRIEDMAN, B; WIEGAND, S; VEJSADA, R; KATO, AC; DECHIARA, TM; YANCOPOULOS, GD				CONOVER, JC; ERICKSON, JT; KATZ, DM; BIANCHI, LM; POUEYMIROU, WT; MCCLAIN, J; PAN, L; HELGREN, M; IP, NY; BOLAND, P; FRIEDMAN, B; WIEGAND, S; VEJSADA, R; KATO, AC; DECHIARA, TM; YANCOPOULOS, GD			NEURONAL DEFICITS, NOT INVOLVING MOTOR-NEURONS, IN MICE LACKING BDNF AND/OR NT4	NATURE			English	Article							NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; CELL-DEATH; BRAIN; MOTONEURONS; RECEPTORS	NERVE growth factor and other neurotrophins signal to neurons through the Trk family of receptor tyrosine kinases(1-6). TrkB is relatively promiscuous in vitro, acting as a receptor for brain-derived neurotrophic factor (BDNF), neurotrophin-4 (NT4) and, to a lesser extent, NT3 (refs 3-5). Mice lacking TrkB(7) show a more severe phenotype than mice lacking BDNF8,9, suggesting that TrkB may act as a receptor for additional ligands in vivo. To explore this possibility, we generated mice lacking NT4 or BDNF as well as mice lacking both neurotrophins. Unlike mice lacking other Trks(7,10,11) or neurotrophins(8,9,12-14), NT4-deficient mice are long-lived and show no obvious neurological defects. Analysis of mutant phenotypes revealed distinct neuronal populations with different neurotrophin requirements. Thus vestibular and trigeminal sensory neurons require BDNF but not NT4, whereas nodose-petrosal sensory neurons require both BDNF and NT4. Motor neurons, whose numbers are drastically reduced in mice lacking TrkB, are not affected even in mice lacking both BDNF and NT4. These results suggest that another ligand, perhaps NT3, does indeed act on TrkB in vivo.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROSCI,CLEVELAND,OH 44106; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; UNIV GENEVA,MED CTR,DEPT PHARMACOL,CH-1211 GENEVA,SWITZERLAND; UNIV GENEVA,MED CTR,DIV CLIN NEUROMUSCULAR RES,CH-1211 GENEVA,SWITZERLAND	Case Western Reserve University; Regeneron; University of Geneva; University of Geneva				Ip, Nancy Yuk-Yu/0000-0002-2763-8907; Bianchi, Lynne/0000-0002-5064-6972				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; BARBACID MJ, 1994, NEUROBIOLOGY, V25, P1386; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; EIDE FF, 1993, EXP NEUROL, V121, P200, DOI 10.1006/exnr.1993.1087; EMFORS P, 1994, NATURE, V368, P147; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HERTZBERG T, 1994, DEV BIOL, V166, P801, DOI 10.1006/dbio.1994.1358; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI L, 1994, J NEUROBIOL, V15, P759; MALSONPIERRE PC, 1990, NEURON, V5, P501; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; POVER CM, 1991, ANAT REC, V231, P573, DOI 10.1002/ar.1092310419; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; THALER CD, 1994, DEV BIOL, V161, P338, DOI 10.1006/dbio.1994.1035; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; VEJSADA R, 1995, EUR J NEUROSCI, V7, P108, DOI 10.1111/j.1460-9568.1995.tb01025.x; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	30	355	361	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					235	238		10.1038/375235a0	http://dx.doi.org/10.1038/375235a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746324				2022-12-24	WOS:A1995QY88100063
J	CRICK, F; KOCH, C				CRICK, F; KOCH, C			ARE WE AWARE OF NEURAL ACTIVITY IN PRIMARY VISUAL-CORTEX	NATURE			English	Article							SELECTIVE CELLS; MACAQUE; MONKEY; ORGANIZATION; CAT	It is usually assumed that people are visually aware of at least some of the neuronal activity in the primary visual area, V1, of the neocortex. But the neuroanatomy of the macaque monkey suggests that, although primates may be aware of neural activity in other visual cortical areas, they are not directly aware of that in area V1. There is some psychophysical evidence in humans that supports this hypothesis.	CALTECH, COMPUTAT & NEURAL SYST PROGRAM, PASADENA, CA 91125 USA	California Institute of Technology	CRICK, F (corresponding author), SALK INST BIOL STUDIES, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Koch, Christof/0000-0001-6482-8067				Barbas H, 1992, Adv Neurol, V57, P91; BARBUR JL, 1993, BRAIN, V116, P1293, DOI 10.1093/brain/116.6.1293; BIRBAUMER N, 1990, PHYSIOL REV, V70, P1, DOI 10.1152/physrev.1990.70.1.1; BLACKWELL KT, 1988, J OPT SOC AM A, V5, P1772, DOI 10.1364/JOSAA.5.001772; BLAKE R, 1989, PSYCHOL REV, V96, P145, DOI 10.1037/0033-295X.96.1.145; COWEY A, 1995, NATURE, V373, P247, DOI 10.1038/373247a0; COWEY A, 1991, TRENDS NEUROSCI, V14, P140, DOI 10.1016/0166-2236(91)90085-9; Crick F., 1990, Seminars in the Neurosciences, V2, P263; CRICK F, 1993, NATURE, V361, P109, DOI 10.1038/361109a0; CRICK F, 1992, SCI AM, V267, P153, DOI 10.1038/scientificamerican0992-152; Crick F., 1994, ASTONISHING HYPOTHES; DESIMONE R, 1991, J COGNITIVE NEUROSCI, V3, P1, DOI 10.1162/jocn.1991.3.1.1; DEVALOIS RL, 1982, VISION RES, V22, P545, DOI 10.1016/0042-6989(82)90113-4; ECCLES JC, 1986, PROC R SOC SER B-BIO, V227, P411, DOI 10.1098/rspb.1986.0031; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FRIES W, 1990, VISUAL NEUROSCI, V4, P205, DOI 10.1017/S0952523800003357; Fuster J M, 1993, Curr Opin Neurobiol, V3, P160, DOI 10.1016/0959-4388(93)90204-C; FUSTERJM, 1989, PREFRONTAL CORTEX; GERFEN CR, 1994, MOTOR COGNITIVE FUNC, P78; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; KOCH C, 1994, LARGE SCALE NEURONAL, P93; LAND EH, 1971, J OPT SOC AM, V61, P1, DOI 10.1364/JOSA.61.000001; LEVITT JB, 1994, J NEUROPHYSIOL, V71, P2517, DOI 10.1152/jn.1994.71.6.2517; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; MYERSON J, 1981, BEHAV ANAL LETT, V1, P149; PICKERSGILL MJ, 1961, Q J EXP PSYCHOL, V13, P168, DOI 10.1080/17470216108416489; ROBINSON DL, 1992, TRENDS NEUROSCI, V15, P127, DOI 10.1016/0166-2236(92)90354-B; ROLAND PE, 1994, TRENDS NEUROSCI, V17, P281, DOI 10.1016/0166-2236(94)90057-4; SAINTCYR JA, 1990, J COMP NEUROL, V298, P129, DOI 10.1002/cne.902980202; SCHEIN SJ, 1990, J NEUROSCI, V10, P3369; Sherk H., 1986, CEREB CORTEX, P467, DOI DOI 10.1007/978-1-4613-2149-1_13; SPARKS DL, 1986, PHYSIOL REV, V66, P118, DOI 10.1152/physrev.1986.66.1.118; UNGERLEIDER LG, 1984, J COMP NEUROL, V223, P368, DOI 10.1002/cne.902230304; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577; YOUNG MP, 1992, NATURE, V358, P152, DOI 10.1038/358152a0; ZEKI S, 1983, PROC R SOC SER B-BIO, V217, P449, DOI 10.1098/rspb.1983.0020; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0; ZEKI S, 1980, NATURE, V284, P412, DOI 10.1038/284412a0	43	579	598	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 11	1995	375	6527					121	123		10.1038/375121a0	http://dx.doi.org/10.1038/375121a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753166				2022-12-24	WOS:A1995QX74100042
J	MOUGNEAU, E; ALTARE, F; WAKIL, AE; ZHENG, SC; COPPOLA, T; WANG, ZE; WALDMANN, R; LOCKSLEY, RM; GLAICHENHAUS, N				MOUGNEAU, E; ALTARE, F; WAKIL, AE; ZHENG, SC; COPPOLA, T; WANG, ZE; WALDMANN, R; LOCKSLEY, RM; GLAICHENHAUS, N			EXPRESSION CLONING OF A PROTECTIVE LEISHMANIA ANTIGEN	SCIENCE			English	Article							MAJOR SURFACE-ANTIGEN; T-CELL LINES; CUTANEOUS LEISHMANIASIS; MURINE LEISHMANIASIS; INTERFERON-GAMMA; MICE; MACROPHAGES; INFECTION; PROMASTIGOTES; RECEPTORS	Parasite-specific CD4(+) T cells have been shown to transfer protection against Leishmania major in susceptible BALB/c mice. An epitope-tagged expression library was used to identify the antigen recognized by a protective CD4(+) T cell clone, The expression library allowed recombinant proteins made in bacteria to be captured by macrophages for presentation to T cells restricted to major histocompatibility complex class II. A conserved 36-kilodalton member of the tryptophan-aspartic acid repeat family of proteins was identified that was expressed in both stages of the parasite life Cycle. A 24-kilodalton portion of this antigen protected susceptible mice when administered as a vaccine with interleukin-12 before infection.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; CNRS, UPR 411, INST PHARMACOL MOLEC & CELLULAIRE, F-06560 VALBONNE, FRANCE; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); University of California System; University of California San Francisco			Coppola, Thierry/I-5036-2016; Waldmann, Rainer/Q-2108-2016; altare, frederic/K-8664-2015	Coppola, Thierry/0000-0003-1018-722X; Waldmann, Rainer/0000-0002-4599-2926; altare, frederic/0000-0002-5077-4616	NIAID NIH HHS [AI26918] Funding Source: Medline; NIDDK NIH HHS [T32 DK07007] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI026918, R01AI026918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007007] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; ANTOINE JC, 1991, INFECT IMMUN, V59, P764, DOI 10.1128/IAI.59.3.764-775.1991; BELOSEVIC M, 1989, J IMMUNOL, V143, P266; BRAKE DA, 1988, J IMMUNOL, V140, P1989; BRAKE DA, 1986, J IMMUNOL, V137, P345; BUTTON LL, 1990, J EXP MED, V171, P589; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; COLOMERGOULD V, 1985, J EXP MED, V162, P902, DOI 10.1084/jem.162.3.902; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73; LANG T, 1994, J CELL SCI, V107, P2137; LIEW FY, 1991, EUR J IMMUNOL, V21, P2489, DOI 10.1002/eji.1830211027; LOCKSLEY RM, 1993, SCIENCE, V261, P1448, DOI 10.1126/science.8367726; MORRIS L, 1992, J IMMUNOL, V149, P2715; MOUGNEAU E, UNPUB; MULLER I, 1989, IMMUNOL REV, V112, P95, DOI 10.1111/j.1600-065X.1989.tb00554.x; MULLER I, 1988, IMMUNOL LETT, V19, P251, DOI 10.1016/0165-2478(88)90151-4; MULLER I, 1989, EUR J IMMUNOL, V19, P865, DOI 10.1002/eji.1830190513; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NICKELL SP, 1987, J IMMUNOL, V138, P914; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F; REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RUSSELL DG, 1992, J CELL SCI, V103, P1193; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SCOTT P, 1990, J IMMUNOL, V144, P1075; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1989, IMMUNOL REV, V112, P161, DOI 10.1111/j.1600-065X.1989.tb00557.x; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; WANG Z, UNPUB; WANG ZE, 1994, P NATL ACAD SCI USA, V91, P12932, DOI 10.1073/pnas.91.26.12932; WANG ZE, 1993, J IMMUNOL, V151, P2077; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; WHITE J, 1989, J IMMUNOL, V143, P1822	36	320	345	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	1995	268	5210					563	566		10.1126/science.7725103	http://dx.doi.org/10.1126/science.7725103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725103				2022-12-24	WOS:A1995QV40700036
J	NEASE, RF; KNEELAND, T; OCONNOR, GT; SUMNER, W; LUMPKINS, C; SHAW, L; PRYOR, D; SOX, HC				NEASE, RF; KNEELAND, T; OCONNOR, GT; SUMNER, W; LUMPKINS, C; SHAW, L; PRYOR, D; SOX, HC			VARIATION IN PATIENT UTILITIES FOR OUTCOMES OF THE MANAGEMENT OF CHRONIC STABLE ANGINA - IMPLICATIONS FOR CLINICAL-PRACTICE GUIDELINES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREFERENCES	Objective.-Although practice guidelines sometimes make recommendations based on symptom severity, they rarely account for how patients feel about their symptoms. To investigate the possible importance of patient preferences in treatment of ischemic heart disease, we assessed attitudes toward symptoms in patients with angina pectoris. Design.-Case series. Setting.-Ambulatory cardiology clinics at two tertiary care medical centers. Patients.-A total of 220 subjects were selected from 589 patients with chronic stable angina referred from cardiologists to achieve patient samples balanced for sex, race, and angina severity. Main Outcome Measures.-We measured patients' attitudes toward their angina using the rating scale, time trade-off, and standard gamble utility metrics. Reliability of measurements was evaluated by repeating the assessments 2 weeks later on 50 willing patients. Results.-While the mean responses followed the expected patterns (those with more severe Canadian Cardiovascular Society scores chose lower utilities), attitudes toward symptoms varied substantially among patients with similarly severe angina. For example, there was a 33% chance that a patient with class II angina had a time trade-off utility that was lower (ie, more bothered by symptoms) than a patient with more severe angina (class III/IV). This variation in utilities was not due to random error in the assessments. Conclusions.-Angina patients with similar functional limitation vary considerably in their tolerance for their symptoms, as measured by utilities. Our findings suggest that guidelines for the management of ischemic heart disease should be based on the preferences of the individual patient rather than on symptom severity alone.	DARTMOUTH COLL, SCH MED, DEPT COMMUNITY & FAMILY MED, CTR EVALUAT CLIN SCI, HANOVER, NH 03755 USA; DARTMOUTH COLL, SCH MED, DEPT MED, HANOVER, NH 03755 USA; UNIV KENTUCKY, DEPT FAMILY PRACTICE, LEXINGTON, KY USA; DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOL, DURHAM, NC 27710 USA	Dartmouth College; Dartmouth College; University of Kentucky; Duke University			Sumner, Walton/H-5045-2019		AHRQ HHS [HS06503-04] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Conover W. J., 1980, PRACTICAL NONPARAMET; COX J, 1992, ANN INTERN MED, V117, P677, DOI 10.7326/0003-4819-117-8-677; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; GRADY D, 1992, ANN INTERN MED, V117, P1038; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; KIRKLIN JW, 1991, CIRCULATION, V83, P1125; NEASE R, 1993, CLIN RES, V41, pA181; NEASE RF, 1994, MED DECIS MAKING, V11, P382; OCONNOR AMC, 1987, J CHRON DIS, V40, P811, DOI 10.1016/0021-9681(87)90133-0; Owens D K, 1993, Jt Comm J Qual Improv, V19, P248; READ JL, 1984, MED DECIS MAKING, V4, P315, DOI 10.1177/0272989X8400400307; Sox HC, 1988, MED DECISION MAKING; SUMNER W, 1991, 15TH P ANN S COMP AP, P701; Weinstein MC, 1980, CLIN DECISION ANAL	16	254	256	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1185	1190		10.1001/jama.273.15.1185	http://dx.doi.org/10.1001/jama.273.15.1185			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT100	7707625				2022-12-24	WOS:A1995QT10000026
J	YIN, JCP; DELVECCHIO, M; ZHOU, H; TULLY, T				YIN, JCP; DELVECCHIO, M; ZHOU, H; TULLY, T			CREB AS A MEMORY MODULATOR - INDUCED EXPRESSION OF A DCREB2 ACTIVATOR ISOFORM ENHANCES LONG-TERM-MEMORY IN DROSOPHILA	CELL			English	Article							CAMP-RESPONSIVE-ELEMENT; APLYSIA SENSORY NEURONS; WITHDRAWAL REFLEX; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; PROTEIN-SYNTHESIS; GILL-WITHDRAWAL; BINDING; MELANOGASTER; PHOSPHORYLATION	Genetic studies of memory formation in Drosophila have revealed that the formation of a protein synthesis-dependent long-term memory (LTM) requires multiple training sessions. LTM is blocked specifically by induced expression of a repressor isoform of the cAMP-responsive element-binding protein (CREB). Here, we report an enhancement of LTM formation after induced expression of an activator isoform of dCREB2. Maximum LTM is achieved after one training session, and its formation depends on phosphorylation of the activator transgene. A model of LTM formation based on differential regulation of CREB isoforms is proposed.			YIN, JCP (corresponding author), COLD SPRING HARBOR LAB,1 BUNGTOWN RD,COLD SPRING HARBOR,NY 11724, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032245] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32245] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ARMSTRONG RC, 1993, ANNU REV NEUROSCI, V16, P17, DOI 10.1146/annurev.ne.16.030193.000313; BACKSAI BJ, 1993, SCIENCE, V260, P222; BAILEY CH, 1994, SEMIN NEUROSCI, V6, P35; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOYNTON S, 1992, GENETICS, V131, P655; BUONOMANO DV, 1990, SCIENCE, V249, P420, DOI 10.1126/science.2165631; Byrne John H., 1993, V27, P47; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CAREW TJ, 1972, SCIENCE, V175, P451, DOI 10.1126/science.175.4020.451; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DURA JM, 1993, J NEUROGENET, V9, P1, DOI 10.3109/01677069309167272; Ebbinghaus, 1885, GEDACHTNIS; ERBER J, 1976, J COMP PHYSIOL PSYCH, V90, P41, DOI 10.1037/h0077258; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GALL CM, 1991, MEMORY ORG LOCUS CHA, P301; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GOELET P, 1986, TRENDS NEUROSCI, V9, P492, DOI 10.1016/0166-2236(86)90157-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENOUGH WT, 1984, TRENDS NEUROSCI, V7, P229, DOI 10.1016/S0166-2236(84)80211-8; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hintzman D. L., 1974, THEORIES COGNITIVE P, P77; Huang Y Y, 1994, Learn Mem, V1, P74; JAFFE K, 1980, PHYSIOL BEHAV, V25, P367, DOI 10.1016/0031-9384(80)90275-9; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KANDEL ER, 1987, SYNAPTIC FUNCTION, P471; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LEWIS D, 1960, QUANTITATIVE METHODS; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; Menzel R., 1990, NEUROBIOLOGY COMP CO, P237; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NAZIF FA, 1991, BRAIN RES, V539, P324, DOI 10.1016/0006-8993(91)91638-H; PALMERINO CC, 1980, SCIENCE, V208, P753, DOI 10.1126/science.7367891; PIROTTA V, 1988, SURVEY MOL CLONING V, P427; QIU YH, 1993, GENE DEV, V7, P1447, DOI 10.1101/gad.7.7b.1447; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; Sokal R. R, 1981, BIOMETRY; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STEWART MG, 1991, NEURAL BEHAVIOURAL P, P305; SUN P, 1984, GENE DEV, V8, P2527; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1993, J NEUROGENET, V9, P55, DOI 10.3109/01677069309167275; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	67	545	570	2	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					107	115		10.1016/0092-8674(95)90375-5	http://dx.doi.org/10.1016/0092-8674(95)90375-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720066	Bronze			2022-12-24	WOS:A1995QR97000012
J	RYAN, M				RYAN, M			RUSSIAN REPORT - ALCOHOLISM AND RISING MORTALITY IN THE RUSSIAN-FEDERATION	BRITISH MEDICAL JOURNAL			English	Article								In the Russian Federation today the high incidence of alcoholism and drunkenness helps to account for rising death rates, more particularly among the male population. During the mid-1980s a significant reduction in deaths from alcohol related diseases was achieved by state action in curtailing the supply of alcohol. However, official data disclose a pattern of sharply increased consumption per head since 1987, with high proof drinks-especially vodka-now forming a larger share in the total. In current economic conditions the effects of a traditional macho drinking culture are exacerbated by a reduction of state control over the quality of alcohol available for purchase. A substantial increase has occurred in deaths from most principal causes, with a disproportionate increase in deaths from non-natural causes, including deaths caused predominantly by alcohol. Average expectation of life at birth has fallen especially sharply for men; by 1993 it had slumped to 59.0 years-that is, to below the age at which a pension starts to be paid.			RYAN, M (corresponding author), UNIV COLL SWANSEA,CTR RUSSIAN & E EUROPEAN STUDIES,SWANSEA SA2 8PP,W GLAM,WALES.							NEMTSOV A, 1994, IZVESZIYA, P19; RYAN M, 1990, CONT SOVIET SOC STAT, P253; 1993, ROSSIISKIE VESTI, V255, P4; 1994, ZDRAVOOKHRANENIE ROS, V3, P3	4	63	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					646	648						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QL984	7703754				2022-12-24	WOS:A1995QL98400023
J	MARTENSON, C; STONE, K; REEDY, M; SHEETZ, M				MARTENSON, C; STONE, K; REEDY, M; SHEETZ, M			FAST AXONAL-TRANSPORT IS REQUIRED FOR GROWTH CONE ADVANCE	NATURE			English	Article							NERVE-CELLS; CYTOSKELETON; DYNAMICS; MEMBRANE; TUBULIN; TENSION	GROWTH cones are capable of advancing despite linkage to a stationary axonal cytoskeleton in chick and murine dorsal root ganglion neurites1,2. Several lines of evidence point to the growth cone as the site of cytoskeletal elongation3,4. Fast axonal transport is probably the means by which cytoskeletal elements5 or cofactors are rapidly moved through the axon. We report that direct, but reversible, inhibition of fast axonal transport with laser optical tweezers inhibits growth cone motility if cytoskeletal attachment to the cell body is maintained. Advancement ceases after a distance-dependent lag period which correlates with the rate of fast axonal transport. But severing the axonal cytoskeleton with the laser tweezers allows growth cones to advance considerably further. We suggest that axon elongation requires fast axonal transport but growth cone motility does not.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University								ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; BAMBURG JR, 1986, NATURE, V321, P788, DOI 10.1038/321788a0; BRAY D, 1979, J CELL SCI, V37, P391; BROWN A, 1992, J CELL BIOL, V119, P867, DOI 10.1083/jcb.119.4.867; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; HOLLENBECK PJ, 1987, J CELL BIOL, V105, P2827, DOI 10.1083/jcb.105.6.2827; KUCIK DF, 1991, J CELL BIOL, V114, P1029, DOI 10.1083/jcb.114.5.1029; LAMOUREUX P, 1989, Nature (London), V340, P159, DOI 10.1038/340159a0; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; OKABE S, 1990, NATURE, V343, P479, DOI 10.1038/343479a0; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; SHAW G, 1977, EXP CELL RES, V104, P55, DOI 10.1016/0014-4827(77)90068-4	14	44	45	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					66	69		10.1038/366066a0	http://dx.doi.org/10.1038/366066a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	7694151				2022-12-24	WOS:A1993MF00700055
J	TAN, YH				TAN, YH			YIN AND YANG OF PHOSPHORYLATION IN CYTOKINE SIGNALING	SCIENCE			English	Editorial Material							OKADAIC ACID MIMICS; TRANSCRIPTION FACTOR; INTERFERON-ALPHA; PROTEIN; TYROSINE; PHOSPHATASE; ACTIVATION; KINASE; CALCINEURIN; EXPRESSION				TAN, YH (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE.							Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAO XM, 1993, J BIOL CHEM, V268, P16949; CAO XM, 1992, J BIOL CHEM, V267, P12991; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVIDSON WF, 1979, J IMMUNOL, V122, P884; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUESDON F, 1993, J BIOL CHEM, V261, P358; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HIGUCHI T, 1990, J INTERFERON RES, V10, P413, DOI 10.1089/jir.1990.10.413; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KORETZKY GA, 1990, NATURE, V346, P2037; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MENSON SD, IN PRESS J BIOL CHEM; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367, DOI 10.1146/annurev.iy.05.040187.002055; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; THOMAS JD, 1993, J BIOL CHEM, V261, P355; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; YAP WH, 1986, SCIENCE, V234, P355, DOI 10.1126/science.2429366; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	31	28	32	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					376	377		10.1126/science.7692598	http://dx.doi.org/10.1126/science.7692598			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	7692598				2022-12-24	WOS:A1993MB85900043
J	FUNG, PA; GAERTIG, J; GOROVSKY, MA; HALLBERG, RL				FUNG, PA; GAERTIG, J; GOROVSKY, MA; HALLBERG, RL			REQUIREMENT OF A SMALL CYTOPLASMIC RNA FOR THE ESTABLISHMENT OF THERMOTOLERANCE	SCIENCE			English	Article							HEAT-SHOCK RESPONSE; III-TRANSCRIBED RNA; TETRAHYMENA-THERMOPHILA; PROTEIN-SYNTHESIS	Thermotolerance is an inducible state that endows cells with an enhanced resistance to thermal killing. Heat shock proteins are believed, and in a few instances have been shown, to be the agents conferring this resistance. The role of a small cytoplasmic RNA (G8 RNA) in developing thermotolerance in Tetrahymena thermophila was investigated by creating a strain devoid of all functional G8 genes. These G8 null cells mounted an apparently normal heat shock response, but they were unable to establish thermotolerance.	SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13244; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	Syracuse University; University of Rochester			Gaertig, Jacek/F-1553-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026973, R01GM046302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46302, GM26973] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		FUNG PA, UNPUB; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GAERTIG JA, 1994, P NATL ACAD SCI USA, V91, P9196; HALLBERG EM, 1992, NUCLEIC ACIDS RES, V20, P912, DOI 10.1093/nar/20.4.912; HALLBERG EM, UNPUB; HALLBERG RL, 1981, CELL, V26, P47, DOI 10.1016/0092-8674(81)90032-5; HALLBERG RL, 1984, MOL CELL BIOL, V4, P2170, DOI 10.1128/MCB.4.10.2170; HALLBERG RL, 1985, MOL CELL BIOL, V5, P2061, DOI 10.1128/MCB.5.8.2061; HALLBERG RL, 1986, MOL CELL BIOL, V6, P2267, DOI 10.1128/MCB.6.6.2267; HALLBERG RL, 1989, STRESS INDUCED PROTE, P107; HALLBERG RL, 1983, MOL CELL BIOL, V3, P502; KAHN RW, 1993, P NATL ACAD SCI USA, V90, P9295, DOI 10.1073/pnas.90.20.9295; KRAUS KW, 1987, P NATL ACAD SCI USA, V84, P383, DOI 10.1073/pnas.84.2.383; KRAUS KW, 1986, MOL CELL BIOL, V6, P3854, DOI 10.1128/MCB.6.11.3854; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MCMULLIN TW, 1987, MOL CELL BIOL, V7, P4414, DOI 10.1128/MCB.7.12.4414; MCMULLIN TW, 1986, MOL CELL BIOL, V6, P2527, DOI 10.1128/MCB.6.7.2527; NOVER L., 1991, HEAT SHOCK RESPONSE; Parsell DA, 1994, BIOL HEAT SHOCK PROT; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365	21	18	18	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1036	1039		10.1126/science.7754381	http://dx.doi.org/10.1126/science.7754381			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754381				2022-12-24	WOS:A1995QY93400037
J	STEPHENS, R; SPURGEON, A; CALVERT, IA; BEACH, J; LEVY, LS; BERRY, H; HARRINGTON, JM				STEPHENS, R; SPURGEON, A; CALVERT, IA; BEACH, J; LEVY, LS; BERRY, H; HARRINGTON, JM			NEUROPSYCHOLOGICAL EFFECTS OF LONG-TERM EXPOSURE TO ORGANOPHOSPHATES IN SHEEP DIP	LANCET			English	Article							BEHAVIORAL-EVALUATION; PESTICIDES; WORKERS; SYSTEM	Organophosphate-based pesticides are widely used throughout the world. The acute effects of over-exposure to such compounds are well known. Concern has also been expressed that long-term exposure may result in damage to the nervous system. In a cross-sectional study, we compared neuropsychological performance in 146 sheep farmers who were exposed to organophosphates in the course of sheep dipping with 143 non-exposed quarry workers (controls). The farmers performed significantly worse than controls in tests to assess sustained attention and speed of information processing. These effects remained after adjustment for covariates. The farmers also showed greater vulnerability to psychiatric disorder than did the controls as measured by the General Health Questionnaire. There were no observed effects on short-term memory and learning. Repeated exposure to organophosphate-based pesticides appears to be associated with subtle changes in the nervous system. Measures should be taken to reduce exposure to organophosphates as far as possible during agricultural operations.	UNIV BIRMINGHAM,INST OCCUPAT HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; HLTH & SAFETY EXECUT,OCCUPAT MED & HYG LAB,SHEFFIELD S3 7HQ,S YORKSHIRE,ENGLAND	University of Birmingham			Stephens, Richard/C-4062-2009	Stephens, Richard/0000-0002-5851-8975				BAKER EL, 1985, J OCCUP ENVIRON MED, V27, P206; BENNETTLEVY J, 1980, BRIT J SOC CLIN PSYC, V19, P177, DOI 10.1111/j.2044-8260.1980.tb00946.x; DAVIES JE, 1991, AM J IND MED, V18, P327; DILLNER L, 1994, BRIT MED J, V308, P1001, DOI 10.1136/bmj.308.6935.1001; Gallo M.A., 1991, HDB PESTICIDE TOXICO, V2; GOLDBERG D, 1985, BRIT MED J, V291, P161, DOI 10.1136/bmj.291.6489.161; MAIZLISH N, 1987, AM J IND MED, V12, P153, DOI 10.1002/ajim.4700120205; MEARNS J, 1994, J CLIN PSYCHOL, V50, P286, DOI 10.1002/1097-4679(199403)50:2<286::AID-JCLP2270500223>3.0.CO;2-P; NIVEN KJM, 1993, IOM TM9303 I OCC MED; NUTLEY BP, 1993, PESTIC SCI, V38, P315, DOI 10.1002/ps.2780380406; RODNITZKY RL, 1975, ARCH ENVIRON HEALTH, V30, P98, DOI 10.1080/00039896.1975.10666651; ROSENSTOCK L, 1991, LANCET, V338, P223, DOI 10.1016/0140-6736(91)90356-T; SAVAGE EP, 1988, ARCH ENVIRON HEALTH, V43, P38, DOI 10.1080/00039896.1988.9934372; STEENLAND K, 1994, AM J PUBLIC HEALTH, V84, P5; STOLLERY BT, 1988, SCAND J WORK ENV HEA, V14, P45, DOI 10.5271/sjweh.1951; STOLLERY BT, 1990, MICROCOMPUTERS PSYCH	16	240	250	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1135	1139		10.1016/S0140-6736(95)90976-1	http://dx.doi.org/10.1016/S0140-6736(95)90976-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QW622	7723544				2022-12-24	WOS:A1995QW62200008
J	SHIMIZU, S; EGUCHI, Y; KOSAKA, H; KAMIIKE, W; MATSUDA, H; TSUJIMOTO, Y				SHIMIZU, S; EGUCHI, Y; KOSAKA, H; KAMIIKE, W; MATSUDA, H; TSUJIMOTO, Y			PREVENTION OF HYPOXIA-INDUCED CELL-DEATH BY BCL-2 AND BCL-XL	NATURE			English	Article							PRE-B-CELLS; CHROMOSOMAL BREAKPOINT; FOLLICULAR LYMPHOMA; GROWTH-FACTOR; C-ELEGANS; GENE; SURVIVAL; PROTEIN; INVOLVEMENT; EXPRESSION	THE proto-oncogene bcl-2, isolated from the t(14;18) chromosomal breakpoint in follicular B-lymphoma(1-3), and a bcl-2related gene bcl-x (ref. 4) prevent apoptotic cell death induced by various treatments(5-8). Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS)(910) expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia), which drastically decreases the net formation of oxygen free radicals and does not increase oxidized lipid, protein or DNA. Furthermore, neither ROS scavenger nor inhibitor of ROS scavenger affects cell death, regardless of the expression of Bcl-2 or Bcl-xL. Thus our data suggest that Bcl-2 and Bcl-xL exert an anti-fell death function by a mechanism other than regulation of ROS activity.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT MED GENET,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PHYSIOL,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University; Osaka University								BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORZILLO GV, 1992, ONCOGENE, V7, P869; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HIROTA K, 1987, CANCER RES, V47, P3742; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; ITOH N, 1993, J IMMUNOL, V151, P621; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KHALBUSS WE, 1991, HEPATOLOGY, V13, P962, DOI 10.1016/0270-9139(91)90271-V; KU RH, 1986, ARCH BIOCHEM BIOPHYS, V247, P183, DOI 10.1016/0003-9861(86)90547-3; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TAKEUCHI T, 1993, BIOCHEM BIOPH RES CO, V194, P57, DOI 10.1006/bbrc.1993.1784; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	28	606	625	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					811	813		10.1038/374811a0	http://dx.doi.org/10.1038/374811a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723826				2022-12-24	WOS:A1995QV31500047
J	NOWAK, MW; KEARNEY, PC; SAMPSON, JR; SAKS, ME; LABARCA, CG; SILVERMAN, SK; ZHONG, W; THORSON, JS; ABELSON, JN; DAVIDSON, N; SCHULTZ, PG; DOUGHERTY, DA; LESTER, HA				NOWAK, MW; KEARNEY, PC; SAMPSON, JR; SAKS, ME; LABARCA, CG; SILVERMAN, SK; ZHONG, W; THORSON, JS; ABELSON, JN; DAVIDSON, N; SCHULTZ, PG; DOUGHERTY, DA; LESTER, HA			NICOTINIC RECEPTOR-BINDING SITE PROBED WITH UNNATURAL AMINO-ACID-INCORPORATION IN INTACT-CELLS	SCIENCE			English	Article							TRANSFER RNA-SYNTHETASE; ACETYLCHOLINE-RECEPTOR; ALPHA-SUBUNIT; RECOGNITION; PHENYLALANINE; CONSTRUCTION; SUPPRESSION; NUCLEOTIDES; MUTATIONS; ANTICODON	The nonsense codon suppression method for unnatural amino acid incorporation has been applied to intact Cells and combined with electrophysiological analysis to probe structure-function relations in the nicotinic acetylcholine receptor, Functional receptors were expressed in Xenopus oocytes when tyrosine and phenylalanine derivatives were incorporated at positions 93, 190, and 198 in the binding site of the a subunit, Subtle changes in the structure of an individual side chain produced readily detectable changes in the function of this large channel protein, At each position, distinct features of side chain structure dominated the dose-response relation, probably by governing the agonist-receptor binding.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT CHEM, BERKELEY, CA 94720 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California Berkeley	NOWAK, MW (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.		Thorson, Jon S/L-3696-2013	Thorson, Jon S/0000-0002-7148-0721; Nowak, Mark/0000-0001-5097-2682; Silverman, Scott/0000-0001-8166-3460				ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ADAMS PR, 1981, J MEMBRANE BIOL, V58, P161, DOI 10.1007/BF01870902; AYLWIN ML, 1994, MOL PHARMACOL, V46, P1149; BAIN JD, 1989, J AM CHEM SOC, V111, P8013, DOI 10.1021/ja00202a052; BIENZ M, 1980, NUCLEIC ACIDS RES, V8, P5169, DOI 10.1093/nar/8.22.5169; CACCHI S, 1992, TETRAHEDRON LETT, V33, P3939, DOI 10.1016/S0040-4039(00)74824-6; COHEN JB, 1991, J BIOL CHEM, V266, P23354; CORNISH VW, 1994, P NATL ACAD SCI USA, V91, P2910, DOI 10.1073/pnas.91.8.2910; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; ELLMAN JA, 1992, METHOD ENZYMOL, V202, P301; England T E, 1980, Methods Enzymol, V65, P65; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Hammett LP, 1937, J AM CHEM SOC, V59, P96, DOI 10.1021/ja01280a022; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; LEVITT LS, 1976, PROG PHYS ORG CHEM, V12, P119; LIN SX, 1984, BIOCHEMISTRY-US, V23, P4109, DOI 10.1021/bi00313a015; MENDEL D, 1991, J AM CHEM SOC, V113, P2758, DOI 10.1021/ja00007a063; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P3957, DOI 10.1073/pnas.87.10.3957; NAZARENKO IA, 1992, NUCLEIC ACIDS RES, V20, P475, DOI 10.1093/nar/20.3.475; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; QUICK MW, 1994, ION CHANNELS EXCITAB, P261; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAMPSON JR, 1992, BIOCHEMISTRY-US, V31, P4161, DOI 10.1021/bi00132a002; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SINE SM, 1994, J BIOL CHEM, V269, P8808; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; THORSON JS, IN PRESS J AM CHEM S; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; Topsom, 1976, PROG PHYS ORG CHEM, V12, P1, DOI DOI 10.1002/9780470171912.CHL; Unger S.H., 1976, PROG PHYS ORG CHEM, V12, P91, DOI 10.1002/9780470171912.ch4; URRY DW, 1993, J AM CHEM SOC, V115, P7509, DOI 10.1021/ja00069a063; YARUS M, 1982, SCIENCE, V218, P646, DOI 10.1126/science.6753149; YOSHII K, 1987, J GEN PHYSIOL, V90, P553, DOI 10.1085/jgp.90.4.553	42	209	276	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					439	442		10.1126/science.7716551	http://dx.doi.org/10.1126/science.7716551			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716551				2022-12-24	WOS:A1995QU57200047
J	KOLETZKO, S; HAISCH, M; SEEBOTH, I; BRADEN, B; HENGELS, K; KOLETZKO, B; HERING, P				KOLETZKO, S; HAISCH, M; SEEBOTH, I; BRADEN, B; HENGELS, K; KOLETZKO, B; HERING, P			ISOTOPE-SELECTIVE NONDISPERSIVE INFRARED SPECTROMETRY FOR DETECTION OF HELICOBACTER-PYLORI INFECTION WITH C-13-UREA BREATH TEST	LANCET			English	Note								C-13-urea breath tests were sampled in 51 subjects with an isotope-selective non-dispersive infrared spectrometer (NDIRS) and compared with the results of conventional isotope-ratio mass-spectrometry (IRMS). Delta-over-baseline values oi both methods correlated well (r=0.976 at 15 min and 0.985 at 30 min, both p<0.0005). With a cut-off for delta-over-baseline values of 5 parts per thousand (ie, 5 per thousand), both methods correctly classified all 36 Helicobacter-pylori-negative and all 15 H-pylori-positive subjects. All infected subjects had values over 11 parts per thousand in all samples with both methods. NDIRS is of equal value as IRMS for the diagnosis of H pylori infection. Because NDIRS gives on-line results and is easier and cheaper, we consider NDIRS useful for clinical practice.	UNIV DUSSELDORF,INST LASER MED,DUSSELDORF,GERMANY; UNIV DUSSELDORF,MED KLIN,DUSSELDORF,GERMANY; UNIV FRANKFURT,MED KLIN,FRANKFURT,GERMANY; MAX PLANCK INST QUANTUM OPT,GARCHING,GERMANY	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Goethe University Frankfurt; Max Planck Society	KOLETZKO, S (corresponding author), UNIV MUNICH,KINDERPOLIKLIN,PETTENKOFERSTR 8A,D-80336 MUNICH,GERMANY.		Braden, Barbara/AAI-7869-2020; Braden, Barbara/AAH-8693-2021	Braden, Barbara/0000-0002-8534-6873; 				BRADEN B, 1994, Z GASTROENTEROL, V32, P198; CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8; DEMMELMAIR H, IN PRESS J PEDIATR G; DILL S, 1990, GUT, V31, P1237, DOI 10.1136/gut.31.11.1237; EGGERS RH, 1990, EUR J GASTROEN HEPAT, V2, P437; GHOOS YF, 1993, GASTROENTEROLOGY, V104, P1640, DOI 10.1016/0016-5085(93)90640-X; HAISCH M, IN PRESS ISOTOPENPRA; LOTTERER E, 1991, Z GASTROENTEROL, V29, P590; VANDENPLAS Y, 1992, PEDIATRICS, V90, P608	9	156	160	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					961	962		10.1016/S0140-6736(95)90704-1	http://dx.doi.org/10.1016/S0140-6736(95)90704-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715299				2022-12-24	WOS:A1995QT91900014
J	TZOURIO, C; TEHINDRAZANARIVELO, A; IGLESIAS, S; ALPEROVITCH, A; CHEDRU, F; DANGLEJANCHATILLON, J; BOUSSER, MG				TZOURIO, C; TEHINDRAZANARIVELO, A; IGLESIAS, S; ALPEROVITCH, A; CHEDRU, F; DANGLEJANCHATILLON, J; BOUSSER, MG			CASE-CONTROL STUDY OF MIGRAINE AND RISK OF ISCHEMIC STROKE IN YOUNG-WOMEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLATELET AGGREGABILITY; PREVALENCE; FEATURES; ADULTS	Objective-To determine whether migraine is a risk factor for ischaemic stroke in young women. Design-A case-control study. Setting-Five hospitals in Paris and suburbs. Subjects-72 women aged under 45 with ischaemic stroke and 173 controls randomly selected from women hospitalised in the same centres. Main outcome measures-Ischaemic stroke confirmed by cerebral computerised tomography or magnetic resonance imaging; history of headache recorded with structured interview, and diagnosis of migraine assessed by reproducibility study. Results-Ischaemic stroke was strongly associated with migraine, both migraine without aura (odds ratio 3.0 (95% confidence interval 1.5 to 5.8)) and migraine with aura (odds ratio 6.2 (2.1 to 18.0)). The risk of ischaemic stroke was substantially increased for migrainous women who were using oral contraceptives (odds ratio 13.9) or who were heavy smokers (greater than or equal to 20 cigarettes/day) (odds ratio 10.2). Conclusions-These results indicate an independent association between migraine and the risk of ischaemic stroke in young women. Although the absolute risk of ischaemic stroke in young women with migraine is low, the reduction of known risk factors for stroke, in particular smoking and use of oral contraceptives, should be considered in this group.	HOP ST ANTOINE, SERV NEUROL, F-75571 PARIS, FRANCE; HOP MEAUX, SERV NEUROL, MEAUX, FRANCE; HOP VERSAILLES, SERV NEUROL, VERSAILLES, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre Hospitalier de Versailles	TZOURIO, C (corresponding author), INSERM, U360, UNITE RECH EPIDEMIOL NEUROL & PSYCHOPATHOL, F-94807 VILLEJUIF, FRANCE.		Tzourio, christophe/L-6344-2019; Tzourio, Christophe I/B-7459-2008; Tzourio, christophe/B-4015-2009	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984				[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; Breslow N, 1980, STATISTICAL METHODS, V32; COUCH JR, 1977, NEUROLOGY, V27, P843, DOI 10.1212/WNL.27.9.843; Fleiss JL, 1981, STAT METHODS RATES P; Gawel M J, 1982, Adv Neurol, V33, P237; HENRICH JB, 1989, J CLIN EPIDEMIOL, V42, P773, DOI 10.1016/0895-4356(89)90075-9; HENRY P, 1992, CEPHALALGIA, V12, P229, DOI 10.1046/j.1468-2982.1992.1204229.x; KALENDOVSKY Z, 1975, ARCH NEUROL-CHICAGO, V32, P13, DOI 10.1001/archneur.1975.00490430035004; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LEVINE SR, 1989, ANN NEUROL, V26, P386, DOI 10.1002/ana.410260312; LIDEGAARD O, 1987, ACTA NEUROL SCAND, V75, P427, DOI 10.1111/j.1600-0404.1987.tb05473.x; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; MARINI C, 1993, NEUROEPIDEMIOLOGY, V12, P70, DOI 10.1159/000110303; MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751; PEARSON AC, 1991, J AM COLL CARDIOL, V18, P1223, DOI 10.1016/0735-1097(91)90539-L; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; SCHOENBERG BS, 1970, NEUROLOGY, V20, P181, DOI 10.1212/WNL.20.2.181; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; TATEMICHI TK, 1992, STROKE PATHOPHYSIOLO, P761; TZOURIO C, 1993, BMJ-BRIT MED J, V307, P289, DOI 10.1136/bmj.307.6899.289; 1990, SAS USERS GUIDE STAT, V1	21	353	364	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	1995	310	6983					830	833		10.1136/bmj.310.6983.830	http://dx.doi.org/10.1136/bmj.310.6983.830			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711619	Green Published			2022-12-24	WOS:A1995QQ85700017
J	AULD, DS; SCHIMMEL, P				AULD, DS; SCHIMMEL, P			SWITCHING RECOGNITION OF 2 TRANSFER-RNA SYNTHETASES WITH AN AMINO-ACID SWAP IN A DESIGNED PEPTIDE	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; GLUTAMINYL-TRANSFER RNA; ESCHERICHIA-COLI; BINDING-SITE; ANTICODON BINDING; SEQUENCES; PROTEIN; IDENTIFICATION; AMINOACYLATION; CODON	The genetic code is based on specific interactions between transfer RNA (tRNA) synthetases and their cognate tRNAs. The anticodons for methionine and isoleucine tRNAs differ by a single nucleotide, and changing this nucleotide in an isoleucine tRNA is sufficient to change aminoacylation specificity to methionine. Results of combinatorial mutagenesis of an anticodon-binding-helix loop peptide were used to design a hybrid sequence composed of amino acid residues from methionyl- and isoleucyl-tRNA synthetases. When the hybrid sequence was transplanted into isoleucyl-tRNA synthetase, active enzyme was generated in vivo and in vitro. The transplanted peptide did not confer function to methionyl-tRNA synthetase, but the substitution of a single amino acid within the transplanted peptide conferred methionylation and prevented isoleucylation. Thus, the swap of a single amino acid in the transplanted peptide switches specificity between anticodons that differ by one nucleotide.			AULD, DS (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER DG, 1982, EUR J BIOCHEM, V127, P449; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BURBAUM JJ, 1991, BIOCHEMISTRY-US, V30, P319, DOI 10.1021/bi00216a002; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1690, DOI 10.1021/bi00869a034; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; GHOSH G, 1990, BIOCHEMISTRY-US, V29, P2220, DOI 10.1021/bi00461a003; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; IACCARINO M, 1971, J BACTERIOL, V105, P527, DOI 10.1128/JB.105.2.527-537.1971; KIM S, 1993, P NATL ACAD SCI USA, V90, P10046, DOI 10.1073/pnas.90.21.10046; KIM SH, 1994, BIOCHEMISTRY-US, V33, P11040, DOI 10.1021/bi00202a025; KIM SH, 1992, J BIOL CHEM, V267, P15563; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRO JA, 1993, P NATL ACAD SCI USA, V90, P2261, DOI 10.1073/pnas.90.6.2261; MEINNEL T, 1991, P NATL ACAD SCI USA, V88, P291, DOI 10.1073/pnas.88.1.291; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MURAMATSU T, 1988, J BIOL CHEM, V263, P9261; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; SCHIMMEL P, 1992, PROTEIN SCI, V1, P1387, DOI 10.1002/pro.5560011018; SCHMIDT E, 1993, P NATL ACAD SCI USA, V90, P6919, DOI 10.1073/pnas.90.15.6919; SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; STARZYK RM, 1989, BIOCHEMISTRY-US, V28, P8479, DOI 10.1021/bi00447a031; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; VALENZUELA D, 1986, BIOCHEMISTRY-US, V25, P4555, DOI 10.1021/bi00364a015; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712	25	43	44	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1994	1996		10.1126/science.7701322	http://dx.doi.org/10.1126/science.7701322			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701322				2022-12-24	WOS:A1995QQ06800044
J	GILMAN, EA; CHENG, KK; WINTER, HR; SCRAGG, R				GILMAN, EA; CHENG, KK; WINTER, HR; SCRAGG, R			TRENDS IN RATES AND SEASONAL DISTRIBUTION OF SUDDEN INFANT DEATHS IN ENGLAND AND WALES, 1988-92	BRITISH MEDICAL JOURNAL			English	Article									UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND	University of Auckland	GILMAN, EA (corresponding author), UNIV BIRMINGHAM,SCH MED,INST PUBL & ENVIRONM HLTH,DEPT EPIDEMIOL & PUBL HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Cheng, Kar/AAL-8899-2021	Cheng, Kar/0000-0002-1516-1857; Scragg, Robert/0000-0003-0013-2620				LITTLE RE, 1990, EPIDEMIOL REV, V12, P241, DOI 10.1093/oxfordjournals.epirev.a036057; MITCHELL EA, 1994, ARCH DIS CHILD, V76, P291; 1993, REPORT CHIEF MED OFF; 1993, DH3932 OPCS MON SER	4	20	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					631	632		10.1136/bmj.310.6980.631	http://dx.doi.org/10.1136/bmj.310.6980.631			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703750	Green Published			2022-12-24	WOS:A1995QL98400016
J	SMALLEY, WE; GRIFFIN, MR; FOUGHT, RL; SULLIVAN, L; RAY, WA				SMALLEY, WE; GRIFFIN, MR; FOUGHT, RL; SULLIVAN, L; RAY, WA			EFFECT OF A PRIOR-AUTHORIZATION REQUIREMENT ON THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS BY MEDICAID PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PAYMENT; THERAPY	Background. Prior authorization - mandatory advance approval for the use of expensive medications - is now the primary method by which Medicaid programs control expenditures for drugs. However, whether this policy reduces expenditures for specific drugs without causing the unwanted substitution of other drugs or medical services has been largely unstudied. We evaluated the effects of a prior-authorization policy involving nongeneric nonsteroidal antiinflammatory drugs (NSAIDs) in the Medicaid program in Tennessee. Methods. We compared monthly Medicaid expenditures that were potentially affected by the policy change during the year before and the two years after its implementation. We studied prescriptions for NSAIDs, other analgesic or antiinflammatory drugs, and psychotropic drugs, as well as outpatient services and inpatient admissions for the management of pain or inflammation. Results. At the midpoint of the base-line year, 495,821 people were enrolled in Medicaid. During that year, mean annualized Medicaid expenditures for NSAID prescriptions amounted to $22.41. Expenditures decreased by 53 percent (95 percent confidence interval, 48 to 57 percent) during the next two years, for an estimated savings of $12.8 million. The reduction in expenditures resulted from the increased use of generic NSAIDs, as well as from a 19 percent decrease in overall NSAID use (95 percent confidence interval, 13 to 25 percent). There was no concomitant increase in Medicaid expenditures for other medical care. Regular users of nongeneric NSAIDs, those most affected by the policy change, had similar reductions in NSAID expenditures and use, with no increase in expenditures for other medical care. Conclusions. Prior-authorization requirements may be highly cost effective with regard to expenditures for NSAIDs, drugs that have very similar efficacy and safety but substantial variation in cost.	VANDERBILT UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,NASHVILLE,TN 37212; VANDERBILT UNIV,SCH MED,DEPT MED,DIV GEN INTERNAL MED,NASHVILLE,TN 37212; TENNESSEE STATE DEPT HLTH,BUR TENNCARE,NASHVILLE,TN	Vanderbilt University; Vanderbilt University; Tennessee Department Health	SMALLEY, WE (corresponding author), VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,A-1124 MCN,NASHVILLE,TN 37232, USA.			Sullivan, Lisa/0000-0003-0726-7149	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007768] Funding Source: NIH RePORTER; AHRQ HHS [HS07768] Funding Source: Medline; FDA HHS [FD-U-0000073] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); FDA HHS		BATCHLOR EE, 1992, OSTEOARTHRITIS DIAGN, P465; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; Gondek K, 1994, Health Care Financ Rev, V15, P1; OLIN BR, 1992, DRUG FACTS COMP; POLLARD MR, 1991, HEALTH AFFAIR, V10, P196, DOI 10.1377/hlthaff.10.2.196; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P831, DOI 10.1001/jama.263.6.831; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; SOUMERAI SB, 1990, HEALTH AFFAIR, V9, P36, DOI 10.1377/hlthaff.9.3.36; TOMITA DK, 1988, PB89143325; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; 1980, INT CLASSIFICATION D; 1993, DRUG EVALUATIONS ANN; 1992, STAT B, V73, P25; 1994, SOCIAL SECURITY B AN, P325	20	137	137	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1612	1617		10.1056/NEJM199506153322406	http://dx.doi.org/10.1056/NEJM199506153322406			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753141	Bronze			2022-12-24	WOS:A1995RC19200006
J	ALMOND, N; KENT, K; CRANAGE, M; RUD, E; CLARKE, B; STOTT, EJ				ALMOND, N; KENT, K; CRANAGE, M; RUD, E; CLARKE, B; STOTT, EJ			PROTECTION BY ATTENUATED SIMIAN IMMUNODEFICIENCY VIRUS IN MACAQUES AGAINST CHALLENGE WITH VIRUS-INFECTED CELLS	LANCET			English	Note							SIV INFECTION; NEF GENE	A vaccine against AIDS will probably have to protect against challenge both by viable virus-infected cells and by cell-free virus. Eight cynomolgus macaques infected with attenuated simian immunodeficiency virus (SIV) were challenged (four each) with cell-free and cell-associated SIV, All were protected, whereas eight controls were all infected after challenge. These findings show that live-attenuated vaccine can confer protection against SIV in macaques, Extrapolation to human beings will require extensive evaluation of the safety of attenuated retroviruses. Alternatively, the mechanism of this potent protection must be understood and reproduced by less hazardous means.	CTR APPL MICROBIOL & RES,SALISBURY,WILTS,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND; HLTH CANADA,LAB CTR DIS CONTROL,BUR HIV AIDS,OTTAWA,ON,CANADA	GlaxoSmithKline; Wellcome Research Laboratories; Health Canada	ALMOND, N (corresponding author), NATL INST BIOL STAND & CONTROLS,BLANCHE LANE S MIMMS,POTTERS BAR EN6 3QG,HERTS,ENGLAND.		Rud, Erling/P-5359-2016	Rud, Erling/0000-0001-8615-0277; Almond, Neil/0000-0001-6105-0616	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; KENT K, 1995, AIDS RES HUM RETROV, V10, P189; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; MILLS KHG, 1992, J MED PRIMATOL, V21, P50; MITCHELL T, 1992, J VIROL, V66, P5696, DOI 10.1128/JVI.66.9.5696-5702.1992; ROSE J, 1995, J VIROL METHODS, V57, P229; RUD EW, 1994, J GEN VIROL, V75, P529, DOI 10.1099/0022-1317-75-3-529; SABIN AB, 1992, P NATL ACAD SCI USA, V89, P8852, DOI 10.1073/pnas.89.18.8852; STOTT EJ, 1991, 6EME C CENT GARD PAR, P261	10	211	213	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1342	1344		10.1016/S0140-6736(95)92540-6	http://dx.doi.org/10.1016/S0140-6736(95)92540-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752758				2022-12-24	WOS:A1995RA14800011
J	GEISS, J; GLOECKLER, G; VONSTEIGER, R; BALSIGER, H; FISK, LA; GALVIN, AB; IPAVICH, FM; LIVI, S; MCKENZIE, JF; OGILVIE, KW; WILKEN, B				GEISS, J; GLOECKLER, G; VONSTEIGER, R; BALSIGER, H; FISK, LA; GALVIN, AB; IPAVICH, FM; LIVI, S; MCKENZIE, JF; OGILVIE, KW; WILKEN, B			THE SOUTHERN HIGH-SPEED STREAM - RESULTS FROM THE SWICS INSTRUMENT ON ULYSSES	SCIENCE			English	Article							POLAR CORONAL HOLE; SOLAR-WIND; MINOR IONS; IONIZATION EQUILIBRIUM; ABUNDANCES; SKYLAB; STATE	The high-speed solar wind streaming from the southern coronal hole was remarkably uniform and steady and was confined by a sharp boundary that extended to the corona and chromosphere. Charge state measurements indicate that the electron temperature in this coronal hole reached a maximum;of about 1.5 million kelvin within 3 solar radii of the sun. This result, combined with the observed lack of depletion of heavy elements, suggests that an additional source of momentum is required to accelerate the polar wind.	UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109; UNIV MARYLAND,DEPT PHYS,COLLEGE PK,MD 20742; MAX PLANCK INST AERON,D-37189 KATLENBURG DUHM,GERMANY; NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20771	University of Michigan System; University of Michigan; University System of Maryland; University of Maryland College Park; Max Planck Society; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	GEISS, J (corresponding author), UNIV BERN,INST PHYS,CH-3012 BERN,SWITZERLAND.		Livi, Stefano/H-5348-2012; Galvin, Antoinette/A-6114-2013; von Steiger, Rudolf/F-6822-2011	von Steiger, Rudolf/0000-0002-3350-0023				[Anonymous], 1989, AIP C, DOI DOI 10.1063/1.37985; ARNAUD M, 1992, ASTROPHYS J, V398, P394, DOI 10.1086/171864; Arnaud M., 1985, Astronomy & Astrophysics Supplement Series, V60, P425; BAME SJ, 1977, J GEOPHYS RES-SPACE, V82, P1487, DOI 10.1029/JA082i010p01487; BOCHSLER P, 1983, NASA CP2280 C PUBL, P613; BOCHSLER P, 1992, SOLAR WIND SEVEN, V3, P323; BURGI A, 1986, SOL PHYS, V103, P347, DOI 10.1007/BF00147835; BURGI A, 1987, J GEOPHYS RES, V92, P1057, DOI 10.1029/JA092iA02p01057; GEISS J, 1994, PHILOS T R SOC A, V349, P213, DOI 10.1098/rsta.1994.0126; GEISS J, 1995, SPACE SCI REV, V72, P49, DOI 10.1007/BF00768753; GEISS J, 1985, RAPPORTS ISOTOPIQUES, P213; GLOECKLER G, 1992, ASTRON ASTROPHYS SUP, V92, P267; GLOECKLER G, 1989, EOS T AGU, V70, P424; GOSLING JT, 1995, SPACE SCI REV, V72, P99, DOI 10.1007/BF00768761; HOLLWEG JV, 1981, J GEOPHYS RES-SPACE, V86, P8899, DOI 10.1029/JA086iA11p08899; HOLLWEG JV, 1986, J GEOPHYS RES-SPACE, V91, P4111, DOI 10.1029/JA091iA04p04111; HOLLWEG JV, 1978, REV GEOPHYS, V16, P689, DOI 10.1029/RG016i004p00689; HUBER MCE, 1974, ASTROPHYS J, V194, pL115, DOI 10.1086/181682; HUNDHAUSEN AJ, 1968, J GEOPHYS RES, V73, P5485, DOI 10.1029/JA073i017p05485; LALLEMENT R, 1986, J GEOPHYS RES, V91, P6751, DOI 10.1029/JA091iA06p06751; MARSDEN RG, 1986, SUN HELIOSPHERE 3 DI, P173; MCKENZIE JF, 1979, ASTROPHYS SPACE SCI, V64, P183, DOI 10.1007/BF00640041; MEYER JP, 1993, ADV SPACE RES, V13, P377, DOI 10.1016/0273-1177(93)90509-A; MUNRO RH, 1977, ASTROPHYS J, V213, P874, DOI 10.1086/155220; NOLTE JT, 1977, SOL PHYS, V51, P459, DOI 10.1007/BF00216379; OWOCKI SP, 1983, ASTROPHYS J, V275, P354, DOI 10.1086/161538; SHULL JM, 1982, ASTROPHYS J SUPPL S, V48, P95, DOI 10.1086/190769; TOUSEY R, 1973, SOL PHYS, V33, P265; VONSTEIGER R, 1989, ASTRON ASTROPHYS, V225, P222; VONSTEIGER R, 1992, ASTROPHYS J, V389, P791, DOI 10.1086/171252; WIELER R, 1993, LUNAR PLANET SCI, V24, P1519; WITHBROE GL, 1971, SOL PHYS, V21, P271	32	217	218	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1033	1036		10.1126/science.7754380	http://dx.doi.org/10.1126/science.7754380			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754380				2022-12-24	WOS:A1995QY93400036
J	PENNINGER, JM; WEN, T; TIMMS, E; POTTER, J; WALLACE, VA; MATSUYAMA, T; FERRICK, D; SYDORA, B; KRONENBERG, M; MAK, TW				PENNINGER, JM; WEN, T; TIMMS, E; POTTER, J; WALLACE, VA; MATSUYAMA, T; FERRICK, D; SYDORA, B; KRONENBERG, M; MAK, TW			SPONTANEOUS RESISTANCE TO ACUTE T-CELL LEUKEMIAS IN TCRV-GAMMA-1.1J-GAMMA-4C-GAMMA-4 TRANSGENIC MICE	NATURE			English	Article							DELTA-LYMPHOCYTES-T; GAMMA-DELTA; MYCOBACTERIUM-TUBERCULOSIS; ANTIGEN; RECEPTOR; EXPRESSION	THE concept of tumour surveillance implies that specific and nonspecific components of the immune system eliminate rumours in the early phase of malignancy(1,2). The immunological mechanisms that control growth-of preneoplastic cells are, however, not known. T cells expressing gamma delta T-cell receptors (TCR) were first described as lymphocytes with reactivity against various tumour cells, which suggests that gamma delta T cells could mediate tumour surveillance(3-6). Here we show that TCRV gamma 1.1J gamma 4C gamma 4 transgenic mice(7) are spontaneously resistant to acute T-cell leukaemias but cannot reject non-haematopoietic tumours. TCRV gamma 1.1J gamma 4C gamma 4(+) hybridomas isolated from these mice react in vitro against almost all haematopoietic tumour cell lines tested. Recognition of tumour cells depends on the gamma delta TCR but is independent of major histocompatibility complex (MHC) class I, MHC class II, or TAP-2 peptide transporter expression. Ligand recognition is influenced by the murine Nromp gene, which confers resistance or susceptibility to tuberculosis, lepra and leishmaniasis(8,9). These data indicate that TCRV gamma 1.1(+) T cells confer spontaneous immunity against haematopoietic rumours in vivo and link innate resistance to bacterial infections with tissue-specific tumour surveillance by gamma delta(+) T cells.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5X 1K9,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5X 1K9,CANADA; UNIV CALIF DAVIS,DEPT VET MICROBIOL & IMMUNOL,DAVIS,CA 95616; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024	University of Toronto; University of Toronto; University of California System; University of California Davis; University of California System; University of California Los Angeles	PENNINGER, JM (corresponding author), UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,500 SHERBOURNE ST,TORONTO,ON M5X 1K9,CANADA.		Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777				ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; BARTON CH, 1994, J EXP MED, V179, P1683, DOI 10.1084/jem.179.5.1683; BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; CORREA I, 1992, P NATL ACAD SCI USA, V89, P653, DOI 10.1073/pnas.89.2.653; DELIBERO G, 1991, J EXP MED, V173, P1311, DOI 10.1084/jem.173.6.1311; FERRICK DA, 1989, CELL, V57, P483, DOI 10.1016/0092-8674(89)90923-9; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; KABELITZ D, 1991, J EXP MED, V173, P1331, DOI 10.1084/jem.173.6.1331; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KLEIN G, 1993, CURR OPIN IMMUNOL, V5, P687, DOI 10.1016/0952-7915(93)90122-9; KRONENBERG M, 1994, CURR OPIN IMMUNOL, V6, P64, DOI 10.1016/0952-7915(94)90035-3; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; MUNK ME, 1990, J IMMUNOL, V145, P2434; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; PARDOLL DM, 1993, CURR OPIN IMMUNOL, V5, P719, DOI 10.1016/0952-7915(93)90127-E; RADZIOCH D, 1991, J LEUKOCYTE BIOL, V50, P263, DOI 10.1002/jlb.50.3.263; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SILVA CL, 1993, IMMUNOLOGY, V78, P35; UYEMURA K, 1992, J EXP MED, V174, P683; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; YEUNG RA, 1989, CELL, V59, P5	23	35	36	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					241	244		10.1038/375241a0	http://dx.doi.org/10.1038/375241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746326				2022-12-24	WOS:A1995QY88100065
J	LUO, Y; HURWITZ, J; MASSAGUE, J				LUO, Y; HURWITZ, J; MASSAGUE, J			CELL-CYCLE INHIBITION BY INDEPENDENT CDK AND PCNA BINDING DOMAINS IN P21(CIP1)	NATURE			English	Article							DEPENDENT KINASES; IDENTIFICATION; SUPPRESSION; SUBUNIT; P21	MAMMALIAN cell-cycle control by antimitogenic signals involves p21(Cip1/WAF1) (refs 1-4), p27(Kip1) (refs 5, 6) and p57(Kip2) (refs 7, 8), a family of proteins that bind to and inhibit cyclin-dependent kinases (CDKs) required for initiation of S phase. The protein p21 also binds to the DNA polymerase 6 processivity factor, proliferating-cell nuclear antigen (PCNA), and inhibits in vitro PCNA-dependent DNA replication(9,10). The CDK and PCNA inhibitory activities of p21 are shown here to be functionally independent and to reside in separate protein domains. The PCNA binding and inhibitory activities, which are not observed with p27 or p57, reside in the C-terminal domain of p21, whereas the CDK inhibitory activity resides in the conserved N-terminal domains of these proteins. When separately overexpressed in mammalian cells, the CDK and PCNA inhibitory domains prevent DNA replication, demonstrating a dual function of p21 as a cell-cycle inhibitor in vivo.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408				ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KELMAN Z, IN PRESS METH ENZYM; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	19	532	554	1	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					159	161		10.1038/375159a0	http://dx.doi.org/10.1038/375159a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753174				2022-12-24	WOS:A1995QX74100055
J	BOGOD, D				BOGOD, D			ADVANCES IN EPIDURAL ANALGESIA FOR LABOR - PROGRESS VERSUS PRUDENCE	LANCET			English	Editorial Material											BOGOD, D (corresponding author), CITY HOSP,DEPT ANAESTHESIA,NOTTINGHAM NG5 1PB,ENGLAND.							CHAMBERLAIN G, 1993, PAIN ITS RELIEF CHIL, P50; CHESTNUT DH, 1990, ANESTHESIOLOGY, V72, P613, DOI 10.1097/00000542-199004000-00006; Collis R E, 1994, Int J Obstet Anesth, V3, P75, DOI 10.1016/0959-289X(94)90173-2; GAMBLING DR, 1988, ANESTH ANALG, V33, P249; RUSSELL R, 1993, BRIT MED J, V306, P1299, DOI 10.1136/bmj.306.6888.1299; SMEDSTAD KG, 1988, CAN J ANAESTH, V35, P234, DOI 10.1007/BF03010616	6	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1129	1130		10.1016/S0140-6736(95)90973-7	http://dx.doi.org/10.1016/S0140-6736(95)90973-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723541				2022-12-24	WOS:A1995QW62200005
J	THOMPSON, NP; MONTGOMERY, SM; POUNDER, RE; WAKEFIELD, AJ				THOMPSON, NP; MONTGOMERY, SM; POUNDER, RE; WAKEFIELD, AJ			IS MEASLES VACCINATION A RISK FACTOR FOR INFLAMMATORY BOWEL-DISEASE	LANCET			English	Article							CROHNS-DISEASE; ULCERATIVE-COLITIS; VIRUS-INFECTION; EPIDEMIOLOGY	Measles virus may persist in intestinal tissue, particularly that affected by Crohn's disease, and early exposure to measles may be a risk factor for the development of Crohn's disease. Crohn's disease and ulcerative colitis occur in the same families and may share a common aetiology. in view of the rising incidence of inflammatory bowel disease (Crohn's disease and ulcerative colitis), we examined the impact of measles vaccination upon these conditions. Prevalences of Crohn's disease, ulcerative colitis, coeliac disease, and peptic ulceration were determined in 3545 people who had received live measles Vaccine in 1964 as part of a measles vaccine trial. A longitudinal birth cohort of 11 407 subjects was one unvaccinated comparison cohort, and 2541 partners of those vaccinated was another. Compared with the birth cohort, the relative risk of developing Crohn's disease in the vaccinated group was 3.01 (95% CI 1.45-6.23) end of developing ulcerative colitis was 2.53 (1.15-5.58). There was no significant difference between these two groups in coeliac disease prevalence. Increased prevalence of inflammatory bowel disease, but not coeliac disease or peptic ulceration, was found in the vaccinated cohort compared with their partners. These findings suggest that measles virus may play a part in the development not only of Crohn's disease but also of ulcerative colitis.	CITY UNIV LONDON,SOCIAL STAT RES UNIT,LONDON,ENGLAND	City University London	THOMPSON, NP (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT MED,INFLAMMATORY BOWEL DIS STUDY GRP,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND.							BARTON JR, 1989, GUT, V30, P618, DOI 10.1136/gut.30.5.618; Butler N.R., 1963, PERINATAL MORTALITY; EKBOM A, 1994, LANCET, V334, P508; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; GRIFFIN DE, 1993, J INFECT DIS, V168, P275, DOI 10.1093/infdis/168.2.275; HALL AJ, 1993, BRIT MED J, V307, P1294, DOI 10.1136/bmj.307.6915.1294; LEWIN J, 1995, GUT, V36, P564, DOI 10.1136/gut.36.4.564; MILLER C, 1992, INT J EPIDEMIOL, V21, P998, DOI 10.1093/ije/21.5.998; RAMSAY MEB, 1994, EPIDEMIOL INFECT, V112, P409, DOI 10.1017/S0950268800057824; RIIS P, 1990, INFLAMMATORY BOWEL D; SANDLER RS, 1994, EPIDEMIOLOGY INFLAMM, P10; STEVENS CE, 1992, PEDIATRICS, V90, P170; THOMPSON NP, IN PRESS EUR J GASTR; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; WHELAN G, 1990, MED CLIN N AM, V74, P1; WURZELMANN JI, 1994, DIGEST DIS SCI, V39, P555, DOI 10.1007/BF02088342; 1966, BRIT MED J, V1, P441; 1975, OPCS SERIES MB2, V2	18	162	164	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1071	1074		10.1016/S0140-6736(95)90816-1	http://dx.doi.org/10.1016/S0140-6736(95)90816-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715338				2022-12-24	WOS:A1995QV41100008
J	GALITSKI, T; ROTH, JR				GALITSKI, T; ROTH, JR			EVIDENCE THAT F-PLASMID TRANSFER REPLICATION UNDERLIES APPARENT ADAPTIVE MUTATION	SCIENCE			English	Article							DIRECTED MUTATION; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; MUTAGENESIS; SELECTION; HYPOTHESIS; REVERSION; UNICORNS	Escherichia coli K12 strain, FC40, has been used extensively in the analysis of adaptive mutability. This strain carries a revertible mutant lac allele on an F plasmid and accumulates Lac(+) (lactose utilizing) revertants, but not unselected mutants, when placed on selective medium. These adaptive mutations are a subset of spontaneous types and their formation depends on the RecABC functions. Data presented here suggest that this phenomenon depends on transfer functions of the F factor. Fertility inhibition eliminates RecA-dependent adaptive reversion. Thus, ''adaptive'' revertants may form during replication from the transfer origin, whereas loci in the nonreplicating chromosome show little mutation.			GALITSKI, T (corresponding author), UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027068] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07464-15, GM27068] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; BRIDGES BA, 1994, MUTAT RES, V307, P149, DOI 10.1016/0027-5107(94)90287-9; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CHEAH KC, 1986, J GEN MICROBIOL, V132, P3269; DAVIS BD, 1989, P NATL ACAD SCI USA, V86, P5005, DOI 10.1073/pnas.86.13.5005; DEMPSEY WB, 1993, BACTERIAL CONJUGATIO, P53; FISHER KW, 1957, J GEN MICROBIOL, V16, P136, DOI 10.1099/00221287-16-1-136; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1994, SCIENCE, V265, P407, DOI 10.1126/science.8023164; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; FOSTER PL, 1994, GENETICS, V138, P253; FOSTER PL, 1992, J BACTERIOL, V174, P1711, DOI 10.1128/jb.174.6.1711-1716.1992; FOSTER PL, 1994, EMBO J, V13, P5240, DOI 10.1002/j.1460-2075.1994.tb06855.x; FOSTER PL, 1991, BOST STUD PHILOS SCI, V129, P213; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; GALITSKI T, UNPUB; GASSON MJ, 1975, J BACTERIOL, V122, P518, DOI 10.1128/JB.122.2.518-525.1975; Hall BG, 1992, CURR OPIN GENET DEV, V2, P943, DOI 10.1016/S0959-437X(05)80120-0; HALL BG, 1992, P NATL ACAD SCI USA, V89, P4300, DOI 10.1073/pnas.89.10.4300; HALL BG, 1993, J BACTERIOL, V175, P6411, DOI 10.1128/jb.175.20.6411-6414.1993; HALL BG, 1994, MOL BIOL EVOL, V11, P159; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; KOCH WH, 1992, J BACTERIOL, V174, P2809, DOI 10.1128/JB.174.9.2809-2815.1992; LEDERBERG J, 1952, J BACTERIOL, V63, P399, DOI 10.1128/JB.63.3.399-406.1952; LENSKI RE, 1993, SCIENCE, V259, P188, DOI 10.1126/science.7678468; LENSKI RE, 1989, P NATL ACAD SCI USA, V86, P2775, DOI 10.1073/pnas.86.8.2775; Luria SE, 1943, GENETICS, V28, P491; MACPHEE DG, 1993, MUTAT RES, V285, P109, DOI 10.1016/0027-5107(93)90058-N; MAENHAUTMICHEL G, 1994, EMBO J, V13, P5229, DOI 10.1002/j.1460-2075.1994.tb06854.x; MCINTIRE SA, 1987, NUCLEIC ACIDS RES, V15, P2029, DOI 10.1093/nar/15.5.2029; Miller J.H., 1972, EXPT MOL GENETICS; MITTLER JE, 1990, NATURE, V344, P173, DOI 10.1038/344173a0; MITTLER JE, 1992, NATURE, V356, P446, DOI 10.1038/356446a0; OVERBYE KM, 1981, J BACTERIOL, V146, P170, DOI 10.1128/JB.146.1.170-178.1981; PETERS JE, 1995, J BACTERIOL, V177, P847, DOI 10.1128/jb.177.3.847-850.1995; RADICELLA JP, 1995, SCIENCE, V268, P418, DOI 10.1126/science.7716545; ROSENBERG SM, 1994, SCIENCE, V265, P405, DOI 10.1126/science.8023163; SANDERSON KE, 1983, CAN J MICROBIOL, V29, P1205, DOI 10.1139/m83-184; SHAPIRO JA, 1984, MOL GEN GENET, V194, P79, DOI 10.1007/BF00383501; STAHL FW, 1992, GENETICS, V132, P865; STEELE DF, 1992, GENETICS, V132, P9; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; Wilkins B, 1993, BACTERIAL CONJUGATIO, P105; WILLETTS N, 1987, CELLULAR MOL BIOL, P1110; WING JP, 1968, J BACTERIOL, V95, P1828, DOI 10.1128/JB.95.5.1828-1834.1968	46	118	120	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					421	423		10.1126/science.7716546	http://dx.doi.org/10.1126/science.7716546			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716546	Green Submitted			2022-12-24	WOS:A1995QU57200041
J	LEE, IM; HSIEH, CC; PAFFENBARGER, RS				LEE, IM; HSIEH, CC; PAFFENBARGER, RS			EXERCISE INTENSITY AND LONGEVITY IN MEN - THE HARVARD ALUMNI HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; TOTAL ENERGY-INTAKE; TIME PHYSICAL-ACTIVITY; LEISURE-TIME; EPIDEMIOLOGIC ANALYSES; COLLEGE ALUMNI; FINNISH MEN; RISK FACTOR; FOLLOW-UP; MORTALITY	Objective.-To examine the independent associations of vigorous (greater than or equal to 6 resting metabolic rate [MET] score) and nonvigorous (<6 MET score) physical activity with longevity. Design.-Prospective cohort study, following up men from 1962 or 1966 through 1988. Setting/Participants.-Subjects were Harvard University alumni, without self-reported, physician-diagnosed cardiovascular disease, cancer, or chronic obstructive pulmonary disease (n=17 321). Men with a mean age of 46 years reported their physical activities on questionnaires at baseline. Main Outcome Measure.-All-cause mortality (3728 deaths). Results.-Total energy expenditure and energy expenditure from vigorous activities, but not energy expenditure from nonvigorous activities, related inversely to mortality. After adjustment for potential confounders, the relative risks of dying associated with increasing quintiles of total energy expenditure were 1.00 (referent), 0.94, 0.95, 0.91 and 0.91, respectively (P [trend]<.05). The relative risks of dying associated with less than 630, 630 to less than 1680, 1680 to less than 3150, 3150 to less than 6300, and 6300 or more kJ/wk expended on vigorous activities were 1.00 (referent), 0.88, 0.92, 0.87, and 0.87, respectively (P[trend]=.007). Corresponding relative risks for energy expended on nonvigorous activities were 1.00 (referent), 0.89, 1.00, 0.98, and 0.92, respectively (P[trend]=.36). Analyses of vigorous and nonvigorous activities were mutually adjusted. Among men who reported only vigorous activities (259 deaths), we observed decreasing age-standardized mortality rates with increasing activity (P=.05); among men who reported only nonvigorous activities (380 deaths), no trend was apparent (P=.99). Conclusions.-These data demonstrate a graded inverse relationship between total physical activity and mortality. Furthermore, vigorous activities but not nonvigorous activities were associated with longevity. These findings pertain only to all cause mortality; nonvigorous exercise has been shown to benefit other aspects of health.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; STANFORD UNIV, SCH MED, DIV EPIDEMIOL, STANFORD, CA 94305 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Stanford University	LEE, IM (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Lee, I-Min/ABD-5409-2021		NCI NIH HHS [CA 09001, CA 44854] Funding Source: Medline; NHLBI NIH HHS [HL 34174] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044854] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, J CLIN EPIDEMIOL, V46, P1403, DOI 10.1016/0895-4356(93)90140-V; AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; Albanes D, 1990, Epidemiology, V1, P65, DOI 10.1097/00001648-199001000-00014; ALESSIO HM, 1993, MED SCI SPORT EXER, V25, P218, DOI 10.1249/00005768-199302000-00010; [Anonymous], 1990, NUTR EPIDEMIOLGY; ARMITAGE P, 1987, STATISTICAL METHODS, P91; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; CAULEY JA, 1987, AM J CLIN NUTR, V45, P14, DOI 10.1093/ajcn/45.1.14; COX DR, 1972, J R STAT SOC B, V34, P187; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; FROELICHER VF, 1990, EXERCISE, FITNESS, AND HEALTH, P429; HAGBERG JM, 1990, EXERCISE, FITNESS, AND HEALTH, P455; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HORTON E S, 1986, Diabetes Metabolism Reviews, V2, P1; HOWE GR, 1986, AM J EPIDEMIOL, V124, P157, DOI 10.1093/oxfordjournals.aje.a114365; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LAKKA TA, 1992, AM J EPIDEMIOL, V136, P806, DOI 10.1093/aje/136.7.806; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; LAPORTE RE, 1982, J CHRON DIS, V35, P787, DOI 10.1016/0021-9681(82)90090-X; LEE IM, 1992, AM J EPIDEMIOL, V135, P169, DOI 10.1093/oxfordjournals.aje.a116269; LEE IM, 1991, J NATL CANCER I, V83, P1324, DOI 10.1093/jnci/83.18.1324; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; LINDSTED KD, 1991, J CLIN EPIDEMIOL, V44, P355, DOI 10.1016/0895-4356(91)90074-J; MAGNUS K, 1979, AM J EPIDEMIOL, V110, P724, DOI 10.1093/oxfordjournals.aje.a112853; MORRIS JN, 1980, LANCET, V2, P1207; MORRIS JN, 1990, BRIT HEART J, V63, P325; NEWSHOLME EA, 1990, EXERCISE, FITNESS, AND HEALTH, P293; OBERMAN A, 1988, HEART DISEASE TXB CA, P1395; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PEKKANEN J, 1987, LANCET, V1, P1473, DOI 10.1016/S0140-6736(87)92218-5; PIKE MC, 1989, AM J EPIDEMIOL, V129, P1312, DOI 10.1093/oxfordjournals.aje.a115254; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P41; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHEKELLE RB, 1987, AM J EPIDEMIOL, V126, P980, DOI 10.1093/oxfordjournals.aje.a114736; SICONOLFI SF, 1985, AM J EPIDEMIOL, V122, P101, DOI 10.1093/oxfordjournals.aje.a114068; Siegel P Z, 1991, MMWR CDC Surveill Summ, V40, P1; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; SMITH GD, 1992, LANCET, V340, P709; Stefanovic-Racic M., 1994, P417; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; WACHOLDER S, 1994, AM J EPIDEMIOL, V140, P848, DOI 10.1093/oxfordjournals.aje.a117333; WASHBURN RA, 1991, J CLIN EPIDEMIOL, V44, P1319, DOI 10.1016/0895-4356(91)90093-O; WOOD PD, 1990, EXERCISE, FITNESS, AND HEALTH, P409; 1992, ALLIED DUNBAR NATION; 1985, GUIDELINES GRADED EX; [No title captured]	50	437	453	1	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1179	1184		10.1001/jama.273.15.1179	http://dx.doi.org/10.1001/jama.273.15.1179			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT100	7707624				2022-12-24	WOS:A1995QT10000025
J	WISNIEWSKI, T; LALOWSKI, M; GOLABEK, A; VOGEL, T; FRANGIONE, B				WISNIEWSKI, T; LALOWSKI, M; GOLABEK, A; VOGEL, T; FRANGIONE, B			IS ALZHEIMERS-DISEASE AN APOLIPOPROTEIN-E AMYLOIDOSIS	LANCET			English	Note							BINDING; PEPTIDE; ALLELE	The presence of the apolipoprotein E4 allele has been identified as a major risk factor for late-onset Alzheimer's disease. Apolipoprotein E has also been found immunohistochemically in Alzheimer's disease lesions. We biochemically isolated amyloid beta from senile plaques and found that a carboxyl-terminal fragment (residues 216-299) of apolipoprotein E co-purified. In vitro this fragment from recombinant apolipoprotein E could form amyloid-like fibrils, which were Congo-red positive. Thus senile plaques may contain both amyloid beta and apolipoprotein E amyloid fibrils.	NYU,MED CTR,DEPT NEUROL,NEW YORK,NY 10016; BIOTECHNOL GEN LTD,REHOVOT,ISRAEL	New York University	WISNIEWSKI, T (corresponding author), NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016, USA.		Wisniewski, Thomas/Q-6525-2019; Lalowski, Maciej/AAB-4151-2019	Wisniewski, Thomas/0000-0002-3379-8966; Lalowski, Maciej/0000-0002-3683-4096	NATIONAL INSTITUTE ON AGING [R01AG008721, R01AG005891, R35AG010953, R37AG005891] Funding Source: NIH RePORTER; NIA NIH HHS [AG05891, AG08721, AG10953] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; PEPYS MB, 1995, IMMUNOLOGICAL DISEAS, P637; Prelli F., 1994, Society for Neuroscience Abstracts, V20, P1642; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C	10	147	151	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					956	958		10.1016/S0140-6736(95)90701-7	http://dx.doi.org/10.1016/S0140-6736(95)90701-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715296	hybrid			2022-12-24	WOS:A1995QT91900011
J	YOUVAN, DC				YOUVAN, DC			GREEN FLUORESCENT PETS	SCIENCE			English	Editorial Material											YOUVAN, DC (corresponding author), PALO ALTO INST MOLEC MED,MT VIEW,CA 94043, USA.							CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; MORIN JG, 1971, J CELL PHYSIOL, V77, P313, DOI 10.1002/jcp.1040770305	2	4	4	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					264	264		10.1126/science.7716519	http://dx.doi.org/10.1126/science.7716519			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716519				2022-12-24	WOS:A1995QT18500028
J	LITTLE, P; KEEFE, M; WHITE, J				LITTLE, P; KEEFE, M; WHITE, J			SELF SCREENING FOR RISK OF MELANOMA - VALIDITY OF SELF MOLE COUNTING BY PATIENTS IN A SINGLE GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							CUTANEOUS MALIGNANT-MELANOMA; DANISH CASE-CONTROL; MELANOCYTIC NEVI; SUNBURN; NAEVI; AUSTRALIA; EXPOSURE; WOMEN	Objective-To validate self screening by patients of high mole counts, assess the within family association of sun protection behaviour and mole counts, and estimate prevalence of risk factors for melanoma. Setting and subjects-Systematic sample of families from a single affluent general practice population in Wessex. Design-Subjects completed a questionnaire about risk factors for melanoma and counted their moles. Subsequently a mole count was done by a general practitioner trained at dermatology clinics. Main outcome measures-Validation of self counts by observer's count. Within family association of sun protection behaviour and mole counts; self reported risk factors. Results-199/237 subjects (84%) returned the questionnaire; 212/237 (89%) were examined, High counts by patients on the front of the trunk (>7 moles of greater than or equal to 2 mm) were reasonably sensitive (79%), predictive (75%), and specific (97%) of the observer's mole counts (kappa=0.74), unlike arm or total body counts. Sun protection behaviour correlated between individuals and other family members (Spearman's coefficient r=0.50, P<0.01), In the past three months 15/114 adults (13.2%, 95% confidence interval 7.0% to 19.1%) reported any change in a mole and 6/114 (5.3%, 2.0% to 11.1%) ''major'' changes; 6/109 adults (5.5%, 2.1% to 11.6%) had both high mole counts and freckling. Conclusions-Asking patients to count trunk moles could be a feasible way of identifying patients at high risk of melanoma. Concentrating on reported major changes in moles should avoid considerable workload in general practice. The generalisability of these findings and the adverse effects, net benefit in earlier diagnosis and prevention, and workload implications of such self screening need further research.	UNIV SOUTHAMPTON,DEPT DERMATOL,SOUTHAMPTON,HANTS,ENGLAND; HLTH CTR,THAME OX9 3JZ,OXON,ENGLAND	University of Southampton	LITTLE, P (corresponding author), UNIV SOUTHAMPTON,FAC MED,ALDERMOOR HLTH CTR,SOUTHAMPTON SO16 5ST,HANTS,ENGLAND.			Little, Paul/0000-0003-3664-1873				BAIN C, 1988, AM J EPIDEMIOL, V127, P703, DOI 10.1093/oxfordjournals.aje.a114851; BERAL V, 1983, BRIT J DERMATOL, V109, P165, DOI 10.1111/j.1365-2133.1983.tb07077.x; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BONETT A, 1986, MED J AUSTRALIA, V144, P680, DOI 10.5694/j.1326-5377.1986.tb113693.x; BYLES JE, 1944, BRIT J DERMATOL, V130, P51; CLARK WM, 1988, ARCH DERMATOL, V114, P732; COOKE KR, 1989, CANCER, V63, P1240, DOI 10.1002/1097-0142(19890315)63:6<1240::AID-CNCR2820630635>3.0.CO;2-9; COOKE KR, 1985, J EPIDEMIOL COMMUNIT, V39, P52; DARCY C, 1994, J NATL CANCER I, V72, P257; ELDER DE, 1989, J INVEST DERMATOL S, V92, P297; ELWOOD JM, 1990, INT J EPIDEMIOL, V19, P801, DOI 10.1093/ije/19.4.801; ELWOOD JM, 1985, BRIT J CANCER, V51, P543, DOI 10.1038/bjc.1985.77; ELWOOD JM, 1994, INT J CANCER, V35, P427; ELWOOD JM, 1994, BRIT MED J, V288, P99; ENGLISH DR, 1988, BRIT MED J, V296, P1285, DOI 10.1136/bmj.296.6632.1285; ENGLISH JSC, 1988, BRIT J DERMATOL, V118, P641, DOI 10.1111/j.1365-2133.1988.tb02564.x; GREEN A, 1985, BRIT J CANCER, V51, P393, DOI 10.1038/bjc.1985.53; GREEN A, 1985, INT J CANCER, V35, P297, DOI 10.1002/ijc.2910350303; GROB JJ, 1990, CANCER, V66, P387, DOI 10.1002/1097-0142(19900715)66:2<387::AID-CNCR2820660232>3.0.CO;2-J; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; JOHNSON N, 1994, BRIT J GEN PRACT, V44, P523; MACHIE R, 1985, BRIT J DERMATOL, V113, P167; MACKIE RM, 1982, BRIT J CANCER, V46, P955, DOI 10.1038/bjc.1982.307; MARKS R, 1994, BRIT MED J, V308, P75, DOI 10.1136/bmj.308.6921.75; MARTEAU T, 1991, BRIT MED J, V301, P26; NEWTON JA, 1994, BRIT MED BULL, V50, P677, DOI 10.1093/oxfordjournals.bmb.a072916; NEWTON JA, 1992, DIAGNOSIS MANAGEMENT, P53; NICHOLLS EM, 1973, CANCER, V32, P191, DOI 10.1002/1097-0142(197307)32:1<191::AID-CNCR2820320129>3.0.CO;2-W; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; PACK GT, 1952, AMA ARCH SURG, V65, P862, DOI 10.1001/archsurg.1952.01260020856010; ROBERTS DL, 1990, CLIN EXP DERMATOL, V15, P406, DOI 10.1111/j.1365-2230.1990.tb02132.x; ROUSH GC, 1988, PREV MED, V17, P273, DOI 10.1016/0091-7435(88)90003-5; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555; WEINSTOCK MA, 1989, PEDIATRICS, V84, P199; ZANETTI R, 1992, EUR J CANCER, V28A, P1172, DOI 10.1016/0959-8049(92)90480-P	36	38	38	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					912	916		10.1136/bmj.310.6984.912	http://dx.doi.org/10.1136/bmj.310.6984.912			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719184	Green Published			2022-12-24	WOS:A1995QR97200027
J	SATOKATA, I; BENSON, G; MAAS, R				SATOKATA, I; BENSON, G; MAAS, R			SEXUALLY DIMORPHIC STERILITY PHENOTYPES IN HOXA10-DEFICIENT MICE	NATURE			English	Article							TESTICULAR DESCENT; MOUSE EMBRYOS; GENE; INVITRO	THE Abdominal B (AbdB) genes constitute a distinct subfamily of homeobox genes that exhibit posterior domains of expression(1,2), including the genital imaginal disc in Drosophila and the developing urogenital system in vertebrates(3,4). We have mutated the AbdB gene Hoxa10 in mice, We report here that homozygotes are fully viable and show an anterior homeotic transformation of lumbar vertebrae. All male homozygotes manifest bilateral cryptorchidism resulting in severe defects in spermatogenesis and increasing sterility with age. Female homozygotes ovulate normally, but about 80% are sterile because of death of embryos between days 2.5 and 3.5 post coitum. This coincides spatially and temporally with expression of maternal Hoxa10 in distal oviductal and uterine epithelium. These results indicate a role for AbdB Hox genes in male and female fertility and suggest that maternal Hoxa10 is required to regulate the expression of a factor that affects the viability of preimplantation embryos.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV GENET,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute								ADAMSON ED, 1993, J CELL BIOCHEM, V53, P280, DOI 10.1002/jcb.240530403; BENSON GV, 1995, MOL CELL BIOL, V15, P1591; BOWMAN P, 1970, J EMBRYOL EXP MORPH, V24, P203; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BROWN JJG, 1991, DEVELOPMENT, V112, P99; CLENICKER S, 1987, GENE DEV, V1, P111; DOLLE P, 1991, GENE DEV, V5, P1767, DOI 10.1101/gad.5.10.1767; ERBACH G, 1994, J BIOL REPROD, V50, P1027; Hogan B, 1986, MANIPULATING MOUSE E, P89; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; Kaufman M.H., 1992, ATLAS MOUSE DEV; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; PARK WH, 1991, J PEDIATR SURG, V26, P615, DOI 10.1016/0022-3468(91)90721-5; POLLARD J, 1991, UTERINE EMBRYONIC FA, P109; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; SAKKAS D, 1990, J REPROD FERTIL, V90, P109, DOI 10.1530/jrf.0.0900109; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; Schultz G A, 1993, Oxf Rev Reprod Biol, V15, P43; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; WELLS LJ, 1944, ANAT REC, V88, P465; WENSING CJG, 1988, HORM RES, V30, P144, DOI 10.1159/000181051	24	435	456	3	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					460	463		10.1038/374460a0	http://dx.doi.org/10.1038/374460a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700356				2022-12-24	WOS:A1995QP89900060
J	SALI, A; SHAKHNOVICH, E; KARPLUS, M				SALI, A; SHAKHNOVICH, E; KARPLUS, M			HOW DOES A PROTEIN FOLD	NATURE			English	Article							GLOBULAR-PROTEINS; DYNAMICS	THE number of all possible conformations of a polypeptide chain is too large to be sampled exhaustively. Nevertheless, protein sequences do fold into unique native states in seconds (the Levinthal paradox). To determine how the Levinthal parades is resolved, we use a lattice Monte Carlo model in which the global minimum (native state) is known. The necessary and sufficient condition for folding in this model is that the native state be a pronounced global minimum on the potential surface. This guarantees thermodynamic stability of the native state at a temperature where the chain does not get trapped in local minima. Folding starts by a rapid collapse from a random-coil state to a random semi-compact globule. It then proceeds by a slow, rate-determining search through the semicompact states to find a transition state from which the chain folds rapidly to the native state. The elements of the folding mechanism that lead to the resolution of the Levinthal parades are the reduced number of conformations that need to be searched in the semicompact globule (similar to 10(10) versus similar to 10(16) for the random coil) and the existence of many (similar to 10(3)) transition states. The results have evolutionary implications and suggest principles for the folding of real proteins.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University								BRYNGELSON JD, 1987, P NATL ACAD SCI USA, V84, P7524, DOI 10.1073/pnas.84.21.7524; BRYNGELSON JD, 1989, J PHYS CHEM-US, V93, P6902, DOI 10.1021/j100356a007; CREIGHTON TE, 1992, PROTEIN FOLDING; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; DILORIO EE, 1993, P NATL ACAD SCI USA, V90, P2025; GO N, 1984, ADV BIOPHYS, V18, P149, DOI 10.1016/0065-227X(84)90010-8; GO N, 1981, BIOPOLYMERS, V20, P1013; HARDING MM, 1991, BIOCHEMISTRY-US, V30, P3120, DOI 10.1021/bi00226a020; HONEYCUTT JD, 1992, BIOPOLYMERS, V32, P695, DOI 10.1002/bip.360320610; KARPLUS M, 1976, NATURE, V260, P404, DOI 10.1038/260404a0; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; Leventhal C, 1969, MOSSBAUER SPECTROSCO, P22; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; METROPOLIS N, 1953, J CHEM PHYS, V21, P1098; MIYAZAWA S, 1985, MACROMOLECULES, V18, P534, DOI 10.1021/ma00145a039; SALI A, 1994, J MOL BIOL, V235, P1614, DOI 10.1006/jmbi.1994.1110; SHAKHNOVICH E, 1991, PHYS REV LETT, V67, P1665, DOI 10.1103/PhysRevLett.67.1665; SHAKHNOVICH EI, 1989, BIOPHYS CHEM, V34, P187, DOI 10.1016/0301-4622(89)80058-4; STETTER KO, 1992, FRONTIERS OF LIFE, P195; SYKES MF, 1963, J CHEM PHYS, V39, P410, DOI 10.1063/1.1734262; TAKETOMI H, 1975, INT J PEPT PROT RES, V7, P445; WETLAUFE.DB, 1973, P NATL ACAD SCI USA, V70, P697, DOI 10.1073/pnas.70.3.697	22	851	862	3	110	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					248	251		10.1038/369248a0	http://dx.doi.org/10.1038/369248a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	7710478				2022-12-24	WOS:A1994NM06700061
J	FREEMAN, GJ; BORRIELLO, F; HODES, RJ; REISER, H; HATHCOCK, KS; LASZLO, G; MCKNIGHT, AJ; KIM, J; DU, LN; LOMBARD, DB; GRAY, GS; NADLER, LM; SHARPE, AH				FREEMAN, GJ; BORRIELLO, F; HODES, RJ; REISER, H; HATHCOCK, KS; LASZLO, G; MCKNIGHT, AJ; KIM, J; DU, LN; LOMBARD, DB; GRAY, GS; NADLER, LM; SHARPE, AH			UNCOVERING OF FUNCTIONAL ALTERNATIVE CTLA-4 COUNTER-RECEPTOR IN B7-DEFICIENT MICE	SCIENCE			English	Article							T-CELL ACTIVATION; INVIVO; EXPRESSION; MOLECULE; ANTIGEN; CLONES	B7 delivers a costimulatory signal through CD28, resulting in interleukin-2 secretion and T cell proliferation. Blockade of this pathway results in T cell anergy. The in vivo role of B7 was evaluated with B7-deficient mice. These mice had a 70 percent decrease in costimulation of the response to alloantigen. Despite lacking B7 expression, activated B cells from these mice bound CTLA-4 and GL1 monoclonal antibody, demonstrating that alternative CTLA-4 ligand or ligands exist. These receptors are functionally important because the residual allogenic mixed lymphocyte responses were blocked by CTLA4Ig. Characterization of these CTLA-4 ligands should lead to strategies for manipulating the immune response.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,IMMUNOL RES DIV,BOSTON,MA 02115; REPLIGEN CORP,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; NIA,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV LYMPHOCYTE BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Borriello, Frank/0000-0003-3957-3685; Lombard, David/0000-0002-4292-0185; Sharpe, Arlene/0000-0002-9736-2109	NCI NIH HHS [CA 40216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORRIELLO F, UNPUB; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; FREEMAN G, UNPUB; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; RAZIWOLF Z, IN PRESS P NATL ACAD; REISER H, 1989, P NATL ACAD SCI USA, V86, P10069, DOI 10.1073/pnas.86.24.10069; SCHREIBER RD, 1985, J IMMUNOL, V134, P1609; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; WILLIAMS IR, 1990, J IMMUNOL, V145, P85; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	21	397	435	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					907	909		10.1126/science.7694362	http://dx.doi.org/10.1126/science.7694362			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	7694362				2022-12-24	WOS:A1993MF43800038
J	BRUGGEMANN, A; PARDO, LA; STUHMER, W; PONGS, O				BRUGGEMANN, A; PARDO, LA; STUHMER, W; PONGS, O			ETHER-A-GO-GO ENCODES A VOLTAGE-GATED CHANNEL PERMEABLE TO K+ AND CA2+ AND MODULATED BY CAMP	NATURE			English	Article							POTASSIUM CHANNEL; XENOPUS OOCYTES; DROSOPHILA-EAG; ION CHANNELS; EXPRESSION; MUTATIONS; CURRENTS; SYSTEM	THE Drosophila ether-a-go-go (eag) mutant is responsible for altered potassium currents in excitable tissue1. These mutants exhibit spontaneous, repetitive firing of action potentials in the motor axons of larval neuromuscular junctions2. The eag gene encodes a polypeptide3 that shares sequence similarities with several different ionic channel proteins, including voltage-gated potassium channels-, an inward rectifier4,5 as well as cyclic-nucleotide-gated channels6. These formal similarities in the derived primary sequences indicate that eag polypeptides might express a new type of ion channel. Here we report the expression by eag RNA in Xenopus oocytes of such a channel which incorporates properties of both voltage- and ligand-gated channels. The permeability of these eag channels to potassium and calcium is dependent on voltage and cyclic AMP. The ability to mediate potassium-outward and calcium-inward currents endows this channel with properties likely to be important in the modulation of synaptic efficiency in both central and peripheral nervous systems.	MAX PLANCK INST EXPTL MED, HERMANN REIN STR 3, D-37075 GOTTINGEN, GERMANY; ZMNH, INST NEURONALE SIGNALVERARBEITUNG, D-20246 HAMBURG, GERMANY; UNIV OVIEDO, DEPT BIOL FUNCT, E-33006 OVIEDO, SPAIN	Max Planck Society; University of Oviedo			Pardo, Luis/C-5066-2013; Stuehmer, Walter/A-2176-2009	Pardo, Luis/0000-0003-1375-4349; Stuehmer, Walter/0000-0002-0642-7764; Bruggemann, Andrea/0000-0002-7325-6715				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; EISENMAN G, 1962, Biophys J, V2, P259; GANETZKY B, 1986, ANNU REV GENET, V20, P13; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEINEMANN SH, 1992, METHOD ENZYMOL, V207, P131; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; LORY P, 1990, J PHYSIOL-LONDON, V429, P95, DOI 10.1113/jphysiol.1990.sp018246; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; PONGS O, 1992, TRENDS PHARMACOL SCI, V13, P359, DOI 10.1016/0165-6147(92)90109-J; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; STOCKER M, 1991, P ROY SOC B-BIOL SCI, V245, P101, DOI 10.1098/rspb.1991.0094; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; TORO L, 1993, BIOPHYS J, V64, pA2; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WHITE MM, 1990, MOL PHARMACOL, V37, P720; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; ZAGOTTA WN, 1989, NEURON, V3, P773, DOI 10.1016/0896-6273(89)90246-8; ZHONG Y, 1991, SCIENCE, V252, P1562, DOI 10.1126/science.2047864	23	196	202	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1993	365	6445					445	448		10.1038/365445a0	http://dx.doi.org/10.1038/365445a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	7692301				2022-12-24	WOS:A1993LZ63300057
J	BRUGGER, P; MARKTL, W; HEROLD, M				BRUGGER, P; MARKTL, W; HEROLD, M			IMPAIRED NOCTURNAL SECRETION OF MELATONIN IN CORONARY HEART-DISEASE	LANCET			English	Note								Patients with coronary heart disease have increased nocturnal urinary noradrenaline. Because melatonin suppresses sympathetic activity, we measured serum melatonin concentrations at night (0200 h) in 15 patients with coronary heart disease. Melatonin was significantly lower in the patients than in 10 healthy controls (median 7.8 [interquartile range 6.5-11.8] vs 36.2 [32.2-42.5] pg/mL, p<0.0001). Thus, impaired nocturnal secretion of melatonin is associated with coronary heart disease. Patients disease nocturnal noradrenaline.	UNIV VIENNA, DEPT PHYSIOL, VIENNA, AUSTRIA; UNIV INNSBRUCK, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA	University of Vienna; University of Innsbruck	BRUGGER, P (corresponding author), INST CARDIOVASC DIAGNOSIS & THERAPY, IMBERGSTR 22, A-5020 SALZBURG, AUSTRIA.							Arendt J., 1985, Pineal Research Reviews, V3, P161; AXELROD J, 1981, J NEUROSURG, V55, P669, DOI 10.3171/jns.1981.55.5.0669; BRUGGER P, 1990, WIEN MED WOCHENSCHR, V14, P375; DOLLINS AB, 1993, PHYSIOL BEHAV, V53, P153, DOI 10.1016/0031-9384(93)90024-A; LYNCH HJ, 1975, SCIENCE, V187, P168; MAHATA SK, 1991, J COMP PHYSIOL B, V161, P81, DOI 10.1007/BF00258750; SHAFI S, 1989, PROC R SOC SER B-BIO, V235, P289, DOI 10.1098/rspb.1989.0001; VAUGHAN GM, 1979, NEUROSCI LETT, V14, P81, DOI 10.1016/0304-3940(79)95348-5; VISWANATHAN M, 1986, LIFE SCI, V38, P73, DOI 10.1016/0024-3205(86)90277-8	9	166	172	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 3	1995	345	8962					1408	1408		10.1016/S0140-6736(95)92600-3	http://dx.doi.org/10.1016/S0140-6736(95)92600-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760612				2022-12-24	WOS:A1995RB44100012
J	REUL, J; WEIS, J; JUNG, A; WILLMES, K; THRON, A				REUL, J; WEIS, J; JUNG, A; WILLMES, K; THRON, A			CENTRAL-NERVOUS-SYSTEM LESIONS AND CERVICAL DISC HERNIATIONS IN AMATEUR DIVERS	LANCET			English	Article								Permanent neuropsychological changes such as memory disturbances and depression have been found in professional divers, even in those who have never had decompression sickness. The changes are probably the result of intravascular gas bubbles insufficient to cause acute symptoms. We examined amateur divers with long histories of self-contained underwater breathing apparatus diving by magnetic resonance imaging and compared them with normal controls. Hyperintense lesions of the subcortical cerebral white matter and degenerative changes of the cervical disks were significantly more common in the divers. 27 of 52 divers had a total of 86 focal hyperintensities versus 10 of 50 controls with 14 focal hyperintensities (p<0.01). 32 divers had at least one degenerated intravertebral disc versus 9 controls (P<0.0001). These results suggest that amateur divers are at risk of accumulating lesions in the central nervous system and in cartilage.	RHEIN WESTFAL TH AACHEN,DEPT NEURORADIOL,AACHEN,GERMANY; RHEIN WESTFAL TH AACHEN,DEPT NEUROPATHOL,AACHEN,GERMANY; RHEIN WESTFAL TH AACHEN,DEPT NEUROL,AACHEN,GERMANY	RWTH Aachen University; RWTH Aachen University; RWTH Aachen University			Weis, Joachim/G-1984-2014; Willmes, Klaus F/A-1268-2014	Weis, Joachim/0000-0003-3280-6773; Willmes, Klaus F/0000-0002-9012-0553				BADDLEY A, 1983, LONG TERM NEUROLOGIC, P165; EDMONDS C, 1985, 9TH P INT S UND HYP; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; NIX WA, 1980, DEUT MED WOCHENSCHR, V105, P302, DOI 10.1055/s-2008-1070654; PALMER AC, 1992, NEUROPATH APPL NEURO, V18, P113, DOI 10.1111/j.1365-2990.1992.tb00773.x; PALMER AC, 1987, LANCET, V2, P1365; POLKINGHORNE PJ, 1988, LANCET, V2, P1381; RINCK PA, 1991, JMRI-J MAGN RESON IM, V1, P293, DOI 10.1002/jmri.1880010306; SMYTH E, 1985, NEW SCI, V1439, P8; TODNEM K, 1991, ELECTROEN CLIN NEURO, V79, P322, DOI 10.1016/0013-4694(91)90127-P; TODNEM K, 1991, BRIT J IND MED, V48, P258; VAERNES RJ, 1982, AVIAT SPACE ENVIR MD, V53, P803; WARREN LP, 1988, AM J ROENTGENOL, V151, P1003, DOI 10.2214/ajr.151.5.1003	13	88	89	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1403	1405		10.1016/S0140-6736(95)92598-8	http://dx.doi.org/10.1016/S0140-6736(95)92598-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760611				2022-12-24	WOS:A1995RB44100010
J	CARLEN, PL; GORDON, M				CARLEN, PL; GORDON, M			CARDIOPULMONARY-RESUSCITATION AND NEUROLOGICAL COMPLICATIONS IN THE ELDERLY	LANCET			English	Editorial Material									UNIV TORONTO,BAYCREST CTR GERIATR CARE,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Baycrest	CARLEN, PL (corresponding author), TORONTO HOSP,RES INST,PLAYFAIR NEUROSCI UNIT,TORONTO,ON M5T 2S8,CANADA.		Carlen, Peter Louis/GLN-7260-2022	Carlen, Peter/0000-0002-3339-8102				BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BEDELL SE, 1983, NEW ENGL J MED, V309, P570; DATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; FINCH CE, 1993, TRENDS NEUROSCI, V16, P104, DOI 10.1016/0166-2236(93)90134-8; GORDON M, 1995, CARDIOL ELDER, V3, P53; JOHNSTON MV, 1994, NEUROBIOL AGING, V15, P235, DOI 10.1016/0197-4580(94)90119-8; KHACHATURIAN ZS, 1987, NEUROBIOL AGING, V8, P345, DOI 10.1016/0197-4580(87)90073-X; LANDFIELD PW, 1994, NEUROBIOL AGING, V15, P579, DOI 10.1016/0197-4580(94)90101-5; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; OLNEY JW, 1994, NEUROBIOL AGING, V15, P259, DOI 10.1016/0197-4580(94)90127-9; ROGOVE HJ, 1995, CRIT CARE MED, V23, P18, DOI 10.1097/00003246-199501000-00007; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TRESCH DD, 1989, AM J MED, V86, P145, DOI 10.1016/0002-9343(89)90259-3; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P	16	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1253	1254		10.1016/S0140-6736(95)90919-2	http://dx.doi.org/10.1016/S0140-6736(95)90919-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746051				2022-12-24	WOS:A1995QY93300003
J	FRIBERG, TR				FRIBERG, TR			RETINAL TEAR AFTER TEETH CLEANING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							DENTAL EXTRACTION				FRIBERG, TR (corresponding author), UNIV PITTSBURGH,PITTSBURGH,PA 15260, USA.							GOPER G, 1977, ZAHN MUND KIEFERHEIL, V65, P278; JAFFE NS, 1984, CATARACT SURG ITS CO, P246; KING LP, 1993, GRAEF ARCH CLIN EXP, V231, P667, DOI 10.1007/BF00921963; MALDEN N, 1993, BRIT DENT J, V174, P334, DOI 10.1038/sj.bdj.4808168; YOUNG LM, 1994, PRINCIPLES PRACTICE, V2, P1084	5	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1493	1493		10.1001/jama.273.19.1493	http://dx.doi.org/10.1001/jama.273.19.1493			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739072				2022-12-24	WOS:A1995QX41800028
J	PICKWORTH, WB				PICKWORTH, WB			CAFFEINE DEPENDENCE	LANCET			English	Editorial Material							DISCRIMINATION				PICKWORTH, WB (corresponding author), NIDA,ADDICT RES CTR,CLIN PHARMACOL BRANCH,POB 5180,BALTIMORE,MD 21224, USA.							GLASS RM, 1994, JAMA-J AM MED ASSOC, V272, P1065, DOI 10.1001/jama.272.13.1065; GRIFFITHS RR, 1990, J PHARMACOL EXP THER, V252, P970; HUGHES JR, J SUB ABUSE, V1, P67; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P397, DOI 10.1007/BF02247412; SILVERMAN K, 1992, NEW ENGL J MED, V327, P1109, DOI 10.1056/NEJM199210153271601; SILVERMAN K, 1992, J EXP ANAL BEHAV, V57, P91, DOI 10.1901/jeab.1992.57-91; Spitzer R., 1985, STRUCTURED CLIN INTE; STRAIN EC, 1994, JAMA-J AM MED ASSOC, V272, P1043, DOI 10.1001/jama.272.13.1043; 1994, BASIS DRUG DEPENDENC; 1994, DIAGNOSTIC STATISTIC	10	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1066	1066		10.1016/S0140-6736(95)90814-5	http://dx.doi.org/10.1016/S0140-6736(95)90814-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715336				2022-12-24	WOS:A1995QV41100006
J	WIJNEN, RMH; BOOSTER, MH; STUBENITSKY, BM; DEBOER, J; HEINEMAN, E; KOOTSTRA, G				WIJNEN, RMH; BOOSTER, MH; STUBENITSKY, BM; DEBOER, J; HEINEMAN, E; KOOTSTRA, G			OUTCOME OF TRANSPLANTATION OF NON-HEART-BEATING DONOR KIDNEYS	LANCET			English	Article							MACHINE PERFUSION; CANINE PANCREAS; PRESERVATION; GRAFTS; PROCUREMENT; REJECTION; ISCHEMIA; TISSUE	To reduce the shortage of kidneys for transplantation, we started a non-heart-beating (NHB) donor programme, and compared the short-term and long-term outcomes of kidneys from NHB donors with those of a matched group of kidneys from heart-beating (HB) donors. 57 NHB kidneys were procured at the University Hospital in Msaastricht and at three regional hospitals in the Netherlands, and were transplanted in 21 transplant centres within the Eurotransplant exchange organisation. 114 matched controls from HB donors were selected from Eurotransplant files. Mean follow-up was 85 months. At 5 years, graft survival was 54% for NHB kidneys and 55% for HB kidneys; patient survival was 75% and 77%. Kidneys from NHB donors had a significantly higher rate of delayed graft function (60% vs 35%), resulting in a longer hospital stay. Primary non-function of the graft was seen as frequently in the NHB donor-kidney group as in the HB group (14% vs 8%, p=0.3). We conclude that NHB donors are a valuable source of kidneys for transplantation.	UNIV LIMBURG HOSP,DEPT SURG,6202 AZ MAASTRICHT,NETHERLANDS; EUROTRANSPLANT FDN,LEIDEN,NETHERLANDS	Maastricht University; Maastricht University Medical Centre (MUMC)			Heineman, Erik/ABG-9592-2021; Wijnen, R.M.H./L-4758-2015					ARIAS J, 1991, TRANSPLANT P, V23, P2581; BELZER FO, 1967, LANCET, V2, P536; BOOSTER MH, 1993, TRANSPLANT P, V25, P3012; BOOSTER MH, 1993, TRANSPLANT P, V25, P3006; BOOSTER MH, 1992, TRANSPLANTATION, V56, P613; BROCKMEYER C, 1993, TRANSPLANTATION, V55, P610; CANAFAX DM, 1986, TRANSPLANTATION, V41, P177, DOI 10.1097/00007890-198602000-00009; CASTELAO AM, 1991, TRANSPLANT P, V23, P2584; COHEN B, 1993, 1992 EUR ANN REP, P31; FUJINO Y, 1993, TRANSPLANTATION, V56, P1083, DOI 10.1097/00007890-199311000-00006; GARVIN PJ, 1980, ARCH SURG-CHICAGO, V115, P180; GORE SM, 1991, BRIT MED J, V302, P149, DOI 10.1136/bmj.302.6769.149; GROENEWOUD AF, 1992, TRANSPLANT INT, V5, pS429; HOFFMANN RM, 1989, TRANSPLANTATION, V47, P32, DOI 10.1097/00007890-198901000-00008; KALLERHOFF M, 1987, UROL RES, V15, P5; KOOTSTRA G, 1991, TRANSPLANT P, V23, P912; KOZAKI M, 1991, TRANSPLANT P, V23, P2575; LAND W, 1994, TRANSPLANTATION, V57, P211, DOI 10.1097/00007890-199401001-00010; MATSUNO N, 1994, TRANSPLANTATION, V57, P293; OPELZ G, 1991, LANCET, V338, P461, DOI 10.1016/0140-6736(91)90540-6; PHILLIPS AO, 1994, BRIT MED J, V308, P575, DOI 10.1136/bmj.308.6928.575a; PLOEG RJ, 1992, LANCET, V340, P129, DOI 10.1016/0140-6736(92)93212-6; PREUSCHOF L, 1991, TRANSPLANT P, V23, P1300; RIJKSEN JFW, 1972, EUROTRANSPLANT MANUA, P30; SCHLUMPF R, 1992, TRANSPLANT INT, V5, pS424; SCHWEIZER RT, 1981, TRANSPLANTATION, V32, P482, DOI 10.1097/00007890-198112000-00005; VARTY K, 1994, BRIT MED J, V308, P575, DOI 10.1136/bmj.308.6928.575; VERDUYN W, 1993, HUM IMMUNOL, V37, P59, DOI 10.1016/0198-8859(93)90143-O; VROEMEN JPA, 1983, NETH J SURG, V35, P50; WAHLBERG JA, 1987, TRANSPLANTATION, V43, P5, DOI 10.1097/00007890-198701000-00002	30	243	247	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1067	1070		10.1016/S0140-6736(95)90815-3	http://dx.doi.org/10.1016/S0140-6736(95)90815-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715337				2022-12-24	WOS:A1995QV41100007
J	KARLOVICH, CA; BONFINI, L; MCCOLLAM, L; ROGGE, RD; DAGA, A; CZECH, MP; BANERJEE, U				KARLOVICH, CA; BONFINI, L; MCCOLLAM, L; ROGGE, RD; DAGA, A; CZECH, MP; BANERJEE, U			IN-VIVO FUNCTIONAL-ANALYSIS OF THE RAS EXCHANGE FACTOR SON OF SEVENLESS	SCIENCE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; DROSOPHILA-RETINA; ADAPTER PROTEIN; GENE-PRODUCT; SH3 DOMAINS; PATHWAY; ACTIVATION; LIGAND; CELLS	The Son of sevenless (Sos) protein functions as a guanine nucleotide transfer factor for Ras and interacts with the receptor tyrosine kinase Sevenless through the protein Drk, a homolog of mammalian Grb2. In vivo structure-function analysis revealed that the amino terminus of Sos was essential for its function in flies. A molecule lacking the amino terminus was a potent dominant negative. In contrast, a Sos fragment lacking the Drk binding sites was functional and its activity was dependent on the presence of the Sevenless receptor. Furthermore, membrane localization of Sos was independent of Drk. A possible role for Drk as an activator of Sos is discussed and a Drk-independent interaction between Sos and Sevenless is proposed that is likely mediated by the pleckstrin homology domain within the amino terminus.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester			daga, andrea/J-1865-2018	daga, andrea/0000-0001-8935-5489; Rogge, Ronald/0000-0002-1875-3938	NATIONAL EYE INSTITUTE [R01EY008152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008375] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY08152-06] Funding Source: Medline; NIGMS NIH HHS [GM-07104, GM-08375] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; FRANCESCHINI N, 1971, KYBERNETIK, V9, P159, DOI 10.1007/BF02215177; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KARLOVICH CA, UNPUB; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, UNPUB; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PERRIMON N, 1994, CURR OPIN CELL BIOL, V6, P260, DOI 10.1016/0955-0674(94)90145-7; ROGGE R, 1992, P NATL ACAD SCI USA, V89, P5271, DOI 10.1073/pnas.89.12.5271; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STERNBERG PW, 1993, ANNU REV GENET, V27, P497, DOI 10.1146/annurev.ge.27.120193.002433; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	25	78	80	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					576	579		10.1126/science.7725106	http://dx.doi.org/10.1126/science.7725106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725106				2022-12-24	WOS:A1995QV40700040
J	GLUCKSMANNKUIS, MA; TAYBER, O; WOOLF, EA; BOUGUELERET, L; DENG, NH; ALPERIN, GD; IRIS, F; HAWKINS, F; MUNRO, C; LAKEY, N; DUYK, G; SCHNEIDER, MC; GENG, L; ZHANG, F; ZHAO, ZH; TOROSIAN, S; ZHOU, J; REEDERS, ST; BORK, P; POHLSCHMIDT, M; LOHNING, C; KRAUS, B; NOWICKA, U; LEUNG, ALS; FRISCHAUF, AM				GLUCKSMANNKUIS, MA; TAYBER, O; WOOLF, EA; BOUGUELERET, L; DENG, NH; ALPERIN, GD; IRIS, F; HAWKINS, F; MUNRO, C; LAKEY, N; DUYK, G; SCHNEIDER, MC; GENG, L; ZHANG, F; ZHAO, ZH; TOROSIAN, S; ZHOU, J; REEDERS, ST; BORK, P; POHLSCHMIDT, M; LOHNING, C; KRAUS, B; NOWICKA, U; LEUNG, ALS; FRISCHAUF, AM			POLYCYSTIC KIDNEY-DISEASE - THE COMPLETE STRUCTURE OF THE PKD1 GENE AND ITS PROTEIN	CELL			English	Article							CELL-ADHESION; CARBOHYDRATE-RECOGNITION; SEQUENCE; GLYCOPROTEINS; DOMAINS; LOCALIZATION; INTEGRINS; MEMBRANES; EPITHELIA; POLARITY	Mutations in the PKD1 gene sire the most common cause of autosomal dominant polycystic kidney disease (ADPKD). Other PKD1-like loci on chromosome 16 are approximately 97% identical to PKD1. To determine the authentic PKD1 sequence, we obtained the genomic sequence of the PKD1 locus and assembled a PKD1 transcript from the sequence of 46 exons. The 14.5 kb PKD1 transcript encodes a 4304 amino acid protein that has a novel domain architecture. The amino-terminal half of the protein consists of a mosaic of previously described domains, including leucine-rich repeats flanked by characteristic cysteine-rich structures, LDL-A and C-type lectin domains, and 14 units of a novel 80 amino acid domain. The presence of these domains suggests that the PKD1 protein is involved in adhesive protein-protein and protein-carbohydrate interactions in the extracellular compartment. We propose a hypothesis that links the predicted properties of the protein with the diverse phenotypic features of ADPKD.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; EUROPEAN MOLEC BIOL LAB,PROT DESIGN GRP,D-69117 HEIDELBERG,GERMANY; MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Cancer Research UK	GLUCKSMANNKUIS, MA (corresponding author), MILLENNIUM PHARMACEUT INC,CAMBRIDGE,MA 02139, USA.		Bork, Peer/F-1813-2013	Bork, Peer/0000-0002-2627-833X				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; [Anonymous], 1994, CELL, V77, P881; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; BEZOUSKA K, 1991, J BIOL CHEM, V226, P11604; BORK P, 1994, CURR OPIN STRUC BIOL, V4, P393, DOI 10.1016/S0959-440X(94)90109-0; BORK P, 1995, TRENDS BIOCH SCI, V20; BROCKL G, 1991, EUR J BIOCHEM, V199, P147, DOI 10.1111/j.1432-1033.1991.tb16102.x; BUTOWSKI RJ, 1985, KIDNEY INT, V28, P744; CALVET JP, 1993, KIDNEY INT, V43, P101, DOI 10.1038/ki.1993.17; CALVET JP, 1994, CURR OPIN NEPHROL HY, V3, P330; CARONE FA, 1994, LAB INVEST, V70, P437; CARONE FA, 1989, KIDNEY INT, V35, P1034, DOI 10.1038/ki.1989.87; CARONE FA, 1993, LAB INVEST, V70, P648; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DOOLITTLE RF, 1993, SCI AM, V269, P50, DOI 10.1038/scientificamerican1093-50; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DVERGSTEN J, 1994, KIDNEY INT, V45, P828, DOI 10.1038/ki.1994.109; European Chromosome 16 Tuberous Sclerosis C., 1993, CELL, V75, P1305; EVAN AP, 1979, KIDNEY INT, V16, P743, DOI 10.1038/ki.1979.191; FOSSDAL R, 1993, HUM GENET, V91, P609; GABOW PA, 1990, AM J KIDNEY DIS, V16, P403, DOI 10.1016/S0272-6386(12)80051-5; GERMINO GG, 1992, GENOMICS, V13, P144, DOI 10.1016/0888-7543(92)90214-D; GRANTHAM JJ, 1990, AM J KIDNEY DIS, V15, P110, DOI 10.1016/S0272-6386(12)80507-5; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HAVERTY TP, 1988, LAB INVEST, V58, P245; HENIKOFF S, 1993, PROTEINS, V17, P97; HIMMELBAUER H, 1991, AM J HUM GENET, V48, P325; HIMMELBAUER H, 1991, AM J HUM GENET, V48, P1017; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; KLINGEL R, 1993, NEPHRON, V65, P111, DOI 10.1159/000187451; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KONTUSAARI S, 1990, J CLIN INVEST, V86, P1465, DOI 10.1172/JCI114863; KOONIN EV, 1994, EMBO J, V13, P493, DOI 10.1002/j.1460-2075.1994.tb06287.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KWON BS, 1993, J INVEST DERMATOL, V100, P134; MOCHII M, 1991, PIGM CELL RES, V4, P41, DOI 10.1111/j.1600-0749.1991.tb00312.x; MYERS KA, 1994, J BIOL CHEM, V269, P9319; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; REEDERS ST, 1992, NAT GENET, V1, P235, DOI 10.1038/ng0792-235; RODRIGUEZBOULAN E, 1989, SCIENCE, V247, P718; ROHDE K, 1993, COMPUT APPL BIOSCI, V9, P183; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROTH GJ, 1991, BLOOD, V77, P5; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SNAREY A, 1994, AM J HUM GENET, V55, P365; SOMLO S, 1992, GENOMICS, V13, P152, DOI 10.1016/0888-7543(92)90215-E; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSIPOURAS P, 1992, NEW ENGL J MED, V326, P905, DOI 10.1056/NEJM199204023261401; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEIS WI, 1992, COLD SPRING HARB SYM, V57, P281, DOI 10.1101/SQB.1992.057.01.033; WELLING LW, 1972, J CLIN INVEST, V51, P1063, DOI 10.1172/JCI106898; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WILSON PD, 1986, KIDNEY INT, V30, P371, DOI 10.1038/ki.1986.194; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAO R, 1994, BBA-GENE STRUCT EXPR, V1219, P697, DOI 10.1016/0167-4781(94)90230-5; YOSHIHARA K, 1994, J BACTERIOL, V176, P6489, DOI 10.1128/JB.176.21.6489-6496.1994	68	525	533	0	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					289	298						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736581	Bronze			2022-12-24	WOS:A1995QV41000018
J	IRNIGER, S; PIATTI, S; MICHAELIS, C; NASMYTH, K				IRNIGER, S; PIATTI, S; MICHAELIS, C; NASMYTH, K			GENES INVOLVED IN SISTER-CHROMATID SEPARATION ARE NEEDED FOR B-TYPE CYCLIN PROTEOLYSIS IN BUDDING YEAST	CELL			English	Article							MATURATION-PROMOTING FACTOR; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN-KINASE; INTERPHASE EXTRACTS; ESCHERICHIA-COLI; DNA-REPLICATION; AMPHIBIAN EGGS; M-PHASE; TRANSCRIPTION	B-type cyclin destruction is necessary for exit from mitosis and the initiation of a new cell cycle. Through the isolation of mutants, we have identified three essential yeast genes, CDC16, CDC23, and CSE1, which are required for proteolysis of the B-type cyclin CLBS but not of other unstable proteins. cdc23-1 mutants are defective in both entering and exiting anaphase. Their failure to exit anaphase can be explained by defective cyclin proteolysis. CDC23 is required at the metaphase/anaphase transition to separate sister chromatids, and we speculate that it might promote proteolysis of proteins that hold sister chromatids together. Proteolysis of CLB2 is initiated in early anaphase, but a fraction of CLB2 remains stable until anaphase is complete.			IRNIGER, S (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403; Piatti, Simonetta/0000-0003-1958-8919				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KOSHLAND D, 1994, CELL, V77, P951, DOI 10.1016/0092-8674(94)90432-4; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LORCA T, 1992, J CELL SCI, V102, P55; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; Maniatis T., 1982, MOL CLONING; MITCHISON TJ, 1992, J CELL BIOL, V119, P569, DOI 10.1083/jcb.119.3.569; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ROSE MD, 1990, LABORATORY COURSE MA; SCHWEITZER B, 1991, YEAST, V7, P265, DOI 10.1002/yea.320070308; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; TUGENDREICH S, 1995, CELL, V81; WAN J, 1992, J BIOL CHEM, V267, P11274; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880	43	377	384	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					269	278		10.1016/0092-8674(95)90337-2	http://dx.doi.org/10.1016/0092-8674(95)90337-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736579	Bronze			2022-12-24	WOS:A1995QV41000016
J	RAUSCHECKER, JP; TIAN, B; HAUSER, M				RAUSCHECKER, JP; TIAN, B; HAUSER, M			PROCESSING OF COMPLEX SOUNDS IN THE MACAQUE NONPRIMARY AUDITORY-CORTEX	SCIENCE			English	Article							RHESUS-MONKEY; VISUAL PROPERTIES; SQUIRREL-MONKEY; MACACA-MULATTA; NEURONS; VOCALIZATIONS; ORGANIZATION; RESPONSES; ANATOMY; SPEECH	Neurons in the superior temporal gyrus of anesthetized rhesus monkeys were exposed to complex acoustic stimuli. Bandpassed noise bursts with defined center frequencies evoked responses that were greatly enhanced over those evoked by pure tons. This finding led to the discovery of at least one new cochleotopic area in the lateral belt of the nonprimary auditory cortex. The best center frequencies of neurons varied along a rostrocaudal axis, and the best bandwidths of the noise bursts varied along a mediolateral axis. When digitized monkey calls were used as stimuli, many neurons showed a preference for some calls over others. Manipulation of the calls' frequency structure and playback of separate components revealed different types of spectral integration. The lateral areas of the monkey auditory cortex appear to be part of a hierarchical sequence in which neurons prefer increasingly complex stimuli and may form an important stage in the preprocessing of communication sounds.	NIMH,NEUROPHYSIOL LAB,POOLESVILLE,MD 20837; HARVARD UNIV,DEPT ANTHROPOL,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT PSYCHOL,PROGRAM NEUROSCI,CAMBRIDGE,MA 02138	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Harvard University; Harvard University			Rauschecker, Josef P/A-4120-2013	Rauschecker, Josef P./0000-0003-4353-9084				BINDER JR, 1994, ANN NEUROL, V35, P662, DOI 10.1002/ana.410350606; BOATMAN D, IN PRESS BRAIN LANGU; Brodmann K., 1908, J PSYCHOL NEUROL, V10, P231; BRUGGE JF, 1973, J NEUROPHYSIOL, V36, P1138, DOI 10.1152/jn.1973.36.6.1138; BURTON H, 1976, J COMP NEUROL, V168, P249, DOI 10.1002/cne.901680204; CREUTZFELDT O, 1989, EXP BRAIN RES, V77, P451, DOI 10.1007/BF00249600; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; DESIMONE R, 1986, J COMP NEUROL, V248, P164, DOI 10.1002/cne.902480203; DESIMONE R, 1987, J NEUROPHYSIOL, V57, P835, DOI 10.1152/jn.1987.57.3.835; FENG AS, 1978, SCIENCE, V202, P645, DOI 10.1126/science.705350; GOUZOULES S, 1984, ANIM BEHAV, V32, P182, DOI 10.1016/S0003-3472(84)80336-X; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; HAUSER MD, 1992, J ACOUST SOC AM, V91, P2175, DOI 10.1121/1.403676; HAUSER MD, 1993, BEHAV ECOL, V4, P194, DOI 10.1093/beheco/4.3.194; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; MERZENICH MM, 1973, BRAIN RES, V50, P275, DOI 10.1016/0006-8993(73)90731-2; MILLER JM, 1972, SCIENCE, V177, P449, DOI 10.1126/science.177.4047.449; MOREL A, 1993, J COMP NEUROL, V335, P437, DOI 10.1002/cne.903350312; PANDYA DN, 1994, J COMP NEUROL, V345, P447, DOI 10.1002/cne.903450311; PANDYA DN, 1972, Z ANAT ENTWICKLUNGS, V139, P127; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PETERSEN SE, 1980, BRAIN RES, V197, P507, DOI 10.1016/0006-8993(80)91137-3; RAUSCHECKER JP, 1993, J NEUROSCI, V13, P4538; RAUSCHECKER JP, 1995, ARO ABSTR, V18, P103; SELDON HL, 1985, CEREB CORTEX, V4, P273; SUGA N, 1992, PHILOS T ROY SOC B, V336, P423, DOI 10.1098/rstb.1992.0078; SUGA N, 1978, SCIENCE, V200, P778, DOI 10.1126/science.644320; TIAN B, 1994, J NEUROPHYSIOL, V71, P1959, DOI 10.1152/jn.1994.71.5.1959; VANECONOMO C, 1925, CYTOARCHITEKTONIK HI; VANESSEN DC, 1983, TRENDS NEUROSCI, V6, P370, DOI 10.1016/0166-2236(83)90167-4; WINTER P, 1973, EXP BRAIN RES, V18, P489; WINTER P, 1966, EXP BRAIN RES, V1, P359; WOLLBERG Z, 1972, SCIENCE, V175, P212, DOI 10.1126/science.175.4018.212; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767; ZEKI SM, 1978, NATURE, V274, P423, DOI 10.1038/274423a0	35	664	669	1	21	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					111	114		10.1126/science.7701330	http://dx.doi.org/10.1126/science.7701330			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701330				2022-12-24	WOS:A1995QR45400038
J	LOMBARDI, V; PIAZZESI, G; FERENCZI, MA; THIRLWELL, H; DOBBIE, I; IRVING, M				LOMBARDI, V; PIAZZESI, G; FERENCZI, MA; THIRLWELL, H; DOBBIE, I; IRVING, M			ELASTIC DISTORTION OF MYOSIN HEADS AND REPRIMING OF THE WORKING STROKE IN MUSCLE	NATURE			English	Article							CONTRACTING MUSCLE; STRIATED-MUSCLE; FIBERS; FROG; TRANSIENTS; MECHANISM	MUSCLE contraction is driven by a cyclical interaction between the globular head domain of myosin and the actin filaments(1-6). We used quick stretches of 5 nm per half sarcomere to synchronize the movements of myosin heads in active single muscle fibres(5,7,8). The intensity of the 14.5 nm X-ray reflection decreased during the stretch, showing that the instantaneous elasticity of muscle(1,5) involves distortion of myosin heads. Head movement continued at about 1,500 s(-1) after the stretch, accompanied by partial force recovery. This indicates a reversal of the force-generating 'working stroke' in the myosin heads(5,8,9) that is smaller and faster than assumed previously(5,10,11). By 50 ms after the stretch, myosin heads have regained both their original conformation and the ability to execute a normal working stroke. This 'repriming' process is slower than that following shortening(12) but much faster than the ATP turnover rate per myosin head.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; UNIV LONDON KINGS COLL,RANDALL INST,LONDON WC2B 5RL,ENGLAND	MRC National Institute for Medical Research; University of London; King's College London	LOMBARDI, V (corresponding author), UNIV FLORENCE,DIPARTIMENTO SCI FISIOL,VIALE GB MORGAGNI 63,I-50134 FLORENCE,ITALY.		Ferenczi, Michael/F-9510-2015	Ferenczi, Michael/0000-0002-0349-331X; Dobbie, Ian/0000-0002-5531-5865	Telethon [239] Funding Source: Medline	Telethon(Fondazione Telethon)		Cecchi G, 1976, Boll Soc Ital Biol Sper, V52, P733; Curtin N A, 1975, J Mechanochem Cell Motil, V3, P147; EISENBERG E, 1978, PROG BIOPHYS MOL BIO, V33, P55; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1981, J PHYSIOL-LONDON, V317, pP12; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY AF, 1981, J PHYSIOL-LONDON, V305, pP15; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; HUXLEY HE, 1982, J MOL BIOL, V159, P637; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; KUSHMERICK MJ, 1969, PROC R SOC SER B-BIO, V174, P315, DOI 10.1098/rspb.1969.0096; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; PIAZZESI G, 1992, J PHYSIOL-LONDON, V445, P659, DOI 10.1113/jphysiol.1992.sp018945; PIAZZESI G, 1995, BIOPHYS J, V98, pS92; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765	21	99	101	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					553	555		10.1038/374553a0	http://dx.doi.org/10.1038/374553a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700382				2022-12-24	WOS:A1995QR06900055
J	TECOTT, LH; SUN, LM; AKANA, SF; STRACK, AM; LOWENSTEIN, DH; DALLMAN, MF; JULIUS, D				TECOTT, LH; SUN, LM; AKANA, SF; STRACK, AM; LOWENSTEIN, DH; DALLMAN, MF; JULIUS, D			EATING DISORDER AND EPILEPSY IN MICE LACKING 5-HT2C SEROTONIN RECEPTORS	NATURE			English	Article							MESSENGER-RNA; NERVOUS-SYSTEM; RAT-BRAIN	SEROTONIN (5-hydroxytryptamine, 5-HT) is a monoaminergic neurotransmitter that is believed to modulate numerous sensory, motor and behavioural processes in the mammalian nervous system(1-3). These diverse responses are elicited through the activation of a large family of receptor subtypes(4). The complexity of this signalling system and the paucity of selective drugs have made it difficult to define specific roles for 5-HT receptor subtypes, or to determine bow serotonergic drugs modulate mood and behaviour. To address these issues, we have generated mutant mice lacking functional 5-HT2C receptors (previously termed 5-HT1C), prominent G-protein-coupled receptors that are widely expressed throughout the brain and spinal cord and which have been proposed to mediate numerous central nervous system (CNS) actions of serotonin(3.5-6). Here we show that 5-HT2C receptor-deficient mice are overweight as a result of abnormal control of feeding behaviour, establishing a role for this receptor in the serotonergic control of appetite. Mutant animals are also prone to spontaneous death from seizures, suggesting that 5-HT2C receptors mediate tonic inhibition of neuronal network excitability.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								BLUNDELL JE, 1992, AM J CLIN NUTR, V55, P155, DOI 10.1093/ajcn/55.1.155s; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; DAILEY JW, 1987, FASEB J, V46, P706; ENGEL J, 1989, SEIZURES EPILEPSY; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; HIMMSHAGEN J, 1991, FRONT NEUROENDOCRIN, V12, P38; HOFFMAN BJ, 1989, FEBS LETT, V247, P453, DOI 10.1016/0014-5793(89)81390-0; JACOBS BL, 1984, HALLUCINOGENS NEUROC, P183; JOBE PC, 1973, LIFE SCI, V13, P1, DOI 10.1016/0024-3205(73)90271-3; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KENNETT GA, 1991, BRIT J PHARMACOL, V103, P2016, DOI 10.1111/j.1476-5381.1991.tb12369.x; KILIAN M, 1973, NEUROPHARMACOLOGY, V12, P681, DOI 10.1016/0028-3908(73)90121-4; KITCHENER SJ, 1994, PSYCHOPHARMACOLOGY, V113, P369, DOI 10.1007/BF02245211; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Milatovich Athena, 1992, Human Molecular Genetics, V1, P681, DOI 10.1093/hmg/1.9.681; MOLINEAUX SM, 1989, P NATL ACAD SCI USA, V86, P6793, DOI 10.1073/pnas.86.17.6793; ORLOFF MJ, 1949, P SOC EXP BIOL MED, V70, P254; PARKINSON WL, 1990, AM J PHYSIOL, V259, pR829, DOI 10.1152/ajpregu.1990.259.4.R829; POMPEIANO M, 1994, MOL BRAIN RES, V23, P163, DOI 10.1016/0169-328X(94)90223-2; SAMANIN R, 1979, N-S ARCH PHARMACOL, V308, P159, DOI 10.1007/BF00499059; SLEIGHT AJ, 1991, SEROTONIN RECEPTOR S, P211; SPARKS DL, 1985, PHARMACOL BIOCHEM BE, V23, P753, DOI 10.1016/0091-3057(85)90067-X; STRACK AM, 1995, AM J PHYSIOL-REG I, V268, pR183, DOI 10.1152/ajpregu.1995.268.1.R183; Tecott L H, 1993, Curr Opin Neurobiol, V3, P310, DOI 10.1016/0959-4388(93)90122-F; TECOTT LH, 1993, P NATL ACAD SCI USA, V90, P1430, DOI 10.1073/pnas.90.4.1430; THOMAS T, 1988, DEV BIOL, V128, P415, DOI 10.1016/0012-1606(88)90303-X; Wilkinson LO, 1991, SEROTONIN RECEPTOR S, P147; WURTMAN J, 1993, NEUROPSYCHOPHARMACOL, V9, P201, DOI 10.1038/npp.1993.56; YU L, 1991, MOL BRAIN RES, V11, P143, DOI 10.1016/0169-328X(91)90116-F	30	1061	1125	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	1995	374	6522					542	546		10.1038/374542a0	http://dx.doi.org/10.1038/374542a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700379				2022-12-24	WOS:A1995QR06900052
J	ALDERDICE, F; RENFREW, M; MARCHANT, S; ASHURST, H; HUGHES, P; BERRIDGE, G; GARCIA, J				ALDERDICE, F; RENFREW, M; MARCHANT, S; ASHURST, H; HUGHES, P; BERRIDGE, G; GARCIA, J			LABOR AND BIRTH IN WATER IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article									RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford			Renfrew, Mary/A-2440-2010; Alderdice, Fiona A/F-5748-2010	Alderdice, Fiona/0000-0003-2404-5644; Renfrew, Mary/0000-0003-2905-403X				MCCANDLISH R, 1993, BIRTH-ISS PERINAT C, V20, P79, DOI 10.1111/j.1523-536X.1993.tb00421.x; 1992, 2ND HOUS COMM HLTH C	2	29	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					837	837		10.1136/bmj.310.6983.837	http://dx.doi.org/10.1136/bmj.310.6983.837			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QQ857	7711622	Green Published			2022-12-24	WOS:A1995QQ85700020
J	NUREKI, O; VASSYLYEV, DG; KATAYANAGI, K; SHIMIZU, T; SEKINE, S; KIGAWA, T; MIYAZAWA, T; YOKOYAMA, S; MORIKAWA, K				NUREKI, O; VASSYLYEV, DG; KATAYANAGI, K; SHIMIZU, T; SEKINE, S; KIGAWA, T; MIYAZAWA, T; YOKOYAMA, S; MORIKAWA, K			ARCHITECTURES OF CLASS-DEFINING AND SPECIFIC DOMAINS OF GLUTAMYL-TRANSFER-RNA SYNTHETASE	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; THERMUS-THERMOPHILUS HB8; DATA-COLLECTION SYSTEM; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; DIFFRACTION DATA; GLTX-GENE; MACROMOLECULAR CRYSTALLOGRAPHY; 3-DIMENSIONAL STRUCTURE; WEISSENBERG CAMERA	The crystal structure of a class I aminoacyl-transfer RNA synthetase, glutamyl-tRNA synthetase (GluRS) from Thermus thermophilus, was solved and refined at 2.5 Angstrom resolution. The amino-terminal half of GluRS shows a geometrical similarity with that of Escherichia coli glutaminyl-tRNA synthetase (GlnRS) of the same subclass in class I, comprising the class I-specific Rossmann fold domain and the intervening subclass-specific alpha/beta domain. These domains were found to have two GluRS-specific, secondary-structure insertions, which then participated in the specific recognition of the D and acceptor stems of tRNA(Glu) as indicated by mutagenesis analyses based on the docking properties of GluRS and tRNA. In striking contrast to the beta-barrel structure of the GlnRS carboxyl-terminal half, the GluRS carboxyl-terminal half displayed an all-alpha-helix architecture, an alpha-helix cage, and mutagenesis analyses indicated that it had a role in the anticodon recognition.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,SCH SCI,DEPT BIOCHEM & BIOPHYS,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Yokoyama, Shigeyuki/N-6911-2015; Kigawa, Takanori/A-7679-2010; Vassylyev, Dmitry/A-9005-2008; Sekine, Shun-ichi/N-5450-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Kigawa, Takanori/0000-0003-0146-9719; Sekine, Shun-ichi/0000-0001-8174-8704				BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRETON R, 1990, J BIOL CHEM, V265, P18248; BRETON R, 1986, J BIOL CHEM, V261, P610; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; CAVARELLI J, 1992, NATURE, V362, P181; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DELARUE M, 1994, EMBO J, V13, P3219, DOI 10.1002/j.1460-2075.1994.tb06623.x; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FETT R, 1991, J BIOL CHEM, V266, P1448; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; HARAYOKOYAMA M, 1984, J BIOCHEM, V96, P1599, DOI 10.1093/oxfordjournals.jbchem.a134990; HARAYOKOYAMA M, 1985, THESIS U TOKYO TOKYO; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LABERGE S, 1989, J BACTERIOL, V171, P3926, DOI 10.1128/jb.171.7.3926-3932.1989; LAMOUR V, 1994, P NATL ACAD SCI USA, V91, P8670, DOI 10.1073/pnas.91.18.8670; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P436; NAKAMURA H, 1987, J PHYS SOC JPN, V56, P1609, DOI 10.1143/JPSJ.56.1609; NUREKI O, 1992, EUR J BIOCHEM, V204, P465, DOI 10.1111/j.1432-1033.1992.tb16656.x; NUREKI O, UNPUB; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OTOWINOWSKI Z, 1988, NATURE, V335, P321; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PUTNEY SD, 1981, SCIENCE, V213, P1497, DOI 10.1126/science.7025207; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHON A, 1988, NATURE, V331, P187, DOI 10.1038/331187a0; Sekine S., UNPUB; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STEITZ TA, 1982, P NATL ACAD SCI-BIOL, V79, P3097, DOI 10.1073/pnas.79.10.3097; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; TANAKA I, 1990, J APPL CRYSTALLOGR, V23, P334, DOI 10.1107/S0021889890004009; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WHITE BN, 1972, CAN J BIOCHEM CELL B, V50, P600, DOI 10.1139/o72-082; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; YAMAO F, 1982, J BIOL CHEM, V257, P1639; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	56	132	135	0	33	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1958	1965		10.1126/science.7701318	http://dx.doi.org/10.1126/science.7701318			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701318				2022-12-24	WOS:A1995QQ06800034
J	FISCHER, KD; ZMUIDZINAS, A; GARDNER, S; BARBACID, M; BERNSTEIN, A; GUIDOS, C				FISCHER, KD; ZMUIDZINAS, A; GARDNER, S; BARBACID, M; BERNSTEIN, A; GUIDOS, C			DEFECTIVE T-CELL RECEPTOR SIGNALING AND POSITIVE SELECTION OF VAV-DEFICIENT CD4(+) CD8(+) THYMOCYTES	NATURE			English	Article							TYROSINE KINASE; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; B-CELLS; PHOSPHORYLATION; ACTIVATION; MICE	DURING lymphocyte development, cellular proliferation and positive and negative selection events ensure the production of T and B lymphocytes bearing highly diverse, but self-tolerant, repertoires of antigen receptors(1,2). These processes are initiated when engagement of growth-factor receptors, or the T-3,T-4 and B-5 lymphocyte antigen receptors, induces tyrosine phosphorylation of specific SH2- and SH3-domain-containing cytoplasmic proteins, including Vav(3,6,7). Here we show that vav(-/-) embryonic stern cells generate only limited numbers of immature and mature T and B lymphocytes in the RAG-2 blastocyst complementation assays. Furthermore, Vav-deficient T lymphocytes showed severely impaired antigen receptor signalling. Finally, we demonstrate that Vav-dependent signalling pathways regulate maturation, but not CD4/ CD8 lineage commitment, during T-cell-receptor-mediated positive selection of immature CD4(+)CD8(+) precursors into mature CD4(+)CD8(-) or CD4(-)CD8(+) T cells.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAM MOLEC BIOL & CANC,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A1,CANADA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; HOSP SICK CHILDREN,RES INST,DIV IMMUNOL & CANC,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5S 1A1,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Bristol-Myers Squibb; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ADAMS JM, 1992, ONCOGENE, V7, P611; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; ASHTONRICKARDT PG, 1994, IMMUNOL TODAY, V15, P362, DOI 10.1016/0167-5699(94)90174-0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GODFREY DI, 1992, J IMMUNOL, V149, P2281; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUIDOS CJ, 1993, MOL MECHANISMS IMMUN, P137; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; ROLINK A, 1991, EUR J IMMUNOL, V21, P2609, DOI 10.1002/eji.1830211044; VANMEERWIJK JPM, 1993, SCIENCE, V261, P911, DOI 10.1126/science.8102208; VONBOEHMER H, CELL, V219, P94; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; ZMUIDZINAS A, 1995, EMBO J, V14, P1	30	282	283	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					474	477		10.1038/374474a0	http://dx.doi.org/10.1038/374474a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700360				2022-12-24	WOS:A1995QP89900064
J	MADDEN, DR; GARBOCZI, DN; WILEY, DC				MADDEN, DR; GARBOCZI, DN; WILEY, DC			THE ANTIGENIC IDENTITY OF PEPTIDE-MHC COMPLEXES - A COMPARISON OF THE CONFORMATIONS OF 5 VIRAL PEPTIDES PRESENTED BY HLA-A2	CELL			English	Article							T-CELL RECOGNITION; CRYSTAL-STRUCTURES; VIRUS PEPTIDE; MOLECULES; PROTEIN; RESOLUTION; EPITOPE; HLA-B27; BINDING; CHAINS	Complexes of five peptides (from HIV-1, influenza A virus, HTLV-1, and hepatitis B virus proteins) bound to the human class I MHC molecule HLA-A2 have been studied by X-ray crystallography. While the peptide termini and their second and C-terminal anchor side chains are bound similarly in all five cases, the main chain and side chain conformations of each peptide are strikingly different in the center of the binding site, and these differences are accessible to direct TCR recognition. Each of the central peptide residues is seen to point up for some bound peptides, but down or sideways for others. Thus, although fixed at its ends, the structure of an MHC-bound peptide appears to be a highly complex function of its entire sequence, potentially sensitive to even small sequence differences. In contrast, MHC structural variation is relatively limited. These results offer a structural framework for understanding the role of nonanchor peptide side chains in both peptide-MHC binding affinity and TCR recognition.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Howard Hughes Medical Institute								ALEXANDER J, 1993, J IMMUNOL, V150, P1; BEDNAREK MA, 1991, J IMMUNOL, V147, P4047; BERTOLETTI A, 1993, J VIROL, V67, P2376, DOI 10.1128/JVI.67.4.2376-2380.1993; BLUESTONE JA, 1992, J EXP MED, V176, P1757, DOI 10.1084/jem.176.6.1757; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, XPLOR MANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CATIPOVIC B, 1992, J EXP MED, V176, P1611, DOI 10.1084/jem.176.6.1611; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; ISHIOKA GY, 1992, J IMMUNOL, V148, P2446; JAMES MNG, 1983, J APPL CRYSTALLOGR, V11, P268; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KOENIG S, 1993, J IMMUNOL, V156, P3874; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCMICHAEL AJ, 1988, P NATL ACAD SCI USA, V85, P9194, DOI 10.1073/pnas.85.23.9194; NAYERSINA R, 1993, J IMMUNOL, V150, P4659; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; PARKER KC, 1992, J IMMUNOL, V149, P3580; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; UTZ U, 1992, J IMMUNOL, V149, P214; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	46	663	696	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					693	708		10.1016/0092-8674(93)90490-H	http://dx.doi.org/10.1016/0092-8674(93)90490-H			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	7694806				2022-12-24	WOS:A1993MH74900015
J	SPENCER, DM; WANDLESS, TJ; SCHREIBER, SL; CRABTREE, GR				SPENCER, DM; WANDLESS, TJ; SCHREIBER, SL; CRABTREE, GR			CONTROLLING SIGNAL-TRANSDUCTION WITH SYNTHETIC LIGANDS	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; LYMPHOCYTE-T ACTIVATION; CYCLOSPORINE-A; ZETA-CHAIN; MATHEMATICAL THEORY; MOLECULAR-CLONING; ATOMIC-STRUCTURE; BINDING SYSTEMS; KINASE-ACTIVITY; PROTEIN	Dimerization and oligomerization are general biological control mechanisms contributing to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. Cell permeable, synthetic ligands were devised that can be used to control the intracellular oligomerization of specific proteins. To demonstrate their utility, these ligands were used to induce intracellular oligomerization of cell surface receptors that lacked their transmembrane and extracellular regions but contained intracellular signaling domains. Addition of these ligands to cells in culture resulted in signal transmission and specific target gene activation. Monomeric forms of the ligands blocked the pathway. This method of ligand-regulated activation and termination of signaling pathways has the potential to be applied wherever precise control of a signal transduction pathway is desired.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305	Harvard University; Howard Hughes Medical Institute; Stanford University								BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FELDMAN H, 1972, ANAL BIOCHEM, V45, P530, DOI 10.1016/0003-2697(72)90216-3; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LYSON T, 1993, CIRC RES, V73, P596, DOI 10.1161/01.RES.73.3.596; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; ORGAN HM, 1993, BIOORG MED CHEM LETT, V3, P657, DOI 10.1016/S0960-894X(01)81248-8; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROSEN MK, 1992, ANGEW CHEM INT EDIT, V31, P384, DOI 10.1002/anie.199203841; ROSEN MK, 1993, J AM CHEM SOC, V115, P821, DOI 10.1021/ja00055a082; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SPENCER DJE, UNPUB; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WAQNDLESS TJ, UNPUB; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; YU LM, 1992, J IMMUNOL, V148, P633	53	666	775	2	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1019	1024		10.1126/science.7694365	http://dx.doi.org/10.1126/science.7694365			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7694365				2022-12-24	WOS:A1993MG18700025
J	MARSH, K; FORSTER, D; WARUIRU, C; MWANGI, I; WINSTANLEY, M; MARSH, V; NEWTON, C; WINSTANLEY, P; WARN, P; PESHU, N; PASVOL, G; SNOW, R				MARSH, K; FORSTER, D; WARUIRU, C; MWANGI, I; WINSTANLEY, M; MARSH, V; NEWTON, C; WINSTANLEY, P; WARN, P; PESHU, N; PASVOL, G; SNOW, R			INDICATORS OF LIFE-THREATENING MALARIA IN AFRICAN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL MALARIA; CLINICAL-FEATURES; FALCIPARUM-MALARIA	Background. About 90 percent of the deaths from malaria are in African children, but criteria to guide the recognition and management of severe malaria have not been validated in them. Methods. We conducted a prospective study of all children admitted to the pediatric ward of a Kenyan district hospital with a primary diagnosis of malaria. We calculated the frequency and mortality rate for each of the clinical and laboratory criteria in the current World Health Organization (WHO) definition of severe malaria, and then used logistic-regression analysis to identify the variables with the greatest prognostic value. Results. We studied 1844 children (mean age, 26.4 months) with a primary diagnosis of malaria, Not included were 18 children who died on arrival and 4 who died of other causes. The mortality rate was 3.5 percent (95 percent confidence interval, 2.7 to 4.3 percent), and 84 percent of the deaths occurred within 24 hours of admission. Logistic-regression analysis identified four key prognostic indicators: impaired consciousness (relative risk, 3.3; 95 percent confidence interval, 1.6 to 7.0), respiratory distress (relative risk, 3.9; 95 percent confidence interval, 2.0 to 7.7), hypoglycemia (relative risk, 3.3; 95 percent confidence interval, 1.6 to 6.7), and jaundice (relative risk, 2.6; 95 percent confidence interval, 1.1 to 6.3). Of the 64 children who died, 54 were among those with impaired consciousness (n = 336; case fatality rate, 11.9 percent) or respiratory distress (n = 251; case fatality rate, 13.9 percent), or both. Hence, this simple bedside index identified 84.4 percent of the fatal cases, as compared with the 79.7 percent identified by the current WHO criteria. Conclusions. In African children with malaria, the presence of impaired consciousness or respiratory distress can identify those at high risk for death.	JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, OXFORD OX3 9DU, ENGLAND; JOHN RADCLIFFE HOSP, DEPT PAEDIAT, OXFORD OX3 9DU, ENGLAND	University of Oxford; University of Oxford	MARSH, K (corresponding author), KENYA GOVT MED RES CTR, CLIN RES CTR, KILIFI UNIT, POB 230, KILIFI, KENYA.		Newton, Charles/C-6222-2009; Newton, Charles RJC/B-7578-2014; Snow, Robert William/AFR-1436-2022; Pasvol, Geoffrey/B-7113-2009	Newton, Charles RJC/0000-0002-6999-5507; Snow, Robert William/0000-0003-3725-6088; Marsh, Vicki/0000-0002-5178-4250	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; KRISHNA S, 1994, T ROY SOC TROP MED H, V88, P67, DOI 10.1016/0035-9203(94)90504-5; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; MOLYNEUX ME, 1989, J ROY SOC MED, V82, P35; MOLYNEUX ME, 1989, Q J MED, V71, P441; NEWTON CRJC, 1990, LANCET, V335, P472, DOI 10.1016/0140-6736(90)90703-8; NEWTON CRJC, 1991, LANCET, V337, P573, DOI 10.1016/0140-6736(91)91638-B; ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y; PASVOL G, 1991, AM J TROP MED HYG, V45, P702, DOI 10.4269/ajtmh.1991.45.702; SNOW RW, 1993, T ROY SOC TROP MED H, V87, P386, DOI 10.1016/0035-9203(93)90007-D; TAYLOR TE, 1993, Q J MED, V86, P99; WARRELL DA, 1987, PARASITOLOGY, V94, pS53, DOI 10.1017/S0031182000085826; White N. J., 1986, Clinics in Tropical Medicine and Communicable Diseases, V1, P55; 1993, 1993 WORLD BANK WORL; [No title captured]	15	779	791	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1399	1404		10.1056/NEJM199505253322102	http://dx.doi.org/10.1056/NEJM199505253322102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY941	7723795				2022-12-24	WOS:A1995QY94100002
J	FORMAN, BM; UMESONO, K; CHEN, J; EVANS, RM				FORMAN, BM; UMESONO, K; CHEN, J; EVANS, RM			UNIQUE RESPONSE PATHWAYS ARE ESTABLISHED BY ALLOSTERIC INTERACTIONS AMONG NUCLEAR HORMONE RECEPTORS	CELL			English	Article							RETINOID-X-RECEPTOR; TATA-BINDING PROTEIN; THYROID-HORMONE; DNA-BINDING; TRANSCRIPTION FACTOR; ACID RECEPTORS; AUXILIARY PROTEIN; ORPHAN RECEPTORS; MAMMALIAN-CELLS; GENE-EXPRESSION	Heterodimerization is a common paradigm among eukaryotic transcription factors. The 9-cis retinoic acid receptor (RXR) serves as a common heterodimerization partner for several nuclear receptors, including the thyroid hormone receptor (T(3)R) and retinoic acid receptor (RAR). This raises the question as to whether these complexes possess dual hormonal responsiveness. We devised a strategy to examine the transcriptional properties of each receptor individually or when tethered to a heterodimeric partner. We find that the intrinsic binding properties of RXR are masked in T(3)R-RXR and RAR-RXR heterodimers. In contrast, RXR is active as a non-DNA-binding cofactor with the NGFI-B/Nurr1 orphan receptors. Heterodimerization of RXR with constitutively active NGFI-B/Nurr1 creates a novel hormone-dependent complex. These findings suggest that allosteric interactions among heterodimers create complexes with unique properties. We suggest that allostery is a critical feature underlying the generation of diversity in hormone response networks.	HOWARD HUGHES MED INST, GENE EXPRESS LAB, SAN DIEGO, CA 92037 USA	Howard Hughes Medical Institute	FORMAN, BM (corresponding author), SALK INST BIOL STUDIES, SAN DIEGO, CA 92037 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NIGMS NIH HHS [GM-26444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026444, R37GM026444] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DAVIS IJ, 1994, MOL CELL BIOL, V14, P3469, DOI 10.1128/MCB.14.5.3469; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEYERS RE, 1993, MOL CELL BIOL, V13, P7953, DOI 10.1128/MCB.13.12.7953; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; UNDERHILL TM, 1994, MOL ENDOCRINOL, V8, P274, DOI 10.1210/me.8.3.274; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	76	566	591	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					541	550		10.1016/0092-8674(95)90075-6	http://dx.doi.org/10.1016/0092-8674(95)90075-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758108	Bronze			2022-12-24	WOS:A1995QZ71000011
J	SCHNEEWEIS, DM; SCHNAPF, JL				SCHNEEWEIS, DM; SCHNAPF, JL			PHOTOVOLTAGE OF RODS AND CONES IN THE MACAQUE RETINA	SCIENCE			English	Article							MONKEY MACACA-FASCICULARIS; TURTLE PHOTORECEPTORS; VISUAL TRANSDUCTION; SALAMANDER; SENSITIVITY; SEGMENTS; CAT	The kinetics, gain, and reliability of light responses of rod and cone photoreceptors are important determinants of overall Visual sensitivity. In voltage recordings from photoreceptors in an intact primate retina, rods were found to be functionally isolated from each other, unlike the tightly coupled rods of cold-blooded vertebrates. Cones were observed to receive excitatory input from rods, which indicates that the cone pathway also processes rod signals, This input might be expected to degrade the spatial resolution of mesopic vision.	UNIV CALIF SAN FRANCISCO,DEPT OPHTHALMOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL EYE INSTITUTE [R01EY007642, F32EY006399] Funding Source: NIH RePORTER; NEI NIH HHS [R01-EY07642, F32-EY06399] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BADER CR, 1979, J PHYSIOL-LONDON, V296, P1; BADER CR, 1982, J PHYSIOL-LONDON, V331, P253, DOI 10.1113/jphysiol.1982.sp014372; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BAYLOR DA, 1971, J PHYSIOL-LONDON, V214, P265, DOI 10.1113/jphysiol.1971.sp009432; BAYLOR DA, 1987, J PHYSIOL-LONDON, V390, P145, DOI 10.1113/jphysiol.1987.sp016691; BAYLOR DA, 1973, J PHYSIOL-LONDON, V234, P163, DOI 10.1113/jphysiol.1973.sp010340; BAYLOR DA, 1986, J PHYSIOL-LONDON, V371, P115, DOI 10.1113/jphysiol.1986.sp015964; BAYLOR DA, 1984, J PHYSIOL-LONDON, V387, P575; BAYLOR DA, 1976, COLD SPRING HARB SYM, V40, P529; CONNER JD, 1977, SCIENCE, V195, P698, DOI 10.1126/science.841308; CONNER JD, 1982, J PHYSIOL-LONDON, V332, P139, DOI 10.1113/jphysiol.1982.sp014406; COPENHAGEN DR, 1983, VISION RES, V4, P363; DETWILER PB, 1980, J PHYSIOL-LONDON, V300, P213, DOI 10.1113/jphysiol.1980.sp013159; FAIN GL, 1975, SCIENCE, V187, P838, DOI 10.1126/science.1114328; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KNIGHT R, 1993, VISION RES, V33, P2203, DOI 10.1016/0042-6989(93)90100-B; KRAFT TW, 1993, J PHYSIOL-LONDON, V464, P747, DOI 10.1113/jphysiol.1993.sp019661; LAMB TD, 1976, J PHYSIOL-LONDON, V263, P257, DOI 10.1113/jphysiol.1976.sp011631; NELSON R, 1977, J COMP NEUROL, V172, P109, DOI 10.1002/cne.901720106; Nelson R., 1985, NEUROCIRCUITRY RETIN, P109; RAVIOLA E, 1973, P NATL ACAD SCI USA, V70, P1677, DOI 10.1073/pnas.70.6.1677; SCHNAPF JL, 1990, J PHYSIOL-LONDON, V427, P681, DOI 10.1113/jphysiol.1990.sp018193; SCHNAPF JL, 1983, J PHYSIOL-LONDON, V343, P147, DOI 10.1113/jphysiol.1983.sp014886; SCHNAPF JL, 1983, NATURE, V296, P862; SMITH RG, 1986, J NEUROSCI, V6, P3505; YAGI T, 1994, J NEUROPHYSIOL, V71, P656, DOI 10.1152/jn.1994.71.2.656	26	239	243	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1053	1056		10.1126/science.7754386	http://dx.doi.org/10.1126/science.7754386			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754386				2022-12-24	WOS:A1995QY93400042
J	DONG, JT; LAMB, PW; RINKERSCHAEFFER, CW; VUKANOVIC, J; ICHIKAWA, T; ISAACS, JT; BARRETT, JC				DONG, JT; LAMB, PW; RINKERSCHAEFFER, CW; VUKANOVIC, J; ICHIKAWA, T; ISAACS, JT; BARRETT, JC			KAI1, A METASTASIS SUPPRESSOR GENE FOR PROSTATE-CANCER ON HUMAN-CHROMOSOME 11P11.2	SCIENCE			English	Article							TRANSMEMBRANE PROTEINS; SYNCYTIUM FORMATION; TUMOR PROGRESSION; MOLECULAR-CLONING; INCLUDING CD9; CELL-FUSION; ANTIGEN; FAMILY; IDENTIFICATION; ANTIBODY	A gene from human chromosome 11p11.2 was isolated and was shown to suppress metastasis when introduced into rat AT6.1 prostate cancer cells. Expression of this gene, designated KAI1, was reduced in human cell lines derived from metastatic prostate tumors. KAI1 specifies a protein of 267 amino acids, with four hydrophobic and presumably transmembrane domains and one large extracellular hydrophilic domain with three potential N-glycosylation sites. KAI1 is evolutionarily conserved, is expressed in many human tissues, and encodes a member of a structurally distinct family of leukocyte surface glycoproteins. Decreased expression of this gene may be involved in the malignant progression of prostate and other cancers.	NIEHS, MOLEC CARCINOGENESIS LAB, ENVIRONM CARCINOGENESIS PROGRAM, RES TRIANGLE PK, NC 27709 USA; JOHNS HOPKINS UNIV, SCH MED, JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21231 USA; CHIBA UNIV, SCH MED, DEPT UROL, CHIBA 260, JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Johns Hopkins University; Johns Hopkins Medicine; Chiba University			Criley, Jasminka/ABF-7288-2021	Dong, Jin-Tang/0000-0003-2349-5782	NCI NIH HHS [CA 58236] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIOT M, 1990, J IMMUNOL, V145, P4322; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; CLASSON BJ, 1989, J EXP MED, V169, P1497, DOI 10.1084/jem.169.4.1497; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Dong J.-K., UNPUB; DRICKAMER K, 1992, CURR OPIN STRUC BIOL, V2, P653; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GIL ML, 1992, J IMMUNOL, V148, P2826; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; Horoszewicz JS, 1980, MODELS PROSTATE CANC, P115; HOTTA H, 1988, CANCER RES, V48, P2955; ICHIKAWA T, 1991, CANCER RES, V51, P3788; ICHIKAWA T, 1992, CANCER RES, V52, P3486; IIZUMI T, 1987, J UROLOGY, V137, P1304, DOI 10.1016/S0022-5347(17)44488-0; IMAI T, 1992, J IMMUNOL, V149, P2879; ISHIKAWA M, 1988, CANCER RES, V48, P665; KAIGHN ME, 1979, INVEST UROL, V17, P16; KONDOH M, 1993, MELANOMA RES, V3, P241; LEVY S, 1991, J BIOL CHEM, V266, P14597; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NICOLSON GL, 1991, BIOESSAYS, V13, P337, DOI 10.1002/bies.950130706; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; RAMSHAW IA, 1983, INT J CANCER, V32, P471, DOI 10.1002/ijc.2910320414; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; ROSENBERG SA, 1987, SURGICAL TREATMENT M; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SIDEBOTTOM E, 1983, BRIT J CANCER, V47, P399, DOI 10.1038/bjc.1983.60; STEEG P S, 1992, Current Opinion in Oncology, V4, P134, DOI 10.1097/00001622-199202000-00018; VUKANOVIC J, 1993, CANCER RES, V53, P1833	35	715	847	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	1995	268	5212					884	886		10.1126/science.7754374	http://dx.doi.org/10.1126/science.7754374			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754374	Green Submitted			2022-12-24	WOS:A1995QX85000041
J	TANAKA, Y; MORITA, CT; TANAKA, Y; NIEVES, E; BRENNER, MB; BLOOM, BR				TANAKA, Y; MORITA, CT; TANAKA, Y; NIEVES, E; BRENNER, MB; BLOOM, BR			NATURAL AND SYNTHETIC NONPEPTIDE ANTIGENS RECOGNIZED BY HUMAN GAMMA-DELTA T-CELLS	NATURE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; EXPANSION; RECEPTOR; PROTEIN; SUBSET	T LYMPHOCYTES express either alpha beta or gamma delta T-cell receptor heterodimers(1,2). Most alpha beta T cells recognize antigenic peptides bound to major histocompatibility complex molecules but the antigen recognition and biological function of gamma delta T cells is unknown. A major human gamma delta T-cell subset expressing V gamma 2 and V delta 2 germline genes, but having diverse junctional sequences, is found in human mycobacterial lesions(3) and responds in vitro to antigens of bacteria and parasites(4-8). In addition, certain haematopoietic tumour cells are specifically recognized and lysed by these T cells(9). V gamma 2V delta 2-bearing T cells were shown to recognize mycobacterial antigens that are protease resistant and phosphatase sensitive(10-13). Because of the difficulty in isolating natural antigens from mycobacterial culture filtrates or extracts, we synthesized a series of monoalkyl phosphates, and found that some, particularly monoethyl phosphate, could mimic the activity of mycobacterial antigens in stimulating these gamma delta T cells(10). Here we report the identification of natural antigens produced by mycobacteria recognized by human V gamma 2V delta 2-bearing T cells as isopentenyl pyrophosphate and related prenyl pyrophosphate derivatives, compounds involved in the synthesis of complex polyisoprenoid compounds in microbial and mammalian cells. Substitution of phosphate for the pyrophosphate moiety, or elimination of the double bond, greatly reduced antigenic activity of these compounds. These results provide formal evidence that, in contrast to recognition of major histocompatibility complex-bound peptide antigens by alpha beta T cells, human gamma delta T cells can recognize naturally occurring small non-peptidic antigens.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Morita, Craig T/C-1365-2011	Morita, Craig T/0000-0001-8496-8294; Tanaka, Yoshimasa/0000-0002-5024-0614				Ames BN, 1966, METHOD ENZYMOL, V8, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; BUKOWSKI JF, 1994, J IMMUNOL, V153, P5133; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; DELIBERO G, 1991, J EXP MED, V173, P1311, DOI 10.1084/jem.173.6.1311; ECKSTEIN F, 1975, BIOCHEMISTRY-US, V23, P5225; FISCH P, 1990, SCIENCE, V250, P1269, DOI 10.1126/science.1978758; GOERLICH R, 1991, EUR J IMMUNOL, V21, P2613, DOI 10.1002/eji.1830211045; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARA T, 1992, J CLIN INVEST, V90, P204, DOI 10.1172/JCI115837; HAVLIR DV, 1991, J CLIN INVEST, V87, P729, DOI 10.1172/JCI115053; KABELITZ D, 1990, J EXP MED, V171, P667, DOI 10.1084/jem.171.3.667; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KNORRE DG, 1976, FEBS LETT, V70, P105, DOI 10.1016/0014-5793(76)80736-3; Marrack P, 1986, Adv Immunol, V38, P1, DOI 10.1016/S0065-2776(08)60005-X; MODLIN RL, 1989, NATURE, V339, P544, DOI 10.1038/339544a0; Myant, 1981, BIOL CHOLESTEROL REL, P123, DOI DOI 10.1016/B978-0-433-22880-6.50010-2; PANCHAMOORTHY G, 1991, J IMMUNOL, V147, P3360; PFEFFER K, 1990, EUR J IMMUNOL, V20, P1175, DOI 10.1002/eji.1830200534; POPJAK G, 1962, J BIOL CHEM, V237, P56; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHOEL B, 1994, EUR J IMMUNOL, V24, P1886, DOI 10.1002/eji.1830240826; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175	27	820	850	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					155	158		10.1038/375155a0	http://dx.doi.org/10.1038/375155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753173				2022-12-24	WOS:A1995QX74100054
J	SCHAFER, WR; KENYON, CJ				SCHAFER, WR; KENYON, CJ			A CALCIUM-CHANNEL HOMOLOG REQUIRED FOR ADAPTATION TO DOPAMINE AND SEROTONIN IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							GENETICS; NEURONS	PROCESSING and storage of information by the nervous system requires the ability to modulate the response of excitable cells to neurotransmitter. A simple process of this type, known as adaptation or desensitization, occurs when prolonged stimulation triggers processes that attenuate the response to neurotransmitter. Here we report that the Caenorhabditis elegans gene unc-2 is required for adaptation to two neurotransmitters, dopamine and serotonin. A loss-of-function mutation in unc-2 resulted in failure to adapt either to paralysis by dopamine or to stimulation of egg laying by serotonin. In addition, unc-2 mutants displayed behaviours similar to those induced by serotonin treatment. We found that unc-2 encodes a homologue of a voltage-sensitive calcium-channel alpha-1 subunit. Expression of unc-2 occurs in two types of neurons implicated in the control of egg laying, a behaviour regulated by serotonin, Unc-2 appears to be required in modulatory neurons to downregulate the response of the egg-laying muscles to serotonin, We propose that adaptation to serotonin occurs through activation of an Unc-2-dependent calcium influx, which modulates the postsynaptic response to serotonin, perhaps by inhibiting the release of a potentiating neuropeptide.			SCHAFER, WR (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Schafer, William/0000-0002-6676-8034				AKERIB CC, 1994, GENETICS, V138, P1105; ALBERTSON DG, 1993, GENETICS, V134, P211; AVERY L, 1993, GENETICS, V133, P897; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; BRENNER S, 1974, GENETICS, V77, P71; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; HERMAN RK, 1984, GENETICS, V108, P165; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; SCHINKMANN K, 1992, J COMP NEUROL, V316, P251, DOI 10.1002/cne.903160209; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SEYDOUX G, IN PRESS METH CELL B; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; SULSTON J, 1975, J COMP NEUROL, V163, P215, DOI 10.1002/cne.901630207; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TRENT C, 1983, GENETICS, V104, P619; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; YANDELL MD, 1994, P NATL ACAD SCI USA, V91, P1381, DOI 10.1073/pnas.91.4.1381; ZHAO C, 1995, NATURE, V373, P74, DOI 10.1038/373074a0	23	225	237	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					73	78		10.1038/375073a0	http://dx.doi.org/10.1038/375073a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723846				2022-12-24	WOS:A1995QW60400058
J	VONKRIES, R; HACHMEISTER, A; GOBEL, U				VONKRIES, R; HACHMEISTER, A; GOBEL, U			REPEATED ORAL VITAMIN-K PROPHYLAXIS IN WEST-GERMANY - ACCEPTANCE AND EFFICACY	BMJ-BRITISH MEDICAL JOURNAL			English	Article											VONKRIES, R (corresponding author), UNIV DUSSELDORF, KINDERKLIN, D-40225 DUSSELDORF, GERMANY.							GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; Schmidt E, 1993, MONATSSCHR KINDERH, V141, P758; VONKRIES R, 1993, THROMB HAEMOSTASIS, V69, P293; 1993, DTSCH ARZTEBLAN, V90, P53; 1992, VITAMIN K PROPHYLAXI	5	24	24	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 29	1995	310	6987					1097	1098		10.1136/bmj.310.6987.1097	http://dx.doi.org/10.1136/bmj.310.6987.1097			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742675	Green Published			2022-12-24	WOS:A1995QW61800014
J	FARROW, SN; WHITE, JHM; MARTINOU, I; RAVEN, T; PUN, KT; GRINHAM, CJ; MARTINOU, JC; BROWN, R				FARROW, SN; WHITE, JHM; MARTINOU, I; RAVEN, T; PUN, KT; GRINHAM, CJ; MARTINOU, JC; BROWN, R			CLONING OF A BCL-2 HOMOLOG BY INTERACTION WITH ADENOVIRUS E1B 19K	NATURE			English	Article							PROGRAMMED CELL-DEATH; HUMAN B-CELLS; APOPTOSIS; PROTEIN; 19-KDA; GENE	NUMBER Of DNA viruses carry apoptosis-inhibiting genes which enable the virus to escape from the host reponse(1-5). The adenovirus E1B 19K protein can inhibit apoptosis induced by E1A, tumour-necrosis factor-alpha, FAS antigen and nerve growth factor deprivation(6-9). The molecular basis of this inhibition remains poorly understood, but the fact that protection is seen in the absence of other viral proteins suggests that E1B 19K targets cellular proteins. We report here the identification of three cellular proteins that bind E1B 19K, One of these is a new member of the bcl-2 family(10-16), which we have called bak (for bcl-2 homologous antagonist/killer). This protein, which is expressed in a wide variety of cell types, binds to E1B 19K and to the Bcl-2 homologue Bcl-x(L) (ref, 17) in yeast, In addition, overexpression of bak in sympathetic neurons deprived of nerve growth factor accelerates apoptosis and blocks the protective effect of co-injected E1B 19K.	GLAXO RES & DEV LTD,DEPT MOLEC VIROL,GREENFORD UB6 0HE,MIDDX,ENGLAND; GLAXO INST MOLEC BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline; GlaxoSmithKline				martinou, Jean-claude/0000-0002-9847-2051; Pun, Tao/0000-0001-5241-2187				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HASHIMOTO S, 1991, INT IMMUN, V343, P343; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	27	464	492	2	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					731	733		10.1038/374731a0	http://dx.doi.org/10.1038/374731a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715729				2022-12-24	WOS:A1995QU30400052
J	LU, Q; MILLER, C				LU, Q; MILLER, C			SILVER AS A PROBE OF PORE-FORMING RESIDUES IN A POTASSIUM CHANNEL	SCIENCE			English	Article							K+ CHANNELS; CYSTEINE-SUBSTITUTION; RECEPTOR-SITE; TEA BLOCKADE; AMINO-ACIDS; ION; SELECTIVITY; STOICHIOMETRY; INACTIVATION; PERMEATION	In voltage-dependent potassium channels, the molecular determinants of ion selectivity are found in the P (pore) region, a stretch of 21 contiguous residues. Cysteine was introduced at each P region position in a Shaker potassium channel. Residues projecting side chains into the pore were identified by means of channel inhibition by a sulfhydryl-reactive potassium ion analog, silver ion. The pattern of silver ion reactivity contradicts a beta barrel architecture of potassium channel pores.	BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254; BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University; Howard Hughes Medical Institute; Brandeis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031768, R01GM031768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ANDERSEN OS, COMMUNICATION; BOGUSZ S, 1992, PROTEIN ENG, V5, P295; BOLAND LM, 1994, BIOPHYS J, V66, P694, DOI 10.1016/S0006-3495(94)80843-4; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; DANCE IG, 1986, POLYHEDRON, V5, P1037, DOI 10.1016/S0277-5387(00)84307-7; DEBIASI M, 1993, BIOPHYS J, V65, P1235, DOI 10.1016/S0006-3495(93)81154-8; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEIGENBOTHAM L, 1993, THESIS HARVARD U; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; LIESEGANG GW, 1977, J AM CHEM SOC, V99, P3240, DOI 10.1021/ja00452a006; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1993, SCIENCE, V261, P1692, DOI 10.1126/science.8397443; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; NYHOLM RS, 1961, P CHEM SOC LONDON, P273; PEROZO E, 1993, NEURON, V11, P353, DOI 10.1016/0896-6273(93)90190-3; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; TAGLIALATELA M, 1993, PFLUG ARCH EUR J PHY, V423, P104, DOI 10.1007/BF00374967; XU M, 1993, J BIOL CHEM, V268, P21505; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157; ZHULKE RD, 1994, SOC NEUR ABSTR, V20, P864	38	175	177	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					304	307		10.1126/science.7716526	http://dx.doi.org/10.1126/science.7716526			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716526				2022-12-24	WOS:A1995QT18500043
J	KOTTKE, TE; TRAPP, MA; FORES, MM; KELLY, AW; JUNG, SH; NOVOTNY, PJ; PANSER, LA				KOTTKE, TE; TRAPP, MA; FORES, MM; KELLY, AW; JUNG, SH; NOVOTNY, PJ; PANSER, LA			CANCER SCREENING BEHAVIORS AND ATTITUDES OF WOMEN IN SOUTHEASTERN MINNESOTA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OLDER WOMEN; MAMMOGRAPHY; PHYSICIANS; SMEAR	Objectives.-To determine the rates at which women received screening Papanicolaou tests, clinical breast examinations, and mammography and to determine the extent to which these women might be expected to respond to screening recommendations from their physicians. Design.-Random-digit-dial telephone interviews conducted in January 1993. Setting.-Fifteen counties in southeastern Minnesota. Subjects.-A sample of 1019 women who completed the telephone interview. Main Outcome Measures.-Self-reported Papanicolaou test, clinical breast examination, acid mammography screening rates, with verification from medical records for a randomly selected subsample of 200 respondents who reported having had a test within 1 year of the interview. Results.-For women aged 18 years and older, 60% (95% confidence interval, +/-3.4%) reported having had a Papanicolaou test within the preceding year. For women 40 years of age and older, 57% (95% confidence interval, +/-3,5%) reported having had a clinical breast examination in the past year, and 46% (95% confidence interval, +/-3,6%) reported having had a screening mammogram within 1 year. The verified 1-year Papanicolaou test and mammogram rates were 35% and 33%, respectively. More than 90% of the respondents expressed a willingness to have these tests if their physicians were to advise them that the tests were indicated. However, 53% and 54% of the respondents, respectively, said that they either did not care or did not want their physicians to remind them when they were due for a Papanicolaou test or a mammogram. Conclusions.-Although self-reported screening rates in this population meet Healthy People 2000 goals, verified rates were significantly below target levels. A substantial proportion of women in this population remain ambivalent about participating in cancer detection programs.			KOTTKE, TE (corresponding author), MAYO CLIN & MAYO FDN,NCI,DESIGNATED MAYO COMPREHENS CANC CTR,HARWICK 6,ROCHESTER,MN 55905, USA.				NCI NIH HHS [CA 57825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA057825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackermann S P, 1992, MMWR CDC Surveill Summ, V41, P17; Akaike H., 1998, P 2 INT S INF THEOR, DOI DOI 10.1007/978-1-4612-1694-0_15; BANDURA A, 1977, SOCIAL LEARNING THEO, P50; CUMMINGS KM, 1983, J FAM PRACTICE, V17, P1029; FREIDSON E, 1970, PROFESSION MED STUDY, P355; KAHNEMAN D, 1982, SCI AM, V246, P160, DOI 10.1038/scientificamerican0182-160; Kee F, 1992, Eur J Cancer Prev, V1, P311, DOI 10.1097/00008469-199206000-00006; KING ES, 1990, AM J PUBLIC HEALTH, V80, P1386, DOI 10.2105/AJPH.80.11.1386; KOTTKE T E, 1990, Journal of General Internal Medicine, V5, pS62, DOI 10.1007/BF02600845; KOTTKE TE, 1993, MAYO CLIN PROC, V68, P785, DOI 10.1016/S0025-6196(12)60638-7; KOTTKE TE, 1994, TOB CONTROL, V3, P46; LERMAN C, 1990, PREV MED, V19, P279, DOI 10.1016/0091-7435(90)90028-I; MOLLEMAN E, 1984, SOC SCI MED, V18, P475, DOI 10.1016/0277-9536(84)90003-0; MOODIE PJS, 1989, NEW ZEAL MED J, V102, P374; MOSELEY R, 1985, J MED PHILOS, V10, P163, DOI 10.1093/jmp/10.2.163; MURRAY M, 1993, J PUBLIC HEALTH MED, V15, P147; RATZAN RM, 1985, J MED PHILOS, V10, P147, DOI 10.1093/jmp/10.2.147; RESNIK MD, 1987, CHOICES INTRO DECISI, P8; Rimer B K, 1990, J Am Board Fam Pract, V3, P26; ROGERS EM, 1983, DIFFUSION INNOVATION, P250; SAWYER JA, 1989, AM J PUBLIC HEALTH, V79, P1036, DOI 10.2105/AJPH.79.8.1036; SKINNER BF, 1959, CUMULATIVE RECORD, P21; STEPTOE A, 1991, SOC SCI MED, V32, P627, DOI 10.1016/0277-9536(91)90141-X; WARNECKE RB, 1976, CANCER, V37, P2015, DOI 10.1002/1097-0142(197604)37:4<2015::AID-CNCR2820370453>3.0.CO;2-X; WEINBERGER M, 1991, J AM GERIATR SOC, V39, P22, DOI 10.1111/j.1532-5415.1991.tb05901.x; ZAPKA JG, 1992, J GERONTOL, V47, P93; 1989, GUIDE CLIN PREVENTIV, P39; 1990, SAS STAT USERS GUIDE, V2, P1071; 1991, PHS9150212 DEP HLTH; 1993, MMWR-MORBID MORTAL W, V42, P1	30	65	66	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1099	1105		10.1001/jama.273.14.1099	http://dx.doi.org/10.1001/jama.273.14.1099			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QR059	7707597				2022-12-24	WOS:A1995QR05900028
J	GLOVER, DM; LEIBOWITZ, MH; MCLEAN, DA; PARRY, H				GLOVER, DM; LEIBOWITZ, MH; MCLEAN, DA; PARRY, H			MUTATIONS IN AURORA PREVENT CENTROSOME SEPARATION LEADING TO THE FORMATION OF MONOPOLAR SPINDLES	CELL			English	Article							MICROTUBULE-ORGANIZING CENTERS; DEPENDENT PROTEIN-KINASE; EARLY DROSOPHILA EMBRYOS; SEA-URCHIN EGGS; CELL-CYCLE; ABNORMAL SPINDLE; DNA-SYNTHESIS; MELANOGASTER; ANAPHASE; MITOSIS	We show that female sterile mutations of aurora (aur) are allelic to mutations in the lethal complementation group ck(10). This lies in a cytogenetic interval, 87A7-A9, that contains eight transcription units. A 250 bp region upstream of both a ur and a divergent transcription unit corresponds to the site of a specific chromatin structure (scs') previously proposed to be a barrier to insulate enhancers of the major hsp70 gene at 87A7. Syncytial embryos derived from aur mothers display closely paired centrosomes at inappropriate mitotic stages and develop interconnected spindles in which the poles are shared. Amorphic alleles result in pupal lethality and in mitotic arrest in which condensed chromosomes are arranged on circular monopolar spindles. The size of the single centrosomal body in these circular figures suggests that lass of function of the serine-threonine protein kinase encoded by aur leads to a failure of the centrosomes to separate and form a bipolar spindle.			GLOVER, DM (corresponding author), UNIV DUNDEE,INST MED SCI,DEPT ANAT & PHYSIOL,CANC RES CAMPAIGN CELL CYCLE GENET GRP,DUNDEE DD1 4HN,SCOTLAND.			Glover, David/0000-0003-0956-0103				BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BAJER AS, 1982, J CELL BIOL, V93, P33, DOI 10.1083/jcb.93.1.33; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAGGESE C, 1979, P NATL ACAD SCI USA, V76, P2385, DOI 10.1073/pnas.76.5.2385; CALLAINI G, 1990, J CELL SCI, V97, P539; CASSIMERIS L, 1994, J CELL SCI, V107, P285; FARKAS G, 1992, NUCLEIC ACIDS RES, V20, P2604, DOI 10.1093/nar/20.10.2604; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; FRASCH M, 1986, J CELL SCI, V82, P155; FREEMAN M, 1986, CELL, V46, P457, DOI 10.1016/0092-8674(86)90666-5; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GAUSZ J, 1981, GENETICS, V98, P775; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GONZALEZ C, 1990, J CELL SCI, V96, P605; GONZALEZ C, 1988, J CELL SCI, V89, P39; GONZALEZ C, 1993, CELL CYCLE PRACTICAL, P163; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HUETTNER ALFRED F., 1933, ZEITSCHR WISS BIOL ABT B ZEITSCHR ZELLFORSCH U MIKROSK ANAT, V19, P119, DOI 10.1007/BF00587553; ISHHOROWICZ D, 1980, J MOL BIOL, V142, P231, DOI 10.1016/0022-2836(80)90047-9; ISHHOROWICZ D, 1979, CELL, V17, P565, DOI 10.1016/0092-8674(79)90264-2; KARR TL, 1986, J CELL BIOL, V102, P1494, DOI 10.1083/jcb.102.4.1494; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; KERYER G, 1990, J CELL SCI, V97, P553; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; LEWIN B, 1994, GENES, V5; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; MAZIA D, 1960, J BIOPHYS BIOCHEM CY, V7, P1, DOI 10.1083/jcb.7.1.1; MINDEN JS, 1989, J CELL BIOL, V109, P505, DOI 10.1083/jcb.109.2.505; NAGANO H, 1981, DEV BIOL, V85, P409, DOI 10.1016/0012-1606(81)90272-4; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PICARD A, 1988, DEV BIOL, V128, P121, DOI 10.1016/0012-1606(88)90273-4; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; RIPOLL P, 1985, CELL, V41, P907, DOI 10.1016/S0092-8674(85)80071-4; ROBERTSON HM, 1988, GENETICS, V118, P461; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SLUDER G, 1985, J CELL SCI, V76, P35; SLUDER G, 1985, J CELL BIOL, V100, P897, DOI 10.1083/jcb.100.3.897; SLUDER G, 1986, BIOL BULL, V170, P538; SPIERER P, 1983, J MOL BIOL, V168, P35, DOI 10.1016/S0022-2836(83)80321-0; SULLIVAN W, 1990, DEVELOPMENT, V110, P331; SUNKEL CE, 1988, J CELL SCI, V89, P25; SZABAD J, 1982, DEV BIOL, V93, P240, DOI 10.1016/0012-1606(82)90256-1; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; VANDRE DD, 1989, J CELL SCI, V94, P245; VANDRE DD, 1986, EUR J CELL BIOL, V41, P72; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VESSEY KB, 1991, J CELL SCI, V98, P233; WANG RJ, 1983, J CELL BIOL, V96, P301, DOI 10.1083/jcb.96.1.301; WARN RM, 1985, EXP CELL RES, V163, P201; WATERS JC, 1993, J CELL BIOL, V122, P361, DOI 10.1083/jcb.122.2.361; WHITFIELD WGF, 1988, J CELL SCI, V89, P467	58	669	684	1	30	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					95	105		10.1016/0092-8674(95)90374-7	http://dx.doi.org/10.1016/0092-8674(95)90374-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720077	Bronze			2022-12-24	WOS:A1995QR97000011
J	NOMURA, A; STEMMERMANN, GN; CHYOU, PH; PEREZPEREZ, GI; BLASER, MJ				NOMURA, A; STEMMERMANN, GN; CHYOU, PH; PEREZPEREZ, GI; BLASER, MJ			HELICOBACTER-PYLORI INFECTION AND THE RISK FOR DUODENAL AND GASTRIC-ULCERATION	ANNALS OF INTERNAL MEDICINE			English	Article						HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; DUODENAL ULCER; PEPTIC ULCER	CAMPYLOBACTER-PYLORI; GASTRODUODENAL DISEASE; SURFACE-PROTEINS; PATHOGENESIS; ERADICATION; RECURRENCE; HAWAII; INFLAMMATION; CARCINOMA; ULCERS	Objective: To determine whether a preexisting Helicobacter pylori infection increases the risk for developing duodenal or gastric ulcer. Design: A nested case-control study based on a cohort of 5443 Japanese-American men who had a physical examination and a phlebotomy from 1967 to 1970. Setting: All 10 general hospitals on the Hawaiian island of Oahu. Patients: 150 patients with gastric ulcer and 65 patients with duodenal ulcer identified in the cohort of study participants after a hospital surveillance period of more than 20 years. Measurements: Stored serum specimens from patients and from matched controls were tested for the presence of serum IgG antibody to H. pylori using enzyme-linked immunosorbent assay. st Results: 93% of the 150 patients with gastric ulcer and 78% of the matched controls had a positive antibody level for H. pylori-specific IgG, yielding an odds ratio of 3.2 (95% Cl, 1.6 to 6.5). For duodenal ulcer, 92% of the 65 patients and 78% of the matched controls had a positive test result, yielding an odds ratio of 4.0 (Cl, 1.1 to 14.2). As the level of antibody to H. pylori increased, a statistically significant increase was noted in the risk for gastric and duodenal ulcer. The association with H. pylori infection was statistically significant for both types of ulcer, even when the diagnosis was made 10 or more years after the serum sample had been obtained. Conclusion: Preexisting H. pylori infection increases the risk for subsequent development of either duodenal or gastric ulcer disease.	UNIV CINCINNATI, SCH MED, DEPT PATHOL, CINCINNATI, OH 45267 USA; VANDERBILT UNIV, MED CTR, SCH MED, DIV INFECT DIS, NASHVILLE, TN 37232 USA	University System of Ohio; University of Cincinnati; Vanderbilt University	NOMURA, A (corresponding author), KUAKINI MED CTR, JAPAN HAWAII CANC STUDY, 347 N KUAKINI ST, HONOLULU, HI 96817 USA.			Perez Perez, Guillermo/0000-0002-0131-5798	NCI NIH HHS [R01 CA 33644] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033644] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J; BLASER MJ, 1991, REV INFECT DIS, V13, pS704; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BRESLOW NE, 1980, IARC SCI PUBL, V32, P164; COGHLAN JG, 1987, LANCET, V2, P1109; COVER TL, 1992, J BIOL CHEM, V267, P10570; DOOLEY CP, 1988, ANN INTERN MED, V108, P70, DOI 10.7326/0003-4819-108-1-70; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; GLASSMAN MS, 1990, DIGEST DIS SCI, V35, P993, DOI 10.1007/BF01537248; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1653, DOI 10.1016/0016-5085(91)90665-8; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; Harrell F., 1983, SUGI SUPPLEMENTAL LI, P267; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; IMAI K, 1991, HELICOBACTER PYLORI, V3, P26; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MACMAHON B, 1970, EPIDEMIOLOGY PRINCIP, P207; MAI UEH, 1991, J CLIN INVEST, V87, P894, DOI 10.1172/JCI115095; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P439, DOI 10.5694/j.1326-5377.1985.tb113444.x; MARSHALL BJ, 1988, LANCET, V2, P1437; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; RABENECK L, 1991, AM J MED, V91, P566; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SIPPONEN P, 1989, GUT, V30, P922, DOI 10.1136/gut.30.7.922; SIPPONEN P, 1990, SCAND J GASTROENTERO, V25, P966, DOI 10.3109/00365529008997621; STEER HW, 1984, GUT, V25, P1203, DOI 10.1136/gut.25.11.1203; STEMMERMANN GN, 1968, JNCI-J NATL CANCER I, V41, P627; STRAUSS RM, 1990, AM J MED, V89, P464, DOI 10.1016/0002-9343(90)90377-P; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; WORMSLEY KG, 1989, SCAND J GASTROENTERO, V24, P53, DOI 10.3109/00365528909091736; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6; WYATT JI, 1987, J CLIN PATHOL, V40, P841, DOI 10.1136/jcp.40.8.841	38	289	298	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1994	120	12					977	981		10.7326/0003-4819-120-12-199406150-00001	http://dx.doi.org/10.7326/0003-4819-120-12-199406150-00001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ964	7741826				2022-12-24	WOS:A1994NQ96400001
J	BAUMHUETER, S; SINGER, MS; HENZEL, W; HEMMERICH, S; RENZ, M; ROSEN, SD; LASKY, LA				BAUMHUETER, S; SINGER, MS; HENZEL, W; HEMMERICH, S; RENZ, M; ROSEN, SD; LASKY, LA			BINDING OF L-SELECTIN TO THE VASCULAR SIALOMUCIN CD34	SCIENCE			English	Article							LYMPHOCYTE HOMING RECEPTOR; ENDOTHELIAL LIGAND; IGG CHIMERA; CELLS; ADHESION; ANTIGEN; INFLAMMATION; VENULES; LECAM-1; INVIVO	The adhesive interactions between leukocyte L-selectin and the endothelium are involved in the migration of lymphocytes through peripheral lymph nodes and of neutrophils to sites of inflammation. A recombinant L-selectin stains high endothelial venules (HEVs) in lymph nodes and recognizes sulfated carbohydrates found on two endothelial glycoproteins, Sgp50 and Sgp90. Amino acid sequencing of purified Sgp90 revealed a protein core identical to that of CD34, a sialomucin expressed on hematopoietic stem cells and endothelium. A polyclonal antiserum to recombinant murine CD34 stains peripheral lymph node endothelium and recognizes Sgp90 that is functionally bound by L-selectin. Thus, an HEV glycoform of CD34 can function as a ligand for L-selectin.	GENENTECH INC, DEPT IMMUNOL, San Francisco, CA 94080 USA; GENENTECH INC, DEPT PROT CHEM, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM IMMUNOL, SAN FRANCISCO, CA 94143 USA	Roche Holding; Genentech; Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Henzel, William/0000-0003-2940-3797	NIGMS NIH HHS [GM 23547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023547, R01GM023547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUMHUETER S, UNPUB; BERENSON RJ, 1988, J CLIN INVEST, V81, P951, DOI 10.1172/JCI113409; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BRADY HR, 1992, J IMMUNOL, V149, P2437; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CIVIN CI, 1984, J IMMUNOL, V133, P157; DELIA D, 1993, BLOOD, V81, P1001; FINA L, 1990, BLOOD, V75, P2417; HENZEL WJ, 1990, ANAL BIOCHEM, V187, P228, DOI 10.1016/0003-2697(90)90448-I; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1993, NATURE, V361, P555; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KATZ RC, 1986, J BEHAV MED, V9, P191, DOI 10.1007/BF00848477; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEY K, 1991, BLOOD, V77, P2553; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SUTHERLAND DR, 1988, LEUKEMIA, V2, P793; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0	27	594	616	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1993	262	5132					436	438		10.1126/science.7692600	http://dx.doi.org/10.1126/science.7692600			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	7692600				2022-12-24	WOS:A1993MB85900063
J	SHUAI, K; STARK, GR; KERR, IM; DARNELL, JE				SHUAI, K; STARK, GR; KERR, IM; DARNELL, JE			A SINGLE PHOSPHOTYROSINE RESIDUE OF STAT91 REQUIRED FOR GENE ACTIVATION BY INTERFERON-GAMMA	SCIENCE			English	Article							ALPHA-INTERFERON; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; BINDING PROTEIN; MUTANT	Interferon-gamma (IFN-gamma) stimulates transcription of specific genes by inducing tyrosine phosphorylation of a 91-kilodalton cytoplasmic protein (termed STAT for signal transducer and activator of transcription). Stat91 was phosphorylated on a single site (Tyr701), and phosphorylation of this site was required for nuclear translocation, DNA binding, and gene activation. Stat84, a differentially spliced product of the same gene that lacks the 38 carboxyl-terminal amino acids of Stat91, did not activate transcription, although it was phosphorylated and translocated to the nucleus and bound DNA. Thus, Stat91 mediates activation of transcription in response to IFN-gamma.	ROCKEFELLER UNIV, MOLEC CELL BIOL LAB, NEW YORK, NY 10021 USA; CLEVELAND CLIN FDN, RES INST, CLEVELAND, OH 44195 USA; IMPERIAL CANC RES FDN, LONDON, ENGLAND	Rockefeller University; Cleveland Clinic Foundation					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32489-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; IMPROTA T, UNPUB; KAWASAKI E, 1990, PRC PROTOCOLS GUIDE, P119; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MULLER M, IN PRESS EMBO J; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, UNPUB; WALAAS SI, 1989, J MOL NEUROSCI, V1, P117, DOI 10.1007/BF02918897	17	718	738	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1993	261	5129					1744	1746		10.1126/science.7690989	http://dx.doi.org/10.1126/science.7690989			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	7690989				2022-12-24	WOS:A1993LY58400029
J	WONG, F; SNIDERMAN, K; LIU, P; ALLIDINA, Y; SHERMAN, M; BLENDIS, L				WONG, F; SNIDERMAN, K; LIU, P; ALLIDINA, Y; SHERMAN, M; BLENDIS, L			TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT-SHUNT - EFFECTS ON HEMODYNAMICS AND SODIUM HOMEOSTASIS IN CIRRHOSIS AND REFRACTORY ASCITES	ANNALS OF INTERNAL MEDICINE			English	Article						HEMODYNAMICS; SODIUM; ASCITES; LIVER CIRRHOSIS; PORTOSYSTEMIC SHUNT, SURGICAL	PORTAL-HYPERTENSION; ELECTROCHEMICAL DETECTION; SYSTEMIC HEMODYNAMICS; RENAL SODIUM; NITRIC-OXIDE; TIPS; PLASMA; CATECHOLAMINES; RETENTION; RENIN	Objective: To assess the effects of transjugular intrahepatic portosystemic shunt (TIPS) on systemic and renal hemodynamics, neurohumoral factors, and sodium homeostasis in patients with cirrhosis and refractory ascites. Design: Prospective study with 1-year follow-up. Setting: Tertiary referral center and university-affiliated hospital. Patients: 7 patients with cirrhosis and refractory ascites had metabolic studies done while receiving a 22 mmol/d sodium, 1 L/d fluid diet. Intervention: TIPS insertion. Measurements: Urinary sodium excretion, systemic and renal hemodynamics, hormonal profile, and central blood volume were measured before, at day 1 after, and at 1 month after TIPS insertion. Results: Immediately after TIPS insertion, mean corrected sinusoid pressure decreased from 18.2 +/- 2.2 mm Hg to 7.7 +/- 1.3 mm Hg (P < 0.001); mean cardiac output increased from 6.83 +/- 0.68 L/min to 8.62 L/min (P = 0.005); and mean systemic Vascular resistance decreased from 1018 +/- 103 dyne.s.cm(-5) to 762 +/- 46 dyne.s.cm(-5) (P = 0.011). Mean plasma renin activity, serum aldosterone levels, and 24-hour urinary sodium excretion (5.8 +/- 0.7 mmol/d before TIPS insertion compared with 6.0 a 1.8 mmol/d 1 day after insertion) were unchanged; mean elevated plasma norepinephrine levels significantly increased. By 1 month after insertion, mean proximal tubular reabsorption of sodium had decreased, and this had led to a mean natriuresis of 15.1 +/- 3.1 mmol/d (P = 0.02 compared with baseline), which was associated with a decrease in plasma renin activity and aldosterone levels to within the normal range. Conclusions: Our results suggest that natriuresis associated with TIPS is delayed and occurs in the presence of increased systemic vasodilatation at 1 month after insertion and that TIPS insertion should not be done in any patients with refractory ascites without careful attention to cardiac and renal status. However, in carefully selected patients, TIPS is a safe and effective means of managing refractory ascites.	TORONTO HOSP, TORONTO, ON M5G 2C4, CANADA; UNIV TORONTO, TORONTO, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								AZOULAY D, 1994, HEPATOLOGY, V19, P129, DOI 10.1016/0270-9139(94)90063-9; BOER WH, 1987, EUR J CLIN INVEST, V17, P442, DOI 10.1111/j.1365-2362.1987.tb01140.x; BOSCH J, 1980, GASTROENTEROLOGY, V78, P92; BRUN C, 1951, J LAB CLIN MED, V37, P955; BURCHELL AR, 1968, ANN SURG, V168, P655, DOI 10.1097/00000658-196810000-00012; CAMPBELL V, 1982, HEPATOLOGY, V2, P54; CHENG KH, 1994, EUR J GASTROEN HEPAT, V6, P749, DOI 10.1097/00042737-199408000-00020; CLARIA J, 1992, HEPATOLOGY, V15, P343, DOI 10.1002/hep.1840150227; CONN HO, 1993, HEPATOLOGY, V17, P148, DOI 10.1016/0270-9139(93)90205-2; ERIKSSON BM, 1982, J CHROMATOGR, V228, P143, DOI 10.1016/S0378-4347(00)80427-2; FERRAL H, 1993, RADIOLOGY, V189, P795, DOI 10.1148/radiology.189.3.8234706; GOODMAN JM, 1992, CAN J CARDIOL, V8, P363; GORDON FD, 1994, GASTROENTEROLOGY, V106, pA900; HUONKER M, 1993, HEPATOLOGY, V18, pA281, DOI 10.1016/0270-9139(93)92647-I; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; LANG F, 1991, HEPATOLOGY, V14, P590, DOI 10.1016/0270-9139(91)90043-U; LEVY M, 1987, AM J PHYSIOL, V253, pF664, DOI 10.1152/ajprenal.1987.253.4.F664; LOTTERER E, 1993, HEPATOLOGY, V18, pA102, DOI 10.1016/0270-9139(93)91938-O; MORALI GA, 1992, J HEPATOL, V16, P249, DOI 10.1016/S0168-8278(05)80128-X; PAK JM, 1994, J HEPATOL, V20, P825, DOI 10.1016/S0168-8278(05)80156-4; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POMIERLAYRARGUE G, 1993, HEPATOLOGY, V18, pA103; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RECTOR WG, 1990, HEPATOLOGY, V12, P455, DOI 10.1002/hep.1840120302; RECTOR WG, 1986, LIVER, V6, P221; ROSSLE M, 1994, NEW ENGL J MED, V330, P165, DOI 10.1056/NEJM199401203300303; SANYAL AJ, 1992, ANN INTERN MED, V117, P443, DOI 10.7326/0003-4819-117-5-443; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; SCHROEDER ET, 1979, KIDNEY INT, V15, P54, DOI 10.1038/ki.1979.8; THOMAS SH, 1991, DIGEST DIS SCI, V36, P1243, DOI 10.1007/BF01307516; THOMSEN K, 1969, PFLUG ARCH EUR J PHY, V308, P180, DOI 10.1007/BF00587025; TOBE SW, 1993, AM J KIDNEY DIS, V21, P472, DOI 10.1016/S0272-6386(12)80392-1; TOMINAGA T, 1988, LIFE SCI, V42, P1861, DOI 10.1016/0024-3205(88)90025-2; TONG L, 1993, GASTROENTEROLOGY, V104, pA1009; WALSER M, 1955, J CLIN INVEST, V34, P1520, DOI 10.1172/JCI103204; WEICKER H, 1984, CLIN CHIM ACTA, V141, P17, DOI 10.1016/0009-8981(84)90162-1; WENSING G, 1990, HEPATOLOGY, V12, P13, DOI 10.1002/hep.1840120104; WONG F, 1993, HEPATOLOGY, V18, P519, DOI 10.1002/hep.1840180308; WONG F, 1994, HEPATOLOGY, V20, P873, DOI 10.1002/hep.1840200415; WONG F, 1995, HEPATOLOGY, V21, P717; WONG F, 1994, HEPATOLOGY, V19, P312	41	181	184	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					816	822		10.7326/0003-4819-122-11-199506010-00002	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741365				2022-12-24	WOS:A1995RA13900002
J	PULENDRAN, B; KANNOURAKIS, G; NOURI, S; SMITH, KGC; NOSSAL, GJV				PULENDRAN, B; KANNOURAKIS, G; NOURI, S; SMITH, KGC; NOSSAL, GJV			SOLUBLE-ANTIGEN CAN CAUSE ENHANCED APOPTOSIS OF GERMINAL-CENTER B-CELLS	NATURE			English	Article							IMMUNE-RESPONSE; AFFINITY MATURATION; SOMATIC MUTATION; C57BL-6 MICE; DEATH; CENTERS; LYMPHOCYTES; REPERTOIRE; ANTIBODIES; PROTEIN	GERMINAL centres are dynamic microenvironments of B-lymphocyte differentiation, which develop in secondary lymphoid tissues during immune responses(1-3). Within germinal centres, activated B lymphocytes proliferate and point mutations are rapidly introduced into the genes encoding their immunoglobulin receptor(4-10). As a result, new specificities of B cells are created, including those with a heightened capacity to bind the immunizing antigen(4-11). Immunoglobulin gene mutation can also lead to reactivity to self antigens(12-14). It has been suggested that any newly formed self-reactive B cells are eliminated within the germinal centre in order to avoid autoimmunity(15,16). Here we present evidence that antigen-specific, high-affinity, germinal-centre B cells are rapidly killed by apoptosis in sits when they encounter soluble antigen. The effect seems to act directly on the B cells, rather than through helper T cells. Furthermore, the apoptosis is unique to germinal-centre cells, and is only incompletely impeded by constitutive expression of the proto-oncogene bcl-2. This phenomenon may reflect clonal deletion of self-reactive B cells within germinal centres.	ROYAL MELBOURNE HOSP, DEPT NEPHROL, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL CHILDRENS HOSP, LARCH CANC RES UNIT, PARKVILLE, VIC 3052, AUSTRALIA	Royal Melbourne Hospital; Royal Children's Hospital Melbourne	PULENDRAN, B (corresponding author), WALTER & ELIZA HALL INST MED RES, PO ROYAL MELBOURNE HOSP, MELBOURNE, VIC 3050, AUSTRALIA.		Pulendran, Bali/AAW-9550-2021	Pulendran, Bali/0000-0001-6517-4333; Smith, Kenneth/0000-0003-3829-4326				ALLEN D, 1988, EMBO J, V7, P1995, DOI 10.1002/j.1460-2075.1988.tb03038.x; ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; DIAMOND B, 1992, A REV IMMUN, V10, P737; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HERZENBERG LA, 1980, J EXP MED, V151, P1071, DOI 10.1084/jem.151.5.1071; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACK RS, 1977, EUR J IMMUNOL, V7, P559, DOI 10.1002/eji.1830070813; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LALOR PA, 1992, EUR J IMMUNOL, V22, P3001, DOI 10.1002/eji.1830221136; LINTON PJ, 1991, J IMMUNOL, V146, P4099; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MACLENNAN ICM, 1990, CURR TOP MICROBIOL I, V159, P138; MCHEYZERWILLIAMS MG, 1993, J EXP MED, V178, P295, DOI 10.1084/jem.178.1.295; NAKAYAMA KI, 1993, SCIENCE, V261, P1548; NISITANI S, 1993, J EXP MED, V178, P1247, DOI 10.1084/jem.178.4.1247; NOSSAL GJV, 1993, P NATL ACAD SCI USA, V90, P3088, DOI 10.1073/pnas.90.7.3088; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; SMITH KGC, 1994, IMMUNITY, V1, P803, DOI 10.1016/S1074-7613(94)80022-7; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; Theofilopoulos A N, 1979, Adv Immunol, V28, P89; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VELS DJ, 1993, J CELL, V75, P229	31	277	282	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					331	334		10.1038/375331a0	http://dx.doi.org/10.1038/375331a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753199				2022-12-24	WOS:A1995RA03000055
J	TRACEY, I; SCOTT, RB; THOMPSON, CH; DUNN, JF; BARNES, PRJ; STYLES, P; KEMP, GJ; RAE, CD; PIKE, M; RADDA, GK				TRACEY, I; SCOTT, RB; THOMPSON, CH; DUNN, JF; BARNES, PRJ; STYLES, P; KEMP, GJ; RAE, CD; PIKE, M; RADDA, GK			BRAIN ABNORMALITIES IN DUCHENNE MUSCULAR-DYSTROPHY - P-31 MAGNETIC-RESONANCE SPECTROSCOPY AND NEUROPSYCHOLOGICAL STUDY	LANCET			English	Article							MUSCLE; IMPAIRMENT; METABOLISM; SKELETAL; NEURONS; CELLS	Duchenne muscular dystrophy (DMD) is one of a range of muscular dystrophies caused by abnormalities of the short arm of the X chromosome (Xp21), which often cause mental retardation in addition to progressive muscular weakness. Normal dystrophin expression is lacking in both skeletal muscle and brain of affected subjects. Phosphorus-Si magnetic resonance spectroscopy has shown several abnormalities in skeletal muscle in DMD. We looked for similar abnormalities in brain in patients with DMD and related the findings to neuropsychological test results. We studied by magnetic resonance spectroscopy 19 boys (aged 76-167 months) diagnosed as having DMD and 19 control boys of similar age (87-135 months). intelligence quotient (IQ) was assessed with the Wechsler Intelligence Scale for children. The DMD patients had significantly higher values than the controls in the brain ratios of inorganic phosphate to adenosine triphosphate (mean 0.53 [SD 0.21] vs 0.36 [0.09], p=0.003), to phosphomonoesters (0.40 [0.07] vs 0.29 [0.07], p=0.0001), and to phosphocreatine (0.44 [0.10] vs 0.37 [0.08], p=0.02). There were significant differences between the DMD patients and the controls in full-scale IQ (76 [16] vs 101 [16], p=0.0001), performance IQ (78 [17] vs 94 [14], p=0.003), and verbal IQ (78 [17] vs 106 [17], p=0.0001). These altered metabolite ratios parallel the findings in dystrophic muscle and suggest bioenergetic similarities in tissues that lack dystrophin.	OXFORD RADCLIFFE HOSP,MRC,BIOCHEM & CLIN MAGNET RESONANCE UNIT,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; RADCLIFFE INFIRM NHS TRUST,DEPT NEUROSURG,RUSSELL CAIRNS UNIT,OXFORD,ENGLAND; JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford; Radcliffe Infirmary; University of Oxford			Thompson, Campbell/E-2885-2010; Kemp, Graham J/A-7540-2008; Rae, Caroline/B-7537-2008	Thompson, Campbell/0000-0002-5164-3327; Kemp, Graham J/0000-0002-8324-9666; Rae, Caroline/0000-0003-0673-8084; Tracey, Irene/0000-0003-4134-6115	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALQUDAH AA, 1990, PEDIATR NEUROL, V6, P57, DOI 10.1016/0887-8994(90)90081-B; ARCHIBALD K C, 1959, Arch Phys Med Rehabil, V40, P150; BARBIROLI B, 1993, J CEREBR BLOOD F MET, V13, P469, DOI 10.1038/jcbfm.1993.61; BATTOCLETTI JH, 1979, MED BIOL ENG COMPUT, V17, P183, DOI 10.1007/BF02440927; Blake Derek J., 1994, Trends in Cell Biology, V4, P19, DOI 10.1016/0962-8924(94)90034-5; BULLFIELD G, 1984, P NATL ACAD SCI USA, V81, P1189; CHAMBERLAIN JS, 1988, SCIENCE, V239, P1416, DOI 10.1126/science.3347839; DUBOWITZ V, 1969, BRAIN, V92, P805, DOI 10.1093/brain/92.4.805; DUNN JF, 1993, P ROY SOC B-BIOL SCI, V251, P201, DOI 10.1098/rspb.1993.0030; DUNN JF, 1991, BIOCHIM BIOPHYS ACTA, V1096, P115, DOI 10.1016/0925-4439(91)90048-E; DUNN JF, 1991, J NEUROL SCI, V103, P226, DOI 10.1016/0022-510X(91)90168-7; DUNN JF, 1993, J NEUROL SCI, V114, P76, DOI 10.1016/0022-510X(93)90052-Z; ERVASTI JM, 1992, CELL, V66, P1121; HODGSON SV, 1992, NEUROMUSCULAR DISORD, V2, P269, DOI 10.1016/0960-8966(92)90059-F; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEURON, V1, P411, DOI 10.1016/0896-6273(88)90191-2; HOPF FW, 1992, BRAIN RES, V578, P49; JAGADHA V, 1988, PEDIATR NEUROL, V4, P87, DOI 10.1016/0887-8994(88)90047-1; KARAGAN NJ, 1979, PSYCHOL BULL, V86, P250; KEMP GJ, 1993, J NEUROL SCI, V116, P201, DOI 10.1016/0022-510X(93)90326-T; KIM TW, 1992, P NATL ACAD SCI USA, V89, P11642, DOI 10.1073/pnas.89.23.11642; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; MONACO AP, 1985, NATURE, V318, P842; Muntoni F, 1991, Neuromuscul Disord, V1, P121, DOI 10.1016/0960-8966(91)90059-2; ROSMAN NP, 1970, NEUROLOGY, V20, P324; SANCHEZ V, 1988, BIOPHYS J, V53, P438; SOLLEE ND, 1985, J CLIN EXP NEUROPSYC, V7, P486, DOI 10.1080/01688638508401280; TRACEY I, 1992, 11TH P ANN M SOC MAG, V2, P2125; WHELAN TB, 1987, DEV MED CHILD NEUROL, V29, P212; YOSHIOKA M, 1980, ARCH DIS CHILD, V55, P589, DOI 10.1136/adc.55.8.589	30	47	49	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1260	1264		10.1016/S0140-6736(95)90923-0	http://dx.doi.org/10.1016/S0140-6736(95)90923-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746055				2022-12-24	WOS:A1995QY93300007
J	PEI, DQ; WEISS, SJ				PEI, DQ; WEISS, SJ			FURIN-DEPENDENT INTRACELLULAR ACTIVATION OF THE HUMAN STROMELYSIN-3 ZYMOGEN	NATURE			English	Article							SECRETORY PATHWAY; METALLOPROTEINASES; PRECURSOR; CLEAVAGE; CELLS; ENDOPROTEASE; INHIBITION; PROTEIN; FUSION; GENE	HUMAN stromelysin-3, a new member of the matrix metalloproteinase family, is expressed in tissues undergoing the active remodelling associated with embryonic development, wound healing and tumour invasion(1-3). But like all other members of the matrix metalloproteinase gene family, stromelysin3 is synthesized as an inactive precursor that must be processed to its mature form in order to express enzymic activity(4,5). Here we identify stromelysin-3 as the first matrix metalloproteinase to be discovered that can be processed directly to its enzymically active form by an obligate intracellular proteolytic event that occurs within the constitutive secretory pathway. Intracellular activation is regulated by an unusual 10-amino-acid insert sandwiched between the pro- and catalytic-domains of stromelysin-3, which is encrypted with an Arg-X-Arg-X-Lys-Arg recognition motif for the Golgi-associated proteinase, furin, a mammalian homologue of the yeast Kex2 pheromone convertase(6,7). A furin-stromelysin-3 processing axis not only differentiates the regulation of this enzyme from all previously characterized matrix metalloproteinases, but also identifies pro-protein convertases as potential targets for therapeutic intervention in matrix-destructive disease states.	UNIV MICHIGAN,CTR COMPREHENS CANC,DEPT INTERNAL MED,DIV HEMATOL ONCOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan								ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Ausubel FM, 1994, CURR PROT MOL BIOL; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEN S, 1981, J BIOL CHEM, V256, P1816; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; DAVIES B, 1993, CANCER RES, V53, P2087; DECROLY E, 1994, J BIOL CHEM, V269, P12240; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; PEI DQ, 1994, J BIOL CHEM, V269, P25849; REHEMTULLA A, 1992, BLOOD, V79, P2349; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; WATANABE T, 1993, FEBS LETT, V320, P215, DOI 10.1016/0014-5793(93)80589-M; WATANABE T, 1991, J BIOL CHEM, V267, P8270; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843	27	518	534	1	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					244	247		10.1038/375244a0	http://dx.doi.org/10.1038/375244a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746327	Green Submitted			2022-12-24	WOS:A1995QY88100066
J	BRUSCHWEILER, R; LIAO, XB; WRIGHT, PE				BRUSCHWEILER, R; LIAO, XB; WRIGHT, PE			LONG-RANGE MOTIONAL RESTRICTIONS IN A MULTIDOMAIN ZINC-FINGER PROTEIN FROM ANISOTROPIC TUMBLING	SCIENCE			English	Article							HETERONUCLEAR NMR-SPECTROSCOPY; TRANSCRIPTION FACTOR-IIIA; INTERNAL CONTROL REGION; DNA-BINDING DOMAIN; 5S RNA GENE; BACKBONE DYNAMICS; RELAXATION	Structural characterization of biomolecules in solution by nuclear magnetic resonance (NMR) spectroscopy is based primarily on the use of interproton distances derived from homonuclear cross-relaxation experiments. Information about short time-scale dynamics, on the other hand, is obtained from relaxation rates of heteronuclear spin pairs such as (N-1H)-N-15. By combining the two types of data and utilizing the dependence of heteronuclear NMR relaxation rates on anisotropic diffusional rotational tumbling, it is possible to obtain structural information about long-range motional correlations between protein domains. This approach was applied to characterize the relative orientations and mobilities of the first three zinc-finger domains of the Xenopus transcription factor TFIIIA in aqueous solution. The data indicate that the motions of the individual zinc-finger domains are highly correlated on time scales shorter than 10 nanoseconds and that the average conformation of the three-finger polypeptide is elongated.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Bruschweiler, Rafael/F-6624-2015	Wright, Peter/0000-0002-1368-0223	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036643] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36643] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; Debye P., 1929, POLAR MOL, P72; FAVRO LD, 1960, PHYS REV, V107, P7; HUNTRESS WT, 1968, J CHEM PHYS, V48, P3524, DOI 10.1063/1.1669645; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LIAO XB, 1994, J BIOMOL NMR, V4, P433; LIAO XY, UNPUB; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAKASEKO Y, 1992, J MOL BIOL, V228, P619, DOI 10.1016/0022-2836(92)90845-B; ORNICHINSKI JG, 1992, BIOCHEMISTRY-US, V31, P3907; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; Perrin F, 1934, J PHYS-PARIS, V5, P497, DOI 10.1051/jphysrad:01934005010049700; Perrin F, 1936, J PHYS-PARIS, V7, P1, DOI 10.1051/jphysrad:01936007010100; Press WH, 1988, NUMERICAL RECIPES C; RADHAKRISHNAN I, UNPUB; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390	24	321	322	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					886	889		10.1126/science.7754375	http://dx.doi.org/10.1126/science.7754375			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754375				2022-12-24	WOS:A1995QX85000042
J	LEE, JE; HOLLENBERG, SM; SNIDER, L; TURNER, DL; LIPNICK, N; WEINTRAUB, H				LEE, JE; HOLLENBERG, SM; SNIDER, L; TURNER, DL; LIPNICK, N; WEINTRAUB, H			CONVERSION OF XENOPUS ECTODERM INTO NEURONS BY NEUROD, A BASIC HELIX-LOOP-HELIX PROTEIN	SCIENCE			English	Review							INTERMEDIATE FILAMENT PROTEIN; PERIPHERAL NERVOUS-SYSTEM; ACHAETE-SCUTE HOMOLOG-1; DNA-BINDING; MESODERM FORMATION; ORGAN FORMATION; MYOGENIN GENE; ALPHA-TUBULIN; HLH PROTEINS; DROSOPHILA	Basic helix-loop-helix (bHLH) proteins are instrumental in determining cell type during development. A bHLH protein, termed NeuroD, for neurogenic differentiation, has now been identified as a differentiation factor for neurogenesis because (i) it is expressed transiently in a subset of neurons in the central and peripheral nervous systems at the time of their terminal differentiation into mature neurons and (ii) ectopic expression of neuroD in Xenopus embryos causes premature differentiation of neuronal precursors. Furthermore, neuroD can convert presumptive epidermal cells into neurons and also act as a neuronal determination gene. However, unlike another previously identified proneural gene (XASH-3), neuroD seems competent to bypass the normal inhibitory influences that usually prevent neurogenesis in ventral and lateral ectoderm and is capable of converting most of the embryonic ectoderm into neurons. The data suggest that neuroD may participate in the terminal differentiation step during vertebrate neuronal development.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; HOWARD HUGHES MED INST, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute								ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1992, DEVELOPMENT, V116, P67; BALAK K, 1987, DEV BIOL, V119, P540, DOI 10.1016/0012-1606(87)90057-1; BAROFFIO A, 1991, DEVELOPMENT, V112, P301; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAND M, 1993, DEVELOPMENT, V119, P1; BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; CABERA CV, 1991, EMBO J, V10, P2965; CABERA CV, 1992, DEVELOPMENT, V115, P893; CAMPOSORTEGA JA, 1994, CELL, V77, P969, DOI 10.1016/0092-8674(94)90437-5; CAMPOSORTEGA JA, 1993, J NEUROBIOL, V24, P1305, DOI 10.1002/neu.480241005; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; CHU DTW, 1989, DEV BIOL, V136, P104, DOI 10.1016/0012-1606(89)90134-6; DALE L, 1987, DEVELOPMENT, V99, P527; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DENT JA, 1989, DEVELOPMENT, V105, P61; DIXON JE, 1989, DEVELOPMENT, V106, P749; DOMINGUEZ M, 1993, EMBO J, V12, P2049, DOI 10.1002/j.1460-2075.1993.tb05854.x; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; EPPERLEIN HH, 1993, ANN ANAT, V175, P483, DOI 10.1016/S0940-9602(11)80207-4; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GODSAVE SF, 1991, DEVELOPMENT, V111, P523; GRAF JD, 1991, METHOD CELL BIOL, V36, P19; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HARLAND RM, 1994, CURR OPIN GENET DEV, V4, P543, DOI 10.1016/0959-437X(94)90070-J; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HARTENSTEIN V, 1993, J COMP NEUROL, V328, P213, DOI 10.1002/cne.903280205; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1992, NEURON, V9, P417, DOI 10.1016/0896-6273(92)90180-L; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOILLENBERG S, UNPUB; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; JACOBSON M, 1968, DEV BIOL, V17, P219, DOI 10.1016/0012-1606(68)90062-6; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JIMENEZ F, 1993, CURR OPIN GENET DEV, V3, P626, DOI 10.1016/0959-437X(93)90099-B; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JONES EA, 1986, CELL, V44, P345, DOI 10.1016/0092-8674(86)90769-5; JONES EA, 1989, DEVELOPMENT, V107, P785; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KIRSTEN J, UNPUB; KOGAWA K, 1991, ENDOCRINOLOGY, V128, P1434, DOI 10.1210/endo-128-3-1434; KORZH V, 1993, DEVELOPMENT, V118, P417; KRAMATSCHEK B, 1994, DEVELOPMENT, V120, P815; KREIG PA, 1987, METHOD ENZYMOL, V155, P397; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LAMBORGHINI JE, 1980, J COMP NEUROL, V189, P323, DOI 10.1002/cne.901890208; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee J.-S., UNPUB; LEWIN B, 1994, CELL, V79, P935, DOI 10.1016/0092-8674(94)90025-6; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NORDLANDER RH, 1989, DEV BRAIN RES, V50, P147, DOI 10.1016/0165-3806(89)90135-1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PENG HB, 1991, METHOD CELL BIOL, V36, P659; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; RIBERA AB, 1993, J NEUROSCI, V13, P4988; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; RONG PM, 1992, DEVELOPMENT, V115, P657; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SADAGHIANI B, 1987, DEV BIOL, V124, P91, DOI 10.1016/0012-1606(87)90463-5; SINGSON A, 1994, GENE DEV, V8, P2058, DOI 10.1101/gad.8.17.2058; SLACK JMW, 1992, DEVELOPMENT, V114, P285; Spemann H., 1938, EMBRYONIC DEV INDUCT; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; SUDARWAT.S, 1971, ROUX ARCH DEV BIOL, V166, P189, DOI 10.1007/BF00650029; SZARO BG, 1988, J COMP NEUROL, V273, P344, DOI 10.1002/cne.902730306; TENDONKELAAR HJ, 1991, ANAT EMBRYOL, V183, P589, DOI 10.1007/BF00187908; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WETTS R, 1993, DEV DYNAM, V198, P54, DOI 10.1002/aja.1001980106; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILSON R, IN PRESS NATURE; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	101	904	936	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	1995	268	5212					836	844		10.1126/science.7754368	http://dx.doi.org/10.1126/science.7754368			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754368				2022-12-24	WOS:A1995QX85000028
J	JIANG, WP; SWIGGARD, WJ; HEUFLER, C; PENG, M; MIRZA, A; STEINMAN, RM; NUSSENZWEIG, MC				JIANG, WP; SWIGGARD, WJ; HEUFLER, C; PENG, M; MIRZA, A; STEINMAN, RM; NUSSENZWEIG, MC			THE RECEPTOR DEC-205 EXPRESSED BY DENDRITIC CELLS AND THYMIC EPITHELIAL-CELLS IS INVOLVED IN ANTIGEN-PROCESSING	NATURE			English	Article							MACROPHAGE MANNOSE RECEPTOR; CARBOHYDRATE-RECOGNITION DOMAINS; LYMPHOCYTES-B; COMPLEX; BINDING; INTERNALIZATION; PROTEIN	DENDRITIC cells and thymic epithelial cells perform important immunoregulatory functions by presenting antigens in the form of peptides bound to cell-surface major histocompatibility complex (MHC) molecules to T cells(1-3). Whereas B cells are known to present specific antigens efficiently through their surface immunoglobins, a comparable mechanism for the capture and efficient presentation of diverse antigens by dendritic cells and thymic epithelial cells has not previously been described. We show here that their antigen-presentation function is associated with the high-level expression of DEC-205, an integral membrane protein homologous to the macrophage mannose receptor and related receptors which are able to bind carbohydrates and mediate endocytosis. DEC-205 is rapidly taken up by means of coated pits and vesicles, and is delivered to a multivesicular endosomal compartment that resembles the MHC class II-containing vesicles implicated in antigen presentation. Rabbit antibodies that bind DEC-205 are presented to reactive T-cell hybridomas 100-fold more efficiently than rabbit antibodies that do not bind DEC-205, Thus DEC-205 is a novel endocytic receptor that can be used by dendritic cells and thymic epithelial cells to direct captured antigens from the extracellular space to a specialized antigen-processing compartment.	ROCKEFELLER UNIV,MOLEC IMMUNOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; ROCKEFELLER UNIV,CELLULAR PHYSIOL LAB,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University			Steinman, Ralph/F-7729-2012; Nussenzweig, Michel/AAE-7292-2019					AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BOOM WH, 1988, J EXP MED, V167, P1350, DOI 10.1084/jem.167.4.1350; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DANIELS BF, 1994, IMMUNITY, V1, P785, DOI 10.1016/S1074-7613(94)80020-0; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; HARRIS N, 1992, BLOOD, V80, P2363; HUGO P, 1993, IMMUNOL REV, V135, P133, DOI 10.1111/j.1600-065X.1993.tb00647.x; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; KLEIJMEER MJ, 1994, J INVEST DERMATOL, V103, P516, DOI 10.1111/1523-1747.ep12395666; KRAAL G, 1986, J EXP MED, V163, P981, DOI 10.1084/jem.163.4.981; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LANZAVEECHIA A, 1985, NATURE, V314, P538; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; ROCK KL, 1984, J EXP MED, V160, P1102, DOI 10.1084/jem.160.4.1102; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	28	746	783	2	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					151	155		10.1038/375151a0	http://dx.doi.org/10.1038/375151a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753172				2022-12-24	WOS:A1995QX74100053
J	SIMSKE, JS; KIM, SK				SIMSKE, JS; KIM, SK			SEQUENTIAL SIGNALING DURING CAENORHABDITIS-ELEGANS VULVAR INDUCTION	NATURE			English	Article							C-ELEGANS; CELL LINEAGES; TYROSINE KINASE; NEMATODE; GENE; PATTERN; ENCODES; LET-23	DURING the induction of the Caenorhabditis elegans vulva, cell signalling causes initially equipotent cells to express a reproducible pattern of cell fates(1,2). The position of the anchor cell determines the pattern of vulval precursor cell fates, such that the closest precursor cell (P6.p) expresses the primary cell fate, the next closest cells (P5.p and P7.p) both express the secondary cell fate, and each of the precursor cells located at a distance (P3.p, P4.p and P8.p) express the tertiary cell fate (Fig. 1a)(3-5). We present data indicating that this stereotypical pattern of cell fates can be generated by sequential signals. We identified genetic mosaic animals in which P5.p and P7.p were defective in the anchor-cell signal-transduction pathway and observed that these cells adopted the secondary cell fate, indicating that anchor-cell signal transduction is not required for the expression of the secondary cell fate. These results suggest that the anchor cell induces P6.p to express the primary cell fate, and that P6.p subsequently induces P5.p and P7.p to express the secondary cell fate.			SIMSKE, JS (corresponding author), STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.							AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AROLAN RV, 1994, EMBO J, V13, P360; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HERMAN RK, 1984, GENETICS, V108, P165; HERMAN RK, 1989, J NEUROGENET, V5, P1, DOI 10.3109/01677068909167261; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER DM, 1993, GENETICS, V135, P741; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	30	109	116	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					142	146		10.1038/375142a0	http://dx.doi.org/10.1038/375142a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753169				2022-12-24	WOS:A1995QX74100050
J	ROBERTSON, MP; MILLER, SL				ROBERTSON, MP; MILLER, SL			PREBIOTIC SYNTHESIS OF 5-SUBSTITUTED URACILS - A BRIDGE BETWEEN THE RNA WORLD AND THE DNA-PROTEIN WORLD	SCIENCE			English	Article							EARTHS PRIMITIVE ATMOSPHERE; ORIGIN; FORMALDEHYDE; EVOLUTION; CARBON; MODEL; WATER; CH4; CO2	Under prebiotic conditions, formaldehyde adds to uracil at the C-5 position to produce 5-hydroxymethyluracil with favorable rates and equilibria. Hydroxymethyluracil adds a variety of nucleophiles, such as ammonia, glycine, guanidine, hydrogen sulfide, hydrogen cyanide, imidazole, indole, and phenol, to give 5-substituted uracils with the side chains of most of the 20 amino acids in proteins. These reactions are sufficiently robust that, if uracil had been present on the primitive Earth, then these substituted uracils would also have been present. The ribozymes of the RNA world would have included many of the functional groups found in proteins today, and their catalytic activities may have been considerably greater than presently assumed.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego								BARNUN A, 1983, J GEOPHYS RES-OCEANS, V88, P6662, DOI 10.1029/JC088iC11p06662; BARNUN A, 1978, ORIGINS LIFE EVOL B, V9, P93, DOI 10.1007/BF00931407; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; DEISTER U, 1990, BER BUNSEN PHYS CHEM, V94, P594, DOI 10.1002/bbpc.19900940512; FERRIS JP, 1966, J AM CHEM SOC, V88, P1074, DOI 10.1021/ja00957a050; FERRIS JP, 1979, J ORG CHEM, V44, P1273, DOI 10.1021/jo01322a019; FERRIS JP, 1975, J AM CHEM SOC, V97, P2962, DOI 10.1021/ja00844a007; FRIEDMANN N, 1971, CHEM EVOLUTION ORIGI, P123; GIBSON HW, 1969, CHEM REV, V69, P673, DOI 10.1021/cr60261a005; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; MILLER SL, 1984, ORIGINS LIFE EVOL B, V14, P83, DOI 10.1007/BF00933643; MOORE ML, 1949, ORG REACTIONS, V5, P301; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; ORO J, 1984, ORIGINS LIFE EVOL B, V14, P237, DOI 10.1007/BF00933663; PINTO JP, 1980, SCIENCE, V210, P183, DOI 10.1126/science.210.4466.183; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; ROBERTSON MP, UNPUB; SANCHEZ RA, 1967, J MOL BIOL, V30, P223; SCHLESINGER G, 1983, J MOL EVOL, V19, P383, DOI 10.1007/BF02101643; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; VISSER CM, 1978, J MOL EVOL, V11, P171, DOI 10.1007/BF01733892; WEBER AL, 1981, J MOL EVOL, V17, P273, DOI 10.1007/BF01795749; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; Woese C, 1967, GENETIC CODE, P179; WONG JTF, 1991, ORIGINS LIFE EVOL B, V21, P165, DOI 10.1007/BF01809445; YANAGAWA H, 1992, J BIOL CHEM, V267, P13320; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972	30	72	73	0	28	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					702	705		10.1126/science.7732378	http://dx.doi.org/10.1126/science.7732378			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732378				2022-12-24	WOS:A1995QW60300043
J	ROELINK, H; PORTER, JA; CHIANG, C; TANABE, Y; CHANG, DT; BEACHY, PA; JESSELL, TM				ROELINK, H; PORTER, JA; CHIANG, C; TANABE, Y; CHANG, DT; BEACHY, PA; JESSELL, TM			FLOOR PLATE AND MOTOR-NEURON INDUCTION BY DIFFERENT CONCENTRATIONS OF THE AMINO-TERMINAL CLEAVAGE PRODUCT OF SONIC HEDGEHOG AUTOPROTEOLYSIS	CELL			English	Article							CELL-CELL COMMUNICATION; POLARITY GENE HEDGEHOG; NERVOUS-SYSTEM; CHICK-EMBRYO; DROSOPHILA; TRANSCRIPTION; EXPRESSION; NOTOCHORD; PROTEINS; PATTERN	The differentiation of floor plate cells and motor neurons can be induced by Sonic hedgehog (SHH), a secreted signaling protein that undergoes autoproteolytic cleavage to generate amino- and carboxy-terminal products. We have found that both floor plate cells and motor neurons are induced by the aminoterminal cleavage product of SHH (SHH-N). the threshold concentration of SHH-N required for motor neuron induction is about 5-fold lower than that required for floor plate induction. Higher concentrations of SHH-N can induce floor plate cells at the expense of motor neuron differentiation. Our results suggest that the induction of floor plate cells and motor neurons by the notochord In vivo is mediated by exposure of neural plate cells to different concentrations of the aminoterminal product of SHH autoproteolytic cleavage.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	ROELINK, H (corresponding author), COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.							ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ALTABA ARI, 1995, IN PRESS MOL CELL NE; ALTABA ARI, 1995, IN PRESS DEV BIOL; Ausubel FM, 1994, CURRENT PROTOCOLS MO; AVERBUCHHELLER L, 1994, P NATL ACAD SCI USA, V91, P3247, DOI 10.1073/pnas.91.8.3247; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURNCROT DA, 1995, MOL CELL BIOL, V15, P2294; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CHANG DT, 1994, DEVELOPMENT, V120, P3339; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERICSON J, 1995, IN PRESS CELL, V81; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LEBER SM, 1990, J NEUROSCI, V10, P2451; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SMITH JC, 1993, CURR BIOL, V3, P582, DOI 10.1016/0960-9822(93)90003-7; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TANABE Y, 1995, IN PRESS CURR BIOL; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TASHIRO S, 1993, GENE, V124, P183; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	59	747	779	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					445	455		10.1016/0092-8674(95)90397-6	http://dx.doi.org/10.1016/0092-8674(95)90397-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736596	hybrid			2022-12-24	WOS:A1995QW89400016
J	ROBERT, LM; CHAMBERLAND, ME; CLEVELAND, JL; MARCUS, R; GOOCH, BF; SRIVASTAVA, PU; CULVER, DH; JAFFE, HW; MARIANOS, DW; PANLILIO, AL; BELL, DM				ROBERT, LM; CHAMBERLAND, ME; CLEVELAND, JL; MARCUS, R; GOOCH, BF; SRIVASTAVA, PU; CULVER, DH; JAFFE, HW; MARIANOS, DW; PANLILIO, AL; BELL, DM			INVESTIGATIONS OF PATIENTS OF HEALTH-CARE WORKERS INFECTED WITH HIV - THE CENTERS-FOR-DISEASE-CONTROL AND PREVENTION DATABASE	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HEALTH PERSONNEL; DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT; ACQUIRED IMMUNODEFICIENCY SYNDROME; RISK	HUMAN-IMMUNODEFICIENCY-VIRUS; LOOK-BACK; TRANSMISSION; SURGEON; DENTISTS; ABSENCE; RISK	Objective: To assess the risk for transmission of the human immunodeficiency virus (HIV) from an infected health care worker to patients. Design: Survey of investigators from health departments, hospitals, and other agencies who had elected to notify patients who had received care from health care workers infected with HIV. Measurements: Information was collected about infected health care workers, their work practices, their patients' HIV test results, procedures that they did on those of their patients who were tested for HIV, and patient notification procedures. Results: As of 1 January 1995, information about investigations of 64 health care workers infected with HIV was reported to the Centers for Disease Control and Prevention; HIV test results were available for approximately 22 171 patients of 51 of the 64 health care workers. For 37 of the 51 workers, no seropositive patients were reported among 13 063 patients tested for HIV. For the remaining 14 health care workers, 113 seropositive patients were reported among 9108 patients. Epidemiologic and laboratory follow-up did not show any health care worker to have been a source of HIV for any of the patients tested. Conclusion: Despite limitations, these data are consistent with previous assessments that state that the risk for transmission of HIV from a health care worker to a patient is very small. These data also support current recommendations that state that retrospective patient notification need not be done routinely.	CTR DIS CONTROL & PREVENT, CTR PREVENT SERV, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	ROBERT, LM (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, HOSP INFECT PROGRAM, 1600 CLIFTON RD, MAILSTOP E-68, ATLANTA, GA 30333 USA.			Marcus, Ruthanne/0000-0002-9094-0674				[Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARMSTRONG FP, 1987, MIL MED, V152, P414; ARNOW PM, 1993, PUBLIC HEALTH REP, V108, P273; BABINCHAK TJ, 1994, CHEST, V106, P681, DOI 10.1378/chest.106.3.681; BEK M, 1994, NEW S WALES PUBLIC H, V5, P83; BELL DM, 1992, INFECT AGENT DIS, V1, P263; CARDO D, 1994, INTERSCIENCE C ANTIM; CHAMBERLAND ME, 1992, ANN INTERN MED, V116, P871, DOI 10.7326/0003-4819-116-10-871; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; CIESIELSKI CA, 1994, ANN INTERN MED, V121, P886, DOI 10.7326/0003-4819-121-11-199412010-00011; Comer R W, 1991, J Dent Educ, V55, P187; Cottone J A, 1992, J Dent Educ, V56, P536; Crawshaw S C, 1994, Commun Dis Rep CDR Rev, V4, pR125; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; DICKINSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1802, DOI 10.1001/jama.269.14.1802; Heuer M A, 1992, J Dent Educ, V56, P528; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; LONGFIELD JN, 1994, J INFECT DIS, V169, P1, DOI 10.1093/infdis/169.1.1; MISHU B, 1993, JAMA-J AM MED ASSOC, V269, P1843, DOI 10.1001/jama.269.14.1843; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; ROGERS AS, 1993, JAMA-J AM MED ASSOC, V269, P1795, DOI 10.1001/jama.269.14.1795; TAPPER ML, 1992, INFECT CONT HOSP EP, V13, P482, DOI 10.1086/646577; Taylor M, 1992, J Dent Educ, V56, P540; VONREYN CF, 1993, JAMA-J AM MED ASSOC, V269, P1807, DOI 10.1001/jama.269.14.1807; YORK AK, 1993, J AM DENT ASSOC, V124, P74, DOI 10.14219/jada.archive.1993.0141	27	64	65	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					653	657		10.7326/0003-4819-122-9-199505010-00002	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702226				2022-12-24	WOS:A1995QV15100002
J	LIPTON, RJ				LIPTON, RJ			DNA SOLUTION OF HARD COMPUTATIONAL PROBLEMS	SCIENCE			English	Article								DNA experiments are proposed to solve the famous ''SAT'' problem of computer science. This is a special case of a more general method that can solve NP-complete problems. The advantage of these results is the huge parallelism inherent in DNA-based computing. It has the potential to yield vast speedups over conventional electronic-based computers for such search problems.			LIPTON, RJ (corresponding author), PRINCETON UNIV, PRINCETON, NJ 08540 USA.							ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; Garey M.R., 1979, COMPUTERS INTRACTABI; LIPTON RJ, 1994, UNPUB SPEEDING COMPU; SHANNON CE, 1949, BELL SYST TECH J, V28, P59, DOI 10.1002/j.1538-7305.1949.tb03624.x; Sinden R.R., 1994, DNA STRUCTURE FUNCTI, V1st ed.	5	715	848	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	1995	268	5210					542	545		10.1126/science.7725098	http://dx.doi.org/10.1126/science.7725098			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725098				2022-12-24	WOS:A1995QV40700030
J	WONG, ROL; CHERNJAVSKY, A; SMITH, SJ; SHATZ, CJ				WONG, ROL; CHERNJAVSKY, A; SMITH, SJ; SHATZ, CJ			EARLY FUNCTIONAL NEURAL NETWORKS IN THE DEVELOPING RETINA	NATURE			English	Article							IMMEDIATE EARLY GENES; CALCIUM WAVES; MAMMALIAN RETINA; GANGLION-CELLS; FERRET RETINA; GLUTAMATE; ASTROCYTES; EXPRESSION; PATTERNS; NEURONS	IN the adult mammalian retina, the principal direction of information flow is along a vertical pathway from photoreceptors to retinal interneurons to ganglion cells, the output neurons of the retina. We report here, however, that initially in development, at a time when the photoreceptors are not yet even present, there are already functionally defined networks within the retina. These networks are spontaneously active rather than visually driven, and they involve horizontal rather than vertical pathways. By means of optical recording using the calcium-sensitive dye Fura-2, we have found that sets of retinal ganglion cells and amacrine cells, a type of retinal interneuron, undergo synchronized oscillations in intracellular calcium concentration, These oscillations are highly correlated among subgroups of neighbouring cells, and spread in a wave-like fashion tangentially across the retina, Thus, in development of retinal circuitry, the initial patterning of neuronal function occurs in the horizontal domain before the adult pattern of vertical information transfer emerges.	STANFORD UNIV, BECKMAN CTR, DEPT PHYSIOL, STANFORD, CA 94305 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; STANFORD UNIV, SCH MED, DEPT NEUROBIOL, STANFORD, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Stanford University								BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; COOK JE, 1991, TRENDS NEUROSCI, V14, P397, DOI 10.1016/0166-2236(91)90028-S; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GREINER JV, 1981, EXP EYE RES, V33, P315, DOI 10.1016/S0014-4835(81)80055-3; HENDERSON Z, 1988, J NEUROSCI, V8, P1194; Katz L C, 1993, Curr Opin Neurobiol, V3, P93, DOI 10.1016/0959-4388(93)90041-V; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; PENN AA, 1994, J NEUROSCI, V14, P3805; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; POW DV, 1994, VISUAL NEUROSCI, V11, P1115, DOI 10.1017/S0952523800006933; RAMOA AS, 1988, J NEUROSCI, V8, P4239; REDBURN DA, 1992, NEUROCHEM RES, V17, P61, DOI 10.1007/BF00966865; ROBINSON SR, 1991, VISION VISUAL DYSFUN, V3, P69; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SPITZER NC, 1994, TRENDS NEUROSCI, V17, P115, DOI 10.1016/0166-2236(94)90120-1; Vaney D.I., 1990, PROGR RETINAL RES, V9, P49, DOI [10.1016/0278-4327(90)90004-2, DOI 10.1016/0278-4327(90)90004-2]; Wong R O, 1993, Curr Opin Neurobiol, V3, P595, DOI 10.1016/0959-4388(93)90061-3; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379; YUSTE R, 1991, NEURON, V6, P333, DOI 10.1016/0896-6273(91)90243-S; ZORUMSKI CF, 1992, PROG NEUROBIOL, V39, P295, DOI 10.1016/0301-0082(92)90020-F	29	238	240	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	1995	374	6524					716	718		10.1038/374716a0	http://dx.doi.org/10.1038/374716a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715725				2022-12-24	WOS:A1995QU30400048
J	MALCOLM, PN; CHAN, TYK; LI, PL; RICHARDS, J; HATELY, W				MALCOLM, PN; CHAN, TYK; LI, PL; RICHARDS, J; HATELY, W			MANAGEMENT OF DYSPEPSIA AMONG ASIANS BY GENERAL-PRACTITIONERS IN EAST LONDON	BRITISH MEDICAL JOURNAL			English	Article							CONSULTATIONS		ROYAL LONDON TRUST,DEPT RADIOL,LONDON E1 1BB,ENGLAND; E LONDON & CITY HLTH AUTHOR,DEPT PUBL HLTH MED,LONDON E3 2AN,ENGLAND	St Georges University London								BALARAJAN R, 1989, BRIT MED J, V299, P958, DOI 10.1136/bmj.299.6705.958; CONRY BG, 1989, BMJ-BRIT MED J, V299, P1443, DOI 10.1136/bmj.299.6713.1443; MURRAY J, 1986, SOC PSYCH PSYCH EPID, V21, P139, DOI 10.1007/BF00582684; 1994, CENSUS USER GUIDE 58; 1993, CENSUS COUNTY REPO 1, V1	5	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					910	911		10.1136/bmj.310.6984.910	http://dx.doi.org/10.1136/bmj.310.6984.910			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719183	Green Published			2022-12-24	WOS:A1995QR97200024
J	EGHOLM, M; BUCHARDT, O; CHRISTENSEN, L; BEHRENS, C; FREIER, SM; DRIVER, DA; BERG, RH; KIM, SK; NORDEN, B; NIELSEN, PE				EGHOLM, M; BUCHARDT, O; CHRISTENSEN, L; BEHRENS, C; FREIER, SM; DRIVER, DA; BERG, RH; KIM, SK; NORDEN, B; NIELSEN, PE			PNA HYBRIDIZES TO COMPLEMENTARY OLIGONUCLEOTIDES OBEYING THE WATSON-CRICK HYDROGEN-BONDING RULES	NATURE			English	Article							PEPTIDE NUCLEIC-ACIDS; DNA; RECOGNITION; REPLICATION; ANTISENSE; STABILITY; THYMINE; HELICES	DNA ANALOGUES are currently being intensely investigated owing to their potential as gene-targeted drugs1-3. Furthermore, their properties and interaction with DNA and RNA could provide a better understanding of the structural features of natural DNA that determine its unique chemical, biological and genetic properties3,4. We recently designed a DNA analogue, PNA, in which the backbone is structurally homomorphous with the deoxyribose backbone and consists of N-(2-aminoethyl)glycine units to which the nucleobases are attached5-9. We showed that PNA oligomers containing solely thymine and cytosine can hybridize to complementary oligonucleotides, presumably by forming Watson-Crick-Hoogsteen (PNA)2-DNA triplexes, which are much more stable than the corresponding DNA-DNA duplexes5-7, and bind to double-stranded DNA by strand displacement5,8. We report here that PNA containing all four natural nucleobases hybridizes to complementary oligonucleotides obeying the Watson-Crick base-pairing rules, and thus is a true DNA mimic in terms of base-pair recognition.	PANUM INST,MED BIOTECHNOL RES CTR,DEPT BIOCHEM B,BLEGDAMSVEJ 3C,DK-2200 COPENHAGEN N,DENMARK; HC ORSTED INST,DEPT ORGAN CHEM,DK-2100 COPENHAGEN 0,DENMARK; ISIS PHARMACEUT,CARLSBAD,CA 92008; RISO NATL LAB,DEPT MAT,POLYMER GRP,DK-4000 ROSKILDE,DENMARK; CHALMERS UNIV TECHNOL,DEPT PHYS CHEM,S-41296 GOTHENBURG,SWEDEN	University of Copenhagen; Isis Pharmaceuticals Inc; Technical University of Denmark; Chalmers University of Technology			Norden, Bengt/ABE-3675-2020; Berg, Rolf H/C-6339-2009	Norden, Bengt/0000-0002-7946-200X; /0000-0001-8771-330X				BORER PN, 1974, J MOL BIOL, V86, P843, DOI 10.1016/0022-2836(74)90357-X; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; CHERNY DY, 1993, P NATL ACAD SCI USA, V90, P1667, DOI 10.1073/pnas.90.5.1667; Crooke Stanley T., 1992, Current Opinion in Biotechnology, V3, P656, DOI 10.1016/0958-1669(92)90012-8; EGHOLM M, 1993, J CHEM SOC CHEM COMM, P800, DOI 10.1039/c39930000800; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P9677, DOI 10.1021/ja00050a068; ESCHENMOSER A, 1992, CHEM SOC REV, V21, P1, DOI 10.1039/cs9922100001; FREIER SM, 1983, BIOCHEMISTRY-US, V22, P6198, DOI 10.1021/bi00295a025; FREIER SM, 1983, BIOPOLYMERS, V22, P1107, DOI 10.1002/bip.360220408; Goodchild J, 1990, BIOCONJUGATE CHEM, V1, P165, DOI 10.1021/bc00003a001; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; Maniatis T., 1982, MOL CLONING; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1993, ANTI-CANCER DRUG DES, V8, P53; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; ORO J, 1960, BIOCHEM BIOPH RES CO, V2, P407, DOI 10.1016/0006-291X(60)90138-8; UHLMANN E, 1990, CHEM REV, V90, P544; VESNAVER G, 1991, P NATL ACAD SCI USA, V88, P3569, DOI 10.1073/pnas.88.9.3569	21	1704	2215	4	252	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					566	568		10.1038/365566a0	http://dx.doi.org/10.1038/365566a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	7692304				2022-12-24	WOS:A1993MA66100061
J	TSUCHIHASHI, Z; KHOSLA, M; HERSCHLAG, D				TSUCHIHASHI, Z; KHOSLA, M; HERSCHLAG, D			PROTEIN ENHANCEMENT OF HAMMERHEAD RIBOZYME CATALYSIS	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; TETRAHYMENA-THERMOPHILA RIBOZYME; RNA ANNEALING ACTIVITIES; PRIMER TRANSFER-RNA; NUCLEOCAPSID PROTEIN; RIBONUCLEASE-P; NUCLEIC-ACIDS; VIRAL-RNA; KINETIC DESCRIPTION	When the recognition sequence of a ribozyme is extended beyond a certain length, turnover is slowed and specificity is decreased. Here, it is shown that a protein can help a ribozyme overcome these general limitations on ribozyme activity. Cleavage of an RNA oligonucleotide by a hammerhead ribozyme is enhanced 10- to 20-fold upon addition of a protein derived from the p7 nucleocapsid (NC) protein of human immunodeficiency virus-type 1. The NC protein also enhances the ability of the ribozyme to discriminate between cleavage of RNA oligonucleotides with differing sequences. These catalytic improvements can be attributed to the strand exchange activity of this RNA binding protein. It is conceivable that endogenous or added proteins may provide analogous increases in ribozyme activity and specificity in vivo.	STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University								ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; DEROCQUIGNY H, 1993, NUCLEIC ACIDS RES, V21, P823; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FERSHT A, 1985, ENZYME STRUCTURE MEC, P111; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; HERSCHLAG D, UNPUB; HERTEL KJ, UNPUB; JOSEPH S, 1993, GENE DEV, V7, P130, DOI 10.1101/gad.7.1.130; JOYCE G, COMMUNICATION; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KHAN R, 1992, J BIOL CHEM, V267, P6689; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LEIS JP, 1978, VIROLOGY, V84, P87, DOI 10.1016/0042-6822(78)90220-9; MERIC C, 1989, J VIROL, V63, P1558; MERIC C, 1984, J MOL BIOL, V173, P531, DOI 10.1016/0022-2836(84)90396-6; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; NISSENMEYER J, 1980, J MOL BIOL, V142, P19, DOI 10.1016/0022-2836(80)90203-X; OERTLE S, 1990, J VIROL, V64, P5757, DOI 10.1128/JVI.64.12.5757-5763.1990; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; ROSSI JJ, 1990, TRENDS BIOTECHNOL, V8, P179, DOI 10.1016/0167-7799(90)90169-X; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SMITH BJ, 1979, NUCLEIC ACIDS RES, V7, P2055; SMITH D, 1992, J BIOL CHEM, V267, P2429; SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011; TALLSJO A, 1993, NUCLEIC ACIDS RES, V21, P51, DOI 10.1093/nar/21.1.51; TSUCHIHASHI Z, UNPUB	44	196	201	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 1	1993	262	5130					99	102		10.1126/science.7692597	http://dx.doi.org/10.1126/science.7692597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ635	7692597				2022-12-24	WOS:A1993LZ63500031
J	MUSIL, LS; GOODENOUGH, DA				MUSIL, LS; GOODENOUGH, DA			MULTISUBUNIT ASSEMBLY OF AN INTEGRAL PLASMA-MEMBRANE CHANNEL PROTEIN, GAP JUNCTION CONNEXIN43, OCCURS AFTER EXIT FROM THE ER	CELL			English	Article							TRANS-GOLGI NETWORK; VIRUS G-PROTEIN; BREFELDIN-A; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; INFLUENZA HEMAGGLUTININ; PRE-GOLGI; ORGANELLE STRUCTURE; LIGAND-BINDING; CELL-SURFACE	Connexin43 (Cx43) is an integral plasma membrane protein that forms gap junctions between vertebrate cells. We have used sucrose gradient fractionation and chemical cross-linking to study the first step in gap junction assembly, oligomerization of Cx43 monomers into connexon channels. In contrast with other plasma membrane proteins, multisubunit assembly of Cx43 was specifically and completely blocked when endoplasmic reticulum (ER)-to-Golgi transport was inhibited by 15-degrees-C incubation, carbonyl cyanide m-chlorophenylhydrazone, or brefeldin A or in CHO cell mutants with temperature-sensitive defects in secretion. Additional experiments indicated that connexon assembly occurred intracellularly, most likely in the trans-Golgi network. These results describe a post-ER assembly pathway for integral membrane proteins and have implications for the relationship between membrane protein oligomerization and intracellular transport.			MUSIL, LS (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.				NEI NIH HHS [EY-02430] Funding Source: Medline; NIGMS NIH HHS [GM-18974] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018974, R01GM018974] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BERTHOUD VM, 1992, EUR J CELL BIOL, V57, P40; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BONATTI S, 1989, J BIOL CHEM, V264, P12590; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Caspar DLD, 1988, GAP JUNCTIONS, P117; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COLLEY KJ, 1987, J BIOL CHEM, V262, P10296; COLLINS PL, 1991, J GEN VIROL, V72, P3095, DOI 10.1099/0022-1317-72-12-3095; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DEMELLO W, 1987, INTERCELLULAR COMMUN, P29; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DORAN JE, 1981, INFECT IMMUN, V33, P683, DOI 10.1128/IAI.33.3.683-689.1981; FISHER AS, 1992, THESIS MIT CAMBRIDGE; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GUTHRIE SC, 1989, TRENDS NEUROSCI, V12, P12, DOI 10.1016/0166-2236(89)90150-1; HENDRIX EM, 1992, MOL REPROD DEV, V33, P27, DOI 10.1002/mrd.1080330105; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JASCUR T, 1991, BIOCHEMISTRY-US, V30, P1908, DOI 10.1021/bi00221a025; JI TH, 1979, BIOCHIM BIOPHYS ACTA, V559, P39, DOI 10.1016/0304-4157(79)90007-8; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kumar N M, 1992, Semin Cell Biol, V3, P3; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MATTER K, 1991, BIOCHEMISTRY-US, V30, P1916, DOI 10.1021/bi00221a026; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; POTTER TA, 1985, P NATL ACAD SCI USA, V82, P2950, DOI 10.1073/pnas.82.9.2950; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; RAHMAN S, 1993, J BIOL CHEM, V268, P1260; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; RICKWOOD D, 1984, CENTRIFUGATION PRACT, P95; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTUNDO RL, 1984, P NATL ACAD SCI-BIOL, V81, P479, DOI 10.1073/pnas.81.2.479; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SHITE S, 1990, J BIOL CHEM, V265, P17385; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; STAROS JV, 1989, METHOD ENZYMOL, V172, P609; STIEGER B, 1988, J CELL BIOL, V106, P1853, DOI 10.1083/jcb.106.6.1853; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; TARTAKOFF A, 1979, J CELL BIOL, V83, P284, DOI 10.1083/jcb.83.2.284; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; VALDIMARSSON G, 1991, MOL REPROD DEV, V30, P18, DOI 10.1002/mrd.1080300103; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YAMADA A, 1988, VIROLOGY, V165, P268, DOI 10.1016/0042-6822(88)90681-2; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838	73	405	411	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					1065	1077		10.1016/0092-8674(93)90728-9	http://dx.doi.org/10.1016/0092-8674(93)90728-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	7691412				2022-12-24	WOS:A1993LY49300013
J	NUEZ, B; MICHALOVICH, D; BYGRAVE, A; PLOEMACHER, R; GROSVELD, F				NUEZ, B; MICHALOVICH, D; BYGRAVE, A; PLOEMACHER, R; GROSVELD, F			DEFECTIVE HEMATOPOIESIS IN FETAL LIVER RESULTING FROM INACTIVATION OF THE EKLF GENE	NATURE			English	Article							BETA-GLOBIN GENE; TRANSGENIC MICE; DEVELOPMENTAL REGULATION; PROMOTER ELEMENT; STEM-CELLS; EXPRESSION; MUTATIONS; SEQUENCE; DISTAL	ERYTHROID Kruppel-like factor (EKLF) was originally isolated from erythroid cell RNA by differential screening and shown to be erythroid-specific, although a low level of EKLF was found in mast cell lines(1,2). EKLF contains three zinc-fingers homologous to those found in the Kruppel family of transcription factors, Because it binds the sequence CCACACCCT, EKLF may affect erythroid development as a result of its ability to bind to the CAC box in the promoter of the beta-globin gene(1,2). Mutation of this element leads to reduced beta-globin expression(3-5) and it appears to mediate the effect of the globin locus control region on the promoter(6). Here we inactivate the EKLF gene through insertion of a lacZ reporter gene by homologous recombination in embryonic stem (ES) cells. Heterozygous EKLF(+/-) mice show that the reporter gene is expressed in a developmentally specific manner in all types of erythroblasts in the fetal liver and adult bone marrow. Homozygous EKLF(-/-) mice appear normal during the embryonic stage of haematopoiesis in the yolk sac, but develop a fatal anaemia during early fetal life when haematopoiesis has switched to the fetal liver. Enucleated erythrocytes are formed but these do not contain the proper amount of haemoglobin. We conclude that the transcription factor EKLF is essential for the final steps of definitive erythropoiesis in fetal liver.	ERASMUS UNIV ROTTERDAM, DEPT HAEMATOL, 3015 GE ROTTERDAM, NETHERLANDS; NATL INST MED RES, DEPT GENE STRUCT & EXPRESS, LONDON NW7 1AA, ENGLAND	Erasmus University Rotterdam; MRC National Institute for Medical Research	NUEZ, B (corresponding author), ERASMUS UNIV ROTTERDAM, MGC DEPT CELL BIOL & GENET, DR MOLEWATERPLEIN 50, 3015 GE ROTTERDAM, NETHERLANDS.			Michalovich, David/0000-0003-4452-5776				ANTONIOU M, 1990, GENE DEV, V4, P1007, DOI 10.1101/gad.4.6.1007; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; CHADA K, 1985, NATURE, V314, P377, DOI 10.1038/314377a0; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ELEOUET JF, 1993, EUR J BIOCHEM, V272, P763; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; EPPERLY BR, 1994, GENE, V131, P249; FENG WC, 1994, J BIOL CHEM, V269, P1492; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KULOZIK AE, 1991, BLOOD, V77, P2054; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; ORKIN SH, 1984, J BIOL CHEM, V259, P8679; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; PLOEMACHER RE, 1993, LEUKEMIA, V7, P1374; Robertson E. J., 1987, TERATOCARCINOMAS EMB; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WONG PMC, 1983, BLOOD, V62, P1280	23	470	483	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					316	318		10.1038/375316a0	http://dx.doi.org/10.1038/375316a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753194	Green Submitted			2022-12-24	WOS:A1995RA03000050
J	GUO, S; KEMPHUES, KJ				GUO, S; KEMPHUES, KJ			PAR-1, A GENE REQUIRED FOR ESTABLISHING POLARITY IN C-ELEGANS EMBRYOS, ENCODES A PUTATIVE SER/THR KINASE THAT IS ASYMMETRICALLY DISTRIBUTED	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PROTEIN-KINASE; CYTOPLASMIC LOCALIZATION; CONSERVED FEATURES; SPLICED LEADER; SEQUENCE; MICROFILAMENTS; FAMILY; IDENTIFICATION; EMBRYOGENESIS	The first cleavage of C. elegans is asymmetric, generating daughter cells with different sizes, cytoplasmic components, and fates. Mutations in the par-1 gene disrupt this asymmetry. We report here that par-1 encodes a putative Ser/Thr kinase with similarity to kinases from yeasts and mammals, Two strong alleles have mutations in the kinase domain, suggesting that kinase activity is essential for par-1 function. PAR-1 protein is localized to the posterior periphery of the zygote and is distributed in a polar fashion preceding the asymmetric divisions of the germline lineage. Because PAR-1 distribution in the germline correlates with the distribution of germline-specific P granules, it is possible that PAR-1 functions in germline development as well as in establishing embryonic polarity.			GUO, S (corresponding author), CORNELL UNIV, GENET & DEV SECT, ITHACA, NY 14853 USA.				NICHD NIH HHS [HD27689] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027689] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; CARLING D, 1994, J BIOL CHEM, V269, P11432; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHENG NN, 1995, GENETICS, V139, P549; Davidson E. H., 1986, GENE ACTIVITY EARLY; FIRE A, 1991, DEVELOPMENT, V113, P503; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1992, NATURE, V357, P254; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HILL DP, 1990, DEVELOPMENT, V108, P159; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; INGLIS JD, 1993, MAMM GENOME, V4, P401, DOI 10.1007/BF00360595; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEVIN DE, 1990, P NATL ACAD SCI USA, V87, P8272, DOI 10.1073/pnas.87.21.8272; LEVIN DE, 1987, P NATL ACAD SCI USA, V84, P6035, DOI 10.1073/pnas.84.17.6035; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MORTON DG, 1992, GENETICS, V130, P771; PARSA I, 1988, CANCER RES, V48, P2265; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIERENBERG E, 1985, COLD SPRING HARB SYM, V50, P59, DOI 10.1101/SQB.1985.050.01.010; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHIERENBERG E, 1988, ROUX ARCH DEV BIOL, V197, P282, DOI 10.1007/BF00380022; SCHNABEL R, 1994, SCIENCE, V263, P1449, DOI 10.1126/science.8128230; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1986, J CELL BIOL, V103, P2241, DOI 10.1083/jcb.103.6.2241; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROME S, 1986, J EMBRYOL EXP MORPH, V97, P15; SULSTON J, 1983, DEV BIOL, V100, P67; TELFER A, 1991, THESIS HARVARD U CAM	48	815	1061	7	138	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					611	620		10.1016/0092-8674(95)90082-9	http://dx.doi.org/10.1016/0092-8674(95)90082-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758115	hybrid			2022-12-24	WOS:A1995QZ71000018
J	KUBOTA, Y; MIMURA, S; NISHIMOTO, SI; TAKISAWA, H; NOJIMA, H				KUBOTA, Y; MIMURA, S; NISHIMOTO, SI; TAKISAWA, H; NOJIMA, H			IDENTIFICATION OF THE YEAST MCM3-RELATED PROTEIN AS A COMPONENT OF XENOPUS DNA-REPLICATION LICENSING FACTOR	CELL			English	Article							CELL-FREE-EXTRACT; NUCLEAR-LOCALIZATION; EGG EXTRACTS; CYCLE; INVITRO; INITIATION; SEQUENCE; MITOSIS; MCM3	Replication licensing factor is thought to be involved in the strict control of the initiation of DNA replication in eukaryotes. We identified a 100 kDa protein as a candidate for the licensing factor in Xenopus egg extracts. This protein was required for replication; it bound to sperm DNA before the formation of nuclei and apparently dissociated from the nuclear DNA during the progression of replication without being transported into the nuclei. An immunologically homologous protein in HeLa cells behaved similarly to the Xenopus protein during the cell cycle. Cloning and sequencing of the cDNAs encoding the Xenopus and human proteins revealed that they are homologs of yeast Mcm3, a putative yeast DNA replication licensing factor.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC GENET,SUITA,OSAKA 565,JAPAN	Osaka University	KUBOTA, Y (corresponding author), OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN.							ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; HUTCHISON C, 1989, J CELL SCI, V93, P605; HUTCHISON CJ, 1988, DEVELOPMENT, V103, P553; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LENO GH, 1994, J CELL BIOL, V127, P5, DOI 10.1083/jcb.127.1.5; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	28	253	255	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					601	609		10.1016/0092-8674(95)90081-0	http://dx.doi.org/10.1016/0092-8674(95)90081-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758114	Bronze			2022-12-24	WOS:A1995QZ71000017
J	OWENS, DK; HARRIS, RA; SCOTT, PM; NEASE, RF				OWENS, DK; HARRIS, RA; SCOTT, PM; NEASE, RF			SCREENING SURGEONS FOR HIV-INFECTION - A COST-EFFECTIVENESS ANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review						COST-BENEFIT ANALYSIS; SURGEONS; HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT; MASS SCREENING	HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; HEALTH-CARE WORKERS; UNITED-STATES-ARMY; HEPATITIS-B VIRUS; CONTROLLED TRIAL; SEXUAL-BEHAVIOR; AIDS EDUCATION; CONDOM USE; TRIMETHOPRIM SULFAMETHOXAZOLE	Objective To determine the cost-effectiveness of a policy to screen surgeons for human immunodeficiency virus (HIV) infection to prevent transmission of HIV to patients having invasive procedures. Design: Cost-effectiveness analysis. Results: A one-time national screening program would identify approximately 137 surgeons with HIV infection (range, 28 to 423 surgeons) and would prevent approximately 4.3 infections (range, 1.9 to 21.3 infections) in patients treated by infected surgeons and 0.9 infections (range, 0 to 12.9 infections) in sexual partners of infected surgeons at a direct cost of $8.1 million and an induced cost of approximately $44 million. It would result in expenditures of $458 000 per year of life saved (range, $147 000 to $687 000 per year of life saved), whereas an annual screening program would result in expenditures of approximately $1.1 million per year of life saved (range, $338 000 to $1 886 000 per year of life saved). If the prevalence of HIV infection in surgeons is estimated to be three times our base-case estimate (an increase from 0.1% to 0.3%), annual screening would result in expenditures of approximately $741 000 per year of life saved. If the probability of seroconversion after a patient is exposed to a contaminated instrument is increased to 5.0% from our base-case estimate of 0.29%, an annual screening program would still cost more than $228 000 per year of life saved. Conclusion: Screening surgeons for HIV to prevent transmission of HIV to patients having invasive procedures requires expenditures per year of life saved that are considerably in excess of those of most accepted health interventions. Surveillance studies of patients treated by surgeons infected with HIV should be continued to confirm that transmission of HIV to patients having invasive procedures is rare.	STANFORD UNIV, STANFORD, CA 94305 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, HANOVER, NH 03756 USA	Stanford University; Dartmouth College	OWENS, DK (corresponding author), DEPT VET AFFAIRS MED CTR, GEN INTERNAL MED SECT 111A, 3801 MIRANDA AVE, PALO ALTO, CA 94304 USA.				AHRQ HHS [RD3 HSO7232-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ANDRULIS DP, 1992, JAMA-J AM MED ASSOC, V267, P2482, DOI 10.1001/jama.267.18.2482; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARNO PS, 1989, JAMA-J AM MED ASSOC, V262, P1493, DOI 10.1001/jama.262.11.1493; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BELL DM, 1992, INFECT AGENT DIS, V1, P263; BENNETT CL, 1992, J ACQ IMMUN DEF SYND, V5, P1; BIDDLECOM AE, 1992, J ACQ IMMUN DEF SYND, V5, P1131; BILLY JOG, 1993, FAM PLANN PERSPECT, V25, P52, DOI 10.2307/2136206; BUIRA E, 1992, J ACQ IMMUN DEF SYND, V5, P737; CALSYN DA, 1992, AM J PUBLIC HEALTH, V82, P573, DOI 10.2105/AJPH.82.4.573; CAMPBELL LS, 1991, SOUTHERN MED J, V84, P22, DOI 10.1097/00007611-199101000-00007; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P337; CHAMBERLAND ME, 1992, ANN INTERN MED, V116, P871, DOI 10.7326/0003-4819-116-10-871; CHAVEY WE, 1994, J FAM PRACTICE, V38, P249; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; ELSADR W, 1994, PHS AHCPR940572 US D; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; FUCHS VR, 1986, HEALTH ECON, P49; GAFNI A, 1993, CAN MED ASSOC J, V148, P913; GALLANT JE, 1994, ANN INTERN MED, V120, P932, DOI 10.7326/0003-4819-120-11-199406010-00006; GARCIA A, 1992, 8 HARV U DUTCH F AID, pC348; GERBERDING JL, 1991, INFECT CONT HOSP EP, V12, P443, DOI 10.1086/646376; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GRAHAM D, 1988, DETAILED DIAGNOSES P; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; Hahn B., 1992, ANN EXPENSES SOURCES; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HEDLUND K, 1990, AIDS 90S SCI POLICY, P256; HELLINGER FJ, 1992, INQUIRY-J HEALTH CAR, V29, P356; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HENDERSON DK, 1994, INFECT CONT HOSP EP, V15, P631, DOI 10.2307/30145273; HIATT RA, 1990, ARCH INTERN MED, V150, P833, DOI 10.1001/archinte.150.4.833; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; HILTS PJ, 1991, NY TIMES        0927, pA8; HUNT AJ, 1991, AIDS, V5, P723, DOI 10.1097/00002030-199106000-00012; JEWETT JF, 1993, JAMA-J AM MED ASSOC, V269, P1144, DOI 10.1001/jama.269.9.1144; KAMENGA M, 1989, AIDS SCI SOCIAL CHAL, V1, P703; KU LC, 1992, FAM PLANN PERSPECT, V24, P100, DOI 10.2307/2135538; LAUPACIS A, 1993, CAN MED ASSOC J, V148, P927; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LETTAU LA, 1992, INFECT CONT HOSP EP, V13, P336, DOI 10.1086/646541; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; LIFSON A, 1989, 5 INT C AIDS MONTR, P60; LINDAN C, 1990, AIDS 90S SCI POLICY, P256; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; LONGINI IM, 1989, STAT MED, V8, P831, DOI 10.1002/sim.4780080708; MACDONALD KL, 1989, ANN INTERN MED, V110, P617, DOI 10.7326/0003-4819-110-8-617; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487; MISHU B, 1993, JAMA-J AM MED ASSOC, V269, P1843, DOI 10.1001/jama.269.14.1843; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; NAYLOR CD, 1993, CAN MED ASSOC J, V148, P921; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; OWENS DK, 1992, AM J MED, V92, P503, DOI 10.1016/0002-9343(92)90747-Y; OWENS DK, 1994, MODELING THE AIDS EPIDEMIC: PLANNING, POLICY, AND PREDICTION, P153; OWENS DK, 1990, AIDS 90S SCI POLICY, V3, P308; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; PADIAN NS, 1990, AM J PUBLIC HEALTH, V80, P990, DOI 10.2105/AJPH.80.8.990; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; PHILLIPS KA, 1994, JAMA-J AM MED ASSOC, V271, P851, DOI 10.1001/jama.271.11.851; ROBACK G, 1992, PHYSICIAN CHARACTERI; ROBERT L, 1993, 1ST NAT F INF DIS NA, P1; ROSENTHAL E, 1991, NY TIMES        1020, pB5; RUSSELL LB, 1989, SCIENCE, V246, P892, DOI 10.1126/science.2510299; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SCHULMAN KA, 1994, INFECT CONT HOSP EP, V15, P147, DOI 10.1086/646882; SCHWARTZ JS, 1990, JAMA-J AM MED ASSOC, V264, P1704, DOI 10.1001/jama.264.13.1704; SELL RL, 1994, INFECT CONT HOSP EP, V15, P635, DOI 10.2307/30145274; SMITH TW, 1991, FAM PLANN PERSPECT, V23, P102, DOI 10.2307/2135820; SONENSTEIN FL, 1989, FAM PLANN PERSPECT, V21, P152, DOI 10.2307/2135805; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V268, P489, DOI 10.1001/jama.268.4.489; VALDISERRI RO, 1988, AM J PUBLIC HEALTH, V78, P801, DOI 10.2105/AJPH.78.7.801; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VITTECOQ D, 1992, 8 HARV U DUTCH F AID, P45; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WELCH J, 1989, LANCET, V1, P205; WENGER NS, 1991, AM J PUBLIC HEALTH, V81, P1580, DOI 10.2105/AJPH.81.12.1580; WENGER NS, 1992, ANN INTERN MED, V117, P905, DOI 10.7326/0003-4819-117-11-905; WITHERS BG, 1992, MIL MED, V157, P80, DOI 10.1093/milmed/157.2.80; WOOD FW, 1990, AM PROFILE OPINIONS; Yawn B P, 1992, Fam Med, V24, P355; 1991, MMWR-MORBID MORTAL W, V40, P377; 1988, MMWR-MORBID MORTAL W, V37, P229; 1992, MMWR-MORBID MORTAL W, V41, P344; 1988, MMWR-MORBID MORTAL W, V37, P239; 1993, STATISTICAL ABSTRACT; 1994, PHYSICIAN CHARACTERI; 1991, NY TIMES        1020, P7; 1992, 8 HARV U DUTCH F AID, pC348; 1993, MMWR-MORBID MORTAL W, V42, P329; 1990, MMWR-MORBID MORTAL W, V39, P489; 1994, SOCIOECONOMIC CHARAC; 1992, STATISTICAL ABSTRACT; 1990, VITAL STATISTICS US; 1990, MMWR-MORBID MORTAL W, V39, P380	108	39	39	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					641	652		10.7326/0003-4819-122-9-199505010-00001	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00001			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702225				2022-12-24	WOS:A1995QV15100001
J	GRAHAM, JR				GRAHAM, JR			HELICOBACTER-PYLORI - HUMAN PATHOGEN OR SIMPLY AN OPPORTUNIST	LANCET			English	Editorial Material							PEPTIC-ULCER DISEASE; GASTRITIS; CAMPYLOBACTER; INFECTION				GRAHAM, JR (corresponding author), SYDNEY HOSP,ALAN MCGUINNESS GASTROENTEROL UNIT,SYDNEY,NSW 2000,AUSTRALIA.							Adelberg, 1982, REV MED MICROBIOLOGY; BAYERDORFFER E, 1993, NEW ENGL J MED, V329, P60, DOI 10.1056/NEJM199307013290116; CHANDRAKUMARAN K, 1994, GUT, V35, P1033, DOI 10.1136/gut.35.8.1033; FALLINGBORG J, 1992, SCAND J GASTROENTERO, V27, P388, DOI 10.3109/00365529209000093; FONG TL, 1991, GASTROENTEROLOGY, V100, P328, DOI 10.1016/0016-5085(91)90199-U; FORBES G, 1994, MED J AUSTRALIA, V161, P291, DOI 10.5694/j.1326-5377.1994.tb127445.x; FORBES GM, 1994, LANCET, V343, P258, DOI 10.1016/S0140-6736(94)91111-8; Gilman A., 1985, PHARM BASIS THERAPEU, Vseventh; KOOP H, 1991, DIGESTION, V48, P230, DOI 10.1159/000200698; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MCCORMICK PA, 1991, GUT, V32, P351, DOI 10.1136/gut.32.4.351; ROSS JS, 1992, AM J PATHOL, V141, P721; SAEED ZA, 1991, DIGEST DIS SCI, V36, P15, DOI 10.1007/BF01300080; STOLTE M, 1992, LANCET, V339, P745, DOI 10.1016/0140-6736(92)90645-J; SUNG JJY, 1995, NEW ENGL J MED, V332, P139, DOI 10.1056/NEJM199501193320302; TAHA AS, 1993, GUT, V34, P580, DOI 10.1136/gut.34.5.580; TALLEY NJ, 1991, J NATL CANCER I, V83, P1734, DOI 10.1093/jnci/83.23.1734; UPPAL R, 1991, ARCH INTERN MED, V151, P760, DOI 10.1001/archinte.151.4.760	19	34	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1095	1097		10.1016/S0140-6736(95)90824-2	http://dx.doi.org/10.1016/S0140-6736(95)90824-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715345				2022-12-24	WOS:A1995QV41100016
J	SERVICE, FJ				SERVICE, FJ			MEDICAL PROGRESS - HYPOGLYCEMIC DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INSULIN-INDUCED HYPOGLYCEMIA; PLASMA-GLUCOSE CONCENTRATION; CHRONIC-RENAL-FAILURE; GROWTH-HORMONE; REACTIVE HYPOGLYCEMIA; POSTPRANDIAL HYPOGLYCEMIA; GLYCEMIC THRESHOLDS; ADRENERGIC-BLOCKADE; AUTOIMMUNE SYNDROME; DIABETES-MELLITUS				SERVICE, FJ (corresponding author), MAYO CLIN & MAYO FDN,DIV ENDOCRINOL & METAB,200 1ST ST SW,ROCHESTER,MN 55905, USA.							AHLQUIST DA, 1980, ANN INTERN MED, V93, P281, DOI 10.7326/0003-4819-93-2-281; ALMIRALL J, 1989, NEPHRON, V53, P273, DOI 10.1159/000185757; ANDREANI D, 1987, HYPOGLYCEMIA, V38, P312; [Anonymous], 1987, DIABETES CARE, V10, P95; ARCHAMBEAUDMOUV.F, 1989, BIOMED PHARMACOTHER, V43, P581; AREM R, 1983, ARCH INTERN MED, V143, P827, DOI 10.1001/archinte.143.4.827; BARRETT CT, 1968, NEW ENGL J MED, V278, P1260, DOI 10.1056/NEJM196806062782304; BEARD CM, 1983, MAYO CLIN PROC, V58, P802; BENZING G, 1969, CIRCULATION, V40, P209, DOI 10.1161/01.CIR.40.2.209; BLOCK MB, 1977, MIL MED, V142, P32; BLOCK MB, 1972, LANCET, V2, P736; BOUCHARD P, 1982, DIABETES, V31, P40, DOI 10.2337/diabetes.31.1.40; BOYLE PJ, 1991, AM J PHYSIOL, V260, pE395, DOI 10.1152/ajpendo.1991.260.3.E395; BOYLE PJ, 1989, AM J PHYSIOL, V256, pE651, DOI 10.1152/ajpendo.1989.256.5.E651; BRESSLER R, 1969, PHARMACOL REV, V21, P105; CHALEW SA, 1984, JAMA-J AM MED ASSOC, V251, P612, DOI 10.1001/jama.251.5.612; CHEN YT, 1984, NEW ENGL J MED, V310, P171, DOI 10.1056/NEJM198401193100306; CLARKE WL, 1979, AM J PHYSIOL, V236, pE147, DOI 10.1152/ajpendo.1979.236.2.E147; COHEN MM, 1971, AM J DIS CHILD, V122, P515, DOI 10.1001/archpedi.1971.02110060085015; COLLINS JE, 1990, ARCH DIS CHILD, V65, P1118, DOI 10.1136/adc.65.10.1118; CONNOR H, 1979, POSTGRAD MED J, V55, P735, DOI 10.1136/pgmj.55.648.735; COX DJ, 1993, DIABETES CARE, V16, P519, DOI 10.2337/diacare.16.2.519; Cryer PE, 1993, HYPOGLYCAEMIA DIABET, P34; DAUGHADAY WH, 1989, ENDOCRIN METAB CLIN, V18, P91, DOI 10.1016/S0889-8529(18)30390-6; DAVIS MR, 1991, J CLIN ENDOCR METAB, V72, P788, DOI 10.1210/jcem-72-4-788; DEFEO P, 1989, AM J PHYSIOL, V256, pE835, DOI 10.1152/ajpendo.1989.256.6.E835; DEFEO P, 1989, AM J PHYSIOL, V257, pE35, DOI 10.1152/ajpendo.1989.257.1.E35; DEFRONZO RA, 1972, DIABETES, V26, P445; DEVIVO DC, 1991, NEW ENGL J MED, V325, P703, DOI 10.1056/NEJM199109053251006; DOHERTY GM, 1991, SURGERY, V110, P989; DOPPMAN JL, 1991, RADIOLOGY, V178, P237, DOI 10.1148/radiology.178.1.1984311; DOPPMAN JL, 1993, RADIOLOGY, V187, P880; FELIG P, 1982, NEW ENGL J MED, V306, P895, DOI 10.1056/NEJM198204153061503; FELIG P, 1970, NEW ENGL J MED, V283, P1436, DOI 10.1056/NEJM197012242832604; FISCHER KF, 1986, NEW ENGL J MED, V315, P1245, DOI 10.1056/NEJM198611133152002; FUSHIMI H, 1980, ENDOCRINOL JAPON, V27, P679; GALIBER AK, 1988, RADIOLOGY, V166, P405, DOI 10.1148/radiology.166.2.2827232; GARBER AJ, 1974, DIABETES, V23, P982, DOI 10.2337/diab.23.12.982; GERICH J, 1979, AM J PHYSIOL, V236, pE380, DOI 10.1152/ajpendo.1979.236.4.E380; GLASGOW AM, 1973, AM J DIS CHILD, V125, P809, DOI 10.1001/archpedi.1973.04160060021004; GOLDMAN J, 1979, J CLIN INVEST, V63, P1050, DOI 10.1172/JCI109374; GOODENOW TJ, 1977, JAMA-J AM MED ASSOC, V237, P1961, DOI 10.1001/jama.237.18.1961; GRANT CS, 1988, WIEN KLIN WOCHENSCHR, V100, P376; Heard C R, 1978, World Rev Nutr Diet, V30, P107; HECHT A, 1959, METABOLISM, V8, P418; HEINIG RE, 1979, ARCH INTERN MED, V139, P1229, DOI 10.1001/archinte.139.11.1229; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HEPBURN DA, 1991, DIABETES CARE, V14, P949, DOI 10.2337/diacare.14.11.949; Hepburn DA, 1993, HYPOGLYCAEMIA DIABET, P93; HIRATA Y, 1983, LANCET, V2, P1037; HOFELDT FD, 1972, AM J CLIN NUTR, V25, P1193; HOGAN MJ, 1983, MAYO CLIN PROC, V58, P491; JOHANSSON C, 1978, ACTA MED SCAND, V204, P509; JOHNSON DD, 1980, JAMA-J AM MED ASSOC, V243, P1151, DOI 10.1001/jama.243.11.1151; KANE LA, 1993, DIABETES CARE, V16, P1298, DOI 10.2337/diacare.16.9.1298; KAO PC, 1994, J CLIN ENDOCR METAB, V78, P1048, DOI 10.1210/jc.78.5.1048; KOGUT MD, 1969, J PEDIATR-US, V74, P853, DOI 10.1016/S0022-3476(69)80220-9; KOJAK G, 1969, AM J PSYCHIAT, V126, P573, DOI 10.1176/ajp.126.4.573; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; LEVIN H, 1990, CAN J ANAESTH, V37, P477, DOI 10.1007/BF03005631; LEVRAN A, 1981, DIABETES, V30, P996, DOI 10.2337/diabetes.30.12.996; LIMBURG PJ, 1993, ANN INTERN MED, V119, P218, DOI 10.7326/0003-4819-119-3-199308010-00007; LIU D, 1992, DIABETOLOGIA, V35, P287, DOI 10.1007/BF00400932; LUYCKX AS, 1971, DIABETES, V20, P435, DOI 10.2337/diab.20.6.435; MACARON CI, 1981, DIABETES CARE, V4, P113, DOI 10.2337/diacare.4.1.113; Madison L L, 1968, Adv Metab Disord, V3, P85; MCCALL AL, 1993, HYPOGLYCAEMIA DIABET, P56; MCMAHON MM, 1989, MAYO CLIN PROC, V64, P1481, DOI 10.1016/S0025-6196(12)65703-6; MERIMEE TJ, 1973, J CLIN ENDOCR METAB, V37, P698, DOI 10.1210/jcem-37-5-698; MERIMEE TJ, 1971, J CLIN INVEST, V50, P574, DOI 10.1172/JCI106527; MILLER DR, 1977, NEW ENGL J MED, V297, P339; MILLER SI, 1980, AM J MED, V68, P649, DOI 10.1016/0002-9343(80)90250-8; MITRAKOU A, 1991, AM J PHYSIOL, V260, pE67, DOI 10.1152/ajpendo.1991.260.1.E67; MITRAKOU A, 1993, NEW ENGL J MED, V329, P834, DOI 10.1056/NEJM199309163291203; NAPPI JM, 1983, WESTERN J MED, V138, P95; NELSON RL, 1983, HYPOGLYCEMIC DISORDE, P97; NORTON JA, 1990, ANN SURG, V212, P615, DOI 10.1097/00000658-199011000-00009; OBRIEN T, 1993, J CLIN ENDOCR METAB, V77, P448, DOI 10.1210/jc.77.2.448; OOI TC, 1980, J ENDOCRINOL INVEST, V3, P45, DOI 10.1007/BF03348216; PALARDY J, 1989, NEW ENGL J MED, V321, P1421, DOI 10.1056/NEJM198911233212101; PEDERSEN J, 1954, ACTA ENDOCRINOL-COP, V15, P33, DOI 10.1530/acta.0.0150033; PHILLIPS RE, 1986, BRIT MED J, V292, P1319, DOI 10.1136/bmj.292.6531.1319; RASCHKE R, 1991, ARCH INTERN MED, V151, P591, DOI 10.1001/archinte.151.3.591; RICH LM, 1990, ARCH INTERN MED, V150, P894, DOI 10.1001/archinte.150.4.894; RIZZA RA, 1979, J CLIN INVEST, V64, P62, DOI 10.1172/JCI109464; ROSCH T, 1992, NEW ENGL J MED, V326, P1721, DOI 10.1056/NEJM199206253262601; ROSEN SG, 1984, J CLIN INVEST, V73, P405, DOI 10.1172/JCI111226; SANTIAGO JV, 1980, J CLIN ENDOCR METAB, V51, P877, DOI 10.1210/jcem-51-4-877; SCHWARTZ NS, 1987, J CLIN INVEST, V79, P777, DOI 10.1172/JCI112884; SERVICE FJ, 1992, J CLIN ENDOCR METAB, V74, P204, DOI 10.1210/jc.74.1.204; SERVICE FJ, 1989, NEW ENGL J MED, V321, P1472, DOI 10.1056/NEJM198911233212109; SERVICE FJ, 1974, ARCH INTERN MED, V134, P336, DOI 10.1001/archinte.134.2.336; SERVICE FJ, 1991, MAYO CLIN PROC, V66, P711, DOI 10.1016/S0025-6196(12)62083-7; SERVICE FJ, 1976, MAYO CLIN PROC, V51, P417; SERVICE FJ, 1993, J CLIN ENDOCR METAB, V76, P655, DOI 10.1210/jc.76.3.655; Service FJ., 1995, ENDOCRINOLOGY, P1605; SERVICE FJ, 1978, AM J MED, V64, P698; Service FJ, 1992, ENDOCRINOLOGIST, V2, P173; SERVICE FJ, 1987, HYPOGLYCEMIA, V38, P45; SKETRIS I, 1984, DRUG INTEL CLIN PHAR, V18, P142, DOI 10.1177/106002808401800210; SNORGAARD O, 1990, BRIT MED J, V300, P16, DOI 10.1136/bmj.300.6716.16; SOVIK O, 1989, ACTA PAEDIATR SCAND, V78, P161, DOI 10.1111/j.1651-2227.1989.tb11052.x; STARKE AAR, 1983, DIABETOLOGIA, V25, P336; Takei M, 1980, J TOKYO WOMENS MED C, V50, P54; TALENTE GM, 1994, ANN INTERN MED, V120, P218, DOI 10.7326/0003-4819-120-3-199402010-00008; TOWLER DA, 1993, DIABETES, V42, P1791, DOI 10.2337/diabetes.42.12.1791; TREEM WR, 1988, NEW ENGL J MED, V319, P1331, DOI 10.1056/NEJM198811173192006; TSALIKIAN E, 1983, HYPOGLYCEMIC DISORDE, P35; TSE TF, 1983, J CLIN INVEST, V72, P278, DOI 10.1172/JCI110967; VENEMAN T, 1993, DIABETES, V42, P1233, DOI 10.2337/diabetes.42.9.1233; VINIK AI, 1991, SURGERY, V109, P1; Whipple AO, 1938, J INT CHIR, V3, P237; WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201; ZIMMERMAN BR, 1983, HYPOGLYCERMIA PATHOG	114	340	349	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	1995	332	17					1144	1152		10.1056/NEJM199504273321707	http://dx.doi.org/10.1056/NEJM199504273321707			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU302	7700289				2022-12-24	WOS:A1995QU30200007
J	RIDKER, PM; STAMPFER, MJ; HENNEKENS, CH				RIDKER, PM; STAMPFER, MJ; HENNEKENS, CH			PLASMA-CONCENTRATION OF LIPOPROTEIN(A) AND THE RISK OF FUTURE STROKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; APOLIPOPROTEIN-A-I; MYOCARDIAL-INFARCTION; CEREBROVASCULAR-DISEASE; SERUM LIPOPROTEIN(A); CEREBRAL INFARCTION; LP(A) LIPOPROTEIN; ARTERY DISEASE; ATHEROSCLEROSIS; MEN	Objective.-To assess prospectively the risk of future stroke associated with baseline concentration of lipoprotein(a), abbreviated Lp(a). Design.-Nested case-control study using baseline plasma samples. Setting.-Men in the Physicians' Health Study. Participants.-A cohort of 14 916 male physicians with no prior history of stroke, transient ischemic attack, or myocardial infarction provided plasma samples at baseline and were followed prospectively for 7.5 years. Samples from 198 physicians who subsequently developed stroke (155 thromboembolic, 35 hemorrhagic, eight indeterminate) were analyzed for Lp(a) concentration together with paired controls, matched for age and smoking habit. Main Outcome Measure.-Fatal and nonfatal stroke. Results.-Median Lp(a) concentration (8.88 mg/dL [0.23 mmol/L] vs 8.55 mg/dL [0.22 mmol/L]), P=.69) and overall distributions of Lp(a) (P=.54) were similar at baseline in men who did and did not develop future stroke. In analyses controlling for age, smoking status, blood pressure, obesity, and the presence of diabetes, the relative risks (RRs) associated with baseline Lp(a) concentration exceeding the 25th, 50th, 75th, 90th, and 95th percentiles of the control distribution were 1.26, 0.99, 1.06, 0.90, and 1.03 (all P values nonsignificant). There was likewise no association in analyses limited to thromboembolic events. For example, among subjects with baseline Lp(a) values exceeding the 95th percentile of the control distribution, the RR of future thromboembolic stroke was 1.01 (P=.9). No evidence of association between Lp(a) and stroke risk was found in analyses limited to individuals with hypercholesterolemia. Conclusions.-Among nearly 15 000 predominantly white, healthy, middle-aged men followed in the Physicians' Health Study for a period of 7.5 years, we found no evidence of association between baseline plasma concentration of Lp(a) and future risk of total or thromboembolic stroke.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV CARDIOVASC DIS, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	RIDKER, PM (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV PREVENT MED, 900 COMMONWEALTH AVE, BOSTON, MA 02115 USA.				NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-26490, HL-34595] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BERG K, 1974, CLIN GENET, V6, P230; BOSTOM AG, 1994, CIRCULATION, V90, P1688, DOI 10.1161/01.CIR.90.4.1688; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HOLLANDERS FD, 1975, POSTGRAD MED J, V51, P386, DOI 10.1136/pgmj.51.596.386; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JOVICIC A, 1993, ATHEROSCLEROSIS, V98, P59, DOI 10.1016/0021-9150(93)90223-H; JURGENS G, 1987, NEUROLOGY, V37, P513, DOI 10.1212/WNL.37.3.513; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KOLTRINGER P, 1985, ATHEROSCLEROSIS, V58, P187, DOI 10.1016/0021-9150(85)90065-6; KOSTNER GM, 1986, EUR NEUROL, V25, P346, DOI 10.1159/000116033; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; KOSTNER GM, 1991, ARCH DIS CHILD, V66, P1054, DOI 10.1136/adc.66.9.1054; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MENDEZ I, 1987, NEUROLOGY, V37, P507, DOI 10.1212/WNL.37.3.507; MURAI A, 1986, ATHEROSCLEROSIS, V59, P199, DOI 10.1016/0021-9150(86)90048-1; NAGAYAMA M, 1994, STROKE, V25, P74, DOI 10.1161/01.STR.25.1.74; PEDROBOTET J, 1992, STROKE, V23, P1556, DOI 10.1161/01.STR.23.11.1556; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SANDKAMP M, 1990, CLIN CHEM, V36, P20; SCANU AM, 1992, JAMA-J AM MED ASSOC, V267, P3326, DOI 10.1001/jama.267.24.3326; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SCHEINER PJ, 1994, ANN EPIDEMIOL, V4, P351; SCHREINER PJ, 1993, ARTERIOSCLER THROMB, V13, P826, DOI 10.1161/01.ATV.13.6.826; SHINTANI S, 1993, STROKE, V24, P965, DOI 10.1161/01.STR.24.7.965; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; SLUNGA L, 1992, SCAND J CLIN LAB INV, V52, P95, DOI 10.3109/00365519209088771; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WOO J, 1990, STROKE, V21, P1407, DOI 10.1161/01.STR.21.10.1407; WOO J, 1991, STROKE, V22, P203, DOI 10.1161/01.STR.22.2.203; ZENKER G, 1986, STROKE, V17, P942, DOI 10.1161/01.STR.17.5.942; ZHUANG YY, 1993, CHINESE MED J-PEKING, V106, P597	39	108	117	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	1995	273	16					1269	1273		10.1001/jama.273.16.1269	http://dx.doi.org/10.1001/jama.273.16.1269			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU571	7715039				2022-12-24	WOS:A1995QU57100029
J	KASHIWABUCHI, N; IKEDA, K; ARAKI, K; HIRANO, T; SHIBUKI, K; TAKAYAMA, C; INOUE, Y; KUTSUWADA, T; YAGI, T; KANG, Y; AIZAWA, S; MISHINA, M				KASHIWABUCHI, N; IKEDA, K; ARAKI, K; HIRANO, T; SHIBUKI, K; TAKAYAMA, C; INOUE, Y; KUTSUWADA, T; YAGI, T; KANG, Y; AIZAWA, S; MISHINA, M			IMPAIRMENT OF MOTOR COORDINATION, PURKINJE-CELL SYNAPSE FORMATION, AND CEREBELLAR LONG-TERM DEPRESSION IN GLUR-DELTA-2 MUTANT MICE	CELL			English	Article							EXCITATORY AMINO-ACIDS; CENTRAL-NERVOUS-SYSTEM; GLUTAMATE-RECEPTOR; NMDA RECEPTOR; FAMILY; POTENTIATION; HIPPOCAMPUS; INDUCTION; CURRENTS; CALCIUM	Of the six glutamate receptor (GluR) channel subunit families identified by molecular cloning, five have been shown to constitute either the AMPA, kainate, or NMDA receptor channel, whereas the function of the delta subunit family remains unknown. The selective localization of the delta 2 subunit or the GluR delta subfamily in cerebellar Purkinje Cells prompted us to examine its possible physiological roles by the gene targeting technique. Analyses of the GluR delta 2 mutant mice reveal that the delta 2 subunit plays important roles in motor coordination, formation of parallel fiber-Purkinje cell synapses and climbing fiber-Purkinje cell synapses, and long-term depression of parallel fiber-Purkinje cell synaptic transmission. These! results suggest a close relationship between synaptic plasticity and synapse formation in the cerebellum.	NIIGATA UNIV,BRAIN RES INST,DEPT PHYSIOL,NIIGATA 951,JAPAN; KYOTO UNIV,FAC MED,DEPT PHYSIOL,KYOTO 606,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT ANAT,SAPPORO,HOKKAIDO 060,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,IBARAKI,OSAKA 305,JAPAN; UNIV TOKYO,FAC MED,DEPT PHARMACOL,TOKYO 113,JAPAN	Niigata University; Kyoto University; Hokkaido University; RIKEN; University of Tokyo	KASHIWABUCHI, N (corresponding author), NIIGATA UNIV,BRAIN RES INST,DEPT NEUROPHARMACOL,NIIGATA 951,JAPAN.		Ikeda, Kazutaka/I-4694-2013	Ikeda, Kazutaka/0000-0001-8342-0278				ARAKI K, 1993, BIOCHEM BIOPH RES CO, V197, P1267, DOI 10.1006/bbrc.1993.2614; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; DUDEK SM, 1993, J NEUROSCI, V13, P2910; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; Goldowitz Dan, 1992, V8, P271; HIRANO T, 1990, NEUROSCI LETT, V119, P145, DOI 10.1016/0304-3940(90)90819-U; HIRANO T, 1994, NEUROSCI LETT, V182, P172, DOI 10.1016/0304-3940(94)90790-0; Hogan B., 1986, MANIPULATING MOUSE E; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LOMELI H, 1993, FEBS LETT, V315, P318, DOI 10.1016/0014-5793(93)81186-4; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MISHINA M, 1993, ANN NY ACAD SCI, V707, P136, DOI 10.1111/j.1749-6632.1993.tb38049.x; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; PERKEL DJ, 1990, P ROY SOC B-BIOL SCI, V241, P116, DOI 10.1098/rspb.1990.0074; RABACCHI S, 1992, SCIENCE, V256, P1823, DOI 10.1126/science.1352066; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SHIBUKI K, 1992, NEUROREPORT, V3, P231, DOI 10.1097/00001756-199203000-00003; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAMAKUNI T, 1984, NEUROSCI LETT, V45, P235, DOI 10.1016/0304-3940(84)90232-5; YAMAZAKI M, 1992, BIOCHEM BIOPH RES CO, V183, P886, DOI 10.1016/0006-291X(92)90566-4	36	482	485	1	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					245	252		10.1016/0092-8674(95)90334-8	http://dx.doi.org/10.1016/0092-8674(95)90334-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736576	Bronze			2022-12-24	WOS:A1995QV41000013
J	MURPHY, TD; KARPEN, GH				MURPHY, TD; KARPEN, GH			INTERACTIONS BETWEEN THE NOD(+) KINESIN-LIKE GENE AND EXTRACENTROMERIC SEQUENCES ARE REQUIRED FOR TRANSMISSION OF A DROSOPHILA MINICHROMOSOME	CELL			English	Article							DISTRIBUTIVE SEGREGATION; SATELLITE DNA; MELANOGASTER; CENTROMERE; PROTEIN; FEMALES; LOCUS; TRANSPOSITION; CHROMOSOMES; MUTATIONS	In this study, we demonstrate a role for extracentromeric sequences in chromosome inheritance. Genetic analyses indicate that transmission of the Drosophila minichromosome Dp1187 is sensitive to the dosage of nod(+), a kinesin-like gene required for the meiotic transmission of achiasmate chromosomes. Minichromosome deletions displayed increased loss rates in females heterozygous for a loss-of-function allele of nod (nod/+). We have analyzed the structures of nod-sensitive deletions and conclude that multiple regions of Dp1187 interact genetically with nod(+) to promote normal chromosome transmission. Most nod(+) interactions are observed with regions that are not essential for centromere function. We propose that normal chromosome transmission requires forces generated outside the kinetochore, perhaps to maintain tension on kinetochore microtubules and stabilize the attachment of achiasmate chromosomes to the metaphase spindle.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	MURPHY, TD (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037, USA.							AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; BAUM M, 1994, MOL BIOL CELL, V5, P747, DOI 10.1091/mbc.5.7.747; BRINKLEY BR, 1991, BIOESSAYS, V13, P675, DOI 10.1002/bies.950131210; CARPENTER AT, 1973, GENETICS, V73, P393; CARPENTER ATC, 1991, CELL, V64, P885, DOI 10.1016/0092-8674(91)90313-N; CARPENTER ATC, 1984, COLD SPRING HARB SYM, V49, P23, DOI 10.1101/SQB.1984.049.01.005; CASSIMERIS L, 1994, J CELL SCI, V107, P285; CLARKE L, 1990, MOL CELL BIOL, V10, P1863, DOI 10.1128/MCB.10.5.1863; FULLER MT, 1995, CELL, V81, P5, DOI 10.1016/0092-8674(95)90364-X; HAWLEY RS, 1993, DEV GENET, V13, P440; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; HSIEH T, 1979, J MOL BIOL, V135, P465, DOI 10.1016/0022-2836(79)90447-9; John B, 1988, HETEROCHROMATIN MOL, P1; KARPEN GH, 1992, GENETICS, V132, P737; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KARPEN GH, 1990, CELL, V63, P97; King R. C., 1970, OVARIAN DEV DROSOPHI; KNOWLES BA, 1991, P NATL ACAD SCI USA, V88, P7165, DOI 10.1073/pnas.88.16.7165; LE MH, IN PRESS GENETICS; LICA LM, 1986, J CELL BIOL, V103, P1145, DOI 10.1083/jcb.103.4.1145; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; RASOOLY RS, 1991, GENETICS, V129, P409; REGAN CL, 1988, GENE DEV, V2, P82, DOI 10.1101/gad.2.1.82; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLEISTER HM, 1992, NUCLEIC ACIDS RES, V20, P3419, DOI 10.1093/nar/20.13.3419; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; THOMPSON SD, 1994, P NATL ACAD SCI USA, V91, P9042; TOWER J, 1993, GENETICS, V133, P347; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WRIGHT TRF, 1974, GENETICS, V76, P511; ZHANG P, 1993, GENETICS, V133, P361; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHANG P, 1990, GENETICS, V125, P115	37	55	57	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					139	148		10.1016/0092-8674(95)90378-X	http://dx.doi.org/10.1016/0092-8674(95)90378-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720069	Bronze			2022-12-24	WOS:A1995QR97000015
J	VALDIVIA, HH; KAPLAN, JH; ELLISDAVIES, GCR; LEDERER, WJ				VALDIVIA, HH; KAPLAN, JH; ELLISDAVIES, GCR; LEDERER, WJ			RAPID ADAPTATION OF CARDIAC RYANODINE RECEPTORS - MODULATION BY MG2+ AND PHOSPHORYLATION	SCIENCE			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE CHANNEL; DEPENDENT PROTEIN-KINASE; RAT VENTRICULAR MYOCYTES; SKELETAL-MUSCLE; ADENINE-NUCLEOTIDE; SINGLE-CHANNEL; CA-2+ RELEASE; HEART-MUSCLE; CA2+ RELEASE	Channel adaptation is a fundamental feature of sarcoplasmic reticulum calcium release channels (called ryanodine receptors, RyRs). It permits successive increases in the intracellular concentration of calcium (Ca2+) to repeatedly but transiently activate channels. Adaptation of RyRs in the absence of magnesium (Mg2+) and adenosine triphosphate is an extremely slow process (taking seconds). Photorelease of Ca2+ from nitrophenyl-EGTA, a photolabile Ca2+ chelator, demonstrated that RyR adaptation is rapid (milliseconds) in canine heart muscle when physiological Mg2+ concentrations are present. Phosphorylation of the RyR by protein kinase A increased the responsiveness of the channel to Ca2+ and accelerated the kinetics of adaptation. These properties of the RyR from heart may also be relevant to other cells in which multiple agonist-dependent triggering events regulate cellular functions.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR MED BIOTECHNOL,BALTIMORE,MD 21201; UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Pennsylvania			Lederer, William/B-1285-2010	Kaplan, Jack/0000-0002-7048-6574	NHLBI NIH HHS [HL25675, R01 HL025675, R01 HL036974, R01 HL030315, HL36974, R37 HL036974, HL30315] Funding Source: Medline; NIGMS NIH HHS [R01 GM053395, R01 GM039500] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030315, R01HL036974, R01HL025675, R37HL036974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500, R01GM053395] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARO I, 1993, J PHYSIOL-LONDON, V465, P21, DOI 10.1113/jphysiol.1993.sp019664; BERS DM, 1989, AM J PHYSIOL, V256, pC109, DOI 10.1152/ajpcell.1989.256.1.C109; BEUCKELMANN DJ, 1988, J PHYSIOL-LONDON, V405, P233, DOI 10.1113/jphysiol.1988.sp017331; CALLEWAERT G, 1988, P NATL ACAD SCI USA, V85, P2009, DOI 10.1073/pnas.85.6.2009; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HOLMBERG SRM, 1990, BIOCHIM BIOPHYS ACTA, V1022, P187, DOI 10.1016/0005-2736(90)90113-3; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEDERER WJ, 1990, SCIENCE, V251, P1371; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; OBRIEN PJ, 1986, CAN J VET RES, V50, P318; ONEILL SC, 1990, AM J PHYSIOL, V258, pC1165, DOI 10.1152/ajpcell.1990.258.6.C1165; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; STRAND MA, 1993, BIOCHIM BIOPHYS ACTA, V1175, P319, DOI 10.1016/0167-4889(93)90224-D; TAKASAGO T, 1989, J BIOCHEM-TOKYO, V106, P872, DOI 10.1093/oxfordjournals.jbchem.a122945; TATE CA, 1985, J BIOL CHEM, V260, P9618; TINKER A, 1992, J GEN PHYSIOL, V100, P479, DOI 10.1085/jgp.100.3.479; VALDIVIA HH, 1991, J BIOL CHEM, V266, P19135; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; VALDIVIA HH, UNPUB; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; YATANI A, 1988, J BIOL CHEM, V263, P9887	32	312	322	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1997	2000		10.1126/science.7701323	http://dx.doi.org/10.1126/science.7701323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701323	Green Accepted			2022-12-24	WOS:A1995QQ06800045
J	SHAWLOT, W; BEHRINGER, RR				SHAWLOT, W; BEHRINGER, RR			REQUIREMENT FOR LIM1 IN HEAD-ORGANIZER FUNCTION	NATURE			English	Article							HOMEO-BOX GENE; MOUSE EMBRYOS; EXPRESSION PATTERN; FROG EMBRYOS; INDUCTION; DOMAIN; CELLS; GASTRULATION; HOMEODOMAIN; ELEGANS	Lim1 is a homeobox gene expressed in the organizer region of mouse embryos. To investigate the role of Lim1 during embryogenesis, a targeted deletion of the Lim1 gene was generated in embryonic stem cells. Embryos homozygous for the null allele lacked anterior head structures but the remaining body axis developed normally. A partial secondary axis developed anteriorly in some mutant embryos. Lim1 is thus an essential regulator of the vertebrate head organizer.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, DEVELOPMENT, V120, P2979; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; BEDDINGTON RSP, 1992, POSTIMPLANTATION DEV, P55; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CONLON FL, 1994, DEVELOPMENT, V120, P1919; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; DOWNS KM, 1993, DEVELOPMENT, V118, P1255; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GERHART J, 1991, GASTRULATION MOVEMEN, P57; GONT LK, 1993, DEVELOPMENT, V119, P991; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; JURAND A, 1974, J EMBRYOL EXP MORPH, V32, P1; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEIR S, 1982, DIFFERENTIATION, V117, P96; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; SASAKI H, 1993, DEVELOPMENT, V118, P47; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SORIANO P, 1991, CELL, V64, P694; Spemann H, 1927, NATURWISSENSCHAFTEN, V15, P946, DOI 10.1007/BF01506755; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPEMANN H, 1931, ROUX ARCH ENTW MECH, V123, P389; TAIRA M, 1994, DEVELOPMENT, V120, P1525; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TAM PPL, 1992, POSTIMPLANTATION DEV, P27; THEILER K, 1989, HOUSE MOUSE; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WADDINGTON CH, 1932, J EXP BIOL, V10, P38; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YAMADA T, 1994, DEVELOPMENT, V120, P3051; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	50	644	655	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					425	430		10.1038/374425a0	http://dx.doi.org/10.1038/374425a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700351				2022-12-24	WOS:A1995QP89900049
J	YANG, YZ; NISWANDER, L				YANG, YZ; NISWANDER, L			INTERACTION BETWEEN THE SIGNALING MOLECULES WNT7A AND SHH DURING VERTEBRATE LIMB DEVELOPMENT - DORSAL SIGNALS REGULATE ANTEROPOSTERIOR PATTERNING	CELL			English	Article							APICAL ECTODERMAL RIDGE; CHICK-EMBRYO; BUD CELLS; MOUSE; GENES; EXPRESSION; SPECIFICATION; DROSOPHILA	Growth and patterning of the vertebrate limb are controlled by the ridge, posterior mesenchyme, and nonridge ectoderm. Fibroblast growth factor 4 (FGF4) and Sonic hedgehog (SHH) can mediate signaling from the ridge and posterior mesenchyme, respectively. Here we show that do rsal ectoderm is required together with FGF4 to maintain Shh expression. Removal of dorsal ectoderm results in loss of posterior skeletal elements, which can be rescued by exogenous SHH. Wnt7a, which is expressed in dorsal ectoderm, provides the signal required for Shh expression and formation of posterior structures. These results provide evidence that all three axes (dorsoventral, proximodistal, and anteroposterior) are intimately linked by the respective signals WNT7a, FGF4, and SHH during limb outgrowth and patterning.	MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University			Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON R, 1993, DEVELOPMENT, V117, P1421; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FEKETE DM, 1993, P NATL ACAD SCI USA, V90, P2350, DOI 10.1073/pnas.90.6.2350; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HELMS J, 1994, DEVELOPMENT, V120, P3267; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MARTIN P, 1986, DEV BIOL, V118, P233, DOI 10.1016/0012-1606(86)90091-6; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARR BA, 1993, DEVELOPMENT, V119, P247; PARR BA, 1995, IN PRESS NATURE; PAUTOU MP, 1977, VERTEBRATE LIMB SOMI, P257; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VOGEL A, 1993, DEVELOPMENT, V119, P199	41	271	279	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					939	947		10.1016/0092-8674(95)90297-X	http://dx.doi.org/10.1016/0092-8674(95)90297-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697724	hybrid			2022-12-24	WOS:A1995QP61200013
J	FRUH, K; AHN, K; DJABALLAH, H; SEMPE, P; VANENDERT, PM; TAMPE, R; PETERSON, PA; YANG, Y				FRUH, K; AHN, K; DJABALLAH, H; SEMPE, P; VANENDERT, PM; TAMPE, R; PETERSON, PA; YANG, Y			A VIRAL INHIBITOR OF PEPTIDE TRANSPORTERS FOR ANTIGEN PRESENTATION	NATURE			English	Article							ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; MHC; COMPLEX; TRANSLOCATION; MOLECULES; GOLGI	CYTOTOXIC T lymphocytes lyse target cells after T-cell-receptor-mediated recognition of class I major histocompatibility complex molecules presenting peptides(1). Antigenic peptides are generated in the cytoplasm by proteasomes(2) and translocated into the lumen of the endoplasmic reticulum (ER) by peptide transporters (TAP)3-6. Herpes simplex virus (HSV) expresses a cytoplasmic protein, ICP47, which seems to interfere with such immune surveillance by mediating retention of 'empty' class I molecules in the ER(7,8). BY expressing ICP47 in HeLa cells under an inducible promoter(9), we show that ICP47 efficiently inhibits peptide transport across the ER membrane such that nascent class I molecules fail to acquire antigenic peptides. This inhibition was overcome by transfecting murine TAP. Further, we demonstrate that ICP47 colocalizes and physically associates with TAP within the cell, Inhibition of peptide translocation by a viral protein indicates a previously undocumented potential mechanism for viral immune evasion.	HOP NECKER ENFANTS MALAD, INSERM, U25, F-75743 PARIS 15, FRANCE; MAX PLANCK INST BIOCHEM, STRUKT BIOL ABT, D-82152 MARTINSRIED, GERMANY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Max Planck Society	FRUH, K (corresponding author), SCRIPPS RES INST, RW JOHNSON PHARMACEUT RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		; Tampe, Robert/H-2953-2015	Djaballah, Hakim/0000-0002-6039-0181; van Endert, Peter/0000-0003-3782-0750; Frueh, Klaus/0000-0001-8014-3877; Tampe, Robert/0000-0002-0403-2160				ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HILL AB, 1994, J IMMUNOL, V152, P2736; JACKSON MR, 1993, ANNU REV CELL BIOL, V9, P207, DOI 10.1146/annurev.cb.09.110193.001231; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; PARHAM P, 1979, J IMMUNOL, V123, P342; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; YANG Y, 1992, J BIOL CHEM, V267, P11669; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	22	525	539	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					415	418		10.1038/375415a0	http://dx.doi.org/10.1038/375415a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760936				2022-12-24	WOS:A1995RB10100056
J	LENNON, VA; KRYZER, TJ; GRIESMANN, GE; OSUILLEABHAIN, PE; WINDEBANK, AJ; WOPPMANN, A; MILJANICH, GP; LAMBERT, EH				LENNON, VA; KRYZER, TJ; GRIESMANN, GE; OSUILLEABHAIN, PE; WINDEBANK, AJ; WOPPMANN, A; MILJANICH, GP; LAMBERT, EH			CALCIUM-CHANNEL ANTIBODIES IN THE LAMBERT-EATON SYNDROME AND OTHER PARANEOPLASTIC SYNDROMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL LUNG-CARCINOMA; AMYOTROPHIC-LATERAL-SCLEROSIS; MYASTHENIC SYNDROME ANTIGEN; ACETYLCHOLINE-RECEPTORS; CA2+ CHANNELS; IGG; AUTOANTIBODIES; PROTEIN; ACTIVATION; RI	Background. Voltage-gated calcium channels in small-cell lung carcinomas may initiate autoimmunity in the paraneoplastic neuromuscular disorder Lambert-Eaton syndrome. The calcium-channel subtype that is responsible is not known. Methods. We compared the effects of antagonists of L-type, N-type, and P/Q-type neuronal calcium channels on the depolarization-dependent influx of calcium-45 in cultured carcinoma cells. Serum samples from patients with various disorders were tested for reactivity with P/Q-type channels solubilized from carcinoma and cerebellar membranes and N-type channels from cerebral cortex. Results. P/Q-type calcium-channel antagonists were the most potent inhibitors of depolarization-induced Ca-45 influx in cultured small-cell carcinoma cell lines. Anti-P/Q-type calcium-channel antibodies were found in serum from all 32 patients with the Lambert-Eaton syndrome and a diagnosis of cancer and in 91 percent of the 33 patients with the Lambert-Eaton syndrome without cancer. Anti-N-type calcium-channel antibodies were found in 49 percent of the 65 patients with the Lambert-Eaton syndrome. Lower titers of anti-P/Q-type and anti-N-type calcium-channel antibodies were found in 54 percent of 70 patients with a paraneoplastic encephalomyeloneuropathic complication of lung, ovarian, or breast carcinoma, 24 percent of 90 patients with cancer but no evident neurologic complications, 23 percent of 78 patients with sporadic amyotrophic lateral sclerosis, and less than 3 percent of 69 patients with myasthenia gravis, epilepsy, or scleroderma. Conclusions. The high frequency of P/Q-type calcium-channel antibodies found in patients with the Lambert-Eaton syndrome implies that antibodies of this specificity have a role in the presynaptic pathophysiology of this disorder.	MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT LAB MED,ROCHESTER,MN 55905; NEUREX CORP,MENLO PK,CA	Mayo Clinic; Mayo Clinic; Mayo Clinic				O'Suilleabhain, Padraig/0000-0002-2981-4791	NATIONAL CANCER INSTITUTE [R01CA037343] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37343] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; CODIGNOLA A, 1993, J BIOL CHEM, V268, P26240; CUNNINGHAM JM, 1985, J NEUROCHEM, V45, P159, DOI 10.1111/j.1471-4159.1985.tb05488.x; DEAIZPURUA HJ, 1988, CANCER RES, V48, P4719; FUKUNAGA H, 1983, P NATL ACAD SCI-BIOL, V80, P7636, DOI 10.1073/pnas.80.24.7636; FURNEAUX HM, 1990, NEW ENGL J MED, V322, P1844, DOI 10.1056/NEJM199006283222604; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; KIERS L, 1991, MAYO CLIN PROC, V66, P1209, DOI 10.1016/S0025-6196(12)62471-9; KRISTIPATI R, 1994, MOL CELL NEUROSCI, V5, P219, DOI 10.1006/mcne.1994.1026; LAMBERT EH, 1988, MUSCLE NERVE, V11, P1133, DOI 10.1002/mus.880111105; Lennon V, 1994, HDB MYASTHENIA GRAVI, P149; LENNON V A, 1990, Annals of Neurology, V28, P281; Lennon V. A., 1993, Society for Neuroscience Abstracts, V19, P1753; LENNON VA, 1994, NEUROLOGY, V44, P2236, DOI 10.1212/WNL.44.12.2236; LENNON VA, 1994, NEUROLOGY, V44, P2412, DOI 10.1212/WNL.44.12.2412; LENNON VA, 1989, MAYO CLIN PROC, V64, P1498, DOI 10.1016/S0025-6196(12)65705-X; LENNON VA, 1994, MUSCLE NERVE       S, V1, pS22; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LEYS K, 1991, ANN NEUROL, V29, P307, DOI 10.1002/ana.410290313; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P11743, DOI 10.1073/pnas.90.24.11743; LOOSER P, 1980, SCHWEIZ MED WSCHR, V110, P1342; LUQUE FA, 1991, ANN NEUROL, V29, P241, DOI 10.1002/ana.410290303; MCCANN FV, 1981, SCIENCE, V212, P1155, DOI 10.1126/science.6262914; Oguro-Okano M., 1993, Society for Neuroscience Abstracts, V19, P1755; OGUROOKANO M, 1992, MAYO CLIN PROC, V67, P1150, DOI 10.1016/S0025-6196(12)61144-6; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; OSUILLEABHAIN PE, 1994, NEUROLOGY, V44, pA157; ROBERTS A, 1985, NATURE, V317, P737, DOI 10.1038/317737a0; ROSENFELD MR, 1993, ANN NEUROL, V33, P113, DOI 10.1002/ana.410330126; SHER E, 1989, LANCET, V2, P640; SHER E, 1991, FASEB J, V5, P2677, DOI 10.1096/fasebj.5.12.1655547; SMITH RG, 1992, NEW ENGL J MED, V327, P1721, DOI 10.1056/NEJM199212103272405; SUGIURA Y, 1995, J NEUROCYTOL, V24, P15, DOI 10.1007/BF01370157; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TRIGGLE DJ, 1989, TRENDS PHARMACOL SCI, V10, P507, DOI 10.1016/0165-6147(89)90051-5; UCHITEL OD, 1992, P NATL ACAD SCI USA, V89, P330; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WILLIAMS CL, 1990, J BIOL CHEM, V265, P1443; WILLIAMS CL, 1991, CELL REGUL, V2, P373, DOI 10.1091/mbc.2.5.373; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	41	425	439	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1467	1474		10.1056/NEJM199506013322203	http://dx.doi.org/10.1056/NEJM199506013322203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739683				2022-12-24	WOS:A1995RA14000003
J	LEGUENNO, B; FORMENTRY, P; WYERS, M; GOUNON, P; WALKER, F; BOESCH, C				LEGUENNO, B; FORMENTRY, P; WYERS, M; GOUNON, P; WALKER, F; BOESCH, C			ISOLATION AND PARTIAL CHARACTERIZATION OF A NEW STRAIN OF EBOLA VIRUS	LANCET			English	Article							ZAIRE; SUDAN	We have isolated a new strain of Ebola virus from a nonfatal human case infected during the autopsy of a wild chimpanzee in the Cote-d'lvoire. The wild troop to which this animal belonged has been decimated by outbreaks of haemorrhagic syndromes. This is the first time that a human infection has been connected to naturally-infected monkeys in Africa. Data from the long-term survey of this troop of chimpanzees could answer questions about the natural reservoir of the Ebola virus.	LAB CENT PATHOL ANIM,BINGERVILLE,COTE IVOIRE; ECOLE NATL VET,HISTOPATHOL ANIM LAB,F-44087 NANTES 30,FRANCE; INST PASTEUR,SERV MICROSCOPIE ELECTR,F-75724 PARIS 15,FRANCE; CHU BICHAT,HISTOPATHOL LAB,F-75877 PARIS 18,FRANCE; UNIV BASEL,INST ZOOL,CH-4051 BASEL,SWITZERLAND; CTR SUISSE RECH SCI,ABIDJAN,COTE IVOIRE	Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Basel	LEGUENNO, B (corresponding author), INST PASTEUR,WHO,COLLABORATING CTR ARBOVIRUSES & HAEMORRHAG FEVERS,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							[Anonymous], 1978, Bull World Health Organ, V56, P271; [Anonymous], 1978, Bull World Health Organ, V56, P247; BARON RC, 1983, B WORLD HEALTH ORGAN, V61, P997; BASKERVILLE A, 1978, J PATHOL, V125, P131, DOI 10.1002/path.1711250303; BOESCH C, 1989, AM J PHYS ANTHROPOL, V78, P547, DOI 10.1002/ajpa.1330780410; EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541; HEYMANN DL, 1980, J INFECT DIS, V142, P372, DOI 10.1093/infdis/142.3.372; JAHRLING PB, 1990, LANCET, V335, P502, DOI 10.1016/0140-6736(90)90737-P; JOHNSON ED, 1993, T ROY SOC TROP MED H, V87, P536, DOI 10.1016/0035-9203(93)90077-4; JOHNSON KM, 1981, J INFECT DIS, V143, P749, DOI 10.1093/infdis/143.5.749; JOHNSON KM, 1977, LANCET, V1, P569; KSIAZEK TG, 1992, J CLIN MICROBIOL, V30, P947, DOI 10.1128/JCM.30.4.947-950.1992; MCCORMICK JB, 1983, J INFECT DIS, V147, P264, DOI 10.1093/infdis/147.2.264; MURPHY F, 1978, PATHOLOGY EBOLA VIRU	14	268	289	1	46	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1271	1274		10.1016/S0140-6736(95)90925-7	http://dx.doi.org/10.1016/S0140-6736(95)90925-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746057				2022-12-24	WOS:A1995QY93300009
J	CHERNOFF, YO; LINDQUIST, SL; ONO, B; INGEVECHTOMOV, SG; LIEBMAN, SW				CHERNOFF, YO; LINDQUIST, SL; ONO, B; INGEVECHTOMOV, SG; LIEBMAN, SW			ROLE OF THE CHAPERONE PROTEIN HSP104 IN PROPAGATION OF THE YEAST PRION-LIKE FACTOR [PSI(+)]	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; OMNIPOTENT SUPPRESSORS; SUP35 GENE; DNA DAMAGE; SCRAPIE; SYSTEM; PRP	The yeast non-Mendelian factor [psi(+)] has been suggested to be a self-modified protein analogous to mammalian prions. Here it is reported that an intermediate amount of the chaperone protein Hsp104 was required for the propagation of the [psi(+)] factor. Overproduction or inactivation of Hsp104 caused the loss of [psi(+)]. These results suggest that chaperone proteins play a role in prion-like phenomena, and that a certain level of chaperone expression can cure cells of prions without affecting viability. This may lead to antiprion treatments that involve the alteration of chaperone amounts or activity.	OKAYAMA UNIV, FAC PHARMACEUT SCI, OKAYAMA 700, JAPAN; ST PETERSBURG STATE UNIV, DEPT GENET, ST PETERSBURG 199034, RUSSIA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	Okayama University; Saint Petersburg State University; University of Chicago; Howard Hughes Medical Institute; University of Chicago	CHERNOFF, YO (corresponding author), UNIV ILLINOIS, DEPT BIOL SCI, CHICAGO, IL 60607 USA.		Inge-Vechtomov, Sergei G/L-4807-2013; Chernoff, Yury O/J-2833-2014	Inge-Vechtomov, Sergei G/0000-0002-2832-6825; Chernoff, Yury/0000-0002-8934-9051				AIGLE M, COMMUNICATION; BOREHAM DR, 1994, RADIAT RES, V137, P190, DOI 10.2307/3578811; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; CHEMOFF YO, UNPUB; CHERNOFF YO, 1992, BIOCHIMIE, V74, P455, DOI 10.1016/0300-9084(92)90086-T; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; CHERNOFF YO, 1992, NATO ASI SER H, V71, P101; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; COX B, 1994, CURR BIOL, V4, P744, DOI 10.1016/S0960-9822(00)00167-6; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; DOEL SM, 1994, GENETICS, V137, P659; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, P627; Kim G., UNPUB; KOUNAKOV KA, UNPUB; LIEBMAN SW, 1979, J BACTERIOL, V139, P1068, DOI 10.1128/JB.139.3.1068-1071.1979; MAGEE T, COMMUNICATION; MCCLANAHAN T, 1984, MOL CELL BIOL, V4, P2356, DOI 10.1128/MCB.4.11.2356; MCCLANAHAN T, 1986, MOL CELL BIOL, V6, P90, DOI 10.1128/MCB.6.1.90; MURAMATSU T, 1993, PHOTOCHEM PHOTOBIOL, V58, P809, DOI 10.1111/j.1751-1097.1993.tb04974.x; ONO B, 1991, CURR GENET, V19, P243, DOI 10.1007/BF00355049; ONO BI, 1986, GENETICS, V114, P363; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PATINO M, UNPUB; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Rothstein R., 1985, DNA CLONING, VII, P45; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SCHIRMER E, UNPUB; SHERMAN F, 1986, LABORATORY COURSE MA; SIKORSKI RS, 1989, GENETICS, V122, P19; STONE DE, 1990, MOL CELL BIOL, V10, P1622, DOI 10.1128/MCB.10.4.1622; Surguchovs AP, 1984, PHYSICOCHEMICAL BIOL, V4, P147; TAULIEN J, UNPUB; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; Tikhodeev O.N., 1990, MOL MECH GENETIC PRO, P218; TREGER JM, 1988, MOL CELL BIOL, V8, P1132, DOI 10.1128/MCB.8.3.1132; TUITE MF, 1994, NATURE, V370, P327, DOI 10.1038/370327a0; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WAKEM LP, 1990, GENETICS, V124, P515; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	48	884	903	2	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	1995	268	5212					880	884		10.1126/science.7754373	http://dx.doi.org/10.1126/science.7754373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754373				2022-12-24	WOS:A1995QX85000040
J	SPRINGER, PS; MCCOMBIE, WR; SUNDARESAN, V; MARTIENSSEN, RA				SPRINGER, PS; MCCOMBIE, WR; SUNDARESAN, V; MARTIENSSEN, RA			GENE TRAP TAGGING OF PROLIFERA, AN ESSENTIAL MCM2-3-5-LIKE GENE IN ARABIDOPSIS	SCIENCE			English	Article							MEDIATED ENHANCER DETECTION; REGULATORY ELEMENTS; CELL-CYCLE; DROSOPHILA; THALIANA; EXPRESSION; AMPLIFICATION; MERISTEM; MUTATION; EXCISION	Gene trap transposon mutagenesis can identify essential genes whose functions in later development are obscured by an early lethal phenotype. In higher plants, many genes are required for haploid gametophyte viability, so that the phenotypic effects of their disruption cannot be readily observed in the diploid plant body. The PROLIFERA (PRL) gene, identified by gene trap transposon mutagenesis in Arabidopsis, is required for megagametophyte and embryo development. Reporter gene expression patterns revealed that PRL was expressed in dividing cells throughout the plant. PRL is related to the MCM2-3-5 family of yeast genes that are required for the initiation of DNA replication.	COLD SPRING HARBOR LAB,LITA ANNENBERG HAZEN GENOME CTR,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory				Sundaresan, Venkatesan/0000-0002-4670-0630; McCombie, W. Richard/0000-0003-1899-0682				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANCROFT I, 1993, PLANT CELL, V5, P631, DOI 10.1105/tpc.5.6.631; BANCROFT I, 1992, MOL GEN GENET, V233, P449, DOI 10.1007/BF00265443; BARKAN A, 1986, EMBO J, V5, P1421, DOI 10.1002/j.1460-2075.1986.tb04378.x; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BUSSEREAU F, 1993, YEAST, V9, P797, DOI 10.1002/yea.320090714; Carlson W. R., 1988, Corn and corn improvement. Third edition., P259; Cone K., 1989, Maize Genetics Cooperation News Letter, P68; CROXDALE J, 1992, DEV BIOL, V149, P158, DOI 10.1016/0012-1606(92)90272-I; DALTON S, COMMUNICATION; DAVIS EL, 1979, CAN J BOT, V57, P971, DOI 10.1139/b79-119; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; FOE VE, 1989, DEVELOPMENT, V107, P1; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FURNER IJ, 1993, PLANT J, V4, P917, DOI 10.1046/j.1365-313X.1993.04060917.x; GLEESON TJ, 1991, COMPUT APPL BIOSCI, V7, P398; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; GROSSNIKLAUS U, UNPUB; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HULSKAMP M, 1995, PLANT CELL, V7, P57, DOI 10.1105/tpc.7.1.57; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KARLINNEUMANN GA, 1991, PLANT CELL, V3, P573, DOI 10.1105/tpc.3.6.573; KAVANGH TA, 1987, EMBO J, V6, P3901; KERTBUNDIT S, 1991, P NATL ACAD SCI USA, V88, P5212, DOI 10.1073/pnas.88.12.5212; LONG D, 1993, P NATL ACAD SCI USA, V90, P10370, DOI 10.1073/pnas.90.21.10370; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; MARTINEZ MC, 1992, P NATL ACAD SCI USA, V89, P7360, DOI 10.1073/pnas.89.16.7360; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; ORRWEAVER TL, 1994, TRENDS GENET, V10, P321, DOI 10.1016/0168-9525(94)90035-3; Patterson E. B., 1978, Maize breeding and genetics. Section 8. Cytogenetics., P693; PYKE KA, 1991, J EXP BOT, V42, P1407, DOI 10.1093/jxb/42.11.1407; REDEI GP, 1965, GENETICS, V51, P857; SCOFIELD SR, 1993, CELL, V75, P507, DOI 10.1016/0092-8674(93)90385-4; SKARNES WC, 1990, BIO-TECHNOL, V8, P827, DOI 10.1038/nbt0990-827; SPRINGER PT, UNPUB; STEEVES TA, 1969, CAN J BOTANY, V47, P1367, DOI 10.1139/b69-195; SUNDARESAN V, UNPUB; TOPPING JF, 1991, DEVELOPMENT, V112, P1009; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; VIZIR IY, 1994, GENETICS, V137, P1111; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; 1991, PROGRAM MANUAL GCG P	48	206	230	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					877	880		10.1126/science.7754372	http://dx.doi.org/10.1126/science.7754372			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754372				2022-12-24	WOS:A1995QX85000039
J	FAN, CM; PORTER, JA; CHIANG, C; CHANG, DT; BEACHY, PA; TESSIERLAVIGNE, M				FAN, CM; PORTER, JA; CHIANG, C; CHANG, DT; BEACHY, PA; TESSIERLAVIGNE, M			LONG-RANGE SCLEROTOME INDUCTION BY SONIC HEDGEHOG - DIRECT ROLE OF THE AMINO-TERMINAL CLEAVAGE PRODUCT AND MODULATION BY THE CYCLIC-AMP SIGNALING PATHWAY	CELL			English	Article							POLARITY GENE HEDGEHOG; FLOOR PLATE; DROSOPHILA; NOTOCHORD; PROTEIN; EMBRYO	A long-range signal encoded by the Sonic hedgehog (Shh) gene has been implicated as the ventral patterning influence from the notochord that induces sclerotome and represses dermomyotome in somite differentiation. Long-range effects of hedgehog (hh) signaling have been suggested to result either from local induction of a secondary diffusible signal or from the direct action of the highly diffusible carboxyterminal product of HH autoproteolytic cleavage. Here we provide evidence that the long-range somite patterning effects of SHH are instead mediated by a direct action of the amino-terminal cleavage product. We also show that pharmacological manipulations to increase the activity of cyclic AMP-dependent protein kinase A can selectively antagonize the effects of the amino-terminal cleavage product. Our results support the operation of a single evolutionarily conserved signaling pathway for both local and direct long-range inductive actions of HH family members.	UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL & NEUROSCI,SAN FRANCISCO,CA 94143; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Johns Hopkins University	FAN, CM (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.							BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BIRAGYN A, 1994, J IMMUNOL METHODS, V168, P235, DOI 10.1016/0022-1759(94)90060-4; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CHANG DT, 1994, DEVELOPMENT, V120, P3339; COLAMARINO SA, 1985, IN PRESS CELL, V81; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; JOHNSON RD, 1994, CELL, V79, P1166; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; KURATANI S, 1994, DEV BIOL, V161, P357, DOI 10.1006/dbio.1994.1037; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; READ AP, 1995, NAT GENET, V9, P333, DOI 10.1038/ng0495-333; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; ROELINK H, 1995, CELL, V81, P446; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TANABE Y, 1995, IN PRESS CURR BIOL; TEILLET MA, 1983, DEV BIOL, V98, P192, DOI 10.1016/0012-1606(83)90349-4; WATTERSON RL, 1954, AM J ANAT, V95, P337, DOI 10.1002/aja.1000950302; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I	43	319	340	1	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					457	465		10.1016/0092-8674(95)90398-4	http://dx.doi.org/10.1016/0092-8674(95)90398-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736597	hybrid			2022-12-24	WOS:A1995QW89400017
J	KUNANUSONT, C; FOY, HM; KREISS, JK; RERKSNGARM, S; PHANUPHAK, P; RAKTHAM, S; PAU, CP; YOUNG, NL				KUNANUSONT, C; FOY, HM; KREISS, JK; RERKSNGARM, S; PHANUPHAK, P; RAKTHAM, S; PAU, CP; YOUNG, NL			HIV-1 SUBTYPES AND MALE-TO-FEMALE TRANSMISSION IN THAILAND	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HETEROSEXUAL TRANSMISSION; DISEASE STAGE; RISK-FACTORS; TYPE-1; INFECTION; POPULATIONS; AIDS; PROSTITUTES; ASSOCIATION	We examined the risk factors for heterosexual transmission of HIV in a case-control study of couples in Thailand. 90 HIV-positive men and their regular sex partners were enrolled at the immune clinic, Chulalongkorn Hospital, where 92% of male index cases had HIV-1 serotype A (subtype E). Most index cases had acquired HIV through sexual intercourse. 95 couples were enrolled at 15 detoxification clinics, where 79% of them had HIV-1 serotype B (subtype B). Most men had acquired HIV through injecting drug use (IDU). The HIV seroconcordance rate was higher in the immune clinic (69%) than in the IDU clinics (48% overall, and 27% after excluding female partners who were IDUs) (p<0.01). The rate was also higher among couples in whom the male index case was infected with serotype A (subtype E) compared with serotype B (subtype B) (70% vs 52%, OR 2.1, 95% CI 1.2-4.2). When we excluded couples in whom the female was also an IDU, the difference in concordance rates was even more pronounced (70% vs 26%, OR 6.8, 95% CI 2.7-17.6). Viral factors or subjects' characteristics may have contributed to the concordance rates. In a multivariate logistic regression analysis, HIV-1 serotype A (subtype E) of male partners (adjusted OR 3.1, 95% CI 1.1-9.0) and history of IDU in female partners (adjusted OR 4.8, 95% CI 1.4-15.9) remained independently associated with HIV seroconcordance. This study suggests that HIV-1 subtype E may be associated with higher risk of heterosexual transmission than subtype B. If so, the predominance of subtype E in Thailand may have contributed to the rapid spread of the HIV epidemic.	UNIV WASHINGTON,SEATTLE,WA 98195; CHULALONGKORN HOSP,BANGKOK,THAILAND; BANGKOK METROPOLITAN ADM,BANGKOK,THAILAND; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341; HIV AIDS COLLABORAT,NONTHABURI,THAILAND	University of Washington; University of Washington Seattle; Chulalongkorn University; Centers for Disease Control & Prevention - USA	KUNANUSONT, C (corresponding author), MINIST PUBL HLTH,DEPT COMMUNICABLE DIS CONTROL,DIV AIDS,NONTHABURI 11000,THAILAND.				FOGARTY INTERNATIONAL CENTER [D43TW000007] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW00007] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; AUWANIT W, 1990, Southeast Asian Journal of Tropical Medicine and Public Health, V21, P53; BONGAARTS J, 1989, AIDS, V3, P373, DOI 10.1097/00002030-198906000-00006; CAMERON DW, 1989, LANCET, V2, P403; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHOTPITAYASUNON.T, 1994, 10TH INT C AIDS YOK; DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083; FIORE JR, 1993, AIDS, V7, P29, DOI 10.1097/00002030-199301000-00004; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; HAMED KA, 1993, J INFECT DIS, V167, P798, DOI 10.1093/infdis/167.4.798; HOLMES KK, 1988, J ACQ IMMUN DEF SYND, V1, P602; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3; MCCUTCHAN FE, 1992, AIDS RES HUM RETROV, V8, P1887, DOI 10.1089/aid.1992.8.1887; MOSS GB, 1991, J INFECT DIS, V164, P588, DOI 10.1093/infdis/164.3.588; MYERS G, 1992, HUMAN RETROVIRUSES A; OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3; OU CY, 1992, AIDS RES HUM RETROV, V8, P1471, DOI 10.1089/aid.1992.8.1471; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005; PAU CP, 1993, 1ST NAT C HUM RETR R; PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; WENIGER B, 1994, 10TH INT C AIDS YOK; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; 1992, BRIT MED J, V304, P809	30	164	168	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1078	1083						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715340				2022-12-24	WOS:A1995QV41100010
J	KING, RW; PETERS, JM; TUGENDREICH, S; ROLFE, M; HIETER, P; KIRSCHNER, MW				KING, RW; PETERS, JM; TUGENDREICH, S; ROLFE, M; HIETER, P; KIRSCHNER, MW			A 20S COMPLEX CONTAINING CDC27 AND CDC16 CATALYZES THE MITOSIS-SPECIFIC CONJUGATION OF UBIQUITIN TO CYCLIN-B	CELL			English	Article							MATURATION-PROMOTING FACTOR; CELL-CYCLE; ASPERGILLUS-NIDULANS; CLAM EMBRYO; DEGRADATION; PROTEIN; EXTRACTS; ANAPHASE; DESTRUCTION; KINASE	Cyclin B is degraded at the onset of anaphase by a ubiquitin-dependent proteolytic system. We have fractionated mitotic Xenopus egg extracts to identify components required for this process. We find that UBC4 and at least one other ubiquitin-conjugating enzyme can support cyclin B ubiquitination. The mitotic specificity of cyclin ubiquitination is determined by a 20S complex that contains homologs of budding yeast CDC16 and CDC27. Because these proteins are required for anaphase in yeast and mammalian cells, we refer to this complex as the anaphase-promoting complex (APC). CDC27 antibodies deplete APC activity, while immunopurified CDC27 complexes are sufficient to complement either interphase extracts or a mixture of recombinant UBC4 and the ubiquitin-activating enzyme E1. These results suggest that APC functions as a regulated ubiquitin-protein ligase that targets cyclin B far destruction in mitosis.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; MITOTIX INC, CAMBRIDGE, MA 02139 USA	Johns Hopkins University	KING, RW (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.				NIGMS NIH HHS [GM26875-17, GM39023-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039023, R01GM026875, R37GM026875] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BAILLY E, 1992, J CELL SCI, V101, P529; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; ENGLE DB, 1988, CELL MOTIL CYTOSKEL, V10, P432, DOI 10.1002/cm.970100310; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIROD PA, 1993, J BIOL CHEM, V268, P955; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; IRNIGER S, 1995, CELL, V81; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; KUANG J, 1991, P NATL ACAD SCI USA, V88, P11530, DOI 10.1073/pnas.88.24.11530; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MALDONADOCODINA G, 1992, J CELL BIOL, V116, P967, DOI 10.1083/jcb.116.4.967; MIRABITO PM, 1993, J CELL BIOL, V120, P959, DOI 10.1083/jcb.120.4.959; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; ODONNELL KL, 1991, J CELL SCI, V99, P711; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHWARTZ AL, 1992, P NATL ACAD SCI USA, V89, P5542, DOI 10.1073/pnas.89.12.5542; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SUAKIN V, 1995, MOL BIOL CELL, V6, P185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81; VANDRE DD, 1986, EUR J CELL BIOL, V41, P72	45	824	836	0	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					279	288		10.1016/0092-8674(95)90338-0	http://dx.doi.org/10.1016/0092-8674(95)90338-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736580	hybrid			2022-12-24	WOS:A1995QV41000017
J	INGERSOLL, AP; KANAMORI, H				INGERSOLL, AP; KANAMORI, H			WAVES FROM THE COLLISIONS OF COMET SHOEMAKER-LEVY-9 WITH JUPITER	NATURE			English	Article							VOYAGER	OBSERVATIONS Of the collisions of the fragments of comet Shoemaker-levy 9 with Jupiter provided an unprecedented opportunity to probe the depths of the planet's atmosphere, Images taken by the Hubble Space Telescope revealed circular rings surrounding five of the impact sites(1). The rings were observed for up to 2.5 hours after the impacts and spread at a constant velocity of 450 m s(-1). There are three types of disturbance that might explain these observations: acoustic waves trapped at the tropopause temperature minimum(2), gravity waves propagating vertically and horizontally in the stratosphere(3), and gravity waves trapped in a stable layer which acts as a horizontal waveguide and is located within the hypothesized tropospheric water cloud(4). Here we show that only the last of these phenomena fan match the speed and relative amplitude of the observed waves, with the requirement that the impacts were deep and the stability of the trapping layer is large. The origin of the stable layer is still uncertain, but if it is produced by moist convection in the water cloud, then the ratio of oxygen to hydrogen on Jupiter must be surprisingly large-approximately ten times that on the Sun.			INGERSOLL, AP (corresponding author), CALTECH,DIV GEOL & PLANETARY SCI,PASADENA,CA 91125, USA.							ACHTERBERG RK, 1989, J ATMOS SCI, V46, P2448, DOI 10.1175/1520-0469(1989)046<2448:ANMATJ>2.0.CO;2; BJORAKER GL, 1986, ICARUS, V66, P579, DOI 10.1016/0019-1035(86)90093-X; CARLSON BE, 1992, ASTROPHYS J, V388, P648, DOI 10.1086/171182; CARLSON RW, IN P0RESS GEOPHYS RE; GOLDREICH P, 1990, ASTROPHYS J, V363, P694, DOI 10.1086/169376; GUILLOT T, 1994, ICARUS, V112, P354, DOI 10.1006/icar.1994.1189; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; HARRINGTON J, 1994, NATURE, V368, P525, DOI 10.1038/368525a0; Hubbard WB, 1989, ORIGIN EVOLUTION PLA, P539; INGERSOLL AP, 1994, GEOPHYS RES LETT, V21, P1083, DOI 10.1029/94GL01057; KANAMORI H, 1993, GEOPHYS RES LETT, V20, P2921, DOI 10.1029/93GL03187; LINDAL GF, 1981, J GEOPHYS RES-SPACE, V86, P8721, DOI 10.1029/JA086iA10p08721; LINDZEN RS, 1968, MON WEATHER REV, V96, P133, DOI 10.1175/1520-0493(1968)096<0133:OIAWT>2.0.CO;2; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426; [No title captured]	15	60	62	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					706	708		10.1038/374706a0	http://dx.doi.org/10.1038/374706a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715724				2022-12-24	WOS:A1995QU30400044
J	BROWN, JS; WELLS, F; DUCKWORTH, G; PAUL, EA; BARNES, NC				BROWN, JS; WELLS, F; DUCKWORTH, G; PAUL, EA; BARNES, NC			IMPROVING NOTIFICATION RATES FOR TUBERCULOSIS	BRITISH MEDICAL JOURNAL			English	Article									LONDON CHEST HOSP,E LONDON TB CTR,LONDON E2 9JX,ENGLAND; ROYAL LONDON HOSP,COMMUNICABLE DIS CONTROL E LONDON & CITY HLTH AUT,LONDON E1 1BB,ENGLAND; ROYAL LONDON HOSP,COLL MED,DEPT EPIDEMIOL & MED STAT,LONDON E1 2AD,ENGLAND	University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital; Barts Health NHS Trust; Royal London Hospital								[Anonymous], 1978, Tubercle, V59, P245; CAPEWELL S, 1984, BRIT J DIS CHEST, V78, P317; HICKMAN M, 1992, BRIT MED J, V304, P1567, DOI 10.1136/bmj.304.6841.1567-c; SHELDON CD, 1992, THORAX, V47, P1015, DOI 10.1136/thx.47.12.1015	4	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					974	974		10.1136/bmj.310.6985.974	http://dx.doi.org/10.1136/bmj.310.6985.974			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728034	Green Published			2022-12-24	WOS:A1995QT90400021
J	MAGEE, JC; JOHNSTON, D				MAGEE, JC; JOHNSTON, D			SYNAPTIC ACTIVATION OF VOLTAGE-GATED CHANNELS IN THE DENDRITES OF HIPPOCAMPAL PYRAMIDAL NEURONS	SCIENCE			English	Article							LONG-TERM POTENTIATION; CA2+ CHANNELS; CALCIUM CHANNELS; GUINEA-PIG; P-TYPE; CELLS; RAT; SODIUM; CA1; DETERMINES	Activation of dendritic voltage-gated ion channels by local synaptic input was tested by simultaneous dendrite-attached patch-clamp recordings and whole-cell somatic voltage recordings made from CA1 pyramidal neurons in hippocampal slices. Schaffer collateral stimulation elicited subthreshold excitatory postsynaptic potentials (EPSPs) that opened voltage-gated sodium and calcium channels in the apical dendrites. The EPSP-activated sodium channels opened near the peak of the EPSP, whereas low voltage-activated calcium channels opened near the EPSP peak and during the decay phase. Dendritic high voltage-activated channels required somatic action potential generation or suprathreshold synaptic trains for activation. Dendritic voltage-gated channels are, therefore, likely to participate in dendritic integration of synaptic events.			MAGEE, JC (corresponding author), BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030, USA.				NIMH NIH HHS [MH44754] Funding Source: Medline; NINDS NIH HHS [NS09482, NS11535] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH044754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011535, P50NS011535] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALZHEIMER C, 1993, J NEUROSCI, V13, P660; ANDERSEN P, 1990, COLD SH Q B, V55, P81; CHRISTIE BR, IN PRESS J NEUROPHYS; DEISZ RA, 1991, J NEUROPHYSIOL, V65, P371, DOI 10.1152/jn.1991.65.2.371; ELLINOR PT, 1993, NATURE, V32, P455; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; FISHER RE, 1990, J NEUROPHYSIOL, V64, P91, DOI 10.1152/jn.1990.64.1.91; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Hille B., 1992, IONIC CHANNELS EXCIT; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JAFFE DB, 1993, J NEUROPHYSIOL, V71, P1065; JASLOVE SW, 1992, NEUROSCIENCE, V47, P495, DOI 10.1016/0306-4522(92)90161-T; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; MAGEE JC, IN PRESS J PHYSL LON; MARKRAM H, 1994, P NATL ACAD SCI USA, V91, P5207, DOI 10.1073/pnas.91.11.5207; MIYAKAWA H, 1992, NEURON, V9, P1163, DOI 10.1016/0896-6273(92)90074-N; MOGUL DJ, 1991, J PHYSIOL-LONDON, V433, P259, DOI 10.1113/jphysiol.1991.sp018425; ODELL TJ, 1991, J PHYSIOL-LONDON, V436, P739, DOI 10.1113/jphysiol.1991.sp018577; OGATA N, 1990, PFLUG ARCH EUR J PHY, V416, P594, DOI 10.1007/BF00382695; SAH P, 1988, J GEN PHYSIOL, V91, P373, DOI 10.1085/jgp.91.3.373; SCHNEIDER T, 1994, BIOPHYS J, V66, pA423; SPRUSTON N, 1994, TRENDS NEUROSCI, V17, P161, DOI 10.1016/0166-2236(94)90094-9; SPRUSTON N, 1993, J NEUROPHYSIOL, V70, P781, DOI 10.1152/jn.1993.70.2.781; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; THIBAULT O, 1993, P NATL ACAD SCI USA, V90, P11792, DOI 10.1073/pnas.90.24.11792; TRAUB RD, 1979, J NEUROPHYSIOL, V42, P476, DOI 10.1152/jn.1979.42.2.476; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WHITE G, 1990, J NEUROPHYSIOL, V64, P1186, DOI 10.1152/jn.1990.64.4.1186; ZHANG JF, 1993, NEUROPHARMACOLOGY, V363, P1075	34	358	363	0	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					301	304		10.1126/science.7716525	http://dx.doi.org/10.1126/science.7716525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716525				2022-12-24	WOS:A1995QT18500042
J	SCHNEEWIND, O; FOWLER, A; FAULL, KF				SCHNEEWIND, O; FOWLER, A; FAULL, KF			STRUCTURE OF THE CELL-WALL ANCHOR OF SURFACE-PROTEINS IN STAPHYLOCOCCUS-AUREUS	SCIENCE			English	Article							MALTOSE-BINDING-PROTEIN; GRAM-POSITIVE BACTERIA; SEQUENCE; GENE; RESISTANCE; REGION; LYSOSTAPHIN; ATTACHMENT; MEMBRANE	Many surface proteins are anchored to the cell wall of Gram-positive bacteria and are involved in the pathogenesis of these organisms. A hybrid molecule was designed that, when expressed in Staphylococcus aureus, was anchored to the cell wall and could be released by controlled enzymatic digestion. By a combination of molecular biology and mass spectrometry techniques, the structure of the cell wall anchor of surface proteins in S. aureus was revealed. After cleavage of surface proteins between threonine and glycine of the conserved LPXTG motif, the carboxyl of threonine is amide-linked to the free amino group of the pentaglycine crossbridge in the staphylococcal cell wall.	UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST NEUROPSYCHIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SCHNEEWIND, O (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024, USA.				NIAID NIH HHS [AI 33985] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033985] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWDER HP, 1965, BIOCHEM BIOPH RES CO, V19, P383, DOI 10.1016/0006-291X(65)90473-0; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FORSGREN A, 1969, ACTA PATHOL MIC SC, V75, P481; FOSTER TJ, 1994, FEMS MICROBIOL LETT, V118, P199, DOI 10.1016/0378-1097(94)90504-5; GAREN A, 1955, VIROLOGY, V1, P347, DOI 10.1016/0042-6822(55)90030-1; GHUYSEN J. M., 1965, BIOCHEMISTRY, V4, P2245, DOI 10.1021/bi00886a043; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GUSS B, 1984, EUR J BIOCHEM, V138, P413, DOI 10.1111/j.1432-1033.1984.tb07931.x; JONES CL, 1986, J BACTERIOL, V166, P29, DOI 10.1128/jb.166.1.29-33.1986; KEHOE MA, 1994, BACTERIAL CELL WALL, P217; LYON BR, 1987, MICROBIOL REV, V51, P88, DOI 10.1128/MMBR.51.1.88-134.1987; MOKS T, 1986, EUR J BIOCHEM, V156, P3577; MUNOZ E, 1967, BIOCHEMISTRY-US, V6, P3659, DOI 10.1021/bi00864a007; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PANCHOLI V, 1989, J EXP MED, V170, P2119, DOI 10.1084/jem.170.6.2119; PANCHOLI V, 1988, J BACTERIOL, V170, P2618, DOI 10.1128/jb.170.6.2618-2624.1988; PATEL AH, 1987, INFECT IMMUN, V55, P3103, DOI 10.1128/IAI.55.12.3103-3110.1987; PETIT JF, 1966, BIOCHEMISTRY-US, V5, P2765; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; RECSEI PA, 1987, P NATL ACAD SCI USA, V84, P1127, DOI 10.1073/pnas.84.5.1127; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; SCHOCKMAN GD, 1983, ANNU REV MICROBIOL, V37, P501; SJOQUIST J, 1972, EUR J BIOCHEM, V29, P572, DOI 10.1111/j.1432-1033.1972.tb02023.x; SJOQUIST J, 1972, EUR J BIOCHEM, V30, P190, DOI 10.1111/j.1432-1033.1972.tb02086.x; SLOAN GL, 1977, BIOCHEM J, V167, P293, DOI 10.1042/bj1670293; STROMINGER JL, 1967, SCIENCE, V156, P213, DOI 10.1126/science.156.3772.213; STROMINGER JL, 1967, FED PROC, V26, P9; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; UHLEN M, 1984, J BIOL CHEM, V259, P1695; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747; YOKOGAWA K, 1974, ANTIMICROB AGENTS CH, V6, P156, DOI 10.1128/AAC.6.2.156	38	372	408	0	36	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					103	106		10.1126/science.7701329	http://dx.doi.org/10.1126/science.7701329			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701329				2022-12-24	WOS:A1995QR45400036
J	BENTLEY, GA; BOULOT, G; KARJALAINEN, K; MARIUZZA, RA				BENTLEY, GA; BOULOT, G; KARJALAINEN, K; MARIUZZA, RA			CRYSTAL-STRUCTURE OF THE BETA-CHAIN OF A T-CELL ANTIGEN RECEPTOR	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; COMPLEX; RESOLUTION; REGION; FAB; IMMUNOGLOBULINS; RECOGNITION; SPECIFICITY; REFINEMENT; EXPRESSION	The crystal structure of the extracellular portion of the beta chain of a murine T cell antigen receptor (TCR), determined at a resolution of 1.7 angstroms, shows structural homology to immunoglobulins. The structure of the first and second hypervariable loops suggested that, in general, they adopt more restricted sets of conformations in TCR beta chains than those found in immunoglobulins; the third hypervariable loop had certain structural characteristics in common with those of immunoglobulin heavy chain variable domains. The variable and constant domains were in close contact, presumably restricting the flexibility of the beta chain. This may facilitate signal transduction from the TCR to the associated CD3 molecules in the TCR-CD3 complex.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850		BENTLEY, GA (corresponding author), INST PASTEUR,CNRS,UNITE IMMUNOL STRUCT 359,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Karjalainen, Klaus/A-2206-2011; Bentley, Graham/B-3623-2011					[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BOULOT G, 1994, J MOL BIOL, V235, P795, DOI 10.1006/jmbi.1994.1037; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1991, J MOL BIOL, V211, P239; CASORATI G, 1993, EUR J IMMUNOL, V23, P586, DOI 10.1002/eji.1830230246; CAZENAVE PA, 1990, CELL, V63, P717, DOI 10.1016/0092-8674(90)90138-5; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FIELDS BA, 1994, J MOL BIOL, V239, P339, DOI 10.1006/jmbi.1994.1373; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOCHSTENBACH F, 1990, J CLIN IMMUNOL, V10, P1, DOI 10.1007/BF00917493; JORES R, 1990, P NATL ACAD SCI USA, V87, P9138, DOI 10.1073/pnas.87.23.9138; Kabat EA, 1991, SEQUENCES PROTEINS I; KANG JS, 1994, J IMMUNOL, V152, P5305; KARJALAINEN K, 1994, CURR OPIN IMMUNOL, V6, P9, DOI 10.1016/0952-7915(94)90027-2; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; KUBO RT, 1989, J IMMUNOL, V142, P2736; LESK AM, 1988, NATURE, V335, P188, DOI 10.1038/335188a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PATTEN P, 1984, NATURE, V312, P40, DOI 10.1038/312040a0; PATTEN PA, 1993, J IMMUNOL, V150, P2281; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SAUL FA, 1992, PROTEINS, V14, P363, DOI 10.1002/prot.340140305; SCHIFFER M, 1973, BIOCHEMISTRY-US, V12, P4620, DOI 10.1021/bi00747a013; SIMON T, 1990, EMBO J, V9, P1056; TRAUNECKER A, 1991, TRENDS BIOTECHNOL, V9, P109, DOI 10.1016/0167-7799(91)90038-J; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	39	257	259	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1984	1987		10.1126/science.7701320	http://dx.doi.org/10.1126/science.7701320			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701320				2022-12-24	WOS:A1995QQ06800041
J	PANDIT, JC				PANDIT, JC			TESTING ACUITY OF VISION IN GENERAL-PRACTICE - REACHING RECOMMENDED STANDARD	BRITISH MEDICAL JOURNAL			English	Article									TORBAY HOSP,DEPT OPHTHALMOL,TORQUAY TQ2 7AA,DEVON,ENGLAND									BLACKHURST DW, 1989, RETINA-J RET VIT DIS, V9, P163, DOI 10.1097/00006982-198909030-00001; RAFFLE A, 1985, MED ASPECTS FITNESS; 1968, BS4274 BRIT STAND I	3	25	26	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1408	1408		10.1136/bmj.309.6966.1408	http://dx.doi.org/10.1136/bmj.309.6966.1408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7755711	Green Published			2022-12-24	WOS:A1994PU76400020
J	SHENKER, A; LAUE, L; KOSUGI, S; MERENDINO, JJ; MINEGISHI, T; CUTLER, GB				SHENKER, A; LAUE, L; KOSUGI, S; MERENDINO, JJ; MINEGISHI, T; CUTLER, GB			A CONSTITUTIVELY ACTIVATING MUTATION OF THE LUTEINIZING-HORMONE RECEPTOR IN FAMILIAL MALE PRECOCIOUS PUBERTY	NATURE			English	Article							ALPHA-1B-ADRENERGIC RECEPTOR; CHORIONIC-GONADOTROPIN; SEXUAL PRECOCITY; GENE; SUBSTITUTIONS; RHODOPSIN; RAT; LH	FAMILIAL male precocious puberty (FMP) is a gonadotropin-independent disorder that is inherited in an autosomal dominant, male-limited pattern1-5. Affected males generally exhibit signs of puberty by age 4. Testosterone production and Leydig cell hyperplasia occur in the context of prepubertal levels of luteinizing hormone (LH)3-5. The LH receptor is a member of the family of G-protein-coupled receptors6,7, and we hypothesized that FMPP might be due to a mutant receptor that is activated in the presence of little or no agonist8-12 . A single A --> G base change that results in substitution of glycine for aspartate at position 578 in the sixth transmembrane helix of the LH receptor was found in affected individuals from eight different families. Linkage of the mutation to FMPP was supported by restriction-digest analysis. COS-7 cells expressing the mutant LH receptor exhibited markedly increased cyclic AMP production in the absence of agonist, suggesting that autonomous Leydig cell activity in FMPP is caused by a constitutively activated LH receptor.	NIDDK,BIOCHEM & METAB LAB,CELL REGULAT SECT,BETHESDA,MD 20892; NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892; KYOTO UNIV,SCH MED,DEPT LAB MED,KYOTO 606,JAPAN; GUNMA UNIV,SCH MED,DEPT OBSTET & GYNECOL,MAEBASHI,GUNMA 371,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Kyoto University; Gunma University	SHENKER, A (corresponding author), NIDDK,MOLEC PATHOPHYSIOL BRANCH,BLDG 10,ROOM 8C-101,BETHESDA,MD 20892, USA.		KOSUGI, Shinji/GYR-2946-2022					ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; HOLLAND FJ, 1991, ENDOCRIN METAB CLIN, V20, P191, DOI 10.1016/S0889-8529(18)30288-3; HUNZICKERDUNN M, 1985, LUTEINIZING HORMONE, P57; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOSUGI S, 1993, MOL ENDOCRINOL, V7, P1009, DOI 10.1210/me.7.8.1009; LAUE L, 1989, NEW ENGL J MED, V320, P496, DOI 10.1056/NEJM198902233200805; LAUE L, 1993, J CLIN ENDOCR METAB, V76, P151, DOI 10.1210/jc.76.1.151; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; Myers R, 1989, PCR TECHNOLOGY PRINC, P71; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; OERTER KE, 1990, J CLIN ENDOCR METAB, V71, P1251, DOI 10.1210/jcem-71-5-1251; REN Q, 1993, J BIOL CHEM, V268, P16483; RIESNER D, 1989, ELECTROPHORESIS, V10, P377, DOI 10.1002/elps.1150100516; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; ROSENTHAL SM, 1983, J CLIN ENDOCR METAB, V57, P571, DOI 10.1210/jcem-57-3-571; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHEDEWIE HK, 1981, J CLIN ENDOCR METAB, V52, P271, DOI 10.1210/jcem-52-2-271; SKLAR CA, 1981, J CLIN ENDOCR METAB, V53, P656, DOI 10.1210/jcem-53-3-656; STONE RK, 1852, AM J M SC, V24, P561; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WALKER SH, 1952, J PEDIATR-US, V41, P251, DOI 10.1016/S0022-3476(52)80001-0; YAGHMAI R, 1992, P NATL ACAD SCI USA, V89, P7890, DOI 10.1073/pnas.89.17.7890	30	597	624	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					652	654		10.1038/365652a0	http://dx.doi.org/10.1038/365652a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	7692306	Green Published			2022-12-24	WOS:A1993MB84600060
J	KORF, B				KORF, B			MOLECULAR MEDICINE - MOLECULAR DIAGNOSIS .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											KORF, B (corresponding author), CHILDRENS HOSP,DIV GENET,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							COOPER DN, 1993, HUM GENET, V92, P211	1	20	20	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1499	1502		10.1056/NEJM199506013322208	http://dx.doi.org/10.1056/NEJM199506013322208			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739688				2022-12-24	WOS:A1995RA14000008
J	TAPLIN, ME; BUBLEY, GJ; SHUSTER, TD; FRANTZ, ME; SPOONER, AE; OGATA, GK; KEER, HN; BALK, SP				TAPLIN, ME; BUBLEY, GJ; SHUSTER, TD; FRANTZ, ME; SPOONER, AE; OGATA, GK; KEER, HN; BALK, SP			MUTATION OF THE ANDROGEN-RECEPTOR GENE IN METASTATIC ANDROGEN-INDEPENDENT PROSTATE-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STEROID BINDING; EXPRESSION; ACID; SEQUENCE; CELLS; IDENTIFICATION; INSENSITIVITY; DEFINITION; TRIALS; DOMAIN	Background. Metastatic prostate cancer is a leading cause of cancer-related death in men. The rate of response to androgen ablation is high, but most patients relapse as a result of the outgrowth of androgen-independent tumor cells. The androgen receptor, which binds testosterone and stimulates the transcription of androgen-responsive genes, regulates the growth of prostate cells. We analyzed the androgen-receptor genes from samples of metastatic androgen-independent prostate cancers to determine whether mutations in the gene have a role in androgen independence. Methods. Complementary DNA was synthesized from metastatic prostate cancers in 10 patients with androgen-independent prostate cancer, and the expression of the androgen-receptor gene was estimated by amplification with the polymerase chain reaction. Exons B through H of the gene were cloned, and mutations were identified by DNA sequencing. The functional effects of the mutations were assessed in cells transfected with mutant genes. Results. All androgen-independent tumors expressed high levels of androgen-receptor gene transcripts, relative to the levels expressed by an androgen-independent prostate-cancer cell line (LNCaP). Point mutations in the androgen-receptor gene were identified in metastatic cells from 5 of the 10 patients examined. One mutation was in the same codon as the mutation found previously in the androgen-independent prostate-cancer cell line. The mutations were not detected in the primary tumors from two of the patients. Functional studies of two of the mutant androgen receptors demonstrated that they could be activated by progesterone and estrogen. Conclusions. Most metastatic androgen-independent prostate cancers express high levels of androgen-receptor gene transcripts. Mutations in androgen-receptor genes are not uncommon and may provide a selective growth advantage after androgen ablation.	BETH ISRAEL HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; UNIV MASSACHUSETTS,MED CTR,DEPT MED,DIV ONCOL,WORCESTER,MA; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Beth Israel Deaconess Medical Center; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R29CA051438] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007516] Funding Source: NIH RePORTER; NCI NIH HHS [R-29 CA51438] Funding Source: Medline; NHLBI NIH HHS [HL07516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BORING CC, 1992, CA-CANCER J CLIN, V42, P127; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; COLOMBEL M, 1992, CANCER RES, V52, P4313; CRAWFORD ED, 1992, BRIT J UROL, V70, P33, DOI 10.1111/j.1464-410X.1992.tb15865.x; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; CULIG Z, 1993, PROSTATE, V22, P11, DOI 10.1002/pros.2990220103; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Dawson N A, 1993, Oncology (Williston Park), V7, P17; DAWSON NA, 1993, ONCOLOGY, V7, P2; Dawson NA, 1993, ONCOLOGY, V7, P17; DEBELLIS A, 1992, MOL ENDOCRINOL, V6, P1909, DOI 10.1210/me.6.11.1909; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUQUA SAW, 1993, J CELL BIOCHEM, V51, P135, DOI 10.1002/jcb.240510204; GADDIPATI JP, 1994, CANCER RES, V54, P2861; GUSSOW D, 1987, J IMMUNOL, V139, P3132; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KARNIK PS, 1994, CANCER RES, V54, P349; LUBAHN DB, 1990, P NATL ACAD SCI USA, V87, P4411; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MARCELLI M, 1990, MOL ENDOCRINOL, V4, P1105, DOI 10.1210/mend-4-8-1105; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P22, DOI 10.1210/mend-4-1-22; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; RISSTALPERS C, 1993, BIOCHEM BIOPH RES CO, V196, P173, DOI 10.1006/bbrc.1993.2231; SCHER HI, 1993, J CLIN ONCOL, V11, P1566, DOI 10.1200/JCO.1993.11.8.1566; SUZUKI H, 1993, J STEROID BIOCHEM, V46, P759, DOI 10.1016/0960-0760(93)90316-O; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VANTINTEREN H, 1993, CANCER-AM CANCER SOC, V72, P3847, DOI 10.1002/1097-0142(19931215)72:12+<3847::AID-CNCR2820721716>3.0.CO;2-J; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1	39	978	1028	2	39	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1393	1398		10.1056/NEJM199505253322101	http://dx.doi.org/10.1056/NEJM199505253322101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY941	7723794	Bronze			2022-12-24	WOS:A1995QY94100001
J	REJTO, PA; BINDEWALD, E; CHANDLER, D				REJTO, PA; BINDEWALD, E; CHANDLER, D			VISUALIZATION OF FAST ENERGY-FLOW AND SOLVENT CAGING IN UNIMOLECULAR DYNAMICS	NATURE			English	Article							CONFORMATIONAL ISOMERIZATION; TRANSITION-STATE; CYCLOHEXANE; LIQUIDS; RELAXATION; ACTIVATION	ENERGY flow in solution between physically or chemically evolving solute molecules and the surrounding solvent significantly affects the nature of chemical dynamics in liquids. It determines the extent to which the statistical theory of reaction rates(1,2) is valid; the transfer of energy between solute and solvent influences the ease with which the transition state evolves into the products-the process central to transition-state theory. But analysing the energy flow in liquid-phase dynamics is difficult because these systems are so complex, and the degrees of freedom are consequently so numerous. Here we present a way to address this challenge. We introduce an approach for visualizing the energy flow directly, and apply it to the isomerization of cyclohexane (between boat and chair conformations) in liquid carbon disulphide, a process for which detailed information about the molecular motions is available from molecular dynamics simulations(8). Our method reveals in pictorial form the formation and relaxation of a solvent cage, and shows that the relaxation has a strong effect on energy flow to and from the transition state on sub-picosecond timescales. We anticipate that this visualization approach will be generally useful for elucidating dynamical molecular processes in solution.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley			Rejto, Paul/M-4782-2019					ANDERSON JB, 1973, J CHEM PHYS, V58, P4684, DOI 10.1063/1.1679032; Bennett C. H., 1977, ACS SYM SER, V46, P63, DOI DOI 10.1021/BK-1977-0046.CH004; BORKOVEC M, 1986, J CHEM PHYS, V85, P146, DOI 10.1063/1.451651; CAMPBELL DM, 1992, J CHEM PHYS, V96, P2717, DOI 10.1063/1.462019; CHANDLER D, 1988, FARADAY DISCUSS, V85, P329, DOI 10.1039/dc9888500329; CHANDLER D, 1978, J CHEM PHYS, V68, P2959, DOI 10.1063/1.436049; CHANDLER D, 1983, SCIENCE, V220, P787, DOI 10.1126/science.220.4599.787; GERTNER BJ, 1991, J AM CHEM SOC, V113, P74, DOI 10.1021/ja00001a014; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; HASHA DL, 1981, J CHEM PHYS, V75, P1571, DOI 10.1063/1.442193; HASHA DL, 1982, J AM CHEM SOC, V104, P2290, DOI 10.1021/ja00372a029; JIMENEZ R, 1994, NATURE, V369, P471, DOI 10.1038/369471a0; Johnston H.S., 1966, GAS PHASE REACTION R; Keck J. C., 1967, ADV CHEM PHYS, V13, P85, DOI 10.1002/9780470140154.ch5; MILLER WH, 1976, ACCOUNTS CHEM RES, V9, P306, DOI 10.1021/ar50104a005; PATRON F, 1991, CHEM PHYS, V152, P121, DOI 10.1016/0301-0104(91)80039-K; PICKETT HM, 1970, J AM CHEM SOC, V92, P7281; REJTO PA, 1994, J PHYS CHEM-US, V98, P12310, DOI 10.1021/j100098a028; SINGER SJ, 1986, J PHYS CHEM-US, V90, P6015, DOI 10.1021/j100280a111; STRAUSS HL, 1971, J CHEM EDUC, V48, P221, DOI 10.1021/ed048p221; Wigner E, 1938, T FARADAY SOC, V34, P0029, DOI 10.1039/tf9383400029; WILSON MA, 1990, CHEM PHYS, V149, P11, DOI 10.1016/0301-0104(90)80127-J	22	11	11	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					129	131		10.1038/375129a0	http://dx.doi.org/10.1038/375129a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753167				2022-12-24	WOS:A1995QX74100045
J	FIELD, K; THOROGOOD, M; SILAGY, C; NORMAND, C; ONEILL, C; MUIR, J				FIELD, K; THOROGOOD, M; SILAGY, C; NORMAND, C; ONEILL, C; MUIR, J			STRATEGIES FOR REDUCING CORONARY RISK-FACTORS IN PRIMARY-CARE - WHICH IS MOST COST-EFFECTIVE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the relative cost effectiveness of a range of screening and intervention strategies for preventing coronary heart disease in primary care. Subjects-7840 patients aged 35-64 years who were participants in a trial of modifying coronary heart disease Ask factors in primary care. Design-Effectiveness of interventions assumed and the potential years of life gained estimated from a risk equation calculated from Framingham study data. Main outcome measure-The cost per year of life gained. Results-The most cost effective strategy was minimal screening of blood pressure and personal history of vascular disease, which cost pound 310-pound 930 per year of life gained for men and pound 1100-pound 3460 for women excluding treatment of raised blood pressure. The extra cost per life year gained by adding smoking history to the screening was pound 400-pound 6300 in men. AU strategies were more cost effective in men than in women and more cost effective in older age groups. Lipid lowering drugs accounted for at least 70% of the estimated costs of all strategies. Cost effectiveness was greatest when drug treatment was limited to those with cholesterol concentrations above 9.5 mmol/l. Conclusions-Universal screening and intervention strategies are an inefficient approach to reducing the coronary heart disease burden. A basic strategy for screening and intervention, targeted at older men with raised blood pressure and limiting the use of cholesterol lowering drugs to those with very high cholesterol concentrations would be most cost effective.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND; GWENT COLL,NEWPORT BUSINESS SCH,NEWPORT NP9 5XR,GWENT,WALES; FLINDERS UNIV S AUSTRALIA,SCH MED,DEPT GEN PRACTICE,ADELAIDE,SA 5001,AUSTRALIA; UNIV OXFORD,RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,GEN PRACTICE RES GRP,OXFORD OX2 6HE,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University of Wales Newport; Flinders University South Australia; Radcliffe Infirmary; University of Oxford				Normand, Charles/0000-0002-0885-5754				ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; LANGHAM SJ, 1994, HLTH CARE NEEDS ASSE, V1, P341; SILAGY C, 1994, J CLIN EPIDEMIOL, V47, P993, DOI 10.1016/0895-4356(94)90114-7; STOTT N, 1994, BRIT MED J, V308, P285, DOI 10.1136/bmj.308.6924.285; 1992, HLTH NATION STRATEGY; 1994, BRIT MED J, V308, P313; 1994, BRIT MED J, V308, P308; 1991, DH123 OFF POP CENS S	8	60	61	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1109	1112		10.1136/bmj.310.6987.1109	http://dx.doi.org/10.1136/bmj.310.6987.1109			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742678	Green Published			2022-12-24	WOS:A1995QW61800018
J	KEMP, KB				KEMP, KB			PUBLIC INFORMATION ON OSTEOPOROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											KEMP, KB (corresponding author), US CONGRESS, OFF TECHNOL ASSESSMENT, WASHINGTON, DC 20510 USA.							1994, PUBLIC INFORMATION O, P70801	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1082	1082		10.1001/jama.273.14.1082	http://dx.doi.org/10.1001/jama.273.14.1082			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707584				2022-12-24	WOS:A1995QR05900006
J	VARTIAINEN, E; SARTI, C; TUOMILEHTO, J; KUULASMAA, K				VARTIAINEN, E; SARTI, C; TUOMILEHTO, J; KUULASMAA, K			DO CHANGES IN CARDIOVASCULAR RISK-FACTORS EXPLAIN CHANGES IN MORTALITY FROM STROKE IN FINLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BLOOD-PRESSURE; COMMUNITY; TRENDS	Objectives-To estimate the extent to which the changes in the main cardiovascular risk factors (blood pressure, smoking, and serum cholesterol concentration) can explain the observed changes in mortality from stroke in Finland during the past 20 years. Design-Predicted changes in mortality from cerebrovascular disease mortality were calculated by a proportional hazards model from data obtained in cross sectional population surveys in 1972, 1977, 1982, 1987, and 1992. Predicted changes were compared with the observed changes in mortality statistics. Setting-North Karelia and Kuopio provinces, Finland. Subjects-16 741 men and 16 389 women aged 30-59 randomly selected from the national population register, of whom 14 054 men and 14 546 women participated. Main outcome measures-levels of risk factors and predicted and observed changes in mortality from cerebrovascular disease. Results-The observed changes in diastolic blood pressure, total serum cholesterol concentration, and smoking in the population from 1972 to 1992 predicted a 44% fall in mortality from stroke in men and changes in diastolic blood pressure and smoking predicted a 34% fall in women. The observed fall in mortality from stroke was 66% in men and 60% in women. Conclusions-Two thirds of the fall in mortality hom stroke in men and half in women can be explained by changes in the three main cardiovascular risk factors.			VARTIAINEN, E (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, MANNERHEIMINTIE 166, SF-00300 HELSINKI, FINLAND.			Kuulasmaa, Kari/0000-0003-2165-1411				BEEVERS DG, 1990, J HUM HYPERTENS, V4, P587; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DOBSON AJ, 1988, STAT MED, V7, P613, DOI 10.1002/sim.4780070508; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KAGAN A, 1980, STROKE, V11, P14, DOI 10.1161/01.STR.11.1.14; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAXWELL MH, 1982, LANCET, V2, P33; MENOTTI A, 1990, INT J EPIDEMIOL, V19, P309, DOI 10.1093/ije/19.2.309; PIETINEN P, 1990, INT CONGR SER, V953, P243; PUSKA P, 1985, PREV MED, V14, P573, DOI 10.1016/0091-7435(85)90078-7; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; STOKES J, 1989, HYPERTENSION, V13, P113; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TUOMILEHTO J, 1992, AM J EPIDEMIOL, V135, P1259, DOI 10.1093/oxfordjournals.aje.a116232; TUOMILEHTO J, 1987, J HUM HYPERTENS, V1, P201; UESHIMA H, 1980, PREV MED, V9, P722, DOI 10.1016/0091-7435(80)90017-1; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460; 1992, 1992 FAO WHO INT C N, P11; 1971, AUTOANALYZER II 26A	24	80	80	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 8	1995	310	6984					901	904		10.1136/bmj.310.6984.901	http://dx.doi.org/10.1136/bmj.310.6984.901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719179	Green Published			2022-12-24	WOS:A1995QR97200020
J	BRAUN, S; CROIZAT, B; LAGRANGE, MC; WARTER, JM; POINDRON, P				BRAUN, S; CROIZAT, B; LAGRANGE, MC; WARTER, JM; POINDRON, P			CONSTITUTIVE MUSCULAR ABNORMALITIES IN CULTURE IN SPINAL MUSCULAR-ATROPHY	LANCET			English	Note								To explore the cause of spinal muscular atrophy (SMA), we used an in-vitro model of nerve-muscle co-cultures in which motoneurons were normal and satellite cells were obtained from SMA patients. In co-cultures initiated with satellite cells from type I and type II SMA patients only, we observed degeneration of the innervated fibres after 1-3 weeks of nerve-muscle co-culture. This process involved vacuolisation, disorganisation, and death of the innervated muscle fibres. This observation points to a muscular implication in the severe forms of SMAs.	UNIV LOUIS PASTEUR STRASBOURG 1,UFR SCI,DEPT IMMUNOL & IMMUNOPHARMACOL,F-67401 ILLKIRCH GRAFFENS,FRANCE; ASSOC FRANCAISE MYOPATHIES,PARIS,FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Braun, Serge/ABC-4313-2021					ASKANAS V, 1987, J NEUROCYTOL, V16, P523, DOI 10.1007/BF01668506; Askanas V, 1992, HDB CLIN NEUROL, P85; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; HENDERSON CE, 1988, REV NEUROL, V144, P730; MELKI J, 1994, SCIENCE, V264, P1474, DOI 10.1126/science.7910982	5	84	84	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					694	695		10.1016/S0140-6736(95)90869-2	http://dx.doi.org/10.1016/S0140-6736(95)90869-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7741893				2022-12-24	WOS:A1995QM73200010
J	LERNBECHER, T; MULLER, U; WIRTH, T				LERNBECHER, T; MULLER, U; WIRTH, T			DISTINCT NF-KAPPA-B REL TRANSCRIPTION FACTORS ARE RESPONSIBLE FOR TISSUE-SPECIFIC AND INDUCIBLE GENE ACTIVATION	NATURE			English	Article							DNA-BINDING ACTIVITY; KAPPA-B; PROTO-ONCOGENE; P65 SUBUNIT; C-REL; ENHANCER; INTERACT; CLONING; SEQUENCES; PROMOTER	THE NF-kappaB/Rel family is a growing class of transcriptional regulators1-11 whose members share the conserved Rel-homology domain, involved in specific DNA binding and dimerization. They interact with the regulatory elements of many different genes and are involved in the regulation of lymphoid-specific and inducible transcription12. We tested whether these factors could alone activate a gene in transgenic mice. We report here that a minimal promoter containing three copies of a binding site for these proteins allows tissue-specific and inducible transgene activation. In lymphoid tissues constitutive transgene expression correlates with the presence of a constitutively active p50/RelB heterodimer. Other organs that only contain the p50 homodimer do not express the transgene. In contrast to this constitutive activity mediated by p50/RelB, the p50/p65 heterodimer (which is NF-kappaB) could confer inducible transgene activation in embryo fibroblasts. Thus two different members of the NF-kappaB/Rel family of transcriptional activators are involved in tissue-specific and inducible gene activation in transgenic mice.	ZENTRUM MOLEK BIOL HEIDELBERG,NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	Ruprecht Karls University Heidelberg			Wirth, Thomas/X-7172-2019					ANNWEILER A, 1992, NUCLEIC ACIDS RES, V20, P1503, DOI 10.1093/nar/20.7.1503; ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P423; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOSH S, 1990, CELL, V62, P1019; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	29	195	198	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					767	770		10.1038/365767a0	http://dx.doi.org/10.1038/365767a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	7692309				2022-12-24	WOS:A1993MC81200068
J	MEHARG, AA; OSBORN, D				MEHARG, AA; OSBORN, D			DIOXINS RELEASED FROM CHEMICAL ACCIDENTS	NATURE			English	Editorial Material							POLYCHLORINATED DIBENZOFURANS; CHLORINATED DIOXINS; COMBUSTION; FURANS				MEHARG, AA (corresponding author), INST TERR ECOL,HUNTINGDON PE17 2LS,CAMBS,ENGLAND.		Meharg, Andrew Alexander/F-8182-2014	Meharg, Andrew Alexander/0000-0003-2019-0449				BERTAZZI PA, 1991, SCI TOTAL ENVIRON, V106, P5, DOI 10.1016/0048-9697(91)90016-8; BUSER HR, 1985, ENVIRON HEALTH PERSP, V60, P259, DOI 10.2307/3429969; CATTABENI F, 1985, NATO C SERIES 1, V11; CHANG R, 1989, CHEMOSPHERE, V19, P481, DOI 10.1016/0045-6535(89)90355-X; CHRISTMANN W, 1990, CHEMOSPHERE, V19, P387; DAO MJ, 1992, J HAZARD MATER, V9, P61; FERNANDEZSALGUE.P, 1995, SCIENCE NEW YORK N Y, V0268; FUNCKE W, 1988, STAUB REINHALT LUFT, V48, P393; HARRAD SJ, 1992, SCI TOTAL ENVIRON, V126, P89, DOI 10.1016/0048-9697(92)90486-C; Hay Alastair, 1982, CHEM SCYTHE LESSONS; HORVATH A, 1995, ENVIRON SCI TECHNOL, V29, pA86, DOI 10.1021/es00002a003; HUTZINGER O, 1985, ENVIRON HEALTH PERSP, V60, P3, DOI 10.2307/3429939; JACOBUS EM, 1993, ENV TOXIC CHEM, V12, P1549; KOESTER CJ, 1992, ENVIRON SCI TECHNOL, V26, P1375, DOI 10.1021/es00031a015; MEHARG AA, 1994, TOXICOL ECOTOXICOL N, V1, P117; NARANG AS, 1991, CHEMOSPHERE, V22, P1029, DOI 10.1016/0045-6535(91)90304-V; PHANEUF D, 1995, ARCH ENVIRON CON TOX, V28, P145, DOI 10.1007/BF00217609; RAPPE C, 1991, BANBURY REPORT, V35; THEISEN J, 1989, CHEMOSPHERE, V19, P423, DOI 10.1016/0045-6535(89)90346-9; 1989, WHO INT PROGRAMME CH, V88; 1994, ACCIDENTS DO HAPPEN; 1995, ENVIRON SCI TECHNOL, V29, pA24	22	64	65	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					353	354		10.1038/375353a0	http://dx.doi.org/10.1038/375353a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760923				2022-12-24	WOS:A1995RB10100022
J	MCKENDRY, RJR				MCKENDRY, RJR			IS RHEUMATOID-ARTHRITIS CAUSED BY AN INFECTION	LANCET			English	Editorial Material							MINOCYCLINE; TETRACYCLINES; INHIBITION				MCKENDRY, RJR (corresponding author), UNIV OTTAWA,FAC MED,RHEUMAT DIS UNIT,OTTAWA,ON,CANADA.							BAGNALL A W, 1957, Can Med Assoc J, V77, P182; BREEDVELD FC, 1990, J RHEUMATOL, V17, P43; ENNIS RS, 1972, ARTHRITIS RHEUM, V15, P108; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; Forestier J, 1935, J LAB CLIN MED, V20, P827; FREEDMAN A, 1952, LANCET, V2, P231; GREENWALD RA, 1987, J RHEUMATOL, V14, P28; KLOPPENBURG M, 1994, ARTHRITIS RHEUM, V37, P629, DOI 10.1002/art.1780370505; KLOPPENBURG M, 1995, J RHEUMATOL, V22, P611; KLOPPENBURG M, 1992, BR J RHEUMATOL, V31, pS41; Lande K, 1927, MUNCH MED WSCHR, V74, P1132; LANGEVITZ P, 1992, J RHEUMATOL, V19, P1502; MATSUURA T, 1992, LANCET, V340, P1553, DOI 10.1016/0140-6736(92)92810-3; NIP LH, 1993, J PERIODONTAL RES, V28, P379, DOI 10.1111/j.1600-0765.1993.tb01082.x; OLSER W, 1920, PRINCIPLES PRACTICE, P1126; PRUZANSKI W, 1992, BIOCHEM PHARMACOL, V44, P1165, DOI 10.1016/0006-2952(92)90381-R; STANDFORD HC, 1990, MANDELL DOUGLAS BENN, P306; TAYLORROBINSON D, 1992, LANCET, V340, P81, DOI 10.1016/0140-6736(92)90399-N; TILLEY BC, 1995, ANN INTERN MED, V122, P81, DOI 10.7326/0003-4819-122-2-199501150-00001	19	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1319	1320		10.1016/S0140-6736(95)92533-3	http://dx.doi.org/10.1016/S0140-6736(95)92533-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752751				2022-12-24	WOS:A1995RA14800004
J	HERINGS, RMC; DEBOER, A; STRICKER, BHC; LEUFKENS, HGM; PORSIUS, A				HERINGS, RMC; DEBOER, A; STRICKER, BHC; LEUFKENS, HGM; PORSIUS, A			HYPOGLYCEMIA ASSOCIATED WITH USE OF INHIBITORS OF ANGIOTENSIN-CONVERTING ENZYME	LANCET			English	Article							CAPTOPRIL; GLUCOSE	The use of angiotensin-converting-enzyme (ACE) inhibitors has been associated with increased insulin sensitivity in diabetic patients. Although such an effect could be beneficial in the treatment of hypertension or congestive heart failure in diabetic patients, it might also precipitate severe hypoglycaemia. To test this hypothesis we carried out a nested case-control study, using data in the Dutch PHARMO system (1986-92), among diabetic patients treated with insulin or with oral antidiabetic drugs, who were admitted to hospital with hypoglycaemia. We identified 94 patients who had been admitted with hypoglycaemia and selected 654 controls from the same cohort. With adjustment for a wide range of potential confounding factors, hypoglycaemia was significantly associated with current use of ACE inhibitors (odds ratio 2.8 [95% CI 1.4-5.7]). Both among users of insulin and among users of oral antidiabetic drugs, use of ACE inhibitors was significantly associated with an increased risk of hospital admission for hypoglycaemia (2.8 [1.2-6.4] and 4.1 [1.4-12.2], respectively). Although ACE inhibitors have several advantages over other antihypertensive drugs in diabetes, the risk of hypoglycaemia should be taken into account. Further investigation of the mechanism is needed since as many as 13.8% of all hospital admissions for hypoglycaemia might be attributable to use of ACE inhibitors.	ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT INTERNAL MED 2,3015 GD ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC	HERINGS, RMC (corresponding author), UNIV UTRECHT,UTRECHT INST PHARMACEUT SCI,DEPT PHARMACOEPIDEMIOL & PHARMACOTHERAPY,POB 80082,3508 TB UTRECHT,NETHERLANDS.		Herings, Ron/AAE-4096-2021	Herings, Ron/0000-0002-2561-8734				ALLAN SG, 1986, LANCET, V1, P1035; ARUAZPANCHECHO C, 1990, AM J MED, V89, P811; BERNE C, 1991, J INTERN MED, V229, P119; DONNELLY R, 1992, J CARDIOVASC PHARM, V20, pS38, DOI 10.1097/00005344-199200111-00007; EVERETT J, 1994, DRUGS, V47, P286, DOI 10.2165/00003495-199447020-00004; FERRIERE M, 1985, ANN INTERN MED, V102, P134, DOI 10.7326/0003-4819-102-1-134_3; HERINGS RMC, 1992, J EPIDEMIOL COMMUN H, V46, P136, DOI 10.1136/jech.46.2.136; HERINGS RMC, 1993, THESIS UTRECHT U UTR; KAHN HA, 1989, STATISTICAL METHODS; OKSA A, 1992, J CARDIOVASC PHARM, V23, P79; PASSA P, 1987, DIABETES CARE, V10, P200, DOI 10.2337/diacare.10.2.200; RETT K, 1988, NEW ENGL J MED, V319, P1609; SEEFELDT T, 1990, DIABETIC MED, V7, P700, DOI 10.1111/j.1464-5491.1990.tb01473.x; SIEGHIERI G, 1992, DIABETIC MED, V9, P732; UEHARA M, 1994, DIABETOLOGIA, V37, P300, DOI 10.1007/BF00398058; WINOCOUR P, 1986, LANCET, V2, P461; 1994, DRUGS THERAPY PERSPE, V4, P10; 1994, PRESCRIRE, V3, P175; 1992, ANATOMICAL THERAPEUT	19	161	165	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1195	1198		10.1016/S0140-6736(95)91988-0	http://dx.doi.org/10.1016/S0140-6736(95)91988-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739305				2022-12-24	WOS:A1995QX86100006
J	KROLEWSKI, AS; LAFFEL, LMB; KROLEWSKI, M; QUINN, M; WARRAM, JH				KROLEWSKI, AS; LAFFEL, LMB; KROLEWSKI, M; QUINN, M; WARRAM, JH			GLYCOSYLATED HEMOGLOBIN AND THE RISK OF MICROALBUMINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STATISTICAL-METHOD; GLUCOSE CONTROL; COMPLICATIONS; NEPHROPATHY; DISEASE	Background. The risk of microalbuminuria in patients with insulin-dependent diabetes mellitus (IDDM) is thought to depend on the degree of hyperglycemia, but the relation between the degree of hyperglycemia and urinary albumin excretion has not been defined. Methods. We measured urinary albumin excretion in three random urine samples obtained at least one month apart from 1613 patients with IDDM. Microalbuminuria or overt albuminuria was considered to be present if the ratio of albumin (in micrograms) to creatinine (in milligrams) was 17 to 299 or greater than or equal to 300, respectively, for men and 25 to 299 or greater than or equal to 300, respectively, for women. Measurements of glycosylated hemoglobin (hemoglobin A(1)) obtained up to four years before the urine testing were used as an index of hyperglycemia. Twelve percent of the patients had overt albuminuria and were excluded from subsequent analyses. Results. The prevalence of microalbuminuria was 18 percent in patients with IDDM. It increased with increasing postpubertal duration of diabetes and, within each six-year interval of disease duration, it increased nonlinearly with the hemoglobin A(1) value. For hemoglobin A(1) values below 10.1 percent, the slope of the relation was almost flat, whereas for values above 10.1 percent, the prevalence of microalbuminuria rose steeply (P<0.001). For example, as the hemoglobin A(1) value increased from 8.1 to 10.1 percent, the odds of microalbuminuria increased by a factor of 1.3, but as the value increased from 10.1 to 12.1 percent, the odds were increased by a factor of 2.4. Conclusions. The risk of microalbuminuria in patients with IDDM increases abruptly above a hemoglobin A(1) value of 10.1 percent (equivalent to a hemoglobin A(1c) value of 8.1 percent), suggesting that efforts to reduce the frequency of diabetic nephropathy should be focused on reducing hemoglobin A(1) values that are above this threshold.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	KROLEWSKI, AS (corresponding author), JOSLIN DIABET CTR, EPIDEMIOL & GENET SECT, 1 JOSLIN PL, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041526] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK41526] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRASS CK, 1994, KIDNEY INT, V46, P613, DOI 10.1038/ki.1994.313; [Anonymous], 1988, SAS STAT GUIDE PERSO; BIRKETT NJ, 1992, AM J EPIDEMIOL, V136, P356, DOI 10.1093/oxfordjournals.aje.a116500; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; COONROD BA, 1993, DIABETES CARE, V16, P1376, DOI 10.2337/diacare.16.10.1376; DAHLJORGENSEN K, 1992, KIDNEY INT, V41, P920, DOI 10.1038/ki.1992.140; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; ERIKSSON J, 1992, DIABETIC MED, V9, P654, DOI 10.1111/j.1464-5491.1992.tb01862.x; JANNER M, 1994, EUR J PEDIATR, V153, P403; JONES RH, 1984, ANAL BIOCHEM, V141, P287, DOI 10.1016/0003-2697(84)90458-5; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; KROLEWSKI AS, 1987, NEW ENGL J MED, V317, P1390; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LARKINS R, 1992, DIABETOLOGIA, V35, P1100; LARKINS RG, 1992, DIABETOLOGIA, V35, P499, DOI 10.1007/BF00400475; LIEVENS MM, 1988, CLIN CHEM, V34, P992; LITTLE RR, 1992, CLIN CHEM, V38, P2472; MACLURE M, 1992, AM J EPIDEMIOL, V135, P96; MENARD L, 1980, CLIN CHEM, V26, P1598; MOGENSEN CE, 1983, DIABETES, V32, P64, DOI 10.2337/diab.32.2.S64; NESTLER JE, 1990, DIABETES, V39, P1212, DOI 10.2337/diabetes.39.10.1212; PUGLIESE G, 1991, DIABETES METAB REV, V7, P35, DOI 10.1002/dmr.5610070106; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; Rothman K, 1986, MODERN EPIDEMIOLOGY; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIEGEL JE, 1992, J AM SOC NEPHROL, V3, pS111; ULM K, 1991, STAT MED, V10, P341, DOI 10.1002/sim.4780100306; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; WARRAM JH, 1995, NEW ENGL J MED, V332, P1305, DOI 10.1056/NEJM199505113321915; Wilson R M, 1985, Diabet Med, V2, P167; YIP J, 1993, BRIT MED J, V306, P1235; 1990, P200 SAS I TECHN REP	33	385	393	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1251	1255		10.1056/NEJM199505113321902	http://dx.doi.org/10.1056/NEJM199505113321902			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW600	7708068				2022-12-24	WOS:A1995QW60000002
J	HEGLUND, NC; WILLEMS, PA; PENTA, M; CAVAGNA, GA				HEGLUND, NC; WILLEMS, PA; PENTA, M; CAVAGNA, GA			ENERGY-SAVING GAIT MECHANICS WITH HEAD-SUPPORTED LOADS	NATURE			English	Article							WALKING	IN many areas of the world that lack a transportation infrastructure, people routinely carry extraordinary loads supported by their heads, for example the Sherpa of the Himalayas and the women of East Africa, It has previously been shown that African women from the Kikuyu and Luo tribes can carry loads substantially more cheaply than army recruits(1); however, the mechanism for their economy has remained unknown, Here we investigate, using a force platform, the mechanics of carrying head-supported loads by Kikuyu and Luo women, The weight-specific mechanical work, required to maintain the motion of the common centre of mass of the body and load, decreases with load in the African women, whereas it increases in control subjects, The decrease in work by the African women is a result of a greater conservation of mechanical energy resulting from an improved pendulum-like transfer of energy during each step, back and forth between gravitational potential energy and kinetic energy of the centre of mass.	UNIV CATHOLIQUE LOUVAIN,UNITE READAPTAT,B-1348 LOUVAIN,BELGIUM; UNIV MILAN,IST FISIOL UMANA,I-20133 MILAN,ITALY	Universite Catholique Louvain; University of Milan	HEGLUND, NC (corresponding author), PHAROS SYST INC,S CHELMSFORD,MA 01824, USA.		Cavagna, Giovanni A/G-3564-2013	Cavagna, Giovanni/0000-0003-3081-0939				ALEXANDER R, 1988, ELASTIC MECHANISMS A, P95; ALEXANDER RM, 1986, NATURE, V319, P623, DOI 10.1038/319623a0; CAVAGNA GA, 1975, J APPL PHYSIOL, V39, P174, DOI 10.1152/jappl.1975.39.1.174; CAVAGNA GA, 1976, J PHYSIOL-LONDON, V262, P639, DOI 10.1113/jphysiol.1976.sp011613; HEGLUND NC, 1981, J EXP BIOL, V93, P333; JONES CDR, 1987, LANCET, V12, P1331; MALOIY GMO, 1986, NATURE, V319, P668, DOI 10.1038/319668a0; PANDOLF KB, 1977, J APPL PHYSIOL, V43, P577, DOI 10.1152/jappl.1977.43.4.577; WILLEMS PA, 1995, J EXP BIOL, V198, P379	9	124	125	0	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					52	54		10.1038/375052a0	http://dx.doi.org/10.1038/375052a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723841				2022-12-24	WOS:A1995QW60400052
J	SCHUMACHER, MA; DIXON, MM; KLUGER, R; JONES, RT; BRENNAN, RG				SCHUMACHER, MA; DIXON, MM; KLUGER, R; JONES, RT; BRENNAN, RG			ALLOSTERIC TRANSITION INTERMEDIATES MODELED BY CROSS-LINKED HEMOGLOBINS	NATURE			English	Article							LIGANDED T-STATE; HUMAN-HEMOGLOBIN; CARBON-MONOXIDE; OXYGEN-BINDING; RESOLUTION; DEOXYHEMOGLOBIN; STEREOCHEMISTRY; DYNAMICS	THE structural end-points of haemoglobin's transition from its low-oxygen-affinity (T) to high-oxygen-affinity CR) state, have been well established by X-ray crystallography(1-7), but short-lived intermediates have proved less amenable to X-ray studies, Here we use chemical crosslinking to fix these intermediates for structural characterization. We describe the X-ray structures of three haemoglobins, alpha(2) beta(1)S(82)beta, alpha(2) beta(1)Tm(82)beta and alpha(2) beta(1,82)Tm(82)beta, which were crosslinked between the amino groups of residues beta Val1 and beta Lys82 by 3,3'-stilbenedicarboxylic acid (S) or trimesic acid (Tm) while in the deoxy state, and saturated with carbon monoxide before crystallization. alpha(2) beta(1)S(82)beta, which has almost normal oxygen affinity, is completely in the R-state conformation; however, alpha(2) beta(1)Tm(82)beta and alpha(2) beta(1,82)Tm(82)beta, both of which have low oxygen affinity, have been prevented from completing their transition into the R state and display many features of a transitional intermediate, These haemoglobins therefore represent a snapshot of the nascent R state.	UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109; UNIV TORONTO,DEPT CHEM,LASH MILLER LABS,TORONTO,ON M5S 1A1,CANADA	University of Michigan System; University of Michigan; University of Toronto	SCHUMACHER, MA (corresponding author), OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.			Kluger, Ronald/0000-0002-1749-2094; Brennan, Richard/0000-0001-7647-485X				ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; [Anonymous], 1968, J CRYST GROWTH, DOI [rg/10.1016/00220248(68)900717, DOI 10.1016/0022-0248(68)90071-7]; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; DELLANO JJM, 1993, J BIOL CHEM, V268, P27004; DEREWENDA Z, 1990, J MOL BIOL, V211, P515, DOI 10.1016/0022-2836(90)90262-K; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P3; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRANKE G, 1894, ARCH LARYNGOL RHINOL, V1, P230; JONES RT, 1993, BIOCHEMISTRY-US, V32, P215, DOI 10.1021/bi00052a028; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KLUGER R, 1992, BIOCHEMISTRY-US, V31, P7551, DOI 10.1021/bi00148a016; LIDDINGTON R, 1992, J MOL BIOL, V228, P551, DOI 10.1016/0022-2836(92)90842-8; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; MUKERJI I, 1994, BIOCHEMISTRY-US, V33, P13132, DOI 10.1021/bi00248a024; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; RODGERS KR, 1994, SCIENCE, V265, P1697, DOI 10.1126/science.8085153; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SILVA MM, 1992, J BIOL CHEM, V267, P17248; SMITH FR, 1991, PROTEINS, V10, P81, DOI 10.1002/prot.340100202; SMITH FR, 1994, PROTEINS, V18, P295, DOI 10.1002/prot.340180310; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124	25	81	82	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					84	87		10.1038/375084a0	http://dx.doi.org/10.1038/375084a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723849	Green Submitted			2022-12-24	WOS:A1995QW60400061
J	HSIEH, JJD; HAYWARD, SD				HSIEH, JJD; HAYWARD, SD			MASKING OF THE CBF1/RBPJ(KAPPA) TRANSCRIPTIONAL REPRESSION DOMAIN BY EPSTEIN-BARR-VIRUS EBNA2	SCIENCE			English	Article							BINDING-PROTEIN GENE; DROSOPHILA HOMOLOG; NUCLEAR ANTIGEN-2; INFECTION; PROMOTER; MOTIF	Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) is a transcriptional activator that is essential for EBV-driven B cell immortalization. EBNA2 is targeted to responsive promoters through interaction with a cellular DNA binding protein, C promoter binding factor 1 (CBF1). A transcriptional repression domain has been identified within CBF1. This domain also interacts with EBNA2, and repression is masked by EBNA2 binding. Thus, EBNA2 acts by countering transcriptional repression. Mutation at amino acid 233 of CBF1 abolishes repression and correlates with a loss-of-function mutation in the Drosophila homolog Su(H).	JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,MOLEC VIROL LABS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NATIONAL CANCER INSTITUTE [R37CA042245, R01CA042245] Funding Source: NIH RePORTER; NCI NIH HHS [CA42245] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAKAWA R, 1993, GENOMICS, V17, P306, DOI 10.1006/geno.1993.1326; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HSIEH JM, UNPUB; Liebowitz David, 1993, P107; LING PD, 1993, J VIROL, V67, P2990, DOI 10.1128/JVI.67.6.2990-3003.1993; LING PD, 1994, J VIROL, V68, P5375, DOI 10.1128/JVI.68.9.5375-5383.1994; LING PD, 1993, P NATL ACAD SCI USA, V90, P9237, DOI 10.1073/pnas.90.20.9237; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; WOISETSCHLAEGER M, 1991, P NATL ACAD SCI USA, V88, P3942, DOI 10.1073/pnas.88.9.3942; ZIMBERSTROBL U, 1993, EMBO J, V12, P167, DOI 10.1002/j.1460-2075.1993.tb05642.x	25	262	269	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					560	563		10.1126/science.7725102	http://dx.doi.org/10.1126/science.7725102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725102				2022-12-24	WOS:A1995QV40700035
J	KOH, JY; GWAG, BJ; LOBNER, D; CHOI, DW				KOH, JY; GWAG, BJ; LOBNER, D; CHOI, DW			POTENTIATED NECROSIS OF CULTURED CORTICAL-NEURONS BY NEUROTROPHINS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; PROGRAMMED CELL-DEATH; CHOLINERGIC NEURONS; GLUTAMATE NEUROTOXICITY; FACTOR DEPRIVATION; PROTEIN-SYNTHESIS; TRK FAMILY; RAT-BRAIN; DEGENERATION; RECEPTOR	The effects of neurotrophins on several forms of neuronal degeneration in murine cortical cell cultures were examined. Consistent with other studies, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 all attenuated the apoptotic death induced by serum deprivation or exposure lo the calcium channel antagonist nimodipine, Unexpectedly, however, 24-hour pretreatment with these same neurotrophins markedly potentiated the necrotic death induced by exposure to oxygen-glucose deprivation or N-methyl-D-aspartate. Thus, certain neurotrophins may have opposing effects on different types of death in the same neurons.	WASHINGTON UNIV, SCH MED, CTR STUDY NERVOUS SYST INJURY, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Koh, Jae-Young/C-9014-2011	Koh, Jae-Young/0000-0002-4318-495X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030337] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 30337] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; BEHERENS MI, UNPUB; BERINGER B, 1993, NEUROREPORT, V4, P1303; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, NEURODEGENERATIVE D, P233; CSERNANSKY CA, 1994, J NEUROSCI RES, V38, P101, DOI 10.1002/jnr.490380113; DAVIES SW, 1992, NEUROSCI LETT, V140, P161, DOI 10.1016/0304-3940(92)90092-L; FERNANDEZSANCHEZ MT, 1993, FEBS LETT, V335, P124, DOI 10.1016/0014-5793(93)80453-2; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Gwag B. J., 1994, Society for Neuroscience Abstracts, V20, P248; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; HEFTI F, 1986, J NEUROSCI, V6, P2155; HENNEBERRY RC, 1989, ANN NY ACAD SCI, V568, P225; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEVINE ES, IN PRESS J NEUROSCI; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORELLI A, 1986, J NEUROCHEM, V47, P375; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P221, DOI 10.1038/jcbfm.1993.27; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; RINGSTEDT T, 1993, DEV BRAIN RES, V72, P119, DOI 10.1016/0165-3806(93)90165-7; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SHIGENO T, 1990, NEUROSCI LETT, V120, P117, DOI 10.1016/0304-3940(90)90182-9; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604; WIDMER HR, 1993, NEUROREPORT, V4, P363, DOI 10.1097/00001756-199304000-00005; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YIP NY, 1993, NEURON, V10, P137	42	333	343	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	1995	268	5210					573	575		10.1126/science.7725105	http://dx.doi.org/10.1126/science.7725105			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725105				2022-12-24	WOS:A1995QV40700039
J	MOON, RE				MOON, RE			FASTING BEFORE SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							GASTRIC FLUID VOLUME; GUIDELINES; CHILDREN; PH; INGESTION; LIQUIDS				MOON, RE (corresponding author), DUKE UNIV,MED CTR,DURHAM,NC, USA.		Moon, Richard/AAF-2170-2019	Moon, Richard/0000-0003-4432-0332				COTE CJ, 1990, ANESTHESIOLOGY, V72, P589, DOI 10.1097/00000542-199004000-00001; GOODWIN APL, 1991, ANAESTHESIA, V46, P1066, DOI 10.1111/j.1365-2044.1991.tb09926.x; GORESKY GV, 1990, CAN J ANAESTH, V37, P493, DOI 10.1007/BF03006313; KALLAR SK, 1993, ANESTH ANALG, V77, P171; MALTBY JR, 1991, CAN J ANAESTH, V38, P425, DOI 10.1007/BF03007577; MENDELSON CL, 1946, AM J OBSTET GYNECOL, V52, P191; MINAMI H, 1984, GASTROENTEROLOGY, V86, P1592; MOORE JG, 1981, DIGEST DIS SCI, V26, P16, DOI 10.1007/BF01307971; PHILLIPS S, 1993, BRIT J ANAESTH, V70, P6, DOI 10.1093/bja/70.1.6; SANDHAR BK, 1989, ANESTHESIOLOGY, V71, P327, DOI 10.1097/00000542-198909000-00001; SCARR M, 1989, CAN MED ASSOC J, V141, P1151; SCHREINER MS, 1990, ANESTHESIOLOGY, V72, P593, DOI 10.1097/00000542-199004000-00002; SNOW J, 1847, INHALATION VAPOUR ET, P43; SPLINTER WM, 1990, CAN J ANAESTH, V37, P36, DOI 10.1007/BF03007481; STRUNIN L, 1993, BRIT J ANAESTH, V70, P1, DOI 10.1093/bja/70.1.1	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1171	1171						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT100	7707615				2022-12-24	WOS:A1995QT10000010
J	AONO, S; ADACHI, Y; UYAMA, E; YAMADA, Y; KEINO, H; NANNO, T; KOIWAI, O; SATO, H				AONO, S; ADACHI, Y; UYAMA, E; YAMADA, Y; KEINO, H; NANNO, T; KOIWAI, O; SATO, H			ANALYSIS OF GENES FOR BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE IN GILBERTS-SYNDROME	LANCET			English	Note							CRIGLER-NAJJAR SYNDROME; IDENTIFICATION; COMPLEX; MUTATION; PATIENT	Gilbert's and Crigler-Najjar syndromes are characterised by unconjugated hyperbilirubinaemia due to complete and partial absence of bilirubin UDP-glucuronosyltransferase (UGT). Nucleotide sequences of the genes for bilirubin UGT were analysed in six patients with Gilbert's syndrome. All patients had a missense mutation caused by a single nucleotide substitution and the mutations were heterozygous. In addition, relatives of patients with Crigler-Najjar syndrome types I and II, and of those with Gilbert's syndrome were analysed. All ten relatives with mild hyperbilirubinaemia were heterozygotes with respect to each defective allele. These results suggest that Gilbert's syndrome is inherited as a dominant trait.	SHIGA UNIV MED SCI,DEPT BIOL,OTSU,SHIGA 52021,JAPAN; KINKI UNIV,SCH MED,DEPT PERINATOL,OSAKA,JAPAN; KINKI UNIV,SCH MED,INST DEV RES,DEPT GENET,OSAKA,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED 1,KUMAMOTO,JAPAN; AICHI CANC CTR,RES INST,DEPT BIOCHEM,AICHI,JAPAN	Shiga University of Medical Science; Kindai University (Kinki University); Kindai University (Kinki University); Kumamoto University; Aichi Cancer Center								AONO S, 1993, BIOCHEM BIOPH RES CO, V197, P1239, DOI 10.1006/bbrc.1993.2610; AONO S, 1994, PEDIATR RES, V35, P629, DOI 10.1203/00006450-199406000-00002; BOSMA PJ, 1992, HEPATOLOGY, V15, P941, DOI 10.1002/hep.1840150531; HERIWEGH KP, 1972, BIOCHEM J, V129, P605; MOGHRABI N, 1993, GENOMICS, V18, P171, DOI 10.1006/geno.1993.1451; PETERS WHM, 1984, J BIOL CHEM, V259, P1701; RITTER JK, 1992, J CLIN INVEST, V90, P150, DOI 10.1172/JCI115829; RITTER JK, 1991, J BIOL CHEM, V266, P1043; RITTER JK, 1992, J BIOL CHEM, V26, P3257; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89	10	150	159	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					958	959		10.1016/S0140-6736(95)90702-5	http://dx.doi.org/10.1016/S0140-6736(95)90702-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715297				2022-12-24	WOS:A1995QT91900012
J	MAPLE, PA; EFSTRATIOU, A; GEORGE, RC; ANDREWS, NJ; SESARDIC, D				MAPLE, PA; EFSTRATIOU, A; GEORGE, RC; ANDREWS, NJ; SESARDIC, D			DIPHTHERIA IMMUNITY IN UK BLOOD-DONORS	LANCET			English	Article							TETANUS; ADULTS; POPULATION; ANTITOXIN; TOXIN	Immunity to diphtheria was determined in serum samples from 1000 UK-born blood donors at the North London Blood Transfusion Centre during a three-month period in 1993; 125 women and 125 men were stratified in 10-year age groups, from 20 to 59. A tissue (vero cell)-culture toxin-neutralisation assay was used to measure serum diphtheria antitoxin concentrations. According to internationally accepted definitions (antitoxin <0.01 IU/mL=susceptibility, 0.01-0.09 IU/mL=basic protection, and greater than or equal to 0.1 IU/mL=full protection), 37.6% of donors were susceptible to diphtheria, 31.5% had basic protection, and 30.9% were fully protected. Log-linear modeling of the influence of age and sex on population immunity showed a significant trend (p<0.001) of decreasing immunity with increasing age: 25.2% of donors aged 20-29 were susceptible compared with 52.8% of those aged 50-59. There was a small sex effect (p=0.052); similar proportions of men and women were susceptible, but fewer women had full protection. There was no age-sex interaction on immunity (p=0.454). Our results suggest that booster immunisation of adults is necessary to increase herd immunity of the adult population.	PUBL HLTH LAB SERV,STAT UNIT,LONDON,ENGLAND; NATL INST BIOL STAND & CONTROLS,DIV BACTERIOL,POTTERS BAR,HERTS,ENGLAND	Public Health England; National Institute for Biological Standards & Control	MAPLE, PA (corresponding author), CENT PUBL HLTH LAB,RESP & SYSTEM INFECT LAB,LONDON NW9 5HT,ENGLAND.			Maple, Peter/0000-0002-5534-5191				AJELLO F, 1991, VACCINE, V9, P502, DOI 10.1016/0264-410X(91)90036-6; CELLESI C, 1989, VACCINE, V7, P417, DOI 10.1016/0264-410X(89)90155-2; CROSSLEY K, 1979, JAMA-J AM MED ASSOC, V242, P2298, DOI 10.1001/jama.242.21.2298; GALAZKA A, 1989, EPIDEMIOL INFECT, V103, P587, DOI 10.1017/S0950268800030983; GALAZKA AM, 1993, WHOEPIGEN9312; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; KWANTES W, 1984, J HYG-CAMBRIDGE, V93, P433, DOI 10.1017/S0022172400065025; MASTERTON RG, 1987, J INFECTION, V15, P27, DOI 10.1016/S0163-4453(87)91351-X; MELVILLESMITH M, 1988, J MED MICROBIOL, V25, P279, DOI 10.1099/00222615-25-4-279; MILLER E, 1994, BRIT MED J, V308, P598, DOI 10.1136/bmj.308.6928.598b; PALMER SR, 1983, BRIT MED J, V286, P624, DOI 10.1136/bmj.286.6365.624; PARISH HJ, 1955, BRIT MED J, V2, P631, DOI 10.1136/bmj.2.4940.631; SESARDIC D, 1992, LANCET, V340, P737, DOI 10.1016/0140-6736(92)92284-M; SIMONSEN O, 1989, DAN MED BULL, V36, P24; WEISS BP, 1983, AM J PUBLIC HEALTH, V73, P802, DOI 10.2105/AJPH.73.7.802; 1989, 2ND WHO M NAT PROGR; 1956, LANCET, V2, P1223; 1978, LANCET, V1, P428; 1961, BRIT MED J, V2, P763; 1953, STATISTICAL REV ENGL; 1944, NEW ANN SERIES 1, V19; 1945, 19445 UK MIN HLTH CI; 1993, JUL WHO M DIPHTH EP; 1957, BRIT MED J, V2, P167; 1994, COMMUNICAB DIS REP, V4, P47; 1955, 555 UK MIN HLTH CIRC; 1990, APR WHO M CONTR DIPH; 1962, BRIT MED J, V2, P149; 1993, SERIES MB2, V18	29	84	86	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					963	965		10.1016/S0140-6736(95)90705-X	http://dx.doi.org/10.1016/S0140-6736(95)90705-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715300				2022-12-24	WOS:A1995QT91900015
J	TODD, CJ; FREEMAN, CJ; CAMILLERIFERRANTE, C; PALMER, CR; HYDER, A; LAXTON, CE; PARKER, MJ; PAYNE, BV; RUSHTON, N				TODD, CJ; FREEMAN, CJ; CAMILLERIFERRANTE, C; PALMER, CR; HYDER, A; LAXTON, CE; PARKER, MJ; PAYNE, BV; RUSHTON, N			DIFFERENCES IN MORTALITY AFTER FRACTURE OF HIP - THE EAST-ANGLIAN AUDIT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate differences between hospitals in clinical management of patients admitted With fractured hip and to relate these to mortality at 90 days. Design-A prospective audit of process and outcome of care based on interviews with patients, abstraction from records with standard proforma, and follow up at three months. Data were analysed with chi(2) test and forward stepwise regression modelling of mortality. Setting-All eight hospitals in East Anglia with trauma orthopaedic departments. Patients-580 consecutive patients admitted for fracture of neck of femur. Main outcome measure-Mortality at 90 days. Results-Patients admitted to each hospital were similar with respect to age, sex, pre-existing illnesses, and activities of daily living before fracture. In all, 560 (97%) were treated surgically, by a range of grades of surgeon. Two hundred and sixty one patients (45%; range between hospitals 10-91%) received pharmaceutical thromboembolic prophylaxis, 502 (93%; 81-99%) perioperative antibiotic prophylaxis. The incidence of fatal pulmonary emboli differed between patients who received and those who did not receive prophylaxis against deep vein thrombosis (P=0.001). Mortality at 90 days was 18%, differing significantly between hospitals (5-23%). One hospital had significantly better survival than the others (odds ratio 0 .14; 95% confidence interval 0.04-0.48; P=0.0016). Conclusions-No single factor or aspect of practice accounted for this protective effect. Lower mortality may be associated with the cumulative effects of several aspects of the organisation of treatment and the management of fracture of the hip, including thromboembolic pharmaceutical prophylaxis, antibiotic prophylaxis, and early mobilisation.	ANGLIA & OXFORD REG HLTH AUTHOR,DIRECTORATE PUBL HLTH MED,CAMBRIDGE,ENGLAND; PETERBOROUGH DIST GEN HOSP,DEPT ORTHOPAED,PETERBOROUGH PE3 6DA,ENGLAND; NORFOLK & NORWICH HEALTHCARE NHS TRUST,NORWICH,NORFOLK,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,ORTHOPAED RES UNIT,CAMBRIDGE,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	TODD, CJ (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,HLTH SERV RES GRP,CAMBRIDGE CB2 2SR,ENGLAND.		Hyder, Adnan/AAT-9503-2021; Todd, Chris/A-7904-2010; Todd, Chris/AAD-8661-2022	Todd, Chris/0000-0001-6645-4505; Todd, Chris/0000-0001-6645-4505; Freeman, Carol/0000-0001-9751-0784				ALTMAN DG, 1980, BRIT MED J, V281, P1336, DOI 10.1136/bmj.281.6251.1336; FREEMAN CJ, 1995, E ANGLIAN AUDIT FRAC; HOLLINGWORTH W, IN PRESS J PUBLIC HL; PARKER MJ, 1993, J BONE JOINT SURG BR, V75, P797, DOI 10.1302/0301-620X.75B5.8376443; Parker MJ., 1993, HIP FRACTURE MANAGEM; Pearse M, 1992, Health Trends, V24, P134; RUSSELL IT, 1992, QUALITY HLTH CARE, V1, P52; SAINSBURY R, 1991, REV CLIN GERONTOL, V1, P67; TODD C, 1993, TIJDSCHRIFT SOCIALE, V71, P72; 1989, FRACTURED NECK FEMUR; 1990, REPORT E ANGLIAN REG; 1994, HOSPITAL EPISODE STA, V1; 1992, BRIT MED J, V305, P567; 1989, CMND555; 1994, HOSPITAL AMBULANCE S	15	246	248	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					904	908		10.1136/bmj.310.6984.904	http://dx.doi.org/10.1136/bmj.310.6984.904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719180	Green Published			2022-12-24	WOS:A1995QR97200021
J	DICKINSON, MH; LIGHTON, JRB				DICKINSON, MH; LIGHTON, JRB			MUSCLE EFFICIENCY AND ELASTIC STORAGE IN THE FLIGHT MOTOR OF DROSOPHILA	SCIENCE			English	Article							INSECT FLIGHT; POWER OUTPUT; MELANOGASTER; METABOLISM	Insects could minimize the high energetic costs of flight in two ways: by employing high-efficiency muscles and by using elastic elements within the thorax to recover energy expended accelerating the wings. However, because muscle efficiency and elastic storage have proven difficult variables to measure, it is not known which of these strategies is actually used. By comparison of mechanical power measurements based on gas exchange with simultaneously measured flight kinematics in Drosophila, a method was developed for determining both the mechanical efficiency and the minimum degree of elastic storage within the flight motor. Muscle efficiency values of 10 percent suggest that insects may minimize energy use in flight by employing an elastic flight motor rather than by using extraordinarily efficient muscles. Further, because of the trade-off between inertial and aerodynamic power throughout the wing stroke, an elastic storage capacity as low as 10 percent may be enough to minimize the energetic costs of flight.	UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	DICKINSON, MH (corresponding author), UNIV CHICAGO,DEPT ORGANISMAL BIOL & ANAT,CHICAGO,IL 60637, USA.		Lighton, John R B/A-9691-2009	Lighton, John/0000-0002-9264-924X				ALEXANDER RM, 1977, NATURE, V265, P114, DOI 10.1038/265114a0; CASEY T, 1988, INSECT FLIGHT, pCH11; CASEY TM, 1981, J EXP BIOL, V91, P117; DICKINSON MH, 1993, J EXP BIOL, V182, P173; ELLINGTON CP, 1985, J EXP BIOL, V115, P293; ELLINGTON CP, 1991, J EXP BIOL, V160, P71; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P145, DOI 10.1098/rstb.1984.0054; FREEMAN P, 1965, 12 INT C ENT LOND, P186; GOTZ K, COMMUNICATION; GOTZ KG, 1968, KYBERNETIK, V4, P199, DOI 10.1007/BF00272517; GOTZ KG, 1987, J EXP BIOL, V128, P35; HEISENBERG M, 1984, VISION DROSOPHILA; Kammer A.E., 1978, Advances in Insect Physiology, V13, P133, DOI 10.1016/S0065-2806(08)60266-0; LAURIEAHLBERG CC, 1985, GENETICS, V111, P845; LEHRMANN FO, 1994, THESIS EBERHARD KARL; LIGHTON JRB, 1991, CONCISE ENCY BIOL BI, P201; PENNYCUICK CJ, 1984, J EXP BIOL, V108, P377; WEISFOGH T, 1960, J EXP BIOL, V37, P889; WEISFOGH T, 1964, 12 INT C ENT; ZANKER JM, 1990, PHILOS T ROY SOC B, V327, P19, DOI 10.1098/rstb.1990.0041	20	171	173	1	27	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					87	90		10.1126/science.7701346	http://dx.doi.org/10.1126/science.7701346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701346				2022-12-24	WOS:A1995QR45400030
J	HOU, XS; CHOU, TB; MELNICK, MB; PERRIMON, N				HOU, XS; CHOU, TB; MELNICK, MB; PERRIMON, N			THE TORSO RECEPTOR TYROSINE KINASE CAN ACTIVATE RAF IN A RAS-INDEPENDENT PATHWAY	CELL			English	Article							NUCLEOTIDE EXCHANGE FACTOR; TERMINAL BODY PATTERN; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; DROSOPHILA-MELANOGASTER; EMBRYONIC TERMINI; GENE TAILLESS; SEVENLESS; TRANSFORMATION; EXPRESSION	Activation of the receptor tyrosine kinase (RTK) torso defines the spatial domains of expression of the transcription factors tailless and huckebein. Previous analyses have demonstrated that Ras1 (p21(ras)) operates upstream of the D-Raf (Raf1) serine/threonine kinase in this signaling pathway. By using a recently developed technique of germline mosaics, we find that D-Raf can be activated by torso in the complete absence of Ras1. This result is supported by analysis of D-Raf activation in the absence of either the exchange factor Son of sevenless (Sos) or the adaptor protein drk (Grb2), as well as by the phenotype of a D-Raf mutation that abolishes binding of Ras1 to D-Raf. Our study provides in vivo evidence that Raf can be activated by an RTK in a Ras-independent pathway.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	HOU, XS (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.		Chou, Tze-Bin/S-1188-2017	Chou, Tze-Bin/0000-0003-2453-0164; Perrimon, Norbert/0000-0001-7542-472X				AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRONNER G, 1994, NATURE, V369, P664, DOI 10.1038/369664a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAROLL MP, 1994, J BIOL CHEM, V269, P1249; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1993, NATURE, V362, P152, DOI 10.1038/362152a0; CASANOVA J, 1994, MECH DEVELOP, V48, P59, DOI 10.1016/0925-4773(94)90006-X; CHOU TB, 1992, GENETICS, V131, P643; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; DUFFY JB, 1994, DEV BIOL, V166, P380, DOI 10.1006/dbio.1994.1324; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEV Z, 1993, RAS SUPERFAMILY GTPA, P187; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; NEUMANSILBERBER, 1984, CELL, V0037; OLIUVIER JP, 1993, SOS CELL, V73, P179; Perkins L A, 1991, In Vivo, V5, P521; PERRIMON N, 1994, TRENDS BIOCHEM SCI, V19, P509, DOI 10.1016/0968-0004(94)90140-6; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; PERRIMON N, 1994, CURR OPIN CELL BIOL, V6, P260, DOI 10.1016/0955-0674(94)90145-7; PIGNONI F, 1992, DEVELOPMENT, V115, P239; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; RONCHI E, 1993, CELL, V74, P347, DOI 10.1016/0092-8674(93)90425-P; ROSE MD, 1990, LABORATORY COURSE MA; Sambrook J., 1989, MOL CLONING LAB MANU; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SWANSON KD, 1992, GENE, V113, P183, DOI 10.1016/0378-1119(92)90394-5; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922	64	110	110	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					63	71		10.1016/0092-8674(95)90371-2	http://dx.doi.org/10.1016/0092-8674(95)90371-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720074	Bronze			2022-12-24	WOS:A1995QR97000008
J	MURRAY, K; SELLECK, P; HOOPER, P; HYATT, A; GOULD, A; GLEESON, L; WESTBURY, H; HILEY, L; SELVEY, L; RODWELL, B; KETTERER, P				MURRAY, K; SELLECK, P; HOOPER, P; HYATT, A; GOULD, A; GLEESON, L; WESTBURY, H; HILEY, L; SELVEY, L; RODWELL, B; KETTERER, P			A MORBILLIVIRUS THAT CAUSED FATAL DISEASE IN HORSES AND HUMANS	SCIENCE			English	Article							COMPARATIVE SEQUENCE-ANALYSIS; RESPIRATORY SYNCYTIAL VIRUS; PHOCINE DISTEMPER VIRUS; AMINO-ACID-SEQUENCES; NUCLEOTIDE-SEQUENCE; MATRIX PROTEIN; MOLECULAR-CLONING; RINDERPEST VIRUS; GENE; PARAMYXOVIRUSES	A morbillivirus has been isolated and added to an increasing list of emerging viral diseases. This virus caused an outbreak of fatal respiratory disease in horses and humans. Genetic analyses show it to be only distantly related to the classic morbilliviruses rinderpest, measles, and canine distemper. When seen by electron microscopy, viruses had 10- and 18-nanometer surface projections that gave them a ''double-fringed'' appearance. The virus induced syncytia that developed in the endothelium of blood vessels, particularly the lungs.	QUEENSLAND DEPT HLTH,CTR PUBL HLTH SCI,BRISBANE,QLD 4000,AUSTRALIA; QUEENSLAND DEPT PRIMARY IND,ANIM RES INST,YEERONGPILLY,QLD 4105,AUSTRALIA; QUEENSLAND HLTH,BRISBANE,QLD 4000,AUSTRALIA	Queensland Health; Queensland Department of Agriculture & Fisheries; Queensland Health	MURRAY, K (corresponding author), CSIRO,AUSTRALIAN ANIM HLTH LAB,RYRIE ST,GEELONG,VIC 3220,AUSTRALIA.		Selvey, Linda/B-8473-2017	Selvey, Linda/0000-0001-8493-0974				BARON MD, 1994, VIROLOGY, V200, P121, DOI 10.1006/viro.1994.1170; BARRETT T, 1993, VIROLOGY, V193, P1010, DOI 10.1006/viro.1993.1217; BEARD CW, 1983, DISEASES POULTRY, P452; BELLINI WJ, 1986, J VIROL, V58, P408, DOI 10.1128/JVI.58.2.408-416.1986; BLUMBERG BM, 1984, J VIROL, V52, P656, DOI 10.1128/JVI.52.2.656-663.1984; CATTANEO R, 1989, VIROLOGY, V173, P415, DOI 10.1016/0042-6822(89)90554-0; CURRAN MD, 1992, ARCH VIROL, V126, P159, DOI 10.1007/BF01309692; DIALLO A, COMMUNICATION; ENAMI M, 1989, J GEN VIROL, V70, P2191, DOI 10.1099/0022-1317-70-8-2191; Felsenstein J., 1989, PHYLIP 3 2 MANUAL; FINCH JT, 1970, J GEN VIROL, V6, P141, DOI 10.1099/0022-1317-6-1-141; GALINSKI MS, 1987, VIROLOGY, V157, P24, DOI 10.1016/0042-6822(87)90309-6; HSU D, 1988, VIROLOGY, V166, P149, DOI 10.1016/0042-6822(88)90156-0; HYATT AD, UNPUB; HYATT AD, 1991, ELECTRON MICROS, P59; JONES TC, 1983, VET PATHOL, P435; Lederberg J., 1992, EMERGING INFECTIONS; LIMO M, 1990, VIROLOGY, V175, P323, DOI 10.1016/0042-6822(90)90216-E; MIYAHARA K, 1992, ARCH VIROL, V124, P255, DOI 10.1007/BF01309807; MONATH TP, 1994, SEMIN VIROL, V5, P133, DOI 10.1006/smvy.1994.1014; MURPHY FA, 1994, SEMIN VIROL, V5, P85, DOI 10.1006/smvy.1994.1009; MURPHY FA, 1993, ADV VIRUS RES, V43, P1; NATHANSON N, 1993, VIRUS RES, V29, P3, DOI 10.1016/0168-1702(93)90122-4; NORRBY E, 1990, P1013; PALMER EL, 1988, ELECT MICROSCOPY VIR, P111; PRINGLE CR, 1991, CLASSIFICATION NOMEN, P242; SAMAL SK, 1991, J GEN VIROL, V72, P1715, DOI 10.1099/0022-1317-72-7-1715; SATAKE M, 1984, J VIROL, V50, P92, DOI 10.1128/JVI.50.1.92-99.1984; SCHEID A, 1987, ANIMAL VIRUS STRUCTU, P233; VANDEUSEN RA, 1983, AVIAN DIS, V27, P745, DOI 10.2307/1590317; VISSER IKG, 1993, J GEN VIROL, V74, P631, DOI 10.1099/0022-1317-74-4-631	31	528	572	1	45	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					94	97		10.1126/science.7701348	http://dx.doi.org/10.1126/science.7701348			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701348				2022-12-24	WOS:A1995QR45400033
J	PERKINS, TT; SMITH, DE; LARSON, RG; CHU, S				PERKINS, TT; SMITH, DE; LARSON, RG; CHU, S			STRETCHING OF A SINGLE TETHERED POLYMER IN A UNIFORM-FLOW	SCIENCE			English	Article							PARTICLES; DNA	The stretching of single, tethered DNA molecules by a flow was directly visualized with fluorescence microscopy. Molecules ranging in length (L) from 22 to 84 micrometers were held stationary against the flow by the optical trapping of a latex microsphere attached to one end. The fractional extension x/L is a universal function of eta vL(0.54+/-0.05), where eta and v are the viscosity and velocity of the flow, respectively. This relation shows that the DNA is not ''free-draining'' (that is, hydrodynamic coupling within the chain is not negligible) even near full extension (similar to 80 percent). This function has the same form over a lone range as the fractional extension versus force applied at the ends of a worm-like chain. For small deformations (<30 percent of full extension), the extension increases with velocity as x similar to v(0.70+/-0.08). The relative size of fluctuations in extension decreases as sigma(x)/x congruent to 0.42 exp(-4.9 x/L). Video images of the fluctuating chain have a cone-like envelope and show as sharp increase in intensity at the free end.	STANFORD UNIV,DEPT PHYS,STANFORD,CA 94305; AT&T BELL LABS,MURRAY HILL,NJ 07974	Stanford University; AT&T; Nokia Corporation; Nokia Bell Labs			Smith, Douglas E/A-3131-2017	Smith, Douglas E/0000-0002-8206-3632; Perkins, Thomas/0000-0003-4826-9490	PHS HHS [33289] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1980, VISCOELASTIC PROPERT; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; BENSIMON D, UNPUB; BIRD RB, 1987, DYNAMICS POLYM LIQUI, V2, P19; BROCHARDWYART F, 1993, EUROPHYS LETT, V23, P105, DOI 10.1209/0295-5075/23/2/005; BROCHARDWYART F, 1994, EUROPHYS LETT, V23, P511; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; DEBYE P, 1948, J CHEM PHYS, V16, P573, DOI 10.1063/1.1746948; DEGENNES PG, 1974, J CHEM PHYS, V60, P5030, DOI 10.1063/1.1681018; Doi M., 1986, THEORY POLYM DYNAMIC; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FIXMAN M, 1973, J CHEM PHYS, V58, P1564, DOI 10.1063/1.1679396; KIRKWOOD JG, 1954, J CHEM PHYS, V22, P1626, DOI 10.1063/1.1740494; KIRKWOOD JG, 1948, J CHEM PHYS, V16, P565, DOI 10.1063/1.1746947; KIRKWOOD JG, 1953, J POLYM SCI, V12, P1; Kuhn W, 1934, KOLLOID Z, V68, P2, DOI 10.1007/BF01451681; Larson R. G., 1988, CONSTITUTIVE EQUATIO; LARSON RG, 1989, MACROMOLECULES, V22, P3004, DOI 10.1021/ma00197a022; LARSON RG, UNPUB; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; SCHURR JM, 1990, BIOPOLYMERS, V29, P1161, DOI 10.1002/bip.360290806; SIMMONS RF, UNPUB; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; VOLOGODSKII A, 1994, MACROMOLECULES, V27, P5623, DOI 10.1021/ma00098a016; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462; ZIMM BH, 1992, Q REV BIOPHYS, V25, P171, DOI 10.1017/S0033583500004662; ZIMM BH, COMMUNICATION	30	514	526	1	96	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					83	87		10.1126/science.7701345	http://dx.doi.org/10.1126/science.7701345			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701345				2022-12-24	WOS:A1995QR45400029
J	SCHABERT, FA; HENN, C; ENGEL, A				SCHABERT, FA; HENN, C; ENGEL, A			NATIVE ESCHERICHIA-COLI OMPF PORIN SURFACES PROBED BY ATOMIC-FORCE MICROSCOPY	SCIENCE			English	Article							OUTER-MEMBRANE	Topographs of two-dimensional porin OmpF crystals reconstituted in the presence of lipids were recorded in solution by atomic force microscopy (AFM) to a lateral resolution of 10 angstroms and a vertical resolution of 1 angstrom. Protein-protein interactions were demonstrated on the basis of the AFM results and earlier crystallographic findings, To assess protein-lipid interactions, the bilayer was modeled with kinked lipids by fitting the head groups to contours determined with AFM. Finally, two conformations of the extracellular porin surface were detected at forces of 0.1 nanonewton, demonstrating the potential of AFM to monitor conformational changes with high resolution.	UNIV BASEL,BIOZENTRUM,INST MICROSCOP STRUCT BIOL,CH-4056 BASEL,SWITZERLAND	University of Basel								BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BUEHLER LK, 1991, J BIOL CHEM, V266, P2446; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; ENGEL A, 1985, NATURE, V317, P643, DOI 10.1038/317643a0; HOENGER A, 1993, J MOL BIOL, V233, P400, DOI 10.1006/jmbi.1993.1520; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; SAXTON WO, 1992, ULTRAMICROSCOPY, V46, P287, DOI 10.1016/0304-3991(92)90020-K; SCHABERT FA, 1994, BIOPHYS J, V67, P2394, DOI 10.1016/S0006-3495(94)80726-X; SEELIG A, 1974, BIOCHEMISTRY-US, V13, P4893; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10471, DOI 10.1021/bi00158a009	15	262	266	1	35	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					92	94		10.1126/science.7701347	http://dx.doi.org/10.1126/science.7701347			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701347				2022-12-24	WOS:A1995QR45400032
J	TARAKHOVSKY, A; TURNER, M; SCHAAL, S; MEE, PJ; DUDDY, LP; RAJEWSKY, K; TYBULEWICZ, VLJ				TARAKHOVSKY, A; TURNER, M; SCHAAL, S; MEE, PJ; DUDDY, LP; RAJEWSKY, K; TYBULEWICZ, VLJ			DEFECTIVE ANTIGEN RECEPTOR-MEDIATED PROLIFERATION OF B-CELLS AND T-CELLS IN THE ABSENCE OF VAV	NATURE			English	Article							TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; SIGNALING PROTEINS; MICE; GENE; ACTIVATION; LACKING; DOMAIN; SH2	CROSSLINKING of B- or T-cell antigen receptors results in the rapid tyrosine phosphorylation of a number of proteins, including Vav, a protein expressed in cells of the haematopoietic system contains an array of structural motifs that include Src-homology domains SH2/SH3(4) and regions of homology to the guanine-nucleotide-exchange nucleotide-exchange protein Dbl, pleckstrin and protein kinase C (refs 5-9). Using the RAG-complementation approach(10), we have analysed in vivo differentiation and in vitro responses of B- and T-lineage cells generated by injection of embryonic stem cells homozygous for a null mutation in the vav gene into blastocysts of RAG-1- or RAG-2-deficient mice. Here we report that antigen receptor-mediated proliferative responses of B and T cells in vitro are severely reduced in the absence of Vav. We also suggest a direct link between the low proliferative response of Vav-deficient B and T cells and the reduced number of these cells in peripheral lymphoid organs of chimaeric mice.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	TARAKHOVSKY, A (corresponding author), UNIV COLOGNE,INST GENET,WEYERTAL 121,D-50931 COLOGNE,GERMANY.		Turner, Martin/N-9976-2014	Turner, Martin/0000-0002-3801-9896; Tybulewicz, Victor/0000-0003-2439-0798; Rajewsky, Klaus/0000-0002-6633-6370				ADAMS JM, 1992, ONCOGENE, V7, P611; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BOGUSKI MS, 1992, NATURE, V358, P113, DOI 10.1038/358113a0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHEN J, 1994, TRANSGENESIS TARGETE, P35; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; GALLAND F, 1992, ONCOGENE, V7, P585; GRUTZMANN R, 1981, THESIS U COLOGNE GER; JUNG S, 1994, J EXP MED, V179, P2023, DOI 10.1084/jem.179.6.2023; KANTOR AB, 1992, P NATL ACAD SCI USA, V89, P3320, DOI 10.1073/pnas.89.8.3320; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; PARSON M, 1986, GENETICS MOL IMMUNOL, V3; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SMITH L, 1986, GENETICS MOL IMMUNOL, V3; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	30	397	403	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					467	470		10.1038/374467a0	http://dx.doi.org/10.1038/374467a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700358				2022-12-24	WOS:A1995QP89900062
J	VANDUIJN, CM; HAVEKES, LM; VAN BROECKHOVEN, C; DEKNIJFF, P; HOFMAN, A				VANDUIJN, CM; HAVEKES, LM; VAN BROECKHOVEN, C; DEKNIJFF, P; HOFMAN, A			APOLIPOPROTEIN-E GENOTYPE AND ASSOCIATION BETWEEN SMOKING AND EARLY-ONSET ALZHEIMERS-DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARKINSONS-DISEASE; BINDING; DEMENTIA; ALLELE	Objective-To investigate the hypothesis that differential survival between smokers and nonsmokers leading to a decrease in the frequency of the e4 allele of the apolipoprotein E gene may explain the inverse relation between smoking history and early onset Alzheimer's disease. Design-A population based case-control study. Setting-The four northern provinces of the Netherlands and metropolitan Rotterdam. Subjects-175 patients with early onset Alzheimer's disease and two independent control groups of 159 and 457 subjects. Main outcome measures-Frequencies of the apolipoprotein e4 allele and relative risk of early onset Alzheimer's disease, Results-The inverse association between smoking history and early onset Alzheimer's disease could not be explained by a decrease in the frequency the apolipoprotein e4 allele, Among of this allele with a family history of dementia subjects with a history of smoking had a strongly reduced risk of early onset Alzheimer's disease (odds ratio 0.10 (95% confidence interval 0.01 to 0.87)). Conclusions-The results suggest that the inverse relation between smoking history and early onset Alzheimer's disease cannot be explained by an increased mortality in carriers of the apolipoprotein e4 allele who smoke, The association is strongly modified by the presence of the apolipoprotein e4 allele as well as by a family history of dementia.	TNO, INST PREVENT & HLTH RES, GAUBIUS LAB, LEIDEN, NETHERLANDS; UNIV ANTWERP, DEPT BIOCHEM, BORN BUNGE FDN, NEUROGENET LAB, B-2020 ANTWERP, BELGIUM	Netherlands Organization Applied Science Research; University of Antwerp	VANDUIJN, CM (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Van Broeckhoven, Christine/M-7853-2019; de Knijff, Peter/Y-2519-2018; Van Broeckhoven, Christine/G-8362-2017	Van Broeckhoven, Christine/0000-0003-0183-7665; de Knijff, Peter/0000-0002-0899-771X; Van Broeckhoven, Christine/0000-0003-0183-7665				BENSHLOMO Y, 1993, LANCET, V342, P1239; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; BRESLOW NE, 1987, INT AGENCY RES CANCE, V82; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Elston RC, 1987, ESSENTIALS BIOSTATIS; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRAVES AB, 1991, INT J EPIDEMIOL, V20, pS48, DOI 10.1093/ije/20.Supplement_2.S48; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HAVEKES LM, 1987, J LIPID RES, V28, P455; HOFMAN A, 1989, NEUROLOGY, V39, P1589, DOI 10.1212/WNL.39.12.1589; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; LARRICK JW, 1993, LANCET, V342, P1238, DOI 10.1016/0140-6736(93)92219-J; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORENS DM, 1994, LANCET, V343, P356, DOI 10.1016/S0140-6736(94)91194-0; POIRIER I, 1994, P SPRINGF M ALZH DIS, P72; RIGGS JE, 1993, LANCET, V342, P793, DOI 10.1016/0140-6736(93)91547-Y; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CM, 1991, BRIT MED J, V302, P1491, DOI 10.1136/bmj.302.6791.1491; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	25	75	76	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 11	1995	310	6980					627	631		10.1136/bmj.310.6980.627	http://dx.doi.org/10.1136/bmj.310.6980.627			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703749	Green Submitted, Green Published			2022-12-24	WOS:A1995QL98400015
J	HARDY, MA; SUNG, RS				HARDY, MA; SUNG, RS			TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											HARDY, MA (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY 10032, USA.							BURKE JF, 1994, NEW ENGL J MED, V331, P358, DOI 10.1056/NEJM199408113310604; CANTAROVICH D, 1994, TRANSPLANTATION, V57, P198, DOI 10.1097/00007890-199401001-00007; COLE EH, 1994, TRANSPLANTATION, V57, P60, DOI 10.1097/00007890-199401000-00012; DUNN SP, 1994, TRANSPLANTATION, V57, P544; GRIFFITH BP, 1994, TRANSPLANTATION, V57, P848, DOI 10.1097/00007890-199403270-00013; HRIEIK DE, 1994, TRANSPLANTATION, V57, P979; LASKOW DA, 1994, TRANSPLANTATION, V57, P640, DOI 10.1097/00007890-199402270-00030; LO CM, 1994, TRANSPLANTATION, V58, P543, DOI 10.1097/00007890-199409150-00003; MCDANIEL DO, 1994, TRANSPLANTATION, V57, P852, DOI 10.1097/00007890-199403270-00014; MEISER BM, 1994, TRANSPLANTATION, V57, P563; MONTAGNINO G, 1994, TRANSPLANTATION, V58, P149, DOI 10.1097/00007890-199405820-00005; NIKAEIN A, 1994, TRANSPLANTATION, V58, P786, DOI 10.1097/00007890-199410150-00006; OPELZ G, 1994, TRANSPLANTATION, V58, P443, DOI 10.1097/00007890-199408270-00009; OPELZ G, 1994, NEW ENGL J MED, V330, P816, DOI 10.1056/NEJM199403243301203; TAKEMOTO S, 1994, NEW ENGL J MED, V331, P760, DOI 10.1056/NEJM199409223311202; YANDZA T, 1994, TRANSPLANTATION, V58, P46, DOI 10.1097/00007890-199407000-00009; 1994, NEW ENGL J MED, V331, P1110	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1723	1725						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752438				2022-12-24	WOS:A1995RB09700046
J	HILL, A; JUGOVIC, P; YORK, I; RUSS, G; BENNINK, J; YEWDELL, J; PLOEGH, H; JOHNSON, D				HILL, A; JUGOVIC, P; YORK, I; RUSS, G; BENNINK, J; YEWDELL, J; PLOEGH, H; JOHNSON, D			HERPES-SIMPLEX VIRUS TURNS OFF THE TAP TO EVADE HOST IMMUNITY	NATURE			English	Article							PEPTIDE TRANSLOCATION; ENDOPLASMIC-RETICULUM; TRANSPORTER; CHAINS; CONSTRUCTION; EXPRESSION; MOLECULES; VARIANTS; HEAVY	MANY viruses have evolved mechanisms to avoid detection by the host immune system, Herpes simplex virus (HSV) expresses an immediate early protein, ICP47, which blocks presentation of viral peptides to MHC class I-restricted cells(1). The properties of the newly synthesized class I molecules in HSV-infected cells resemble those of cell lines deficient in the transporter associated with antigen processing (TAP) in that class I molecules are retained in the endoplasmic reticulum(1,2), and the heavy chain and beta(2)-microglubulin subunits dissociate in detergent extracts but the complex can be stabilized by peptides(1). We show here that ICP47 binds to TAP and prevents peptide translocation into the endoplasmic reticulum.	MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8N 325,CANADA; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	McMaster University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	HILL, A (corresponding author), MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139, USA.		York, Ian/X-9351-2019; yewdell, jyewdell@nih.gov jonathan/A-1702-2012	York, Ian/0000-0002-3478-3344; 				ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P3932, DOI 10.1073/pnas.89.9.3932; COUPAR BEH, 1988, GENE, V68, P1, DOI 10.1016/0378-1119(88)90593-8; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; CROMME FV, 1994, J EXP MED, V170, P335; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; HEEMELS MT, 1994, IMMUNITY, V1, P775, DOI 10.1016/S1074-7613(94)80019-7; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; HEEMELS MT, 1995, REV BIOCH, V64, P463; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HILL AB, 1994, J IMMUNOL, V152, P3736; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MAVROMARANAZOS P, 1986, J VIROL, V60, P807, DOI 10.1128/JVI.60.2.807-812.1986; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; ROESLE J, 1994, J EXP MED, V180, P1591; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUMACHER TNM, 1994, P NATL ACAD SCI USA, V91, P13004, DOI 10.1073/pnas.91.26.13004; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; STAM NJ, 1986, J IMMUNOL, V137, P2299; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	29	729	744	0	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					411	415		10.1038/375411a0	http://dx.doi.org/10.1038/375411a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760935				2022-12-24	WOS:A1995RB10100055
J	KIM, JS; KIM, Y; MARTI, K; KERRIDGE, JF				KIM, JS; KIM, Y; MARTI, K; KERRIDGE, JF			NITROGEN ISOTOPE ABUNDANCES IN THE RECENT SOLAR-WIND	NATURE			English	Article								ALTHOUGH lunar crystalline rocks are essentially devoid of nitrogen, the same is not true of the lunar regolith. The nitrogen contents of individual regolith samples (which can be as high as 0.012% by mass) correlate strongly with abundances of noble gases known to be implanted in the lunar surface by solar radiation, indicating that lunar regolith nitrogen is also predominantly of solar origin(1). The large variability in N-15/N-14 ratios measured in different regolith samples may thus reflect long-term changes in tbe isotopic composition of the solar radiation(1). But attempts to explain these variations have been hampered by the lack of any firm constraint on N-15/N-14 in, the present solar wind. Here we report measurements of nitrogen isotopes from two lunar samples that have had simple (and relatively recent) exposure histories. We find that nitrogen implanted in the lunar surface during the past 10(5) to 5 x 10(7) years has a N-15/N-14 ratio approximately 40 parts per thousand higher than that in the terrestrial atmosphere, which is substantially lower than most previous estimates(2,3). This isotopic signature probably represents the best measure of N-15/N-14 in, the present-day solar wind.	UNIV CALIF SAN DIEGO,DEPT CHEM 0317,LA JOLLA,CA 92093	University of California System; University of California San Diego								ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BECKER RH, 1994, METEORITICS, V29, P724, DOI 10.1111/j.1945-5100.1994.tb00790.x; BECKER RH, 1975, 6TH P LUN SCI C, P2131; BECKER RH, 1976, 7TH P LUN SCI C, P441; BECKER RH, 1977, P LUNAR PLANET SCI C, P3685; Behrmann C., 1973, P LUNAR PLANET SCI C, P1957; Cameron A., 1982, ESSAYS NUCL ASTROPHY, P23; FRICK U, 1988, 18TH P LUN PLAN SCI, P87; GEISS J, 1982, GEOCHIM COSMOCHIM AC, V46, P529, DOI 10.1016/0016-7037(82)90156-9; Geiss J., 1991, SUN TIME, P98; HEYMANN D, 1975, MOON PLANETS, V13, P81, DOI 10.1007/BF00567509; KERIDGE JF, 1980, ANCIENT SUN, P475; KERRIDGE JF, 1993, REV GEOPHYS, V31, P423, DOI 10.1029/93RG01953; KERRIDGE JF, 1975, SCIENCE, V188, P162, DOI 10.1126/science.188.4184.162; KERRIDGE JF, 1991, 21ST P LUN PLAN SCI, P301; KIM Y, 1992, LUNAR PLANET SCI, V23, P693; KOHL CP, 1978, P LUNAR PLANET SCI C, P2299; MARTI K, 1973, 4TH LUN SCI C, P2037; NORRIS SJ, 1983, 14TH P LUN PLAN SCI; RAO MN, 1958, GEOCHIM COSMOCHIM AC, V58, P4231; RAY J, 1982, LUNAR PLANET; WIELER R, IN PRESS ASTROPHYS J; YANIV A, 1981, ASTROPHYS J, V247, pL143, DOI 10.1086/183609	23	20	20	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					383	385		10.1038/375383a0	http://dx.doi.org/10.1038/375383a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760930				2022-12-24	WOS:A1995RB10100046
J	SMITH, EJ; MARSDEN, RG; PAGE, DE				SMITH, EJ; MARSDEN, RG; PAGE, DE			ULYSSES ABOVE THE SUNS SOUTH-POLE - AN INTRODUCTION	SCIENCE			English	Article								Ulysses has explored the field and particle environment of the sun's polar region. The solar wind speed was fast and nearly constant above -50 degrees latitude. Compositional differences were observed in slow (low-latitude) solar wind and in fast (high-latitude) solar wind. The radial magnetic field did not change with latitude, implying that polar cap magnetic fields are transported, toward the equator. The intensity of galactic cosmic rays was nearly independent of latitude. Their access to the polar region is opposed by outward-traveling, large amplitude waves in the magnetic field.	EUROPEAN SPACE TECHNOL CTR,EUROPEAN SPACE AGCY,DEPT SPACE SCI,2200 AG NOORDWIJK,NETHERLANDS	European Space Agency	SMITH, EJ (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.							BALOGH A, 1995, SCIENCE, V268, P1007, DOI 10.1126/science.268.5213.1007; FOUKAL PV, 1990, SOLAR ASTROPHYSICS; GEISS J, 1995, SCIENCE, V268, P1033, DOI 10.1126/science.7754380; GRZEDZIELSKI S, 1990, COSPAR C SERIES, V1; PHILLIPS JL, 1995, SCIENCE, V268, P1030, DOI 10.1126/science.268.5213.1030; SIMPSON JA, 1995, SCIENCE, V268, P1019, DOI 10.1126/science.268.5213.1019; SMITH EJ, 1991, EOS T AGU, V72, P241; WENZEL KP, 1992, ASTRON ASTROPHYS SUP, V92, P207; Zirin H, 1988, ASTROPHYSICS SUN; 1992, ASTRON ASTROPHYS S, V92, P207	10	48	49	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1005	1007		10.1126/science.7754377	http://dx.doi.org/10.1126/science.7754377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754377				2022-12-24	WOS:A1995QY93400027
J	RASTINEJAD, F; PERLMANN, T; EVANS, RM; SIGLER, PB				RASTINEJAD, F; PERLMANN, T; EVANS, RM; SIGLER, PB			STRUCTURAL DETERMINANTS OF NUCLEAR RECEPTOR ASSEMBLY ON DNA DIRECT REPEATS	NATURE			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; BINDING DOMAIN; RESPONSE ELEMENTS; X-RECEPTOR; VITAMIN-D; GLUCOCORTICOID RECEPTOR; GENE ENCODES; RXR-BETA; IDENTIFICATION	Nuclear receptor heterodimers recognize response elements composed of two direct repeats of the consensus sequence 5'-AGGTCA-3' separated by one to five base pairs. The 1.9 Angstrom crystal structure of the complex formed by the DNA-binding domains of the 9-cis retinoic acid receptor and thyroid hormone receptor bound to a thyroid-response element shows that the subunits interact through a DNA-supported interface involving the carboxy-terminal extension of the DNA-binding domain of the thyroid hormone receptor. The stereochemistry suggests a mechanism by which heterodimers recognize the inter-half-site spacing between direct repeats.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Yale University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Salk Institute			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FIOCCO MM, 1994, J MOL BIOL, V235, P709; FREEDMAN L, IN PRESS 9TH P WORKS; GEWIRTH DT, IN PRESS NATURE STRU; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUO ZJ, 1994, EUR J BIOCHEM, V223, P381, DOI 10.1111/j.1432-1033.1994.tb19004.x; MADAN AP, 1993, P NATL ACAD SCI USA, V90, P3588, DOI 10.1073/pnas.90.8.3588; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; NELSON CC, 1993, MOL ENDOCRINOL, V7, P1185, DOI 10.1210/me.7.9.1185; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; OTWINOWSKI Z, 1991, MLPHARE CCP4 P, P80; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRESLEY JP, 1988, J APPL CRYSTALLOGR, V21, P572; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1993, STRUCTURE, V1, P187, DOI 10.1016/0969-2126(93)90020-H; SMITH DP, 1994, NUCLEIC ACIDS RES, V22, P66, DOI 10.1093/nar/22.1.66; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; XU W, 1993, COLD SPRING HARB SYM, V58, P133, DOI 10.1101/SQB.1993.058.01.017; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	50	453	463	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					203	211		10.1038/375203a0	http://dx.doi.org/10.1038/375203a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746322				2022-12-24	WOS:A1995QY88100053
J	MARTOGLIO, B; HOFMANN, MW; BRUNNER, J; DOBBERSTEIN, B				MARTOGLIO, B; HOFMANN, MW; BRUNNER, J; DOBBERSTEIN, B			THE PROTEIN-CONDUCTING CHANNEL IN THE MEMBRANE OF THE ENDOPLASMIC-RETICULUM IS OPEN LATERALLY TOWARD THE LIPID BILAYER	CELL			English	Article							SIGNAL-RECOGNITION PARTICLE; MICROSOMAL-MEMBRANES; SECRETORY PROTEIN; BIOSYNTHETIC INCORPORATION; DOCKING PROTEIN; MESSENGER-RNA; TRANSLOCATION; SEQUENCE; ELONGATION; CHAIN	Lipids and proteins were found to contact a nascent type II membrane protein, as well as a nascent secretory protein, during their insertion into the membrane of the endoplasmic reticulum. This suggests that the protein-conducting channel is open laterally toward the lipid bilayer during an early stage of protein insertion. Contact to lipids was confined to the hydrophobic core region of the respective signal or signal anchor sequence. Thus, the nascent polypeptide is positioned in the translocation complex such that the signal or signal anchor sequence faces the lipid bilayer, whereas the hydrophilic, translocating portion is in proteinaceous environment.	ETH ZURICH, BIOCHEM LAB, CH-8092 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich	MARTOGLIO, B (corresponding author), UNIV HEIDELBERG, ZENTRUM MOLEK BIOL, D-69052 HEIDELBERG, GERMANY.			Hofmann, Michael Werner/0000-0002-2729-6062				ALBERTS B, 1988, MOL BIOL CELL; BAIN JD, 1991, J ORG CHEM, V56, P4615, DOI 10.1021/jo00015a011; BALDINI G, 1988, BIOCHEMISTRY-US, V27, P7951, DOI 10.1021/bi00420a054; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRUNNER J, 1989, METHOD ENZYMOL, V172, P628; BRUNNER J, 1993, CHEM SOC REV, V22, P183, DOI 10.1039/cs9932200183; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; ENGELMANN DM, 1991, CELL, V23, P411; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GLASER KB, 1986, BIOCHEM PHARMACOL, V35, P449, DOI 10.1016/0006-2952(86)90218-2; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HIGH S, 1993, J BIOL CHEM, V268, P26745; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPP J, 1987, J BIOL CHEM, V262, P1680; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1985, CURRENT TOPICS MEMBR, V24; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323	41	239	239	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 21	1995	81	2					207	214		10.1016/0092-8674(95)90330-5	http://dx.doi.org/10.1016/0092-8674(95)90330-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736572	Bronze, Green Published			2022-12-24	WOS:A1995QV41000009
J	GLANCY, JM; GARRATT, CJ; WOODS, KL; DEBONE, DP				GLANCY, JM; GARRATT, CJ; WOODS, KL; DEBONE, DP			QT DISPERSION AND MORTALITY AFTER MYOCARDIAL-INFARCTION	LANCET			English	Article							2-YEAR FOLLOW-UP; SUDDEN-DEATH; INTERVAL PROLONGATION; DISCHARGE; MAGNESIUM; RISK	QT dispersion may serve as a measure of variability in ventricular recovery time and may be a means of identifying patients at risk of arrhythmias and sudden death after acute myocardial infarction. We investigated this possibility on electrocardiograms (ECGs) recorded 2 or 3 days after infarction (early) and at least 4 weeks later (late). 163 patients who died between 1 day and 5 years after infarct were compared with an equal number of survivors matched for age and sex. 53 of the patients who died and 82 survivors also had late ECGs. There was no difference in early QT dispersion between the patients who died and the survivors (mean QT(c) dispersion 112.1 [SD 44.4] vs 109.9 [42.7] ms(1/2)). QT(c) dispersion fell significantly from early to late ECGs in survivors (110.9 [48.5] to 76.5 [28.8] ms(1/2)), but not in patients who died during follow-up (108.0 [51.0] to 98.9 [43.1] ms(1/2)). The difference between the groups in the mean change was significant (34.4 [55.2] vs 9.1 [60.8] ms(1/2), p=0.016). QT dispersion measured on an ECG recorded 2 or 3 days after acute myocardial infarction does not predict mortality during the next 5 years. Increased QT dispersion on ECGs recorded at least 4 weeks after infarct may be associated with subsequent mortality, but this finding must be confirmed in a prospective trial.	UNIV LEICESTER,DIV CARDIOL,LEICESTER,LEICS,ENGLAND; UNIV LEICESTER,DEPT MED & THERAPEUT,DIV CLIN PHARMACOL,LEICESTER,LEICS,ENGLAND	University of Leicester; University of Leicester								AHNVE S, 1984, AM HEART J, V108, P395, DOI 10.1016/0002-8703(84)90631-8; BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; BHULLAR HK, 1993, J ELECTROCARDIOL, V26, P321, DOI 10.1016/0022-0736(93)90053-G; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; BUTROUS GS, 1989, CLIN ASPECTS VENTRIC, P379; DAVEY P, 1994, BRIT HEART J, V71, P268; DAY CP, 1990, BRIT HEART J, V63, P342; DOROGHAZI RM, 1977, AM J CARDIOL, V41, P684; ELDAR M, 1990, BRIT HEART J, V63, P273; GLANCY JM, 1994, CLIN SCI S30, V86, P18; HIGHAM P, 1994, BRIT HEART J, V71, P508; HIGHAM PD, 1991, CIRCULATION S2, V13, P61; LAUNBJERG J, 1994, BRIT MED J, V308, P1196, DOI 10.1136/bmj.308.6938.1196; LEPESCHKIN E, 1952, CIRCULATION, V6, P378, DOI 10.1161/01.CIR.6.3.378; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; POHJOLASINTONEN S, 1986, AM J CARDIOL, V57, P1066, DOI 10.1016/0002-9149(86)90675-2; POTRATZ J, 1993, EUR HEART J S, V114, P254; PYE M, 1993, BRIT HEART J, V71, P511; SCHWARTZ PJ, 1978, CIRCULATION, V57, P1074, DOI 10.1161/01.CIR.57.6.1074; SHEN AC, 1972, AM J PATHOL, V67, P417; WARD D E, 1988, European Heart Journal, V9, P139; WHEELAN K, 1986, AM J CARDIOL, V57, P745, DOI 10.1016/0002-9149(86)90606-5; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; ZARDINI P, 1993, AM J CARDIOL, V72, pG98, DOI 10.1016/0002-9149(93)90114-R; 1983, NEW ENGL J MED, V309, P331	25	256	258	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					945	948		10.1016/S0140-6736(95)90697-5	http://dx.doi.org/10.1016/S0140-6736(95)90697-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715292				2022-12-24	WOS:A1995QT91900007
J	DAMBROSIO, D; HIPPEN, KL; MINSKOFF, SA; MELLMAN, I; PANI, G; SIMINOVITCH, KA; CAMBIER, JC				DAMBROSIO, D; HIPPEN, KL; MINSKOFF, SA; MELLMAN, I; PANI, G; SIMINOVITCH, KA; CAMBIER, JC			RECRUITMENT AND ACTIVATION OF PTP1C IN NEGATIVE REGULATION OF ANTIGEN RECEPTOR SIGNALING BY FC-GAMMA-RIIB1	SCIENCE			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASES; FC-GAMMA RECEPTOR; LYMPHOCYTES-B; CROSS-LINKING; MOTH-EATEN; PHOSPHOTYROSINE PHOSPHATASE; IMMUNODEFICIENT MUTANT; MOTHEATEN LOCUS; SH2 DOMAINS	Coligation of the Fc receptor on B cells, Fc gamma RIIB1, with the B cell antigen receptor (BCR) leads to abortive BCR signaling. Here it was shown that the Fc gamma RIIB1 recruits the phosphotyrosine phosphatase PTP1C after BCR coligation. This association is mediated by the binding of a 13-amino acid tyrosine-phosphorylated sequence to the carboxyl terminal Src homology 2 domain of PTP1C and activates PTP1C. Inhibitory signaling and PTP1C recruitment are dependent on the presence of the tyrosine within the 13-amino acid sequence. Inhibitory signaling mediated by Fc gamma RIIB1 is deficient in motheaten mice which do not express functional PTP1C. Thus, PTP1C is an effector of BCR-Fc gamma RIIB1 negative signal cooperativity.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80206; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Yale University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pani, Giovambattista/AAB-1446-2019; Siminovitch, Katherine/K-1475-2013; Mellman, Ira/ABG-5896-2020	Pani, Giovambattista/0000-0001-7133-8728; Cambier, John/0000-0002-7803-242X				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN PL, 1971, IMMUNOLOGY, V21, P967; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; DAMBROSIO D, UNPUB; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FRIDMAN WH, 1992, IMMUNOL REV, V125, P49, DOI 10.1111/j.1600-065X.1992.tb00625.x; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GREEN MC, 1975, J HERED, V66, P250, DOI 10.1093/oxfordjournals.jhered.a108625; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; JONES B, 1986, J IMMUNOL, V136, P348; JUSTEMENT LB, 1989, J IMMUNOL, V143, P881; KIM KJ, 1979, J IMMUNOL, V122, P549; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHLER H, 1977, J IMMUNOL, V119, P1979; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PHILLIPS NE, 1983, J IMMUNOL, V130, P602; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1976, J IMMUNOL, V116, P936; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SHULTZ LD, 1988, CURR TOP MICROBIOL, V137, P216; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WILSON HA, 1987, J IMMUNOL, V138, P1712; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	42	526	529	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					293	297		10.1126/science.7716523	http://dx.doi.org/10.1126/science.7716523			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716523				2022-12-24	WOS:A1995QT18500040
J	HARGREAVES, MR; FIROOZAN, S; FORFAR, JC				HARGREAVES, MR; FIROOZAN, S; FORFAR, JC			PRESCRIPTION OF REGULAR ASPIRIN IN PATIENTS WITH CHEST PAIN REFERRED TO A CARDIOLOGY OUTPATIENT-CLINIC	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANGINA; TRIAL				HARGREAVES, MR (corresponding author), JOHN RADCLIFFE HOSP, DEPT CARDIAC, OXFORD OX3 9DU, ENGLAND.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; CANNON PJ, 1988, LANCET, V1, P979; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835	4	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	1995	310	6982					777	777		10.1136/bmj.310.6982.777	http://dx.doi.org/10.1136/bmj.310.6982.777			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711583	Green Published			2022-12-24	WOS:A1995QP60900019
J	AZUMA, M; ITO, D; YAGITA, H; OKUMURA, K; PHILLIPS, JH; LANIER, LL; SOMOZA, C				AZUMA, M; ITO, D; YAGITA, H; OKUMURA, K; PHILLIPS, JH; LANIER, LL; SOMOZA, C			B70 ANTIGEN IS A 2ND LIGAND FOR CTLA-4 AND CD28	NATURE			English	Article							T-CELL ACTIVATION; COSTIMULATORY SIGNAL; LYMPHOCYTES-T; B-CELLS; EXPRESSION; AMPLIFICATION; SUPERFAMILY; MECHANISM; RECEPTOR; B7/BB-1	THE membrane antigen B7/BB1 (refs 1, 2) is expressed on activated B cells, macrophages and dendritic cells, and binds to a counter-receptor, CD28, expressed on T lymphocytes and thymocytes3. Interaction between CD28 and B7 results in potent costimulation of T-cell activation initiated through the CD3/T-cell receptor complex4,5. Discrepancies between results with anti-CD28 and anti-B7 antibodies have suggested the existence of a second ligand for CD28 and CTLA-4 (refs 3, 6-8). We have generated a monoclonal antibody, IT2, that reacts with a 70K glycoprotein (B70). B70 complementary DNA was cloned from a B-lymphoblastoid cell line library and encodes a new protein of the immunoglobulin superfamily with limited homology to B7. B70 is expressed on resting monocytes and dendritic cells and on activated, but not resting, T, NK and B lymphocytes. IT2 substantially inhibited the binding of a CTLA4-immunoglobulin fusion protein to human B-lymphoblastoid cell lines and, together with anti-B7 antibody, completely blocked CTLA-4 binding. Further IT2 efficiently inhibited primary allogeneic mixed lymphocyte responses. These findings indicate that B70 is a second ligand for CD28 and CTLA-4 and may play an important role for costimulation of T cells in a primary immune response.	UNIV TOKYO,FAC MED,DEPT ORAL & MAXILLOFACIAL SURG,BUNKYO KU,TOKYO 113,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304	University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	AZUMA, M (corresponding author), JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,HONGO 2-1-1,BUNKYO KU,TOKYO 113,JAPAN.		Azuma, Miyuki/AAT-8928-2021; Lanier, Lewis L/E-2139-2014	Azuma, Miyuki/0000-0002-3529-4585; Lanier, Lewis L/0000-0003-1308-3952				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; AZUMA M, 1992, J IMMUNOL, V149, P1115; AZUMA M, 1993, J IMMUNOL, V150, P2091; AZUMA M, 1993, J EXP MED, V177, P845, DOI 10.1084/jem.177.3.845; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; DOMLO NK, 1991, EUR J IMMUNOL, V21, P1277; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LANIER L L, 1991, Methods (Orlando), V2, P192, DOI 10.1016/S1046-2023(05)80061-1; LANIER LL, 1988, J IMMUNOL, V141, P3478; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; NORTON SD, 1992, J IMMUNOL, V149, P1556; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; VALLE A, 1991, INT IMMUNOL, V3, P229, DOI 10.1093/intimm/3.3.229; YOKOCHI T, 1982, J IMMUNOL, V128, P823; YOUNG JW, 1992, J CLIN INVEST, V90, P229, DOI 10.1172/JCI115840	24	910	981	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					76	79		10.1038/366076a0	http://dx.doi.org/10.1038/366076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	7694153				2022-12-24	WOS:A1993MF00700058
J	LARDER, BA; KELLAM, P; KEMP, SD				LARDER, BA; KELLAM, P; KEMP, SD			CONVERGENT COMBINATION THERAPY CAN SELECT VIABLE MULTIDRUG-RESISTANT HIV-1 IN-VITRO	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS; HIGH-LEVEL RESISTANCE; NONNUCLEOSIDE INHIBITORS; ZIDOVUDINE AZT; TYPE-1; SENSITIVITY; REPLICATION; MUTATION; SUSCEPTIBILITIES	THE reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1) is the target for many inhibitors1. Amino-acid substitutions in functional regions of the enzyme that abolish reverse transcriptase activity also prevent HIV-1 replication2,3. But selection pressure by drugs such as AZT (3'-azido-3'-deoxythymidine, zidovudine)4-6, ddI(2',3'-dideoxyinosine)7,8 and non-nucleoside reverse transcriptase inhibitors (NNRTIs)9-14 causes outgrowth of resistant variants due to non-lethal mutations in the enzyme7,9-16. Reports of synergy17-19 and lack of cross-resistance between reverse transcriptase inhibitors (refs 7, 9, 10, 12-14, 17, 18, 20, 21), plus the reversal of AZT resistance by mutations induced by ddI7 and NNRTIs14, have indicated that specific drug combinations directed at reverse transcriptase might curtail resistance. Chow et al.22 extended this concept in a report that specific multiple combinations of resistance mutations in the reverse transcriptase can significantly impair HIV-1 replication. They concluded that evolutionary limitations may exist to prevent the emergence of multidrug resistance to inhibitors of reverse transcriptase22. We report here that HIV-1 co-resistant to AZT, ddI and the NNRTI nevirapine23 can be readily selected in cell culture starting with dual AZT- and ddI-resistant virus. We found no evidence for 'replication incompatible' combinations of resistance mutations, although a mutation (M184-->V) conferring oxathiolane-cytosine nucleoside resistance in reverse transcriptase24,25 completely suppressed AZT resistance in a triple-resistant background. These in vitro observations suggest that triple drug combination therapy might ultimately result in co-resistant HIV-1, although they do not preclude assessment of such combinations for treatment of HIV-1 disease.			LARDER, BA (corresponding author), WELLCOME RES LABS,ANTIVIRAL THERAPEUT RES UNIT,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND.		Larder, Brendan/AAB-3106-2020	Kellam, Paul/0000-0003-3166-4734				BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0; CHOW YK, 1993, NATURE, V364, P679, DOI 10.1038/364679a0; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; DUEWEKE TJ, 1993, P NATL ACAD SCI USA, V90, P4713, DOI 10.1073/pnas.90.10.4713; EMINI EA, 1993, NATURE, V364, P679, DOI 10.1038/364679b0; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; JOHNSON VA, 1991, J INFECT DIS, V164, P646, DOI 10.1093/infdis/164.4.646; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1992, ANTIMICROB AGENTS CH, V36, P2664, DOI 10.1128/AAC.36.12.2664; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Larder Brendan A., 1993, P527; MCLEOD GX, 1992, ANTIMICROB AGENTS CH, V36, P920, DOI 10.1128/AAC.36.5.920; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653	29	145	155	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					451	453		10.1038/365451a0	http://dx.doi.org/10.1038/365451a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	7692302				2022-12-24	WOS:A1993LZ63300059
J	FUKUNAGA, R; ISHIZAKAIKEDA, E; NAGATA, S				FUKUNAGA, R; ISHIZAKAIKEDA, E; NAGATA, S			GROWTH AND DIFFERENTIATION SIGNALS MEDIATED BY DIFFERENT REGIONS IN THE CYTOPLASMIC DOMAIN OF GRANULOCYTE-COLONY-STIMULATING FACTOR-RECEPTOR	CELL			English	Article							HEMATOPOIETIC-CELLS; HUMAN MYELOPEROXIDASE; MOLECULAR-CLONING; MYELOID-LEUKEMIA; CHROMOSOMAL GENE; EXPRESSION; MACROPHAGE; CDNA; IDENTIFICATION; PROLIFERATION	Granulocyte colony-stimulating factor (G-CSF) is a cytokine that regulates the proliferation and differentiation of neutrophils. The G-CSF receptor (G-CSFR) is a member of the hemopoietic growth factor receptor family. A G-CSFR expression plasmid was introduced into interleukin-3 (IL-3)-dependent mouse myeloid precursor FDC-P1 cells that normally do not respond to G-CSF. G-CSF stimulated proliferation of the transformants, down-regulated Thy-1 and F4/80 antigens on the cell surface, and induced expression of neutrophil-specific genes such as myeloperoxidase (MPO) and leukocyte elastase. On the other hand, neither granulocyte/macrophage colony-stimulating factor (GM-CSF) nor IL-3 induced MPO gene expression, but they inhibited G-CSFR-mediated MPO gene expression. These results suggested that the G-CSFR, but not the IL-3/GM-CSF receptors, transduced the neutrophilic differentiation signal into cells. Mutational analysis of the G-CSFR indicated that the N-terminal region of its cytoplasmic domain is sufficient to transduce the proliferation signal into cells, while the C-terminal region plays an essential role in transducing the differentiation signal.	OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN				Nagata, Shigekazu/AAG-3203-2019; Fukunaga, Rikiro/CAG-2891-2022	Nagata, Shigekazu/0000-0001-9758-8426; 				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BAINTON DF, 1990, HEMATOLOGY, P761; BASCH RS, 1982, EUR J IMMUNOL, V12, P359, DOI 10.1002/eji.1830120502; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P1556; DEMETRI GD, 1991, BLOOD, V78, P2791; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HOLMES KL, 1988, IMMUNOL TODAY, V9, P344, DOI 10.1016/0167-5699(88)91335-7; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P1232; LEE KH, 1991, J EXP MED, V173, P1257, DOI 10.1084/jem.173.5.1257; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; METCALF D, 1992, P NATL ACAD SCI USA, V89, P2819, DOI 10.1073/pnas.89.7.2819; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORISHITA K, 1987, J BIOL CHEM, V262, P15208; MORISHITA K, 1987, J BIOL CHEM, V262, P3844; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAGATA S, 1993, GROWTH FACTORS, V8, P99, DOI 10.3109/08977199309046930; NAGATA S, 1991, Progress in Growth Factor Research, V3, P131, DOI 10.1016/S0955-2235(05)80004-3; NAGATA S, 1990, HDB EXPT PHARM, V95, P699; NICOLA NA, 1983, J BIOL CHEM, V258, P9017; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; OKANO K, 1987, J BIOCHEM-TOKYO, V102, P13, DOI 10.1093/oxfordjournals.jbchem.a122024; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAKAHASHI H, 1988, J BIOL CHEM, V263, P2543; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TESHIMA T, 1990, EXP HEMATOL, V18, P316; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VENTURELLI D, 1989, NUCLEIC ACIDS RES, V17, P5852, DOI 10.1093/nar/17.14.5852; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	45	254	257	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1079	1087		10.1016/0092-8674(93)90729-A	http://dx.doi.org/10.1016/0092-8674(93)90729-A			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	7691413				2022-12-24	WOS:A1993LY49300014
J	WJST, M; REITMEIR, P; DOLD, S; WULFF, A; NICOLAI, T; VONLOEFFELHOLZCOLBERG, EF; VONMUTIUS, E				WJST, M; REITMEIR, P; DOLD, S; WULFF, A; NICOLAI, T; VONLOEFFELHOLZCOLBERG, EF; VONMUTIUS, E			ROAD TRAFFIC AND ADVERSE-EFFECTS ON RESPIRATORY HEALTH IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							AIR-POLLUTION; LUNG-FUNCTION; PULMONARY-FUNCTION; PASSIVE SMOKING; SYMPTOMS; ENVIRONMENT; CHILDHOOD; EXPOSURE	Objectives-To examine whether road traffic in a big city has a direct effect on pulmonary function and respiratory symptoms in children. Design-Cross sectional study. Setting-Of all 7445 fourth grade children (aged 9-11 years) in Munich, 6537 were examined. Of the children with German nationality and the same residence during the past five years and known exposure data, 4678 questionnaires and 4320 pulmonary function tests could be analysed. Main outcome measures-Variables of pulmonary function by forced expiration and respiratory symptoms reported in a questionnaire; census data on car traffic collected in the school district. Results-Density of car traffic ranged from 7000 to 125000 cars per 24 hours. Multiple regression analysis of peak expiratory flow showed a significant decrease of 0.71% (95% confidence interval 1.08% to 0.33%) per increase of 25000 cars daily passing through the school district on the main road. Maximum expiratory flow when 25% vital capacity had been expired was decreased by 0.68% (1.11% to 0.25%). In contrast, response to cold air challenge was not increased. The adjusted odds ratio for the cumulative prevalence of recurrent wheezing with the same exposure was 1.08 (1.01 to 1.16). Cumulative prevalence of recurrent dyspnoea was increased, with an odds ratio of 1.10 (1.00 to 1.20). Lifetime prevalence of asthma (odds ratio 1.04; 0.89 to 1.21) and recurrent bronchitis (1.05; 0.98 to 1.12) were not significantly increased. Conclusions-High rates of road traffic diminish forced expiratory flow and increase respiratory symptoms in children.	TECH UNIV MUNICH,INST UMWELTHYG & TOXIKOL,D-80636 MUNICH,GERMANY; UNIV MUNICH,DR VON HAUNERSCHE KINDERKLIN,D-80337 MUNICH,GERMANY; STADT GESUNDHEITSBEHORDE,D-80335 MUNICH,GERMANY	Technical University of Munich; University of Munich	WJST, M (corresponding author), GSF,FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST MED INFORMAT & SYST FORSCH,POB 1129,D-85758 OBERSCHLEISSHEIM,GERMANY.							AMES RG, 1984, ARCH ENVIRON HEALTH, V39, P389, DOI 10.1080/00039896.1984.10545870; AROSSA W, 1987, ARCH ENVIRON HEALTH, V42, P170, DOI 10.1080/00039896.1987.9935817; Atkinson R., 1988, AIR POLLUTION AUTOMO, P99; BROMBERG PA, 1988, AIR POLLUTION AUTOMO, P465; BURCHFIEL CM, 1986, AM REV RESPIR DIS, V133, P966; CHARPIN D, 1988, ARCH ENVIRON HEALTH, V43, P22, DOI 10.1080/00039896.1988.9934369; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; DOLD S, 1992, MONATSSCHR KINDERH, V140, P763; EVANS RG, 1988, AM J IND MED, V14, P25, DOI 10.1002/ajim.4700140105; FARLEY JM, 1992, ANNU REV PHARMACOL, V32, P67, DOI 10.1146/annurev.pharmtox.32.1.67; GAMBLE J, 1987, ENVIRON RES, V42, P201, DOI 10.1016/S0013-9351(87)80022-1; GODLEE F, 1991, BRIT MED J, V303, P1539, DOI 10.1136/bmj.303.6816.1539; GOREN AI, 1988, ENVIRON RES, V46, P107, DOI 10.1016/S0013-9351(88)80025-2; HIGGINS ITT, 1990, AM REV RESPIR DIS, V141, P1136, DOI 10.1164/ajrccm/141.5_Pt_1.1136; HOPPENBROUWERS T, 1990, LUNG S, V68, P35; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; KOENIG JQ, 1988, J ALLERGY CLIN IMMUN, V81, P1055, DOI 10.1016/0091-6749(88)90180-7; MURAKAMI M, 1990, Journal of Human Ergology, V19, P101; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204, DOI 10.1093/oxfordjournals.aje.a116073; NGANGA LW, 1992, AM REV RESPIR DIS, V145, P48, DOI 10.1164/ajrccm/145.1.48; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53, DOI 10.1080/00039896.1993.9938393; ROMIEU I, 1992, AM J EPIDEMIOL, V136, P1524, DOI 10.1093/oxfordjournals.aje.a116474; SAMET JM, 1933, TOXICOLOGY LUNG, P311; SAMSON PJ, 1988, POLLUTION AUTOMOBILE, P77; SCHWARTZ J, 1992, ARCH ENVIRON HEALTH, V47, P116, DOI 10.1080/00039896.1992.10118764; SPEIZER FE, 1973, ARCH ENVIRON HEALTH, V26, P313, DOI 10.1080/00039896.1973.10666289; ULFVARSON U, 1990, AM J IND MED, V17, P341, DOI 10.1002/ajim.4700170306; VEDAL S, 1987, AM J PUBLIC HEALTH, V77, P694, DOI 10.2105/AJPH.77.6.694; VONMUTIUS E, 1991, MUNCHEN MED WOCHEN, V133, P675; WARDLAW AJ, 1993, CLIN EXP ALLERGY, V23, P81, DOI 10.1111/j.1365-2222.1993.tb00303.x; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; Yokoyama Y, 1985, Tokai J Exp Clin Med, V10, P379; 1989, SAS USERS GUIDE STAT; 1987, AIR QUALITY GUIDELIN; 1990, UMWELTATLAS MUNCHEN; 1990, BELASTUNGSBEBIET MUN; 1988, BERICHT IMMISSIONSME; 1985, AM REV RESPIR DIS, V131, P666; 1990, STATISCHE TASCHENBUC	40	325	330	0	35	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					596	600		10.1136/bmj.307.6904.596	http://dx.doi.org/10.1136/bmj.307.6904.596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	7691304	Green Published, Bronze			2022-12-24	WOS:A1993LW14900016
J	HSU, HL; XIONG, J; GOEDDEL, DV				HSU, HL; XIONG, J; GOEDDEL, DV			THE TNF RECEPTOR 1-ASSOCIATED PROTEIN TRADD SIGNALS CELL-DEATH AND NF-KAPPA-B ACTIVATION	CELL			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; EXPRESSION; DOMAIN; MONOCYTOGENES; ANTIBODIES; RESISTANT; INFECTION; SYSTEM; VIRUS	Many diverse activities of tumor necrosis factor (TNF) are signaled through TNF receptor 1 (TNFR1). We have identified a novel 34 kDa protein, designated TRADD, that specifically interacts with an intracellular domain of TNFR1 known to be essential for mediating programmed cell death. Overexpression of TRADD leads to two major TNF-induced responses, apoptosis and activation of NF-kappa B. The C-terminal 118 amino acids of TRADD are sufficient to trigger both of these activities and likewise sufficient for interaction with the death domain of TNFR1. TRADD-mediated cell death can be suppressed by the crmA gene, which encodes a specific inhibitor of the interleukin-1 beta-converting enzyme. However, NF-kappa B activation by TRADD is not inhibited by crmA expression, demonstrating that the signaling pathways for TNF-induced cell death and NF-kappa B activation are distinct.			HSU, HL (corresponding author), TULARIK INC,270 E GRAND AVE,S SAN FRANCISCO,CA 94080, USA.							AUSUBEL FM, 1994, CURR PROT MOL BIOL, V1; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GEHR G, 1992, J IMMUNOL, V149, P911; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; HU MH, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; IWABUCHI K, 1993, ONCOGENE, V8, P1693; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KRUPPA G, 1992, J IMMUNOL, V148, P3152; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MIURA M, 1993, CELL, V75, P656; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; RAY CA, 1992, CELL, V69, P587; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONG HY, 1994, J BIOL CHEM, V269, P22492; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOMEI LD, 1991, CURR COMM CELL MOL B, V3, P5; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG GHW, 1994, J IMMUNOL, V152, P1751; WONG GHW, 1992, J IMMUNOL, V149, P3550	44	1682	1756	0	37	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					495	504		10.1016/0092-8674(95)90070-5	http://dx.doi.org/10.1016/0092-8674(95)90070-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758105	Bronze			2022-12-24	WOS:A1995QZ71000006
J	FLORIN, THJ; HILLS, BA				FLORIN, THJ; HILLS, BA			DOES COUNTERPERFUSION SUPERSATURATION CAUSE GAS CYSTS IN PNEUMATOSIS CYSTOIDES COLI, AND CAN BREATHING HELIOX REDUCE THEM	LANCET			English	Article							INTESTINALIS; EXCRETION	The pathogenesis of pneumatosis cystoides coli remains obscure in the absence of an explanation for why pockets of gas should form in the first place and why they should be maintained in the wall and mesentery of the colon. Counterperfusion supersaturation could explain the formation and location of the gas cysts, which occur mostly near brood vessels on the mesenteric border of the colon, and the absence of methane gas in them. The hypothesis can be tested by treating patients with pneumatosis cystoides coli with heliox.	MATER MISERICORDIAE HOSP,MATER RES INST,BRISBANE,QLD 4101,AUSTRALIA	Mater Research	FLORIN, THJ (corresponding author), UNIV QUEENSLAND,DEPT MED,ST LUCIA,QLD 4067,AUSTRALIA.		Florin, Tim HJ/F-1890-2010					BLENKARN GD, 1971, AEROSPACE MED, V42, P141; CHRISTL SU, 1993, GASTROENTEROLOGY, V104, P392, DOI 10.1016/0016-5085(93)90406-3; COLLINS JM, 1978, J APPL PHYSIOL, V44, P914, DOI 10.1152/jappl.1978.44.6.914; ECKER JA, 1971, AM J GASTROENTEROL, V56, P125; ELLIS BW, 1980, BRIT MED J, V280, P763, DOI 10.1136/bmj.280.6216.763-a; FORGACS P, 1973, LANCET, V1, P579; GILLON J, 1979, GUT, V20, P1008, DOI 10.1136/gut.20.11.1008; HABOUBI NY, 1984, HISTOPATHOLOGY, V8, P145, DOI 10.1111/j.1365-2559.1984.tb02329.x; HAYDUK W, 1974, AICHE J, V20, P611, DOI 10.1002/aic.690200329; Hills B.A., 1988, BIOL SURFACTANT; HILLS BA, 1977, J APPL PHYSIOL, V42, P758, DOI 10.1152/jappl.1977.42.5.758; HILLS BA, 1969, CLIN SCI, V36, P185; HILLS BA, 1983, AM J PHYSIOL, V244, P561; HILS BA, 1977, DECOMPRESSION SICKNE; HUGHES DTD, 1966, GUT, V7, P553, DOI 10.1136/gut.7.5.553; KOSS LG, 1952, AMA ARCH PATHOL, V53, P523; LAMBERTSEN CJ, 1975, J APPL PHYSIOL, V39, P434, DOI 10.1152/jappl.1975.39.3.434; LEVITT MD, 1971, NEW ENGL J MED, V284, P1394, DOI 10.1056/NEJM197106242842502; MAHMOOD A, 1993, ARCH BIOCHEM BIOPHYS, V300, P280, DOI 10.1006/abbi.1993.1039; MCKAY LF, 1985, GUT, V26, P69, DOI 10.1136/gut.26.1.69; READ NW, 1984, GUT, V25, P839, DOI 10.1136/gut.25.8.839; REINHOFF WF, 1959, ANN SURG, V149, P593; STIENNON OA, 1951, AMA AM J DIS CHILD, V81, P651, DOI 10.1001/archpedi.1951.02040030664004; VANDERLINDEN W, 1979, SCAND J GASTROENTERO, V14, P173, DOI 10.3109/00365527909179864	24	26	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1220	1222		10.1016/S0140-6736(95)91996-1	http://dx.doi.org/10.1016/S0140-6736(95)91996-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739311				2022-12-24	WOS:A1995QX86100014
J	WILLEMSEN, R; MOHKAMSING, S; DEVRIES, B; DEVYS, D; VANDENOUWELAND, A; MANDEL, JL; GALJAARD, H; OOSTRA, B				WILLEMSEN, R; MOHKAMSING, S; DEVRIES, B; DEVYS, D; VANDENOUWELAND, A; MANDEL, JL; GALJAARD, H; OOSTRA, B			RAPID ANTIBODY-TEST FOR FRAGILE-X SYNDROME	LANCET			English	Note							CGG REPEAT; FMR-1; CARRIERS	Fragile X syndrome is the most common known cause of inherited mental retardation. Identification of patients and carriers of fragile X syndrome is usually done with a DNA test system but we have developed a rapid antibody to identify fragile X patients. This non-invasive test requires only 1 or 2 drops of blood and can be used for screening large groups of mentally retarded people and neonates for fragile X syndrome.	ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS; UNIV STRASBOURG 1,CU,INSERM,CNRS,INST GENET & BIOL MOLEC & CELLULAIRE,STRASBOURG,FRANCE	Erasmus University Rotterdam; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Devys, Didier/0000-0001-9655-3512				DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; OOSTRA BA, 1993, J MED GENET, V30, P410, DOI 10.1136/jmg.30.5.410; ROUSSEAU F, 1991, J MED GENET, V28, P830, DOI 10.1136/jmg.28.12.830; ROUSSEAU F, 1994, AM J HUM GENET, V55, P225; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536	9	137	140	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1147	1148		10.1016/S0140-6736(95)90979-6	http://dx.doi.org/10.1016/S0140-6736(95)90979-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723547				2022-12-24	WOS:A1995QW62200011
J	HEBERT, DN; FOELLMER, B; HELENIUS, A				HEBERT, DN; FOELLMER, B; HELENIUS, A			GLUCOSE TRIMMING AND REGLUCOSYLATION DETERMINE GLYCOPROTEIN ASSOCIATION WITH CALNEXIN IN THE ENDOPLASMIC-RETICULUM	CELL			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; INFLUENZA-VIRUS HEMAGGLUTININ; BINDING-PROTEINS; DISULFIDE BONDS; MICROSOMES; PURIFICATION; MEMBRANE; GLUCOSYLTRANSFERASE; INHIBITORS; MATURATION	To determine the role of N-linked oligosaccharides in the folding of glycoproteins, we analyzed the processing of in vitro translated influenza hemagglutinin (HA) in dog pancreas microsomes. We found that binding to calnexin, a membrane-bound molecular chaperone, was specific to molecules that possessed monoglucosylated core glycans. In the microsomes, these were generated either by glucose removal from the original triglucosylated core oligosaccharide by glucosidases I and II or by reglucosylation of already unglucosylated high mannose glycans. Release of fully folded HA from calnexin required the removal of the remaining glucose by glucosidase II. The results provided an explanation for trimming and reglucosylation activities in the endoplasmic reticulum and established a direct correlation between glycosylation and folding.			HEBERT, DN (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06520, USA.				NIGMS NIH HHS [GM38346] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038346] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ATKINSON PH, 1984, J CELL BIOL, V98, P2245, DOI 10.1083/jcb.98.6.2245; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRADA D, 1984, EUR J BIOCHEM, V141, P149, DOI 10.1111/j.1432-1033.1984.tb08169.x; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DOMS RW, 1985, J BIOL CHEM, V260, P2973; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HETTKAMP H, 1984, EUR J BIOCHEM, V142, P85, DOI 10.1111/j.1432-1033.1984.tb08253.x; HIRAIZUMI S, 1993, J BIOL CHEM, V268, P9927; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KERN G, 1993, PROTEIN SCI, V2, P1862, DOI 10.1002/pro.5560021108; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LE AQ, 1994, J BIOL CHEM, V269, P7514; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; MICHAEL JM, 1980, ARCH BIOCHEM BIOPHYS, V199, P249, DOI 10.1016/0003-9861(80)90278-7; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PIND S, 1994, J BIOL CHEM, V289, P12784; RAJOGAPALAN S, 1994, SCIENCE, V263, P387; ROBERTS PC, 1993, J VIROL, V67, P3048, DOI 10.1128/JVI.67.6.3048-3060.1993; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; TATU U, 1995, IN PRESS EMBO J; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; WADA I, 1994, J BIOL CHEM, V269, P7464; WADA I, 1991, J BIOL CHEM, V266, P19599; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	51	448	453	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					425	433		10.1016/0092-8674(95)90395-X	http://dx.doi.org/10.1016/0092-8674(95)90395-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736594	hybrid			2022-12-24	WOS:A1995QW89400014
J	SPRUSTON, N; SCHILLER, Y; STUART, G; SAKMANN, B				SPRUSTON, N; SCHILLER, Y; STUART, G; SAKMANN, B			ACTIVITY-DEPENDENT ACTION-POTENTIAL INVASION AND CALCIUM INFLUX INTO HIPPOCAMPAL CA1 DENDRITES	SCIENCE			English	Article							LONG-TERM POTENTIATION; SOURCE-DENSITY ANALYSIS; PYRAMIDAL CELLS; CA2+ ENTRY; SYNAPTIC TRANSMISSION; NEURONS; RECORDINGS; ACTIVATION; DISCHARGE	The temporal and spatial profile of activity-evoked changes in membrane potential and intracellular calcium concentration in the dendrites of hippocampal CA1 pyramidal neurons was examined with simultaneous somatic and dendritic patch-pipette recording and calcium imaging experiments. Action potentials are initiated close to the soma of these neurons and backpropagate into the dendrites in an activity-dependent manner; those occurring early in a train propagate actively, whereas those occurring later fail to actively invade the distal dendrites. Consistent with this finding, dendritic calcium transients evoked by single action potentials do not significantly attenuate with distance from the soma, whereas those evoked by trains attenuate substantially. Failure of action potential propagation into the distal dendrites often occurs at branch points. Consequently, neighboring regions of the dendritic tree can experience different voltage and calcium signals during repetitive action potential firing. The influence of backpropagating action potentials on synaptic integration and plasticity will therefore depend on both the extent of dendritic branching and the pattern of neuronal activity.			SPRUSTON, N (corresponding author), MAX PLANCK INST MED RES,ZELLPHYSIOL ABT,JAHNSTR 29,D-69120 HEIDELBERG,GERMANY.		Hausser, Michael/AAW-6827-2020; stuart, greg j/F-7328-2011	Hausser, Michael/0000-0002-2673-8957; stuart, greg/0000-0001-9395-2219; Spruston, Nelson/0000-0003-3118-1636				ANDERSEN P, 1966, EXP BRAIN RES, V2, P247; ANDERSEN P, 1966, ACTA PHYSIOL SCAND, V66, P461, DOI 10.1111/j.1748-1716.1966.tb03224.x; ANDERSEN P, 1960, ACTA PHYSIOL SCAND, V48, P178, DOI 10.1111/j.1748-1716.1960.tb01856.x; BLAND BH, 1993, PROG NEUROBIOL, V41, P157, DOI 10.1016/0301-0082(93)90007-F; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COLLING SB, 1994, NEUROSCI LETT, V172, P73, DOI 10.1016/0304-3940(94)90665-3; CRAGG BG, 1955, J PHYSIOL-LONDON, V129, P608, DOI 10.1113/jphysiol.1955.sp005382; Eccles, 2013, PHYSL SYNAPSES; FUJITA Y, 1962, J NEUROPHYSIOL, V25, P209, DOI 10.1152/jn.1962.25.2.209; GOLDSTEIN SS, 1974, BIOPHYS J, V14, P731, DOI 10.1016/S0006-3495(74)85947-3; GROVER LM, 1990, NATURE, V347, P447; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HERRERAS O, 1990, J NEUROPHYSIOL, V64, P1429, DOI 10.1152/jn.1990.64.5.1429; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JEFFERYS JGR, 1979, J PHYSIOL-LONDON, V289, P375, DOI 10.1113/jphysiol.1979.sp012742; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; LUSCHER C, 1994, J NEUROPHYSIOL, V72, P634, DOI 10.1152/jn.1994.72.2.634; LUSCHER G, 1994, J NEUROPHYSIOL, V72, P622; MAGEE JC, IN PRESS J PHYSL LON; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MIYAKAWA H, 1986, BRAIN RES, V399, P303, DOI 10.1016/0006-8993(86)91520-9; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; POOLOS NP, 1990, BRAIN RES, V524, P342, DOI 10.1016/0006-8993(90)90714-M; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; REGEHR WG, 1992, J NEUROSCI, V12, P4202; RICHARDSON TL, 1987, J NEUROPHYSIOL, V58, P981, DOI 10.1152/jn.1987.58.5.981; SCHILLER J, IN PRESS J PHYSL LON; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325, DOI 10.1113/jphysiol.1995.sp020521; STUART G, 1994, NEURON, V13, P703, DOI 10.1016/0896-6273(94)90037-X; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TURNER RW, 1989, J NEUROPHYSIOL, V62, P1375, DOI 10.1152/jn.1989.62.6.1375; TURNER RW, 1991, J NEUROSCI, V11, P2270; WONG RKS, 1979, P NATL ACAD SCI USA, V76, P986, DOI 10.1073/pnas.76.2.986	36	660	667	0	21	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					297	300		10.1126/science.7716524	http://dx.doi.org/10.1126/science.7716524			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716524				2022-12-24	WOS:A1995QT18500041
J	KRIEG, AM; YI, AK; MATSON, S; WALDSCHMIDT, TJ; BISHOP, GA; TEASDALE, R; KORETZKY, GA; KLINMAN, DM				KRIEG, AM; YI, AK; MATSON, S; WALDSCHMIDT, TJ; BISHOP, GA; TEASDALE, R; KORETZKY, GA; KLINMAN, DM			CPG MOTIFS IN BACTERIAL-DNA TRIGGER DIRECT B-CELL ACTIVATION	NATURE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; BINDING; OLIGONUCLEOTIDES; PHOSPHOROTHIOATE; STIMULATION; LYMPHOCYTES; FRAGMENTS; MICE	UNMETHYLATED CpG dinucleotides are more frequent in the genomes of bacteria and viruses than of vertebrates. We report here that bacterial DNA and synthetic oligodeoxynucleotides containing unmethylated CPG dinucleotides induce murine B cells to proliferate and secrete immunoglobulin in vitro and in vivo. This activation is enhanced by simultaneous signals delivered through the antigen receptor. Optimal B-cell activation requires a DNA motif in which an unmethylated CpG dinucleotide is flanked by two 5' purines and two 3' py,rimidines. Oligodeoxynucleotides containing this CpG motif induce more than 95% of all spleen B cells to enter the cell cycle. These data suggest a possible evolutionary link between immune defence based on the recognition of microbial DNA and the phenomenon of CpG suppression' in vertebrates. The potent immune activation by CpG oligonucleotides has implications for the design and interpretation of studies using 'antisense' oligonucleotides and points to possible new applications as adjuvants.	UNIV IOWA,COLL MED,DEPT PATHOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT MICROBIOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL,IOWA CITY,IA 52242; VET AFFAIRS MED CTR,IOWA CITY,IA 52246; US FDA,CTR BIOL EVALUAT & RES,RETROVIRAL IMMUNOL SECT,BETHESDA,MD 20892	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Food & Drug Administration (FDA)	KRIEG, AM (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.		Koretzky, Gary/AAU-5381-2021; Krieg, Arthur M/K-8109-2019; Krieg, Art/R-6166-2019	Bishop, Gail/0000-0002-1291-5078; Teasdale, Rebecca M./0000-0002-1981-7032; Waldschmidt, Thomas/0000-0001-6147-6991				AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; Agrawal S, 1992, Antisense Res Dev, V2, P261; Bayever E, 1992, Antisense Res Dev, V2, P109; Bayever E, 1993, Antisense Res Dev, V3, P383; BENNETT RM, 1985, J CLIN INVEST, V76, P2182, DOI 10.1172/JCI112226; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BISHOP GA, 1991, J IMMUNOL, V147, P1107; CARDON LR, 1994, P NATL ACAD SCI USA, V91, P3799, DOI 10.1073/pnas.91.9.3799; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; DARZYNKIEWICZ Z, 1976, P NATL ACAD SCI USA, V73, P2881, DOI 10.1073/pnas.73.8.2881; DEFRANCO AL, 1982, J EXP MED, V155, P1523, DOI 10.1084/jem.155.5.1523; HAN J, 1994, ANTISENSE RES DEV, V4, P53, DOI 10.1089/ard.1994.4.53; KLINMAN DM, 1990, J IMMUNOL, V144, P506; KRAPF F, 1989, CLIN EXP IMMUNOL, V75, P336; KRIEG AM, 1989, J IMMUNOL, V143, P2448; KRIEG AM, 1992, IMMUNOMETHODS, V1, P191; LEIBSON HJ, 1981, J EXP MED, V154, P1681, DOI 10.1084/jem.154.5.1681; LISZIEWICZ J, 1994, P NATL ACAD SCI USA, V91, P7942, DOI 10.1073/pnas.91.17.7942; MARRACK P, 1994, CELL, V76, P323, DOI 10.1016/0092-8674(94)90339-5; Matson S, 1992, Antisense Res Dev, V2, P325; MESSINA JP, 1991, J IMMUNOL, V147, P1759; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; RICHARDSON B, 1990, ARTHRITIS RHEUM, V33, P1665, DOI 10.1002/art.1780331109; SANO H, 1989, SCAND J IMMUNOL, V30, P51, DOI 10.1111/j.1365-3083.1989.tb01188.x; SANO H, 1983, J IMMUNOL, V130, P187; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Zhao Q, 1993, Antisense Res Dev, V3, P53	29	2870	3398	7	171	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					546	549		10.1038/374546a0	http://dx.doi.org/10.1038/374546a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700380				2022-12-24	WOS:A1995QR06900053
J	ZHANG, R; ALT, FW; DAVIDSON, L; ORKIN, SH; SWAT, W				ZHANG, R; ALT, FW; DAVIDSON, L; ORKIN, SH; SWAT, W			DEFECTIVE SIGNALING THROUGH THE T-CELL AND B-CELL ANTIGEN RECEPTORS IN LYMPHOLD CELLS LACKING THE VAV PROTOONCOGENE	NATURE			English	Article							TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; CROSS-LINKING; EXPRESSION; KINASE; CD40; REARRANGEMENT; STIMULATION; REQUIREMENT	THE product of the vav proto-oncogene(1), p95(vav) or Vav, is tyrosine phosphorylated upon stimulation of T and B cells by antigen(2-4) and other(5-8) receptors, and contains motifs associated,vith signal transduction(1,9-11). To determine its role in vivo, we used vav-gene-targeted embryonic stem(12) cells and RAG-2(-/-) blastocyst complementation(13). The vav(-/-)-RAG-2(-/-) chimaeras displayed thymic atrophy with reduced numbers of peripheral T cells. Whereas the total number of B cells was normal, the subset of peritoneal B-1 (CD5(+))(14) cells was missing. The vav(-/-) T and B cells were hyporeactive when stimulated through antigen receptors, but vav(-/-) T cells proliferated on exposure to phorbol ester and calcium ionophore(15), whereas B cells responded normally to bacterial mitogen, lipopolysaccharide or the CD40 ligand(16-18). Thus, we have established here a functional role for vav in the control of T- and B-cell development and activation.	CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)								ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOGUSKI MS, 1992, NATURE, V358, P113, DOI 10.1038/358113a0; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; HERZENBERG LA, 1993, IMMUNOL TODAY, V14, P79, DOI 10.1016/0167-5699(93)90063-Q; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIENER PA, 1993, J BIOL CHEM, V268, P24442; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; MANDLER R, 1993, J EXP MED, V178, P1577, DOI 10.1084/jem.178.5.1577; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PIATANIAS LC, 1994, J BIOL CHEM, V269, P3143; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TESTI R, 1989, J IMMUNOL, V142, P1854; VONBOEHMER H, 1981, IMMUNOL REV, V54, P27; Weiss A, 1991, Semin Immunol, V3, P313; ZHANG R, 1994, P NATL ACAD SCI USA, V91, P12755, DOI 10.1073/pnas.91.26.12755	26	377	383	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					470	473		10.1038/374470a0	http://dx.doi.org/10.1038/374470a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700359				2022-12-24	WOS:A1995QP89900063
J	CONTER, V; CORTINOVIS, I; ROGARI, P; RIVA, L				CONTER, V; CORTINOVIS, I; ROGARI, P; RIVA, L			WEIGHT GROWTH IN INFANTS BORN TO MOTHERS WHO SMOKED DURING PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							MATERNAL SMOKING; BIRTH-WEIGHT; AGE; CHILD	Objective-To determine whether maternal smoking during pregnancy causes impairment in grow-th after birth. Design-Longitudinal study. Setting-Six medical university centres of six towns of north, central, and south Italy. Subjects-12 987 babies (10 238 born from nonsmoking mothers, 2276 from mothers smoking one to nine cigarettes a day, and 473 from mothers smoking greater than or equal to 10 cigarettes a day) entered the study. Main outcome measures-Difference in weight gain between children born to smoking mothers and those born to non-smoking mothers. Weight was measured at birth and at 3 and 6 months of age. Maternal smoking habit was derived from interview on third or fourth day after delivery. Results-Compared with children born to mothers who did not smoke during pregnancy, the birth weights of children born to mothers who smoked up to nine cigarettes a day were 88 g (girls) and 107 g (boys) lower; in children born to mothers who smoked greater than or equal to 10 cigarettes a day weights were 168 g and 247 g lower. At six months of age for the first group the mean weight for girls was 9 g (95% confidence interval -47 g to 65 g) higher and for boys 64 g (-118 g to -10 g) lower than that of children born to mothers who did not smoke. The corresponding figures for the second group were 38 g (-141 g to 85 g) lower for girls and 24 g (-136 g to 88 g) lower for boys. Conclusions-The deficits of weight at birth in children born to mothers who smoked during pregnancy are overcome by 6 months of age. These deficits are probably not permanent when smoking habit during pregnancy is not associated with other unfavourable variables (such as lower socioeconomic class).	UNIV MILAN,IST STAT MED & BIOMETRIA,I-20133 MILAN,ITALY; OSPED SAN GERARDO,DEPT PAEDIAT,MONZA,ITALY; OSPED MELEGNANO,DEPT PAEDIAT,MELEGNANO,ITALY	University of Milan; San Gerardo Hospital			Ivan, Cortinovis/M-9301-2017	Ivan, Cortinovis/0000-0001-8750-302X				BARR HM, 1984, PEDIATRICS, V74, P336; BORACCHI P, 1986, Genus, V42, P53; BUTLER NR, 1972, BMJ-BRIT MED J, V2, P127, DOI 10.1136/bmj.2.5806.127; BUTLER NR, 1973, BRIT MED J, V4, P573, DOI 10.1136/bmj.4.5892.573; Cortinovis I., 1993, Acta Medica Auxologica (Milan), V25, P13; CORTINOVIS I, 1986, Genus, V42, P13; De Scrilli A, 1986, Genus, V42, P37; FOGELMAN KR, 1988, BRIT MED J, V297, P1233, DOI 10.1136/bmj.297.6658.1233; FOX NL, 1990, INT J EPIDEMIOL, V19, P66, DOI 10.1093/ije/19.1.66; HARDY JB, 1972, LANCET, V2, P1332; MILANI S, 1983, SOC SCI MED, V17, P803, DOI 10.1016/0277-9536(83)90031-X; RANTAKALLIO P, 1983, ACTA PAEDIATR SCAND, V72, P747, DOI 10.1111/j.1651-2227.1983.tb09805.x; RONA RJ, 1985, INT J EPIDEMIOL, V2, P402; SEXTON M, 1984, JAMA-J AM MED ASSOC, V251, P911, DOI 10.1001/jama.251.7.911; 1982, B MENSILE STATISTI S	15	70	70	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					768	771		10.1136/bmj.310.6982.768	http://dx.doi.org/10.1136/bmj.310.6982.768			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711580	Green Published			2022-12-24	WOS:A1995QP60900016
J	CHONG, JHA; TAPIARAMIREZ, J; KIM, S; TOLEDOARAL, JJ; ZHENG, YC; BOUTROS, MC; ALTSHULLER, YM; FROHMAN, MA; KRANER, SD; MANDEL, G				CHONG, JHA; TAPIARAMIREZ, J; KIM, S; TOLEDOARAL, JJ; ZHENG, YC; BOUTROS, MC; ALTSHULLER, YM; FROHMAN, MA; KRANER, SD; MANDEL, G			REST - A MAMMALIAN SILENCER PROTEIN THAT RESTRICTS SODIUM-CHANNEL GENE-EXPRESSION TO NEURONS	CELL			English	Article							NERVE GROWTH-FACTOR; RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; AMPLIFICATION; INITIATION; REPRESSION; EUKARYOTES; ELEMENT; CELLS; YEAST	Expression of the type II voltage-dependent sodium channel gene is restricted to neurons by a silencer element active in nonneuronal cells. We have cloned cDNA coding for a transcription factor (REST) that binds to this silencer element. Expression of a recombinant REST protein confers the ability to silence type II reporter genes in neuronal cell types lacking the native REST protein, whereas expression of a dominant negative form of REST in nonneuronal cells relieves silencing mediated by the native protein. REST transcripts in developing mouse embryos are detected ubiquitously outside of the nervous system. We propose that expression of the type II sodium channel gene in neurons reflects a default pathway that is blocked in nonneuronal cells by the presence of REST.	SUNY STONY BROOK,DEPT PHARMACOL,STONY BROOK,NY 11794; UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Pennsylvania	CHONG, JHA (corresponding author), SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794, USA.		Toledo-Aral, Juan J/F-2613-2015; IBIS, TERAPIA CELULA/P-3297-2015; Boutros, Michael/C-3566-2008	Toledo-Aral, Juan J/0000-0001-7512-7135; Boutros, Michael/0000-0002-9458-817X; Tapia, Jose/0000-0002-4641-7181				BARTEL PL, 1994, CELLULAR INTERACTION, P153; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DARCANGELO G, 1993, J CELL BIOL, V4, P915; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GREEN JBA, 1994, CELL, V77, P317, DOI 10.1016/0092-8674(94)90145-7; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; JAN YN, 1995, NEURON, V14, P1; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KRANER S, 1991, BIOMED RES-TOKYO, V12, P27; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LEWIN G, 1994, CELL, V79, P935; LI KJ, 1993, SCIENCE, V262, P1870; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LINDSELL P, 1994, J PHYSL, V480, P405; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; NEDIVI E, 1992, J NEUROSCI, V12, P691; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P998; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sherman F., 1986, METHODS YEAST GENETI; TOLEDOARAL JJ, 1995, NEURON, V14, P607, DOI 10.1016/0896-6273(95)90317-8; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; ZHAO C, 1995, NATURE, V373, P74, DOI 10.1038/373074a0	46	898	917	1	31	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					949	957		10.1016/0092-8674(95)90298-8	http://dx.doi.org/10.1016/0092-8674(95)90298-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697725	hybrid			2022-12-24	WOS:A1995QP61200014
J	REINKE, P; FIETZE, E; ODEHAKIM, S; PROSCH, S; LIPPERT, J; EWERT, R; VOLK, HD				REINKE, P; FIETZE, E; ODEHAKIM, S; PROSCH, S; LIPPERT, J; EWERT, R; VOLK, HD			LATE-ACUTE VENAL ALLOGRAFT-REJECTION AND SYMPTOMLESS CYTOMEGALOVIRUS-INFECTION	LANCET			English	Note							RECIPIENTS	The role of cytomegalovirus infection in allograft injury is controversial. A subgroup of renal graft recipients who bad histologically proven late-acute rejection did not respond to conventional anti-rejection therapy (80% graft loss within 1 year). These patients showed an expansion of memory-type CD8 peripheral-blood T cells that expressed interferon-gamma mRNA and an association with clinically symptomless cytomegalovirus infection (82% PCR positive, 42% antigenaemia). Antiviral therapy with ganciclovir resulted in stable improved graft function in 17 of 21 treated patients with cytomegalovirus-associated late-acute rejection. The results underline the clinical relevance of cytomegalovirus-related graft injury and offer a novel therapeutic approach.	FREE UNIV BERLIN,KLINIKUM CHARITE,INST MED IMMUNOL,D-10098 BERLIN,GERMANY; FREE UNIV BERLIN,KLINIKUM CHARITE,INST VIROL,D-10098 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	REINKE, P (corresponding author), FREE UNIV BERLIN,KLINIKUM CHARITE,MED NEPHROL CLIN 5,D-10098 BERLIN,GERMANY.		volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668; Reinke, Petra/0000-0003-0771-4375				ALMOND PS, 1994, TRANSPLANTATION, V55, P752; CAPPEL R, 1978, ARCH VIROL, V56, P149, DOI 10.1007/BF01317289; DOCKE WD, 1994, LANCET, V343, P268, DOI 10.1016/S0140-6736(94)91116-9; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; PLATZER C, 1909, TRANSPLANTATION, V58, P264; RAO KV, 1989, TRANSPLANTATION, V47, P290, DOI 10.1097/00007890-198902000-00019; REINKE P, 1994, TRANSPLANTATION, V58, P35, DOI 10.1097/00007890-199407150-00007; REIPERT B, 1992, CLIN EXP IMMUNOL, V89, P143; SIMMONS RL, 1970, TRANSPL P, V2, P419; Tolkoff-Rubin N E, 1992, Curr Opin Nephrol Hypertens, V1, P243, DOI 10.1097/00041552-199212000-00009	10	168	174	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1737	1738		10.1016/S0140-6736(94)92887-8	http://dx.doi.org/10.1016/S0140-6736(94)92887-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7741857				2022-12-24	WOS:A1994PY28100010
J	BELLA, J; EATON, M; BRODSKY, B; BERMAN, HM				BELLA, J; EATON, M; BRODSKY, B; BERMAN, HM			CRYSTAL-STRUCTURE AND MOLECULAR-STRUCTURE OF A COLLAGEN-LIKE PEPTIDE AT 1.9-ANGSTROM RESOLUTION	SCIENCE			English	Article							TRIPLE-HELICAL PEPTIDE; CIRCULAR-DICHROISM; N-PROTEINASE; SUBSTITUTION; CHAIN; CONFORMATION; REFINEMENT; KINK; PARAMETERS; CYSTEINE	The structure of a protein triple helix has been determined at 1.9 angstrom resolution by x-ray crystallographic studies of a collagen-like peptide containing a single substitution of the consensus sequence. This peptide adopts a triple-helical structure that confirms the basic features determined from fiber diffraction studies on collagen: supercoiling of polyproline II helices and interchain hydrogen bonding that follows the model II of Rich and Crick. In addition, the structure provides new information concerning the nature of this protein fold. Each triple helix is surrounded by a cylinder of hydration, with an extensive hydrogen bonding network between water molecules and peptide acceptor groups. Hydroxyproline residues have a critical role in this water network. The interaxial spacing of triple helices in the crystal is similar to that in collagen fibrils, and the water networks linking adjacent triple helices in the crystal structure are likely to be present in connective tissues. The breaking of the repeating (X-Y-Gly), pattern by a Gly-->Ala substitution results in a subtle alteration of the conformation, with a local untwisting of the triple helix. At the substitution site, direct interchain hydrogen bonds are replaced with interstitial water bridges between the peptide groups. Similar conformational changes may occur in Gly-->X mutated collagens responsible for the diseases osteogenesis imperfecta, chondrodysplasias, and Ehlers-Danlos syndrome IV.	RUTGERS STATE UNIV,DEPT CHEM,PISCATAWAY,NJ 08855; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick			Bella, Jordi/F-3794-2018	Bella, Jordi/0000-0003-0443-4562; Berman, Helen/0000-0002-3337-0660	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019626] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021589] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 19626] Funding Source: Medline; NIGMS NIH HHS [GM 21589] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN FH, 1983, ACCOUNTS CHEM RES, V16, P146, DOI 10.1021/ar00089a001; BELLA J, UNPUB; BERG RA, 1970, J BIOL CHEM, V245, P5759; BOGAERT R, 1992, J BIOL CHEM, V267, P22522; BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, X PLOR VERSION 3 1; CAMPBELLSMITH PJ, 1978, ACTA CRYSTALLOGR A, V34, P3; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fair C K, 1990, MOLEN; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; FRASER RDB, 1983, J MOL BIOL, V167, P497, DOI 10.1016/S0022-2836(83)80347-7; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LEIKIN S, 1994, P NATL ACAD SCI USA, V91, P276, DOI 10.1073/pnas.91.1.276; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; LIGHTFOOT SJ, 1992, J BIOL CHEM, V267, P25521; LONG CG, 1992, J MOL BIOL, V225, P1, DOI 10.1016/0022-2836(92)91020-P; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; MACRAE TP, 1973, CONFORMATION FIBROUS; MILLER MH, 1976, J POLYM SCI POL SYM, P171; OKUYAMA K, 1981, J MOL BIOL, V152, P427, DOI 10.1016/0022-2836(81)90252-7; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; RAMACHANDRAN GN, 1955, NATURE, V176, P593, DOI 10.1038/176593a0; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; RICH A, 1955, NATURE, V176, P915, DOI 10.1038/176915a0; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; SAKAKIBARA S, 1972, J MOL BIOL, V65, P371, DOI 10.1016/0022-2836(72)90288-4; VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023; VOGEL BE, 1988, J BIOL CHEM, V263, P19249	35	845	866	3	168	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					75	81		10.1126/science.7695699	http://dx.doi.org/10.1126/science.7695699			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7695699				2022-12-24	WOS:A1994PK58200028
J	PEAD, L; MASKELL, R				PEAD, L; MASKELL, R			STUDY OF URINARY-TRACT INFECTION IN CHILDREN IN ONE HEALTH DISTRICT	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD; WOMEN	Objective-To determine the number of children who had urine specimens sent for culture, who had infections or sterile pyuria, and who were investigated further. To relate the laboratory findings to the results of imaging. Design-One year survey of urine specimens submitted to a laboratory; review of previous and subsequent laboratory reports; review of the findings of imaging of the urinary tract. Setting-Portsmouth and South East Hampshire health district. Subjects-An estimated population of 89 086 children aged 12 years or under. Main outcome measures-Urine bacterial count and results of imaging. Results-12 551 urine specimens were submitted from 7450 children, 3138 boys and 4312 girls. 2238 children had infection or sterile pyuria at least once during the study (13.9/1000 boys, 37/1000 girls). 996 (45%) of the children with infection or sterile pyuria underwent some form of imaging. 128 children who;had infection or sterile pyuria were already known to have urinary tract abnormalities and 114 children had newly identified abnormalities (1.0/1000 boys, 1.5/1000 girls). 50 (44%) of the children with newly detected abnormalities had no pyuria and 48 (42%) had bacterial counts below 10(8)/1. Eight children who had sterile pyuria on presentation were found to have abnormalities on imaging. Conclusions-Urinary tract infection is much commoner in children than is widely believed. Low bacterial counts, the absence of pyuria, or a finding of sterile pyuria should not be disregarded.	ST MARYS HOSP,PUBL HLTH LAB,PORTSMOUTH PO3 6AQ,HANTS,ENGLAND									ASSCHER AW, 1973, LANCET, V2, P1; BUYS H, 1994, BRIT MED J, V308, P690, DOI 10.1136/bmj.308.6930.690; CHIU N-C, 1989, Acta Paediatrica Sinica, V30, P225; JADRESIC L, 1993, BRIT MED J, V307, P761, DOI 10.1136/bmj.307.6907.761; KASS EH, 1956, T ASSOC AM PHYSICIAN, V69, P56; KASS EH, 1957, ARCH INTERN MED, V100, P709, DOI 10.1001/archinte.1957.00260110025004; KUNIN CM, 1964, MEDICINE, V43, P91; KUNIN CM, 1993, ANN INTERN MED, V119, P454, DOI 10.7326/0003-4819-119-6-199309150-00002; MASKELL R, 1989, J INFECTION, V19, P207, DOI 10.1016/S0163-4453(89)90669-5; MASKELL R, 1989, BRIT J UROL, V63, P7, DOI 10.1111/j.1464-410X.1989.tb05113.x; MASKELL R, 1982, URINARY TRACT INFECT, P24; RICKWOOD AMK, 1992, BRIT MED J, V304, P663, DOI 10.1136/bmj.304.6828.663; STAMM WE, 1980, NEW ENGL J MED, V303, P409, DOI 10.1056/NEJM198008213030801; 1975, ARCH DIS CHILD, V50, P90; 1991, JR COLL PHYSICIANS L, V25, P36	15	17	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					631	634		10.1136/bmj.309.6955.631	http://dx.doi.org/10.1136/bmj.309.6955.631			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	7695692	Green Published			2022-12-24	WOS:A1994PG02000017
J	BELFORT, M				BELFORT, M			AN EXPANDING UNIVERSE OF INTRONS	SCIENCE			English	Editorial Material							GROUP-I INTRON; TETRAHYMENA				BELFORT, M (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,DAVID AXELROD INST PUBL HLTH,ALBANY,NY 12201, USA.			Belfort, Marlene/0000-0002-1592-5618				AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; COPERTINO DW, 1991, EMBO J, V10, P433, DOI 10.1002/j.1460-2075.1991.tb07965.x; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; KUHSEL MG, 1990, SCIENCE, V250, P1570, DOI 10.1126/science.2125748; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MORI M, 1990, CELL, V60, P629; MORI M, 1992, CELL, V70, P803; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747	14	29	31	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1009	1010		10.1126/science.7694364	http://dx.doi.org/10.1126/science.7694364			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7694364				2022-12-24	WOS:A1993MG18700023
J	BERENDES, R; VOGES, D; DEMANGE, P; HUBER, R; BURGER, A				BERENDES, R; VOGES, D; DEMANGE, P; HUBER, R; BURGER, A			STRUCTURE-FUNCTION ANALYSIS OF THE ION-CHANNEL SELECTIVITY FILTER IN HUMAN ANNEXIN-V	SCIENCE			English	Article							MOLECULAR-STRUCTURE; BILAYER-MEMBRANES; RECEPTOR CHANNELS; CALCIUM; CRYSTAL; RESOLUTION; PROTEINS; BINDING; FAMILY	Electrophysiology and structural studies were performed on an annexin V variant c containing a mutation of glutamic acid-95 to serine in the center of the pore region. The mutation resulted in a lower single channel conductance for calcium and a strongly increased conductance for sodium and potassium, indicating that glutamic acid-95 is a crucial constituent of the ion selectivity filter. There were only minor differences in the crystal structures of mutant and wild-type annexin V around the mutation site; however, the mutant showed structural differences elsewhere, including the presence of a calcium binding site in domain III unrelated to the mutation. Analysis of the membrane-bound form of annexin V by electron microscopy revealed no differences between the wild type and mutant.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society			demange, pascal JP/U-3561-2018	demange, pascal JP/0000-0002-9572-9990				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BERENDES R, UNPUB; BRUNGER AT, 1990, X PLOR MANUAL; BURGER A, 1993, FEBS LETT, V329, P25, DOI 10.1016/0014-5793(93)80185-W; Burger A., UNPUB; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CONCHA NO, 1993, SCIENCE, V2261, P1321; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DINGLEDINE R, 1992, J NEUROSCI, V12, P4080; EGJEBERG J, 1993, P NATL ACAD SCI USA, V90, P755; FATT P, 1958, J PHYSIOL-LONDON, V142, P516, DOI 10.1113/jphysiol.1958.sp006034; FERRERMONTIEL AV, 1993, FEBS LETT, V324, P185, DOI 10.1016/0014-5793(93)81390-L; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HOPPE W, 1957, Z ELEKTROCHEM, V61, P1076; HUBER R, 1965, ACTA CRYSTALLOGR, V19, P353, DOI 10.1107/S0365110X65003444; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; HUBER R, 1990, FEBS LETT, V275, P15, DOI 10.1016/0014-5793(90)81428-Q; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KARSHIKOV A, 1992, EUR BIOPHYS J BIOPHY, V20, P337, DOI 10.1007/BF00196592; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P50; LEWITBENTLEY A, 1992, EUR J BIOCHEM, V210, P73, DOI 10.1111/j.1432-1033.1992.tb17392.x; MEALY T, 1993, BIOCHEMISTRY-US, V32, P5411; MEERS P, 1990, BIOCHEMISTRY-US, V29, P3325, DOI 10.1021/bi00465a025; Moss S. E, 1992, ANNEXINS; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SOPKOVA J, IN PRESS J MOL BIOL; Steigemann W., 1974, THESIS TU MUNCHEN GE; UZGIRIS EE, 1983, NATURE, V301, P125, DOI 10.1038/301125a0	37	102	103	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					427	430		10.1126/science.7692599	http://dx.doi.org/10.1126/science.7692599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	7692599				2022-12-24	WOS:A1993MB85900060
J	PINGLETON, SK				PINGLETON, SK			PULMONARY AND CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASTHMA; DEATH; RISK				PINGLETON, SK (corresponding author), UNIV KANSAS,MED CTR,KANSAS CITY,KS 66103, USA.							[Anonymous], 1992, CRIT CARE MED, V20, P864; BONE RC, 1994, JAMA-J AM MED ASSOC, V271, P1412; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HAAHTELA T, 1993, NEW ENGL J MED, V331, P700; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; MALFMO NA, 1991, NEW ENGL J MED, V321, P285; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; ROUBY JJ, 1994, AM J RESP CRIT CARE, V150, P776, DOI 10.1164/ajrccm.150.3.8087352; SLY MS, 1994, ANN ALLERGY, V73, P259; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; 1989, NATIONAL HEART LUNG; 1991, 913042 US DEP HLTH H	19	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1717	1718						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752434				2022-12-24	WOS:A1995RB09700042
J	BRAHAMS, D				BRAHAMS, D			CLARIFICATION OF THE EGGSHELL SKULL DOCTRINE	LANCET			English	Editorial Material																		1994, LANCET, V343, P1217	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1430	1430		10.1016/S0140-6736(95)92614-3	http://dx.doi.org/10.1016/S0140-6736(95)92614-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760618	Bronze			2022-12-24	WOS:A1995RB44100025
J	SHOKAT, KM; GOODNOW, CC				SHOKAT, KM; GOODNOW, CC			ANTIGEN-INDUCED B-CELL DEATH AND ELIMINATION DURING GERMINAL-CENTER IMMUNE-RESPONSES	NATURE			English	Article							SOMATIC MUTATION; ANTIBODY; EXPRESSION; CENTERS; SPECIFICITY; GENERATION; SELECTION; LYSOZYME; PROTEINS; CHAIN	DURING an immune response, hypermutation of immunoglobulin genes in B cells proliferating within germinal centres (GCs) generates variant antibodies that react with higher affinity against either foreign or self antigens(1-9). Several experiments suggest that self-reactive B cells may be censored at this stage of the immune response(10-12), but the rarity of these cells and the dynamic nature of GC reactions have prevented direct analysis. We have developed a new approach to visualize the fate of antigen-specific B cells during GC reactions by seeding an ongoing immune response with lysozyme-specific B cells from immunoglobulin-gene transgenic animals. Administration of soluble antigen at the peak of the GC response rapidly eliminates lysozyme-specific GC B cells in two waves of apoptosis, one within the GC and a second in cells that have redistributed to lymphoid zones that are rich in T cells. Elimination of these cells is inhibited by constitutive expression of the follicular lymphoma proto-oncogene bcl-2. These findings reveal censoring steps that may normally prevent affinity maturation of autoantibodies to systemic autoantigens, and might be used by pathogenic microorganisms or in clinical strategies to interfere with antibody responses.	STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, BECKMAN CTR, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University			Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155				BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DIAMOND B, 1984, P NATL ACAD SCI-BIOL, V81, P5841, DOI 10.1073/pnas.81.18.5841; DIAMOND B, 1992, ANNU REV IMMUNOL, V10, P731, DOI 10.1146/annurev.iy.10.040192.003503; DINTZIS HM, 1992, P NATL ACAD SCI USA, V89, P1113, DOI 10.1073/pnas.89.3.1113; GAMMON G, 1987, IMMUNOL REV, V98, P53; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GRAY D, 1994, J EXP MED, V180, P141, DOI 10.1084/jem.180.1.141; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; LAGASSE E, 1992, BLOOD, V79, P1907; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LINTON PJ, 1991, J IMMUNOL, V146, P4099; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; NOSSAL GJV, 1993, P NATL ACAD SCI USA, V90, P3088, DOI 10.1073/pnas.90.7.3088; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PRAGER EM, 1971, J BIOL CHEM, V246, P523; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0	29	333	340	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					334	338		10.1038/375334a0	http://dx.doi.org/10.1038/375334a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753200				2022-12-24	WOS:A1995RA03000056
J	HALL, IP; WHEATLEY, A; WILDING, P; LIGGETT, SB				HALL, IP; WHEATLEY, A; WILDING, P; LIGGETT, SB			ASSOCIATION OF GLU-27 BETA(2)-ADRENOCEPTOR POLYMORPHISM WITH LOWER AIRWAY REACTIVITY IN ASTHMATIC SUBJECTS	LANCET			English	Note								Cells expressing the Glu 27 beta(2)-adrenoceptor polymorphism show attenuated down-regulation of the receptor after long-term exposure to agonist. We studied beta(2)-adrenoceptor genotype for the Gln/Glu 27 polymorphism and airway reactivity in 65 patients with mild to moderate asthma. Glu 27 homozygotes had a four-fold higher geometric mean methacholine PD20 (provocative dose) than individuals who were homozygous for the wild-type (Gln 27) form of the receptor; heterozygotes had an intermediate value (3.23, 0.86, 1.96 mu mol, respectively), These data suggest that beta(2)-adrenoceptor genotype is important in the establishment of the asthmatic phenotype.	CITY HOSP,RESP MED UNIT,NOTTINGHAM NG5 1PB,ENGLAND; UNIV CINCINNATI,MED CTR,DEPT PULM & CRIT CARE MED,CINCINNATI,OH 45267	University of Nottingham; University System of Ohio; University of Cincinnati	HALL, IP (corresponding author), UNIV NOTTINGHAM HOSP,DEPT MED,DIV THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND.		liggett, stephen b/E-7453-2012	Hall, Ian/0000-0001-9933-3216; Henry, Amanda/0000-0001-6299-7676; Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL 45967] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL045967, R37HL045967, R01HL045967] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, IN PRESS AM J RESPIR; GUNNEBERG A, 1993, CLIN CHEM, V39, P2157; Postma D. S., 1994, European Respiratory Journal, V7, p423S; REISHAUS E, 1993, AM J RESPIR CELL MOL, V8, P334; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	6	260	273	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1213	1214		10.1016/S0140-6736(95)91994-5	http://dx.doi.org/10.1016/S0140-6736(95)91994-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739309				2022-12-24	WOS:A1995QX86100012
J	POWER, JP; LAWLOR, E; DAVIDSON, F; HOLMES, EC; YAP, PL; SIMMONDS, P				POWER, JP; LAWLOR, E; DAVIDSON, F; HOLMES, EC; YAP, PL; SIMMONDS, P			MOLECULAR EPIDEMIOLOGY OF AN OUTBREAK OF INFECTION WITH HEPATITIS-C VIRUS IN RECIPIENTS OF ANTI-D IMMUNOGLOBULIN	LANCET			English	Note								In a retrospective investigation of possible transmission of hepatitis C virus (HCV) by anti-rhesus D immunoglobulin (anti-D) in 1977, we compared variants infecting anti-D recipients in Ireland of one of the implicated batches with those of epidemiologically unrelated HCV-infected individuals. All 100 of the recipients of the batch investigated to date were infected with a single genotype (type 1), consistent with a single-source outbreak, whereas a wider range of genotypes (1, 2, and 3) were found in anti-HCV positive individuals from Ireland infected by different routes. Nucleotide sequences from a 222 base fragment from tbe NS-5 region of the genome amplified from stored aliquots of the implicated batch closely matched those detected in anti-D recipients 17 years after the transmission event. This study shows the value of molecular epidemiological techniques for identifying distant sources of infection, and for the epidemiological investigation of the current distribution and transmission of HCV in different populations.	UNIV EDINBURGH, DEPT MED MICROBIOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; ST FINBARRS HOSP, BLOOD TRANSFUS SERV BOARD, CORK, IRELAND; BLOOD TRANSFUS SERV BOARD, DUBLIN 4, IRELAND; EDINBURGH & SE SCOTLAND BLOOD TRANSFUS SERV, EDINBURGH, MIDLOTHIAN, SCOTLAND; UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND	University of Edinburgh; University of Oxford			Holmes, Edward/GVR-9499-2022	Simmonds, Peter/0000-0002-7964-4700; Holmes, Edward/0000-0001-9596-3552				DITTMANN S, 1991, J HEPATOL, V13, P323, DOI 10.1016/0168-8278(91)90076-N; HOLMES EC, 1993, NATURE, V364, P766, DOI 10.1038/364766b0; LAU JYN, 1995, J INFECT DIS, V171, P281, DOI 10.1093/infdis/171.2.281; MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884, DOI 10.1128/JCM.32.4.884-892.1994; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; POWER JP, 1994, LANCET, V344, P1166, DOI 10.1016/S0140-6736(94)90679-3; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; VIAZOV S, 1994, J VIROL METHODS, V48, P81, DOI 10.1016/0166-0934(94)90091-4	8	112	118	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 13	1995	345	8959					1211	1213		10.1016/S0140-6736(95)91993-7	http://dx.doi.org/10.1016/S0140-6736(95)91993-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739308				2022-12-24	WOS:A1995QX86100011
J	van der Maas, PJ; PIJNENBORG, L; VANDELDEN, JJM				van der Maas, PJ; PIJNENBORG, L; VANDELDEN, JJM			CHANGES IN DUTCH OPINIONS ON ACTIVE EUTHANASIA, 1966 THROUGH 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL DECISIONS; LIFE; END		UNIV UTRECHT, CTR BIOETH & HLTH LAW, ROTTERDAM, NETHERLANDS	Utrecht University	van der Maas, PJ (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.							Adriaansens H. P. M., 1981, VRIJWILLIG INITIATIE; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; Ester P., 1993, INDIVIDUALIZING SOC; Inglehart RonaldF., 1977, SILENT REVOLUTION; Mayer William G., 1992, CHANGING AM MIND WHY; PIJNENBORG L, 1994, BMJ-BRIT MED J, V309, P1209, DOI 10.1136/bmj.309.6963.1209; SCHUYT C, 1991, OP ZOEK NAAR HART VE; Seper F., 1980, DECLARATION EUTHANAS; Stimson J. A., 1991, PUBLIC OPINION AM MO; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1992, HEALTH POLICY, V22, P1; VANDELDEN JJM, 1993, HASTINGS CENT REP, V23, P24, DOI 10.2307/3562919; 1994, 1994 SOC CULT PLANN; 1988, EUTHANASIE PASTORAAT; 1987, BIOETHICS, V1, P163	15	53	53	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1411	1414		10.1001/jama.273.18.1411	http://dx.doi.org/10.1001/jama.273.18.1411			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW279	7723147				2022-12-24	WOS:A1995QW27900010
J	PETERSEN, C				PETERSEN, C			CRYPTOSPORIDIUM AND THE FOOD-SUPPLY	LANCET			English	Editorial Material											PETERSEN, C (corresponding author), SAN FRANCISCO GEN HOSP,DIV INFECT DIS,SAN FRANCISCO,CA 94110, USA.							BIER JW, 1991, J TROP MED PUBL 1222, pS144; DUPONT HL, IN PRESS N ENGL J ME; FLANIGAN T, 1992, ANN INTERN MED, V116, P840, DOI 10.7326/0003-4819-116-10-840; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MCANULTY JM, 1994, JAMA-J AM MED ASSOC, V272, P1597, DOI 10.1001/jama.272.20.1597; MCGOWAN I, 1993, AIDS, V7, P349, DOI 10.1097/00002030-199303000-00007; MILLARD PS, 1994, JAMA-J AM MED ASSOC, V272, P1592, DOI 10.1001/jama.272.20.1592; MOLBAK K, 1993, BRIT MED J, V307, P417, DOI 10.1136/bmj.307.6901.417; NEWMAN RD, 1994, ANN INTERN MED, V120, P500, DOI 10.7326/0003-4819-120-6-199403150-00009; Ungar B. L. P., 1990, Cryptosporidiosis of man and animals., P59	10	10	10	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1128	1129		10.1016/S0140-6736(95)90972-9	http://dx.doi.org/10.1016/S0140-6736(95)90972-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723540				2022-12-24	WOS:A1995QW62200004
J	BARBERIS, A; PEARLBERG, J; SIMKOVICH, N; FARRELL, S; REINAGEL, P; BAMDAD, C; SIGAL, G; PTASHNE, M				BARBERIS, A; PEARLBERG, J; SIMKOVICH, N; FARRELL, S; REINAGEL, P; BAMDAD, C; SIGAL, G; PTASHNE, M			CONTACT WITH A COMPONENT OF THE POLYMERASE-II HOLOENZYME SUFFICES FOR GENE ACTIVATION	CELL			English	Article							TRANSCRIPTION FACTOR-TFIIB; SACCHAROMYCES-CEREVISIAE; GAL11 PROTEIN; INITIATION; BINDING; COMPLEX; MECHANISM; GALACTOSE; MUTATION; DOMAIN	In yeast strains bearing the point mutation called GAL11P (for potentiator), certain GAL4 derivatives lacking any classical activating region work as strong activators. The P mutation confers upon GAL11, a component of the RNA polymerase II holoenzyme, the ability to interact with a portion of the dimerization region of GAL4, The region of GAL11 affected by the P mutation is evidently functionally inert in ordinary cells, suggesting that this mutation is of no functional significance beyond creating an artificial target for the GAL4 dimerization fragment. From these observations and further analyses of GAL11, we propose that a single activator-holoenzyme contact can trigger gene activation simply by recruiting the latter to DNA.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,PROGRAM BIOPHYS,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Harvard University			Reinagel, Pamela/ABI-7659-2020	Reinagel, Pamela/0000-0002-6338-2611				BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAREY M, 1994, NATURE, V368, P402, DOI 10.1038/368402a0; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; FASSLER JS, 1989, MOL CELL BIOL, V9, P5602, DOI 10.1128/MCB.9.12.5602; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HARLOW E, 1988, ANTIBODIES LABORATOR; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; JOUNG JK, 1994, SCIENCE, V265, P1863, DOI 10.1126/science.8091212; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LONG RM, 1991, MOL CELL BIOL, V11, P2311, DOI 10.1128/MCB.11.4.2311; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NOGI Y, 1980, CURR GENET, V2, P115, DOI 10.1007/BF00420623; PTASHNE M, 1992, GENETIC SWITCH GENE; PTASHNE M, 1988, NATURE, V335, P983; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; REINAGEL P, 1994, THESIS HARVARD U CAM; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; Rose MD., 1990, METHODS YEAST GENETI; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SAKURAI H, 1993, P NATL ACAD SCI USA, V90, P8382, DOI 10.1073/pnas.90.18.8382; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; SUZUKI Y, 1988, MOL CELL BIOL, V12, P4806; THOMPSON CM, 1993, CELL, V73, P1367; THOMPSON CM, 1995, IN PRESS P NATL ACAD; VALLIER LG, 1991, GENETICS, V129, P675; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	53	238	245	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					359	368		10.1016/0092-8674(95)90389-5	http://dx.doi.org/10.1016/0092-8674(95)90389-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736588	Bronze			2022-12-24	WOS:A1995QW89400008
J	LARSSON, SH; CHARLIEU, JP; MIYAGAWA, K; ENGELKAMP, D; RASSOULZADEGAN, M; ROSS, A; CUZIN, F; VANHEYNINGEN, V; HASTIE, ND				LARSSON, SH; CHARLIEU, JP; MIYAGAWA, K; ENGELKAMP, D; RASSOULZADEGAN, M; ROSS, A; CUZIN, F; VANHEYNINGEN, V; HASTIE, ND			SUBNUCLEAR LOCALIZATION OF WT1 IN SPLICING OR TRANSCRIPTION FACTOR DOMAINS IS REGULATED BY ALTERNATIVE SPLICING	CELL			English	Article							ZINC FINGER PROTEIN; WILMS-TUMOR LOCUS; CELL-NUCLEUS; GENE; RNA; SNRNP; INVIVO; DNA; PURIFICATION; RECOGNITION	WT1 is a tumor suppressor gene with a key role in urogenital development and the pathogenesis of Wilms' tumor. Two alternative splice sites in the WT1 transcript allow the gene to encode four proteins. These carry four Kruppel-type zinc fingers and to date have primarily been implicated in transcriptional control of genes involved in growth regulation. However, here we demonstrate colocalization of WT1 with splicing factors in the fetal kidney and testis and in expressing cell lines. Using immunoprecipitation, we show that two WT1 isoforms directly associate with one or a limited number of components in the spliceosomes and coiled bodies. Moreover, COS cell expression studies suggest that alternative splicing within the WT1 zinc finger region determines whether the protein localizes mainly with splicing factors or with DNA in transcription factor domains in the nucleus. We propose that WT1 plays roles in posttranscriptional processing of RNA as well as in transcription.	UNIV NICE, INSERM, U273, F-06108 NICE 2, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	LARSSON, SH (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Rassoulzadegan, Minoo/O-7939-2016; van Heyningen, Veronica/B-8039-2008; VAN HEYNINGEN, Veronica/GYE-0531-2022	van Heyningen, Veronica/0000-0003-0359-0141; 	MRC [MC_U127527199] Funding Source: UKRI; Medical Research Council [MC_U127527199] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOSHER J, 1992, J VIROL, V66, P3140, DOI 10.1128/JVI.66.5.3140-3150.1992; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bruening Wendy, 1994, Seminars in Developmental Biology, V5, P333, DOI 10.1006/sedb.1994.1042; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARMOFONSECA M, 1991, EMBO J, V10, P1863, DOI 10.1002/j.1460-2075.1991.tb07712.x; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; DAVIS MR, 1992, INT J CANCER, V52, P881, DOI 10.1002/ijc.2910520609; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARLOW E, 1988, ANNU REV GENET, V28, P523; Hogan B., 1986, MANIPULATING MOUSE E; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KENT GRL, 1994, THESIS U EDINBURGH M; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LAMM GM, 1993, BIOCHIM BIOPHYS ACTA, V1173, P247, DOI 10.1016/0167-4781(93)90122-T; Lamond Angus I., 1993, Trends in Cell Biology, V3, P198, DOI 10.1016/0962-8924(93)90214-L; MATTAJ IW, 1994, NATURE, V372, P727, DOI 10.1038/372727a0; Moore M., 1993, RNA WORLD, P303; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; NEWMAN A, 1994, CURR OPIN CELL BIOL, V6, P360, DOI 10.1016/0955-0674(94)90027-2; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PAN ZQ, 1988, SCIENCE, V241, P1328, DOI 10.1126/science.2970672; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RASSOULZADEGAN M, 1993, CELL, V75, P997, DOI 10.1016/0092-8674(93)90543-Y; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; Sambrook J., 1989, MOL CLONING LAB MANU; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	51	423	434	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					391	401		10.1016/0092-8674(95)90392-5	http://dx.doi.org/10.1016/0092-8674(95)90392-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736591	Bronze			2022-12-24	WOS:A1995QW89400011
J	ALKEMA, MJ; VANDERLUGT, NMT; BOBELDIJK, RC; BERNS, A; VANLOHUIZEN, M				ALKEMA, MJ; VANDERLUGT, NMT; BOBELDIJK, RC; BERNS, A; VANLOHUIZEN, M			TRANSFORMATION OF AXIAL SKELETON DUE TO OVEREXPRESSION OF BMI-1 IN TRANSGENIC MICE	NATURE			English	Article							POSITION-EFFECT VARIEGATION; POSTERIOR SEX COMBS; NULL MUTATION; RETINOIC ACID; DROSOPHILA; GENE; CHROMATIN; MOUSE; MYC; LYMPHOMAGENESIS	THE oncogene bmi-1, which was originally found to be involved in B- and T-cell lymphoma formation(1-3) encodes a protein with a domain of homology to the Drosophila protein Posterior sex combs (Psc) and its relative Suppressor 2 of Zeste (Su(z)2) (refs 4 and 5), Psc is a member of the Polycomb-group gene family, which is required to maintain the repression of homeotic genes that regulate the identities of Drosophila segments(6). The possibility that bmi-1 may play a similar role in vertebrates was suggested by our previous finding(7) that mice lacking the bmi-1 gene show posterior transformations of the axial skeleton. Here we report that transgenic mice overexpressing Bmi-1 protein show the opposite phenotype, namely a dose-dependent anterior transformation of vertebral identity, The anterior expression boundary of the Hoxc-5 gene is shifted in the posterior direction, indicating that Bmi-1 is involved in the repression of Hox genes. We propose that Bmi-1 is a member of a vertebrate Polycomb complex that regulates segmental identity by repressing Hox genes throughout development.	NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,DEPT BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute; University of Amsterdam								ADLER PN, 1991, DEV GENET, V12, P349, DOI 10.1002/dvg.1020120504; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CONDIE BG, 1993, DEVELOPMENT, V119, P579; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FRANKE A, 1993, EMBO J, V12, P1513; GAUNT SJ, 1990, DEVELOPMENT, V109, P329; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KRESS C, 1990, DEVELOPMENT, V109, P775; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEVY LS, 1993, ONCOGENE, V8, P1833; LOCKE J, 1988, GENETICS, V120, P181; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MARTIN EC, 1993, DEVELOPMENT, V117, P641; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PELLEGRI F, 1994, GENETICS, V136, P1341; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RASTELLI L, 1992, EMBO J, V11, P2941; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; SHARP EJ, 1994, DEV BIOL, V161, P379, DOI 10.1006/dbio.1994.1039; SIMON J, 1992, DEVELOPMENT, V114, P493; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0	28	148	152	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					724	727		10.1038/374724a0	http://dx.doi.org/10.1038/374724a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715727				2022-12-24	WOS:A1995QU30400050
J	MANGTANI, P; JOLLEY, DJ; WATSON, JM; RODRIGUES, LC				MANGTANI, P; JOLLEY, DJ; WATSON, JM; RODRIGUES, LC			SOCIOECONOMIC DEPRIVATION AND NOTIFICATION RATES FOR TUBERCULOSIS IN LONDON DURING 1982-91	BRITISH MEDICAL JOURNAL			English	Article							NEW-YORK-CITY; OUTBREAK; HOMELESS; SHELTER	Objectives-To investigate the association between four sociodemographic measures (unemployment, overcrowding, low social class, and the proportion of migrants from areas of high prevalence of tuberculosis) and average level and rate of change of notification rates for tuberculosis. Design-Ecological analysis of both the average and the rate of change of standardised annual notification rates for tuberculosis from 1982-91 and sociodemographic measures from the 1981 and 1991 censuses. Setting-32 London boroughs. Subjects and data-Sociodemographic measures from the 1981 and 1991 censuses and tuberculosis notification rates for 1982-91. Main outcome measures-A measure of the association between average levels and rate of change in tuberculosis notification rates and four sociodemographic measures in 1981 and between the rate of change in tuberculosis notification rates between 1981 and 1991 and changes in sociodemographic measures between 1981 and 1991. Results-The average level of notifications was correlated with overcrowding and the proportion of migrants but not with unemployment or social class. No significant association was found between the rate of change in notification rates and sociodemographic measures in 1981. An association was found between increases in unemployment and the Fate of change in notification rates, but the effect was small. Changes in the levels of unemployment explained 23% of the variation between boroughs in the rate of change in their notification rates. Conclusion-The average tuberculosis notification rates were related to overcrowding and the proportion of migrants in 1981. Only increases in unemployment from 1981 to 1991, however, were significantly associated with the rate of change in notifications over the same period.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; Public Health England	MANGTANI, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		RODRIGUES, LAURA CUNHA/AAO-4130-2021	Mangtani, Punam/0000-0001-7074-2999				BRADLEY BL, 1988, BMJ-BRIT MED J, V297, P595, DOI 10.1136/bmj.297.6648.595; BRESLOW NE, 1980, STATISTICAL METHODS, V2; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CARSTAIRS V, 1989, COMMUNITY MED, V11, P210, DOI 10.1093/oxfordjournals.pubmed.a042469; DRUCKER E, 1994, LANCET, V343, P1482, DOI 10.1016/S0140-6736(94)92588-7; GREENLAND S, 1989, INT J EPIDEMIOL, V18, P269, DOI 10.1093/ije/18.1.269; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PATEL KR, 1985, BRIT J DIS CHEST, V79, P60, DOI 10.1016/0007-0971(85)90008-7; RAMSDEN SS, 1988, J ROY COLL PHYS LOND, V22, P16; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; SHELDON CD, 1992, THORAX, V47, P1015, DOI 10.1136/thx.47.12.1015; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; TEALE C, 1991, J INFECTION, V23, P327, DOI 10.1016/0163-4453(91)93224-Z; Townsend PP., 1988, HLTH DEPRIVATION INE; WATSON JM, 1993, THORAX, V48, P199, DOI 10.1136/thx.48.3.199; WATSON JM, 1993, BRIT MED J, V306, P221, DOI 10.1136/bmj.306.6872.221; WATSON JM, 1991, COMMUN DIS REP CDR R, V1, P13; 1988, MMWR-MORBID MORTAL W, V36, P817; 1979, TUBERCLE, V191, P194; 1982, BRIT MED J, V284, P1454; 1985, BRIT MED J, V291, P658; 1992, THORAX, V47, P770	24	81	85	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					963	966		10.1136/bmj.310.6985.963	http://dx.doi.org/10.1136/bmj.310.6985.963			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728030	Green Published			2022-12-24	WOS:A1995QT90400017
J	ESPINAL, MA; REINGOLD, AL; KOENIG, E; LAVANDERA, M; SANCHEZ, S				ESPINAL, MA; REINGOLD, AL; KOENIG, E; LAVANDERA, M; SANCHEZ, S			SCREENING FOR ACTIVE TUBERCULOSIS IN HIV TESTING CENTER	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS-DRUG-USERS; INFECTED PATIENTS; OUTBREAK	In industrialised nations HIV-seropositive individuals can be offered shin testing for tuberculosis (TB) and isoniazid prophylaxis, but this approach is neither practicable nor affordable in most developing countries. in Santo Domingo, Dominican Republic, we offered skin testing and a brief clinical examination for active TB to people requesting HIV testing at one centre. 200 newly detected HIV-positive individuals and 200 age and sex-matched HIV-negative ones were compared. 39 (9.7%) of the 400 individuals seeking HIV testing had active TB; 29 were HIV positive and 10 were HIV negative (adjusted odds ratio 3.3, 95% CI 1.3-8.7; p=0.01). In multivariate analysis, the strongest independent predictors of active TB were 10 mm or more of induration on skin testing, a history of chronic cough, lymphadenopathy, and HIV infection. Of the patients diagnosed with TB, 85% had one or more symptoms readily ascertainable in a brief screening questionnaire. Screening for TB at HIV-testing sites could be an effective approach to early detection of active TB among not just HIV-positive but also HIV-negative people. integrating screening for TB into HIV testing schemes could help to reduce the spread of TB and allow patients with TB to be diagnosed and treated earlier.	UNIV CALIF BERKELEY,SCH PUBL HLTH,DIV PUBL HLTH BIOL & EPIDEMIOL,BERKELEY,CA 94720; NATL LAB PUBL HLTH,SANTO DOMINGO,DOMINICAN REP; MINIST HLTH,NATL TB CONTROL PROGRAM,SANTO DOMINGO,DOMINICAN REP	University of California System; University of California Berkeley					FOGARTY INTERNATIONAL CENTER [D43TW000003] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW00003-03] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BOUVET E, 1993, AIDS, V7, P1453, DOI 10.1097/00002030-199311000-00008; CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DIPERRI G, 1989, LANCET, V2, P1502; DUCOS J, 1992, 7 INT C AIDS AMST; Espinal M, 1994, Bol Oficina Sanit Panam, V116, P452; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; GARCIA V, 1993, NEUMOS, V8, P169; GARCIA V, 1992, NEUMOS, V7, P9; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; HARRIES AD, 1990, LANCET, V335, P390; JOHNSON MP, 1992, J INFECT DIS, V166, P194, DOI 10.1093/infdis/166.1.194; LONG R, 1991, AM REV RESPIR DIS, V143, P69, DOI 10.1164/ajrccm/143.1.69; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; SANCHEZ S, 1993, NEUMOS, V8, P55; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SNIDER DE, 1994, TUBERCULOSIS PATHOGE; Sutherland I, 1976, Adv Tuberc Res, V19, P1; 1994, TUBER LUNG DIS, V75, P96; 1989, MMWR-MORBID MORTAL W, V38, P243; 1989, MMWR-MORBID MORTAL W, V38, P236	21	23	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					890	893		10.1016/S0140-6736(95)90010-1	http://dx.doi.org/10.1016/S0140-6736(95)90010-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707812				2022-12-24	WOS:A1995QR06700010
J	CHRIST, WJ; ASANO, O; ROBIDOUX, ALC; PEREZ, M; WANG, YA; DUBUC, GR; GAVIN, WE; HAWKINS, LD; MCGUINNESS, PD; MULLARKEY, MA; LEWIS, MD; KISHI, Y; KAWATA, T; BRISTOL, JR; ROSE, JR; ROSSIGNOL, DP; KOBAYASHI, S; HISHINUMA, L; KIMURA, A; ASAKAWA, N; KATAYAMA, K; YAMATSU, I				CHRIST, WJ; ASANO, O; ROBIDOUX, ALC; PEREZ, M; WANG, YA; DUBUC, GR; GAVIN, WE; HAWKINS, LD; MCGUINNESS, PD; MULLARKEY, MA; LEWIS, MD; KISHI, Y; KAWATA, T; BRISTOL, JR; ROSE, JR; ROSSIGNOL, DP; KOBAYASHI, S; HISHINUMA, L; KIMURA, A; ASAKAWA, N; KATAYAMA, K; YAMATSU, I			E5531, A PURE ENDOTOXIN ANTAGONIST OF HIGH POTENCY	SCIENCE			English	Article							GRAM-NEGATIVE ENDOTOXIN; LIPID-A; ESCHERICHIA-COLI; SEPTIC SHOCK; INFLAMMATORY MEDIATORS; LIPOPOLYSACCHARIDE; SEPSIS; BIOSYNTHESIS; NEUTROPHILS; MACROPHAGES	Shock due to Gram-negative bacterial sepsis is a consequence of acute inflammatory response to lipopolysaccharide (LPS) or endotoxin released from bacteria. LPS is a major constituent of the outer membrane of Gram-negative bacteria, and its terminal disaccharide phospholipid (lipid A) portion contains the key structural features responsible for toxic activity. Based on the proposed structure of nontoxic Rhodobacter capsulatus lipid A, a fully stabilized endotoxin antagonist E5531 has been synthesized. In vitro, E5531 demonstrated potent antagonism of LPS-mediated cellular activation in a variety of systems. In vivo, E5531 protected mice from LPS-induced lethality and, in cooperation with an antibiotic, protected mice from a lethal infection of viable Escherichia coli.	EISAI RES INST,ANDOVER,MA 01810; EISAI & CO LTD,TSUKUBA RES LABS,TSUKUBA,IBARAKI 30026,JAPAN	Eisai Co Ltd; Eisai Co Ltd								BILLIAU A, 1991, EUR J CLIN INVEST, V21, P559, DOI 10.1111/j.1365-2362.1991.tb01410.x; BONE RC, 1993, CLIN MICROBIOL REV, V6, P57, DOI 10.1128/CMR.6.1.57-68.1993; BONE RC, 1991, CHEST, V100, P802, DOI 10.1378/chest.100.3.802; BULAWA CE, 1984, J BIOL CHEM, V259, P4846; BUNNELL E, 1995, 24TH ED SCI S SOC CR; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; CHRIST WJ, 1836, Patent No. 935050; CHRIST WJ, UNPUB; CROSBY HA, 1994, J MED MICROBIOL, V40, P23, DOI 10.1099/00222615-40-1-23; DANNER RL, 1990, PHARMACEUT RES, V7, P260, DOI 10.1023/A:1015874012484; DANNER RL, 1987, J CLIN INVEST, V80, P605, DOI 10.1172/JCI113112; DOFFERHOFF ASM, 1991, SCAND J INFECT DIS, V23, P745, DOI 10.3109/00365549109024303; ENDO S, 1992, CIRC SHOCK, V38, P264; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; GLAUSER MP, 1994, J CLIN INFECT DIS S2, V18, pS205; GOLENBOCK DT, 1987, INFECT IMMUN, V55, P2471, DOI 10.1128/IAI.55.10.2471-2476.1987; IMOTO M, 1985, TETRAHEDRON LETT, V26, P1545, DOI 10.1016/S0040-4039(00)98548-4; KAWATA T, 1992, 32ND INT C ANT AG CH, P1360; KRAUSS JH, 1989, EUR J BIOCHEM, V180, P519, DOI 10.1111/j.1432-1033.1989.tb14677.x; LOPPNOW H, 1990, INFECT IMMUN, V58, P3743, DOI 10.1128/IAI.58.11.3743-3750.1990; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PRINS JM, 1994, ANTIMICROB AGENTS CH, V38, P1211, DOI 10.1128/AAC.38.6.1211; PROCTOR RA, 1986, INFECT IMMUN, V52, P905, DOI 10.1128/IAI.52.3.905-907.1986; QURESHI N, 1988, J BIOL CHEM, V263, P5502; RAY BL, 1984, J BIOL CHEM, V259, P4852; Rokke O, 1988, Prog Clin Biol Res, V272, P247; ROSSIGNOL D, 1992, 3IND INT C ANT AG CH, P1361; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; VOGEL SN, 1980, J IMMUNOL, V124, P2004; WANG SC, 1994, SURGERY, V116, P339; WELBOURN CRB, 1992, BRIT J SURG, V79, P998, DOI 10.1002/bjs.1800791006	33	297	313	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					80	83		10.1126/science.7701344	http://dx.doi.org/10.1126/science.7701344			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701344				2022-12-24	WOS:A1995QR45400028
J	TJOELKER, LW; WILDER, C; EBERHARDT, C; STAFFORINI, DM; DIETSCH, G; SCHIMPF, B; HOOPER, S; LETRONG, H; COUSENS, LS; ZIMMERMAN, GA; YAMADA, Y; MCINTYRE, TM; PRESCOTT, SM; GRAY, PW				TJOELKER, LW; WILDER, C; EBERHARDT, C; STAFFORINI, DM; DIETSCH, G; SCHIMPF, B; HOOPER, S; LETRONG, H; COUSENS, LS; ZIMMERMAN, GA; YAMADA, Y; MCINTYRE, TM; PRESCOTT, SM; GRAY, PW			ANTIINFLAMMATORY PROPERTIES OF A PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE	NATURE			English	Article							PAF ACETYLHYDROLASE; PLASMA; CELLS; PHOSPHOLIPIDS; SECRETE; RELEASE	PLATELET-ACTIVATING factor (PAF) is a potent pro-inflammatory phospholipid that activates cells involved in inflammation(1,2). The biological activity of PAF depends on its structural features, namely an ether linkage at the sn-1 position and an acetate group at the sn-2 position. The actions of PAF are abolished by hydrolysis of the acetyl residue, a reaction catalysed by PAF acetylhydrolase. There are at least two forms of this enzyme-one intracellular and another that circulates in plasma and is likely to regulate inflammation. Here we report the molecular cloning and characterization of the human plasma PAF acetylhydrolase. The unique sequence contains a Gly-Xaa-Ser-Xaa-Gly motif commonly found in lipases. Recombinant PAF acetylhydrolase has the substrate specificity and lipoprotein association of the native enzyme, and blocks inflammation in vivo: it markedly decreases vascular leakage in pleurisy and paw oedema, suggesting that PAF acetylhydrolase might be a useful therapy for severe acute inflammation.	UNIV UTAH,ECCLES INST HUMAN GENET,PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,INST CARDIOVASC RES & TRAINING,SALT LAKE CITY,UT 84112; ICOS CORP,BOTHELL,WA 98021	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Icos Corporation								BLANK ML, 1981, J BIOL CHEM, V256, P175; CHAPUS C, 1988, BIOCHIMIE, V70, P1223, DOI 10.1016/0300-9084(88)90188-5; CYGLER M, 1993, PROTEIN SCI, V2, P366; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; GRAHAM RM, 1994, CRIT CARE MED, V22, P204, DOI 10.1097/00003246-199402000-00009; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HENRIQUES MGMO, 1992, BRIT J PHARMACOL, V106, P579, DOI 10.1111/j.1476-5381.1992.tb14378.x; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; MAKI N, 1988, P NATL ACAD SCI USA, V85, P728, DOI 10.1073/pnas.85.3.728; MIOZZARI GF, 1978, J BACTERIOL, V133, P1457, DOI 10.1128/JB.133.3.1457-1466.1978; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; NARAHARA H, 1993, ARCH BIOCHEM BIOPHYS, V301, P275, DOI 10.1006/abbi.1993.1144; PATEL KD, 1992, J BIOL CHEM, V267, P15168; SATOH K, 1991, J CLIN INVEST, V87, P476, DOI 10.1172/JCI115020; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TANAKA T, 1993, BIOCHIM BIOPHYS ACTA, V1166, P264, DOI 10.1016/0005-2760(93)90107-K; TARBET EB, 1991, J BIOL CHEM, V266, P16667; TETTA C, 1990, INT ARCH ALLER A IMM, V91, P244, DOI 10.1159/000235124; VENABLE ME, 1993, J LIPID RES, V34, P691; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YOSHIDA JI, 1986, J PHARM PHARMACOL, V38, P878, DOI 10.1111/j.2042-7158.1986.tb03375.x; ZIMMERMAN GA, 1992, INFLAMMATION BASIC P, V2, P149	27	447	482	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					549	553		10.1038/374549a0	http://dx.doi.org/10.1038/374549a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700381				2022-12-24	WOS:A1995QR06900054
J	ROSEN, MK; YAMAZAKI, T; GISH, GD; KAY, CM; PAWSON, T; KAY, LE				ROSEN, MK; YAMAZAKI, T; GISH, GD; KAY, CM; PAWSON, T; KAY, LE			DIRECT DEMONSTRATION OF AN INTRAMOLECULAR SH2-PHOSPHOTYROSINE INTERACTION IN THE CRK PROTEIN	NATURE			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; SH3 DOMAINS; V-CRK; BINDING; SRC; IDENTIFICATION; PRODUCT; PEPTIDE	MANY signal transduction processes are mediated by the binding Of Src-homology-2 (SH2) domains to phosphotyrosine (pTyr)-containing proteins(1). Although most SH2-pTyr interactions occur between tao different types of molecules, some appear to involve only a single molecular type. It has been proposed that the enzymatic activity and substrate recognition of the Src-family kinases(2-4), and the protein-binding and transforming activity of Crk-family adaptor proteins(5), are regulated by intramolecular SH2-pTyr interactions. In addition, the DNA-binding activity of Stat transcription factors seems to be regulated by SH2-mediated homodimerization(6). Here we examine the phosphorylated and non-phosphorylated forms of murine Crk II (p-mCrk and mCrk, respectively)(7-9) using a combination of physical techniques. The Crk protein contains a single SH2 domain and two SH3 domains in the order SH2-SH3-SH3. There is a tyrosine-phosphorylation site between the two SH3 domains at residue 221 which is phosphorylated in vivo by the Abl tyrosine kinase(5). Using NMR spectroscopic analysis, we show here that the SH2 domain of purified p-mCrk is bound to pTyr, and by hydrodynamic measurements that the phosphorylated protein is monomeric, These results provide direct demonstration of an intramolecular SH2-pTyr interaction in a signalling molecule.	UNIV TORONTO, DEPT MED GENET, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, DEPT CHEM & BIOCHEM, TORONTO, ON M5S 1A8, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAMME MOLEC BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV ALBERTA, DEPT BIOCHEM, MRC, PROT STRUCT & FUNCT GRP, EDMONTON, AB T6G 2H7, CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Alberta	ROSEN, MK (corresponding author), UNIV TORONTO, PROT ENGN NETWORK CTR EXCELLENCE, MED SCI BLDG, TORONTO, ON M5S 1A8, CANADA.		Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013					BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; ODA T, 1994, J BIOL CHEM, V269, P22925; OGAWA S, 1994, ONCOGENE, V9, P1669; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VOGEL HJ, 1989, METHOD ENZYMOL, V177, P263; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YU HT, 1994, NAT STRUCT BIOL, V1, P417, DOI 10.1038/nsb0794-417; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	27	106	108	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 30	1995	374	6521					477	479		10.1038/374477a0	http://dx.doi.org/10.1038/374477a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700361				2022-12-24	WOS:A1995QP89900065
J	BARKER, DJP; MARTYN, CN; OSMOND, C; WIELD, GA				BARKER, DJP; MARTYN, CN; OSMOND, C; WIELD, GA			ABNORMAL LIVER GROWTH IN-UTERO AND DEATH FROM CORONARY HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							ADULT LIFE				BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BOCHNER CJ, 1987, AM J OBSTET GYNECOL, V157, P703, DOI 10.1016/S0002-9378(87)80033-9; Gruenwald P, 1974, CIBA F S, V27, P3; MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142, DOI 10.1111/j.1365-2141.1995.tb08920.x	5	72	74	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					703	704		10.1136/bmj.310.6981.703	http://dx.doi.org/10.1136/bmj.310.6981.703			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711538	Green Published			2022-12-24	WOS:A1995QN46100020
J	IMAI, K; NAKACHI, K				IMAI, K; NAKACHI, K			CROSS-SECTIONAL STUDY OF EFFECTS OF DRINKING GREEN TEA ON CARDIOVASCULAR AND LIVER-DISEASES	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BODY IRON STORES; (-)-EPIGALLOCATECHIN GALLATE; ULTRAVIOLET-LIGHT; FREE-RADICALS; CANCER; CHOLESTEROL; CONSUMPTION; RISK; FLAVONOIDS	Objective-To investigate the association between consumption of green tea and various serum markers in a Japanese population, with special reference to preventive effects of green tea against cardiovascular disease and disorders of the liver. Design-Cross sectional study. Setting-Yoshimi, Japan. Subjects-1371 men aged over 40 years resident in Yoshimi and surveyed on their living habits including daily consumption of green tea. Their peripheral blood samples were subjected to several biochemical assays. Results-Increased consumption of green tea was associated with decreased serum concentrations of total cholesterol (P for trend <0.001) and triglyceride (P for trend=0 . 02) and an increased proportion of high density lipoprotein cholesterol together with a decreased proportion of low and very low lipoprotein cholesterols (P for trend=0 . 02), which resulted in a decreased atherogenic index (P for trend=0.02). Moreover, increased consumption of green tea, especially more than 10 cups a day, was related to decreased concentrations of hepatological markers in serum, aspartate aminotransferase (P for trend=0 . 06), alanine transferase (P for trend=0 . 07), and ferritin (P for trend=0 . 02). Conclusion-The inverse association between consumption of green tea and various serum markers shows that green tea may act protectively against cardiovascular disease and disorders of the liver.			IMAI, K (corresponding author), SAITAMA CANC CTR,RES INST,DEPT EPIDEMIOL,KOMURO 818,INA,SAITAMA 362,JAPAN.							BROWN CA, 1993, J EPIDEMIOL COMMUN H, V47, P171, DOI 10.1136/jech.47.3.171; CHISAKA T, 1988, CHEM PHARM BULL, V36, P227; CONNEY AH, 1992, PREV MED, V21, P361, DOI 10.1016/0091-7435(92)90043-H; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; FUJIKI H, 1992, PREV MED, V21, P503, DOI 10.1016/0091-7435(92)90057-O; GREEN MS, 1992, PREV MED, V21, P532, DOI 10.1016/0091-7435(92)90061-L; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; HUSAIN SR, 1987, PHYTOCHEMISTRY, V26, P2489, DOI 10.1016/s0031-9422(00)83860-1; IKEDA I, 1992, BIOCHIM BIOPHYS ACTA, V1127, P141, DOI 10.1016/0005-2760(92)90269-2; KONO S, 1992, PREV MED, V21, P526, DOI 10.1016/0091-7435(92)90060-U; MURAMATSU K, 1986, J NUTR SCI VITAMINOL, V32, P613, DOI 10.3177/jnsv.32.613; NAKACHI K, 1992, JPN J CANCER RES, V83, P798, DOI 10.1111/j.1349-7006.1992.tb01983.x; NAKACHI K, 1991, CANCER RES, V51, P5177; NAKACHI K, 1993, CANCER RES, V53, P2994; NAKAYAMA T, 1994, CANCER RES S, V54; OSAWA T, 1990, BASIC LIFE SCI, V52, P139; SANO M, 1986, CHEM PHARM BULL, V34, P221; SELBY JV, 1988, INT J CANCER, V41, P677, DOI 10.1002/ijc.2910410507; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STENSVOLD I, 1992, PREV MED, V21, P546, DOI 10.1016/0091-7435(92)90062-M; STEVENS RG, 1986, J NATL CANCER I, V76, P605, DOI 10.1093/jnci/76.4.605; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056/NEJM198810203191603; WANG ZY, 1992, CANCER RES, V52, P1162; WANG ZY, 1989, MUTAT RES, V223, P273, DOI 10.1016/0165-1218(89)90120-1; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; Yoshizawa S., 1987, PHYTOTHER RES, V1, P44, DOI [10.1002/ptr.2650010110, DOI 10.1002/PTR.2650010110]; YOUNG W, 1967, NATURE, V216, P1015, DOI 10.1038/2161015a0; ZHAO BL, 1989, CELL BIOPHYS, V14, P175, DOI 10.1007/BF02797132	30	340	343	1	31	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					693	696		10.1136/bmj.310.6981.693	http://dx.doi.org/10.1136/bmj.310.6981.693			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711535	Green Published			2022-12-24	WOS:A1995QN46100017
J	MACKINNON, R; ALDRICH, RW; LEE, AW				MACKINNON, R; ALDRICH, RW; LEE, AW			FUNCTIONAL STOICHIOMETRY OF SHAKER POTASSIUM CHANNEL INACTIVATION	SCIENCE			English	Article								Shaker potassium channels from Drosophila are composed of four identical subunits. The contribution of a single subunit to the inactivation gating transition was investigated. Channels carrying a specific mutation in a single subunit can be labeled in a heterogeneous population and studied quantitatively with scorpion toxin sensitivity as a selection tag. Linkage within a single subunit of a mutation that removes the inactivation gate to a second mutation that affects scorpion toxin sensitivity demonstrates that only a single gate is necessary to produce inactivation. The inactivation rate constant for channels with a single gate was one-fourth that of channels with four gates. In contrast, the rate of recovery from inactivation was independent of the number of gates. It appears that each of the four open inactivation gates in a Shaker potassium channel is independent, but only one of the four gates closes in a mutually exclusive manner.	STANFORD UNIV,MED CTR,SCH MED,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University	MACKINNON, R (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.				NINDS NIH HHS [NS23294] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023294] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	8	162	168	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					757	759		10.1126/science.7694359	http://dx.doi.org/10.1126/science.7694359			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	7694359				2022-12-24	WOS:A1993MD95200047
J	FRANKLIN, JE				FRANKLIN, JE			ADDICTION MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											FRANKLIN, JE (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611, USA.							BOHN MJ, 1994, AM J ADDICTION, V3, P91; BROWN SA, 1995, AM J PSYCHIAT, V152, P45; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; HASIN D, 1994, ALCOHOL CLIN EXP RES, V18, P1348, DOI 10.1111/j.1530-0277.1994.tb01435.x; KRANZLER HR, 1994, ARCH GEN PSYCHIAT, V51, P720; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P898; LEVIN ED, 1994, J CLIN PSYCHOPHARM, V14, P41; MUELLER TI, 1994, AM J PSYCHIAT, V151, P701; SAITZ R, 1994, JAMA-J AM MED ASSOC, V272, P519, DOI 10.1001/jama.272.7.519; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P1723; SWIFT RM, 1994, AM J PSYCHIAT, V151, P1463; TIIHONEN J, 1994, AM J PSYCHIAT, V151, P1505; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; 1987, DIAGNOSTIC STATISTIC; 1994, DIAGNOSTIC STATISTIC	15	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1656	1657		10.1001/jama.273.21.1656	http://dx.doi.org/10.1001/jama.273.21.1656			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB097	7752401				2022-12-24	WOS:A1995RB09700009
J	VELANDIA, M; FRIDKIN, SK; CARDENAS, V; BOSHELL, J; RAMIREZ, G; BLAND, L; IGLESIAS, A; JARVIS, W				VELANDIA, M; FRIDKIN, SK; CARDENAS, V; BOSHELL, J; RAMIREZ, G; BLAND, L; IGLESIAS, A; JARVIS, W			TRANSMISSION OF HIV IN DIALYSIS CENTER	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BENZALKONIUM CHLORIDE; HEMODIALYSIS; PREVALENCE; BLOOD	In August, 1993, 13 dialysis patients at one dialysis centre. in Colombia, South America, were found to be HIV positive, and this prompted an epidemiological investigation. We carried out a cohort study of all dialysis centre patients during January, 1992 to December, 1993 (epidemic period) to determine risk factors for HIV seroconversion. Haemodialysis and medical records were reviewed, dialysis centre staff and surviving patients were interviewed, and dialysis practices were observed. Stored sera from all dialysis centre patients were tested for HIV antibody. 12 (52%) of 23 patients tested positive for HIV antibody by enzyme immunoassay and western blot during the epidemic period. Of the 23 tested, 9 (39%) converted from HIV antibody negative to positive (seroconverters) and 10 (44%) remained HIV negative (seronegatives). The HIV seroconversion rate was higher among patients dialysed at the centre while a new patient, who was HIV seropositive, was dialysed there (90% vs 0%; p<0.01), or when the dialysis centre reprocessed access needles, dialysers, and bloodlines (60% vs 0%). While 2 of 9 HIV seroconverters had had sex with prostitutes, none had received unscreened blood products or had other HIV risk factors. No surgical or dental procedures were associated with HIV seroconversion. Dialysers were reprocessed separately with 5% formaldehyde and were labelled for use on the same patient. Access needles were reprocessed by soaking them in a common container with a low-level disinfectant, benzalkonium chloride; 4 pairs of needles were placed in one pan creating the potential for cross-contamination or use of one patient's needles on another patient. HIV transmission at the dialysis centre was confirmed, Improperly reprocessed patient-care equipment, most probably access needles, is the likely mechanism of transmission. This outbreak was discovered by accident and similar transmission may be occurring in many other countries where low-level disinfectants are used to sterilise critical patient-care equipment.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,INVEST & PREVENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333; COLOMBIAN FIELD EPIDEMIOL TRAINING PROGRAM,BOGOTA,COLOMBIA; NATL INST HLTH,BOGOTA,COLOMBIA; IND UNIV SANTANDER,SCH MED,SANTANDER,SPAIN	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA				Velandia-Gonzalez, Martha/0000-0002-7636-3604				ARDUINO MJ, 1993, DIALYSIS TRANSPLANT, V22, P652; ARDUINO MJ, 1993, DIALYSIS TRANSPLANT, V22, P701; BLANK S, 1994, LANCET, V344, P512, DOI 10.1016/S0140-6736(94)91900-3; BURCHOVSKY G, 1988, 4TH INT C AIDS STOCK; CHANT K, 1994, LANCET, V342, P1548; CHIRGWIN K, 1989, AIDS, V3, P731, DOI 10.1097/00002030-198911000-00007; DEAN AG, 1991, EPI INFO VERSION 5 0; DYER E, 1993, BRIT MED J, V307, P584; FAVERO MS, 1989, ASPECTS RENAL CARE, P55; FAVERO MS, 1991, MANUAL CLIN MICROBIO, P183; Favero MS, 1992, HOSPITAL INFECTIONS, P375; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; KASLOW RA, 1976, JAMA-J AM MED ASSOC, V236, P2407, DOI 10.1001/jama.236.21.2407; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MARCUS R, 1991, AM J MED, V90, P614, DOI 10.1016/S0002-9343(05)80014-2; MARTIN D, 1991, EPIDEMIOLOGY, V2, P359, DOI 10.1097/00001648-199109000-00008; NAKASHIMA AK, 1987, J CLIN MICROBIOL, V25, P1014, DOI 10.1128/JCM.25.6.1014-1018.1987; NAUS JI, 1965, J AM STAT ASSOC, V60, P532, DOI 10.2307/2282688; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; PLOTT RT, 1990, ARCH DERMATOL, V126, P1441, DOI 10.1001/archderm.126.11.1441; POKROVSKY VV, 1988, 5TH INT C AIDS STOCK; RENGITO B, 1995, 7 C PAN AM INF CART; Rothman K, 1986, MODERN EPIDEMIOLOGY; Tokars J I, 1994, ASAIO J, V40, P1020, DOI 10.1097/00002480-199410000-00021; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; WAINBERG MA, 1990, J CLIN MICROBIOL, V28, P156, DOI 10.1128/JCM.28.1.156-158.1990; WALLENSTEIN S, 1980, AM J EPIDEMIOL, V111, P367, DOI 10.1093/oxfordjournals.aje.a112908; 1992, MMWR-MORBID MORTAL W, V41, P823; 1987, MMWR-MORBID MORTAL W, V36, pS1; 1993, REC PRACT REUSE HEMO; 1992, MMWR-MORBID MORTAL W, V41, P344; 1992, MMWR-MORBID MORTAL W, V41, P575	32	51	51	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1417	1422		10.1016/S0140-6736(95)92603-8	http://dx.doi.org/10.1016/S0140-6736(95)92603-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760615	Bronze			2022-12-24	WOS:A1995RB44100015
J	SCHROEDER, PL; FILLER, SJ; RAMIREZ, B; LAZARCHIK, DA; VAEZI, MF; RICHTER, JE				SCHROEDER, PL; FILLER, SJ; RAMIREZ, B; LAZARCHIK, DA; VAEZI, MF; RICHTER, JE			DENTAL EROSION AND ACID REFLUX DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						DENTAL ENAMEL; GASTROESOPHAGEAL REFLUX; DENTIN; GASTRIC ACID	GASTROESOPHAGEAL REFLUX; ANOREXIA-NERVOSA; HIATUS-HERNIA; BULIMIA; MANIFESTATIONS; COMPLICATIONS; ASSOCIATION; VOLUNTEERS; POPULATION; ENAMEL	Objective: To determine the relation between gastroesophageal reflux disease and dental erosion using ambulatory 24-hour esophageal pH testing. Design: Cross-sectional observational study. Setting: Tertiary referral center. Patients: The dental group consisted of 12 patients with idiopathic dental erosion who were identified by dentists and screened for gastroesophageal reflux disease using 24-hour pH testing. The gastroenterology group consisted of 30 patients who had 24-hour pH testing in the esophageal laboratory and who were referred for dental evaluation (10 did not have reflux, 10 had distal reflux, and 10 had proximal reflux). Measurements: 24-hour esophageal pH monitoring using a pH probe in the distal and proximal esophagus; Complete dental examination with particular attention to the presence and severity of dental erosion; plaque; gingival damage; and decayed, missing, and filled teeth. Analysis of saliva for pH, flow rates, buffering capacity, and calcium and phosphorus levels. Standardized questionnaire to ascertain possible causes of dental erosion and presence of reflux symptoms. Results: Ten of the 12 patients in the dental group (83% [95% Cl, 52% to 98%]) had gastroesophageal reflux on esophageal pH monitoring. Nine had distal and 7 had proximal reflux. Seven had reflux in the upright position only, 1 had reflux in the supine position only, and 2 had both upright and supine reflux. No saliva abnormalities were found. Ten patients had typical symptoms of gastroesophageal reflux, but dietary or mechanical problems that may have been causing dental erosion were not identified. In the gastroenterology group, upright reflux was seen in 5 of the 10 patients with distal reflux and in all 10 patients with proximal reflux. In addition, 40% of patients in the gastroenterology group (12 of 30) had dental erosion (4 of the 10 with distal reflux [40%], 7 of the 10 with proximal reflux [70%], and only 1 of the 10 without reflux [10%]; P = 0.02 for those with reflux compared with those without reflux). The cumulative dental erosion score correlated with proximal upright reflux when all 24 study patients with erosion were analyzed (r = 0.55 [P < 0.01]); this correlation was even stronger in the subgroup of 12 patients with abnormal amounts of proximal upright reflux (r = 0.84 [P = 0.001]). Conclusion: Dental erosion is a common finding in patients with gastroesophageal reflux disease and should be considered an atypical manifestation of this disease.	UNIV ALABAMA, DIV GASTROENTEROL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham								Allan D N, 1969, Br Dent J, V126, P311; ASHER C, 1987, BRIT DENT J, V162, P384, DOI 10.1038/sj.bdj.4806141; BARISH CF, 1985, ARCH INTERN MED, V145, P1882, DOI 10.1001/archinte.145.10.1882; BOYLE JT, 1985, AM REV RESPIR DIS, V131, pS16; CATE HJT, 1968, BRIT J IND MED, V25, P249; CENTERWALL BS, 1986, AM J EPIDEMIOL, V123, P641, DOI 10.1093/oxfordjournals.aje.a114283; DAWES C, 1970, J DENT RES, V49, P1263, DOI 10.1177/00220345700490061501; DESCHNER WK, 1989, AM J GASTROENTEROL, V84, P1; DREWNOWSKI A, 1988, AM J PSYCHIAT, V145, P753; DUCOLONE A, 1987, AM REV RESPIR DIS, V135, P327; ECCLES JD, 1974, J DENT, V2, P153, DOI 10.1016/0300-5712(74)90044-X; ECCLES JD, 1978, LANCET, V2, P479; FRASER D, 1987, FUNDAMENTALS CLIN CH, P721; FRASER D, 1987, FUNDAMENTALS CLIN CH, P716; HELLSTROM I, 1977, SCAND J DENT RES, V85, P71; HOWDEN GF, 1971, BRIT DENT J, V131, P455, DOI 10.1038/sj.bdj.4802772; IRWIN RS, 1993, CHEST, V104, P1511, DOI 10.1378/chest.104.5.1511; JACOB P, 1991, GASTROENTEROLOGY, V100, P305, DOI 10.1016/0016-5085(91)90196-R; JARVINEN V, 1988, ORAL SURG ORAL MED O, V65, P298, DOI 10.1016/0030-4220(88)90113-2; JARVINEN V, 1992, CARIES RES, V26, P391; JONES RRH, 1989, J DENT RES, V68, P1275, DOI 10.1177/00220345890680081201; KAHRILAS PJ, 1987, GASTROENTEROLOGY, V92, P466, DOI 10.1016/0016-5085(87)90143-0; KATZMAN MA, 1984, INT J EAT DISORDER, V3, P53; KOUFMAN JA, 1991, LARYNGOSCOPE, V101, P1; KRASSE B, 1985, CARIES RISK, P41; LEVINE RS, 1973, J DENT, V2, P85, DOI 10.1016/S0300-5712(73)80025-9; LOC J, 1963, ACTA ODONTOL SCAND, V21, P532; LUSSI A, 1991, COMMUNITY DENT ORAL, V19, P286, DOI 10.1111/j.1600-0528.1991.tb00169.x; LYNCH JB, 1947, BRIT J IND MED, V4, P84; MALCOLM D, 1961, BRIT J IND MED, V18, P63; Mandel I D, 1977, J Dent Guid Counc Handicap, V16, P3; MILOSEVIC A, 1989, BRIT DENT J, V167, P66, DOI 10.1038/sj.bdj.4806915; MYLLARNIEMI H, 1985, ANN SURG, V202, P159, DOI 10.1097/00000658-198508000-00004; NEBEL OT, 1976, AM J DIG DIS, V21, P953, DOI 10.1007/BF01071906; PETERSEN PE, 1991, COMMUNITY DENT ORAL, V19, P104, DOI 10.1111/j.1600-0528.1991.tb00121.x; PINDBORG JJ, 1970, PATHOLOGY DENT HARD, P312; RICHTER JE, 1992, DIGEST DIS SCI, V37, P849, DOI 10.1007/BF01300382; RICHTER JE, 1987, DIGEST DIS SCI, V32, P583, DOI 10.1007/BF01296157; ROBERTS MW, 1987, J AM DENT ASSOC, V115, P407, DOI 10.14219/jada.archive.1987.0262; SILNESS J, 1964, Acta Odontol Scand, V22, P121, DOI 10.3109/00016356408993968; SINCLAIR JW, 1991, AMBULATORY ESOPHAGEA, P23; SOGNNAES RF, 1972, J AM DENT ASSOC, V84, P571, DOI 10.14219/jada.archive.1972.0116; SREEBNY LM, 1988, DIAGNOSIS COMPENDIUM, V9, P569; SUDDICK RP, 1980, BIOL BASIS DENTAL CA, P132; TAYLOR G, 1992, J DENT CHILD, V59, P182; TUOMINEN M, 1989, SCAND J WORK ENV HEA, V15, P335, DOI 10.5271/sjweh.1841; WOLTGENS J H M, 1985, Clinical Preventive Dentistry, V7, P8; ZIPKIN I, 1949, J DENT RES, V28, P613, DOI 10.1177/00220345490280061301	48	115	121	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					809	815		10.7326/0003-4819-122-11-199506010-00001	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741364				2022-12-24	WOS:A1995RA13900001
J	MARTI, E; BUMCROT, DA; TAKADA, R; MCMAHON, AP				MARTI, E; BUMCROT, DA; TAKADA, R; MCMAHON, AP			REQUIREMENT OF 19K FORM OF SONIC HEDGEHOG FOR INDUCTION OF DISTINCT VENTRAL CELL-TYPES IN CNS EXPLANTS	NATURE			English	Article							POLARITY GENE HEDGEHOG; FLOOR PLATE; DROSOPHILA; TRANSCRIPTION; NOTOCHORD; PATTERN; EMBRYO; SYSTEM	THE identity and patterning of ventral cell types in the vertebrate central nervous system depends on cell interactions(1). For example, induction of a specialized population of ventral midline cells, the Boor plate, appears to require contact-mediated signalling by the underlying notochord, whereas diffusible signals from the notochord and floor plate can induce ventrolaterally positioned motor neurons. Sonic hedgehog (Shh), a vertebrate hedgehog-family member, is processed to generate two peptides (M(r) 19K and 26/27K) which are secreted by both of these organizing centres(2,30). Moreover, experiments in a variety of vertebrate embryos(3-5), and in neural explants in vitro(5), indicate that Shh can mediate floor-plate induction. Here we have applied recombinant Shh peptides to neural explants in serum-free conditions. High concentrations of Shh bound to a matrix induce floor plate and motor neurons, and addition of Shh to the medium leads to dose-dependent induction of motor neurons. All inducing activity resides in a highly conserved amino-terminal peptide (M(r) 19K). Moreover, antibodies that specifically recognize this peptide block induction of motor neurons by the notochord. We propose that Shh acts as a morphogen to induce distinct ventral cell types in the vertebrate central nervous system.			MARTI, E (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, 16 DIVIN AVE, CAMBRIDGE, MA 02138 USA.		MARTI, ELISA/K-7814-2014; McMahon, Andrew P/ABE-7520-2020	MARTI, ELISA/0000-0001-5839-7133; Takada, Ritsuko/0000-0002-1615-056X				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; CHANG DT, 1994, DEVELOPMENT, V120, P3339; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Fietz MJ, 1994, DEVELOPMENT S, V120, P43; FIETZ MJ, IN PRESS CURR BIOL; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARTI E, IN PRESS DEVELOPMENT; MOHLER J, 1988, GENETICS, V120, P1061; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SMITH JC, 1993, CURR BIOL, V3, P582, DOI 10.1016/0960-9822(93)90003-7; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	30	421	450	0	15	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					322	325		10.1038/375322a0	http://dx.doi.org/10.1038/375322a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753196				2022-12-24	WOS:A1995RA03000052
J	REY, FA; HEINZ, FX; MANDL, C; KUNZ, C; HARRISON, SC				REY, FA; HEINZ, FX; MANDL, C; KUNZ, C; HARRISON, SC			THE ENVELOPE GLYCOPROTEIN FROM TICK-BORNE ENCEPHALITIS-VIRUS AT 2 ANGSTROM RESOLUTION	NATURE			English	Article							WEST NILE FLAVIVIRUS; PROTEIN-E; NUCLEOTIDE-SEQUENCE; RESISTANT MUTANTS; INFLUENZA-VIRUS; NEUROVIRULENCE; EXPRESSION; MICE; SELECTION; VIRULENCE	The crystallographically determined structure of a soluble fragment from the major envelope protein of a flavivirus reveals an unusual architecture. The flat, elongated dimer extends in a direction that would be parallel to the viral membrane. Residues that influence binding of monoclonal antibodies lie on the outward-facing surface of the protein. The clustering of mutations that affect virulence in various flaviviruses indicates a possible receptor binding site and, together with other mutational and biochemical data, suggests a picture for the fusion-activating, conformational change triggered by low pH.	HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA; UNIV VIENNA, INST VIROL, A-1095 VIENNA, AUSTRIA	Harvard University; Howard Hughes Medical Institute; University of Vienna	REY, FA (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.		Rey, Felix/B-6497-2012	Rey, Felix/0000-0002-9953-7988				ALLISON SL, 1995, J VIROL, V69, P695, DOI 10.1128/JVI.69.2.695-700.1995; BLUM M, 1990, THESIS HARVARD U; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CECILIA D, 1991, VIROLOGY, V181, P70, DOI 10.1016/0042-6822(91)90471-M; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; GAO GF, 1994, J GEN VIROL, V75, P609, DOI 10.1099/0022-1317-75-3-609; GUIRAKHOO F, 1993, VIROLOGY, V194, P219, DOI 10.1006/viro.1993.1252; GUIRAKHOO F, 1991, J GEN VIROL, V72, P1323, DOI 10.1099/0022-1317-72-6-1323; GUIRAKHOO F, 1992, VIROLOGY, V191, P921, DOI 10.1016/0042-6822(92)90267-S; HASEGAWA H, 1992, VIROLOGY, V191, P158, DOI 10.1016/0042-6822(92)90177-Q; HEINZ FX, 1994, VIROLOGY, V198, P109, DOI 10.1006/viro.1994.1013; HEINZ FX, 1986, ADV VIRUS RES, V31, P103, DOI 10.1016/S0065-3527(08)60263-8; HEINZ FX, 1991, J VIROL, V65, P5579, DOI 10.1128/JVI.65.10.5579-5583.1991; HEINZ FX, 1990, IMMUNOCHEMISTRY VIRU, V2, P289; HOLZMANN H, 1995, ARCH VIROL, V140, P213, DOI 10.1007/BF01309857; HOLZMANN H, 1990, J VIROL, V64, P5156, DOI 10.1128/JVI.64.10.5156-5159.1990; JENNINGS AD, 1994, J INFECT DIS, V169, P512, DOI 10.1093/infdis/169.3.512; JIANG WR, 1993, J GEN VIROL, V74, P931, DOI 10.1099/0022-1317-74-5-931; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWANO H, 1993, J VIROL, V67, P6567, DOI 10.1128/JVI.67.11.6567-6575.1993; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEWIS JA, 1993, VIROLOGY, V197, P216, DOI 10.1006/viro.1993.1582; LOBIGS M, 1990, VIROLOGY, V176, P587, DOI 10.1016/0042-6822(90)90029-Q; MANDL CW, 1989, J VIROL, V63, P564, DOI 10.1128/JVI.63.2.564-571.1989; MANDL CW, 1988, VIROLOGY, V166, P197, DOI 10.1016/0042-6822(88)90161-4; Monath T.P., 1990, VIROLOGY, P763; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; NOWAK T, 1987, VIROLOGY, V156, P127, DOI 10.1016/0042-6822(87)90443-0; PLETNEV AG, 1993, J VIROL, V67, P4956, DOI 10.1128/JVI.67.8.4956-4963.1993; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; ROEHRIG JT, 1989, VIROLOGY, V171, P49, DOI 10.1016/0042-6822(89)90509-6; ROEHRIG JT, 1990, VIROLOGY, V177, P668, DOI 10.1016/0042-6822(90)90532-V; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SUMIYOSHI H, 1987, VIROLOGY, V161, P497, DOI 10.1016/0042-6822(87)90144-9; Theiler M, 1937, J EXP MED, V65, P787, DOI 10.1084/jem.65.6.787; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; WENGLER G, 1989, J VIROL, V63, P2521, DOI 10.1128/JVI.63.6.2521-2526.1989; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	44	1154	1261	1	63	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					291	298		10.1038/375291a0	http://dx.doi.org/10.1038/375291a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753193				2022-12-24	WOS:A1995RA03000042
J	IKONEN, E; TAGAYA, M; ULLRICH, O; MONTECUCCO, C; SIMONS, K				IKONEN, E; TAGAYA, M; ULLRICH, O; MONTECUCCO, C; SIMONS, K			DIFFERENT REQUIREMENTS FOR NSF, SNAP, AND RAB PROTEINS IN APICAL AND BASOLATERAL TRANSPORT IN MDCK CELLS	CELL			English	Article							SENSITIVE FUSION PROTEIN; VESICULAR TRANSPORT; PLASMA-MEMBRANE; GOLGI-NETWORK; SCHIZOSACCHAROMYCES-POMBE; ATTACHMENT PROTEINS; EPITHELIAL-CELLS; ALPHA-SNAP; GENE; VESICLES	We used an in vitro system based on streptolysin O-permeabilized MDCK cells to study the involvement of NSF, SNAP, SNAREs, and Rab proteins in polarized membrane transport of epithelial cells. In MDCK cells, transport from the trans-Golgi network (TGN) to the basolateral plasma membrane is inhibited by anti-NSF antibodies and stimulated by alpha-SNAP. In contrast, transport from the TGN to the apical cell surface is not affected by anti-NSF antibodies or alpha-SNAP. Furthermore, apical transport is insensitive to Rab-GDI and tetanus and botulinum neurotoxins, which inhibit basolateral transport, These results provide evidence that the Rab-NSF-SNAP-SNARE mechanism operates in basolateral transport, while other molecules constitute the machinery for vesicular delivery in the apical pathway.	TOKYO COLL PHARM, SCH LIFE SCI, HACHIOJI 19203, TOKYO, JAPAN; UNIV PADUA, CTR CONSIGLIO NAZL RIC BIOMEMBRANE, DIPARTIMENTO SCI BIOMED, I-35121 PADUA, ITALY	Tokyo University of Pharmacy & Life Sciences; University of Padua	IKONEN, E (corresponding author), EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAM, D-69012 HEIDELBERG, GERMANY.			Simons, Kai/0000-0002-9231-9996				BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BOULAN ER, 1980, CELL, V20, P45, DOI 10.1016/0092-8674(80)90233-0; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1992, METHOD ENZYMOL, V219, P319; CRAIGHEAD MW, 1993, MOL BIOL CELL, V4, P1069, DOI 10.1091/mbc.4.10.1069; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; FIELDER K, 1994, EMBO J, V13, P1729; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FULLER SD, 1985, EMBO J, V4, P2475, DOI 10.1002/j.1460-2075.1985.tb03959.x; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HAUBRUCK H, 1990, EMBO J, V9, P1957, DOI 10.1002/j.1460-2075.1990.tb08323.x; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; HUGHSON E, 1988, MOL BIOL INFECTIOUS, P79; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAFONT F, 1994, NATURE, V372, P801; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SIMONS K, 1995, IN PRSS HARVEY LECT; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUMIDA M, 1994, J BIOL CHEM, V269, P20636; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; ULLRICH O, 1995, INPRESS METH ENZYMOL; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	60	216	217	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					571	580		10.1016/0092-8674(95)90078-0	http://dx.doi.org/10.1016/0092-8674(95)90078-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758111	Bronze			2022-12-24	WOS:A1995QZ71000014
J	ZHENG, H; JIANG, MH; TRUMBAUER, ME; SIRINATHSINGHJI, DJS; HOPKINS, R; SMITH, DW; HEAVENS, RP; DAWSON, GR; BOYCE, S; CONNER, MW; STEVENS, KA; SLUNT, HH; SISODIA, SS; CHEN, HY; VANDERPLOEG, LHT				ZHENG, H; JIANG, MH; TRUMBAUER, ME; SIRINATHSINGHJI, DJS; HOPKINS, R; SMITH, DW; HEAVENS, RP; DAWSON, GR; BOYCE, S; CONNER, MW; STEVENS, KA; SLUNT, HH; SISODIA, SS; CHEN, HY; VANDERPLOEG, LHT			BETA-AMYLOID PRECURSOR PROTEIN-DEFICIENT MICE SHOW REACTIVE GLIOSIS AND DECREASED LOCOMOTOR-ACTIVITY	CELL			English	Article							ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; RAT-BRAIN; GENE; EXPRESSION; MOUSE; DOMAIN; CDNA	In several pedigrees of early onset familial Alzheimer's disease (FAD), point mutations in the beta-amyloid precursor protein (APP) gene are genetically linked to the disease. This finding implicates APP in the pathogenesis of Alzheimer's disease in these individuals. To understand the in vivo function of APP and its processing, we have generated an APP-null mutation in mice. Homozygous APP-deficient mice were viable and fertile. However, the mutant animals weighed 15%-20% less than age-matched wild-type controls. Neurological evaluation showed that the APP-deficient mice exhibited a decreased locomotor activity and forelimb grip strength, indicating a compromised neuronal or muscular function. In addition, four out of six homozygous mice showed reactive gliosis at 14 weeks of age, suggesting an impaired neuronal function as a result of the APP-null mutation.	MERCK SHARP & DOHME LTD, RES LABS, NEUROSCI RES CTR, West Point, PA 19486 USA; JOHNS HOPKINS UNIV, SCH MED, NEUROPATHOL LAB, BALTIMORE, MD 21205 USA	Merck & Company; Johns Hopkins University	ZHENG, H (corresponding author), MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT GENET & MOLEC BIO, ANIM RESOURCES LAB, RAHWAY, NJ 07065 USA.							Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FISHER S, 1991, P NATL ACAD SCI USA, V88, P1779, DOI 10.1073/pnas.88.5.1779; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; IZUMI R, 1992, GENE, V112, P189, DOI 10.1016/0378-1119(92)90375-Y; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOO EH, 1993, P NATL ACAD SCI USA, V90, P4748, DOI 10.1073/pnas.90.10.4748; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; KOSIK KS, 1992, NEUROBIOLOGY AGING, V13; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; MANN DMA, 1989, NEUROBIOL AGING, V10, P397, DOI 10.1016/0197-4580(89)90073-0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRICE DL, 1994, ANNU REV MED, V45, P435; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SARKOZI E, 1994, EXP NEUROL, V128, P27, DOI 10.1006/exnr.1994.1109; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMALL DH, 1993, ANN NY ACAD SCI, V695, P169, DOI 10.1111/j.1749-6632.1993.tb23047.x; SOLA C, 1993, EUR J NEUROSCI, V5, P795, DOI 10.1111/j.1460-9568.1993.tb00931.x; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	51	544	563	2	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					525	531		10.1016/0092-8674(95)90073-X	http://dx.doi.org/10.1016/0092-8674(95)90073-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758106	hybrid			2022-12-24	WOS:A1995QZ71000009
J	NUDLER, E; KASHLEV, M; NIKIFOROV, V; GOLDFARB, A				NUDLER, E; KASHLEV, M; NIKIFOROV, V; GOLDFARB, A			COUPLING BETWEEN TRANSCRIPTION TERMINATION AND RNA-POLYMERASE INCHWORMING	CELL			English	Article							ELONGATION FACTOR-SII; ESCHERICHIA-COLI; TERNARY COMPLEXES; GENE-EXPRESSION; INVITRO; PROTEIN; DNA	Advancement of RNA polymerase of E. coli occurs in alternating laps of monotonic and inchworm-like movement. Cycles of inchworming are encoded in DNA and involve straining and relaxation of the ternary complex accompanied by characteristic leaping of DNA and RNA footprints. We demonstrate that the oligo(T) tract that constitutes a normal part of transcription terminators acts as an inchworming signal so that the leap coincides with the termination event. Prevention of leaping with a roadblock of cleavage-defective EcoRI protein results in suppression of RNA chain release at a termination site. The results indicate that straining and relaxation of RNA polymerase are steps in the termination mechanism.	RUSSIAN ACAD SCI, INST MOLEC GENET, MOSCOW 123182, RUSSIA	Russian Academy of Sciences	NUDLER, E (corresponding author), PUBL HLTH RES INST, 455 1ST AVE, NEW YORK, NY 10016 USA.			Nudler, Evgeny/0000-0002-8811-3071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DAUBE SS, 1995, IN PRESS P NATL ACAD; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; LEE F, 1977, P NATL ACAD SCI USA, V74, P4365, DOI 10.1073/pnas.74.10.4365; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; REINES D, 1989, J BIOL CHEM, V264, P10799; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SEVERINOV K, 1994, J BIOL CHEM, V269, P31701; STUDIER FW, 1981, J MOL BIOL, V153, P503, DOI 10.1016/0022-2836(81)90405-8; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG MT, 1989, J BIOL CHEM, V264, P2634; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	31	106	107	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					351	357		10.1016/0092-8674(95)90388-7	http://dx.doi.org/10.1016/0092-8674(95)90388-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736587	Bronze			2022-12-24	WOS:A1995QW89400007
J	OCHS, A; ROSSLE, M; HAAG, K; HAUENSTEIN, KH; DEIBERT, P; SIEGERSTETTER, V; HUONKER, M; LANGER, M; BLUM, HE				OCHS, A; ROSSLE, M; HAAG, K; HAUENSTEIN, KH; DEIBERT, P; SIEGERSTETTER, V; HUONKER, M; LANGER, M; BLUM, HE			THE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT-SHUNT PROCEDURE FOR REFRACTORY ASCITES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERITONEOVENOUS SHUNTS; INTRAVENOUS ALBUMIN; PROSPECTIVE TRIAL; CIRRHOSIS; PARACENTESIS; SURVIVAL; LEVEEN	Background. Previous studies have suggested that the transjugular placement of an intrahepatic stent to establish a portosystemic shunt is an effective treatment of uncomplicated ascites accompanying variceal bleeding. We studied the stent shunt for use in patients with liver cirrhosis and ascites refractory to medical treatment. Methods. Fifty of 62 consecutive patients with cirrhosis and refractory ascites were treated with the stent shunt - an expandable stent of metallic mesh placed between a major branch of the portal vein and one of the hepatic veins. Patients were followed for a mean (+/-SD) of 426+/-333 days. Results. The stent shunt was successfully placed in all patients and reduced the pressure gradient between the portal vein and the inferior vena cava by an average of 63 percent. Thirty-seven patients (74 percent) had complete responses (total remission of ascites within three months), and nine patients (18 percent) had partial responses. Four patients did not respond, including two who died within two weeks of shunt placement. After the procedure, 25 patients had hepatic encephalopathy, as compared with 20 patients before the procedure; although encephalopathy improved in 3 patients, new encephalopathy developed in 8 patients. In the 28 of the 33 patients followed for more than six months who were evaluated, the mean serum creatinine concentration was 1.5+/-0.09 mg per deciliter (133+/-8 mu mol per liter) before placement of the stent shunt, 1.5+/-1.6 mg per deciliter (133+/-141 mu mol per liter) one week after the procedure, and 0.9+/-0.3 mg per deciliter (80+/-27 mu mol per liter) after six months (P=0.008 for the comparison of concentrations before and six months after the procedure). Renal function did not improve in the six patients with organic kidney disease. Procedure-related complications developed in 16 patients. During followup, an additional 29 patients died - 10 of progressive liver disease and 19 of other causes. Survival for at least one year was associated with a patient's being under 60 years of age, having a serum bilirubin level before placement of the stent shunt of less than 1.3 mg per deciliter (22 mu mol per liter), and having a complete response. Conclusions. Our findings in an uncontrolled prospective study suggest that the transjugular intrahepatic portosystemic stent-shunt procedure was an effective treatment for many patients with liver cirrhosis and refractory ascites, but mortality from underlying diseases was substantial.	UNIV FREIBURG,SCH MED,DEPT MED,D-79106 FREIBURG,GERMANY; UNIV FREIBURG,SCH MED,DEPT RADIOL,D-79106 FREIBURG,GERMANY	University of Freiburg; University of Freiburg			Deibert, Peter/AAE-4623-2020					ARROYO V, 1986, SEMIN LIVER DIS, V6, P353, DOI 10.1055/s-2008-1040617; Arroyo V, 1989, GASTROENTEROL INT, V2, P195; BERNHOFT RA, 1982, ARCH SURG-CHICAGO, V117, P631; BORIES P, 1986, J HEPATOL, V3, P212, DOI 10.1016/S0168-8278(86)80028-9; BURCHELL AR, 1968, ANN SURG, V168, P655, DOI 10.1097/00000658-196810000-00012; CAMPBELL DP, 1973, AM J SURG, V126, P748, DOI 10.1016/S0002-9610(73)80062-5; CAPONE RR, 1978, DIGEST DIS SCI, V23, P867; ELCHEROTH J, 1994, WORLD J SURG, V18, P240; EPSTEIN M, 1994, J AM SOC NEPHROL, V4, P1735; EPSTEIN M, 1989, NEW ENGL J MED, V321, P1675, DOI 10.1056/NEJM198912143212410; FERRAL H, 1993, RADIOLOGY, V189, P795, DOI 10.1148/radiology.189.3.8234706; FERRO D, 1992, SCAND J GASTROENTERO, V27, P852, DOI 10.3109/00365529209000153; FRANCO D, 1988, ARCH SURG-CHICAGO, V123, P987; FULENWIDER JT, 1986, ARCH SURG-CHICAGO, V121, P351; GINES P, 1988, GASTROENTEROLOGY, V94, P1493, DOI 10.1016/0016-5085(88)90691-9; GINES P, 1991, NEW ENGL J MED, V325, P829, DOI 10.1056/NEJM199109193251201; HAUENSTEIN KH, 1995, INTERVENTIONAL RADIO, V194, P175; KELLERMAN PS, 1990, ANN INTERN MED, V112, P889, DOI 10.7326/0003-4819-112-12-889; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; LAKE JR, 1993, TRANSPLANT P, V25, P1766; LEVEEN HH, 1974, ANN SURG, V180, P580, DOI 10.1097/00000658-197410000-00023; LLOVET JM, 1993, AM J GASTROENTEROL, V88, P388; MARTINET JP, 1994, HEPATOLOGY, V20, pA113; MOSKOVITZ M, 1990, AM J GASTROENTEROL, V85, P917; OCHS A, 1993, J HEPATOL, V18, P217, DOI 10.1016/S0168-8278(05)80249-1; ORLOFF MJ, 1970, ANN NY ACAD SCI, V170, P213, DOI 10.1111/j.1749-6632.1970.tb37015.x; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; ROSSLE M, 1994, NEW ENGL J MED, V330, P165, DOI 10.1056/NEJM199401203300303; RUNYON BA, 1994, NEW ENGL J MED, V330, P337, DOI 10.1056/NEJM199402033300508; SALERNO F, 1993, AM J GASTROENTEROL, V88, P514; SAUNDERS JB, 1981, BRIT MED J, V282, P263, DOI 10.1136/bmj.282.6260.263; SCHOLZ DG, 1989, AM J GASTROENTEROL, V84, P540; SMART HL, 1990, J HEPATOL, V10, P191, DOI 10.1016/0168-8278(90)90051-R; STANLEY MM, 1989, NEW ENGL J MED, V321, P1632, DOI 10.1056/NEJM198912143212403; Tamaki A, 1968, Surg Forum, V19, P324; VILLARREAL LG, 1993, GASTROENTEROL HEPATO, V16, P18	36	387	389	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1192	1197		10.1056/NEJM199505043321803	http://dx.doi.org/10.1056/NEJM199505043321803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700312				2022-12-24	WOS:A1995QV41500003
J	FRANKLIN, KA; NILSSON, JB; SAHLIN, C; NASLUND, U				FRANKLIN, KA; NILSSON, JB; SAHLIN, C; NASLUND, U			SLEEP-APNEA AND NOCTURNAL ANGINA	LANCET			English	Note							MECHANISMS; APNEA	Hypoxaemia occurs with sloop apnoea and might induce nocturnal angina. Sleep apnoea was found in 9 of 10 patients with nocturnal angina pectoris. Nocturnal angina diminished during treatment of sleep apnoea by continuous positive airway-pressure, and the number of nocturnal myocardial ischaemic events measured by computerised vector-cardiography was reduced.	UNIV HOSP NO SWEDEN,DEPT INTERNAL MED,S-90185 UMEA,SWEDEN	Umea University	FRANKLIN, KA (corresponding author), UNIV HOSP NO SWEDEN,DEPT PULM MED & ALLERGOL,S-90185 UMEA,SWEDEN.			Franklin, Karl/0000-0002-5306-1697; Naslund, Ulf/0000-0003-4100-8298				BALFORS EM, 1994, AM J RESP CRIT CARE, V150, P1587, DOI 10.1164/ajrccm.150.6.7952619; CHIERCHIA S, 1980, CIRCULATION, V61, P759, DOI 10.1161/01.CIR.61.4.759; GUILLEMINAULT C, 1984, LANCET, V1, P126; JENSEN SM, 1994, CORONARY ARTERY DIS, V5, P507; QUYYUMI AA, 1984, LANCET, V1, P1207; SULLIVAN CE, 1981, LANCET, V1, P862; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	7	189	193	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1085	1087		10.1016/S0140-6736(95)90820-X	http://dx.doi.org/10.1016/S0140-6736(95)90820-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715342				2022-12-24	WOS:A1995QV41100012
J	WILKINSON, P; HANSELL, DM; JANSSENS, J; RUBENS, M; RUDD, RM; TAYLOR, AN; MCDONALD, C				WILKINSON, P; HANSELL, DM; JANSSENS, J; RUBENS, M; RUDD, RM; TAYLOR, AN; MCDONALD, C			IS LUNG-CANCER ASSOCIATED WITH ASBESTOS EXPOSURE WHEN THERE ARE NO SMALL OPACITIES ON THE CHEST RADIOGRAPH	LANCET			English	Article							WORKERS; MORTALITY	This study was designed to test the hypothesis that the risk of lung cancer from asbestos exposure is confined to persons with radiographic evidence of pulmonary fibrosis. Occupational and smoking histories were obtained from 271 patients with a confirmed diagnosis of primary lung cancer and 678 referents (279 with other respiratory disease and 399 with cardiac disease). Histories were reviewed blind to assess the timing, duration, and probability of exposure to asbestos. To allow for a lag between asbestos exposure and the development of lung cancer, subjects were classified by the time they had spent in an occupation entailing definite or probable exposure more than 15 years before diagnosis. The presence and extent of fibrosis was assessed blindly from chest radiographs by three readers and scored for small opacities with the ILO 1989 International Classification of Radiographs of the Pneumoconioses. 93 (34.3%) cases had worked in an occupation with definite or probable asbestos exposure compared with 176 (25. 8%) referents (crude odds ratio for lung cancer 1.49, 95% CI 1.09-2.04). After adjustment for age, sex, smoking history, and area of referral, the odds ratio (95% CI) was 2.03 (1.00-4.13) in the subgroup of 211 with a median ILO score for small parenchymal opacities of 1/0 or more, and 1.56 (1.02-2.39) in the 738 with a score of 0/1 or less (ie, those without radiological evidence of pulmonary fibrosis). These results suggest that asbestos is associated with lung cancer even in the absence of radiologically apparent pulmonary fibrosis.	ROYAL BROMPTON HOSP,LONDON SW3 6LY,ENGLAND; NATL HEART & LUNG INST,LONDON SW3 6LY,ENGLAND; LONDON CHEST HOSP,LONDON E2 9JX,ENGLAND	Royal Brompton Hospital; Imperial College London; University of London; Queen Mary University London				Wilkinson, Paul/0000-0001-7456-259X				DOLL R, 1981, CAUSES CANC, P1238; HUGHES JM, 1991, BRIT J IND MED, V48, P229; IRVINE HD, 1993, BMJ-BRIT MED J, V306, P1503, DOI 10.1136/bmj.306.6891.1503; KIPEN HM, 1987, BRIT J IND MED, V44, P96; LIDDELL FDK, 1980, BRIT J IND MED, V37, P257; LIDDELL FDK, 1977, BRIT J IND MED, V34, P85; MARTISCHNIG M, 1977, BMJ-BRIT MED J, V1, P756; MCDONALD AD, 1980, CANCER, V46, P1650, DOI 10.1002/1097-0142(19801001)46:7<1650::AID-CNCR2820460726>3.0.CO;2-Y; MCDONALD JC, 1981, QUANTIFICATION OCCUP, P73; MCLEOD TC, 1983, RADIOLOGY, V149, P353; MEREDITH SK, 1994, OCCUP MED-OXFORD, V44, P183, DOI 10.1093/occmed/44.4.183; RECKLAKE MR, 1991, MINERAL FIBERS HLTH, P105; SLUISCREMER GK, 1989, BRIT J IND MED, V46, P537; STAPLES CA, 1989, AM REV RESPIR DIS, V139, P1502, DOI 10.1164/ajrccm/139.6.1502; 1980, OCCUPATIONAL SAFETY, V22; CANCER STATISTIC MB1, V20	16	72	73	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1074	1078		10.1016/S0140-6736(95)90817-X	http://dx.doi.org/10.1016/S0140-6736(95)90817-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715339				2022-12-24	WOS:A1995QV41100009
J	PHILLIPS, JH; GUMPERZ, JE; PARHAM, P; LANIER, LL				PHILLIPS, JH; GUMPERZ, JE; PARHAM, P; LANIER, LL			SUPERANTIGEN-DEPENDENT, CELL-MEDIATED CYTOTOXICITY INHIBITED BY MHC CLASS-I RECEPTORS ON T-LYMPHOCYTES	SCIENCE			English	Article							NATURAL-KILLER-CELLS; ENTEROTOXIN-B; NK CLONES; SPECIFICITY; EXPRESSION; SUSCEPTIBILITY; STIMULATION; PROTECTION; COMPLEX; ALLELES	Bacterial superantigens bind with high affinity to major histocompatibility complex (MHC) class II antigens on antigen-presenting cells and with T cell antigen receptor (TCR) beta chains on T lymphocytes,which results in the T cell activation responsible for toxic shock syndrome and food poisoning, Many cytotoxic T lymphocyte (CTL) clones were shown to have receptors for human leukocyte antigen (HLA) class I molecules that inhibited superantigen-induced cytotoxicity against appropriate class I-bearing target cells. One type of inhibitory receptor, NKB1, was present on CD4(+) and CD8(+)TCR alpha beta(+) CTL clones and blocked the killing of staphylococcal enterotoxin B (SEB)-coated targets bearing certain polymorphic HLA-B molecules. Expression of HLA-A, -B, and -C molecules on the SEE-coated targets also protected against cytolysis mediated by many NKB1-negative T cell clones, suggesting the presence of additional inhibitory MHC class I receptors. These HLA class I receptors may limit tissue destruction and possibly autoimmunity caused by activated T lymphocytes.	STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305	Stanford University; Stanford University	PHILLIPS, JH (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT HUMAN IMMUNOL,901 CALIF AVE,PALO ALTO,CA 94304, USA.		Lanier, Lewis L/E-2139-2014	Lanier, Lewis L/0000-0003-1308-3952	NIAID NIH HHS [AI22039] Funding Source: Medline; NIGMS NIH HHS [GM07276] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022039] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133; HEWITT CRA, 1992, J EXP MED, V175, P1493, DOI 10.1084/jem.175.6.1493; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; LANIER L L, 1991, Methods (Orlando), V2, P192, DOI 10.1016/S1046-2023(05)80061-1; LANIER LL, 1983, J IMMUNOL, V131, P1789; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; MINASI LAE, 1993, J EXP MED, V177, P1451, DOI 10.1084/jem.177.5.1451; MOLLICK JA, 1989, SCIENCE, V244, P817, DOI 10.1126/science.2658055; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; Phillips J. A., UNPUB; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; SHIMIZU Y, 1989, EUR J IMMUNOL, V19, P447, DOI 10.1002/eji.1830190306; STORKUS WJ, 1989, P NATL ACAD SCI USA, V86, P2361, DOI 10.1073/pnas.86.7.2361; SUNDSTEDT A, 1994, IMMUNOLOGY, V82, P117; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2	27	310	314	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					403	405		10.1126/science.7716542	http://dx.doi.org/10.1126/science.7716542			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716542				2022-12-24	WOS:A1995QU57200035
J	THOMAS, SA; MATSUMOTO, AM; PALMITER, RD				THOMAS, SA; MATSUMOTO, AM; PALMITER, RD			NORADRENALINE IS ESSENTIAL FOR MOUSE FETAL DEVELOPMENT	NATURE			English	Article								CATECHOLAMINES such as noradrenaline and adrenaline have been implicated in numerous physiological processes(1-4) but, although catecholamine synthesis begins at mid-gestation(5), previous studies have provided little evidence for any role in early development(6,7). Furthermore, there are several case reports of humans with noradrenaline deficiency(8). To investigate this, we used gene targeting(9) to produce mice lacking dopamine beta-hydroxylase and therefore unable to synthesize noradrenaline or adrenaline. We report here that in heterozygous mothers, most homozygous embryos died in utero, and only about 5% reached adulthood. Survival probably depends on catecholamine transfer across the placenta because, in homozygous mothers, all embryos die in utero. Mortality was due to lack of noradrenaline in utero because it could be prevented by treatment with dihydroxyphenylserine, a precursor that can be converted to noradrenaline in the absence of dopamine beta-hydroxylase. Mutant embryos had a histological phenotype similar to that of embryos deficient in tyrosine hydroxylase(10), suggesting that death might be due to cardiovascular failure.	UNIV WASHINGTON,SCH MED,VET ADM MED CTR,CTR GERENTOL RES EDUC & CLIN,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	THOMAS, SA (corresponding author), UNIV WASHINGTON,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM,SL-15,SEATTLE,WA 98195, USA.		Matsumoto, Alvin/AAH-6096-2020					ANGELETTI PU, 1970, P NATL ACAD SCI USA, V65, P114, DOI 10.1073/pnas.65.1.114; [Anonymous], 1989, SCIENCE; BERTI F, 1965, MED PHARMACOL EXP, V13, P227; KUDLACZ EM, 1990, J DEV PHYSIOL, V13, P243; LEVIMONT.R, 1966, PHARMACOL REV, V18, P619; ROBERTSON D, 1991, HYPERTENSION, V18, P1, DOI 10.1161/01.HYP.18.1.1; ROSEN TS, 1979, J PHARMACOL EXP THER, V208, P118; Rosenblueth A, 1937, AUTONOMIC NEUROEFFEC; Schlumpf M., 1980, BIOGENIC AMINES DEV, P567	9	443	450	2	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					643	646		10.1038/374643a0	http://dx.doi.org/10.1038/374643a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715704				2022-12-24	WOS:A1995QT18900060
J	ZABNER, J; COUTURE, LA; GREGORY, RJ; GRAHAM, SM; SMITH, AE; WELSH, MJ				ZABNER, J; COUTURE, LA; GREGORY, RJ; GRAHAM, SM; SMITH, AE; WELSH, MJ			ADENOVIRUS-MEDIATED GENE-TRANSFER TRANSIENTLY CORRECTS THE CHLORIDE TRANSPORT DEFECT IN NASAL EPITHELIA OF PATIENTS WITH CYSTIC-FIBROSIS	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ELECTROLYTE TRANSPORT; EXPRESSION; PATHOGENESIS; PERMEABILITY; CHANNEL; CELLS	To evaluate the potential of direct transfer of cystic fibrosis transmembrane conductance regulator (CFTR) cDNA for the treatment of cystic fibrosis (CF), we administered an E1-deficient adenovirus, encoding CFTR, to a defined area of nasal airway epithelium of three individuals with CF. This treatment corrected the Cl- transport defect that is characteristic of CF-affected epithelia. After treatment, there was a decrease in the elevated basal transepithelial voltage, and the normal response to a cAMP agonist was restored. We found no evidence of viral replication or virus-associated adverse effects, even at the highest dose tested (25 MOI). These data represent a small step in achieving long-term improvement of CF lung function by gene therapy.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT OTOLARYNGOL,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Sanofi-Aventis; Genzyme Corporation	ZABNER, J (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.			Graham, Scott/0000-0003-2969-2998; Zabner, Joseph/0000-0002-9606-1339; Welsh, Michael/0000-0002-1646-6206				ALTON EWF, 1987, THORAX, V342, P815; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHASSE JF, 1989, M S-MED SCI, V5, P331, DOI 10.4267/10608/3974; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DICKSON D, 1993, NATURE, V365, P4; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; GRAHAM FL, 1992, VACCINES NEW APPROAC, P363; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; MARIASSY AT, 1992, COMP BIOL NORMAL LUN, P63; MASTRANGELI A, 1993, J CLIN INVEST, V91, P225, DOI 10.1172/JCI116175; MATSUSE T, 1992, AM REV RESPIR DIS, V146, P177, DOI 10.1164/ajrccm/146.1.177; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1993, HUM GENE THER, V4, P461, DOI 10.1089/hum.1993.4.4-461; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; TAUSSIG LM, 1973, J PEDIATR-US, V82, P380, DOI 10.1016/S0022-3476(73)80110-6; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; Weibel E.R., 1963, MORPHOMETRY HUMAN LU, DOI DOI 10.1007/978-3-642-87553-3; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WIDDICOMBE JH, 1985, P NATL ACAD SCI USA, V82, P6167, DOI 10.1073/pnas.82.18.6167; ZABNER J, 1993, IN PRESS NATURE GENE	32	583	664	1	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 22	1993	75	2					207	216		10.1016/0092-8674(93)80063-K	http://dx.doi.org/10.1016/0092-8674(93)80063-K			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	7691415				2022-12-24	WOS:A1993MD88500003
J	KANE, RL; KANE, RA				KANE, RL; KANE, RA			LONG-TERM-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATIONS; NURSING-HOME; SERVICES				KANE, RL (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455, USA.							ARRAS J, 1995, BRINGING HOSPITAL HO; EUSTIS NN, 1992, GENERATIONS, V16, P17; HARRINGTON C, 1993, GERONTOLOGIST, V33, P790, DOI 10.1093/geront/33.6.790; HARRINGTON C, 1993, INQUIRY-J HEALTH CAR, V30, P429; Kane RA, 1993, ASSISTED LIVING US N; KANE RL, 1992, GERONTOLOGIST, V32, P771, DOI 10.1093/geront/32.6.771; KANE RL, 1983, J GERONTOL, V38, P385, DOI 10.1093/geronj/38.4.385; KANE RL, 1990, GERONTOLOGIST, V30, P291, DOI 10.1093/geront/30.3.291; KANE RL, 1994, GERONTOLOGIST, V34, P598, DOI 10.1093/geront/34.5.598; KANE RL, 1991, NEW ENGL J MED, V324, P627, DOI 10.1056/NEJM199102283240910; MANTON KG, 1994, MED CARE, V32, P277, DOI 10.1097/00005650-199403000-00007; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; NEWCOMER R, 1990, GERONTOLOGIST, V30, P86, DOI 10.1093/geront/30.1.86; NEWCOMER R, 1990, HEALTH SERV RES, V25, P425; SIMONRUSINOWITZ L, 1993, GERONTOLOGIST, V33, P159, DOI 10.1093/geront/33.2.159; 1994, GAOHEHE94167 US GEN; 1994, GAOHEHS9526 US GEN A	17	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1690	1691		10.1001/jama.273.21.1690	http://dx.doi.org/10.1001/jama.273.21.1690			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB097	7752419				2022-12-24	WOS:A1995RB09700027
J	CHONG, JPJ; MAHBUBANI, HM; KHOO, CY; BLOW, JJ				CHONG, JPJ; MAHBUBANI, HM; KHOO, CY; BLOW, JJ			PURIFICATION OF AN MCM-CONTAINING COMPLEXES A COMPONENT OF THE DNA-REPLICATION LICENSING SYSTEM	NATURE			English	Article							CELL-FREE-EXTRACTS; SUBCELLULAR-LOCALIZATION; YEAST; CYCLE; INITIATION; PROTEIN; FAMILY; NUCLEI	REPLICATION licensing factor (RLF) ensures that eukaryotic chromosomal DNA is replicated exactly once in each cell cycle(1-4). On exit from metaphase, RLF is activated and binds to or modifies chromatin. This modification (the 'licence') is required for subsequent DNA replication; the licence is also inactivated in the process of replication. Active RLF is not imported into the nucleus, so further DNA replication cannot occur until the DNA is relicensed by passage throught mitosis. We have developed an assay to purify RLF from Xenopus eggs(4). Activity resolves into two components, RLF-M and RLF-B, both of which are required for licensing, RLF-M has been purified to apparent homogeneity: it consists of three polypeptides, one of which is a Xenopus homologue of the yeast MCM3 protein. Xenopus Mcm3 associates with chomatin in G1 and is removed during replication, consistent with its being a component of the RLF system.	IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND; WELLCOME CRC INST, CAMBRIDGE CB2 1QR, ENGLAND				Blow, J. Julian/B-3977-2009; Chong, James/AAC-4957-2019	Blow, J. Julian/0000-0002-9524-5849; Chong, James/0000-0001-9447-7421	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BUCCI S, 1993, INT J DEV BIOL, V37, P509; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; CREVEL G, 1991, EMBO J, V10, P4361, DOI 10.1002/j.1460-2075.1991.tb05014.x; DEROEPER A, 1977, NATURE, V265, P469, DOI 10.1038/265469a0; FORSBURG SL, 1994, J CELL SCI, V107, P2779; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; KUBOTA Y, IN PRESS CELL; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAITI AK, 1992, J MOL BIOL, V224, P545, DOI 10.1016/0022-2836(92)90543-S; MIYAKE S, 1993, MOL BIOL CELL, V4, P1003, DOI 10.1091/mbc.4.10.1003; SHIVJI MKK, 1994, J CURR BIOL, V4, P1062; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1994, J CELL SCI, V107, P253; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	28	319	321	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 1	1995	375	6530					418	421		10.1038/375418a0	http://dx.doi.org/10.1038/375418a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760937				2022-12-24	WOS:A1995RB10100057
J	PERKINS, AC; SHARPE, AH; ORKIN, SH				PERKINS, AC; SHARPE, AH; ORKIN, SH			LETHAL BETA-THALASSEMIA IN MICE LACKING THE ERYTHROID CACCC-TRANSCRIPTION FACTOR EKLF	NATURE			English	Article							HUMAN GAMMA-GLOBIN; TARGETED MUTATION; MAMMALIAN-CELLS; TRANSGENIC MICE; FACTOR GATA-1; GENE; BINDING; EXPRESSION; EXTRACTION; PROMOTER	GLOBIN genes are regulated in a tissue-specific and developmental stage-specific manner, with the beta-globin gene being the last to be activated in the beta-gene cluster(1). CACCC-nucleotide sequences, which bind multiple nuclear proteins, including ubiquitously expressed Sp1 and erythroid Kruppel-like factor (EKLF), are among the cis-regulatory sequences critical for transcription of globin and non-globin erythroid-expressed genes(2-5). To determine the function of EKLF in vivo, we created mice deficient in EKLF by gene targeting(6). These embryos die of anaemia during fetal liver erythropoiesis and show the molecular and haematological features of beta-globin deficiency, found in beta-thalassaemia. Although it is expressed at all stages, EKLF is not required for yolk sac erythropoiesis, erythroid commitment or expression of other potential target genes. Its stage-specific and beta-globin-gene-specific requirement suggests that EKLF may facilitate completion of the fetal-to-adult (haemoglobin gamma to beta) switch in humans.	CHILDRENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute			Perkins, Andrew/AAJ-9696-2020; Brugnara, Carlo/A-8041-2010; Perkins, Andrew C/M-3216-2014; Perkins, Andrew/X-4180-2019	Brugnara, Carlo/0000-0001-8192-8713; Perkins, Andrew C/0000-0003-3644-7093; Perkins, Andrew/0000-0003-3644-7093				ALTER BP, 1982, HEMOGLOBIN, V6, P517, DOI 10.3109/03630268209083764; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; FENG WC, 1994, J BIOL CHEM, V269, P1493; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LLOYD JA, 1992, MOL CELL BIOL, V12, P1561, DOI 10.1128/MCB.12.4.1561; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONAGH KT, 1992, HEMATOLOGY INFANCY C; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NATHAN DG, 1966, AM J MED, V41, P815, DOI 10.1016/0002-9343(66)90039-8; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PORCHER C, 1991, J BIOL CHEM, V266, P10562; Sambrook J., 1989, MOL CLONING LAB MANU; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; THIEN SL, 1993, BLOOD, V82, P961; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675	29	519	531	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					318	322						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753195				2022-12-24	WOS:A1995RA03000051
J	HUG, C; JAY, PY; REDDY, I; MCNALLY, JG; BRIDGMAN, PC; ELSON, EL; COOPER, JA				HUG, C; JAY, PY; REDDY, I; MCNALLY, JG; BRIDGMAN, PC; ELSON, EL; COOPER, JA			CAPPING PROTEIN-LEVELS INFLUENCE ACTIN ASSEMBLY AND CELL MOTILITY IN DICTYOSTELIUM	CELL			English	Article							F-ACTIN; LENGTH DISTRIBUTION; BINDING PROTEINS; AMEBOID CELLS; DISCOIDEUM; FILAMENTS; POLYMERIZATION; IDENTIFICATION; MORPHOGENESIS; STIMULATION	Actin assembly is important for cell motility, but the mechanism of assembly and how it relates to motility in vivo is largely unknown. In vitro, actin assembly can be controlled by proteins, such as capping protein, that bind filament ends. To investigate the function of actin assembly in vivo, we altered the levels of capping protein in Dictyostelium cells and found changes in resting and chemoattractant-induced actin assembly that were consistent with the in vitro properties of capping protein in capping but not nucleation. Significantly, overexpressers moved faster and underexpressers moved slower than control cells. Mutants also exhibited changes in cytoskeleton architecture. These results provide insights into in vivo actin assembly and the role of the actin cytoskeleton in motility.	WASHINGTON UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	HUG, C (corresponding author), WASHINGTON UNIV,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110, USA.		Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Cooper, John/0000-0002-0933-4571	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026150] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38838, GM 38542] Funding Source: Medline; NINDS NIH HHS [NS 26150] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; CASELLA JF, 1994, J BIOL CHEM, V269, P6992; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; COOPER JA, 1984, J CELL BIOL, V99, P217, DOI 10.1083/jcb.99.1.217; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Cooper John A., 1993, P34; CORTESE JD, 1988, J CELL BIOL, V107, P1477, DOI 10.1083/jcb.107.4.1477; COX D, 1994, J CELL BIOL, V128, P819; DOOLITTLE KW, 1995, DEV BIOL, V167, P118, DOI 10.1006/dbio.1995.1011; FURUKAWA R, 1993, BIOCHEMISTRY-US, V32, P12346, DOI 10.1021/bi00097a010; HALL AL, 1989, J CELL BIOL, V109, P2207, DOI 10.1083/jcb.109.5.2207; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HARTMAN R, 1993, COMPUT METH PROG BIO, V39, P195, DOI 10.1016/0169-2607(93)90021-C; HARTMANN H, 1989, J BIOL CHEM, V264, P12639; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HUG C, 1992, J CELL BIOL, V116, P923, DOI 10.1083/jcb.116.4.923; JACOBSON K, 1984, P NATL ACAD SCI-BIOL, V81, P6747, DOI 10.1073/pnas.81.21.6747; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; LIU TY, 1992, MOL BIOL CELL, V3, P1403, DOI 10.1091/mbc.3.12.1403; MADDEN TL, 1994, J CELL BIOL, V126, P169, DOI 10.1083/jcb.126.1.169; NELLEN W, 1988, BIOCHEM BIOPH RES CO, V154, P54, DOI 10.1016/0006-291X(88)90648-1; PODOLSKI JL, 1988, J BIOL CHEM, V263, P638; PODOLSKI JL, 1990, J BIOL CHEM, V265, P1312; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAFER DA, 1994, J CELL BIOL, V127, P453, DOI 10.1083/jcb.127.2.453; SIEGERT F, 1994, J CELL SCI, V107, P97; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; VOGEL G, 1980, J CELL BIOL, V86, P456; WATTS RG, 1994, CELL MOTIL CYTOSKEL, V28, P155, DOI 10.1002/cm.970280207; WEBER A, 1994, BIOCHEMISTRY-US, V33, P4780, DOI 10.1021/bi00182a005; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; ZANER KS, 1988, J BIOL CHEM, V263, P4532	40	144	145	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					591	600		10.1016/0092-8674(95)90080-2	http://dx.doi.org/10.1016/0092-8674(95)90080-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758113	Bronze			2022-12-24	WOS:A1995QZ71000016
J	DAUTERMAN, K; PAK, PH; MAUGHAN, WL; NUSSBACHER, A; ARIE, S; LIU, CP; KASS, DA				DAUTERMAN, K; PAK, PH; MAUGHAN, WL; NUSSBACHER, A; ARIE, S; LIU, CP; KASS, DA			CONTRIBUTION OF EXTERNAL FORCES TO LEFT-VENTRICULAR DIASTOLIC PRESSURE - IMPLICATIONS FOR THE CLINICAL USE OF THE STARLING LAW	ANNALS OF INTERNAL MEDICINE			English	Article						VENTRICULAR FUNCTION, LEFT; VENTRICULAR DYSFUNCTION, LEFT; HEART CATHETERIZATION; CARDIAC OUTPUT; DIASTOLIC	VOLUME RELATIONS; PERICARDIUM; DOGS; CURVE; NITROGLYCERIN; RELAXATION; MECHANISM; AFTERLOAD; REDUCTION; OCCLUSION	Objective: To test whether a substantial proportion of measured resting left ventricular diastolic pressure stems from forces external to the left ventricle (such as right-heart filling) in normal and chronically diseased hearts. Design: Nonrandomized study with single intervention. Setting: University hospital. Patients: 29 patients referred for cardiac catheterization who had normal left ventricles and ejection fractions (n = 12); chronic heart disease due to idiopathic dilated cardiomyopathy (n = 6); ischemic heart disease(n = 6); or left ventricular hypertrophy (n = 5). Intervention: Acute reduction of external forces imposed on the left ventricle using balloon obstruction of inferior vena caval inflow to the right heart. Measurements: Continuous catheter-derived left ventricular pressure-volume data before and after abrupt obstruction of inferior vena caval inflow. Diastolic pressures were measured at the same volume just before atrial systole before and after sudden decrease of external (right-heart and pericardial) forces. The resulting decline in pressure was a measure of the contribution of these external forces to resting left ventricular diastolic pressure. Results: The decline in pressure when external forces were released averaged -19% +/- 13% with minimal change in left ventricular end-diastolic volume (-3.66% +/- 6.7%) and cardiac output (-5% +/- 8%). In all patients combined, the decline in pressure when external forces (Delta P-d) were released correlated with resting left ventricular diastolic pressure (LVP(d)) given by: Delta P-d = 0.38 x (LVP(d) 6) [r = 0.86, P < 0.0001]. This indicates that when resting diastolic pressure was more than 6 mm Hg, almost 38% of the pressure was due to external factors. This percentage was similar among all subgroups. Furthermore, the left ventricular diastolic pressure could be reduced by this percentage with only minimal compromise to ventricular filling and cardiac output. Conclusions: A substantial proportion of measured resting left ventricular diastolic pressure stems from forces extrinsic to the left ventricle rather than from diastolic stiffness in the left ventricle itself. This markedly influences the dependence of cardiac output on filling pressure and has important implications for clinical application of the Starling law.	JOHNS HOPKINS MED INST, BALTIMORE, MD 21205 USA; INST CORACAO, SAO PAULO, BRAZIL; VET GEN HOSP, TAIPEI, TAIWAN	Johns Hopkins University; Johns Hopkins Medicine; Universidade de Sao Paulo					NHLBI NIH HHS [HL-47511] Funding Source: Medline; NIA NIH HHS [AG-12249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALDERMAN EL, 1976, CIRCULATION, V54, P662, DOI 10.1161/01.CIR.54.4.662; APPLEGATE RJ, 1990, AM J PHYSIOL, V258, pH1079, DOI 10.1152/ajpheart.1990.258.4.H1079; APPLEGATE RJ, 1992, AM J PHYSIOL, V262, pH1725, DOI 10.1152/ajpheart.1992.262.6.H1725; BHARGAVA V, 1983, AM HEART J, V105, P995, DOI 10.1016/0002-8703(83)90402-7; BLANCHARD DG, 1992, CIRCULATION, V85, P1414, DOI 10.1161/01.CIR.85.4.1414; BRAUNWALD E, 1963, AM J MED, V34, P147, DOI 10.1016/0002-9343(63)90049-4; BRODIE BR, 1977, J CLIN INVEST, V59, P59, DOI 10.1172/JCI108622; CARROLL JD, 1986, CIRCULATION, V74, P815, DOI 10.1161/01.CIR.74.4.815; FREEMAN GL, 1984, CIRC RES, V54, P294, DOI 10.1161/01.RES.54.3.294; GILBERT JC, 1989, CIRC RES, V64, P827, DOI 10.1161/01.RES.64.5.827; JANICKI JS, 1980, AM J PHYSIOL, V238, pH494, DOI 10.1152/ajpheart.1980.238.4.H494; JANICKI JS, 1990, CIRCULATION, V81, P15; KASS DA, 1988, CATHETER CARDIO DIAG, V15, P192, DOI 10.1002/ccd.1810150314; KASS DA, 1993, ANN INTERN MED, V119, P466, DOI 10.7326/0003-4819-119-6-199309150-00004; KASS DA, 1990, CIRCULATION, V81, P447, DOI 10.1161/01.CIR.81.2.447; KINGMA I, 1986, AM J CARDIOL, V57, P673, DOI 10.1016/0002-9149(86)90857-X; LANKFORD EB, 1990, AM J PHYSIOL, V258, pH1933, DOI 10.1152/ajpheart.1990.258.6.H1933; LEWINTER MM, 1982, CIRC RES, V50, P501, DOI 10.1161/01.RES.50.4.501; LUDBROOK PA, 1979, CIRCULATION, V59, P21, DOI 10.1161/01.CIR.59.1.21; LUDBROOK PA, 1977, CIRCULATION, V56, P937, DOI 10.1161/01.CIR.56.6.937; RAFF GL, 1981, CIRC RES, V48, P813, DOI 10.1161/01.RES.48.6.813; ROSS J, 1979, CIRCULATION, V59, P32, DOI 10.1161/01.CIR.59.1.32; SHIRATO K, 1978, CIRCULATION, V57, P1191, DOI 10.1161/01.CIR.57.6.1191; SLINKER BK, 1989, AM J PHYSIOL, V256, pH567, DOI 10.1152/ajpheart.1989.256.2.H567; STARLING EH, 1978, CIRC RES, V42, P433; TYBERG JV, 1978, EUR J CARDIOL, V7, P163; TYSON GS, 1984, CIRC RES, V54, P173, DOI 10.1161/01.RES.54.2.173	27	80	80	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					737	742		10.7326/0003-4819-122-10-199505150-00001	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717595				2022-12-24	WOS:A1995QX14700001
J	MORROW, JD; FREI, B; LONGMIRE, AW; GAZIANO, JM; LYNCH, SM; SHYR, Y; STRAUSS, WE; OATES, JA; ROBERTS, LJ				MORROW, JD; FREI, B; LONGMIRE, AW; GAZIANO, JM; LYNCH, SM; SHYR, Y; STRAUSS, WE; OATES, JA; ROBERTS, LJ			INCREASE IN CIRCULATING PRODUCTS OF LIPID-PEROXIDATION (F-2-ISOPROSTANES) IN SMOKERS - SMOKING AS A CAUSE OF OXIDATIVE DAMAGE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY LIPOPROTEIN; HUMAN-BLOOD-PLASMA; VITAMIN-C STATUS; CIGARETTE-SMOKING; PROSTANOIDS F2-ISOPROSTANES; ANTIOXIDANT; MACROPHAGES; METABOLITES; CAROTENES; MECHANISM	Background. It has been hypothesized that the pathogenesis of diseases induced by cigarette smoking involves oxidative damage by free radicals. However, definitive evidence that smoking causes the oxidative modification of target molecules in vivo is lacking. We conducted a study to determine whether the production of F-2-isoprostanes, which are novel products of lipid peroxidation, is enhanced in persons who smoke. Methods. We measured the levels of free F-2-isoprostanes in plasma, the levels of F-2-isoprostanes esterified to plasma lipids, and the urinary excretion of metabolites of F-2-isoprostanes in 10 smokers and 10 nonsmokers matched for age and sex. The short-term effects of smoking (three cigarettes smoked over 30 minutes) and the effects of two weeks of abstinence from smoking on levels of F-2-isoprostanes in the circulation were also determined in the smokers. Results. Plasma levels of free and esterified F-2-isoprostanes were significantly higher in the smokers (mean +/-SD, 242+/-147 and 574+/-217 pmol per liter, respectively) than in the nonsmokers (103+/-19 and 345+/-65 pmol per liter; P = 0.02 for free F-2-isoprostanes and P = 0.03 for esterified F-2-isoprostanes). Smoking had no short-term effects on the circulating levels of F-2-isoprostanes. However, the levels of free and esterified F-2-isoprostanes fell significantly after two weeks of abstinence from smoking (250+/-156 and 624+/-214 pmol per liter, respectively, before the cessation of smoking, as compared with 156+/-67 and 469+/-108 pmol per liter after two weeks' cessation; P=0.03 for free F-2-isoprostanes and P = 0.02 for esterified F-2-isoprostanes). Conclusions. The increased levels of F-2-isoprostanes in the circulation of persons who smoke support the hypothesis that smoking can cause the oxidative modification of important biologic molecules in vivo.	VANDERBILT UNIV, DEPT MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, DEPT PREVENT MED, DIV BIOSTAT, NASHVILLE, TN 37232 USA; BOSTON UNIV, SCH MED, WHITAKER CARDIOVASC INST, BOSTON, MA 02118 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, CARDIOL SECT, BOSTON, MA USA	Vanderbilt University; Vanderbilt University; Boston University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University	MORROW, JD (corresponding author), VANDERBILT UNIV, DEPT PHARMACOL, 221 KIRKLAND HALL, 506 MRB, NASHVILLE, TN 37232 USA.		Lynch, Sean M/A-9354-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, R01GM042056, R37GM042056] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49954] Funding Source: Medline; NIGMS NIH HHS [GM-15431, GM-42056] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AWAD JA, 1993, J BIOL CHEM, V268, P4161; Bridges A B, 1993, Eur J Med, V2, P205; CAILLEUX A, 1993, FREE RADICAL RES COM, V18, P323, DOI 10.3109/10715769309147499; CANTIN A, 1985, EUR J RESPIR DIS, V66, P7; CHOW CK, 1993, ANN NY ACAD SCI, V686, P289, DOI 10.1111/j.1749-6632.1993.tb39189.x; CHOW CK, 1986, J AM COLL NUTR, V5, P305; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; DOLL R, 1978, J EPIDEMIOL COMMUN H, V32, P303, DOI 10.1136/jech.32.4.303; DUTHIE GG, 1991, AM J CLIN NUTR, V53, pS1061, DOI 10.1093/ajcn/53.4.1061S; FREI B, 1991, BIOCHEM J, V277, P133, DOI 10.1042/bj2770133; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HARATS D, 1989, ATHEROSCLEROSIS, V79, P245, DOI 10.1016/0021-9150(89)90130-5; HESS D, 1991, INT J VITAM NUTR RES, V61, P232; HOIDAL JR, 1983, CHEST, V83, P679, DOI 10.1378/chest.83.4.679; KALRA J, 1991, INT J EXP PATHOL, V72, P1; KANNEL WB, 1981, AM HEART J, V101, P319, DOI 10.1016/0002-8703(81)90197-6; KYEREMATEN GA, 1982, CLIN PHARMACOL THER, V32, P769, DOI 10.1038/clpt.1982.235; LEHR HA, 1993, FREE RADICAL BIO MED, V14, P573, DOI 10.1016/0891-5849(93)90138-K; LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; MOHLER ER, 1992, CIRCULATION, V86, P865; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1994, METHOD ENZYMOL, V233, P163; OBRIEN PJ, 1988, FREE RADICAL BIO MED, V4, P169, DOI 10.1016/0891-5849(88)90025-1; PELLETIER O, 1970, AM J CLIN NUTR, V23, P520; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROBERTS LJ, 1987, CRC HDB EICOSANOIDS, V1, P233; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SCHONFELD G, 1989, ENDOCRINOLOGY, V3, P2424; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; YOKODE M, 1988, P NATL ACAD SCI USA, V85, P2344, DOI 10.1073/pnas.85.7.2344	34	1167	1190	2	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1198	1203		10.1056/NEJM199505043321804	http://dx.doi.org/10.1056/NEJM199505043321804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700313	Bronze			2022-12-24	WOS:A1995QV41500004
J	CHATTERJEE, S; STRUHL, K				CHATTERJEE, S; STRUHL, K			CONNECTING A PROMOTER-BOUND PROTEIN TO TBP BYPASSES THE NEED FOR A TRANSCRIPTIONAL ACTIVATION DOMAIN	NATURE			English	Article							CRYSTAL-STRUCTURE; TATA ELEMENTS; YEAST; BINDING; INVITRO; SPECIFICITY; MECHANISM; MUTANTS; COMPLEX; CLONING	BIOCHEMICAL analyses have suggested potential targets for transcriptional activation domains, which include several components of the RNA polymerase II machinery(1-7), as well as the chromatin template(8-12). Here we examine the mechanism of transcriptional activation in yeast cells by connecting a heterologous DNA-binding domain (LexA) to the TATA-binding protein (TBP), LexA-TBP efficiently activates transcription from a promoter containing a LexA operator upstream of a TATA element, Activation is promoter-specific and is sensitive to mutations on the DNA-binding surface of TBP; hence it is not due to a fortuitous activation domain on TBP, Thus a promoter-bound protein lacking an activation domain can stimulate transcription if it is directly connected to TBP. This suggests that recruitment of TBP to the promoter can be a rate-limiting step for transcription in vivo, and that interactions between activation domains and factors that function after TBP recruitment can be bypassed for activation.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								ARNDT KM, 1992, MOL CELL BIOL, V12, P2372, DOI 10.1128/MCB.12.5.2372; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; CORMACK BP, 1994, GENE DEV, V8, P1335, DOI 10.1101/gad.8.11.1335; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x	31	174	176	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					820	822		10.1038/374820a0	http://dx.doi.org/10.1038/374820a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723828				2022-12-24	WOS:A1995QV31500050
J	MURAKAMI, H; OKAYAMA, H				MURAKAMI, H; OKAYAMA, H			A KINASE FROM FISSION YEAST RESPONSIBLE FOR BLOCKING MITOSIS IN S-PHASE	NATURE			English	Article							DNA-POLYMERASE-ALPHA; SCHIZOSACCHAROMYCES-POMBE; GENE; REPAIR; REPLICATION; DIVISION; MUTANTS; CLONING; RAD1	IN virtually all eukaryotes, mitosis starts after the completion of DNA synthesis, This orderly process is ensured by the checkpoint mechanism that blocks:the onset of mitosis while DNA is being Synthesized or is damaged, In the fission yeast Schizosaccharomyces pombe, this mechanism involves some rad(+) and hus(+) genes(1-4). However, it is not known how the checkpoint system monitors these events, Recently a multicopy suppressor of a temperature-sensitive DNA polymerase-alpha mutant was isolated, This gene, named cds1(+) (checking DNA synthesis), encodes a typical protein kinase, Here we report that this protein kinase is a key component of the DNA replication-monitoring S/G2 checkpoint system, Our data suggest that its primary role is to monitor DNA synthesis by interacting: with DNA polymerase alpha and send a signal to block the onset of mitosis while DNA synthesis is in progress.	JRDC,ERATO,OKAYAMA CELL SWITCHING PROJECT,SAKYO KU,KYOTO,JAPAN		MURAKAMI, H (corresponding author), UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN.							ALKHODAIRY, 1994, MOL BIOL CELL, V5, P147; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; Allen JB, 1994, GENE DEV, V8, P2416; DAMAGNEZ V, 1991, MOL GEN GENET, V226, P182, DOI 10.1007/BF00273602; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; MURRAY JM, 1991, NUCLEIC ACIDS RES, V19, P3525, DOI 10.1093/nar/19.13.3525; NASMYTH KA, 1977, CELL, V12, P101; PECK VM, 1993, BIOCHEM BIOPH RES CO, V190, P325, DOI 10.1006/bbrc.1993.1051; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; SINGH J, 1993, NATURE, V361, P271, DOI 10.1038/361271a0; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; SUNNERHAGEN P, 1990, MOL CELL BIOL, V10, P3750, DOI 10.1128/MCB.10.7.3750; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHENG P, 1993, MOL CELL BIOL, V9, P5829	22	254	260	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					817	819		10.1038/374817a0	http://dx.doi.org/10.1038/374817a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723827				2022-12-24	WOS:A1995QV31500049
J	MIYAZAKI, T; LIU, ZJ; KAWAHARA, A; MINAMI, Y; YAMADA, K; TSUJIMOTO, Y; BARSOUMIAN, EL; PERLMUTTER, RM; TANIGUCHI, T				MIYAZAKI, T; LIU, ZJ; KAWAHARA, A; MINAMI, Y; YAMADA, K; TSUJIMOTO, Y; BARSOUMIAN, EL; PERLMUTTER, RM; TANIGUCHI, T			3 DISTINCT IL-2 SIGNALING PATHWAYS MEDIATED BY BCL-2, C-MYC, AND LCK COOPERATE IN HEMATOPOIETIC-CELL PROLIFERATION	CELL			English	Article							RECEPTOR-BETA-CHAIN; PROTEIN-TYROSINE KINASE; INTERLEUKIN-2 RECEPTOR; FOLLICULAR LYMPHOMA; LIGAND-BINDING; TRANSDUCTION; APOPTOSIS; DEATH; ACTIVATION; LINE	Two interleukin-2 receptor-dependent signaling pathways have thus far been identified: the c-fos/c-jun induction pathway mediated by src family protein-tyrosine kinases and the c-myo induction pathway. Here, we provide evidence for the existence of a third, rapamycin-sensitive pathway, which results in the induction of another proto-oncogene, bcl-2. In the hematopoietic cell line BAF-B03, the expression of any two of lckF505 (an active form of p56(lck)), Bcl-2, or c-Myc is sufficient to promote transit of the cell cycle, regardless of the activation state of the third pathway. We also provide evidence that epidermal growth factor receptor signaling may act through the same pathway that involves p56(lck). These studies demonstrate a novel approach to dissecting signaling pathways regulating cellular proliferation.	NIPPON BOEHRINGER INGELHEIM CO LTD,INST MOLEC & CELLULAR BIOL,KAWANISHI,HYOGO 66601,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,SUITA,OSAKA 565,JAPAN; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	Boehringer Ingelheim; Osaka University; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Tokyo	MIYAZAKI, T (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADAOKA,SUITA,OSAKA 565,JAPAN.		Miyazaki, Tadaaki/D-9368-2012					ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COLLINS MKL, 1993, TRENDS BIOCHEM SCI, V18, P307, DOI 10.1016/0968-0004(93)90042-L; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DOI T, 1989, EUR J IMMUNOL, V19, P2375, DOI 10.1002/eji.1830191229; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTANI H, 1993, J BIOL CHEM, V268, P22733; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SATOH T, 1992, J BIOL CHEM, V267, P25423; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	46	349	361	2	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					223	231		10.1016/0092-8674(95)90332-1	http://dx.doi.org/10.1016/0092-8674(95)90332-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736574	Bronze			2022-12-24	WOS:A1995QV41000011
J	WATT, PM; LOUIS, EJ; BORTS, RH; HICKSON, ID				WATT, PM; LOUIS, EJ; BORTS, RH; HICKSON, ID			SGS1 - A EUKARYOTIC HOMOLOG OF ESCHERICHIA-COLI RECQ THAT INTERACTS WITH TOPOISOMERASE-II IN-VIVO AND IS REQUIRED FOR FAITHFUL CHROMOSOME SEGREGATION	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; PROTEIN; MITOSIS; MEIOSIS; YEAST; MUTANTS; NONDISJUNCTION; RECOMBINATION; TRANSMISSION	Topoisomerase II (topo II) catalyzes the decatenation of interlinked DNA molecules and is essential for chromosome segregation. To test the hypothesis that the noncatalytic C-terminal domain of topo II is necessary for mediating interactions with other proteins required for chromosome segregation, we used a two-hybrid cloning strategy to identify proteins that interact with S. cerevisiae topo II in vivo. One protein identified (Sgs1p) is structurally related to E. coli RecQ protein and contains helicase signature! motifs. Strains lacking Sgs1p exhibit elevated levels of chromosome missegregation during both mitotic and meiotic division. We propose a model to account for the interaction of a topoisomerase and a helicase in the faithful segregation of newly replicated eukaryotic chromosomes.	UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, YEAST GENET GRP, OXFORD OX3 9DU, ENGLAND	University of Oxford	WATT, PM (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND LABS, OXFORD OX3 9DU, ENGLAND.		Hickson, Ian/AAJ-7548-2020; Louis, Edward/B-7920-2008	Louis, Edward/0000-0003-1157-3608; Hickson, Ian/0000-0002-0583-566X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; Ausubel FM, 1994, CURRENT PROTOCOLS MO; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTWELL LH, 1985, GENETICS, V110, P381; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; KAMIGUCHI Y, 1993, HUM GENET, V90, P533; KOONIN EV, 1991, NATURE, V352, P290, DOI 10.1038/352290c0; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LOUIS EJ, 1989, GENETICS, V123, P81; LUISIDELUCA C, 1989, GENETICS, V122, P269; Luria SE, 1943, GENETICS, V28, P491; MCCUSKER JH, 1988, GENETICS, V119, P303; MORTIMER RK, 1981, P NATL ACAD SCI-BIOL, V78, P5778, DOI 10.1073/pnas.78.9.5778; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; PETERSON CL, 1994, CELL, V79, P389, DOI 10.1016/0092-8674(94)90247-X; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; ROSE D, 1993, MOL CELL BIOL, V13, P3445, DOI 10.1128/MCB.13.6.3445; SAMEJIMA I, 1993, J CELL SCI, V105, P135; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SPENCER F, 1990, GENETICS, V124, P237; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; WANG JC, 1991, J BIOL CHEM, V266, P6659; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	38	375	379	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 21	1995	81	2					253	260		10.1016/0092-8674(95)90335-6	http://dx.doi.org/10.1016/0092-8674(95)90335-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736577	Bronze			2022-12-24	WOS:A1995QV41000014
J	DARCANGELO, G; MIAO, GG; CHEN, SC; SOARES, HD; MORGAN, JI; CURRAN, T				DARCANGELO, G; MIAO, GG; CHEN, SC; SOARES, HD; MORGAN, JI; CURRAN, T			A PROTEIN RELATED TO EXTRACELLULAR-MATRIX PROTEINS DELETED IN THE MOUSE MUTANT REELER	NATURE			English	Article							NEURAL CELL-ADHESION; GENE; MICE; CEREBELLUM; MUTATIONS; MOLECULES; ENCODES; BRAIN	THE autosomal recessive mouse mutation reeler(1-3) leads to impaired motor coordination, tremors and ataxia(4). Neurons in affected mice fail to reach their correct locations in the developing brain, disrupting the organization of the cerebellar and cerebral cortices and other laminated regions(5-8). Here we use a previously characterized reeler allele (rl(tg))(9) to clone a gene, reelin, deleted in two reeler alleles. Normal but not mutant mice express reelin in embryonic and postnatal neurons during periods of neuronal migration. The encoded protein resembles extracellular matrix proteins involved in cell adhesion. The reeler phenotype thus seems to reflect a failure of early events associated with brain lamination which are normally controlled by reelin.	HOFFMANN LA ROCHE INC, NEUROGENET PROGRAM, NUTLEY, NJ 07110 USA	Roche Holding	DARCANGELO, G (corresponding author), HOFFMANN LA ROCHE INC, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA.		Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019; Curran, Tom/C-1164-2008; Morgan, James/GRO-2905-2022; Curran, Tom/F-5234-2018; Morgan, James/N-8104-2018	Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Morgan, James/0000-0002-8920-1065; Curran, Tom/0000-0003-1444-7551; D'Arcangelo, Gabriella/0000-0003-1575-1010				BAR I, IN P0RESS GENOMICS; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; DERER P, 1983, J HIRNFORSCH, V24, P209; DERNONCOURT C, 1991, GENOMICS, V11, P1167, DOI 10.1016/0888-7543(91)90049-K; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FLAHERTY L, 1992, P NATL ACAD SCI USA, V89, P2859, DOI 10.1073/pnas.89.7.2859; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; GODFRAIND C, 1988, DEV BRAIN RES, V42, P99, DOI 10.1016/0165-3806(88)90205-2; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GOFFINET AM, 1992, INT J DEV BIOL, V36, P101; GUENET JL, 1981, MOUSE NEWS LETT, V41; HAMBURGH M, 1963, DEV BIOL, V8, P165, DOI 10.1016/0012-1606(63)90040-X; HEIJNE GV, 1984, J MOL BIOL, V173, P243; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LUGO DI, 1989, MOL ENDOCRINOL, V3, P1313, DOI 10.1210/mend-3-8-1313; MARIANI J, 1977, PHILOS T R SOC B, V281, P1, DOI 10.1098/rstb.1977.0121; MIAO GG, 1994, P NATL ACAD SCI USA, V91, P11050, DOI 10.1073/pnas.91.23.11050; MISCHEL PS, 1995, J NEUROPATH EXP NEUR, V54, P137, DOI 10.1097/00005072-199503000-00001; MONTGOMERY JC, IN PRESS MAMM GENOME; OGAWA, IN PRESS NEURONS; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; STANFIELD BB, 1979, J COMP NEUROL, V185, P461, DOI 10.1002/cne.901850304; TERASHIMA T, 1986, J COMP NEUROL, V252, P264, DOI 10.1002/cne.902520209; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	30	1411	1437	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	1995	374	6524					719	723		10.1038/374719a0	http://dx.doi.org/10.1038/374719a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715726				2022-12-24	WOS:A1995QU30400049
J	HE, X; SAINTJEANNET, JP; WOODGETT, JR; VARMUS, HE; DAWID, IB				HE, X; SAINTJEANNET, JP; WOODGETT, JR; VARMUS, HE; DAWID, IB			GLYCOGEN-SYNTHASE KINASE-3 AND DORSOVENTRAL PATTERNING IN XENOPUS EMBRYOS	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; MESODERM INDUCTION; SPEMANN ORGANIZER; VENTRALIZING FACTOR; AXIAL MESODERM; BODY AXIS; EXPRESSION; DROSOPHILA; WINGLESS; XWNT-8	Glycogen synthase kinase 3 (GSK-3) is homologous to the product of the Drosophila gene shaggy (zeste-white 3), which is required for signalling by wingless during Drosophila development. To test whether GSK-3 is also involved in vertebrate pattern formation, its role was investigated during early Xenopus development. It was found that dominant-negative GSK-3 mutants induced dorsal differentiation, whereas wild-type GSK-3 induced ventralization. These results indicate that GSK-3 is required for ventral differentiation, and suggest that dorsal differentiation may involve the suppression of GSK-3 activity by a wingless/wnt-related signal.	NICHHD,GENET MOLEC LAB,BETHESDA,MD 20892; ONTARIO CANC INST,TORONTO,ON M4X 1K9,CANADA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Toronto; University Toronto Affiliates; University Health Network Toronto	HE, X (corresponding author), NCI,VARMUS LAB,BLDG 49,ROOM 4A56,BETHESDA,MD 20892, USA.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BOHN H, 1992, J EMBRYOL EXP MORPH, V28, P185; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, J BIOL CHEM, V289, P6259; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; GERHART J, 1989, DEVELOPMENT, V107, P37; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OGURA K, 1994, GENE DEV, V8, P2389, DOI 10.1101/gad.8.20.2389; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SATO SM, 1991, DEVELOPMENT, V112, P747; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STANBOLIC V, 1994, BIOCHEM J, V303, P701; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1994, SEMIN CANCER BIOL, V5, P269	50	440	449	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					617	622		10.1038/374617a0	http://dx.doi.org/10.1038/374617a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715701				2022-12-24	WOS:A1995QT18900051
J	DENHEIJER, M; BLOM, HJ; GERRITS, WBJ; ROSENDAAL, FR; HAAK, HL; WIJERMANS, PW; BOS, GMJ				DENHEIJER, M; BLOM, HJ; GERRITS, WBJ; ROSENDAAL, FR; HAAK, HL; WIJERMANS, PW; BOS, GMJ			IS HYPERHOMOCYSTEINAEMIA A RISK FACTOR FOR RECURRENT VENOUS THROMBOSIS	LANCET			English	Article							PLASMA HOMOCYSTEINE; HOMOCYSTINURIA; DEFICIENCY; ARTERIAL; DISEASE	Several studies have shown a relation between hyperhomocysteinaemia and arterial Vascular disease. We looked at the association between hyperhomocysteinaemia and Venous thrombosis which could be clinically important as hyperhomocysteinaemia is easily corrected by Vitamin supplementation. We studied 185 patients with a history of recurrent venous thrombosis and 220 controls from the general population. Homocysteine concentrations were measured before and 6 h after oral methionine loading. We defined hyperhomocysteinaemia as the homocysteine concentration above the fasting or the postmethionine Value found for the 90th percentile of the controls. Of the 185 patients with recurrent thrombosis, 46 (25%) had fasting homocysteine concentrations above the 90th percentile or the controls (odds ratio is 3.1 [1.8-5.5]). After adjustment for age, sex, and menopausal status the odds ratio was 2.0 (1.5-2.7). Similar results were found for the post-methionine Value (unadjusted odds ratio 3.1 [1.7-5.5], adjusted 2.6 [1.9-3.5]). Hyperhomocysteinaemia is a common risk factor for recurrent Venous thrombosis and can lead to a two-fold or three-fold increase in risk.	UNIV NIJMEGEN HOSP,PAEDIAT & NEUROL LAB,6500 HB NIJMEGEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT HEMATOL,2333 AA LEIDEN,NETHERLANDS	Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	DENHEIJER, M (corresponding author), MUNICIPAL HOSP LEYENBURG,DEPT HEMATOL,THE HAGUE,NETHERLANDS.		Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496; Blom, Henk/0000-0001-5202-9241				ANDERSSON A, 1992, EUR J CLIN INVEST, V22, P79, DOI 10.1111/j.1365-2362.1992.tb01940.x; [Anonymous], 1985, THEORETICAL EPIDEMIO; BIENVENU T, 1991, PRESSE MED, V20, P985; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRATTSTROM L, 1991, HAEMOSTASIS, V21, P51; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; FRANKEN DG, 1994, ARTERIOSCLER THROMB, V14, P465, DOI 10.1161/01.ATV.14.3.465; HEIJEER M, 1994, FIBRINOLYSIS S2, V8, P91; MCCULLY KS, 1987, RES COMMUN CHEM PATH, V56, P349; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MIETTINEN OS, 1974, AM J EPIDEMIOL, V99, P352; MUDD SH, 1985, AM J HUM GENET, V37, P1; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1990, BLOOD, V75, P895; RODGERS GM, 1988, J CLIN INVEST, V81, P1911, DOI 10.1172/JCI113538; Schlesselman JJ, 1982, CASE CONTROL STUDIES; STAMPFER MJ, 1993, JAMA-J AM MED ASSOC, V270, P2726, DOI 10.1001/jama.270.22.2726; UBBINK JB, 1993, CLIN INVESTIGATOR, V71, P993, DOI 10.1007/BF00180030; UELAND PM, 1993, ATHEROSCLEROTIC CARD, P183	20	320	321	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					882	885		10.1016/S0140-6736(95)90008-X	http://dx.doi.org/10.1016/S0140-6736(95)90008-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707810	Green Submitted			2022-12-24	WOS:A1995QR06700008
J	BYSKOV, AG; ANDERSEN, CY; NORDHOLM, L; THOGERSEN, H; XIA, GL; WASSMANN, O; ANDERSEN, JV; GUDDAL, E; ROED, T				BYSKOV, AG; ANDERSEN, CY; NORDHOLM, L; THOGERSEN, H; XIA, GL; WASSMANN, O; ANDERSEN, JV; GUDDAL, E; ROED, T			CHEMICAL-STRUCTURE OF STEROLS THAT ACTIVATE OOCYTE MEIOSIS	NATURE			English	Article							FOLLICULAR-FLUID; GRANULOSA-CELLS; MATURATION; INVITRO; HYPOXANTHINE; ZYMOSTEROL; SUBSTANCE; REDUCTASE	GONADOTROPHINS and various growth factors, but not sex steroids, can induce resumption of meiosis in vitro, but only in oocytes enclosed by cumulus-granulosa cells(1). Follicular purines prevent resumption of meiosis(2,3). This process can be overcome, in vitro, by a transient elevation of cyclic AMP resulting in the production of a diffusible meiosis-inducing substance secreted by the cumulus cells(4). A meiosis-inducing activity has been detected in gonads of different species, for example, in preovulatory follicular fluid of women(5) and in mouse testes(6). We report here the isolation and characterization of meiosis-activating sterols from human follicular fluid and bull testes and the synthesis of two closely related C-29 sterols. All these sterols induce a resumption of meiosis in cultured cumulus-enclosed and naked mouse oocytes indicating their nonspecificity across species and sex. This family of sterols is for the first time considered crucial to meiosis.	NOVO NORDISK AS, DK-2760 MALOV, DENMARK	Novo Nordisk	BYSKOV, AG (corresponding author), UNIV COPENHAGEN HOSP, RIGSHOSP,DEPT OBSTET & GYNECOL,REPROD BIOL LAB, SECT 5712, BLEGDAMSVEJ 9, DK-2100 COPENHAGEN, DENMARK.			Andersen, Claus Yding/0000-0001-7681-253X				ABERNETHY D, 1976, STEROIDS, V27, P297, DOI 10.1016/0039-128X(76)90052-0; ANDERSEN CY, 1990, J CLIN ENDOCR METAB, V71, P1375, DOI 10.1210/jcem-71-5-1375; AOYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P659, DOI 10.1016/S0006-291X(86)80470-3; BYSKOV AG, 1976, DEV BIOL, V52, P193, DOI 10.1016/0012-1606(76)90239-6; BYSKOV AG, 1993, MOL REPROD DEV, V34, P47, DOI 10.1002/mrd.1080340108; COULON J, 1986, CAN J MICROBIOL, V32, P738, DOI 10.1139/m86-134; DOLLE RE, 1989, J AM CHEM SOC, V111, P278, DOI 10.1021/ja00183a042; DONAHOE PK, 1987, RECENT PROG HORM RES, V43, P431; DOWNS SM, 1985, P NATL ACAD SCI USA, V82, P454, DOI 10.1073/pnas.82.2.454; DOWNS SM, 1993, MOL REPROD DEV, V35, P82, DOI 10.1002/mrd.1080350114; DURHAM CR, 1985, MOL CELL ENDOCRINOL, V40, P211, DOI 10.1016/0303-7207(85)90177-7; EMMONS GT, 1989, MAGN RESON CHEM, V27, P1012, DOI 10.1002/mrc.1260271103; EPPIG JJ, 1978, J REPROD FERTIL, V53, P99, DOI 10.1530/jrf.0.0530099; JOSSO N, 1986, PHYSIOL REV, V66, P1038, DOI 10.1152/physrev.1986.66.4.1038; MAITRA U S, 1989, Steroids, V53, P597, DOI 10.1016/0039-128X(89)90034-2; MCNATTY KP, 1979, J CLIN ENDOCR METAB, V49, P687, DOI 10.1210/jcem-49-5-687; PONSINET G, 1965, B SOC CHIM FR, P3682; RICE C, 1981, J REPROD FERTIL, V62, P245, DOI 10.1530/jrf.0.0620245; SCHROEPFER GJ, 1988, CHEM PHYS LIPIDS, V47, P187, DOI 10.1016/0009-3084(88)90012-6; SMITH DM, 1980, J REPROD FERTIL, V60, P331, DOI 10.1530/jrf.0.0600331; TAYLOR UF, 1981, J LIPID RES, V22, P171; Wassarman Paul M., 1994, P79; WESTERGAARD L, 1985, FERTIL STERIL, V44, P663; XIA GL, 1994, MOL REPROD DEV, V39, P17, DOI 10.1002/mrd.1080390104	24	281	304	1	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 6	1995	374	6522					559	562		10.1038/374559a0	http://dx.doi.org/10.1038/374559a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	QR069	7700384				2022-12-24	WOS:A1995QR06900057
J	SABERI, K; HAFTER, ER				SABERI, K; HAFTER, ER			A COMMON NEURAL CODE FOR FREQUENCY-MODULATED AND AMPLITUDE-MODULATED SOUNDS	NATURE			English	Article							INFERIOR COLLICULUS; AUDITORY-CORTEX; VISUAL-SYSTEM; NEURONS; SENSITIVITY; CAT; AM; RESPONSES; PATTERNS; STIMULI	MOST naturally occurring sounds are modulated in amplitude or frequencg; important examples include animal vocalizations and species-specific communication signals in mammals, insects, reptiles, birds and amphibians(1-9). Deciphering the information from amplitude-modulated (AM) sounds is a well-understood process, requiring a phase locking of primary auditory afferents to the modulation envelopes(10-12). The mechanism for decoding frequency modulation (FM) is not as clear because the FM envelope is flat (Fig. 1). One biological solution is to monitor amplitude fluctuations in frequency-tuned cochlear filters as the instantaneous frequency of the FM sweeps through the passband of these filters, This view postulates an FM-to-AM transduction whereby a change in frequency is transmitted as a change in amplitude(13,14). This is an appealing idea because, if such transduction occurs early in the auditory pathway, it provides a neurally economical solution to how the auditory system encodes these important sounds. Here we illustrate that an FM and AM sound must be transformed into a common neural code in the brain stem. Observers can accurately determine if the phase of an FM presented to one ear is leading or lagging, by only a fraction of a millisecond, the phase of an AM presented to the other ear. A single intracranial image is perceived, the spatial position of which is a function of this phase difference.	UNIV CALIF BERKELEY,DEPT PSYCHOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	SABERI, K (corresponding author), UNIV FLORIDA,DEPT PSYCHOL,CTR HEARING RES,GAINESVILLE,FL 32611, USA.		Saberi, Kourosh/GXG-0944-2022					BAILEY WJ, 1993, J INSECT BEHAV, V6, P141, DOI 10.1007/BF01051500; BRILLET C, 1991, Bioacoustics, V3, P33; CARLSON C R, 1980, Investigative Ophthalmology and Visual Science, P165; CARR CE, 1990, J NEUROSCI, V10, P3227; COSCIA E M, 1991, Bioacoustics, V3, P275; DEAR SP, 1993, NATURE, V364, P620, DOI 10.1038/364620a0; HENNING GB, 1975, VISION RES, V15, P887, DOI 10.1016/0042-6989(75)90228-X; HENNING GB, 1980, J ACOUST SOC AM, V68, P446, DOI 10.1121/1.384756; HUBER F, 1985, SCI AM, V253, P60, DOI 10.1038/scientificamerican1285-60; JAMAR JHT, 1984, VISION RES, V24, P243, DOI 10.1016/0042-6989(84)90126-3; JAVEL E, 1980, J ACOUST SOC AM, V68, P133, DOI 10.1121/1.384639; KLUMP GM, 1992, ADV BIOSCI, V83, P353; KUWADA S, 1979, SCIENCE, V206, P586, DOI 10.1126/science.493964; Rayleigh,, 1907, PHILOS MAG, V13, P214, DOI 10.1080/14786440709463595; MASATAKA N, 1983, Primates, V24, P40, DOI 10.1007/BF02381452; MENDELSON JR, 1985, BRAIN RES, V327, P331, DOI 10.1016/0006-8993(85)91530-6; RAYLEIGH, 1976, NATURE, V14, P32; REES A, 1983, HEARING RES, V10, P301, DOI 10.1016/0378-5955(83)90095-3; ROBISSON P, 1993, ETHOLOGY, V94, P279; RYAN MJ, 1988, SCIENCE, V240, P1786, DOI 10.1126/science.240.4860.1786; Schreiner CE, 1988, AUDITORY FUNCTION, P337; SHU ZJ, 1993, NATURE, V364, P721, DOI 10.1038/364721a0; SIMMONS JA, 1979, SCIENCE, V203, P16, DOI 10.1126/science.758674; SMITH RL, 1980, HEARING RES, V2, P123, DOI 10.1016/0378-5955(80)90034-9; WHITFIEL.IC, 1965, J NEUROPHYSIOL, V28, P655, DOI 10.1152/jn.1965.28.4.655; YIN TCT, 1990, J NEUROPHYSIOL, V64, P465, DOI 10.1152/jn.1990.64.2.465; ZHOU YX, 1993, SCIENCE, V261, P98, DOI 10.1126/science.8316862; Zwicker E, 1952, ACUSTICA          S3, V2, P125	28	78	78	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					537	539		10.1038/374537a0	http://dx.doi.org/10.1038/374537a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700378				2022-12-24	WOS:A1995QR06900050
J	CARROLL, D; SMITH, GD; SHEFFIELD, D; SHIPLEY, MJ; MARMOT, MG				CARROLL, D; SMITH, GD; SHEFFIELD, D; SHIPLEY, MJ; MARMOT, MG			PRESSOR REACTIONS TO PSYCHOLOGICAL STRESS AND PREDICTION OF FUTURE BLOOD-PRESSURE - DATA FROM THE WHITEHALL-II STUDY	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR REACTIVITY; ESSENTIAL-HYPERTENSION; MENTAL STRESS; STABILITY; DISEASE	Objective-To examine whether reactions of blood pressure to future blood pressure. Design-Blood pressure was recorded at a medical screening examination after which presser reactions to a psychological stress task were determined. Follow up measurement of blood pressure was undertaken, on average, 4.9 years later. Setting-20 civil service departments in London. Subjects-1003 male civil servants aged between 35 and 55 years at entry to the study. Main outcome measure-Blood pressure at follow up screening. Results-Reactions of systolic blood pressure to stress correlated positively with systolic blood pressure at follow up screening (r = 0.22, P < 0.01). The dominant correlate of follow up blood pressure was blood pressure at initial screening (r = 0.60 P < 0.01 between initial and follow up systolic blood pressure; r = 0.59, P < 0.01 between initial and follow up diastolic blood pressure). Stepwise multiple regression analysis indicated that reactions to the stressor provided minimal prediction of follow up blood pressure over and above that afforded by blood pressure at initial screening. In the case of follow up systolic blood pressure, systolic reactions to stress accounted for only 1% of follow up variance; systolic blood pressure at initial screening accounted for 34%. With regard to diastolic blood pressure at follow up, the independent contribution from diastolic reactions to stress was less than 1%. Conclusion-Pressor reactions to psychological stress provide minimal independent prediction of blood pressure at follow up. Measurement of reactivity is not a useful clinical index of the course of future blood pressure.	UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,BRISTOL BS8 2PR,AVON,ENGLAND; UNIV LONDON UNIV COLL,UNIV COLL & MIDDLESEX SCH MED,DEPT EPIDEMIOL & PUBL HLTH,LONDON WC1E 6BT,ENGLAND	University of Bristol; University of London; University College London	CARROLL, D (corresponding author), GLASGOW CALDONIAN UNIV,DEPT PSYCHOL,GLASGOW G4 0BA,LANARK,SCOTLAND.		Marmot, M G/Y-3920-2019; Davey Smith, George/A-7407-2013	Marmot, M G/0000-0002-2431-6419; Davey Smith, George/0000-0002-1407-8314; Sheffield, David/0000-0001-9121-1783	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER; Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 ROI HL36310-04] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome Trust)		[Anonymous], 1981, CARDIOVASCULAR PSYCH, DOI DOI 10.4324/9781315081762; ARMSTRONG HG, 1950, AM HEART J, V39, P484, DOI 10.1016/0002-8703(50)90246-8; BORGHI C, 1986, J CARDIOVASC PHARM, V8, pS138, DOI 10.1097/00005344-198608005-00030; CARROLL D, 1991, PSYCHOPHYSIOLOGY, V28, P438, DOI 10.1111/j.1469-8986.1991.tb00728.x; CARROLL D, 1986, PSYCHOPHYSIOLOGY, V23, P174, DOI 10.1111/j.1469-8986.1986.tb00613.x; CORESH J, 1992, HYPERTENSION, V19, P218; DITTO B, 1986, PSYCHOPHYSIOLOGY, V23, P62, DOI 10.1111/j.1469-8986.1986.tb00596.x; DRUMMOND PD, 1985, PSYCHOPHYSIOLOGY, V22, P621, DOI 10.1111/j.1469-8986.1985.tb01656.x; EICH RH, 1967, J CHRON DIS, V20, P583, DOI 10.1016/0021-9681(67)90035-5; FALKNER B, 1981, HYPERTENSION, V3, P521, DOI 10.1161/01.HYP.3.5.521; FREDRIKSON M, 1982, BIOL PSYCHOL, V15, P63, DOI 10.1016/0301-0511(82)90031-X; FREDRIKSON M, 1990, Annals of Behavioral Medicine, V12, P30, DOI 10.1207/s15324796abm1201_3; GALLACHER JEJ, 1985, J EPIDEMIOL COMMUNIT, V39, P200; HARLAN WR, 1964, AM J CARDIOL, V13, P683, DOI 10.1016/0002-9149(64)90205-X; HASTRUP JL, 1980, PSYCHOPHYSIOLOGY, V17, P317; HAYES RJ, 1988, STAT MED, V7, P915, DOI 10.1002/sim.4780070903; HOROWITZ RI, 1984, HYPERTENSION, V6, P295; KEYS A, 1971, ARCH INTERN MED, V128, P201, DOI [10.1001/archinte.128.2.201, 10.1001/archinte.1971.00310200037002]; LIGHT KC, 1981, PSYCHOPHYSIOLOGY, V18, P216, DOI 10.1111/j.1469-8986.1981.tb03021.x; LIGHT KC, 1992, PSYCHOSOM MED, V54, P217, DOI 10.1097/00006842-199203000-00007; LLABRE MM, 1991, PSYCHOPHYSIOLOGY, V28, P701, DOI 10.1111/j.1469-8986.1991.tb01017.x; MANUCK S B, 1990, Annals of Behavioral Medicine, V12, P17, DOI 10.1207/s15324796abm1201_2; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MATTHEWS KA, 1993, HYPERTENSION, V22, P479, DOI 10.1161/01.HYP.22.4.479; MCKINNEY ME, 1985, PSYCHOPHYSIOLOGY, V22, P453, DOI 10.1111/j.1469-8986.1985.tb01632.x; MENKES MS, 1989, HYPERTENSION, V14, P524, DOI 10.1161/01.HYP.14.5.524; MURPHY JK, 1991, PSYCHOPHYSIOLOGY, V28, P447, DOI 10.1111/j.1469-8986.1991.tb00730.x; OLDHAM PD, 1962, J CHRON DIS, V15, P969, DOI 10.1016/0021-9681(62)90116-9; PARATI G, 1988, J HYPERTENS, V6, P481, DOI 10.1097/00004872-198806000-00008; PICKERING T G, 1990, Annals of Behavioral Medicine, V12, P3, DOI 10.1207/s15324796abm1201_1; Pickering TG, 1991, AM J HYPERTENS, V4, P611; Raven J.C., 1960, GUIDE STANDARD PROGR; ROGERS S, 1988, J EPIDEMIOL COMMUN H, V42, P321, DOI 10.1136/jech.42.4.321; SHERWOOD A, 1990, INT J PSYCHOPHYSIOL, V10, P95, DOI 10.1016/0167-8760(90)90050-N; THOMAS CB, 1982, JOHNS HOPKINS MED J, V151, P93; Turner J., 1992, INDIVIDUAL DIFFERENC; WOOD DL, 1984, HYPERTENSION, V6, P301, DOI 10.1161/01.HYP.6.3.301	37	111	112	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					771	776		10.1136/bmj.310.6982.771	http://dx.doi.org/10.1136/bmj.310.6982.771			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QP609	7711581	Green Published			2022-12-24	WOS:A1995QP60900017
J	MILLS, JL; MCPARTLIN, JM; KIRKE, PN; LEE, YJ; CONLEY, MR; WEIR, DG; SCOTT, JM				MILLS, JL; MCPARTLIN, JM; KIRKE, PN; LEE, YJ; CONLEY, MR; WEIR, DG; SCOTT, JM			HOMOCYSTEINE METABOLISM IN PREGNANCIES COMPLICATED BY NEURAL-TUBE DEFECTS	LANCET			English	Article							VITAMIN SUPPLEMENTATION; PLASMA; PREVENTION; METHIONINE; FOLATE; SERUM; ACID	Folic acid taken around the time of conception can prevent many neural-tube defects, Women with low-normal vitamin B-12 values may also be at increased risk. We considered whether homocysteine metabolism via the enzyme methionine synthase, which requires both folate and B-12, could be the critical defect in folate-related neural tube defects. Blood was obtained during pregnancies that produced 81 infants with neural-tube defects and 323 normal children, Samples were assayed for homocysteine, methylmalonic acid, plasma folate, red-cell folate, and B-12. Mothers of children with neural-tube defects had significantly higher homocysteine values (8.62 [SD 2.8] mu mol/L) than did B-12-matched controls (7.96 [2.5] mu mol/L, p=0.03). The difference was significant (p=0.004) in the lower half of the B-12 distribution after adjusting for plasma folate. Our study shows that an abnormality in homocysteine metabolism, apparently related to methionine synthase, is present in many women who give birth to children with neural-tube defects. Overcoming this abnormality is likely to be the mechanism by which folic acid prevents neural-tube defects. These findings suggest that the most effective periconceptional prophylaxis to prevent neural-tube defects may require B-12 as well as fotic acid.	HLTH RES BOARD,DUBLIN,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT CLIN MED,DUBLIN,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN,IRELAND	Health Research Board - Ireland; Trinity College Dublin; Trinity College Dublin	MILLS, JL (corresponding author), NICHHD,DESPR,PEDIAT EPIDEMIOL SECT,EPIDEMIOL BRANCH,6100 EXECUT BLVD,ROOM 7B03,BETHESDA,MD 20892, USA.			Mills, James/0000-0003-4496-332X				ADAMS MJ, 1993 SOC EP RES ANN; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; COELHO CND, 1989, J NUTR, V119, P1716, DOI 10.1093/jn/119.11.1716; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; ESSIEN FB, 1993, J NUTR, V123, P27, DOI 10.1093/jn/123.1.27; KANG SS, 1991, AM J HUM GENET, V48, P546; KIRKE PN, 1993, Q J MED, V86, P703; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; MCMURRAY CH, 1986, J CHROMATOGR, V378, P201, DOI 10.1016/S0378-4347(00)80713-6; SMITHELLS RW, 1983, LANCET, V1, P1027; STEEGERSTHEUNIS.RP, 1991, NEW ENGL J MED, V324, P199; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; 1991, LANCET, V338, P131	13	560	576	0	30	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					149	151		10.1016/S0140-6736(95)90165-5	http://dx.doi.org/10.1016/S0140-6736(95)90165-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7741859				2022-12-24	WOS:A1995QC55000008
J	COOK, SJ; MCCORMICK, F				COOK, SJ; MCCORMICK, F			INHIBITION BY CAMP OF RAS-DEPENDENT ACTIVATION OF RAF	SCIENCE			English	Article							CYCLIC-AMP; PROTEIN-KINASE; TYROSINE KINASES; CHOLERA-TOXIN; MAP KINASE; CELL-PROLIFERATION; GROWTH; PATHWAY; SHC; EXPRESSION	Activation of the Raf and extracellular signal-regulated kinases (ERKs) (or mitogen-activated protein kinases) are key events in mitogenic signaling, but little is known about interactions with other signaling pathways. Agents that raise levels of intracellular cyclic adenosine 3',5'-monophosphate (cAMP) blocked DNA synthesis and signal transduction in Rat1 cells exposed to epidermal growth factor (EGF) or lysophosphatidic acid. In the case of EGF, receptor tyrosine kinase activity and association with the signaling molecules Grb2 and Shc were unaffected by cAMP. Likewise, EGF-dependent accumulation of the guanosine 5'-triphosphate-bound form of Ras was unaffected. In contrast, activation of Raf-1 and ERK kinases was inhibited. Thus, cAMP appears to inhibit signal transmission from Ras by preventing Ras-dependent activation of Raf-1.			COOK, SJ (corresponding author), ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806, USA.				NCI NIH HHS [UO1 CA51992-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; COOK S, UNPUB; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOTTESMAN MM, 1986, CANCER SURV, V5, P291; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KAUR G, 1992, CANCER RES, V52, P3340; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P88; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD SG, IN PRESS MOL CELL BI; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; NODA N, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RALL TW, 1957, J BIOL CHEM, V224, P463; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAKODA T, 1992, ONCOGENE, V7, P1705; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SUTHERLAND EW, 1972, SCIENCE, V177, P401, DOI 10.1126/science.177.4047.401; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANDOP C, 1984, J BIOL CHEM, V259, P696; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITFIELD JF, 1987, CANCER METAST REV, V5, P205, DOI 10.1007/BF00046999; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	46	932	948	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1069	1072		10.1126/science.7694367	http://dx.doi.org/10.1126/science.7694367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7694367				2022-12-24	WOS:A1993MG18700040
J	GALIONE, A; WHITE, A; WILLMOTT, N; TURNER, M; POTTER, BVL; WATSON, SP				GALIONE, A; WHITE, A; WILLMOTT, N; TURNER, M; POTTER, BVL; WATSON, SP			CGMP MOBILIZES INTRACELLULAR CA2+ IN SEA-URCHIN EGGS BY STIMULATING CYCLIC ADP-RIBOSE SYNTHESIS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CALCIUM; ACTIVATION; RELEASE; ENZYME	MANY hormones or neurotransmitters act at cell surface receptors to increase the intracellular free calcium concentration, triggering a wide range of cellular responses1. As the source of this Ca2+ is often internal stores, additional messengers are required to convey the hormonal message from the plasma membrane. Cyclic ADP-ribose (cADPR) has been proposed as the endogenous activator of Ca2+-induced Ca2+ release by the ryanodine receptor in sea urchin eggs and in several mammalian cell types2-8,22. A second messenger role for cADPR requires that its intracellular levels be under the control of extracellular stimuli. Here we demonstrate a novel action of 3',5'-cyclic guanosine monophosphate (cGMP) in stimulating the synthesis of cADPR from beta-NAD+ by activating its synthetic enzyme ADP-ribosyl cyclase9-11 in sea urchin eggs and egg homogenates. We suggest that cADPR may transduce signals generated by cell surface receptors or gaseous transmitters linked to cGMP production.	UNIV BATH,SCH PHARM & PHARMACOL,BATH BA2 7AY,AVON,ENGLAND; UNIV BATH,INST LIFE SCI,BATH BA2 7AY,AVON,ENGLAND	University of Bath; University of Bath	GALIONE, A (corresponding author), UNIV OXFORD,DEPT PHARMACOL,MANSFIELD RD,OXFORD OX1 3QT,ENGLAND.		Watson, Stephen P/Q-6292-2016; Potter, Barry/AAX-4781-2020; Galione, Antony/E-5884-2011; Potter, Barry VL/A-1845-2012	Watson, Stephen P/0000-0002-7846-7423; Galione, Antony/0000-0002-4132-7646				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P504; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HOFMANN F, 1985, EUR J BIOCHEM, V150, P85, DOI 10.1111/j.1432-1033.1985.tb08991.x; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1993, J BIOL CHEM, V268, P293; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; POTTER BVL, 1992, INTRACELLULAR MESSEN, V20, P273; RUSKINO N, 1989, J BIOL CHEM, V264, P11725; SWANN K, 1987, MOL BIOL INVERTEBRAT, P45; TAKESAWA S, 1993, SCIENCE, V259, P370; WHALLEY T, 1992, MOL BIOL CELL, V3, P373, DOI 10.1091/mbc.3.3.373; WHITAKER M, 1993, DEVELOPMENT, V117, P1; Whitaker M.J., 1989, MECHANISMS EGG ACTIV, P159; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X	22	272	276	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					456	459		10.1038/365456a0	http://dx.doi.org/10.1038/365456a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	7692303				2022-12-24	WOS:A1993LZ63300061
J	TEMPLETON, GL; ILLING, LA; YOUNG, L; CAVE, MD; STEAD, WW; BATES, JH				TEMPLETON, GL; ILLING, LA; YOUNG, L; CAVE, MD; STEAD, WW; BATES, JH			RISK FOR TRANSMISSION OF MYCOBACTERIUM-TUBERCULOSIS AT THE BEDSIDE AND DURING AUTOPSY	ANNALS OF INTERNAL MEDICINE			English	Note								Objective: To emphasize the differing infectious potentials of a patient with tuberculosis. Setting: Hospital ward and autopsy room. Design: An epidemiologic investigation of tuberculin skin test conversions in a clinical setting and during autopsy when results of tuberculin tests done before exposure were available for all participants. Measurements: Tuberculin skin test results after the discovery of tuberculosis exposure from a patient with unsuspected tuberculosis for comparison with the test results before exposure; culture of sputum and autopsy material for Mycobacterium tuberculosis; and DNA fingerprinting of organisms. Intervention: Preventive therapy for persons with skin test conversion. Results: None of the 40 skin test-negative health care workers caring for the patient for 3 weeks on an open medical ward showed a skin test conversion, even though they had not used respiratory precautions. By contrast, among personnel present during the 3-hour autopsy, the test results of all five nonreactors converted from negative to positive (mean reaction, 24 mm). Two of these persons had a positive sputum culture 8 weeks later. The DNA fingerprints of all three isolates were identical. Conclusions: A patient who did not transmit tuberculosis before death released a prodigious number of tubercle bacilli during autopsy.	UNIV ARKANSAS, COLL MED, LITTLE ROCK, AR 72204 USA; ARKANSAS STATE DEPT HLTH, LITTLE ROCK, AR 72205 USA	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock	TEMPLETON, GL (corresponding author), JOHN L MCCLELLAN MEM VET ADM HOSP, 4300 W 7TH ST, LITTLE ROCK, AR 72205 USA.				NIAID NIH HHS [AI 01136] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001136] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; FRAMPTON MW, 1992, ANN INTERN MED, V117, P312, DOI 10.7326/0003-4819-117-4-312; HARRINGTON JM, 1976, BRIT MED J, V1, P759, DOI 10.1136/bmj.1.6012.759; HEDVALL ERIK, 1940, AMER REV TUBERC, V41, P770; HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286; JOHNSON GK, 1991, J MED VIROL, V33, P47, DOI 10.1002/jmv.1890330110; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; KOHN GJ, 1992, DIAGN MICR INFEC DIS, V15, P527, DOI 10.1016/0732-8893(92)90103-Z; MEADE GM, 1948, AM REV TUBERC PULM, V58, P675; MORRIS SI, 1946, AM REV TUBERC PULM, V54, P140; NARDELL EA, 1993, MED CLIN N AM, V77, P1315, DOI 10.1016/S0025-7125(16)30196-1; OSLER W, 1892, PRINCIPLES PRACTICE, P198; REID DD, 1957, BMJ-BRIT MED J, V2, P10, DOI 10.1136/bmj.2.5035.10; RIEDER HL, 1991, CHEST, V100, P678, DOI 10.1378/chest.100.3.678; RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069; RILEY RL, 1961, AIRBORNE INFECTION, P91; SLOAN R. A., 1942, New York State Journal of Medicine, V42, P133	17	90	92	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					922	925		10.7326/0003-4819-122-12-199506150-00005	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755227				2022-12-24	WOS:A1995RC27000005
J	TONG, MJ; ELFARRA, NS; REIKES, AR; CO, RL				TONG, MJ; ELFARRA, NS; REIKES, AR; CO, RL			CLINICAL OUTCOMES AFTER TRANSFUSION-ASSOCIATED HEPATITIS-C	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC ACTIVE HEPATITIS; NON-B-HEPATITIS; POSTTRANSFUSION HEPATITIS; NON-A; FOLLOW-UP; VIRUS	Background. The extent of serious complications in people who have acquired chronic hepatitis C after a blood transfusion is unclear. Methods. We studied 131 patients with chronic posttransfusion hepatitis C who were referred to our center between February 1980 and June 1994. Eighty-two other patients were excluded because they had multiple transfusions, hemophilia, intravenous drug use, human immunodeficiency virus infection, hepatitis B infection, hemochromatosis, or alcoholic liver disease. Liver biopsies were performed in 101 patients; biopsies were not performed in the other 30 patients, all with signs of cirrhosis, because the results of coagulation tests were abnormal. Results. The mean age of the patients was 57 years (range, 21 to 81) at the time of our initial evaluation. The mean age at the time of the blood transfusion was 35 years (range, 1 to 76). The mean duration of follow-up after presentation to us was 3.9 years (range, 1 to 15). Eighty-eight of the patients (67.2 percent) initially had fatigue, and 89 (67.9 percent) had hepatomegaly. Twenty-seven patients (20.6 percent) initially had chronic hepatitis, 30 (22.9 percent) had chronic active hepatitis, 67 (51.1 percent) had cirrhosis, and 7 (5.3 percent) had hepatocellular carcinoma. Hepatocellular carcinoma developed in an additional seven patients an average of 36 months (range, 7 to 121) after the initial visit. During follow-up, 20 patients (15.3 percent) died: 8 from complications of cirrhosis (1 after a liver transplantation); 11 from hepatocellular carcinoma; and 1, with chronic active hepatitis, from pneumonia. Conclusions. in a group of patients seen at a referral center, chronic post-transfusion hepatitis C was a progressive disease and, in some patients, led to death from either liver failure or hepatocellular carcinoma.			TONG, MJ (corresponding author), HUNTINGTON MEM HOSP, CTR LIVER, 744 FAIRMOUNT AVE, PASADENA, CA 91105 USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; BOYER JL, 1976, GASTROENTEROLOGY, V70, P1161; CHIEN DY, 1993, J GASTROEN HEPATOL, V8, pS33; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KORETZ RL, 1993, ANN INTERN MED, V119, P110, DOI 10.7326/0003-4819-119-2-199307150-00003; LUDWIG J, 1993, GASTROENTEROLOGY, V105, P274, DOI 10.1016/0016-5085(93)90037-D; MATTSSON L, 1988, LIVER, V8, P184; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; TONG MJ, 1994, WESTERN J MED, V160, P133; TONG MJ, 1987, HEPATOLOGY, V7, P713, DOI 10.1002/hep.1840070416; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9	13	1024	1056	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1463	1466		10.1056/NEJM199506013322202	http://dx.doi.org/10.1056/NEJM199506013322202			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739682				2022-12-24	WOS:A1995RA14000002
J	SAINSBURY, R; HAWARD, B; RIDER, L; JOHNSTON, C; ROUND, C				SAINSBURY, R; HAWARD, B; RIDER, L; JOHNSTON, C; ROUND, C			INFLUENCE OF CLINICIAN WORKLOAD AND PATTERNS OF TREATMENT ON SURVIVAL FROM BREAST-CANCER	LANCET			English	Article								Chemotherapy and hormone therapy prolong disease-free and overall survival for patients with breast cancer in the clinical-trial setting, but it is not clear if this translates into a benefit on a population basis. It is also not clear if surgical caseload has any influence on survival. We used cancer-registry data from 12 861 patients with breast cancer treated in Yorkshire, UK, between 1979 and 1988, and found that patients of surgeons with higher rates of usage of chemotherapy and hormone therapy (regional mean usage 9.3%, range 0-46%) had prolonged survival. There was considerable variation in survival of breast cancer patients between surgeons, but their rate of use of chemotherapy and hormone therapy explained about 26% of this survival variation. Had the practice of the surgeons with the better outcomes been used by all treating clinicians, 5-year survival would have increased by about 4-5%, Examination of differences in survival as a function of consultant caseload demonstrated poorer results amongst those surgeons treating less than 30 new cases of breast cancer per year (risk ratio [95% CI] for treating >30 compared with <10=0.85 [0.77-0.93]). We recommend that patients with breast cancer be dealt with only by clinicians who see more than 30 new cases per year and who have a full range of treatment options available within a multidisciplinary setting.	COOKRIDGE HOSP,YORKSHIRE CANC ORG,DEPT CANC STUDIES,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND; COOKRIDGE HOSP,YORKSHIRE CANC ORG,CLIN TRIALS & RES UNIT,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND; COOKRIDGE HOSP,YORKSHIRE CANC ORG,YORKSHIRE CANC REGISTRY,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND	Cookridge Hospital; Cookridge Hospital; University of Leeds; Cookridge Hospital	SAINSBURY, R (corresponding author), ROYAL INFIRM,DEPT SURG,HUDDERSFIELD HD3 3EA,W YORKSHIRE,ENGLAND.							BERINO F, IN PRESS IARC SCI PU, V132; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS S, 1987, JNCI-J NATL CANCER I, V78, P471; GILLIS CR, 1991, LANCET, V337, P611, DOI 10.1016/0140-6736(91)91673-I; HENDERSON R, 1955, STAT MED, V14, P161; KRAMER S, 1984, J CLIN ONCOL, V2, P917, DOI 10.1200/JCO.1984.2.8.917; LUFT HS, 1987, HEALTH SERV RES, V22, P157; LUFT HS, 1990, HOSPITAL VOLUME PHYS; MATTHEWS HR, 1986, BRIT J SURG, V73, P621; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; MORPHET C, 1992, INTERPRETATION SMALL, P62; SAINSBURY JRC, 1995, BRIT J CANCER, V71, P1275; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; 1994, CONSULTATIVE DOCUMEN; 1995, MACMILLAN DIRECTORY; 1995, PROVISION BREAST SER	17	309	310	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1265	1270		10.1016/S0140-6736(95)90924-9	http://dx.doi.org/10.1016/S0140-6736(95)90924-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746056				2022-12-24	WOS:A1995QY93300008
J	MONACO, HL; RIZZI, M; CODA, A				MONACO, HL; RIZZI, M; CODA, A			STRUCTURE OF A COMPLEX OF 2 PLASMA-PROTEINS - TRANSTHYRETIN AND RETINOL-BINDING PROTEIN	SCIENCE			English	Article							CRYSTAL-STRUCTURE DETERMINATION; HUMAN SERUM TRANSTHYRETIN; AMINO-ACID-SEQUENCE; HEREDITARY AMYLOIDOSIS; PRE-ALBUMIN; PREALBUMIN; RESOLUTION; VARIANT; RECOGNITION; REFINEMENT	The three-dimensional structure of the complex formed by two plasma proteins, transthyretin and retinol-binding protein, was determined from x-ray diffraction data to a nominal resolution of 3.1 angstroms. One tetramer of transthyretin was bound to two molecules of retinol-binding protein. The two retinol-binding protein molecules established molecular interactions with the same transthyretin dimer, and each also made contacts with one of the other two monomers. Thus, the other two potential binding sites in a transthyretin tetramer were blocked. The amino acid residues of the retinol-binding protein that were involved in the contacts were close to the retinol-binding protein that were involved in the contacts were close to the retinol-binding site.			MONACO, HL (corresponding author), UNIV PAVIA,DEPT GENET,I-27100 PAVIA,ITALY.			Monaco, Hugo L./0000-0002-2067-0365				AQVIST J, 1992, J MOL GRAPHICS, V10, P120, DOI 10.1016/0263-7855(92)80065-L; BENSON MD, 1983, ARTHRITIS RHEUM, V26, P1493, DOI 10.1002/art.1780261211; BENSON MD, 1993, METABOLIC BASIS INHE, P6262; BERNI R, 1994, J BIOL CHEM, V269, P23395; BERNI R, 1990, EUR J BIOCHEM, V192, P507, DOI 10.1111/j.1432-1033.1990.tb19254.x; BLAKE CCF, 1974, J MOL BIOL, V88, P1, DOI 10.1016/0022-2836(74)90291-5; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BRUNGER AT, 1992, XPLOR SYSTEM CRYSTAL; CISZAK E, 1992, P NATL ACAD SCI USA, V89, P6644, DOI 10.1073/pnas.89.14.6644; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; DUAN W, 1991, EUR J BIOCHEM, V200, P679, DOI 10.1111/j.1432-1033.1991.tb16232.x; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; HELLER J, 1975, J BIOL CHEM, V250, P3019; HORWITZ J, 1974, J BIOL CHEM, V249, P7181; JACOBSON DR, 1990, AM J HUM GENET, V47, P127; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; KOPELMAN M, 1976, BIOCHIM BIOPHYS ACTA, V439, P449, DOI 10.1016/0005-2795(76)90082-9; MARIUZZA RA, 1987, ANNU REV BIOPHYS BIO, V16, P139; MONACO HL, 1994, J MOL BIOL, V244, P110, DOI 10.1006/jmbi.1994.1708; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOY N, 1992, BIOCHEMISTRY-US, V31, P11118, DOI 10.1021/bi00160a023; PETERSON PA, 1971, J BIOL CHEM, V246, P44; RASK L, 1979, FEBS LETT, V104, P55, DOI 10.1016/0014-5793(79)81084-4; RASK L, 1974, EUR J BIOCHEM, V44, P1, DOI 10.1111/j.1432-1033.1974.tb03451.x; RAZ A, 1969, J BIOL CHEM, V244, P3230; STEINRAUF LK, 1993, J BIOL CHEM, V268, P2425; SUNDELIN J, 1985, J BIOL CHEM, V260, P6472; TERRY CJ, 1993, EMBO J, V12, P735, DOI 10.1002/j.1460-2075.1993.tb05707.x; TRAGARDH L, 1980, J BIOL CHEM, V255, P9243; UENO S, 1990, BIOCHEM BIOPH RES CO, V169, P143, DOI 10.1016/0006-291X(90)91445-X; VANJAARSVELD PP, 1973, J BIOL CHEM, V248, P4698; WALLACE MR, 1988, AM J HUM GENET, V43, P182; WOJTCZAK A, 1993, J BIOL CHEM, V268, P6202; WOJTCZAK A, 1992, J BIOL CHEM, V267, P353; ZANOTTI G, 1993, J MOL BIOL, V230, P613, DOI 10.1006/jmbi.1993.1173; ZANOTTI G, 1993, J BIOL CHEM, V268, P10728; ZAPPONI MC, 1992, EUR J BIOCHEM, V210, P937, DOI 10.1111/j.1432-1033.1992.tb17498.x	39	340	366	0	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1039	1041		10.1126/science.7754382	http://dx.doi.org/10.1126/science.7754382			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754382				2022-12-24	WOS:A1995QY93400038
J	SAUER, F; FONDELL, JD; OHKUMA, Y; ROEDER, RG; JACKLE, H				SAUER, F; FONDELL, JD; OHKUMA, Y; ROEDER, RG; JACKLE, H			CONTROL OF TRANSCRIPTION BY KRUPPEL THROUGH INTERACTIONS WITH TFIIB AND TFIIE-BETA	NATURE			English	Article							ACTIVATION DOMAIN; RNA-POLYMERASE; DROSOPHILA; INITIATION; PROTEIN; REPRESSION; MECHANISM; SEQUENCE; BINDING; STRIPE	THE zinc-finger protein Kruppel (Kr)(1) is an integral part of the Drosophila segmentation gene cascade(2) and is essential in organogenesis during later embryonic development(3). In tissue culture, Kr regulates transcription(4-9). Monomeric Kr can act as a transcriptional activator, whereas Kr dimers formed at high concentrations cause repression(6). Here we show that Kr-dependent control of transcription involves functional interactions with components of the basal RNA polymerase II transcription machinery, which includes the initiation factors TFIIA, B, E, F, H and I (refs 10, 11) as well as the TATA-binding protein (TBP) and TBP-associated factors (TAFs) contained in the multisubunit TFIID (ref. 12). Our results indicate that when acting from a site close to a basal promoter, monomeric Kr interacts with TFIIB to activate transcription, whereas an interaction of the Kr dimer with TFIIE beta w, a subunit of TFIIE, results in transcriptional repression.	MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,D-37077 GOTTINGEN,GERMANY; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021	Max Planck Society; Rockefeller University								CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KIM TK, IN PRESS P NATN ACAD; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LILLIE JW, 1991, NATURE, V338, P39; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LU H, 1992, NATURE, V358, P841; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SAUER F, 1993, THESIS U OSNABRUCK G; SCHMUCKER D, 1992, NEURON, V5, P1025; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHUO P, 1990, GENE DEV, V5, P254	30	132	135	1	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					162	164		10.1038/375162a0	http://dx.doi.org/10.1038/375162a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753175				2022-12-24	WOS:A1995QX74100056
J	WILLIAMS, AC				WILLIAMS, AC			DOPAMINE, DYSTONIA, AND THE DEFICIENT COFACTOR	LANCET			English	Editorial Material							TETRAHYDROBIOPTERIN				WILLIAMS, AC (corresponding author), UNIV BIRMINGHAM,SCH MED,BIRMINGHAM,W MIDLANDS,ENGLAND.							FINK JK, 1988, NEUROLOGY, V38, P707, DOI 10.1212/WNL.38.5.707; FURUKAWA Y, 1993, ADV NEUROL, V60, P562; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; LEWITT PA, 1986, NEUROLOGY, V36, P760, DOI 10.1212/WNL.36.6.760; LOVENBERG W, 1979, SCIENCE, V204, P624, DOI 10.1126/science.432666; NYGAARD TG, 1993, NAT GENET, V5, P386, DOI 10.1038/ng1293-386; RAJPUT AH, 1994, ANN NEUROL, V35, P396, DOI 10.1002/ana.410350405; Segawa M., 1971, SHINRYO TOKYO, V24, P667; TAKAHASHI H, 1994, ANN NEUROL, V35, P354, DOI 10.1002/ana.410350317; WILLIAMS A, 1979, LANCET, V2, P410; WILLIAMS AC, 1980, J NEUROL NEUROSUR PS, V43, P735, DOI 10.1136/jnnp.43.8.735	11	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1130	1130		10.1016/S0140-6736(95)90974-5	http://dx.doi.org/10.1016/S0140-6736(95)90974-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723542				2022-12-24	WOS:A1995QW62200006
J	FULOP, V; MOIR, JWB; FERGUSON, SJ; HAJDU, J				FULOP, V; MOIR, JWB; FERGUSON, SJ; HAJDU, J			THE ANATOMY OF A BIFUNCTIONAL ENZYME - STRUCTURAL BASIS FOR REDUCTION OF OXYGEN TO WATER AND SYNTHESIS OF NITRIC-OXIDE BY CYTOCHROME CD(1)	CELL			English	Article							PSEUDOMONAS-AERUGINOSA; PARACOCCUS-DENITRIFICANS; THIOSPHAERA-PANTOTROPHA; PROTEIN; GENE; DEHYDROGENASE; REFINEMENT; RESOLUTION; LOCATION; SEQUENCE	Cytochrome cd(1)-nitrite reductase is a bifunctional enzyme that catalyzes the one-electron reduction of nitrite to nitric oxide and the four-electron reduction of oxygen to water. The 1.55 Angstrom crystal structure of the dimeric enzyme from Thiosphaera pantotropha is reported here. The protein was sequenced from the X-ray structure. Each subunit contains a covalent c heme with two axial His ligands (His-17, His-69) and a unique noncovalent d(1) heme ligated by Tyr-25 and His-200. The d(1) heme is the mononuclear iron center where both oxygen and nitrite reduction take place. The two types of heme are located in separate domains whose arrangement suggests a mechanism requiring domain movement during catalysis.	UNIV OXFORD, OXFORD CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND	University of Oxford; University of Oxford	FULOP, V (corresponding author), UNIV OXFORD, MOLEC BIOPHYS LAB, REX RICHARDS BLDG, OXFORD OX1 3QU, ENGLAND.		Fulop, Vilmos/AAZ-7720-2021	Moir, James/0000-0003-2972-5235				AKEY CW, 1980, J MOL BIOL, V136, P19, DOI 10.1016/0022-2836(80)90364-2; ALEFOUNDER PR, 1980, BIOCHEM J, V192, P231, DOI 10.1042/bj1920231; ALLEN FH, 1991, J CHEM INF COMP SCI, V31, P187, DOI 10.1021/ci00002a004; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BERGER H, 1980, BIOCHIM BIOPHYS ACTA, V622, P355, DOI 10.1016/0005-2795(80)90047-1; BLATT Y, 1979, BIOCHEMISTRY-US, V18, P2917, DOI 10.1021/bi00580a037; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BRITTAIN T, 1992, EUR J BIOCHEM, V209, P793, DOI 10.1111/j.1432-1033.1992.tb17350.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; CHOTHIA C, 1993, STRUCTURE, V1, P217, DOI 10.1016/0969-2126(93)90010-E; DEBOER APN, 1994, ANTON LEEUW INT J G, V66, P111, DOI 10.1007/BF00871635; FULOP V, 1993, J MOL BIOL, V232, P1211, DOI 10.1006/jmbi.1993.1473; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HOROWITZ PM, 1982, J BIOL CHEM, V257, P9258; HUYNH BH, 1982, J BIOL CHEM, V257, P9576; JOHNSON MK, 1980, BIOCHEM J, V189, P285, DOI 10.1042/bj1890285; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; JUNGST A, 1991, MOL GEN GENET, V225, P241, DOI 10.1007/BF00269855; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; LAM Y, 1969, BIOCHIM BIOPHYS ACTA, V180, P459, DOI 10.1016/0005-2728(69)90025-5; LUDWIG W, 1993, INT J SYST BACTERIOL, V43, P363, DOI 10.1099/00207713-43-2-363; MAKINEN MW, 1983, SCIENCE, V222, P929, DOI 10.1126/science.6415814; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; MOIR JWB, 1993, THESIS OXFORD U OXFO; Moore G. R., 1990, CYTOCHROMES C EVOLUT; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; OHSHIMA T, 1993, J FERMENT BIOENG, V76, P82, DOI 10.1016/0922-338X(93)90061-C; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PARR SR, 1977, BIOCHEM J, V167, P447, DOI 10.1042/bj1670447; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SARASTE M, 1994, FEBS LETT, V341, P1, DOI 10.1016/0014-5793(94)80228-9; SILVESTRINI MC, 1989, FEBS LETT, V254, P33, DOI 10.1016/0014-5793(89)81004-X; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; SMITH GB, 1992, APPL ENVIRON MICROB, V58, P376, DOI 10.1128/AEM.58.1.376-384.1992; SUTHERLAND J, 1986, BIOCHEM J, V233, P893, DOI 10.1042/bj2330893; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; TAKANO T, 1979, J MOL BIOL, V133, P185, DOI 10.1016/0022-2836(79)90257-2; TIMKOVICH R, 1985, ARCH BIOCHEM BIOPHYS, V240, P689, DOI 10.1016/0003-9861(85)90077-3; VANDEROOST J, 1994, FEMS MICROBIOL LETT, V121, P1, DOI 10.1016/0378-1097(94)90137-6; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P113; WALSH TA, 1979, BIOCHEM J, V177, P29, DOI 10.1042/bj1770029; WU WS, 1987, J AM CHEM SOC, V109, P3149, DOI 10.1021/ja00244a050; XIA ZX, 1992, J BIOL CHEM, V267, P22289; YAMANAKA T, 1963, BIOCHIM BIOPHYS ACTA, V67, P379	50	255	265	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					369	377		10.1016/0092-8674(95)90390-9	http://dx.doi.org/10.1016/0092-8674(95)90390-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736589	Bronze			2022-12-24	WOS:A1995QW89400009
J	WILSON, C; SZOSTAK, JW				WILSON, C; SZOSTAK, JW			IN-VITRO EVOLUTION OF A SELF-ALKYLATING RIBOZYME	NATURE			English	Article							RNA	RNA enzymes are postulated to have catalysed all chemical reactions in the earliest living cells. This idea is now investigated in a search for alkyl transferases from a pool of random sequence RNAs. Selection for self-biotinylation yields a transfer RNA-like ribozyme that efficiently catalyses carbon-nitrogen bond formation. Ribozymes can thus promote reactions other than those involving the RNA sugar-phosphate backbone, suggesting that RNA may be capable of a broad range of catalytic activities.	MASSACHUSETTS GEN HOSP,DEPT BIOL MOLEC,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital								ALHAKIM AH, 1988, BIOCHEM J, V251, P935, DOI 10.1042/bj2510935; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FAMULOK M, 1994, J AM CHEM SOC, V116, P1698, DOI 10.1021/ja00084a010; FERSHT A, 1985, ENZYME STRUCTURE MEC, P57; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PRUDENTJR, 1994, SCIENCE, V264, P1924; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; TRAMONTANO A, 1988, J AM CHEM SOC, V110, P2282, DOI 10.1021/ja00215a045; WILSON C, 1992, CURR OPIN STRUC BIOL, V2, P749	19	194	208	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					777	782		10.1038/374777a0	http://dx.doi.org/10.1038/374777a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723823				2022-12-24	WOS:A1995QV31500035
J	INGAMELLS, S; SAUNDERS, NJ; BURGE, D				INGAMELLS, S; SAUNDERS, NJ; BURGE, D			GASTROSCHISIS AND REDUCED FETAL HEART-RATE-VARIABILITY	LANCET			English	Note								Most liveborn babies with gastroschisis do well after surgical repair, although about one-eighth of affected cases die late in utero. Our practice is to use weekly computerised cardiotocograph (CTG) analysis after week 34 of gestation in cases of gastroschisis. In a look-back at the records in 18 such singleton pregnancies, CTG showed 7 to be highly abnormal or preterminal. All but 1 of these 7 had a normal fetal heart rate. In all 7 cases, delivery was expedited. Only 1 infant had neurological sequelae, and in all the abdominal defect was successfully repaired. Monitoring of these high-risk pregnancies with serial computerised CTG may be helpful in timing delivery.	PRINCESS ANNE HOSP,SOUTHAMPTON SO16 5YA,HANTS,ENGLAND									COHEN WR, 1986, CLIN OBSTET GYNECOL, V29, P73, DOI 10.1097/00003081-198603000-00011; CRAWFORD RAF, 1992, BRIT J OBSTET GYNAEC, V99, P899, DOI 10.1111/j.1471-0528.1992.tb14438.x; DAWES GS, 1991, J PERINAT MED, V19, P39, DOI 10.1515/jpme.1991.19.1-2.39; DEVRIES PA, 1980, J PEDIATR SURG, V15, P245, DOI 10.1016/S0022-3468(80)80130-8; FRIES MH, 1993, J ULTRAS MED, V12, P583; LINDHAM S, 1981, ACTA PAEDIATR SCAND, V70, P55, DOI 10.1111/j.1651-2227.1981.tb07173.x; SMITH JH, 1988, BRIT J OBSTET GYNAEC, V95, P980, DOI 10.1111/j.1471-0528.1988.tb06501.x; STREET P, 1991, AM J OBSTET GYNECOL, V165, P515, DOI 10.1016/0002-9378(91)90277-X; TORFS C, 1990, J PEDIATR-US, V116, P1, DOI 10.1016/S0022-3476(05)81637-3; VISSER GHA, 1990, AM J OBSTET GYNECOL, V162, P698, DOI 10.1016/0002-9378(90)90989-K	10	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1024	1025		10.1016/S0140-6736(95)90760-2	http://dx.doi.org/10.1016/S0140-6736(95)90760-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723500				2022-12-24	WOS:A1995QU57300012
J	AGUILARBRYAN, L; NICHOLS, CG; WECHSLER, SW; CLEMENT, JP; BOYD, AE; GONZALEZ, G; HERRERASOSA, H; NGUY, K; BRYAN, J; NELSON, DA				AGUILARBRYAN, L; NICHOLS, CG; WECHSLER, SW; CLEMENT, JP; BOYD, AE; GONZALEZ, G; HERRERASOSA, H; NGUY, K; BRYAN, J; NELSON, DA			CLONING OF THE BETA-CELL HIGH-AFFINITY SULFONYLUREA RECEPTOR - A REGULATOR OF INSULIN-SECRETION	SCIENCE			English	Article							SENSITIVE K+ CHANNELS; PANCREATIC B-CELLS; PROTEIN-PHOSPHORYLATION; POTASSIUM CHANNELS; GLYBURIDE ANALOG; STRUCTURAL MODEL; BINDING-SITES; HIT CELLS; ATP; MEMBRANE	Sulfonylureas are a class of drugs widely used to promote insulin secretion in the treatment of non-insulin-dependent diabetes mellitus. These drugs interact with the sulfonylurea receptor of pancreatic beta cells and inhibit the conductance of adenosine triphosphate (ATP)-dependent potassium (K-ATP) channels. Cloning of complementary DNAs for the high-affinity sulfonylurea receptor indicates that it is a member of the ATP-binding cassette or traffic ATPase superfamily with multiple membrane-spanning domains and two nucleotide binding folds. The results suggest that the sulfonylurea receptor may sense changes in ATP and ADP concentration, affect K-ATP channel activity, and thereby modulate insulin release.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110	Baylor College of Medicine; Washington University (WUSTL); Washington University (WUSTL)	AGUILARBRYAN, L (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Nichols, Colin/D-6336-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044311, R01DK041898] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45742] Funding Source: Medline; NIDDK NIH HHS [DK44311, DK41898] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1992, J BIOL CHEM, V267, P14934; AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8218; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Ashford M. L. J, 1990, POTASSIUM CHANNELS S, P300; BERNARDI H, 1992, BIOCHEMISTRY-US, V31, P6328, DOI 10.1021/bi00142a023; BOKVIST K, 1991, P ROY SOC B-BIOL SCI, V243, P139, DOI 10.1098/rspb.1991.0022; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COOK DL, 1991, TRENDS NEUROSCI, V14, P411, DOI 10.1016/0166-2236(91)90033-Q; DEWEILLE JR, 1992, J BIOL CHEM, V267, P4557; DUNNE MJ, 1989, FEBS LETT, V250, P262, DOI 10.1016/0014-5793(89)80734-3; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GILON P, 1993, J BIOL CHEM, V268, P22265; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KHAN RN, 1993, P ROY SOC B-BIOL SCI, V253, P225, DOI 10.1098/rspb.1993.0107; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1983, MICROBIOL REV, V47, P1; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NELSON DA, 1992, J BIOL CHEM, V267, P14928; NICHOLS CG, 1991, BIOPHYS J, V60, P1164, DOI 10.1016/S0006-3495(91)82152-X; NIKI I, 1991, BIOCHIM BIOPHYS ACTA, V1133, P95, DOI 10.1016/0167-4889(91)90246-T; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PANTEN U, 1992, HORM METAB RES, V24, P549, DOI 10.1055/s-2007-1003387; QSHFORD ML, 1994, NATURE, V370, P456; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RAJAN AS, 1993, J BIOL CHEM, V268, P15221; RONNER P, 1993, DIABETES, V42, P1760, DOI 10.2337/diabetes.42.12.1760; SCHWANSTECHER C, 1992, MOL PHARMACOL, V41, P480; SCHWANSTECHER M, 1991, N-S ARCH PHARMACOL, V343, P83; SKEER JM, 1994, FEBS LETT, V338, P98, DOI 10.1016/0014-5793(94)80124-X; STURGESS NC, 1985, LANCET, V31, P474; TERZIC A, 1994, CARDIOVASC RES, V28, P746, DOI 10.1093/cvr/28.6.746; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; 1991, PROGRAM MANUAL GCG P	42	1182	1218	2	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					423	426		10.1126/science.7716547	http://dx.doi.org/10.1126/science.7716547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716547				2022-12-24	WOS:A1995QU57200042
J	COLONNA, M; SAMARIDIS, J				COLONNA, M; SAMARIDIS, J			CLONING OF IMMUNOGLOBULIN-SUPERFAMILY MEMBERS ASSOCIATED WITH HLA-C AND HLA-B RECOGNITION BY HUMAN NATURAL-KILLER-CELLS	SCIENCE			English	Article							NK CLONES; ALLOANTIGEN RECOGNITION; ANTIGEN RECOGNITION; EXPRESSION; MOLECULES; SPECIFICITY; RECEPTORS; LYSIS; GENE; HETEROGENEITY	Cytotoxicity by natural killer (NK) cells is inhibited by major histocompatibility complex (MHC) class I molecules on target cells. This inhibition may be mediated by NK receptors with different MHC specificities. A family of four NK-specific complementary DNAs (cDNAs), designated NKATs (NK-associated transcripts), was identified that encoded related transmembrane proteins, characterized by an extracellular region with two or three immunoglobulin-superfamily domains and by a cytoplasmic domain with an unusual antigen receptor activation motif (ARAM). The distribution of these cDNAs was clonotypic and correlated with NK cell inhibition by particular class I alleles. Thus, NKAT cDNAs may encode receptors for class I molecules on NK cells.			COLONNA, M (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.			Colonna, Marco/0000-0001-5222-4987				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; ARM JP, 1991, J BIOL CHEM, V266, P15966; BARCLAY AN, 1993, LEUKOCYTE ANTIGEN FA, P64; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P7983, DOI 10.1073/pnas.89.17.7983; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KORNBLUTH J, 1982, J IMMUNOL, V129, P2831; LANIER LL, 1983, J IMMUNOL, V131, P1789; LARSEN CJ, 1988, LEUKEMIA, V2, P247; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MALNATI MS, 1995, SCIENCE, V267, P1016, DOI 10.1126/science.7863326; MELERO I, 1994, J IMMUNOL, V152, P1662; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1990, J EXP MED, V172, P1589, DOI 10.1084/jem.172.6.1589; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; STORKUS WJ, 1991, CRIT REV IMMUNOL, V10, P393; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	33	689	725	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					405	408		10.1126/science.7716543	http://dx.doi.org/10.1126/science.7716543			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716543				2022-12-24	WOS:A1995QU57200036
J	PAPAVASILIOU, F; MISULOVIN, Z; SUH, HK; NUSSENZWEIG, MC				PAPAVASILIOU, F; MISULOVIN, Z; SUH, HK; NUSSENZWEIG, MC			THE ROLE OF IG-BETA IN PRECURSOR B-CELL TRANSITION AND ALLELIC EXCLUSION	SCIENCE			English	Article							ANTIGEN RECEPTOR COMPLEX; T-CELL; TRANSGENIC MICE; LYMPHOCYTE-B; LIGHT-CHAIN; PRE-B; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; GENE REARRANGEMENT; IMMUNOGLOBULIN-MU	Lymphocytes express multicomponent receptor complexes that mediate diverse antigen-dependent and antigen-independent responses. Despite the central role of antigen-independent events in B cell development, little is known about the mechanisms by which they are initiated. The association between the membrane immunoglobulin (Ig) M heavy chain (m mu) and the Ig alpha-Ig beta heterodimer is now shown to be essential in inducing both the transition from progenitor to precursor B cells and subsequent allelic exclusion in transgenic mice. The cytoplasmic domain of Ig beta is sufficient to induce these early antigen-independent events by a mechanism that requires conserved tyrosine residues in this protein.	ROCKEFELLER UNIV,MOLEC IMMUNOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University			Nussenzweig, Michel/AAE-7292-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI037526, R29AI033890, R01AI033890, R01AI037526] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37526, AI33890] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON SJ, 1993, NATURE, V365, P552, DOI 10.1038/365552a0; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GRUPP SA, 1993, J BIOL CHEM, V268, P25776; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; IGLESIAS A, 1993, EUR J IMMUNOL, V23, P2622, DOI 10.1002/eji.1830231036; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; LOVE PJ, 1994, J EXP MED, V180, P1485; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MATSUO T, 1993, J IMMUNOL, V150, P3766; METZGER H, 1992, J IMMUNOL, V149, P1477; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MITCHELL RN, 1991, J BIOL CHEM, V266, P8856; MOMBAERTS P, 1992, CELL, V66, P869; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PATEL KJ, 1993, CELL, V74, P939, DOI 10.1016/0092-8674(93)90473-4; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PFEFFER K, 1994, ANNU REV IMMUNOL, V12, P367, DOI 10.1146/annurev.immunol.12.1.367; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1994, CURR OPIN IMMUNOL, V12, P196; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; SHINKAI Y, 1992, CELL, V66, P855; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WEGNER AMK, 1992, CELL, V68, P83; YAGITA H, 1989, P NATL ACAD SCI USA, V86, P645, DOI 10.1073/pnas.86.2.645; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043	52	123	124	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					408	411		10.1126/science.7716544	http://dx.doi.org/10.1126/science.7716544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716544				2022-12-24	WOS:A1995QU57200037
J	MAIGNAN, S; GUILLOTEAU, JP; FROMAGE, N; ARNOUX, B; BECQUART, J; DUCRUIX, A				MAIGNAN, S; GUILLOTEAU, JP; FROMAGE, N; ARNOUX, B; BECQUART, J; DUCRUIX, A			CRYSTAL-STRUCTURE OF THE MAMMALIAN GRB2 ADAPTER	SCIENCE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SH3 DOMAINS; TYROSINE KINASES; PROTEIN; RAS	The mammalian growth factor receptor- binding protein Grb2 is an adaptor that mediates activation of guanine nucleotide exchange on Ras. Grb2 binds to the receptor through its SH2 domain and to the carboxyl-terminal domain of Son of sevenless through its two SH3 domains. It is thus a key element in the signal transduction pathway. The crystal structure of Grb2 was determined to 3.1 angstrom resolution. The asymmetric unit is composed of an embedded dimer. The interlaced junctions between the SH2 and SH3 domains bring the two adjacent faces of the SH3 domains in van der Waals contact but leave room for the binding of proline-rich peptides.	UNIV PARIS SUD, STRUCT BIOL LAB, CNRS, UNITE MIXTE RECH, F-91198 GIF SUR YVETTE, FRANCE; RHONE POULENC RORER, SERV BIOCHIM, F-94403 Vitry Sur Seine, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Sanofi-Aventis								BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BORCHERT TV, 1994, FEBS LETT, V341, P79, DOI 10.1016/0014-5793(94)80244-0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIKOL V, 1995, J MOL BIOL, V246, P344, DOI 10.1006/jmbi.1994.0089; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	181	194	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	1995	268	5208					291	293		10.1126/science.7716522	http://dx.doi.org/10.1126/science.7716522			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716522				2022-12-24	WOS:A1995QT18500039
J	MEDA, L; CASSATELLA, MA; SZENDREI, GI; OTVOS, L; BARON, P; VILLALBA, M; FERRARI, D; ROSSI, F				MEDA, L; CASSATELLA, MA; SZENDREI, GI; OTVOS, L; BARON, P; VILLALBA, M; FERRARI, D; ROSSI, F			ACTIVATION OF MICROGLIAL CELLS BY BETA-AMYLOID PROTEIN AND INTERFERON-GAMMA	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; ALZHEIMERS-DISEASE; NITRIC-OXIDE; NEURODEGENERATION; MACROPHAGES; CYTOKINES; INVITRO; RELEASE	ALZHEIMER'S disease is the most common cause of progressive intellectual failure(1). The lesions that develop, called senile plaques, are extracellular deposits principally composed of insoluble aggregates of beta-amyloid protein (A beta), infiltrated by reactive microglia and astrocytes(2,3). Although A beta, and a portion of it, the fragment 25-35 (A beta(25-35)), have been shown to exert a direct toxic effect on neurons(4-6), the role of microglia in such neuronal injury remains unclear(7). Here we report a synergistic effect between A beta and interferon-gamma (IFN-gamma) in triggering the production of reactive nitrogen intermediates and tumour-necrosis factor-alpha (TNF-alpha) from microglia. Furthermore, using co-culture experiments, we show that activation of microglia with IFN-gamma and A beta leads to neuronal cell injury in vitro. These findings suggest that A beta and IFN-gamma activate microglia to produce reactive nitrogen intermediates and TNF-alpha, and this may have a role in the pathogenesis of neuronal degeneration observed in ageing and Alzheimer's disease.	UNIV VERONA,INST GEN PATHOL,I-37134 VERONA,ITALY; UNIV MILAN,INST NEUROL,I-20122 MILAN,ITALY; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV FERRARA,INST GEN PATHOL,I-44100 FERRARA,ITALY	University of Verona; University of Milan; The Wistar Institute; University of Ferrara			villalba, martin/AAG-2604-2020; villalba, martin/N-7123-2017; Cassatella, M A/B-8037-2013; Ferrari, Davide/F-5644-2015	villalba, martin/0000-0002-4385-4888; villalba, martin/0000-0002-4385-4888; Cassatella, M A/0000-0001-7824-1806; Ferrari, Davide/0000-0002-5727-9204				AGRESTI C, 1991, DEV BIOL, V144, P16, DOI 10.1016/0012-1606(91)90474-H; ARANJO DM, 1992, BRAIN RES, V569, P141; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHAO CC, 1993, J IMMUNOL, V151, P1473; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CORRADIN SB, 1993, GLIA, V7, P255, DOI 10.1002/glia.440070309; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DICKSON D, 1990, Society for Neuroscience Abstracts, V16, P1267; DING AH, 1988, J IMMUNOL, V141, P2407; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HERNANDEZCASELL.T, 1993, J IMMUNOL, V151, P3999; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OSWALD IP, 1992, P NATL ACAD SCI USA, V89, P8676, DOI 10.1073/pnas.89.18.8676; OTVOS L, 1993, EUR J BIOCHEM, V211, P249, DOI 10.1111/j.1432-1033.1993.tb19893.x; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; PIKE CJ, 1993, J NEUROSCI, V13, P1676; SELKOE DJ, 1987, SCIENCE, V235, P873, DOI 10.1126/science.3544219; SHER PK, 1990, BRAIN RES BULL, V25, P697, DOI 10.1016/0361-9230(90)90045-2; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; VILLALBA M, 1994, J BIOL CHEM, V269, P2468; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849	27	1193	1242	1	101	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					647	650		10.1038/374647a0	http://dx.doi.org/10.1038/374647a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715705				2022-12-24	WOS:A1995QT18900061
J	BLAIR, SN; KOHL, HW; BARLOW, CE; PAFFENBARGER, RS; GIBBONS, LW; MACERA, CA				BLAIR, SN; KOHL, HW; BARLOW, CE; PAFFENBARGER, RS; GIBBONS, LW; MACERA, CA			CHANGES IN PHYSICAL-FITNESS AND ALL-CAUSE MORTALITY - A PROSPECTIVE-STUDY OF HEALTHY AND UNHEALTHY MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; FOLLOW-UP; PREDICTOR	Objective.-To evaluate the relationship between changes in physical fitness and risk of mortality in men. Design.-Prospective study, with two clinical examinations (mean internal between examinations, 4.9 years) to assess change or lack of change in physical fitness as associated with risk of mortality during follow-up after the subsequent examination (mean follow-up from subsequent examination, 5.1 years). Setting.-Preventive medicine clinic. Study Participants.-Participants were 9777 men given two preventive medical examinations, each of which included assessment of physical fitness by maximal exercise tests and evaluation of health status. Main Outcome Measures.-All-cause (n=223) and cardiovascular disease (n=87) mortality. Results.-The highest age-adjusted all-cause death rate was observed in men who were unfit at both examinations (122.0/10000 man-years); the lowest death rate was in men who were physically fit at both examinations (39.6/10000 man-years). Men who improved from unfit to fit between the first and subsequent examinations had an age-adjusted death rate of 67.7/10 000 man-years. This is a reduction in mortality risk of 44% (95% confidence internal, 25% to 59%) relative to men who remained unfit at both examinations, Improvement in fitness was associated With lower death rates after adjusting for age, health status, and other risk factors of premature mortality, For each minute increase in maximal treadmill time between examinations, there was a corresponding 7.9% (P=.001) decrease in risk of mortality. Similar results were seen when the group was stratified by health status, and for cardiovascular disease mortality. Conclusions.-Men who maintained or improved adequate physical fitness were less likely to die from all causes and from cardiovascular disease during follow-up than persistently unfit men. Physicians should encourage unfit men to improve their fitness by starting a physical activity program.	COOPER CLIN,DALLAS,TX; STANFORD UNIV,SCH MED,STANFORD,CA 94305; UNIV S CAROLINA,SCH PUBL HLTH,COLUMBIA,SC 29208	Cooper Institute; Stanford University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	BLAIR, SN (corresponding author), COOPER INST AEROB RES,DIV EPIDEMIOL,12330 PRESTON RD,DALLAS,TX 75230, USA.		wright, beth/V-7496-2019		NIA NIH HHS [AG06945] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006945, R37AG006945] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American College of Sports Medicine position stand, 1990, MED SCI SPORTS EXERC, V22, P265; BALKE B, 1959, U S Armed Forces Med J, V10, P675; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Bond, 1989, AGING HLTH CARE SOCI, P27; Bouchard C., 1994, PHYSICAL ACTIVITY FI, P106; BOUCHARD C, 1994, PHYSICAL ACTIVITY FI; BRUCE RA, 1983, J AM COLL CARDIOL, V2, P565, DOI 10.1016/S0735-1097(83)80286-1; COX DR, 1972, J R STAT SOC B, V34, P187; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; ERIKSSEN J, 1986, ACTA MED SCAND S, V711, P189; HEIN HO, 1992, J INTERN MED, V232, P471, DOI 10.1111/j.1365-2796.1992.tb00619.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES, P300; LIE H, 1985, EUR HEART J, V6, P147, DOI 10.1093/oxfordjournals.eurheartj.a061829; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1994, MED SCI SPORT EXER, V26, P857; PETERS RK, 1983, JAMA-J AM MED ASSOC, V249, P3052, DOI 10.1001/jama.249.22.3052; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; SOBOLSKI J, 1987, AM J EPIDEMIOL, V125, P601, DOI 10.1093/oxfordjournals.aje.a114573; WILHELMSEN L, 1981, CARDIOLOGY, V68, P1, DOI 10.1159/000173310	23	1414	1455	0	103	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1093	1098		10.1001/jama.273.14.1093	http://dx.doi.org/10.1001/jama.273.14.1093			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707596				2022-12-24	WOS:A1995QR05900027
J	FRASCH, M				FRASCH, M			INDUCTION OF VISCERAL AND CARDIAC MESODERM BY ECTODERMAL DPP IN THE EARLY DROSOPHILA EMBRYO	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; HOMEOBOX-CONTAINING GENE; VENTRALIZING FACTOR; BETA FAMILY; GERM LAYERS; CELL FATES; XENOPUS; EXPRESSION; PATTERN; REPRESSION	AFTER gastrulation, progenitor cells of the cardiac, visceral and body wall musculature arise at defined positions within the mesodermal layer of the Drosophila embryo(1-4). The regulatory mechanisms underlying this process of pattern formation are largely unknown, although ablation experiments carried out in other insects indicate that inductive influences from ectodermal cells have major roles in embryonic mesoderm differentiation(5,6). An early and important event in the regional subdivision of the mesoderm is the restriction of tinman expression to dorsal mesodermal cells(2,3). Genetic analysis has shown that this homeobox gene controls the formation of the visceral musculature and the heart from dorsal portions of the mesoderm(3,7). We now show that an inductive signal from dorsal ectodermal cells is required for activation of tinman in the underlying mesoderm and present evidence that Decapentaplegic (Dpp), a member of the transforming growth factor-beta superfamily(8), serves as a signalling molecule in this process. This demonstrates that the spatial expression of dpp in the ectoderm determines which cells of the mesoderm become competent to develop into visceral mesoderm and the heart.			FRASCH, M (corresponding author), CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029, USA.		Frasch, Manfred/H-7002-2013	Frasch, Manfred/0000-0003-1373-9798				ANDERSON MG, 1995, GENE DEV, V9, P123, DOI 10.1101/gad.9.1.123; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Bate Michael, 1993, P1013; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; BRAND AH, 1993, DEVELOPMENT, V118, P401; DALE L, 1992, DEVELOPMENT, V115, P573; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; Haget A., 1953, Bulletin Biol Paris, V87, P123; HOCH M, 1990, EMBO J, V9, P2587, DOI 10.1002/j.1460-2075.1990.tb07440.x; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IP YT, 1991, CELL, V64, P439; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; JONES CM, 1992, DEVELOPMENT, V115, P639; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LOGAN M, 1993, DEVELOPMENT, V118, P865; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; Poulson D. F., 1950, BIOL DROSOPHILA, P168; Seidel F, 1940, NATURWISSENSCHAFTEN, V28, P433, DOI 10.1007/BF01557878; SMITH JC, 1987, DEVELOPMENT, V99, P3; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; WHARTON KA, 1993, DEVELOPMENT, V117, P807	30	352	355	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					464	467		10.1038/374464a0	http://dx.doi.org/10.1038/374464a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700357				2022-12-24	WOS:A1995QP89900061
J	EVANS, P; GRAY, DP				EVANS, P; GRAY, DP			VALUE OF SCREENING FOR SECONDARY CAUSES OF HYPERLIPIDEMIA IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article											EVANS, P (corresponding author), UNIV EXETER,POSTGRAD MED SCH,INST GEN PRACTICE,EXETER EX2 5DW,DEVON,ENGLAND.			PEREIRA GRAY, DENIS/0000-0001-7917-3841				BRUNZELL JD, 1988, CECIL TXB MED, P1143; Gray D J, 1979, J R Coll Gen Pract, V29, P666; LEWIS B, 1987, OXFORD TXB MED, V9, P111; 1992, 55 ROYAL COLL GEN PR; 1988, EUR HEART J, V9, P571	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					509	510		10.1136/bmj.309.6953.509	http://dx.doi.org/10.1136/bmj.309.6953.509			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	7755687	Green Published			2022-12-24	WOS:A1994PD30800018
J	WILLIS, MC; HICKE, BJ; UHLENBECK, OC; CECH, TR; KOCH, TH				WILLIS, MC; HICKE, BJ; UHLENBECK, OC; CECH, TR; KOCH, TH			PHOTO-CROSS-LINKING OF 5-IODOURACIL SUBSTITUTED RNA AND DNA TO PROTEINS	SCIENCE			English	Article							PHOTOCHEMICAL CROSS-LINKING; LAC REPRESSOR PROTEIN; 5-BROMOURACIL-SUBSTITUTED DNA; RIBONUCLEIC-ACID; OPERATOR DNA; BROMODEOXYURIDINE; IDENTIFICATION; COMPLEX; REGION; SITE	5-Iodouracil-substituted RNA and DNA were crosslinked regiospecifically to associated proteins in yields of 70 to 94% of bound nucleic acid. Irradiation of the iodouracil chromophore with monochromatic, long-wavelength ultraviolet radiation (325 nanometers) eliminates excitation of other nucleic acid and protein chromophores. The combination of high crosslinking yields, excellent specificity, and elimination of photodamage to other chromophores represents an important advance toward the precise identification of contacts in nucleoprotein complexes.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV COLORADO,HOWARD HUGHES MED INST,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder					NIGMS NIH HHS [GM-36944, GM-28039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028039, R01GM036944, R01GM028039, R37GM036944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN TD, 1991, J BIOL CHEM, V266, P6113; BARBIER B, 1984, BIOCHEMISTRY-US, V23, P2933, DOI 10.1021/bi00308a013; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; CAREY J, 1983, BIOCHEMISTRY-US, V22, P4723, DOI 10.1021/bi00289a017; DIETZ TM, 1987, J AM CHEM SOC, V109, P1793, DOI 10.1021/ja00240a032; DIETZ TM, 1987, PHOTOCHEM PHOTOBIOL, V46, P971, DOI 10.1111/j.1751-1097.1987.tb04879.x; FANG GW, 1993, GENE DEV, V7, P870, DOI 10.1101/gad.7.5.870; GOTT JM, 1991, BIOCHEMISTRY-US, V30, P6290, DOI 10.1021/bi00239a030; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; HICKE BJ, UNPUB; Hutchinson F., 1980, PROG MOL SUBCELL BIO, V7, P1; KATOUZIANSAFADI M, 1991, PHOTOCHEM PHOTOBIOL, V53, P611, DOI 10.1111/j.1751-1097.1991.tb08487.x; KATOUZIANSAFADI M, 1991, NUCLEIC ACIDS RES, V19, P4937, DOI 10.1093/nar/19.18.4937; KHALILI K, 1988, EMBO J, V7, P1205, DOI 10.1002/j.1460-2075.1988.tb02932.x; LIN SY, 1974, P NATL ACAD SCI USA, V71, P947, DOI 10.1073/pnas.71.3.947; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; OGATA R, 1977, P NATL ACAD SCI USA, V74, P4973, DOI 10.1073/pnas.74.11.4973; SAITO I, 1990, BIOORGANIC PHOTOCHEM, V1, P317; Shetlar M.D., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P105; TANNER NK, 1988, BIOCHEMISTRY-US, V27, P8852, DOI 10.1021/bi00424a025; UHLENBECK C, 1988, NUCLEIC ACIDS, V16, P11725; WEINTRAUB H, 1973, COLD SPRING HARB SYM, V38, P247, DOI 10.1101/SQB.1974.038.01.028; WICK KL, 1991, J BIOL CHEM, V266, P6106; WILLIS M, UNPUB; WOLFES H, 1986, EUR J BIOCHEM, V159, P267, DOI 10.1111/j.1432-1033.1986.tb09863.x	25	175	197	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1255	1257		10.1126/science.7694369	http://dx.doi.org/10.1126/science.7694369			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	7694369				2022-12-24	WOS:A1993MH32400036
J	SANCHEZGUERRERO, J; COLDITZ, GA; KARLSON, EW; HUNTER, DJ; SPEIZER, FE; LIANG, MH				SANCHEZGUERRERO, J; COLDITZ, GA; KARLSON, EW; HUNTER, DJ; SPEIZER, FE; LIANG, MH			SILICONE BREAST IMPLANTS AND THE RISK OF CONNECTIVE-TISSUE DISEASES AND SYMPTOMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; REVISED CRITERIA; WOMEN; POLYMYOSITIS; EPIDEMIOLOGY; SCLERODERMA; DERMATOMYOSITIS; CLASSIFICATION; AUGMENTATION	Background. Silicone breast implants have been linked to a variety of illnesses, the most controversial of which are connective-tissue diseases and symptoms. To study this relation, we analyzed data from 14 years of follow-up of the Nurses' Health Study cohort. Methods. Women who were free from connective-tissue disease in June 1976 were followed through May 31, 1990, before there was widespread media coverage of the possible association of breast implants and connective-tissue diseases. Information was collected through biennial and supplementary mailed questionnaires and blinded reviews of medical records with the use of standardized criteria. Relative risk, the measure of association, was defined as the incidence rate of connective-tissue disease among women with breast implants divided by the corresponding incidence rate among women without breast implants. Results. Among 87,501 women who were eligible for follow-up, 516 were confirmed as having definite connective-tissue diseases and 1183 as having breast implants (of which 876 were silicone-gel-filled, 170 saline-filled, 67 double-lumen, 14 polyurethane-coated, and 56 of unknown type). The mean (+/-SD) period of follow-up after surgery was 9.9+/-6.4 years (range, 1 month to 40.5 years). Three of the patients with definite connective-tissue disease - all had rheumatoid arthritis - had implants (one silicone-gel-filled, one saline-filled, and one double-lumen). The age-adjusted relative risk of a definite connective-tissue disease among women with any type of implant was 0.6 (95 percent confidence interval, 0.2 to 2.0), as compared with women without implants. For women with silicone-gel-filled implants, the comparable relative risk was 0.3 (95 percent confidence interval, 0 to 1.9). The relative risk of self-reported signs or symptoms of connective-tissue disease for women with implants was 1.5 (95 percent confidence interval, 0.9 to 2.4); the risk of having any 1 of 41 signs, symptoms, or laboratory features of connective-tissue disease was 0.7 (95 percent confidence interval, 0.3 to 1.6). Conclusions. In a large cohort study, we did not find an association between silicone breast implants and connective-tissue diseases, defined according to a variety of standardized criteria, or signs and symptoms of these diseases.	HARVARD UNIV,SCH MED,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,RB BRIGHAM MULTIP ARTHRIT & MUSCULOSKEL DIS CTR,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308, R01AR042630] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356-08S1] Funding Source: Medline; NIAMS NIH HHS [AR36308, AR42630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P328; ANGELL M, 1994, NEW ENGL J MED, V330, P1748, DOI 10.1056/NEJM199406163302409; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BORENSTEIN D, 1994, SEMIN ARTHRITIS RHEU, V24, P1, DOI 10.1016/0049-0172(94)90102-3; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COOK RR, 1995, J CLIN EPIDEMIOL, V48, P519, DOI 10.1016/0895-4356(94)00208-8; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; DUGOWSON CE, 1991, ARTHRITIS RHEUM-US, V34, P1502; FESSEL WJ, 1974, ARCH INTERN MED, V134, P1027, DOI 10.1001/archinte.134.6.1027; FOX RI, 1986, SCAND J RHEUMATOL S, V61, P28; FREUNDLICH B, 1994, SEMIN ARTHRITIS RHEU, V24, P44, DOI 10.1016/0049-0172(94)90109-0; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GILTAY EJ, 1994, ANN RHEUM DIS, V53, P194, DOI 10.1136/ard.53.3.194; GOLDMAN JA, 1992, ARTHRITIS RHEUM, V35, pS65; HOCHBERG MC, 1985, ARTHRITIS RHEUM-US, V28, P80, DOI 10.1002/art.1780280113; HOCHBERG MC, 1994, ARTHRITIS RHEUM, V37, P1249; KARLSON EW, IN PRESS ANN EPIDEMI; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; MEDSGER TA, 1970, AM J MED, V48, P715, DOI 10.1016/S0002-9343(70)80006-7; MEDSGER TA, 1971, ANN INTERN MED, V74, P714, DOI 10.7326/0003-4819-74-5-714; MICHET CJ, 1985, MAYO CLIN PROC, V60, P105, DOI 10.1016/S0025-6196(12)60294-8; ODDIS CV, 1990, J RHEUMATOL, V17, P1329; Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, 1980, ARTHRITIS RHEUM, V23, P581; ROTHMAN KJ, 1979, PHS NIH791649 PUBL; SANCHEZGUERRERO J, 1994, ARTHRITIS RHEUM-US, V37, P158; SILMAN A, 1988, BRIT J RHEUMATOL, V27, P286; SOLOMON G, 1994, SEMIN ARTHRITIS RHEU, V24, P29, DOI 10.1016/0049-0172(94)90107-4; STEEN V, 1988, Arthritis and Rheumatism, V31, pS57; STROM BL, 1994, J CLIN EPIDEMIOL, V47, P1211, DOI 10.1016/0895-4356(94)90109-0; SYMMONS DPM, 1992, ARTHRITIS RHEUM, V35, P126; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VASEY FB, 1994, SEMIN ARTHRITIS RHEU, V24, P22, DOI 10.1016/0049-0172(94)90106-6; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011; WELLS KE, 1994, PLAST RECONSTR SURG, V93, P907, DOI 10.1097/00006534-199404001-00002; WIGLEY FM, 1992, ARTHRITIS RHEUM, V35, pS46; 1992, CAN MED ASSOC J, V147, P1141; 1993, STATA REFERENCE MANU	39	314	323	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 22	1995	332	25					1666	1670		10.1056/NEJM199506223322502	http://dx.doi.org/10.1056/NEJM199506223322502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD996	7760867				2022-12-24	WOS:A1995RD99600002
J	MEEHAN, TP; HENNEN, J; RADFORD, MJ; PETRILLO, MK; ELSTEIN, P; BALLARD, DJ				MEEHAN, TP; HENNEN, J; RADFORD, MJ; PETRILLO, MK; ELSTEIN, P; BALLARD, DJ			PROCESS AND OUTCOME OF CARE FOR ACUTE MYOCARDIAL-INFARCTION AMONG MEDICARE BENEFICIARIES IN CONNECTICUT - A QUALITY IMPROVEMENT DEMONSTRATION PROJECT	ANNALS OF INTERNAL MEDICINE			English	Article								Objective: To evaluate the feasibility of linking claims-based pattern analysis with medical record review in the assessment of quality of hospital care among Medicare beneficiaries with acute myocardial infarction. Design: An analysis of risk-adjusted mortality after hospital admission for acute myocardial infarction using the regression model from the Health Care Financing Administration for predicting mortality rates. Hospital records for 300 patients admitted for myocardial infarction were abstracted to evaluate the accuracy of diagnostic coding and the adequacy of claims data-based risk adjustment and to assess process measures of quality care. Setting: Six Connecticut hospitals in the pilot study of the Medicare Hospital information Project. Patients: Medicare beneficiaries 65 years of age or older who were hospitalized with a primary diagnosis of acute myocardial infarction from 1989 to 1991. Main Outcome Measures: Principal diagnosis code verification rates for acute myocardial infarction; observed mortality rates at 30 and 365 days; 30-day standardized mortality ratios; and utilization rates for thrombolytic agents, aspirin, and beta-blockers. Results: The coding of acute myocardial infarction diagnosis had an overall accuracy of 96%. Little change was noted in relative mortality ratio hospital rank order after the exclusion of 13 patients who did not fulfill criteria for acute myocardial infarction and after additional risk adjustment with Killip class data. Utilization rates for therapies among eligible patients were as follows: aspirin, 73%; beta-blockers, 41%; and thrombolytic agents, 43%. The use of thrombolytic agents was associated with a lower 30-day mortality; the use of thrombolytic agents, aspirin, and beta-blockers was related to lower mortality rates at 1 year after discharge; and the use of these three therapies was lower in the two hospitals with the highest risk-adjusted mortality. Conclusions: Medicare principal diagnosis codes for acute myocardial infarction were accurate in the six study hospitals. Therapies that have been endorsed by clinicians in Connecticut were underused in elderly patients. Pattern analysis of Medicare claims data can be useful as a quality-of-care screening tool; however, additional clinical information is required to stimulate quality improvement efforts within hospitals.	EMORY UNIV, CTR CLIN EVALUAT SCI, DECATUR, GA 30030 USA; CONNECTICUT PEER REVIEW ORG, MIDDLETOWN, CT 06457 USA; KERR L WHITE INST HLTH SERV RES, DECATUR, GA USA; UNIV CONNECTICUT, SCH MED, FARMINGTON, CT USA; US HLTH CARE FINANCING ADM, OFF PROGRAM ASSESSMENT & INFORMAT, BALTIMORE, MD 21207 USA	Emory University; University of Connecticut			Ballard, David J/H-1062-2018	Radford, Martha/0000-0001-7503-9557				BALLARD DJ, 1994, HEALTH SERV RES, V28, P771; BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Corn R F, 1981, Inquiry, V18, P351; COX DR, 1972, J R STAT SOC B, V34, P187; DEMLO LK, 1978, MED CARE, V16, P995, DOI 10.1097/00005650-197812000-00003; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Feldman S E, 1993, Med Care Rev, V50, P123, DOI 10.1177/107755879305000202; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; Hayes R P, 1994, Med Care Rev, V51, P39, DOI 10.1177/107755879405100103; HAYES RP, 1994, CLIN PERFORMANCE QUA, V2, P233; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KRAKAUER H, 1991, STAT MED, V10, P521, DOI 10.1002/sim.4780100405; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; NASH DB, 1992, JAMA-J AM MED ASSOC, V268, P917, DOI 10.1001/jama.268.7.917; SULLIVAN LW, 1992, MEDICARE HOSPITAL S, V55	19	57	57	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					928	936		10.7326/0003-4819-122-12-199506150-00007	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RC270	7755229				2022-12-24	WOS:A1995RC27000007
J	TANZI, RE				TANZI, RE			CLINICAL IMPLICATIONS OF BASIC RESEARCH - A PROMISING ANIMAL-MODEL OF ALZHEIMERS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											TANZI, RE (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02129, USA.		Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454				GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290	3	10	15	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1512	1513		10.1056/NEJM199506013322212	http://dx.doi.org/10.1056/NEJM199506013322212			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739692				2022-12-24	WOS:A1995RA14000012
J	TONKIN, SL; DAVIS, SL; GUNN, TR				TONKIN, SL; DAVIS, SL; GUNN, TR			NASAL ROUTE FOR INFANT RESUSCITATION BY MOTHERS	LANCET			English	Article							AIRWAY	In infants under 6 months of age air normally enters the trachea by the nose because the tongue fills the oral cavity, and the oral route is open only when the infant is making muscular efforts such as crying or gasping. The present recommendation for infant resuscitation is for the resuscitator's mouth to cover the mouth and nose of the baby. We set out to test whether this recommendation is feasible. We measured the dimensions of the faces of 28 babies aged between 2 and 4 months (the age when resuscitation is most often needed) and of the mouths of 25 of their mothers. Only 2 mothers would have been able to cover with their mouths the nose and closed mouth of 2 babies (not their own). The mannequins often used to teach adults to resuscitate infants are misleading because they present a wide open mouth, thus implying that that is the preferred route. We recommend that the nasal route of air entry be taught to parents for resuscitation of babies who have stopped breathing.	UNIV AUCKLAND,AUCKLAND,NEW ZEALAND	University of Auckland	TONKIN, SL (corresponding author), NEW ZEALAND COT DEATH ASSOC,POB 28-177,AUCKLAND,NEW ZEALAND.							GUNN TR, 1989, PEDIATRICS, V84, P73; SIEBERT J R, 1991, Pediatric Pathology, V11, P813; TONKIN S, 1975, PEDIATRICS, V55, P650; TONKIN SL, 1988, NEW ZEAL MED J, V101, P261; WILSON SL, 1980, J APPL PHYSIOL, V48, P500, DOI 10.1152/jappl.1980.48.3.500; 1992, JAMA-J AM MED ASSOC, V268, P2184; 1994, PUBLIC HLTH COMMISSI	7	25	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1353	1354		10.1016/S0140-6736(95)92543-0	http://dx.doi.org/10.1016/S0140-6736(95)92543-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752760				2022-12-24	WOS:A1995RA14800014
J	JABRI, E; CARR, MB; HAUSINGER, RP; KARPLUS, PA				JABRI, E; CARR, MB; HAUSINGER, RP; KARPLUS, PA			THE CRYSTAL-STRUCTURE OF UREASE FROM KLEBSIELLA-AEROGENES	SCIENCE			English	Article							JACK-BEAN UREASE; SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; HELICOBACTER-PYLORI; BETA-MERCAPTOETHANOL; PROTEIN-STRUCTURE; EC 3.5.1.5; NICKEL; GENES; SEQUENCE	The crystal structure of urease from Klebsiella aerogenes has been determined at 2.2 Angstrom resolution and refined to an R factor of 18.2 percent. The enzyme contains four structural domains: three with novel folds playing structural roles, and an (alpha beta)8 barrel domain, which contains the bi-nickel center. The two active site nickels are 3.5 Angstrom apart. One nickel ion is coordinated by three ligands (with low occupancy of a fourth ligand) and the second is coordinated by five ligands. A carbamylated lysine provides an oxygen ligand to each nickel, explaining why carbon dioxide is required for the activation of urease apoenzyme. The structure is compatible with a catalytic mechanism whereby urea ligates Ni-1 to complete its tetrahedral coordination and a hydroxide ligand of Ni-2 attacks the carbonyl carbon. A surprisingly high structural similarity between the urease catalytic domain and that of the zinc-dependent adenosine deaminase reveals a remarkable example of active site divergence.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Cornell University; Michigan State University; Michigan State University				Karplus, Paul/0000-0001-8725-6292; Hausinger, Robert/0000-0002-3643-2054; Jabri, Evelyn/0000-0002-5117-1892	NIGMS NIH HHS [5T32-GM08384-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008384] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER J, 1993, SCIENCE, V260, P159, DOI 10.1126/science.8469968; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BENNING MM, 1994, BIOCHEMISTRY-US, V33, P15001, DOI 10.1021/bi00254a008; BLAKELEY RL, 1983, BIOCHIM BIOPHYS ACTA, V744, P219, DOI 10.1016/0167-4838(83)90094-8; BOUTONNET NS, 1994, PROTEIN SCI, V3, P769; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CARR MB, IN PRESS MECHANISMS; CHOTHIA C, 1986, EMBO J, V4, P823; CLAYTON CL, 1990, NUCLEIC ACIDS RES, V18, P362, DOI 10.1093/nar/18.2.362; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DICKERSO.RE, 1968, ACTA CRYSTALL B-STRU, VB 24, P997, DOI 10.1107/S0567740868003626; DIXON NE, 1975, J AM CHEM SOC, V97, P4131, DOI 10.1021/ja00847a045; DIXON NE, 1980, CAN J BIOCHEM CELL B, V58, P1335, DOI 10.1139/o80-181; DIXON NE, 1980, CAN J BIOCHEM CELL B, V58, P481, DOI 10.1139/o80-064; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FARBER GK, 1993, CURR OPIN STRUC BIOL, V3, P409, DOI 10.1016/S0959-440X(05)80114-9; FINNEGAN MG, 1991, J AM CHEM SOC, V113, P4030, DOI 10.1021/ja00010a076; GRIFFITH DP, 1979, UROL RES, V7, P215; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HARTMAN FC, 1993, ANNU REV BIOCHEM, V63, P197; HAUSINGER RP, 1993, BIOCH NICKEL, pCH4; Hausinger RP, 1993, BIOCH NICKEL; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JABRI E, 1992, J MOL BIOL, V227, P934, DOI 10.1016/0022-2836(92)90232-9; JABRI E, UNPUB; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSE J, 1991, FEMS MICROBIOL LETT, V80, P277, DOI 10.1111/j.1574-6968.1991.tb04675.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LABIGNE A, 1991, J BACTERIOL, V173, P1920, DOI 10.1128/jb.173.6.1920-1931.1991; LEE A, 1993, INFECT IMMUN, V61, P1601, DOI 10.1128/IAI.61.5.1601-1610.1993; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARTIN PR, 1992, J BIOL CHEM, V267, P20024; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; MOBLEY HLT, IN PRESS MICROBIOL R; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; PARK IS, 1995, SCIENCE, V267, P1156, DOI 10.1126/science.7855593; PARK IS, 1993, PROTEIN SCI, V2, P1034, DOI 10.1002/pro.5560020616; PARK IS, 1993, J PROTEIN CHEM, V12, P51, DOI 10.1007/BF01024914; Polacco Joseph C., 1993, V145, P65; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; REARDON D, IN PRESS FASEB J; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Sumner JB, 1926, J BIOL CHEM, V69, P435; TAKISHIMA K, 1988, EUR J BIOCHEM, V175, P151, DOI 10.1111/j.1432-1033.1988.tb14177.x; TODD MJ, 1989, J BIOL CHEM, V264, P15835; TODD MJ, 1987, J BIOL CHEM, V262, P5963; TODD MJ, 1991, J BIOL CHEM, V266, P10260; TODD MJ, 1991, J BIOL CHEM, V266, P24327; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WANG S, 1993, INORG CHEM, V33, P1589; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; 1994, ACTA CRYSTALLOGR, V50, P760	60	737	776	6	100	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					998	1004		10.1126/science.7754395	http://dx.doi.org/10.1126/science.7754395			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754395				2022-12-24	WOS:A1995QY93400026
J	FENG, Y; ZHANG, FP; LOKEY, LK; CHASTAIN, JL; LAKKIS, L; EBERHART, D; WARREN, ST				FENG, Y; ZHANG, FP; LOKEY, LK; CHASTAIN, JL; LAKKIS, L; EBERHART, D; WARREN, ST			TRANSLATIONAL SUPPRESSION BY TRINUCLEOTIDE REPEAT EXPANSION AT FMR1	SCIENCE			English	Article							FRAGILE-X-SYNDROME; EUKARYOTIC MESSENGER-RNAS; CGG-REPEAT; SECONDARY STRUCTURE; I LOCUS; INITIATION; INSTABILITY; METHYLATION; PROTEIN; GENE	Fragile X syndrome is the result of the unstable expansion of a trinucleotide repeat in the 5'-untranslated region of the FMR1 gene. Fibroblast subclones from a mildly affected patient, each containing stable FMR1 alleles with 57 to 285 CGG repeats, were shown to exhibit normal steady-state levels of FMR1 messenger RNA. However, FMR protein was markedly diminished from transcript with more than 200 repeats. Such transcripts were associated with stalled 40S ribosomal subunits. These results suggest that a structural RNA transition beyond 200 repeats impedes the linear 40S migration along the 5'-untranslated region. This results in translational inhibition by trinucleotide repeat expansion.	EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Emory University; Howard Hughes Medical Institute; Emory University; Emory University			Warren, Stephen T/A-2498-2012	Feng, Yue/0000-0002-7905-2182	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521, R01HD020521] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BAIRN SB, 1988, MOL CELL BIOL, V8, P1591; BROWN WT, 1993, JAMA-J AM MED ASSOC, V270, P1569, DOI 10.1001/jama.270.13.1569; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; DANOFF A, 1988, J BIOL CHEM, V263, P16461; DEVRIES BBA, 1993, EUR J HUM GENET, V1, P72; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FENG Y, 1995, AM J HUM GENET, V56, P106; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; HAGERMAN R, UNPUB; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HEITZ D, 1992, J MED GENET, V29, P794, DOI 10.1136/jmg.29.11.794; HIRST MC, 1994, HUM MOL GENET, V3, P1553, DOI 10.1093/hmg/3.9.1553; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KNIGHT SJL, 1992, AM J MED GENET, V43, P217, DOI 10.1002/ajmg.1320430135; KOZAK M, 1991, GENE EXPRESSION, V1, P117; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KRUYER H, 1994, AM J HUM GENET, V54, P437; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; MACDONALD ME, 1993, GENOME REARRANGEMENT, V7, pCH2; MCCONKIEROSELL A, 1993, AM J HUM GENET, V53, P800; MERENSTEIN SA, 1994, J AM ACAD CHILD PSY, V33, P1316, DOI 10.1097/00004583-199411000-00014; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; ROUSSEAU F, 1994, AM J HUM GENET, V55, P225; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SNOW K, 1993, AM J HUM GENET, V53, P1217; SNOW K, 1994, HUM MOL GENET, V3, P1543, DOI 10.1093/hmg/3.9.1543; STALEY L, 1993, AM J DIS CHILD, V147, P724; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; Taylor A. K., 1994, American Journal of Human Genetics, V55, pA18; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; WARREN ST, 1995, ANNU REV NEUROSCI, V18, P77, DOI 10.1146/annurev.neuro.18.1.77; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213	43	258	262	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					731	734		10.1126/science.7732383	http://dx.doi.org/10.1126/science.7732383			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732383				2022-12-24	WOS:A1995QW60300052
J	PARSONS, LM; FOX, PT; DOWNS, JH; GLASS, T; HIRSCH, TB; MARTIN, CC; JERABEK, PA; LANCASTER, JL				PARSONS, LM; FOX, PT; DOWNS, JH; GLASS, T; HIRSCH, TB; MARTIN, CC; JERABEK, PA; LANCASTER, JL			USE OF IMPLICIT MOTOR IMAGERY FOR VISUAL SHAPE-DISCRIMINATION AS REVEALED BY PET	NATURE			English	Article							CEREBRAL BLOOD-FLOW; VOLUNTARY MOVEMENTS; CORTEX; BRAIN	POSITRON emission tomography (PET) can be used to map brain regions that are active when a visual object (for example, a hand) is discriminated from its mirror form. Chronometric studies(1-3) suggest that viewers 'solve' this visual shape task by mentally modelling it as a reaching task, implicitly moving their left hand into the orientation of any left-hand stimulus (and conversely for a right-hand stimulus). Here we describe an experiment in which visual and somatic processing are dissociated by presenting right hands to the left visual field and vice versa, Frontal (motor), parietal (somatosensory) and cerebellar (sensorimotor) regions similar to those activated by actual(4,5) and imagined(6-8) movement are strongly activated, whereas primary somatosensory and motor cortices are not, We conclude that mental imagery is realized at intermediate-to-high order, modality-specific cortical systems, but does not require primary cortex and is not constrained to the perceptual systems of the presented stimuli.	UNIV TEXAS, DEPT PSYCHOL, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin	PARSONS, LM (corresponding author), UNIV TEXAS, HLTH SCI CTR, CTR RES IMAGING, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.		Fox, Peter/B-4725-2010; Lancaster, Jack L/F-2994-2010; Galantucci, Bruno/E-5770-2010	Fox, Peter/0000-0002-0465-2028; Parsons, Lawrence/0000-0001-7498-8742				Andersen RA, 1987, HDB PHYSL 1, VV, P483; BIEDERMAN I, 1990, INVITATION COGNITIVE, V2, P41; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; DECETY J, 1994, NATURE, V371, P600, DOI 10.1038/371600a0; DUM RP, 1991, LIFE SCI R, V50, P383; FOX P T, 1987, Society for Neuroscience Abstracts, V13, P1433; FOX PT, 1989, J NUCL MED, V30, P141; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GOLDBERG ME, 1990, J NEUROPHYSIOL, V64, P489, DOI 10.1152/jn.1990.64.2.489; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; Heilman KM., 1993, CLIN NEUROPSYCHOLOGY, P279; Heilman KM., 1993, INT J CLIN NEUROPSYC, V3dr edn, P141; HINTON GE, 1988, COGNITION, V30, P1, DOI 10.1016/0010-0277(88)90002-9; Johnson-Laird PN., 1989, FDN COGNITIVE SCI, P469; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; Marr D., 1982, VISION; PARSONS LM, 1994, J EXP PSYCHOL HUMAN, V20, P709, DOI 10.1037/0096-1523.20.4.709; PARSONS LM, 1987, J EXP PSYCHOL GEN, V116, P172, DOI 10.1037/0096-3445.116.2.172; PARSONS LM, 1987, COGNITIVE PSYCHOL, V19, P178, DOI 10.1016/0010-0285(87)90011-9; PERRETT DI, 1994, CARN S COGN, P33; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.neuro.13.1.25; POSNER MJ, 1994, IMAGES MIND, V30, P90; ROLAND PE, 1982, J NEUROPHYSIOL, V48, P467, DOI 10.1152/jn.1982.48.2.467; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P118, DOI 10.1152/jn.1980.43.1.118; Shepard RN., 1982, J HIST BEHAV SCI, V19, P301, DOI 10.2307/1422825; STEIN JF, 1991, BRAIN SPACE, P185; Talairach J., 1988, COPLANAR STEREOTAXIC; TANJI J, 1994, NEUROSCI RES, V19, P251, DOI 10.1016/0168-0102(94)90038-8; TARR MJ, 1995, PSYCHON B REV, V2, P55, DOI 10.3758/BF03214412; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549	30	522	530	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					54	58		10.1038/375054a0	http://dx.doi.org/10.1038/375054a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723842				2022-12-24	WOS:A1995QW60400053
J	ZHAO, JH; HOGAN, EM; BEVENSEE, MO; BORON, WF				ZHAO, JH; HOGAN, EM; BEVENSEE, MO; BORON, WF			OUT-OF-EQUILIBRIUM CO2/HCO3- SOLUTIONS AND THEIR USE IN CHARACTERIZING A NEW K/HCO3 COTRANSPORTER	NATURE			English	Article							SQUID GIANT-AXONS; INTRACELLULAR-PH; MECHANISM; CELL	IN typical physiological solutions, CO2 is in equilibrium with HCO3- and H+ (CO2 + H2O reversible arrow HCO3- + H+). Because one cannot independently alter CO2 and HCO3- concentrations and pH, it is impossible to distinguish between the effects of CO2 and HCO3- on physiological processes. Here we describe a continuous-flow, rapid-mixing approach for generating out-of-equilibrium CO2/HCO3- solutions with a physiological pH and CO2 (but little HCO3-), or pH and HCO3- (but little CO2). We have exploited these out-of-equilibrium solutions to introduce HCO3- exclusively to either the outside or inside of a squid giant axon, and verify the presence of a new K/HCO3 cotransporter. The out-of-equilibrium approach could be useful in a variety of applications for independently controlling CO2 and HCO3- concentrations and pH.			ZHAO, JH (corresponding author), YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510, USA.		Boron, Walter/ABI-1564-2020	Boron, Walter/0000-0003-4741-7287				AICKIN CC, 1994, J PHYSIOL-LONDON, V479, P301, DOI 10.1113/jphysiol.1994.sp020297; BARO I, 1989, J PHYSIOL-LONDON, V417, pP161; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; BORON WF, 1983, J GEN PHYSIOL, V81, P373, DOI 10.1085/jgp.81.3.373; BRAZEAU P, 1953, AM J PHYSIOL, V175, P33, DOI 10.1152/ajplegacy.1953.175.1.33; BRINLEY FJ, 1967, J GEN PHYSIOL, V50, P2303, DOI 10.1085/jgp.50.10.2303; CABANTCHIK ZI, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; DALZIEL K, 1953, BIOCHEM J, V55, P79, DOI 10.1042/bj0550079; DORMAN PJ, 1954, J CLIN INVEST, V33, P82, DOI 10.1172/JCI102874; Eigen M., 1961, Z PHYS CHEM FRANKFUR, V30, P130; FRANKENHAEUSER B, 1956, J PHYSIOL-LONDON, V131, P341, DOI 10.1113/jphysiol.1956.sp005467; GIBBONS BH, 1963, J BIOL CHEM, V238, P3502; HINKE JAM, 1967, GLASS ELECTRODES HYD, P464; HO C, 1963, J BIOL CHEM, V238, P3499; HOGAN EM, IN PRESS J GEN PHYSL; NATTIE EE, 1995, LUNG BIOL HLTH DIS, V79, P473; POCOCK G, 1992, EUR J NEUROSCI, V4, P136, DOI 10.1111/j.1460-9568.1992.tb00860.x; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROSSIBERNARDI L, 1968, J BIOL CHEM, V243, P1297; ROUGHTON FJW, 1941, J AM CHEM SOC, V63, P29; THOMAS RC, 1976, NATURE, V262, P54, DOI 10.1038/262054a0	22	56	56	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					636	639		10.1038/374636a0	http://dx.doi.org/10.1038/374636a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715702				2022-12-24	WOS:A1995QT18900058
J	HU, QJ; KLIPPEL, A; MUSLIN, AJ; FANTL, WJ; WILLIAMS, LT				HU, QJ; KLIPPEL, A; MUSLIN, AJ; FANTL, WJ; WILLIAMS, LT			RAS-DEPENDENT INDUCTION OF CELLULAR-RESPONSES BY CONSTITUTIVELY ACTIVE PHOSPHATIDYLINOSITOL-3 KINASE	SCIENCE			English	Article							DIFFERENT SIGNALING PATHWAYS; PROTEIN; 3-KINASE; YEAST; DOWNSTREAM; RAPAMYCIN	Phosphatidylinositol (PI)-3 kinase is one of many enzymes stimulated by growth factors. A constitutively activated mutant, p110*, that functions independently of growth factor stimulation was constructed to determine the specific responses regulated by PI-3 kinase. The p110* protein exhibited high specific activity as a PI-3 kinase and as a protein kinase. Expression of p110* in NIH 3T3 cells induced transcription from the fos promoter. Coexpression of dominant negative Ras blocked this response. When expressed in Xenopus laevis oocytes, p110* increased the amount of guanosine 5'-triphosphate-bound Ras, caused activation of the Ras effector Raf-1, and induced Ras-dependent oocyte maturation. These findings show that PI-3 kinase can Stimulate diverse Ras-dependent cellular processes, including oocyte maturation and fos transcription.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [R01 HL32898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FANTL WJ, UNPUB; FISH TM, 1987, MOL CELL BIOL, V7, P3490; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; Hu Q-L, UNPUB; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2685; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MULSIN AJ, UNPUB; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	33	514	529	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					100	102		10.1126/science.7701328	http://dx.doi.org/10.1126/science.7701328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701328				2022-12-24	WOS:A1995QR45400035
J	SCHIPANI, E; KRUSE, K; JUPPNER, H				SCHIPANI, E; KRUSE, K; JUPPNER, H			A CONSTITUTIVELY ACTIVE MUTANT PTH-PTHRP RECEPTOR IN JANSEN-TYPE METAPHYSEAL CHONDRODYSPLASIA	SCIENCE			English	Article							RHODOPSIN; MUTATIONS; GENE	A single heterozygous nucleotide exchange in exon M2 of the gene encoding the parathyroid hormone-parathyroid hormone-related peptide (PTH-PTHrP) receptor was identified in a patient with Jansen-type metaphyseal chondrodysplasia, which changes a strictly conserved histidine residue at position 223 in the receptor's first intracellular loop to arginine. Constitutive, ligand-independent adenosine 3',5'-monophosphate accumulation was observed in COS-7 cells expressing the mutant PTH-PTHrP receptor but not in cells expressing the wild-type receptor. This finding explains the severe ligand-independent hypercalcemia and hypophosphatemia, and most likely the abnormal formation of endochondral bone, in this rare form of short-limbed dwarfism.	MASSACHUSETTS GEN HOSP,DEPT MED,ENDOCRINE UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CHILDRENS SERV,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114; UNIV LUBECK,PADIATRIE KLIN,D-23538 LUBECK,GERMANY	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Lubeck					PHS HHS [R01 46718] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; Broadus Arthur E., 1994, P259; de Haas W H, 1969, J Bone Joint Surg Br, V51, P290; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; Frame B, 1980, PEDIAT DIS RELATED C, P269; GRAM PB, 1959, J BONE JOINT SURG AM, V41, P951, DOI 10.2106/00004623-195941050-00015; HOLT JF, 1969, CLIN DELINEATION BIR, V5, P73; Jansen M, 1934, Z ORTHOP CHIR, V61, P253; Juppner H, 1994, Curr Opin Nephrol Hypertens, V3, P371; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KIKUCHI S, 1976, J BONE JOINT SURG BR, V58, P102, DOI 10.1302/0301-620X.58B1.1270485; KRONENBERG HM, 1993, HDB EXPT PHARM, P185; KRUSE K, 1993, EUR J PEDIATR, V152, P912, DOI 10.1007/BF01957529; LANSKE B, 1994, BONE MINER RES S1, V9, P121; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LEE K, 1994, ENDOCRINOLOGY, V134, P441, DOI 10.1210/en.134.1.441; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; Rao DS, 1979, VITAMIN D BASIC RES, P1173; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCHIPANI E, 1992, P NATL ACAD SCI USA, V89, P2732; SCHIPANI E, IN PRESS J CLIN ENDO; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0	27	493	515	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					98	100		10.1126/science.7701349	http://dx.doi.org/10.1126/science.7701349			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701349				2022-12-24	WOS:A1995QR45400034
J	VERNOS, I; RAATS, J; HIRANO, T; HEASMAN, J; KARSENTI, E; WYLIE, C				VERNOS, I; RAATS, J; HIRANO, T; HEASMAN, J; KARSENTI, E; WYLIE, C			XKLP1, A CHROMOSOMAL XENOPUS KINESIN-LIKE PROTEIN ESSENTIAL FOR SPINDLE ORGANIZATION AND CHROMOSOME POSITIONING	CELL			English	Article							OOCYTES; SEQUENCE; INVITRO; MICROTUBULES; CYTOKERATIN; DROSOPHILA; INDUCTION; EXTRACTS; EMBRYOS; CYCLE	Xklp1 is a novel Xenopus kinesin-like protein with a motor domain at the amino terminus, nuclear localisation sequences in the stalk, and a putative zinc fingerlike sequence in the tail. It is nuclear during interphase and chromosomal during mitosis. During late anaphase, a fraction of the protein relocalizes to the spindle interzone and accumulates in the midbody during telophase. Depletion of Xklp1 protein by antisense oligo knockout in oocytes leads to defective mitosis during the first cell cycles following fertilization. The bipolarity of spindles assembled in vitro in the presence of anti-Xklp1 antibodies is unstable, and the chromosomes fail to congress on the metaphase plate.	EUROPEAN MOLEC BIOL LAB,CELL BIOPHYS PROGRAMME,D-69117 HEIDELBERG,GERMANY; UNIV MINNESOTA,SCH MED,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT PEDIAT,MINNEAPOLIS,MN 55455; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; WELLCOME CANC RES CAMPAIGN INST,CAMBRIDGE CB2 1QR,ENGLAND	European Molecular Biology Laboratory (EMBL); University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Francisco	VERNOS, I (corresponding author), EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Hirano, Tatsuya/F-6008-2011; Vernos, Isabelle/C-1687-2015	Hirano, Tatsuya/0000-0002-4219-6473; Vernos, Isabelle/0000-0003-1469-9214	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; BLOOM GS, 1995, PROTEIN PROFILE, V1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FEINBERG AP, 1983, ANAL BIOCHEM, V137, P266; FRANZ JK, 1986, P NATL ACAD SCI USA, V83, P6475, DOI 10.1073/pnas.83.17.6475; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GORBSKY GJ, 1992, BIOESSAYS, V14, P73, DOI 10.1002/bies.950140202; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HARLOW E, 1988, ANTIBODIES LABORATOR; HEASMAN J, 1994, DEVELOPMENT, V120, P49; HEASMAN J, 1991, METHOD CELL BIOL, V36, P213; HEASMAN J, 1992, DEV S, V116, P119; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAZIA D, 1987, INT REV CYTOL, V100, P49; MILLER L, 1977, IN VITRO CELL DEV B, V13, P557; MURRAY AW, 1991, METHOD CELL BIOL, V36, P573; NICKLAS RB, 1985, J CELL BIOL, V100, P1, DOI 10.1083/jcb.100.1.1; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pereira Andrea, 1994, V13, P269; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; ROSENFELD R, 1993, J BIOMOL STRUCT DYN, V11, P557, DOI 10.1080/07391102.1993.10508015; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; STELZER EHK, 1989, P SOC PHOTOOPT INSTR, V1028, P146; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; TORPEY N, 1992, NATURE, V357, P413, DOI 10.1038/357413a0; TORPEY NP, 1990, DEVELOPMENT, V110, P1185; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; VERNOS I, 1993, DEV BIOL, V157, P232, DOI 10.1006/dbio.1993.1127; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	42	209	212	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					117	127		10.1016/0092-8674(95)90376-3	http://dx.doi.org/10.1016/0092-8674(95)90376-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720067	Bronze			2022-12-24	WOS:A1995QR97000013
J	DONAHUE, TM				DONAHUE, TM			EVOLUTION OF WATER RESERVOIRS ON MARS FROM D/H RATIOS IN THE ATMOSPHERE AND CRUST	NATURE			English	Article							MARTIAN ATMOSPHERE; ESCAPE; ABUNDANCE; HYDROGEN; HDO	ANCIENT fluvial networks on the surface of Mars suggest that it was warm and wet over three billion years ago. Surface features resembling massive outflow channels provide evidence that, even more recently, the martian crust contained the equivalent of a planet-wide reservoir of water several hundred metres deep(1,2). But arguments based on the isotopic fractionation(3,4) and present-day escape rate of hydrogen in the martian atmosphere require only 0.5 metres of crustal water today and about six metres in the past(5). An additional constraint on the evolution of the isotopic composition of martian water has recently been obtained(6) from measurements of the deuterium to hydrogen ratio of hydrous minerals in the SNC meteorites-meteorites that almost certainly originated on Mars. Here I show that these new data require that the modern crustal reservoirs of martian water must be quite large, at least several metres in global-equivalent depth. The deuterium enrichment of the present martian atmosphere then implies that the reservoir of crustal water on ancient Mars was several hundred metres deep, consistent with the geological evidence(3,4).			DONAHUE, TM (corresponding author), UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109, USA.							ATREYA SK, 1994, J GEOPHYS RES-PLANET, V99, P13133, DOI 10.1029/94JE01085; Bjoraker G. L., 1989, B AM ASTRON SOC, V21, P990; CARR MH, 1987, NATURE, V326, P30, DOI 10.1038/326030a0; CARR MH, 1990, ICARUS, V87, P210, DOI 10.1016/0019-1035(90)90031-4; CARR MH, 1979, J GEOPHYS RES, V84, P2995, DOI 10.1029/JB084iB06p02995; FOX JL, 1993, GEOPHYS RES LETT, V20, P1747, DOI 10.1029/93GL01118; HUNTEN DM, 1973, J ATMOS SCI, V30, P1481, DOI 10.1175/1520-0469(1973)030<1481:TEOLGF>2.0.CO;2; HUNTEN DM, 1973, J ATMOS SCI, V30, P736; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JAKOSKY BM, 1990, J GEOPHYS RES-SOLID, V95, P1475, DOI 10.1029/JB095iB02p01475; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; KRASNOPOLSKY VA, 1993, ICARUS, V101, P33, DOI 10.1006/icar.1993.1003; LIU SC, 1976, ICARUS, V28, P231, DOI 10.1016/0019-1035(76)90035-X; LUHMANN JG, 1992, GEOPHYS RES LETT, V19, P2151, DOI 10.1029/92GL02485; MCELROY MB, 1972, SCIENCE, V177, P986, DOI 10.1126/science.177.4053.986; NAIR H, 1994, ICARUS, V111, P124, DOI 10.1006/icar.1994.1137; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; YUNG YL, 1988, ICARUS, V76, P146, DOI 10.1016/0019-1035(88)90147-9	19	52	52	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					432	434		10.1038/374432a0	http://dx.doi.org/10.1038/374432a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700352	Green Submitted			2022-12-24	WOS:A1995QP89900051
J	BROWN, NL; SATTLER, CA; PADDOCK, SW; CARROLL, SB				BROWN, NL; SATTLER, CA; PADDOCK, SW; CARROLL, SB			HAIRY AND EMC NEGATIVELY REGULATE MORPHOGENETIC FURROW PROGRESSION IN THE DROSOPHILA EYE	CELL			English	Article							POLARITY GENE HEDGEHOG; CELL-INTERACTIONS; PATTERN-FORMATION; NERVOUS-SYSTEM; PRONEURAL GENE; ACHAETE; EXTRAMACROCHAETAE; DIFFERENTIATION; EXPRESSION; RETINA	The initial steps of pattern formation in the developing Drosophila eye involve the coordination of cell cycles, changes in cell shape, and the specification of the R8 photoreceptor cell. These events begin several cell rows ahead of the morphogenetic furrow and are positively regulated by secreted signaling proteins and the proneural HLH transcription factor atonal (ate). Two HLH regulatory proteins that function to suppress neuronal development in other tissues, extra macrochaetae (emc) and hairy (h), are expressed ahead of the morphogenetic furrow. While neither h nor emc is required for photoreceptor cell determination, in emc-h-clones the morphogenetic furrow and differentiated eye field advance up to eight ommatidial rows ahead of adjacent wild-type tissue. This indicates that morphogenetic furrow progression and neuronal differentiation are negatively regulated by a combination of anteriorly expressed HLH regulatory proteins.	UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706; UNIV WISCONSIN,BOCK LABS,MADISON,WI 53706; UNIV WISCONSIN,MCARDLE LAB,MADISON,WI 53706	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			, Nadean/HCH-9314-2022		NCI NIH HHS [CA-07175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BLAIR S, 1992, DEVELOPMENT, V119, P339; BODENSTEIN D, 1953, INSECT PHYSL, P822; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BROWN NL, 1991, DEVELOPMENT, V113, P1245; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CARROLL SB, 1989, GENE DEV, V3, P905, DOI 10.1101/gad.3.6.905; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; CUBAS P, 1992, EMBO J, V11, P3385, DOI 10.1002/j.1460-2075.1992.tb05417.x; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P246; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; ELLIS HM, 1994, MECH DEVELOP, V47, P65, DOI 10.1016/0925-4773(94)90096-5; GARCIAALONSO L, 1988, ROUX ARCH DEV BIOL, V197, P328; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; NOWEL MS, 1980, J EMBRYOL EXP MORPH, V60, P329; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; ORENIC TV, 1993, DEVELOPMENT, V118, P9; PADDOCK SW, 1993, BIOTECHNIQUES, V1, P442; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; SHELTON PMJ, 1974, J EMBRYOL EXP MORPH, V32, P337; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; WHITE RH, 1963, J EXP ZOOL, V148, P223; WOLFF T, 1991, DEVELOPMENT, V113, P841; Wolff Tanya, 1993, P1277; XU T, 1993, DEVELOPMENT, V117, P1223; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	43	121	122	1	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					879	887		10.1016/0092-8674(95)90291-0	http://dx.doi.org/10.1016/0092-8674(95)90291-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697718	Bronze			2022-12-24	WOS:A1995QP61200007
J	SHAW, AD; SJOLIN, SU; MCQUEEN, MM				SHAW, AD; SJOLIN, SU; MCQUEEN, MM			LESSON OF THE WEEK - CRUSH SYNDROME FOLLOWING UNCONSCIOUSNESS - NEED FOR URGENT ORTHOPEDIC REFERRAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE-RENAL-FAILURE; TRAUMATIC RHABDOMYOLYSIS; LIMB COMPRESSION		ROYAL INFIRM, ORTHOPAED TRAUMA UNIT, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh								BETTER OS, 1990, NEW ENGL J MED, V322, P825; Bywaters EGL, 1941, BRIT MED J, V1941, P427, DOI 10.1136/bmj.1.4185.427; HEPPENSTALL RB, 1988, CLIN ORTHOP RELAT R, V226, P138; KIKTA MJ, 1987, ARCH SURG-CHICAGO, V122, P1078; MATSEN FA, 1975, CLIN ORTHOP RELAT R, P8, DOI 10.1097/00003086-197511000-00003; MUBARAK S, 1975, CLIN ORTHOP RELAT R, P81, DOI 10.1097/00003086-197511000-00012; OWEN CA, 1979, NEW ENGL J MED, V300, P1169, DOI 10.1056/NEJM197905243002101; RON D, 1984, ARCH INTERN MED, V144, P277, DOI 10.1001/archinte.144.2.277; RORABECK CH, 1981, J TRAUMA, V21, P446; [No title captured]	10	32	33	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	1994	309	6958					857	859		10.1136/bmj.309.6958.857	http://dx.doi.org/10.1136/bmj.309.6958.857			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7695702	Green Published			2022-12-24	WOS:A1994PK50100028
J	TABCHARANI, JA; ROMMENS, JM; HOU, YX; CHANG, XB; TSUI, LC; RIORDAN, JR; HANRAHAN, JW				TABCHARANI, JA; ROMMENS, JM; HOU, YX; CHANG, XB; TSUI, LC; RIORDAN, JR; HANRAHAN, JW			MULTIION PORE BEHAVIOR IN THE CFTR CHLORIDE CHANNEL	NATURE			English	Article							CYSTIC-FIBROSIS GENE; CALCIUM CHANNELS; CONDUCTANCE; CELLS; SELECTIVITY; MUTAGENESIS; EXPRESSION; INVITRO	CYSTIC fibrosis transmembrane conductance regulator (CFTR) is a non-rectifying, low-conductance channel1,2 regulated by ATP3 and phosphorylation, which mediates apical chloride conductance in secretory epithelia5,6 and malfunctions in cystic fibrosis (CF)7,8. Mutations at Lys 335 and Arg 347 in the sixth predicted transmembrane helix of CFTR alter its halide selectivity in whole-cell studies9 and its single channel conductance10, but the physical basis of these alterations is unknown and permeation in CFTR is poorly understood. Here we present evidence that wild-type CFTR can contain more than one anion simultaneously. The conductance of CFTR passes through a minimum when channels are bathed in mixtures of two permeant anions. This anomalous mole fraction effect can be abolished by replacing Arg 347 with an aspartate and can be toggled on or off by varying the pH after the same residue is replaced with a histidine. Thus the CFTR channel should provide a convenient model in which to study multi-ion pore behaviour and conduction. The loss of multiple occupancy may explain how naturally occurring CF mutations at this site cause disease.	MCGILL UNIV,DEPT PHYSIOL,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM & CLIN BIOCHEM,TORONTO M5S 1A1,ONTARIO,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA	McGill University; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Hanrahan, John/AGG-1926-2022; Tsui, Lap-chee/A-1081-2010	Hanrahan, John/0000-0001-9080-2039; 				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AUDREZET MP, 1993, HUM MOL GENET, V2, P51, DOI 10.1093/hmg/2.1.51; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CHANG XB, 1993, J BIOL CHEM, V268, P11304; Cremonesi Laura, 1992, Human Mutation, V1, P314, DOI 10.1002/humu.1380010409; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hille B., 1992, IONIC CHANNELS EXCIT; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1989, J MEMBRANE BIOL, V112, P109, DOI 10.1007/BF01871272; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	21	209	209	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					79	82		10.1038/366079a0	http://dx.doi.org/10.1038/366079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	7694154				2022-12-24	WOS:A1993MF00700059
J	CASANO, AA				CASANO, AA			REIMBURSEMENT OVER THE ATLANTIC	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											CASANO, AA (corresponding author), ALBANY MED CTR, A38, 47 NEW SCOTLAND AVE, ALBANY, NY 12208 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					957	958		10.7326/0003-4819-122-12-199506150-00012	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755234				2022-12-24	WOS:A1995RC27000012
J	LIU, X; ERNFORS, P; WU, H; JAENISCH, R				LIU, X; ERNFORS, P; WU, H; JAENISCH, R			SENSORY BUT NOT MOTOR-NEURON DEFICITS IN MICE LACKING NT4 AND BDNF	NATURE			English	Article							TYROSINE PROTEIN-KINASE; NEUROTROPHIC FACTOR; RECEPTOR; TRKB; SURVIVAL	NEUROTROPHINS play important roles in neuronal survival during vertebrate development(1-3). Neurotrophin-4 (NT4), alone or in combination with brain-derived neurotrophic factor (BDNF), has been suggested to be necessary for the survival of peripheral sensory neurons and central nervous system (CNS) neurons, including motor neurons(4-16). To define the role of NT4 in vivo, we generated mice lacking NT4 by gene targeting. NT4-deficient mice were viable but exhibited a loss of sensory neurons in the nodose-petrosal and geniculate ganglia. In contrast, motor neurons of the facial nucleus and sympathetic neurons of the superior cervical ganglion were unaffected, and there was no obvious loss of dopaminergic neurons in the substantia nigra. In mice lacking both NT4 and BDNF14,15, facial motor neurons remained unaffected, whereas the loss of sensory neurons was more severe than with either mutation alone. Thus NT4 is required during development for the survival of some peripheral sensory neurons but not sympathetic or motor neurons.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	LIU, X (corresponding author), MIT,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.			Ernfors, Patrik/0000-0002-1140-3986				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; DAVIES AM, 1993, J NEUROSCI, V13, P4961; DICICCOBLOOM E, 1993, NEURON, V11, P1101, DOI 10.1016/0896-6273(93)90223-E; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; FISCHER W, 1994, P NATL ACAD SCI USA, V91, P8607, DOI 10.1073/pnas.91.18.8607; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HYMAN C, 1994, J NEUROSCI, V14, P335; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; IP NY, 1994, ANN NEUROL, V35, pS13, DOI 10.1002/ana.410350706; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0	29	317	320	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					238	241		10.1038/375238a0	http://dx.doi.org/10.1038/375238a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746325				2022-12-24	WOS:A1995QY88100064
J	SRIDHAR, MK				SRIDHAR, MK			WHY DO PATIENTS WITH EMPHYSEMA LOSE WEIGHT	LANCET			English	Editorial Material							OBSTRUCTIVE PULMONARY-DISEASE; TUMOR-NECROSIS-FACTOR; MALNOURISHED PATIENTS		UNIV GLASGOW,DEPT HUMAN NUTR,GLASGOW G61 1BD,LANARK,SCOTLAND	University of Glasgow	SRIDHAR, MK (corresponding author), UNIV GLASGOW,DEPT RESP MED,GLASGOW G61 1BD,LANARK,SCOTLAND.							BAIN M, 1994, EUR RESPIR J, V7, P248; DEGODY I, 1994, AM J RESP CRIT CARE, V149, P1017; DIFRANCIA M, 1994, AM J RESP CRIT CARE, V150, P1453, DOI 10.1164/ajrccm.150.5.7952575; DONAHOE M, 1989, AM REV RESPIR DIS, V140, P385, DOI 10.1164/ajrccm/140.2.385; ELBORN JS, 1993, CLIN SCI, V85, P563, DOI 10.1042/cs0850563; ENGELEN MPKJ, 1994, EUR RESPIR J, V7, P1793, DOI 10.1183/09031936.94.07101793; FILLEY GF, 1968, AM J MED, V44, P26, DOI 10.1016/0002-9343(68)90234-9; FOWLER J, 1898, DISEASES LUNGS, P171; GREEN JH, 1992, CLIN SCI, V83, P109, DOI 10.1042/cs0830109; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P467; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; ROGERS RM, 1992, AM REV RESPIR DIS, V146, P1511, DOI 10.1164/ajrccm/146.6.1511; WILSON DO, 1989, AM REV RESPIR DIS, V139, P1435, DOI 10.1164/ajrccm/139.6.1435	13	29	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1190	1191		10.1016/S0140-6736(95)91984-8	http://dx.doi.org/10.1016/S0140-6736(95)91984-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739302				2022-12-24	WOS:A1995QX86100002
J	TRAYNELIS, SF; HARTLEY, M; HEINEMANN, SF				TRAYNELIS, SF; HARTLEY, M; HEINEMANN, SF			CONTROL OF PROTON SENSITIVITY OF THE NMDA RECEPTOR BY RNA SPLICING AND POLYAMINES	SCIENCE			English	Article							D-ASPARTATE RECEPTOR; EXCITATORY AMINO-ACIDS; PROTEIN-KINASE-C; HIPPOCAMPAL-NEURONS; SECONDARY-STRUCTURE; GLUCOSE DEPRIVATION; INDUCED CURRENTS; SINGLE-CHANNEL; RAT; GLUTAMATE	The function of the N-methyl-D-aspartate (NMDA)-preferring glutamate receptor can be regulated by extracellular pH, a process that may be important during ischemia in the brain or during seizures. Protons inhibit NMDA receptor function by 50 percent at pH 7.3 through interactions with the NR1 subunit, and both polyamines and NR1 exon 5 potentiate receptor function through relief of the tonic proton inhibition present at physiological pH. A single amino acid (lysine 211) was identified that mediates the effects of exon 5 in the rat brain. Electroneutral substitutions at this position restored pH sensitivity and, consequently, polyamine relief of tonic inhibition. This effect, together with the structural similarities between polyamines and the surface loop encoded by exon 5, suggest that exon 5 may act as a tethered pH-sensitive constitutive modulator of NMDA receptor function.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037	Salk Institute	TRAYNELIS, SF (corresponding author), EMORY UNIV,DEPT PHARMACOL,ATLANTA,GA 30322, USA.				NINDS NIH HHS [NS08549, NS28709] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028709] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANANTHARAM V, 1992, FEBS LETT, V305, P27, DOI 10.1016/0014-5793(92)80648-Z; ARANEDA RC, 1993, NEUROSCI LETT, V152, P107, DOI 10.1016/0304-3940(93)90495-7; BALESTRINO M, 1988, J PHYSIOL-LONDON, V396, P247, DOI 10.1113/jphysiol.1988.sp016961; BATES RG, 1978, ANAL CHEM, V50, P1295, DOI 10.1021/ac50031a026; BENVENISTE M, 1993, J PHYSIOL-LONDON, V464, P131, DOI 10.1113/jphysiol.1993.sp019627; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHRISTENSEN BN, 1990, NEURON, V5, P471, DOI 10.1016/0896-6273(90)90086-U; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; DINGLEDINE R, 1990, TRENDS PHARMACOL SCI, V11, P334, DOI 10.1016/0165-6147(90)90238-4; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; HIRSCHMAN SZ, 1967, BIOPOLYMERS, V5, P227, DOI 10.1002/bip.1967.360050209; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISHII T, 1993, J BIOL CHEM, V268, P2836; KAKU DA, 1993, SCIENCE, V260, P1516, DOI 10.1126/science.8389056; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MELDRUM BS, 1992, EPILEPSY RES, V12, P189, DOI 10.1016/0920-1211(92)90040-Z; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; OBRENOVITCH TP, 1990, J NEUROPHYSIOL, V64, P1125, DOI 10.1152/jn.1990.64.4.1125; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; REYNOLDS IJ, 1990, J PHARMACOL EXP THER, V255, P1001; ROCK DM, 1992, MOL PHARMACOL, V41, P83; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SIESJO BK, 1985, PROG BRAIN RES, V63, P121; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STANDAERT DG, 1993, NEUROSCI LETT, V152, P161, DOI 10.1016/0304-3940(93)90508-I; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; TEMPLETON DM, 1985, CAN J CHEM, V63, P3122, DOI 10.1139/v85-515; TOMBAUGH GC, 1993, J NEUROCHEM, V61, P793, DOI 10.1111/j.1471-4159.1993.tb03589.x; TOMBAUGH GC, 1990, BRAIN RES, V506, P343, DOI 10.1016/0006-8993(90)91277-N; TRAYNELIS SF, 1991, J PHYSIOL-LONDON, V433, P727, DOI 10.1113/jphysiol.1991.sp018453; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; VYKLICKY L, 1990, J PHYSIOL-LONDON, V430, P497, DOI 10.1113/jphysiol.1990.sp018304; WILLIAMS K, 1994, MOL PHARMACOL, V46, P161; WILLIAMS K, 1990, NEURON, V5, P199, DOI 10.1016/0896-6273(90)90309-4; ZHANG L, 1994, P NATL ACAD SCI USA, V91, P10883, DOI 10.1073/pnas.91.23.10883; ZHENG X, 1994, NEURON, V12, P1	54	332	342	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					873	876		10.1126/science.7754371	http://dx.doi.org/10.1126/science.7754371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754371				2022-12-24	WOS:A1995QX85000038
J	TOWNEND, JN; LITTLER, WA				TOWNEND, JN; LITTLER, WA			CARDIAC VAGAL ACTIVITY - A TARGET FOR INTERVENTION IN HEART-DISEASE	LANCET			English	Editorial Material							CONVERTING ENZYME-INHIBITION; ACUTE MYOCARDIAL-INFARCTION; FAILURE; HYDRALAZINE; MORTALITY; TRIAL; TONE				TOWNEND, JN (corresponding author), UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT CARDIOVASC MED,BIRMINGHAM,W MIDLANDS,ENGLAND.			Townend, Jonathan/0000-0002-5881-5806				ABLAD B, 1991, J AM COLL CARDIOL, V17, pA1545; BINKLEY PF, 1993, J AM COLL CARDIOL, V21, P655, DOI 10.1016/0735-1097(93)90098-L; BONADUCE D, 1994, CIRCULATION, V90, P108, DOI 10.1161/01.CIR.90.1.108; CASADEI B, 1993, CIRCULATION, V88, P353, DOI 10.1161/01.CIR.88.2.353; COATS AJS, 1992, CIRCULATION, V85, P2119, DOI 10.1161/01.CIR.85.6.2119; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; ECKBERG DL, 1971, NEW ENGL J MED, V285, P877, DOI 10.1056/NEJM197110142851602; FARRELL TG, 1992, BRIT HEART J, V67, P129; FONAROW GC, 1992, J AM COLL CARDIOL, V19, P842, DOI 10.1016/0735-1097(92)90529-V; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LAROVERE MT, 1994, CIRCULATION, V90, P838, DOI 10.1161/01.CIR.90.2.838; LUMBERS ER, 1979, J PHYSIOL-LONDON, V294, P69, DOI 10.1113/jphysiol.1979.sp012915; MALLIANI A, 1994, BRIT HEART J, V71, P1; TOWNEND JN, IN PRESS HYPERTENSIO; WILKSTRAND J, 1992, EUR HEART J SD, V113, P111; ZUANETTI G, 1987, CIRC RES, V61, P429, DOI 10.1161/01.RES.61.3.429	16	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					937	938		10.1016/S0140-6736(95)90694-0	http://dx.doi.org/10.1016/S0140-6736(95)90694-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715289				2022-12-24	WOS:A1995QT91900004
J	GILLMAN, MW; CUPPLES, LA; GAGNON, D; POSNER, BM; ELLISON, RC; CASTELLI, WP; WOLF, PA				GILLMAN, MW; CUPPLES, LA; GAGNON, D; POSNER, BM; ELLISON, RC; CASTELLI, WP; WOLF, PA			PROTECTIVE EFFECT OF FRUITS AND VEGETABLES ON DEVELOPMENT OF STROKE IN MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SPONTANEOUSLY HYPERTENSIVE RATS; BLOOD-PRESSURE; PLASMA HOMOCYST(E)INE; JAPANESE MEN; CARDIOVASCULAR MORTALITY; RISK-FACTORS; DIETARY; CONSUMPTION; ALCOHOL	Objective.-To examine the effect of fruit and vegetable intake on risk of stroke among middle-aged men over 20 years of follow-up. Design.-Cohort. Setting.-The Framingham Study, a population-based longitudinal study. Participants.-All 832 men, aged 45 through 65 years, who were free of cardiovascular disease at baseline (1966 through 1969). Measurements and Data Analysis.-The diet of each subject was assessed at baseline by a single 24-hour recall. The estimated total number of servings per day of fruits and vegetables was the exposure variable for this analysis. Using Kaplan-Meier survival analysis, we examined age-adjusted cumulative incidence of stroke by quintile of servings per day. To adjust for multiple covariates, we used proportional hazards regression to calculate the relative risk (RR) of stroke for each increment of three servings per day. Main Outcome Measure.-Incidence of completed strokes and transient ischemic attacks. Results.-At baseline, the mean (+/-SD) number of fruit and vegetable servings per day was 5.1 (+/-2.8). During follow-up there were 97 incident strokes, including 73 completed strokes and 24 transient ischemic attacks. Age-adjusted risk of stroke decreased across increasing quintile of servings per day (log rank P for trend, .01). Age-adjusted RR for all stroke, including transient ischemic attack, was 0.78 (95% confidence interval [CI], 0.62 to 0.98) for each increase of three servings per day. For completed stroke the RR was 0.74 (95% CI, 0.57 to 0.96); for completed stroke of ischemic origin the RR was 0.76 (95% CI, 0.57 to 1.02); and for completed stroke of hemorrhagic origin, 0.49 (95% CI, 0.25 to 0.95). Adjustment for body mass index, cigarette smoking, glucose intolerance, physical activity, blood pressure, serum cholesterol, and intake of energy, ethanol, and fat did not materially change the results. Conclusion.Intake of fruits and vegetables may protect against development of stroke in men.	HARVARD UNIV,COMMUNITY HLTH PLAN,BOSTON,MA 02215; BOSTON UNIV,SCH PUBL HLTH,BOSTON,MA; BOSTON UNIV,SCH MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,EVANS DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02118; FRAMINGHAM HEART DIS EPIDEMIOL STUDY,FRAMINGHAM,MA	Harvard University; Boston University; Boston University; Boston University; Boston University; Framingham Heart Study	GILLMAN, MW (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,126 BROOKLINE AVE,SUITE 200,BOSTON,MA 02215, USA.			Ellison, Robert Curtis/0000-0002-0582-7467; Gagnon, David/0000-0002-6367-3179; Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL048236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01 HC 38038, R29 HL 48236] Funding Source: Medline; NINDS NIH HHS [R01 NS 17950] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELL LL, 1952, J BIOL CHEM, V195, P357; ACHESON RM, 1983, LANCET, V1, P1191; ATKINS D, 1993, ANN INTERN MED, V119, P136, DOI 10.7326/0003-4819-119-2-199307150-00008; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; BRATTSTROM L, 1992, NEUROL RES, V14, P81, DOI 10.1080/01616412.1992.11740017; COULL BM, 1990, STROKE, V21, P572, DOI 10.1161/01.STR.21.4.572; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; GARCIAPALMIERI MR, 1980, AM J CLIN NUTR, V33, P1818, DOI 10.1093/ajcn/33.8.1818; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GORDON T, 1981, CIRCULATION, V63, P500, DOI 10.1161/01.CIR.63.3.500; IKEDA K, 1987, J NUTR SCI VITAMINOL, V33, P31, DOI 10.3177/jnsv.33.31; KAGAN A, 1985, STROKE, V16, P390, DOI 10.1161/01.STR.16.3.390; KANNEL WB, 1987, AM HEART J, V113, P1489, DOI 10.1016/0002-8703(87)90666-1; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; Klag M J, 1993, Ann Epidemiol, V3, P571; KLATSKY AL, 1987, J AM COLL CARDIOL, V9, P78; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LEE CN, 1988, NEW ENGL J MED, V318, P995; MANN GV, 1962, AM J CLIN NUTR, V11, P200, DOI 10.1093/ajcn/11.3.200; MANSON JE, 1993, J AM COLL NUTR, V12, P426, DOI 10.1080/07315724.1993.10718332; MANSON JE, 1994, CIRCULATION, V89, P932; MANSON JE, 1993, CIRCULATION, V87, P678; MARMOT MG, 1992, LANCET, V339, P344, DOI 10.1016/0140-6736(92)91659-V; MCGEE D, 1985, INT J EPIDEMIOL, V14, P97, DOI 10.1093/ije/14.1.97; OMURA T, 1987, SOC SCI MED, V24, P401, DOI 10.1016/0277-9536(87)90212-7; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; ROUSE IL, 1983, LANCET, V1, P5; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SACKS FM, 1988, AM J CLIN NUTR, V48, P795, DOI 10.1093/ajcn/48.3.795; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; SWAIN JF, 1990, NEW ENGL J MED, V322, P147, DOI 10.1056/NEJM199001183220302; SYME SL, 1975, AM J EPIDEMIOL, V102, P477, DOI 10.1093/oxfordjournals.aje.a112185; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TILLOTSON JL, 1973, AM J CLIN NUTR, V26, P177, DOI 10.1093/ajcn/26.2.177; TOBIAN L, 1986, J HYPERTENS        S, V5, pS205; VERLANGIERI AJ, 1985, MED HYPOTHESES, V16, P7, DOI 10.1016/0306-9877(85)90035-0; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; WOLF PA, 1986, NEW ENGL J MED, V315, P1087, DOI 10.1056/NEJM198610233151709; YAMORI Y, 1984, HYPERTENSION, V6, P49, DOI 10.1161/01.HYP.6.1.49; 1994, HEART STROKE FACTS 1; 1991, HLTH PEOPLE 2000 NAT; 1989, RECOMMENDED DIETARY	47	368	376	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1113	1117		10.1001/jama.273.14.1113	http://dx.doi.org/10.1001/jama.273.14.1113			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707599				2022-12-24	WOS:A1995QR05900030
J	STRYKER, J; COATES, TJ; DECARLO, P; HAYNESSANSTAD, K; SHRIVER, M; MAKADON, HJ				STRYKER, J; COATES, TJ; DECARLO, P; HAYNESSANSTAD, K; SHRIVER, M; MAKADON, HJ			PREVENTION OF HIV-INFECTION - LOOKING BACK, LOOKING AHEAD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIDS; BEHAVIORS; IMPACT	For some, the occurrence of as many as 40 000 new human immunodeficiency virus (HIV) infections in the United States each year is evidence that HIV education and prevention efforts have failed. To the contrary, more than a decade of experience with HIV has demonstrated that lasting changes in behavior needed to avoid infection can occur as a result of carefully tailored, targeted, credible, and persistent HIV risk-reduction efforts. Given experience in other health behavior change endeavors, no interventions are likely to reduce the incidence of HIV infection to zero; indeed, insisting on too high a standard for HIV risk-reduction programs may actually undermine their effectiveness. A number of social, cultural, and attitudinal barriers continue to thwart the implementation of promising HIV risk-reduction programs. The remote prospects for a successful prophylactic vaccine for HIV and the difficulty in finding effective drug treatments have underscored the importance of sustained attention to HIV prevention and education. A series of ''correlates of immunity'' are identified-precedents that must exist to establish effective HIV prevention programs. These include sound policies promoting HIV risk reduction; access to health and social services, condoms, needles, and syringes; interventions shown to motivate behavioral change; organizations capable of reaching those at risk; and development and diffusion of technologies to interrupt the spread of the virus.	MOBILIZAT AGAINST AIDS,SAN FRANCISCO,CA; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV GEN MED & PRIMARY CARE,BOSTON,MA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	STRYKER, J (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,CTR AIDS PREVENT STUDIES,74 NEW MONTGOMERY,SUITE 600,SAN FRANCISCO,CA 94105, USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; BAYER R, 1994, AM J PUBLIC HEALTH, V84, P895, DOI 10.2105/AJPH.84.6.895; BURRIS S, 1993, AIDS LAW TODAY NEW G; CATANIA JA, 1993, SCIENCE, V258, P1101; CATES W, 1992, NEW ENGL J MED, V327, P492, DOI 10.1056/NEJM199208133270711; CHOI KH, 1994, NEW ENGL J MED, V331, P406, DOI 10.1056/NEJM199408113310619; CHOI KH, 1994, AIDS, V8, P1371, DOI 10.1097/00002030-199410000-00003; COHEN J, 1993, SCIENCE, V259, P1112, DOI 10.1126/science.8438161; EKSTRAND ML, 1990, AM J PUBLIC HEALTH, V80, P973, DOI 10.2105/AJPH.80.8.973; FERREROS C, 1990, 6TH INT C AIDS SAN F; FIFE D, 1992, J ACQ IMMUN DEF SYND, V6, P1111; FISHBEIN M, 1993, J APPL SOC PSYCHOL, V23, P687, DOI 10.1111/j.1559-1816.1993.tb01110.x; GERBERT B, 1990, AM J PUBLIC HEALTH, V80, P467, DOI 10.2105/AJPH.80.4.467; Gorman M, 1989, Med Anthropol, V10, P159; HAHN RA, 1991, SOC SCI MED, V33, P1, DOI 10.1016/0277-9536(91)90444-H; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; JARLAIS DCD, 1992, ANN AM ACAD POLIT SS, V521, P42; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; KAPLAN EH, 1989, EVALUATION REV, V13, P107, DOI 10.1177/0193841X8901300201; KEGELES SM, IN PRESS AM J PUBLIC; KELLY JA, 1993, AM PSYCHOL, V48, P1023, DOI 10.1037/0003-066X.48.10.1023; KIRBY D, 1994, PUBLIC HEALTH REP, V109, P339; LIFSON AR, 1994, LANCET, V343, P1306, DOI 10.1016/S0140-6736(94)92462-7; Lurie P, 1993, PUBLIC HLTH IMPACT N; MASCOLA JR, 1994, JAMA-J AM MED ASSOC, V272, P488, DOI 10.1001/jama.272.6.488; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MERSON M, 1994, 10TH INT C AIDS YOK; MOATTI JP, 1992, HEALTH POLICY, V21, P233, DOI 10.1016/0168-8510(92)90021-3; Perrow Charles, 1990, AIDS DISASTER FAILUR; PHILIPSON TJ, 1994, ISSUES SCI TECHNOL, V10, P33; RABIN SA, 1994, PUBLIC HLTH REP, V195, P42; RAMAH M, 1992, IDS PREVENTION ED WO; ROSENBERG PS, 1994, NEW ENGL J MED, V330, P789, DOI 10.1056/NEJM199403173301114; SHRIVER M, 1994, 5 CORRELATES IMMUNIT; STALL R, 1994, BRIT MED J, V309, P685, DOI 10.1136/bmj.309.6956.685; STEVENSON HC, 1994, AIDS EDUC PREV, V6, P126; STRYKER J, 1994, AM J PUBLIC HEALTH, V84, P1901, DOI 10.2105/AJPH.84.12.1901; WASSERFALLEN F, 1993, 9TH INT C AIDS BERL; WIEBEL W, 1993, 9 INT C AIDS BERL; 1990, MMWR-MORBID MORTAL W, V39, P1; 1995, MMWR-MORBID MORTAL W, V44, P64; 1994, NEW HLTH STRATEGY AI; 1993, MMWR-MORBID MORTAL W, V41, P1; 1992, EFFECTIVE APPROACHES; 1993, BEHAVIORAL SOCIAL SC; 1994, HIV PREVENTIVE VACCI; 1994, MMWR-MORBID MORTAL W, V42, P988; 1994, EFFECTIVENESS AIDS O; 1993, CHALLENGE HIV AID CO; 1992, HIV INCIDENCE PREVAL	50	54	54	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1143	1148		10.1001/jama.273.14.1143	http://dx.doi.org/10.1001/jama.273.14.1143			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QR059	7707604				2022-12-24	WOS:A1995QR05900035
J	EIDT, S; BAYERDORFFER, E; STOLTE, M				EIDT, S; BAYERDORFFER, E; STOLTE, M			TREAT THE INFECTION AND CURE THE CANCER	LANCET			English	Editorial Material							HELICOBACTER-PYLORI; LYMPHOID-TISSUE		UNIV MUNICH,DEPT MED 2,W-8000 MUNICH,GERMANY; CLIN BAYREUTH,INST PATHOL,BAYREUTH,GERMANY	University of Munich; Klinikum Bayreuth	EIDT, S (corresponding author), UNIV COLOGNE,INST PATHOL,W-5000 COLOGNE,GERMANY.							ALBRECHT S, 1991, J AM ACAD DERMATOL, V24, P621, DOI 10.1016/0190-9622(91)70095-J; BAYERDORFFER E, 1994, GASTROENTEROLOGY, V106, pA370; CALVERT R, 1995, LANCET, V345, P9; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; KAMEL OW, 1993, NEW ENGL J MED, V328, P1317, DOI 10.1056/NEJM199305063281806; LOGAN RPH, 1994, LANCET, V344, P1078, DOI 10.1016/S0140-6736(94)91729-9; OROURKE EA, 1994, J PATHOL, V173, P166; ROONEY CM, 1995, LANCET, V345, P26; STOLTE M, 1993, LANCET, V342, P568, DOI 10.1016/0140-6736(93)91404-A; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; Young L S, 1992, Semin Cancer Biol, V3, P273	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					874	875		10.1016/S0140-6736(95)90004-7	http://dx.doi.org/10.1016/S0140-6736(95)90004-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707806				2022-12-24	WOS:A1995QR06700004
J	GIDER, S; AWSCHALOM, DD; DOUGLAS, T; MANN, S; CHAPARALA, M				GIDER, S; AWSCHALOM, DD; DOUGLAS, T; MANN, S; CHAPARALA, M			CLASSICAL AND QUANTUM MAGNETIC PHENOMENA IN NATURAL AND ARTIFICIAL FERRITIN PROTEINS	SCIENCE			English	Article							MAMMALIAN FERRITIN; ANTIFERROMAGNETS; ABSORPTION; PARTICLES	Artificial ferritin has been synthesized with control of both the magnetic state (antiferromagnetic or ferrimagnetic) and the particle size over an order of magnitude in the number of iron atoms. The magnetic properties of the artificial ferritin were compared with those of natural horse spleen ferritin in a range of temperatures (20 millikelvin to 300 kelvin) and fields (1 nanotesla to 27 tesla). In the classical regime, the blocking temperature was found to correlate with the average particle size. A correlation was also observed in the quantum regime between the resonance frequency of macroscopic quantum tunneling of the Neel vector and the particle size. At high magnetic fields (to 27 tesla), a spin flop transition with a strong dependence on orientation was seen in the natural ferritin, providing evidence of antiferromagnetism in this system.	UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106; UNIV BATH,SCH CHEM,BATH BA2 7AY,AVON,ENGLAND; NATL HIGH MAGNET FIELD LAB,TALLAHASSEE,FL 32306	University of California System; University of California Santa Barbara; University of Bath; State University System of Florida; Florida State University			Douglas, Trevor/F-2748-2011; Mann, Stephen/D-1332-2012; Douglas, Trevor/GRS-0012-2022	Mann, Stephen/0000-0003-3012-8964; Douglas, Trevor/0000-0002-7882-2704				AWSCHALOM DD, 1992, PHYS REV LETT, V68, P3092, DOI 10.1103/PhysRevLett.68.3092; AWSCHALOM DD, 1992, SCIENCE, V258, P414, DOI 10.1126/science.258.5081.414; AWSCHALOM DD, 1993, PHYS REV LETT, V71, P4276, DOI 10.1103/PhysRevLett.71.4276; BARBARA B, 1990, PHYS LETT A, V145, P205, DOI 10.1016/0375-9601(90)90682-E; BAUMINGER ER, 1989, HYPERFINE INTERACT, V50, P489, DOI 10.1007/BF02407681; BELL SH, 1984, BIOCHIM BIOPHYS ACTA, V787, P227, DOI 10.1016/0167-4838(84)90313-3; BLAISE A, 1973, INT C MAGNETISM, P280; BULTE JWM, 1994, INVEST RADIOL, V29, pS214, DOI 10.1097/00004424-199406001-00071; CERDAN S, 1989, MAGN RESON MED, V12, P151, DOI 10.1002/mrm.1910120202; CHANTRELL RW, 1991, IEEE T MAGN, V27, P3570, DOI 10.1109/20.102929; CHAPARALA M, 1992, AIP C P, V273; CHAPARALA M, 1992, SUPERCONDUCTIVITY IT, P407; CHARLES SW, 1990, J MAGN MAGN MATER, V85, P277, DOI 10.1016/0304-8853(90)90066-Y; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; FRANKEL RB, 1991, HYPERFINE INTERACT, V66, P71, DOI 10.1007/BF02395857; GIRARDET JL, 1970, J APPL PHYS, V41, P1002, DOI 10.1063/1.1658785; GITTLEMA.JI, 1974, PHYS REV B, V9, P3891, DOI 10.1103/PhysRevB.9.3891; HARRISON PM, 1973, INORGANIC BIOCHEMIST, V1, P253; HUNT C, 1994, HYPERFINE INTERACT, V91, P821, DOI 10.1007/BF02064613; KEFFER F, 1973, PHYS REV LETT, V31, P1061, DOI 10.1103/PhysRevLett.31.1061; KEFFER F, 1966, HDB PHYSIK FERROMAGN, V18, P134; KRIVE IV, 1990, J PHYS-CONDENS MAT, V2, P9457, DOI 10.1088/0953-8984/2/47/020; MACARA IG, 1972, BIOCHEM J, V126, P151, DOI 10.1042/bj1260151; MACKLE P, 1993, J AM CHEM SOC, V115, P8471, DOI 10.1021/ja00071a076; MANN S, 1987, J MOL BIOL, V198, P405, DOI 10.1016/0022-2836(87)90290-7; MELDRUM FC, 1991, NATURE, V349, P684, DOI 10.1038/349684a0; MELDRUM FC, 1992, SCIENCE, V257, P522, DOI 10.1126/science.1636086; MILLS DL, 1968, PHYS REV LETT, V20, P18, DOI 10.1103/PhysRevLett.20.18; PANKHURST QA, 1993, J PHYS-CONDENS MAT, V5, P8487, DOI 10.1088/0953-8984/5/45/002; SERVICE RF, 1994, SCIENCE, V264, P510, DOI 10.1126/science.264.5158.510; STPIERRE TG, 1989, BIOMINERALIZATION CH, P295; TEJADA J, 1994, Z PHYS CONDENS MATTE, V6, P263; TREFFRY A, 1978, BIOCHEM J, V171, P313, DOI 10.1042/bj1710313	33	221	223	1	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					77	80		10.1126/science.7701343	http://dx.doi.org/10.1126/science.7701343			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701343				2022-12-24	WOS:A1995QR45400027
J	HE, ZG; HENRICKSEN, LA; WOLD, MS; INGLES, CJ				HE, ZG; HENRICKSEN, LA; WOLD, MS; INGLES, CJ			RPA INVOLVEMENT IN THE DAMAGE-RECOGNITION AND INCISION STEPS OF NUCLEOTIDE EXCISION-REPAIR	NATURE			English	Article							REPLICATION PROTEIN-A; DNA BINDING-PROTEIN; SIMIAN VIRUS-40 DNA; PIGMENTOSUM GROUP-G; XERODERMA-PIGMENTOSUM; INVITRO; COMPLEMENTATION; SUBUNIT; VP16; P53	HUMAN replication protein (RPA) functions in DNA replication(1-4), homologous recombination(5) and nucleotide excision repair(6). This multisubunit single-stranded DNA-binding protein(1,2) may be required to make unique protein-protein contacts because heterologous single-stranded binding proteins cannot substitute for RPA in these diverse DNA transactions(5-7). We report here that, by using affinity chromatography and immunoprecipitation, we found that human RPA bound specifically and directly to two excision repair proteins, the xeroderma pigmentosum damage-recognition protein XPA (refs 8, 9) and the endonuclease XPG (refs 10-13). Although it had been suggested that RPA might function before the DNA synthesis repair stage(14.15), our finding that a complex of RPA and XPA showed a striking cooperativity in binding to DNA lesions indicates that RPA may function at the very earliest stage of excision repair. In addition, by binding XPG, RPA may target this endonuclease to damaged DNA.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5G 1L6,CANADA; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Toronto; University of Toronto; University of Iowa			Wold, Marc/F-5806-2010	Wold, Marc/0000-0002-4580-1624				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CLUGSTON CK, 1992, CANCER RES, V52, P6375; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	30	370	383	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					566	569		10.1038/374566a0	http://dx.doi.org/10.1038/374566a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700386				2022-12-24	WOS:A1995QR06900059
J	BARTON, JS; TRIPP, JH; MCNINCH, AW				BARTON, JS; TRIPP, JH; MCNINCH, AW			NEONATAL VITAMIN-K PROPHYLAXIS IN THE BRITISH-ISLES - CURRENT PRACTICE AND TRENDS	BRITISH MEDICAL JOURNAL			English	Article							HEMORRHAGIC-DISEASE; NEWBORN				BARTON, JS (corresponding author), ROYAL DEVON & EXETER HOSP,DEPT CHILD HLTH,EXETER EX2 5DW,DEVON,ENGLAND.							CHAMBERLAIN R, 1975, BRIT BIRTHS 1970, V1; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; HANDEL J, 1991, BRIT MED J, V303, P1109, DOI 10.1136/bmj.303.6810.1109; MCNINCH AW, 1991, BRIT MED J, V303, P1105, DOI 10.1136/bmj.303.6810.1105; 1992, VITAMIN K PROPHYLAXI	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					632	633		10.1136/bmj.310.6980.632	http://dx.doi.org/10.1136/bmj.310.6980.632			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703751	Green Published			2022-12-24	WOS:A1995QL98400017
J	GENUIS, SJ; GENUIS, SK				GENUIS, SJ; GENUIS, SK			ADOLESCENT SEXUAL INVOLVEMENT - TIME FOR PRIMARY PREVENTION	LANCET			English	Editorial Material							EDUCATION; SWEDEN; SCHOOL											BOWIE WR, 1993, CAN J OBSTET GYNECOL, V5, P399; GENUIS SJ, 1993, J SOC OBSTET GYNECOL, V15, P552; GRIFFIN GC, 1993, POSTGRAD MED, V93, P21; GULLY PR, 1992, CAN MED ASSOC J, V147, P893; HAUSSER D, 1994, PEDIATRICS, V93, P580; HERLITZ C, 1992, SCAND J SOC MED, V20, P102, DOI 10.1177/140349489202000207; HOWARD M, 1990, FAM PLANN PERSPECT, V22, P21, DOI 10.2307/2135434; KLEIN J, 1994, NEWSWEEK, V123, P29; MCKEOWN DJ, 1993, SEXUAL HLTH DATA REP; PERSSON E, 1992, GENITOURIN MED, V68, P26; POWELL MG, 1993, CAN J OBSTET GYNECOL, V5, P383; POWELL MG, 1993, TREAT FEMALE PATIENT, V7, P10; ROSENFELD WD, 1991, PEDIATR ANN, V20, P303, DOI 10.3928/0090-4481-19910601-07; STOUT JW, 1989, PEDIATRICS, V83, P375; VINCENT ML, 1987, JAMA-J AM MED ASSOC, V257, P3382, DOI 10.1001/jama.257.24.3382; 1993, PROG HUM REPROD RES, V27, P6; 1991, MMWR-MORBID MORTAL W, V39, P929	17	14	14	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					240	241		10.1016/S0140-6736(95)90229-5	http://dx.doi.org/10.1016/S0140-6736(95)90229-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QD532	7741863				2022-12-24	WOS:A1995QD53200015
J	HAKAMA, M; HOLLI, K; ISOLA, J; KALLIONIEMI, OP; KARKKAINEN, A; VISAKORPI, T; PUKKALA, E; SAARENMAA, I; GEIGER, U; IKKALA, J; NIEMINEN, T; GODENHJELM, K; KOIVULA, T				HAKAMA, M; HOLLI, K; ISOLA, J; KALLIONIEMI, OP; KARKKAINEN, A; VISAKORPI, T; PUKKALA, E; SAARENMAA, I; GEIGER, U; IKKALA, J; NIEMINEN, T; GODENHJELM, K; KOIVULA, T			AGGRESSIVENESS OF SCREEN-DETECTED BREAST CANCERS	LANCET			English	Article							DNA FLOW-CYTOMETRY; PROGNOSTIC VALUE; MAMMOGRAPHY; EXPRESSION; FEATURES; SURVIVAL	It is not clear whether screening for breast cancer works as public hearth policy and whether early indicators of effect predict an ultimate reduction in mortality. The malignant potentials of 248 breast cancers detected by the screening service in Finland were compared with those of 490 control cancers diagnosed before the screening service was established. Aggressiveness was assessed by DNA flow cytometry and clinical status by cancer size and node involvement. After the first screening round, the results of DNA flow cytometry were the same in cancers diagnosed by screening and in controls; these findings are consistent with the hypothesis that the biological aggressiveness of breast cancer remains constant as the cancer progresses. The proportion of patients with node-negative and small T1 cancers after the first screening was higher among the screened population than among controls, indicating earliness of diagnosis among those screened. Cancers diagnosed in the first round had a low malignant potential, as indicated by the DNA flow-cytometry and by clinical stage. Lower aggressiveness of cancers found by screening than of control cancers would indicate overdiagnosis or length-biased sampling, but not earliness of diagnosis. Screening with mammography is practised as a public health policy in Finland. The results predict that the mortality reduction found in randomised trials can be repeated with a screening service.	FINNISH CANC REGISTRY, SF-00170 HELSINKI, FINLAND; TAMPERE UNIV HOSP, TAMPERE, FINLAND; UNIV TAMPERE, DEPT BIOMED SCI, SF-33101 TAMPERE, FINLAND; PIRKANMAA CANC SOC, TAMPERE, FINLAND; HATANPAA HOSP, TAMPERE, FINLAND; SATAKUNTA CANC SOC, PORI, FINLAND; KYMENLAAKSO CANC SOC, KOTKA, FINLAND	Finnish Cancer Registry; Tampere University; Tampere University Hospital; Tampere University	HAKAMA, M (corresponding author), UNIV TAMPERE, DEPT PUBL HLTH, BOX 607, SF-33101 TAMPERE, FINLAND.		Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332				CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; COLE P, 1978, SCREENING CANCER REP; DAY NE, 1991, CANCER SCREENING, P391; DAY NE, 1988, SCREENING BREAST CAN; DONN AS, 1985, B CANCER, V72, P381; HAKAMA M, 1991, BRIT J CANCER, V64, P962, DOI 10.1038/bjc.1991.436; ISOLA J, 1993, J CLIN ONCOL, V11, P36, DOI 10.1200/JCO.1993.11.1.36; ISOLA J, 1992, J NATL CANCER I, V84, P874; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; KALLIONIEMI OP, 1991, CYTOMETRY, V12, P413, DOI 10.1002/cyto.990120506; KALLIONIEMI OP, 1988, INT J CANCER, V42, P697, DOI 10.1002/ijc.2910420511; KALLIONIEMI OP, 1988, CANCER, V62, P88; MILLER AB, 1991, CANCER SCREENING, P1; PEETERS PHM, 1989, INT J EPIDEMIOL, V18, P295, DOI 10.1093/ije/18.2.295; POLLEI SR, 1987, RADIOLOGY, V163, P459, DOI 10.1148/radiology.163.2.3562827; SAXEN E, 1964, ANN MED EXP BIOL FEN, V42, P1; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; UYTERLINDE AM, 1991, INT J CANCER, V48, P173, DOI 10.1002/ijc.2910480204; Zelen M., 1976, BREAST CANCER TRENDS, P287	20	46	47	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					221	224						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7741862				2022-12-24	WOS:A1995QD53200009
J	HERTZMAN, PA; CLAUW, DJ; KAUFMAN, LD; VARGA, J; SILVER, RM; THACKER, HL; MEASE, P; ESPINOZA, LR; PINCUS, T				HERTZMAN, PA; CLAUW, DJ; KAUFMAN, LD; VARGA, J; SILVER, RM; THACKER, HL; MEASE, P; ESPINOZA, LR; PINCUS, T			THE EOSINOPHILIA-MYALGIA-SYNDROME - STATUS OF 205 PATIENTS AND RESULTS OF TREATMENT 2 YEARS AFTER ONSET	ANNALS OF INTERNAL MEDICINE			English	Review							TOXIC OIL SYNDROME; RHEUMATOID-ARTHRITIS; FOLLOW-UP; TRYPTOPHAN; INGESTION; FASCIITIS	Objective: To describe the course of the eosinophilia-myalgia syndrome during a 2-year period. Design: 15 physicians completed a structured review;form to describe symptoms, physical findings, laboratory data, and responses to treatments in 205 patients with the eosinophilia-myalgia syndrome at the onset of illness and after 18 to 24 months of follow-up. Setting: 15 university and private clinical practice settings. Patients: 205 patients for whom follow-up data were available and who met four criteria at diagnosis: eosinophil count of 1000 cells/mm(3) or greater; presence of fasciitis, peripheral neuropathy, polyradiculopathy, interstitial pulmonary disease, pulmonary hypertension, or myocardial involvement; history of L-tryptophan consumption; and absence of other conditions that could account for these findings. Intervention: Empirical interventions by the physicians. Measurements: Symptoms, physical findings, laboratory test results, biopsy findings, radiographic reports, therapeutic interventions, and responses to these interventions. Results: After 18 to 24 months, all symptoms except cognitive changes were reported to have improved in most patients. Nearly all physical findings were also reported to have improved or resolved in most patients; only peripheral neuropathy was unchanged. No evidence of ongoing inflammatory disease was reported. Prednisone was reported to be helpful in 79% of patients who received it during the acute phase of the syndrome. No other treatment was reported to be consistently beneficial. Conclusions: 18 to 24 months after the onset of illness, most symptoms and physical findings in most patients with the eosinophilia-myalgia syndrome resolved or improved. Cognitive changes were reported to be worse in 32% of patients. Prednisone was helpful in the acute phase of illness. No treatment was clearly valuable in management of the later phase of the syndrome.	VANDERBILT UNIV, SCH MED, DEPT MED, DIV RHEUMATOL & IMMUNOL, NASHVILLE, TN 37232 USA; LOS ALAMOS MED CTR, LOS ALAMOS, NM 87544 USA; GEORGETOWN UNIV, MED CTR, WASHINGTON, DC 20007 USA; SUNY STONY BROOK, DIV RHEUMATOL ALLERGY & CLIN IMMUNOL, STONY BROOK, NY 11794 USA; THOMAS JEFFERSON UNIV, PHILADELPHIA, PA 19107 USA; MED UNIV S CAROLINA, CHARLESTON, SC 29425 USA; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; MINOR & JAMES MED CTR, SEATTLE, WA 98104 USA; LOUISIANA STATE UNIV, MED CTR, NEW ORLEANS, LA USA	Vanderbilt University; Georgetown University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Jefferson University; Medical University of South Carolina; Cleveland Clinic Foundation; Louisiana State University System					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R18AR021393] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 21393] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALONSORUIZ A, 1986, SEMIN ARTHRITIS RHEU, V15, P200, DOI 10.1016/0049-0172(86)90017-X; ALONSORUIZ A, 1993, MEDICINE, V72, P285, DOI 10.1097/00005792-199309000-00001; CLAUW DJ, 1990, JAMA-J AM MED ASSOC, V263, P1502; CULPEPPER RC, 1991, ANN INTERN MED, V115, P437, DOI 10.7326/0003-4819-115-6-437; DUFFY J, 1992, HOSP PRACT, V27, P65; FREUNDLICH B, 1990, ANN INTERN MED, V112, P758, DOI 10.7326/0003-4819-112-10-758; GUADINO EA, 1995, IN PRESS NEUROPSYCHI; HERTZMAN P A, 1991, Arthritis and Rheumatism, V34, pS131; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; HERTZMAN PA, 1993, ARTHRITIS RHEUM, V36, pS115; HERTZMAN PA, 1991, J RHEUMATOL, V18, P867; HERTZMAN PA, 1995, J RHEUMATOL, V22, P161; HERTZMAN PA, 1993, J RHEUMATOL, V20, P1707; KAUFMAN LD, 1991, LANCET, V337, P1071, DOI 10.1016/0140-6736(91)91717-9; KAUFMAN LD, 1994, RHEUM DIS CLIN N AM, V20, P973; KAUFMAN LD, 1994, ARTHRITIS RHEUM-US, V37, P84, DOI 10.1002/art.1780370112; KAUFMAN LD, 1995, J RHEUMATOL, V22, P282; KILBOURNE EM, 1991, J AM COLL CARDIOL, V18, P711, DOI 10.1016/0735-1097(91)90794-A; KILBOURNE EM, 1992, EPIDEMIOL REV, V14, P16, DOI 10.1093/oxfordjournals.epirev.a036085; KRUPP LB, 1993, NEUROLOGY, V43, P931, DOI 10.1212/WNL.43.5.931; PHILEN RM, 1991, ARCH INTERN MED, V151, P533, DOI 10.1001/archinte.151.3.533; PHILEN RM, 1993, SEMIN ARTHRITIS RHEU, V23, P104, DOI 10.1016/S0049-0172(05)80017-4; PINCUS T, 1992, J RHEUMATOL, V19, P1874; PINCUS T, 1994, ANN INTERN MED, V120, P26, DOI 10.7326/0003-4819-120-1-199401010-00005; PINCUS T, 1989, ANN INTERN MED, V110, P259, DOI 10.7326/0003-4819-110-4-259; SACK KE, 1992, SOUTHERN MED J, V85, P878, DOI 10.1097/00007611-199209000-00005; SILVER RM, 1991, ARCH DERMATOL, V127, P1214, DOI 10.1001/archderm.127.8.1214; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; THACKER HL, 1991, CLEV CLIN J MED, V58, P400, DOI 10.3949/ccjm.58.5.400; VARGA J, 1991, J RHEUMATOL, V18, P259; WOLFE F, 1991, J RHEUMATOL, V18, P643; 1989, MMWR MORBMORTAL WKLY, V38, P765; 1990, JAMA-J AM MED ASSOC, V263, P633	33	30	33	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					851	855		10.7326/0003-4819-122-11-199506010-00008	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741371				2022-12-24	WOS:A1995RA13900008
J	COOPER, JR				COOPER, JR			INCLUDING NARCOTIC ADDICTION TREATMENT IN AN OFFICE-BASED PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							METHADONE-MAINTENANCE				COOPER, JR (corresponding author), NIDA,DIV CLIN SERV & RES,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							Ball J.C., 2012, EFFECTIVENESS METHAD; COOPER JR, 1989, JAMA-J AM MED ASSOC, V262, P1664, DOI 10.1001/jama.262.12.1664; DOLE VP, 1992, JAMA-J AM MED ASSOC, V267, P2234, DOI 10.1001/jama.267.16.2234; GRAHAM LA, 1994, NOV NAT I DRUG AB ME; MOLINARI SP, 1994, J LAW MED ETHICS, V22, P231, DOI 10.1111/j.1748-720X.1994.tb01300.x; NOVICK DM, 1988, JAMA-J AM MED ASSOC, V259, P3299, DOI 10.1001/jama.259.22.3299; PAYTE JT, 1994, 25TH AM SOC ADD MED; 1970, L91513 PUB; 1974, L93281 PUB; 1994, DEV ANTIADDICTION ME; 1984, L98473 PUB; 1995, FEDERAL REGULATION M	12	27	28	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	1995	273	20					1619	1620		10.1001/jama.273.20.1619	http://dx.doi.org/10.1001/jama.273.20.1619			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY541	7745777				2022-12-24	WOS:A1995QY54100031
J	HAQ, TA; MASON, HS; CLEMENTS, JD; ARNTZEN, CJ				HAQ, TA; MASON, HS; CLEMENTS, JD; ARNTZEN, CJ			ORAL IMMUNIZATION WITH A RECOMBINANT BACTERIAL-ANTIGEN PRODUCED IN TRANSGENIC PLANTS	SCIENCE			English	Article							ESCHERICHIA-COLI; IMMUNE-RESPONSE; VIBRIO-CHOLERAE; B-SUBUNIT; PROTEINS; ENTEROTOXIN; VACCINE; TOXIN; IDENTIFICATION; TRANSLOCATION	The binding subunit of Escherichia coli heat-labile enterotoxin (LT-B) is a highly active oral immunogen. Transgenic tobacco and potato plants were made with the use of genes encoding LT-B or an LT-B fusion protein with a microsomal retention sequence. The plants expressed the foreign peptides, both of which formed oligomers that bound the natural ligand. Mice immunized by gavage produced serum and gut mucosal anti-LT-B immunoglobulins that neutralized the enterotoxin in cell protection assays. Feeding mice fresh transgenic potato tubers also caused oral immunization.	TEXAS A&M UNIV, ALBERT B ALKEK INST BIOSCI & TECHNOL, PLANT BIOTECHNOL PROGRAM, HOUSTON, TX 77030 USA; TULANE UNIV, MED CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, NEW ORLEANS, LA 70112 USA	Texas A&M University System; Tulane University					PHS HHS [1 R01 A136519-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARNTZEN CJ, 1994, VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P339; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CARDENAS L, 1993, INFECT IMMUN, V61, P4629; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENTS JD, 1978, INFECT IMMUN, V21, P1036, DOI 10.1128/IAI.21.3.1036-1039.1978; CLEMENTS JD, 1984, INFECT IMMUN, V46, P564, DOI 10.1128/IAI.46.2.564-569.1984; DEAIZPURUA HJ, 1988, J EXP MED, V167, P440, DOI 10.1084/jem.167.2.440; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; HOLMGREN J, 1983, PROG ALLERGY, V33, P106; HOLMGREN J, 1992, IMMUNOBIOLOGY, V184, P157, DOI 10.1016/S0171-2985(11)80473-0; HOLMGREN J, 1993, VACCINE, V11, P1179, DOI 10.1016/0264-410X(93)90039-Z; HORSCH RB, 1991, PLANT MOL BIOL MANUA; JEFFERSON RA, 1987, EMBO J, V6, P3901; JONES JDG, 1985, EMBO J, V4, P2411, DOI 10.1002/j.1460-2075.1985.tb03949.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON HS, 1988, PLANT MOL BIOL, V11, P845, DOI 10.1007/BF00019524; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; MESTECKY J, 1989, CURR TOP MICROBIOL, V146, P3; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PELTOLA H, 1991, LANCET, V338, P1285, DOI 10.1016/0140-6736(91)92590-X; PERL A, 1991, PLANT SCI, V73, P87, DOI 10.1016/0168-9452(91)90129-V; SACK DA, 1975, INFECT IMMUN, V11, P334, DOI 10.1128/IAI.11.2.334-336.1975; SACK RB, 1980, J INFECT DIS, V142, P279, DOI 10.1093/infdis/142.2.279; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; WANDELT CI, 1992, PLANT J, V2, P181; WENZLER H, 1989, PLANT SCI, V63, P79, DOI 10.1016/0168-9452(89)90103-9	28	474	553	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 5	1995	268	5211					714	716		10.1126/science.7732379	http://dx.doi.org/10.1126/science.7732379			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732379				2022-12-24	WOS:A1995QW60300047
J	KIMHA, J; KERR, K; MACDONALD, PM				KIMHA, J; KERR, K; MACDONALD, PM			TRANSLATIONAL REGULATION OF OSKAR MESSENGER-RNA BY BRUNO, AN OVARIAN RNA-BINDING PROTEIN, IS ESSENTIAL	CELL			English	Article							BICOID MESSENGER-RNA; EARLY DROSOPHILA EMBRYO; GERM-CELL FORMATION; ANTEROPOSTERIOR POLARITY; EXUPERANTIA GENE; POSTERIOR POLE; LOCALIZATION; PATTERN; NANOS; ELEMENTS	Oskar (osk) protein directs the deployment of nanos (nos), the posterior body-patterning morphogen in Drosophila. To avoid inappropriate activation of nos, osk activity must appear only at the posterior pole of the oocyte, where the osk mRNA becomes localized during oogenesis. Here, we show that translation of osk mRNA is, and must be, repressed prior to its localization; absence of repression allows osk protein to accumulate throughout the oocyte, specifying posterior body patterning throughout the embryo. Translational repression is mediated by an ovarian protein, bruno, that binds specifically to bruno response elements (BREs), present in multiple copies in the osk mRNA 3'UTR. Addition of BREs to a heterologous mRNA renders it sensitive to translational repression in the ovary.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University								BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; CHRISTERSON LB, 1994, GENE DEV, V8, P614, DOI 10.1101/gad.8.5.614; DALBY B, 1993, EMBO J, V12, P1219, DOI 10.1002/j.1460-2075.1993.tb05763.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; EPHRUSSI A, 1991, CELL, V68, P37; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; HAY B, 1990, DEVELOPMENT, V109, P425; HAZELRIGG T, 1990, GENETICS, V126, P607; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LEHMANN R, 1991, DEVELOPMENT, V112, P679; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MACDONALD PM, 1993, DEVELOPMENT, V118, P1233; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; NEWMARK PA, 1994, DEVELOPMENT, V120, P1303; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WEBSTER PJ, 1994, DEVELOPMENT, V120, P2027; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1992, SEM DEV BIOL, V3, P399	40	364	368	0	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					403	412		10.1016/0092-8674(95)90393-3	http://dx.doi.org/10.1016/0092-8674(95)90393-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736592	Bronze			2022-12-24	WOS:A1995QW89400012
J	LUNARDIISKANDAR, Y; BRYANT, JL; ZEMAN, RA; LAM, VH; SAMANIEGO, F; BESNIER, JM; HERMANS, P; THIERRY, AR; GILL, P; GALLO, RC				LUNARDIISKANDAR, Y; BRYANT, JL; ZEMAN, RA; LAM, VH; SAMANIEGO, F; BESNIER, JM; HERMANS, P; THIERRY, AR; GILL, P; GALLO, RC			TUMORIGENESIS AND METASTASIS OF NEOPLASTIC KAPOSIS-SARCOMA CELL-LINE IN IMMUNODEFICIENT MICE BLOCKED BY A HUMAN-PREGNANCY HORMONE	NATURE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LONG-TERM CULTURE; GROWTH-FACTOR; EXPRESSION; MECHANISMS; AUTOCRINE; PARACRINE; INVITRO; DEATH; HTLV	KAPOSI's sarcoma (KS) occurs more often in men than in women and HIV-1-associated KS has a high occurrence in homosexual men (over 30%). Most cultures of KS tumours yield cells with properties of hyperplastic (not malignant) endothelial cells under the control of several cytokines(1-7). The role of HIV-1 may be in promoting high levels of some cytokines and providing stimulation to angiogenesis by the HIV-1 Tat protein(8), which synergizes with basic fibroblast growth factor in promoting these effects(9), Here,ve describe an immortalized AIDS-KS cell line (KS Y-1) and show that these cells produce malignant metastatic tumours in nude mice and are killed in vitro and in vivo (apparently by apoptosis) by a pregnancy hormone, the beta-chain of human chorionic gonadotropin. Similarly, chorionic gonadotropin kills KS SLK, cells from another neoplastic cell line (established from a non-HIV-associated KS)(10), as well as the hyperplastic KS cells from clinical specimens grown in short-term culture, but does not kill normal endothelial cells, These results provide evidence that KS can evolve into a malignancy and have implications for the hormonal treatment of this tumour.	NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA; NIDR, ANIM CARE UNIT, BETHESDA, MD 20892 USA; GYNECOL & OBSTET MED CTR, F-75017 PARIS, FRANCE; FREE UNIV BRUSSELS, HOP ST PIERRE, DEPT MALAD INFECT, B-1000 BRUSSELS, BELGIUM; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90033 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Southern California			thierry, alain/F-9492-2014					ASHITAKA Y, 1980, CHORIONIC GONADOTROP, P147; CAI J, 1994, AM J PATHOL, V145, P74; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; ELMAZAR MMA, 1989, REPROD TOXICOL, V3, P135, DOI 10.1016/0890-6238(89)90047-6; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FAN C, 1987, J CLIN ENDOCR METAB, V64, P313, DOI 10.1210/jcem-64-2-313; HORNE CHW, 1979, INVEST CELL PATHOL, V2, P217; JOHNSON MR, 1993, ACTA ENDOCRINOL-COP, V129, P121, DOI 10.1530/acta.0.1290121; KORNYEI JL, 1993, BIOL REPROD, V49, P1149, DOI 10.1095/biolreprod49.6.1149; LUNARDIISKANDAR Y, 1993, J EXP MED, V177, P741, DOI 10.1084/jem.177.3.741; MARKHAM PD, 1983, INT J CANCER, V31, P413, DOI 10.1002/ijc.2910310404; MARTIN MC, 1991, BASIC CLIN ENDOCRINO, P543; MASOOD R, 1994, AIDS RES HUM RETROV, V10, P969, DOI 10.1089/aid.1994.10.969; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAHRAOUI Y, 1992, CELL IMMUNOL, V139, P318, DOI 10.1016/0008-8749(92)90074-Y; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SLEGAL B, 1990, CANCER, V65, P492; STIMSON WH, 1983, IMMUNOLOGY REPRODUCT, P281; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; TORRY RJ, 1992, AM J REPROD IMMUNOL, V27, P171, DOI 10.1111/j.1600-0897.1992.tb00746.x; WIDE L, 1980, CHORIONIC GONADOTROP, P37	26	206	229	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 4	1995	375	6526					64	68		10.1038/375064a0	http://dx.doi.org/10.1038/375064a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723844	Green Submitted			2022-12-24	WOS:A1995QW60400056
J	HEBERT, LE; SCHERR, PA; BECKETT, LA; ALBERT, MS; PILGRIM, DM; CHOWN, MJ; FUNKENSTEIN, HH; EVANS, DA				HEBERT, LE; SCHERR, PA; BECKETT, LA; ALBERT, MS; PILGRIM, DM; CHOWN, MJ; FUNKENSTEIN, HH; EVANS, DA			AGE-SPECIFIC INCIDENCE OF ALZHEIMERS-DISEASE IN A COMMUNITY POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEMENTING ILLNESSES; SENILE DEMENTIA; UNITED-STATES; PREVALENCE; PERIODS; LUNDBY; RATES	Objective.-To determine age-specific incidence rates of clinically diagnosed Alzheimer's disease. Design.-Cohort, followed a mean of 4.3 years. Setting.-East Boston, Mass. Participants.-Of 2313 persons aged 65 years and older who were initially free of Alzheimer's disease, 1601 participated in the ascertainment of incident disease (80% of survivors), 409 declined participation, and 303 died before the end of the follow-up period. A stratified sample of 642 persons received detailed clinical evaluation. Outcome Measure.-Diagnosis of new probable Alzheimer's disease through structured clinical evaluation including neurologic, neuropsychological, and psychiatric examination. Community incidence rates were computed by 5-year age groups, adjusted for gender, single year of age, length of follow-up interval, and sampling design. Results.-The estimated annual incidence of Alzheimer's disease in the population was 0.6% (95% confidence interval [CI], 0.3% to 0.9%) for persons aged 65 to 69 years, 1.0% (95% CI, 0.6% to 1.4%) for persons aged 70 to 74 years, 2.0% (95% CI, 1.3% to 2.7%) for persons aged 75 to 79 years, 3.3% (95% CI, 2.2% to 4.4%) for persons aged 80 to 84 years, and 8.4% (95% CI, 3.7% to 13.1%) for persons aged 85 years and older. Conclusions.-The incidence of Alzheimer's disease is substantial and is approximately 14 times higher among persons older than 85 years compared with those between 65 and 69 years of age.	RUSH UNIV,RUSH ALZHEIMERS DIS CTR,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612; CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,AGING STUDIES BRANCH,ATLANTA,GA 30341; MASSACHUSETTS GEN HOSP,DEPT PSYCHIAT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; HARVARD COMMUNITY HLTH PLAN,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115	Rush University; Rush University; Centers for Disease Control & Prevention - USA; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	HEBERT, LE (corresponding author), RUSH INST AGING,1645 W JACKSON BLVD,SUITE 675,CHICAGO,IL 60612, USA.				NATIONAL INSTITUTE ON AGING [P30AG010161, R01AG005362, U01AG006789] Funding Source: NIH RePORTER; NIA NIH HHS [AG06789, AG10161, AG05362] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKESSON HO, 1969, HUM HERED, V19, P546, DOI 10.1159/000152266; ALBERT M, 1991, INT J NEUROSCI, V57, P167, DOI 10.3109/00207459109150691; ARONSON MK, 1991, ARCH INTERN MED, V151, P989, DOI 10.1001/archinte.1991.00400050129024; BACHMAN DL, 1993, NEUROLOGY, V43, P515, DOI 10.1212/WNL.43.3_Part_1.515; BECKETT LA, 1992, J CLIN EPIDEMIOL, V45, P393, DOI 10.1016/0895-4356(92)90040-T; Benton A.L., 1974, REVISED VISUAL RETEN; COPELAND JRM, 1992, BRIT J PSYCHIAT, V161, P230, DOI 10.1192/bjp.161.2.230; Cornoni-Huntley J., 1986, ESTABLISHED POPULATI; EVANS DA, 1990, MILBANK Q, V68, P267, DOI 10.2307/3350099; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; EVANS DA, 1990, AM J EPIDEMIOL, V134, P403; EVANS RA, 1993, OSTEOPOROSIS INT, V3, P71, DOI 10.1007/BF01623376; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; GRUENBERG EM, 1987, SOC STRESS DISEASE; HAGNELL O, 1981, NEUROPSYCHOBIOLOGY, V7, P201, DOI 10.1159/000117852; JARVIK LF, 1980, ARCH GEN PSYCHIAT, V37, P280; KAPLAN E, 1976, BOSTON NAMING TEST; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; KAY DWK, 1966, J PSYCHOSOM RES, V10, P3, DOI 10.1016/0022-3999(66)90128-0; KOKMEN E, 1988, NEUROLOGY, V38, P975, DOI 10.1212/WNL.38.6.975; LARSSON T, 1963, ACTA PSYCHIATR SCA S, V167, P1; LAUNER LJ, 1992, NEUROEPIDEMIOLOGY, V11, P127, DOI 10.1159/000110922; MATTIS S, 1976, GERIATRIC PSYCHIATRY; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIRSKY A, 1978, ED BRAIN 77 YB 2; MOLSA PK, 1982, ACTA NEUROL SCAND, V65, P541; MORGAN K, 1992, NEUROEPIDEMIOLOGY, V11, P80, DOI 10.1159/000110995; MOSS MB, 1986, ARCH NEUROL-CHICAGO, V43, P239, DOI 10.1001/archneur.1986.00520030031008; NILSSON LV, 1984, ACTA PSYCHIAT SCAND, V70, P478, DOI 10.1111/j.1600-0447.1984.tb01237.x; RORSMAN B, 1986, NEUROPSYCHOBIOLOGY, V15, P122, DOI 10.1159/000118254; RUBIN EH, 1989, ARCH NEUROL-CHICAGO, V46, P379, DOI 10.1001/archneur.1989.00520400033016; SAYETTA RB, 1986, J CHRON DIS, V39, P271, DOI 10.1016/0021-9681(86)90049-4; SCHOENBERG BS, 1987, ANN NEUROL, V22, P724, DOI 10.1002/ana.410220608; SPENCER G, 1984, US BUREAU CENSUS P25, V952; TAEUBER CM, 1983, US BUREAU CENSUS P23, V128; TORREY BB, 1987, US BUREAU CENSUS P95, V78	36	326	336	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1354	1359		10.1001/jama.273.17.1354	http://dx.doi.org/10.1001/jama.273.17.1354			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV307	7715060				2022-12-24	WOS:A1995QV30700020
J	BLUMBERG, HM; WATKINS, DL; BERSCHLING, JD; ANTLE, A; MOORE, P; WHITE, N; HUNTER, M; GREEN, B; RAY, SM; MCGOWAN, JE				BLUMBERG, HM; WATKINS, DL; BERSCHLING, JD; ANTLE, A; MOORE, P; WHITE, N; HUNTER, M; GREEN, B; RAY, SM; MCGOWAN, JE			PREVENTING THE NOSOCOMIAL TRANSMISSION OF TUBERCULOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						INFECTION CONTROL; TUBERCULOSIS; CROSS INFECTION; HEALTH PERSONNEL; TUBERCULIN TEST	HUMAN-IMMUNODEFICIENCY-VIRUS; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HIV-INFECTED PATIENTS; OUTBREAK	Objective: To study the efficacy of expanded tuberculosis infection control measures consisting primarily of administrative controls. Design: Descriptive case series. Setting: University-affiliated, inner-city hospital. Interventions: Introduction of expanded tuberculosis infection control measures (including an expanded respiratory isolation policy). Measurements: The number of tuberculosis exposure episodes and skin test conversion rates of health care workers were measured before and after implementation of expanded infection control measures. Tuberculosis exposure episodes (the number of patients who were not placed in respiratory isolation at admission but who subsequently had a diagnosis of acid-fast bacilli smear-positive pulmonary tuberculosis during that admission or within 2 weeks of discharge) were compared for two time periods: the 8 months before and the 28 months after implementation of infection control measures. Tuberculin skin test conversion rates among health care workers were evaluated during a 2.5-year period. Results: After expanded infection control measures were implemented, the number of tuberculosis exposure episodes decreased from 4.4 per month (35 episodes among 103 patient admissions for potentially infectious tuberculosis over 8 months) to 0.6 per month (18 episodes among 358 patient admissions for smear-positive pulmonary tuberculosis over 28 months) (odds ratio, 9.72; 95% CI, 4.99 to 19.25 [P < 0.001]). The cumulative number of days per month that potentially infectious patients with tuberculosis were not in isolation decreased from 35.4 to 3.3 (P < 0.001). A concomitant decrease in tuberculin skin test conversion rates in health care workers was seen; 6-month tuberculin skin test conversion rates decreased steadily from 3.3% (118 conversions in 3579 health care workers; 1/92 to 6/92), 1.7%, 1.4%, 0.6%, to 0.4% (23 conversions in 5153 workers [1/94 to 6/94]) (P < 0.001). Conclusions: Infection control measures effectively prevented nosocomial transmission of tuberculosis to health care workers. Administrative controls appear to be the most important component of a tuberculosis infection control program and should be the first focus of such a program, especially at public hospitals, where resources are most likely to be limited.	GRADY MEM HOSP, CLIN MICROBIOL LAB, ATLANTA, GA 30335 USA; GRADY MEM HOSP, DEPT EPIDEMIOL, ATLANTA, GA 30335 USA; GRADY MEM HOSP, OCCUPAT HLTH SERV, ATLANTA, GA 30365 USA		BLUMBERG, HM (corresponding author), EMORY UNIV, SCH MED, DIV INFECT DIS, 69 BUTLER ST SE, ATLANTA, GA 30303 USA.		mcgowan, john e/G-5404-2011; Blumberg, Henry/W-2156-2019	Blumberg, Henry/0000-0002-3110-2443; Ray, Susan/0000-0002-6327-088X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003078] Funding Source: NIH RePORTER; NHLBI NIH HHS [K07 HL03078-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn J., 1995, Journal of Investigative Medicine, V43, p38A; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BEEKMANN SE, 1993, INFECT CONT HOSP EP, V14, P228; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECKER MD, 1993, INFECT CONT HOSP EP, V14, P689, DOI 10.1086/646671; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FELLA P, 1994, AM J INFECT CONTROL, V22, P100; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FLORA GS, 1990, CHEST, V98, P1056, DOI 10.1378/chest.98.5.1056; GREIFINGER R, 1992, Morbidity and Mortality Weekly Report, V41, P507; HAAS DW, 1994, AM J MED, V96, P439, DOI 10.1016/0002-9343(94)90171-6; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; JACOBS RF, 1994, CLIN INFECT DIS, V19, P1, DOI 10.1093/clinids/19.1.1; JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W; Kent PT, 1985, GUIDE LEVEL 3 LAB; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MATHUR P, 1994, ARCH INTERN MED, V154, P306, DOI 10.1001/archinte.154.3.306; MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206; NOLTE FS, 1995, IN PRESS MANUAL CLIN; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P305; SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7; ZAZA S, 1992, 1992 WORLD C TUB BET; E74193 AM SOC TEST M; 1992, MMWR-MORBID MORTAL W, V41, P55	32	146	149	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					658	663		10.7326/0003-4819-122-9-199505010-00003	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702227				2022-12-24	WOS:A1995QV15100003
J	ENDRIZZI, JA; CRONK, JD; WANG, WD; CRABTREE, GR; ALBER, T				ENDRIZZI, JA; CRONK, JD; WANG, WD; CRABTREE, GR; ALBER, T			CRYSTAL-STRUCTURE OF DCOH, A BIFUNCTIONAL, PROTEIN-BINDING TRANSCRIPTIONAL COACTIVATOR	SCIENCE			English	Article							NUCLEAR FACTOR-I; DIMERIZATION DOMAIN; 4A-CARBINOLAMINE DEHYDRATASE; DNA-BINDING; ACTIVATION DOMAINS; RAT-LIVER; HOMEODOMAIN; HYDROXYLASE; PROMOTERS; RECOGNITION	DCoH, the dimerization cofactor of hepatocyte nuclear factor-1, stimulates gene expression by associating with specific DNA binding proteins and also catalyzes the dehydration of the biopterin cofactor of phenylalanine hydroxylase. The x-ray crystal structure determined at 3 angstrom resolution reveals that DCoH forms a tetramer containing two saddle-shaped grooves that comprise likely macromolecule binding sites. Two equivalent enzyme active sites flank each saddle, suggesting that there is a spatial connection between the catalytic and binding activities. Structural similarities between the DCoH fold and nucleic acid-binding proteins argue that the saddle motif has evolved to bind diverse ligands or that DCoH unexpectedly may bind nucleic acids.	STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,MOLEC & GENET MED UNIT,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University	ENDRIZZI, JA (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.		Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928				BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; CITRON BA, 1992, P NATL ACAD SCI USA, V89, P11891, DOI 10.1073/pnas.89.24.11891; CITRON BA, 1993, AM J HUM GENET, V53, P768; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; CRONK JD, UNPUB; DAVIS MD, 1992, FEBS LETT, V302, P73, DOI 10.1016/0014-5793(92)80288-R; DEFRANCESCO R, 1991, BIOCHEMISTRY-US, V30, P143, DOI 10.1021/bi00215a021; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; HANSEN LP, 1994, THESIS STANFORD U ST; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; HUANG CY, 1973, J BIOL CHEM, V248, P4235; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAUFMAN S, 1970, J BIOL CHEM, V245, P4751; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V360, P520; KIM Y, 1993, NATURE, V360, P512; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P921; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; LAZARUS RA, 1983, J BIOL CHEM, V258, P960; LEE AL, 1994, BIOCHEMISTRY-US, V33, P13775, DOI 10.1021/bi00250a031; LUNDQVIST T, 1994, STRUCTURE, V2, P937, DOI 10.1016/S0969-2126(94)00095-6; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; NAGAI K, 1991, NATURE, V348, P515; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PASTORE A, 1992, PROTEIN ENG, V5, P749, DOI 10.1093/protein/5.8.749; PASTORE A, 1991, BIOCHEMISTRY-US, V30, P148, DOI 10.1021/bi00215a022; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; STEIGEMANN W, 1991, PROTEIN VERSION 3 1; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VONSTRANDMANN EP, IN PRESS DEVELOPMENT; WANG BC, 1985, METHOD ENZYMOL, V115, P90; ZENG WL, 1993, DEVELOPMENT, V118, P339; ZHAO GS, 1994, P NATL ACAD SCI USA, V91, P1366, DOI 10.1073/pnas.91.4.1366; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	53	56	56	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					556	559		10.1126/science.7725101	http://dx.doi.org/10.1126/science.7725101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725101				2022-12-24	WOS:A1995QV40700034
J	STJOHNSTON, D				STJOHNSTON, D			THE INTRACELLULAR-LOCALIZATION OF MESSENGER-RNAS	CELL			English	Review							XENOPUS-OOCYTES; DROSOPHILA OOGENESIS; BICOID RNA; POSTERIOR DETERMINANT; INSITU HYBRIDIZATION; BINDING PROTEIN; VEGETAL CORTEX; ANTERIOR POLE; GERM PLASM; TGF-BETA		UNIV CAMBRIDGE, DEPT GENET, CAMBRIDGE CB2 1QR, ENGLAND	University of Cambridge	STJOHNSTON, D (corresponding author), UNIV CAMBRIDGE, INST CANC RES CAMPAIGN, WELLCOME TRUST, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.		St Johnston, Daniel/C-9568-2009	St Johnston, Daniel/0000-0001-5582-3301	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; Ainger K., 1993, Molecular Biology of the Cell, V4, p421A; BASSELL GJ, 1994, J CELL BIOL, V126, P863, DOI 10.1083/jcb.126.4.863; BASSELL GJ, 1994, NEURON, V12, P571, DOI 10.1016/0896-6273(94)90213-5; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BRUCKENSTEIN DA, 1990, NEURON, V5, P809, DOI 10.1016/0896-6273(90)90340-L; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DALBY B, 1993, EMBO J, V12, P1219, DOI 10.1002/j.1460-2075.1993.tb05763.x; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DAVIS I, 1993, COLD SPRING HARB SYM, V58, P793, DOI 10.1101/SQB.1993.058.01.086; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; DING D, 1993, MOL CELL BIOL, V13, P3773, DOI 10.1128/MCB.13.6.3773; DING D, 1993, BIOESSAYS, V15, P651, DOI 10.1002/bies.950151004; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; Driever Wolfgang, 1993, P301; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; ELINSON RP, 1993, DEV BIOL, V160, P554, DOI 10.1006/dbio.1993.1329; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GERGEN JP, 1988, GENE DEV, V2, P1179, DOI 10.1101/gad.2.9.1179; GUTZEIT H, 1986, ROUX ARCH DEV BIOL, V195, P173, DOI 10.1007/BF02439435; HILL MA, 1993, J CELL BIOL, V122, P825, DOI 10.1083/jcb.122.4.825; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; JEFFERY WR, 1983, DEV BIOL, V99, P408, DOI 10.1016/0012-1606(83)90290-7; JONGENS TA, 1992, CELL, V70, P569, DOI 10.1016/0092-8674(92)90427-E; JONGENS TA, 1994, GENE DEV, V8, P2123, DOI 10.1101/gad.8.18.2123; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Kim-Ha Jeongsil, 1993, Development (Cambridge), V119, P169; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; KLEIMAN R, 1990, NEURON, V5, P821, DOI 10.1016/0896-6273(90)90341-C; KLOC M, 1995, DEVELOPMENT, V121, P287; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; KU M, 1993, DEVELOPMENT, V119, P1161; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; LITMAN P, 1994, NEURON, V13, P1463, DOI 10.1016/0896-6273(94)90432-4; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MACDONALD PM, 1993, DEVELOPMENT, V118, P1233; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MORRIS EJ, 1994, J CELL SCI, V107, P377; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; NEWMARK PA, 1994, DEVELOPMENT, V120, P1303; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; RAFF JW, 1990, DEVELOPMENT, V110, P1249; RAN B, 1994, DEVELOPMENT, V120, P1233; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHWARTZ SP, 1992, P NATL ACAD SCI USA, V89, P11895, DOI 10.1073/pnas.89.24.11895; STEPHENSON EC, 1988, GENE DEV, V2, P1655, DOI 10.1101/gad.2.12a.1655; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TORRE ER, 1992, J NEUROSCI, V12, P762; TRAPP BD, 1987, P NATL ACAD SCI USA, V84, P7773, DOI 10.1073/pnas.84.21.7773; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; WILSON IA, 1995, IN PRESS BIOCH J; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	88	467	473	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 21	1995	81	2					161	170		10.1016/0092-8674(95)90324-0	http://dx.doi.org/10.1016/0092-8674(95)90324-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736568	Bronze			2022-12-24	WOS:A1995QV41000003
J	ZHOU, QY; QUAIFE, CJ; PALMITER, RD				ZHOU, QY; QUAIFE, CJ; PALMITER, RD			TARGETED DISRUPTION OF THE TYROSINE-HYDROXYLASE GENE REVEALS THAT CATECHOLAMINES ARE REQUIRED FOR MOUSE FETAL DEVELOPMENT	NATURE			English	Article							SUPERIOR CERVICAL-GANGLION; MICE; RAT; CELLS; PHENOTYPE; PROTOONCOGENE; NEURONS; BRAIN	TYROSINE hydroxylase catalyses the initial, rate-limiting step in the catecholamine biosynthetic pathway. Catecholamines, which include dopamine, noradrenaline, and adrenaline, are important neurotransmitters and hormones that regulate visceral functions, motor coordination and arousal in adults(1). The gene encoding tyrosine hydroxylase becomes transcriptionally active in developing neuroblasts during mid-gestation of rodent embryos, before the onset of neurotransmission(2-6). Here we show that inactivation of both tyrosine hydroxylase alleles results in mid-gestational lethality: about 90% of mutant embryos die between embryonic days 11.5 and 15.5, apparently of cardiovascular failure. Administration of L-DOPA (dihydroxyphenylalanine), the product of the tyrosine hydroxylase reaction, to pregnant females results in complete rescue of mutant mice in utero. Without further treatment, however, they die before weaning. We conclude that catecholamines are essential for mouse fetal development and postnatal survival.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	ZHOU, QY (corresponding author), UNIV WASHINGTON, HOWARD HUGHES MED INST, SL-15, SEATTLE, WA 98195 USA.							BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; COCHARD P, 1978, P NATL ACAD SCI USA, V75, P2986, DOI 10.1073/pnas.75.6.2986; COOPER JR, 1991, BIOCH BASIS NEUROPHA, P221; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DELATORRE JC, 1980, J NEUROSCI METH, V3, P1, DOI 10.1016/0165-0270(80)90029-1; GERSHON MD, 1984, J NEUROSCI, V4, P2269; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HALL AK, 1991, J NEUROSCI, V11, P472; IWATA N, 1992, BIOCHEM BIOPH RES CO, V182, P348, DOI 10.1016/S0006-291X(05)80151-2; JONAKAIT GM, 1989, J HISTOCHEM CYTOCHEM, V37, P1; KATO T, 1987, BIOCHEM PHARMACOL, V36, P3051, DOI 10.1016/0006-2952(87)90223-1; Kaufman M.H., 1992, ATLAS MOUSE DEV; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; OMALLEY KL, 1988, NUCLEIC ACIDS RES, V16, P4437; RUBIN E, 1985, J NEUROSCI, V5, P673; Sambrook J., 1989, MOL CLONING LAB MANU; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPECHT LA, 1981, J COMP NEUROL, V199, P233, DOI 10.1002/cne.901990207; TEITELMAN G, 1979, P NATL ACAD SCI USA, V76, P509, DOI 10.1073/pnas.76.1.509; TEITELMAN G, 1981, DEV BIOL, V86, P348, DOI 10.1016/0012-1606(81)90192-5; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M	22	375	384	0	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 13	1995	374	6523					640	643		10.1038/374640a0	http://dx.doi.org/10.1038/374640a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715703				2022-12-24	WOS:A1995QT18900059
J	LEMAIRE, P; GARRETT, N; GURDON, JB				LEMAIRE, P; GARRETT, N; GURDON, JB			EXPRESSION CLONING OF SIAMOIS, A XENOPUS HOMEOBOX GENE EXPRESSED IN DORSAL VEGETAL CELLS OF BLASTULAS AND ABLE TO INDUCE A COMPLETE SECONDARY AXIS	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; MESODERM INDUCTION; SPEMANN ORGANIZER; VENTRALIZING FACTOR; INJECTED XWNT-8; LAEVIS EMBRYOS; MESSENGER-RNAS; EARLY RESPONSE; GASTRULA; HOMOLOG	Using an expression cloning strategy that relies on a functional assay, we have cloned a novel Xenopus homeobox-containing gene, Siamois. Embryos injected in a ventral-vegetal blastomere with as little as 5 pg of Siamois mRNA develop a complete secondary axis, but the progeny of the injected cells do not participate in the secondary axis formation. In normal development, Siamois mRNA is first detected shortly after the midblastula transition, which is earlier than mRNAs for goosecoid or Xbrachyury, and is present most abundantly in the dorsal endoderm of early gastrulae. The activation of this gene can be obtained cell autonomously in dispersed embryo cells. These results indicate that Siamois may play an important role in the formation of the Nieuwkoop center.	CANC RES CAMPAIGN INST,WELLCOME TRUST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	CRUK Cambridge Institute; Wellcome Trust Sanger Institute; University of Cambridge			Lemaire, Patrick/D-4237-2009; Lemaire, Patrick/P-8228-2019; Lemaire, Patrick/B-5560-2012	Lemaire, Patrick/0000-0003-4925-2009; Lemaire, Patrick/0000-0003-4925-2009; GURDON, JOHN/0000-0002-5621-3799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DALE L, 1987, DEVELOPMENT, V99, P527; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, J BIOL CHEM, V269, P6259; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1986, DEV BIOL, V115, P340, DOI 10.1016/0012-1606(86)90254-X; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HEWITT JE, 1994, HUM MOL GENET, V3, P1287, DOI 10.1093/hmg/3.8.1287; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KATO K, 1992, P NATL ACAD SCI USA, V90, P1310; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KU M, 1993, DEVELOPMENT, V119, P1161; LEMAIRE P, 1994, DEVELOPMENT, V120, P1191; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; Vize P. D., 1991, METHOD CELL BIOL, V36, P368	30	469	477	1	15	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					85	94		10.1016/0092-8674(95)90373-9	http://dx.doi.org/10.1016/0092-8674(95)90373-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720076	Bronze			2022-12-24	WOS:A1995QR97000010
J	MOL, CD; ARVAI, AS; SLUPPHAUG, G; KAVLI, B; ALSETH, I; KROKAN, HE; TAINER, JA				MOL, CD; ARVAI, AS; SLUPPHAUG, G; KAVLI, B; ALSETH, I; KROKAN, HE; TAINER, JA			CRYSTAL-STRUCTURE AND MUTATIONAL ANALYSIS OF HUMAN URACIL-DNA GLYCOSYLASE - STRUCTURAL BASIS FOR SPECIFICITY AND CATALYSIS	CELL			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; VACCINIA VIRUS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; MISMATCH-REPAIR; CODING SEQUENCE; GENE; GENOME; ENZYME	Crystal structures of the DNA repair enzyme human uracil-DNA glycosylase (UDG), combined with mutational analysis, reveal the structural basis for the specificity of the enzyme. Within the classic alpha/beta told of UDG, sequence-conserved residues form a positively charged, active-site groove the width of duplex DNA, at the C-terminal edge of the central four-stranded parallel beta sheet. In the UDG-6-aminouracil complex, uracil binds at the base of the groove within a rigid preformed pocket that confers selectivity for uracil over other bases by shape complementarity and by main chain and Asn-204 side chain hydrogen bonds. Main chain nitrogen atoms are positioned to stabilize the oxyanion intermediate generated by His-268 acting via nucleophilic attack or general base mechanisms. Specific binding of uracil flipped out from a DNA duplex provides a structural mechanism for damaged base recognition.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV TRONDHEIM, UNIGEN CTR MOLEC BIOL, N-7005 TRONDHEIM, NORWAY	Scripps Research Institute			Slupphaug, Geir/AAN-3794-2020; Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Slupphaug, Geir/0000-0002-7498-3500	NIGMS NIH HHS [GM 46312] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046312] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Barnes DE, 1993, CURR OPIN CELL BIOL, V5, P424, DOI 10.1016/0955-0674(93)90007-D; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CROUZET J, 1990, J BACTERIOL, V172, P5980, DOI 10.1128/jb.172.10.5980-5990.1990; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; ELLIS SR, 1989, MOL CELL BIOL, V9, P1611, DOI 10.1128/MCB.9.4.1611; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HAUG T, 1994, FEBS LETT, V353, P180, DOI 10.1016/0014-5793(94)01042-0; IMPELLIZZERI KJ, 1991, J BACTERIOL, V173, P6807, DOI 10.1128/jb.173.21.6807-6810.1991; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; KUHN LA, 1992, J MOL BIOL, V228, P13, DOI 10.1016/0022-2836(92)90487-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEJEAN V, 1990, NUCLEIC ACIDS RES, V18, P6693, DOI 10.1093/nar/18.22.6693; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MOORE MH, 1994, EMBO J, V13, P1495, DOI 10.1002/j.1460-2075.1994.tb06410.x; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MULLER SJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P197, DOI 10.1016/0167-4781(91)90055-Q; MYERS LC, 1994, CURR OPIN STRUC BIOL, V4, P51, DOI 10.1016/S0959-440X(94)90059-0; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; PERCIVAL KJ, 1989, J BIOL CHEM, V264, P2593; READ RJ, 1975, ACTA CRYSTALLOGR A, V42, P140; RICHARDSON JS, 1990, PREDICTION PROTEIN S, P2; ROSEMAN NA, 1987, J VIROL, V61, P1398, DOI 10.1128/JVI.61.5.1398-1406.1987; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SHCHELKUNOV SN, 1993, DOKL AKAD NAUK+, V328, P629; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SLUPPHAUG G, 1991, NUCLEIC ACIDS RES, V19, P5131, DOI 10.1093/nar/19.19.5131; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; TALPAERTBORLE M, 1982, J BIOL CHEM, V257, P1208; TARTAGLIA J, 1990, J GEN VIROL, V71, P1517, DOI 10.1099/0022-1317-71-7-1517; TELFORD EAR, 1992, VIROLOGY, V189, P304, DOI 10.1016/0042-6822(92)90706-U; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; UPTON C, 1993, P NATL ACAD SCI USA, V90, P4518, DOI 10.1073/pnas.90.10.4518; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776; WITTWER CU, 1985, BIOCHIM BIOPHYS ACTA, V832, P308, DOI 10.1016/0167-4838(85)90264-X; WORRAD DM, 1988, J VIROL, V62, P4774, DOI 10.1128/JVI.62.12.4774-4777.1988; YASUI A, 1992, MUTAT RES, V273, P231, DOI 10.1016/0921-8777(92)90084-G; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	59	339	351	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 24	1995	80	6					869	878		10.1016/0092-8674(95)90290-2	http://dx.doi.org/10.1016/0092-8674(95)90290-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697717	Bronze			2022-12-24	WOS:A1995QP61200006
J	MARRS, KA; ALFENITO, MR; LLOYD, AM; WALBOT, V				MARRS, KA; ALFENITO, MR; LLOYD, AM; WALBOT, V			A GLUTATHIONE-S-TRANSFERASE INVOLVED IN VACUOLAR TRANSFER ENCODED BY THE MAIZE GENE BRONZE-2	NATURE			English	Article							CONJUGATE EXPORT PUMP; STRUCTURAL-ANALYSIS; ZEA-MAYS; TOBACCO; PROTOPLASTS; ARABIDOPSIS; EXPRESSION; MEMBRANE; PROTEIN; FAMILY	GLUTATHIONE S-transferases (GSTs) are enzymes that detoxify heterocyclic compounds (xenobiotics) by covalently linking glutathione to the substrate, forming a glutathione S-conjugate(1,2). A glutathione pump in the vacuolar membrane of barley actively sequesters herbicide-glutathione S-conjugates; glutathionation allows recognition and entry of the conjugates into vacuoles(3). The protein encoded by the Bronze-2 gene in maize performs the last genetically defined step in anthocyanin biosynthesis, resulting in the deposition of red and purple pigments in the vacuoles of maize tissues(4). We show here that Bz2 encodes a GST with activity in maize, transformed Arabidopsis thaliana plants and Escherichia coli. We demonstrate that anthocyanins extracted from maize protoplasts expressing BZ2 are conjugated with glutathione, and that vanadate, a known inhibitor of the glutathione pump(3) in plant vacuolar membranes, inhibits the accumulation of anthocyanins in the vacuole. These results provide a biochemical function for BZ2, and suggest a common mechanism for the ability of plants to sequester structurally similar but functionally diverse molecules in the vacuole.			MARRS, KA (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.			Walbot, Virginia/0000-0002-1596-7279				BODEAU JP, 1992, MOL GEN GENET, V233, P379, DOI 10.1007/BF00265434; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Coe E. H. Jr., 1988, Corn and corn improvement. Third edition., P81; CZAMECKA E, 1988, MOL CELL BIOL, V8, P113; DROOG FNJ, 1993, PLANT MOL BIOL, V21, P965, DOI 10.1007/BF00023595; DUDLER R, 1991, MOL PLANT MICROBE IN, V4, P14, DOI 10.1094/MPMI-4-014; GOFF SA, 1990, EMBO J, V9, P2517, DOI 10.1002/j.1460-2075.1990.tb07431.x; GROVE G, 1988, NUCLEIC ACIDS RES, V16, P425, DOI 10.1093/nar/16.2.425; Harborne J. B. M. T. J. M. H., 1975, FLAVONOIDS; HARBORNE JB, 1986, PHYTOCHEMISTRY, V25, P1887, DOI 10.1016/S0031-9422(00)81168-1; HARBORNE JB, 1987, PHYTOCHEMISTRY, V26, P2417, DOI 10.1016/S0031-9422(00)84738-X; IRZYK GP, 1982, PLANT PHYSIOL, V102, P803; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; LAMOUREUX GL, 1983, PESTICIDE CHEM HUMAN, P295; LAMOUREUX GL, 1981, SULFUR PESTICIDE ACT, P133; LLOYD AM, 1992, SCIENCE, V258, P1773, DOI 10.1126/science.1465611; Mannervik B, 1981, Methods Enzymol, V77, P231; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; NASH J, 1993, PLANT PHYSIOL, V100, P464; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PILUKA S, 1994, J BIOL CHEM, V269, P27566; SANDERMANN H, 1992, TRENDS BIOCHEM SCI, V17, P82, DOI 10.1016/0968-0004(92)90507-6; SCHMITZ G, 1992, MOL GEN GENET, V233, P269, DOI 10.1007/BF00587588; SHAH DM, 1986, PLANT MOL BIOL, V6, P203, DOI 10.1007/BF00015226; TAKAHASHI Y, 1991, PLANT J, V1, P327, DOI 10.1046/j.1365-313X.1991.t01-2-00999.x; TAYLOR JL, 1990, MOL PLANT MICROBE IN, V3, P72; TIMMERMAN KP, 1989, PHYSIOL PLANTARUM, V77, P465, DOI 10.1111/j.1399-3054.1989.tb05668.x; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VANDERZAAL EJ, 1991, PLANT MOL BIOL, V16, P983, DOI 10.1007/BF00016071; WALBOT V, 1994, MAYDICA, V39, P19	30	446	503	5	92	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					397	400		10.1038/375397a0	http://dx.doi.org/10.1038/375397a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760932				2022-12-24	WOS:A1995RB10100051
J	LOTAN, R; XU, XC; LIPPMAN, SM; RO, JY; LEE, JS; LEE, JJ; HONG, WK				LOTAN, R; XU, XC; LIPPMAN, SM; RO, JY; LEE, JS; LEE, JJ; HONG, WK			SUPPRESSION OF RETINOIC ACID RECEPTOR-BETA IN PREMALIGNANT ORAL LESIONS AND ITS UP-REGULATION BY ISOTRETINOIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; MESSENGER-RNA LEVELS; HUMAN LUNG-CANCER; NUCLEAR RECEPTORS; VITAMIN-A; EXPRESSION; LINES; KERATINOCYTES; KERATIN-19; TISSUES	Background. Retinoids are effective in the treatment and prevention of certain human cancers. Most of their actions are thought to result from changes in gene expression mediated by nuclear retinoic acid receptors and retinoid X receptors. We conducted a study to determine whether the expression of these receptors was altered in premalignant oral lesions and, if so, whether their expression could be restored by treatment with isotretinoin. Methods. We performed in situ hybridization of retinoic acid receptors and retinoid X receptors using antisense riboprobes in specimens of oral mucosa from 7 normal subjects and specimens of premalignant oral lesions from 52 patients before treatment with isotretinoin and from 39 of the 52 patients after three months of treatment. Results. All the normal specimens expressed retinoic acid receptor-beta messenger RNA (mRNA). In contrast, retinoic acid receptor-beta mRNA was detected in only 21 of the 52 premalignant oral lesions (P = 0.003). Thirty-five of the 39 specimens available for evaluation after treatment expressed retinoic acid receptor-beta mRNA (P<0.001). All normal and premalignant specimens expressed similar levels of mRNA for retinoic acid receptor-alpha and retinoic acid receptor-gamma and the three types of retinoid X receptors, alpha, beta, and gamma. The levels of retinoic acid receptor-beta mRNA increased in the specimens from 18 of the 22 patients who had responses to isotretinoin and in 8 of the 17 specimens from the patients without responses (P = 0.04). Conclusions. The expression of retinoic acid receptor-beta mRNA is selectively lost in premalignant oral lesions and can be restored by treatment with isotretinoin. Restoration of the expression of retinoic acid receptor-beta mRNA is associated with a clinical response. Retinoic acid receptor-beta may have a role in mediating the response to retinoids and may be a useful intermediate biologic marker in trials of these agents for the prevention of oral carcinogenesis.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT THORAC HEAD & NECK MED ONCOL, HOUSTON, TX USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT PATHOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOMATH, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	LOTAN, R (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL 108, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.		Center, Univ of Texas-M D Anderson Cancer/AAE-8182-2019; Lee, Jack/P-7331-2019	Center, Univ of Texas-M D Anderson Cancer/0000-0001-5469-9214; Lee, Jack/0000-0002-4584-929X	NATIONAL CANCER INSTITUTE [U01CA046303, P01CA052051] Funding Source: NIH RePORTER; NCI NIH HHS [CA46303, P01 CA 52051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTSCH D, 1992, EMBO J, V11, P2283, DOI 10.1002/j.1460-2075.1992.tb05287.x; BENNER SE, 1994, J NATL CANCER I, V86, P140, DOI 10.1093/jnci/86.2.140; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHIESA F, 1992, ORAL ONCOL, V28B, P97; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; CROWE DL, 1991, DIFFERENTIATION, V48, P199, DOI 10.1111/j.1432-0436.1991.tb00258.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FRANGIONI JV, 1994, J CELL SCI, V107, P827; GEBERT, 1992, ONCOGENE, V7, P821; GEBERT JF, 1991, ONCOGENE, V6, P1859; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Gudas Lorraine J., 1994, P443; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Haq R, 1991, Biochem Biophys Res Commun, V180, P1137; HARNISH DC, 1990, DIFFERENTIATION, V45, P103, DOI 10.1111/j.1432-0436.1990.tb00463.x; Hong Waun Ki, 1994, P597; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; KATO S, 1992, BIOCHEM J, V286, P755, DOI 10.1042/bj2860755; KRUYT FAE, 1993, MOL ENDOCRINOL, V7, P604, DOI 10.1210/me.7.4.604; LIPPMAN SM, 1993, NEW ENGL J MED, V328, P15, DOI 10.1056/NEJM199301073280103; LIPPMAN SM, 1994, J CLIN ONCOL, V12, P851, DOI 10.1200/JCO.1994.12.4.851; LIPPMAN SM, 1990, JNCI-J NATL CANCER I, V82, P555, DOI 10.1093/jnci/82.7.555; LOTAN R, 1991, BIOMED PHARMACOTHER, V45, P145, DOI 10.1016/0753-3322(91)90102-Y; Mangelsdorf David J., 1994, P319; MEYSKENS FL, 1994, J NATL CANCER I, V86, P539, DOI 10.1093/jnci/86.7.539; MIQUEL C, 1992, MOL BIOL REP, V17, P35; MORRISSKAY G, 1992, CANCER SURV, V14, P181; NERVI C, 1991, EXP CELL RES, V195, P163, DOI 10.1016/0014-4827(91)90512-S; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; VERMA AK, 1992, J NUTR, V122, P2144, DOI 10.1093/jn/122.11.2144; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Woolson R. F, 1987, STATISTICAL METHODS; XU XC, 1994, DIAGN MOL PATHOL, V3, P122, DOI 10.1097/00019606-199406000-00009; XU XC, 1994, CANCER RES, V54, P3580	43	369	372	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1405	1410		10.1056/NEJM199505253322103	http://dx.doi.org/10.1056/NEJM199505253322103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY941	7723796	Bronze			2022-12-24	WOS:A1995QY94100003
J	MICHIELS, F; HABETS, GGM; STAM, JC; VANDERKAMMEN, RA; COLLARD, JG				MICHIELS, F; HABETS, GGM; STAM, JC; VANDERKAMMEN, RA; COLLARD, JG			A ROLE FOR RAC IN TIAM1-INDUCED MEMBRANE RUFFLING AND INVASION	NATURE			English	Article							GTP-BINDING-PROTEIN; ONCOGENE PRODUCT; RHO GDI; EXCHANGE; TRANSFECTION; CELLS; GENE	RHO-LIKE GTPases have been implicated in the regulation of the actin cytoskeleton which controls the morphology, adhesion and motility of cells(1-3). Like Ras proteins, they become activated when bound GDP is exchanged for GTP, a process catalysed by GDP-dissociation stimulator (GDS) proteins(4). Several GDS proteins specific for Rho-like GTPases have been identified(5-8). Most of these contain a conserved catalytic domain, the DBL-homology (DH) domain(9), and activate Cdc42 or Rho but not Rac(5-8). We have isolated the invasion-inducing Tiam1 gene, which also encodes a protein with a DH domain(10). Here we show that Tiam1 is a GDS protein for Rho-like GTPases in vitro. In fibroblasts, Tiam1 induces a similar phenotype as constitutively activated (V12)Rac1, including membrane ruffling, and this is inhibited by dominant negative (N17)Rac1. Moreover, T-lymphoma cells expressing V12Rac1 become invasive, indicating that the Tiam1-Rac signalling pathway could be operating in the invasion and metastasis of tumour cells.	NETHERLANDS CANC INST, DIV CELL BIOL, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute								BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; COLLARD JG, 1987, CANCER RES, V47, P754; COOK S, 1994, NATURE, V369, P361, DOI 10.1038/369361a0; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HABETS GGM, 1995, ONCOGENE, V10, P1371; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HORLI Y, 1994, EMBO J, V13, P4776; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	26	508	521	1	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					338	340		10.1038/375338a0	http://dx.doi.org/10.1038/375338a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753201				2022-12-24	WOS:A1995RA03000057
J	WARLOW, C				WARLOW, C			ENDARTERECTOMY FOR ASYMPTOMATIC CAROTID STENOSIS	LANCET			English	Editorial Material							POPULATION; PREVALENCE; BRUIT				WARLOW, C (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP NHS TRUST,DEPT CLIN NEUROSCI,EDINBURGH,MIDLOTHIAN,SCOTLAND.							[Anonymous], 1992, Mayo Clin Proc, V67, P513; CLAGETT GP, 1984, SURGERY, V96, P823; HALLIDAY AW, 1994, EUR J VASCULAR SURG, V8, P703; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; LAGNEAU P, 1993, J MAL VASCUL, V18, P209; MEISSNER I, 1987, JAMA-J AM MED ASSOC, V258, P2704; MITCHELL J R, 1962, Br Med J, V1, P1293; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; PRATI P, 1992, STROKE, V23, P1705, DOI 10.1161/01.STR.23.12.1705; RICCI S, 1991, CEREBROVASC DIS, V1, P16, DOI 10.1159/000108810; ROTHWELL PM, 1994, STROKE, V25, P2435, DOI 10.1161/01.STR.25.12.2435; WIEBERS DO, 1990, STROKE, V21, P984, DOI 10.1161/01.STR.21.7.984; 1991, LANCET, V337, P1235; 1995, JAMA-J AM MED ASSOC, V273, P1421; 1995, LANCET, V345, P209; 1991, STROKE, V22, P1229; 1993, MANAGEMENT PATIENTS; 1991, NEW ENGL J MED, V325, P445	19	68	69	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1254	1255		10.1016/S0140-6736(95)90920-6	http://dx.doi.org/10.1016/S0140-6736(95)90920-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746052				2022-12-24	WOS:A1995QY93300004
J	COLAMARINO, SA; TESSIERLAVIGNE, M				COLAMARINO, SA; TESSIERLAVIGNE, M			THE AXONAL CHEMOATTRACTANT NETRIN-1 IS ALSO A CHEMOREPELLENT FOR TROCHLEAR MOTOR AXONS	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD; C-ELEGANS; NEURITE OUTGROWTH; GUIDES CELL; NEURONS; RAT; OCULOMOTOR; EXPRESSION; GUIDANCE	Extending axons are guided in part by diffusible chemoattractants that lure them to their targets and by diffusible chemorepellents that keep them away from nontarget regions. Floor plate cells at the ventral midline of the neural tube express a diffusible chemoattractant, netrin-1, that attracts a group of ventrally directed axons. Here we report that floor plate cells also have a long-range repulsive effect on a set of axons, trochlear motor axons, that grow dorsally away from the floor plate in vivo. COS cells secreting recombinant netrin-1 mimic this effect, suggesting that netrin-1 is a bifunctional guidance cue that simultaneously attracts some axons to the floor plate while steering others away. This bifunctionality of netrin-1 in vertebrates mirrors the dual actions of UNC-6, a C. elegans homolog of netrin-1, which is involved in guiding both dorsal and ventral migrations in the nematode.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, DEV BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, NEUROSCI PROGRAM, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	COLAMARINO, SA (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA.							ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; ALTMAN J, 1981, J COMP NEUROL, V198, P677, DOI 10.1002/cne.901980409; BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; CHEDOTAL A, 1995, EUR J NEUROSCI, V7, P198, DOI 10.1111/j.1460-9568.1995.tb01056.x; COWAN WM, 1967, J EXP ZOOL, V164, P267, DOI 10.1002/jez.1401640210; DEROUICHE A, 1994, J COMP NEUROL, V341, P340, DOI 10.1002/cne.903410305; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; FRITZSCH B, 1993, DEV BRAIN RES, V74, P122, DOI 10.1016/0165-3806(93)90091-N; FRITZSCH B, 1990, NEUROSCI LETT, V114, P129, DOI 10.1016/0304-3940(90)90060-M; FRITZSCH B, 1988, CELL TISSUE RES, V252, P223; FRITZSCH B, 1995, IN PRESS J NEUROBIOL; GODEMENT P, 1987, DEVELOPMENT, V101, P697; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GUTHRIE S, 1995, IN PRESS NEURON, V14; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATESZ C, 1990, NEUROSCI LETT, V116, P1, DOI 10.1016/0304-3940(90)90376-K; MATTHES D, 1985, CELL, V81, P631; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; MURPHY EH, 1990, J COMP NEUROL, V295, P685; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; PRINCE JT, 1992, DEV BRAIN RES, V68, P193, DOI 10.1016/0165-3806(92)90061-Z; PUELLES L, 1977, ANAT EMBRYOL, V150, P187, DOI 10.1007/BF00316650; RAMONYCAJAL S, 1892, CELLULE, V9, P119; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SINCLAIR JOHN G., 1958, TEXAS REPTS BIOL AND MED, V16, P253; SOHAL GS, 1985, J COMP NEUROL, V239, P227, DOI 10.1002/cne.902390209; SOHAL GS, 1977, EXP NEUROL, V56, P227, DOI 10.1016/0014-4886(77)90152-2; SOHAL GS, 1991, J COMP NEUROL, V304, P187, DOI 10.1002/cne.903040204; SOHAL GS, 1991, J NEUROSCI, V23, P10; SONNTAG R, 1987, NEUROSCI LETT, V77, P143, DOI 10.1016/0304-3940(87)90576-3; Szekely G, 1993, Adv Anat Embryol Cell Biol, V128, P1; TAMADA A, 1995, IN PRESS NEURON, V14; TESSIERLAVIGNE M, 1994, CURR OPIN GENET DEV, V4, P596, DOI 10.1016/0959-437X(94)90078-H; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; WEHRLE B, 1990, DEVELOPMENT, V110, P401; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	50	492	505	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					621	629		10.1016/0092-8674(95)90083-7	http://dx.doi.org/10.1016/0092-8674(95)90083-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758116	Bronze			2022-12-24	WOS:A1995QZ71000019
J	DESTAFANO, F				DESTAFANO, F			EFFECTS OF AGENT-ORANGE EXPOSURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							VIETNAM VETERANS; ADIPOSE-TISSUE; DIBENZOFURANS; DIOXINS				DESTAFANO, F (corresponding author), MARSHFIELD MED RES & EDUC FDN,MARSHFIELD,WI 54449, USA.							ERICKSON JD, 1984, JAMA-J AM MED ASSOC, V252, P903, DOI 10.1001/jama.252.7.903; JORDAN BK, 1991, ARCH GEN PSYCHIAT, V48, P207, DOI 10.1001/archpsyc.1991.01810270019002; KAHN PC, 1988, JAMA-J AM MED ASSOC, V259, P1661, DOI 10.1001/jama.259.11.1661; KANG HK, 1991, AM J PUBLIC HEALTH, V81, P344, DOI 10.2105/AJPH.81.3.344; SCHECTER A, 1987, 7TH INT S CHLOR DIOX; WOLFE WH, 1990, JAMA-J AM MED ASSOC, V264, P1824, DOI 10.1001/jama.264.14.1824; 1988, JAMA-J AM MED ASSOC, V259, P2715; 1989, HLTH STATUS VIETNAM, V2; 1990, ARCH INTERN MED, V150, P2495; 1988, JAMA-J AM MED ASSOC, V259, P2708; 1990, ARCH INTERN MED, V150, P2485; 1990, ARCH INTERN MED, V150, P2473; 1988, JAMA-J AM MED ASSOC, V260, P1249; 1987, JAMA-J AM MED ASSOC, V257, P790; 1988, JAMA-J AM MED ASSOC, V259, P2701	15	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1494	1494		10.1001/jama.273.19.1494	http://dx.doi.org/10.1001/jama.273.19.1494			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739073				2022-12-24	WOS:A1995QX41800029
J	BLACKSTONE, M				BLACKSTONE, M			COLORECTAL ADENOMAS ON FOLLOW-UP COLONOSCOPY - IS THE CANCER RISK UNCHANGED	LANCET			English	Editorial Material							POLYPS				BLACKSTONE, M (corresponding author), UNIV CHICAGO,DEPT MED,GASTROENTEROL SECT,CHICAGO,IL 60637, USA.							ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; HOFF G, 1986, SCAND J GASTROENTERO, V21, P853, DOI 10.3109/00365528609011130; NEUGUT AI, 1995, GASTROENTEROLOGY, V108, P402, DOI 10.1016/0016-5085(95)90066-7; OBRIEN MJ, 1990, GASTROENTEROLOGY, V98, P371, DOI 10.1016/0016-5085(90)90827-N; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	7	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1126	1127		10.1016/S0140-6736(95)90970-2	http://dx.doi.org/10.1016/S0140-6736(95)90970-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723538				2022-12-24	WOS:A1995QW62200002
J	MA, JKC; HIATT, A; HEIN, M; VINE, ND; WANG, F; STABILA, P; VANDOLLEWEERD, C; MOSTOV, K; LEHNER, T				MA, JKC; HIATT, A; HEIN, M; VINE, ND; WANG, F; STABILA, P; VANDOLLEWEERD, C; MOSTOV, K; LEHNER, T			GENERATION AND ASSEMBLY OF SECRETORY ANTIBODIES IN PLANTS	SCIENCE			English	Article							LOCAL PASSIVE-IMMUNIZATION; IMMUNOGLOBULIN-A; MONOCLONAL-ANTIBODIES; STREPTOCOCCUS-MUTANS; EPITHELIAL TRANSPORT; MUCOSAL IMMUNITY; J-CHAIN; IGA; EXPRESSION; COMPONENT	Four transgenic Nicotiana tabacum plants were generated that expressed a murine monoclonal antibody kappa chain, a hybrid immunoglobulin A-G heavy chain, a murine joining chain, and a rabbit secretory component, respectively. Successive sexual crosses between these plants and filial recombinants resulted in plants that expressed all four protein chains simultaneously. These chains were assembled into a functional, high molecular weight secretory immunoglobulin that recognized the native streptococcal antigen I/II cell surface adhesion molecule. In plants, single cells are able to assemble secretory antibodies, whereas two different cell types are required in mammals. Transgenic plants may be suitable for large-scale production of recombinant secretory immunoglobulin A for passive mucosal immunotherapy. Plant cells also possess the requisite mechanisms for assembly and expression of other complex recombinant protein molecules.	PLANET BIOTECHNOL, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT CELL BIOL, DIV PLANT BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN FRANCISCO, SCH MED, SAN FRANCISCO, CA 94143 USA	Scripps Research Institute; University of California System; University of California San Francisco	MA, JKC (corresponding author), UNITED MED & DENT SCH, GUYS HOSP, DEPT IMMUNOL, 28TH FLOOR, GUYS TOWER, LONDON SE1 9RT, ENGLAND.			mostov, keith/0000-0002-8123-6247; van Dolleweerd, Craig/0000-0002-1380-6930; Ma, Julian/0000-0003-0767-0042	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHNEN DJ, 1986, J CLIN INVEST, V77, P1841, DOI 10.1172/JCI112510; APODACA G, 1993, J BIOL CHEM, V268, P20380; BARNES WM, 1990, P NATL ACAD SCI USA, V87, P9183, DOI 10.1073/pnas.87.23.9183; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BESSEN D, 1988, J EXP MED, V167, P1945, DOI 10.1084/jem.167.6.1945; BRANDTZAEG P, 1984, NATURE, V311, P71, DOI 10.1038/311071a0; CARAYANNOPOULOS L, 1994, P NATL ACAD SCI USA, V91, P8348, DOI 10.1073/pnas.91.18.8348; HEIN MB, 1991, BIOTECHNOL PROGR, V7, P455, DOI 10.1021/bp00011a011; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; KILIAN M, 1988, MICROBIOL REV, V52, P296, DOI 10.1128/MMBR.52.2.296-303.1988; KNIGHT KL, 1975, J IMMUNOL, V115, P595; LEHNER T, 1985, INFECT IMMUN, V50, P796, DOI 10.1128/IAI.50.3.796-799.1985; MA JKC, 1994, EUR J IMMUNOL, V24, P131, DOI 10.1002/eji.1830240120; MA JKC, 1990, INFECT IMMUN, V58, P3407, DOI 10.1128/IAI.58.10.3407-3414.1990; MACH JP, 1970, NATURE, V228, P1278, DOI 10.1038/2281278a0; MATSUUCHI L, 1986, P NATL ACAD SCI USA, V83, P456, DOI 10.1073/pnas.83.2.456; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; SCHNEIDERMAN RD, 1989, P NATL ACAD SCI USA, V86, P7561, DOI 10.1073/pnas.86.19.7561; SMITH R, 1989, ORAL MICROBIOL IMMUN, V4, P153, DOI 10.1111/j.1399-302X.1989.tb00243.x; UNDERDOWN BJ, 1974, J IMMUNOL, V112, P949; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991	24	407	498	1	37	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					716	719		10.1126/science.7732380	http://dx.doi.org/10.1126/science.7732380			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732380				2022-12-24	WOS:A1995QW60300048
J	KIEFER, MC; BRAUER, MJ; POWERS, VC; WU, JJ; UMANSKY, SR; TOMEI, LD; BARR, PJ				KIEFER, MC; BRAUER, MJ; POWERS, VC; WU, JJ; UMANSKY, SR; TOMEI, LD; BARR, PJ			MODULATION OF APOPTOSIS BY THE WIDELY DISTRIBUTED BCL-2 HOMOLOG BAK	NATURE			English	Article							PROGRAMMED CELL-DEATH; MOLECULAR-CLONING; GENE; PROTEIN; RNA	MEMBERS Of the Bcl-2 family of proteins are characterized by their ability to modulate cell death, Bcl-2 and some of its homologues inhibit apoptosis(1-4), whereas other family members, such as Bax, will accelerate apoptosis under certain conditions(5). Here we describe the identification and characterization of a complementary DNA that encodes a previously unknown Bcl-2 homologue designated Bak. Like Bax, the bak gene product primarily enhances apoptotic cell death following an appropriate stimulus. Unlike Bax, however, Bak can inhibit cell death in an Epstein-Barr-virus-transformed cell line. The widespread tissue distribution of Bak messenger RNA, including those containing long-lived, terminally differentiated cell types, suggests that cell-death-inducing activity is broadly distributed, and that tissue-specific modulation of apoptosis is controlled primarily by regulation of molecules that inhibit apoptosis.			KIEFER, MC (corresponding author), LXR BIOTECHNOL INC, 1401 MARINA WAY S, RICHMOND, CA 94804 USA.							BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sambrook J., 1989, MOL CLONING LAB MANU; STRIKE LE, 1984, J IMMUNOL, V132, P1798; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; WILDE CD, 1982, NATURE, V297, P83, DOI 10.1038/297083a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAPF J, 1990, J BIOL CHEM, V265, P14892	19	483	507	2	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					736	739		10.1038/374736a0	http://dx.doi.org/10.1038/374736a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715731				2022-12-24	WOS:A1995QU30400054
J	HIDALGO, P; MACKINNON, R				HIDALGO, P; MACKINNON, R			REVEALING THE ARCHITECTURE OF A K+ CHANNEL PORE THROUGH MUTANT CYCLES WITH A PEPTIDE INHIBITOR	SCIENCE			English	Article							POTASSIUM CHANNEL; TEA BLOCKADE; BINDING-SITE; CHARYBDOTOXIN; ION; TETRAETHYLAMMONIUM; SELECTIVITY; REGION	Thermodynamic mutant cycles provide a formalism for studying energetic coupling between amino acids on the interaction surface in a protein-protein complex. This approach was applied to the Shaker potassium channel and to a high-affinity peptide inhibitor (scorpion toxin) that binds to its pore entryway. The assignment of pairwise interactions defined the spatial arrangement of channel amino acids with respect to the known inhibitor structure. A strong constraint was placed on the Shaker channel pore-forming region by requiring its amino-terminal border to be 12 to 15 angstroms from the central axis. This method is directly applicable to sodium, calcium, and other ion channels where inhibitor or modulatory proteins bind with high affinity.			HIDALGO, P (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.		Hidalgo, Patricia/I-7506-2013	Hidalgo, Patricia/0000-0002-4162-6590	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; DEBIASI M, 1993, BIOPHYS J, V64, pA341; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GROSS AF, UNPUB; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HILLE B, 1975, IONIC SELECTIVITY NA, P255; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KREZEL AM, UNPUB; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; PARK CS, 1991, P NATL ACAD SCI USA, V88, P2046, DOI 10.1073/pnas.88.6.2046; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	23	417	424	1	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					307	310		10.1126/science.7716527	http://dx.doi.org/10.1126/science.7716527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716527				2022-12-24	WOS:A1995QT18500044
J	SMITH, AB; ESKO, JD; HAJDUK, SL				SMITH, AB; ESKO, JD; HAJDUK, SL			KILLING OF TRYPANOSOMES BY THE HUMAN HAPTOGLOBIN-RELATED PROTEIN	SCIENCE			English	Article							GENE; IDENTIFICATION; BRUCEI; LIVER	African trypanosomes cause disease in humans and animals. Trypanosoma brucei brucei affects cattle but not humans because of its sensitivity to a subclass of human high density lipoproteins (HDLs) called trypanosome lytic factor (TLF). TLF contains two apolipoproteins that are sufficient to cause lysis of T. b. brucei in vitro. These proteins were identified as the human haptoglobin-related protein and paraoxonase-arylesterase. An antibody to haptoglobin inhibited TLF activity. TLF was shown to exhibit peroxidase activity and to be inhibited by catalase. These results suggest that TLF kills trypanosomes by oxidative damage initiated by its peroxidase activity.	UNIV ALABAMA,SCH MED & DENT,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [AI273316] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAERNSTEIN HD, 1963, J PARASITOL, V49, P12, DOI 10.2307/3275663; BENSI G, 1985, EMBO J, V4, P119, DOI 10.1002/j.1460-2075.1985.tb02325.x; BONKOVSKY HL, 1991, AM J MED SCI, V301, P32, DOI 10.1097/00000441-199101000-00006; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONNELL GE, 1959, BIOCHEM J, V72, P115, DOI 10.1042/bj0720115; FAWCETT HAC, 1990, BIOCHIM BIOPHYS ACTA, V1048, P187, DOI 10.1016/0167-4781(90)90055-7; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; KINO K, 1980, J BIOL CHEM, V255, P9616; MAEDA N, 1985, J BIOL CHEM, V260, P6698; MCEVOY SM, 1988, J BIOL CHEM, V263, P15740; MESHNICK SR, 1977, BIOCHEM PHARMACOL, V26, P1923, DOI 10.1016/0006-2952(77)90167-8; MESHNICK SR, 1978, J EXP MED, V148, P569, DOI 10.1084/jem.148.2.569; MOLINA HA, 1989, IMMUNOLOGY, V66, P289; OSHIRO S, 1988, J BIOL CHEM, V263, P16032; RIFKIN MR, 1978, EXP PARASITOL, V46, P189, DOI 10.1016/0014-4894(78)90131-5; SEED JR, 1990, J PROTOZOOL, V37, P393, DOI 10.1111/j.1550-7408.1990.tb01163.x; TYTLER EM, 1995, MOL BIOCHEM PARASIT, V69, P9, DOI 10.1016/0166-6851(94)00172-J; YANG FM, 1983, P NATL ACAD SCI-BIOL, V80, P5875, DOI 10.1073/pnas.80.19.5875; ZECH R, 1993, CHEM-BIOL INTERACT, V87, P85, DOI 10.1016/0009-2797(93)90028-W; [No title captured]	21	147	152	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					284	286		10.1126/science.7716520	http://dx.doi.org/10.1126/science.7716520			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716520				2022-12-24	WOS:A1995QT18500037
J	ACHESON, A; CONOVER, JC; FANDL, JP; DECHIARA, TM; RUSSELL, M; THADANI, A; SQUINTO, SP; YANCOPOULOS, GD; LINDSAY, RM				ACHESON, A; CONOVER, JC; FANDL, JP; DECHIARA, TM; RUSSELL, M; THADANI, A; SQUINTO, SP; YANCOPOULOS, GD; LINDSAY, RM			A BDNF AUTOCRINE LOOP IN ADULT SENSORY NEURONS PREVENTS CELL DEATH	NATURE			English	Article							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; NEUROTROPHIC FACTOR; MESSENGER-RNA; DOPAMINERGIC-NEURONS; BRAIN; RECEPTOR; TRKB; NGF; CELLS	DURING the initial phase of their development, sensory neurons of the dorsal root ganglion (DRG) require target-derived trophic support for their survival(1-3), but as they mature they lose this requirement. Because many of these neurons express BDNF (brain-derived neurotrophic factor) messenger RNA(4,5) we hypothesized that BDNF might act as an autocrine survival factor in adult DRG neurons, thus explaining their lack of dependence on exogenous growth factors. When cultured adult DRG cells were treated with antisense oligonucleotides to BDNF, expression of BDNF protein was reduced by 80%, and neuronal survival was reduced by 35%. These neurons could be rescued by exogenous BDNF or neurotrophin-3, but not by other growth factors. Similar results were obtained with single-neuron microcultures, whereas microcultures derived from mutant mice lacking BDNF were unaffected by antisense oligonucleotides. Our results strongly support an autocrine role for BDNF in mediating the survival of a subpopulation of adult DRG neurons.			ACHESON, A (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Lindsay, Ronald/GQP-8001-2022	Conover, Joanne/0000-0003-0375-0141				ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; AGRIS CH, 1986, BIOCHEMISTRY-US, V25, P6268, DOI 10.1021/bi00368a065; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; DOHERTY P, 1987, J NEUROCHEM, V49, P1676, DOI 10.1111/j.1471-4159.1987.tb02425.x; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GALL CM, 1992, MOL CELL NEUROSCI, V3, P56, DOI 10.1016/1044-7431(92)90009-Q; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, J NEUROSCI, V13, P3394; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSON EM, 1986, TRENDS NEUROSCI, V9, P33, DOI 10.1016/0166-2236(86)90012-3; JOHNSON EM, 1985, NATURE, V314, P751, DOI 10.1038/314751a0; JONES KR, 1994, CELL, V76, P889; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Lindsay RM, 1992, SENSORY NEURONS DIVE, P404; MCMAHON SB, 1994, NEURON, V12, P1161, DOI 10.1016/0896-6273(94)90323-9; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORRISON RS, 1991, J BIOL CHEM, V266, P728; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; WETMORE C, 1990, EXP NEUROL, V109, P141, DOI 10.1016/0014-4886(90)90068-4; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x; WUPONG S, 1992, PHARMACEUT RES, V9, P1010, DOI 10.1023/A:1015846209681; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280	30	621	641	1	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					450	453		10.1038/374450a0	http://dx.doi.org/10.1038/374450a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700353				2022-12-24	WOS:A1995QP89900057
J	QIU, RG; CHEN, J; KIRN, D; MCCORMICK, F; SYMONS, M				QIU, RG; CHEN, J; KIRN, D; MCCORMICK, F; SYMONS, M			AN ESSENTIAL ROLE FOR RAC IN RAS TRANSFORMATION	NATURE			English	Article							EXPRESSION; CELLS	THE GTPase Rac(1) is a key component in the reorganization of the actin cytoskeleton that is induced by growth factors or oncogenic Ras(1). Here we investigate the role of Rac(1) in cell transformation and show that Rat(1) fibroblasts expressing activated Val-12 Rac(1) (Rac(1) with valine at residue 12) display all the hallmarks of malignant transformation. In a focus-forming assay in NIH3T3 fibroblasts to measure the efficiency of transformation, we found that dominant-negative Asn-17 Rac(1) inhibited focus formation by oncogenic Ras, but not by RafCAAX, a Raf kinase targeted to the plasma membrane by virtue of the addition of a carboxyterminal localization signal from K-Ras. This indicates that Rac is essential for transformation by Ras. In addition, Val-12 Rac(1) synergizes strongly with RafCAAX in focus-formation assays, indicating that oncogenic Ras drives both the Rac and MAP-kinase pathways, which cooperate to cause transformation.			QIU, RG (corresponding author), ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806, USA.							AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; HAWKINS PT, IN PRESS CURR BIOL; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SELF AJ, 1993, ONCOGENE, V8, P655; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320	19	771	781	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					457	459		10.1038/374457a0	http://dx.doi.org/10.1038/374457a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700355				2022-12-24	WOS:A1995QP89900059
J	GRECO, L; POWER, C; PECKHAM, C				GRECO, L; POWER, C; PECKHAM, C			ADULT OUTCOME OF NORMAL-CHILDREN WHO ARE SHORT OR UNDERWEIGHT AT AGE 7 YEARS	BRITISH MEDICAL JOURNAL			English	Article							GROWTH; NEWCASTLE; TYNE; COMMUNITY; HEIGHT; BIRTH	Objectives-To evaluate the adult growth outcome (at age 23) of children who are short or underweight at age 7 years in whom no identifiable pathological cause exists for their poor growth. Design-Longitudinal follow up of a birth cohort. Setting-The national child development study (1958 birth cohort) of Great Britain. Subjects-523 children with a height or a weight below the fifth centile at age 7. Of these, 70 (13 . 4%) were excluded because they had a longstanding illness that could account for their poor growth. The remaining 453 subjects, who were followed to age 23, provided the base group from which those with additional data, such as parental height, were obtained. Results-55/174 (31 . 6%) boys who were short at age 7 became short men; 60/211 (28 . 4%) girls who were short at age 7 became short women. Among boys who were underweight at age 7, 46/160 (28 . 7%) were still underweight at age 23, while 61/200 (30 . 5%) girls underweight at age 7 became underweight women. Having short parents did not increase the probability of being small as an adult. Children with delayed puberty were as likely to remain small as those in whom puberty was not delayed. Conclusions-One in three normal children who was short or underweight at age 7 became a short or underweight adult. This informs the management of short children and may be valuable when prolonged growth hormone treatment for short stature is being considered.	INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,LONDON WC1 1EH,ENGLAND	University of London; University College London	GRECO, L (corresponding author), UNIV NAPLES FEDERICO II,VIA PANSINI,I-80131 NAPLES,ITALY.							ALBERMAN E, 1991, ANN HUM BIOL, V18, P27; BAILEY BJR, 1994, ANN HUM BIOL, V21, P1, DOI 10.1080/03014469400003032; BLAND JM, 1994, BRIT MED J, V309, P780, DOI 10.1136/bmj.309.6957.780; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; BROOK CGD, 1991, ARCH DIS CHILD, V66, P85, DOI 10.1136/adc.66.1.85; BUTLER GE, 1990, ANN HUM BIOL, V17, P177, DOI 10.1080/03014469000000952; FERRI E, 1993, LIFE 3O 5TH FOLLOW U; FOGELMAN K, 1983, GROWING UP GREAT BRI; GOLDSTEIN H, 1971, HUM BIOL, V43, P92; GRECO L, 1990, ARCH DIS CHILD-FETAL, V65, P373, DOI 10.1136/adc.65.4_Spec_No.373; GULLIFORD MC, 1991, ARCH DIS CHILD, V66, P235, DOI 10.1136/adc.66.2.235; HERMANUSSEN M, 1988, ANN HUM BIOL, V15, P103, DOI 10.1080/03014468800009521; HINDMARSH PC, 1988, ACTA PEDIATR SCAND S, V343, P73; KNIGHT I, 1984, HEIGHTS WEIGHTS ADUL; LACEY KA, 1974, ARCH DIS CHILD, V49, P417, DOI 10.1136/adc.49.6.417; LACEY KA, 1974, LANCET, V1, P42; MILLER FJW, 1972, BRIT J PREV SOC MED, V26, P224; MILNER RDG, 1986, LANCET, V1, P483; PINTOR C, 1989, LANCET, V1, P1226; POWER C, 1988, INT J OBESITY, V2, P445; Power C., 1991, HLTH CLASS EARLY YEA; RONA RJ, 1981, BRIT MED BULL, V37, P265, DOI 10.1093/oxfordjournals.bmb.a071713; ROSENBAUM S, 1986, ANN HUM BIOL, V12, P115; SKUSE DH, 1985, ARCH DIS CHILD, V60, P173, DOI 10.1136/adc.60.2.173; STARK O, 1981, BMJ-BRIT MED J, V283, P13, DOI 10.1136/bmj.283.6283.13; VOSS LD, 1992, BMJ-BRIT MED J, V305, P1400, DOI 10.1136/bmj.305.6866.1400	26	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					696	700		10.1136/bmj.310.6981.696	http://dx.doi.org/10.1136/bmj.310.6981.696			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711536	Green Published			2022-12-24	WOS:A1995QN46100018
J	FREEMAN, GJ; GRIBBEN, JG; BOUSSIOTIS, VA; NG, JW; RESTIVO, VA; LOMBARD, LA; GRAY, GS; NADLER, LM				FREEMAN, GJ; GRIBBEN, JG; BOUSSIOTIS, VA; NG, JW; RESTIVO, VA; LOMBARD, LA; GRAY, GS; NADLER, LM			CLONING OF B7-2 - A CTLA-4 COUNTER-RECEPTOR THAT COSTIMULATES HUMAN T-CELL PROLIFERATION	SCIENCE			English	Article							ACTIVATION; INTERLEUKIN-2; ANTIGEN-B7; INDUCTION; ANERGY	Although presentation of antigen to the T cell receptor is necessary for the initiation of an immune response, additional molecules expressed on antigen-presenting cells deliver essential costimulatory signals. T cell activation, in the absence of costimulation, results in T cell anergy. The B7-1 protein is a costimulator molecule that regulates interleukin-2 (IL-2) secretion by signaling through the pathway that uses CD28 and CTLA-4 (hereafter referred to as the CD28 pathway). We have cloned a counter-receptor of CD28 and CTLA-4, termed B7-2. Although only 26 percent identical to B7-1, B7-2 also costimulates IL-2 production and T cell proliferation. Unlike B7-1, B7-2 messenger RNA is constitutively expressed in unstimulated B cells. It is likely that B7-2 provides a critical early costimulatory signal determining if the T cell will contribute to an immune response or become anergic.	REPLIGEN CORP,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	FREEMAN, GJ (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115, USA.		Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616	NCI NIH HHS [CA 40216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUSSIOTIS VA, IN PRESS J EXP MED; BOUSSIOTIS VA, IN PRESS P NATL ACAD; FREEDMAN AS, 1987, J IMMUNOL, V139, P3260; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FREEMAN G, UNPUB; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1993, SCIENCE, V262; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; NICKOLOFF BJ, 1993, AM J PATHOL, V142, P1029; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; YOKOCHI T, 1982, J IMMUNOL, V128, P823	18	898	1006	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					909	911		10.1126/science.7694363	http://dx.doi.org/10.1126/science.7694363			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	7694363				2022-12-24	WOS:A1993MF43800039
J	HAO, Y; CRENSHAW, T; MOULTON, T; NEWCOMB, E; TYCKO, B				HAO, Y; CRENSHAW, T; MOULTON, T; NEWCOMB, E; TYCKO, B			TUMOR-SUPPRESSOR ACTIVITY OF H19 RNA	NATURE			English	Article							NORMAL HUMAN CHROMOSOME-11; WILMS-TUMOR; CELL-DIFFERENTIATION; GENE; EXPRESSION; MOUSE; TUMORIGENICITY; ALLELES	Loss of heterozygosity in certain human embryonal tumours implicates a tumour-suppressor gene at chromosome 11p15.5 and selective loss of maternal alleles suggests that this gene is paternally imprinted1-4. The human H19 gene maps to 11p15.5, is expressed in differentiating fetal cells5-11 and is paternally imprinted12-16. We report here that two embryonal tumour cell lines, RD and G401, showed growth retardation and morphological changes when transfected with an H19 expression construct. More importantly, clonogenicity in soft agar and tumorigenicity in nude mice were abrogated in the G401-H19 transfectants. In addition to demonstrating its tumour-suppressor potential, this transfection system should help structural and functional studies of the enigmatic H19 gene.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,DIV NEUROPATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,DIV PEDIAT HEMATOL ONCOL,NEW YORK,NY 10032; NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016	Columbia University; Columbia University; Columbia University; New York University								BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; GARVIN AJ, 1992, AM J PATHOL, V142, P375; HAN DKM, 1992, CIRC RES, V71, P711, DOI 10.1161/01.RES.71.3.711; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PAL N, 1990, ONCOGENE, V5, P1665; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RACHMILEWITZ J, 1992, MOL REPROD DEV, V32, P196, DOI 10.1002/mrd.1080320303; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; REINER S, 1993, NATURE, V362, P747; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WILES MV, 1988, DEVELOPMENT, V104, P403; WILLIAMS JC, 1989, LANCET, V1, P283; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	24	584	600	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					764	767		10.1038/365764a0	http://dx.doi.org/10.1038/365764a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	7692308				2022-12-24	WOS:A1993MC81200067
